<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25082394</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-2213</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of Asian natural products research</Title>
<ISOAbbreviation>J Asian Nat Prod Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Polygalasaponin F inhibits secretion of inflammatory cytokines via NF-κB pathway regulation.</ArticleTitle>
<Pagination>
<MedlinePgn>865-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/10286020.2014.918962</ELocationID>
<Abstract>
<AbstractText>To study the anti-neuroinflammatory mechanisms of polygalasaponin F (PS-F), ELISA method was used to detect the secretion of inflammatory cytokines. Western blot was used to detect the protein expression and phosphorylation levels. Immunofluorescence assay was used to observe the NF-κB nuclear translocation. PS-F could inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases (iNOS). As for MAPK-signaling pathway, PS-F could only inhibit the phosphorylation levels of p38 MAPK, but did not significantly affect the phosphorylation levels of JNK and ERK1/2 protein kinases. PS-F could inhibit NF-κB nuclear translocation in a dose-dependent manner. The results of Western blot assay were consistent with immunofluorescence assays. Meanwhile, p38-specific inhibitor SB203580 (20 μM) and p65-specific inhibitor PDTC (100 μM) were, respectively, administered as a positive control. In addition, PS-F could significantly inhibit the cytotoxicity of conditioned medium prepared by LPS-stimulated BV-2 microglia (LPS conditioned media) to neuronal PC12 cells and improve cell viability. PS-F inhibits the secretions of neuroinflammatory cytokines by the regulation of NF-κB-signaling pathway. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>a State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Department of Pharmacology , Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100050 , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Yu-He</ForeName>
<Initials>YH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Yan-Na</ForeName>
<Initials>YN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Wen-Fen</ForeName>
<Initials>WF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Chuang-Jun</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Dong-Ming</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Nai-Hong</ForeName>
<Initials>NH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Asian Nat Prod Res</MedlineTA>
<NlmUniqueID>100888334</NlmUniqueID>
<ISSNLinking>1028-6020</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C573752">polygalasaponin F</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>31C4KY9ESH</RegistryNumber>
<NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.13.39</RegistryNumber>
<NameOfSubstance UI="C496319">NOS2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.13.39</RegistryNumber>
<NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052247">Nitric Oxide Synthase Type II</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016716">PC12 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012503">Saponins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">NF-κB</Keyword>
<Keyword MajorTopicYN="N">neuroinflammation</Keyword>
<Keyword MajorTopicYN="N">p38</Keyword>
<Keyword MajorTopicYN="N">polygalasaponin F</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25176222</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-2213</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of Asian natural products research</Title>
<ISOAbbreviation>J Asian Nat Prod Res</ISOAbbreviation>
</Journal>
<ArticleTitle>l-3-n-Butylphthalide attenuates β-amyloid-induced toxicity in neuroblastoma SH-SY5Y cells through regulating mitochondrion-mediated apoptosis and MAPK signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>854-64</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/10286020.2014.939586</ELocationID>
<Abstract>
<AbstractText>Alzheimer's disease (AD) is a progressive neurodegenerative disease. Amyloid-β protein (Aβ), the hallmark of AD, invokes a cascade of mitochondrial dysfunction and eventually leads to neuronal death. l-3-n-Butylphthalide (l-NBP) has shown the potent neuroprotective effects in stroke and AD animal models. The present study is to evaluate the neuroprotective effect of l-NBP on Aβ25-35-induced neuronal injury and the possible mechanism in the human neuroblastoma SH-SY5Y cells. Our results showed that l-NBP significantly attenuated Aβ25-35-induced cell death and reduced neuronal apoptosis. l-NBP significantly inhibited Aβ25-35-induced mitochondrial dysfunction, including mitochondrial membrane potential reduction, and reactive oxygen species production. Furthermore, l-NBP could partially reverse the elevations of Aβ25-35-induced active caspase-3, caspase-9, and cytochrome c expressions, and the downregulation of anti-apoptosis protein Bcl-2. Moreover, l-NBP markedly inhibited the activations of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway. These results demonstrated that l-NBP was capable of protecting neuronal cells from Aβ25-35-induced toxicity through a mitochondrial-dependent apoptotic pathway. Thus, l-NBP shows promising candidate of multi-target neuronal protective agent for the treatment of AD. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lei</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>a State Key Laboratory of Bioactive Substances and Functions of Natural Medicines , Institute of Materia Medica, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Beijing 100050 , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Chun-Yang</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Dong-Mei</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Xiao-Liang</ForeName>
<Initials>XL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peng</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Asian Nat Prod Res</MedlineTA>
<NlmUniqueID>100888334</NlmUniqueID>
<ISSNLinking>1028-6020</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>822Q956KGM</RegistryNumber>
<NameOfSubstance UI="C027125">3-n-butylphthalide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000544">Alzheimer Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016229">Amyloid beta-Peptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001572">Benzofurans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053453">Caspase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
<Keyword MajorTopicYN="N">Aβ</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">l-3-n-butylphthalide</Keyword>
<Keyword MajorTopicYN="N">mitochondria</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174743</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Médecine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Towards a better understanding of the molecular mechanisms of P. falciparum resistance to artemisinin].</ArticleTitle>
<Pagination>
<MedlinePgn>727-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008004</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Khim</LastName>
<ForeName>Nimol</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Unité d'épidémiologie moléculaire du paludisme Institut Pasteur du Cambodge, 5, boulevard Monivong, BP 983, 101 Phnom Penh, Cambodge.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Witkowski</LastName>
<ForeName>Benoit</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Unité d'épidémiologie moléculaire du paludisme Institut Pasteur du Cambodge, 5, boulevard Monivong, BP 983, 101 Phnom Penh, Cambodge.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Duru</LastName>
<ForeName>Valentine</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Unité d'épidémiologie moléculaire du paludisme Institut Pasteur du Cambodge, 5, boulevard Monivong, BP 983, 101 Phnom Penh, Cambodge.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ariey</LastName>
<ForeName>Frédéric</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Unité d'épidémiologie moléculaire du paludisme Institut Pasteur du Cambodge, 5, boulevard Monivong, BP 983, 101 Phnom Penh, Cambodge.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mercereau-Puijalon</LastName>
<ForeName>Odile</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Unité d'épidémiologie moléculaire du paludisme Institut Pasteur du Cambodge, 5, boulevard Monivong, BP 983, 101 Phnom Penh, Cambodge.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ménard</LastName>
<ForeName>Didier</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Unité d'épidémiologie moléculaire du paludisme Institut Pasteur du Cambodge, 5, boulevard Monivong, BP 983, 101 Phnom Penh, Cambodge.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<VernacularTitle>La résistance de P. falciparum à l'artémisinine - vers une meilleure compréhension des mécanismes moléculaires parasitaires.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9RMU91N5K2</RegistryNumber>
<NameOfSubstance UI="C031327">artemisinine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000962">Antimalarials</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D037621">Artemisinins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004351">Drug Resistance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016778">Malaria, Falciparum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000469">parasitology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010963">Plasmodium falciparum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011110">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174751</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Médecine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Collective cell migrations].</ArticleTitle>
<Pagination>
<MedlinePgn>751-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008012</ELocationID>
<Abstract>
<AbstractText>Historically centered on the study of individual cell motility, the field of cell migration has recently moved up one level to look at cooperative behaviour within migratory cell populations. It is now well established that numerous physiological and pathological migration events involve collectively migrating cells rather than solitary cells or concomitantly migrating individual cells. In this review, we first discuss the criteria allowing a given migratory event to be classified as collective cell migration. We then summarize the main concepts that rule collective cell migration in epithelial and mesenchymal tissues with a main focus on mechanisms controlling polarity and directionality in cell collectives. </AbstractText>
<CopyrightInformation>© 2014 médecine/sciences – Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Theveneau</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Centre de biologie du développement, unité mixte de recherche 5547, CNRS, université Paul Sabatier ; 118, route de Narbonne, 31400 Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>David</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Inserm U1024, CNRS unité mixte de recherche 8197, F-75005 Paris, France - École normale supérieure (ENS), institut de biologie de l'ENS (IBENS), F-75230 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Migrations cellulaires collectives.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016764">Cell Polarity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047108">Embryonic Development</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007109">Immunity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014945">Wound Healing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25174755</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0767-0974</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>30</Volume>
<Issue>8-9</Issue>
<PubDate>
<MedlineDate>2014 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Médecine sciences : M/S</Title>
<ISOAbbreviation>Med Sci (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Ferroptosis, a new form of cell death relevant to the medical treatment of cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>779-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1051/medsci/20143008016</ELocationID>
<Abstract>
<AbstractText>Ferroptosis is a form of cell death that has recently been reported during exposure to erastin, a chemical compound identified in a screen for molecules able to kill cancer cells carrying an active Ras oncogene. In cells exposed to inducers of ferroptosis, a catastrophic alteration of the cellular redox metabolism occurs, resulting in massive lipid peroxidation in the plasma membrane and loss of cell viability. We present our recent observations suggesting that sorafenib, the only medical treatment with proven efficacy against hepatocellular carcinoma, induces ferroptosis, a new anti-oncogenic mode of action of this drug. The discovery of ferroptosis sheds light on the critical adaptations of the redox metabolism in cancer cells. It might also foster the discovery of new biomarkers and innovative approaches for the treatment of cancer. </AbstractText>
<CopyrightInformation>© 2014 médecine/sciences – Inserm.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lachaier</LastName>
<ForeName>Emma</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, université de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Louandre</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, université de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ezzoukhry</LastName>
<ForeName>Zakaria</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Inserm U1053, université de Bordeaux Segalen, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Godin</LastName>
<ForeName>Corinne</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, université de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mazière</LastName>
<ForeName>Jean-Claude</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chauffert</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, université de Picardie Jules Verne, Amiens, France - service d'oncologie médicale, CHU Amiens, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Galmiche</LastName>
<ForeName>Antoine</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>EA 4666, université de Picardie Jules Verne, Amiens, France - service de biochimie, centre de biologie humaine (CBH), CHU Amiens Sud, 80054 Salouel Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>La ferroptose, une nouvelle forme de mort cellulaire applicable au traitement médical des cancers.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Med Sci (Paris)</MedlineTA>
<NlmUniqueID>8710980</NlmUniqueID>
<ISSNLinking>0767-0974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C477224">erastin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010084">Oxidation-Reduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25150980</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4679</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature cell biology</Title>
<ISOAbbreviation>Nat. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.</ArticleTitle>
<Pagination>
<MedlinePgn>889-901</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb3021</ELocationID>
<Abstract>
<AbstractText>Cancer-associated fibroblasts (CAFs) drive tumour progression, but the emergence of this cell state is poorly understood. A broad spectrum of metalloproteinases, controlled by the Timp gene family, influence the tumour microenvironment in human cancers. Here, we generate quadruple TIMP knockout (TIMPless) fibroblasts to unleash metalloproteinase activity within the tumour-stromal compartment and show that complete Timp loss is sufficient for the acquisition of hallmark CAF functions. Exosomes produced by TIMPless fibroblasts induce cancer cell motility and cancer stem cell markers. The proteome of these exosomes is enriched in extracellular matrix proteins and the metalloproteinase ADAM10. Exosomal ADAM10 increases aldehyde dehydrogenase expression in breast cancer cells through Notch receptor activation and enhances motility through the GTPase RhoA. Moreover, ADAM10 knockdown in TIMPless fibroblasts abrogates their CAF function. Importantly, human CAFs secrete ADAM10-rich exosomes that promote cell motility and activate RhoA and Notch signalling in cancer cells. Thus, Timps suppress cancer stroma where activated-fibroblast-secreted exosomes impact tumour progression.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shimoda</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Principe</LastName>
<ForeName>Simona</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jackson</LastName>
<ForeName>Hartland W</ForeName>
<Initials>HW</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luga</LastName>
<ForeName>Valbona</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, M5G 1X5, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Molyneux</LastName>
<ForeName>Sam D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shao</LastName>
<ForeName>Yang W</ForeName>
<Initials>YW</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aiken</LastName>
<ForeName>Alison</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Waterhouse</LastName>
<ForeName>Paul D</ForeName>
<Initials>PD</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Karamboulas</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hess</LastName>
<ForeName>Franz M</ForeName>
<Initials>FM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Toxicology, RWTH Aachen University, 52074 Aachen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohtsuka</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Keio University, School of Medicine, Tokyo 160-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Yasunori</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Keio University, School of Medicine, Tokyo 160-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ailles</LastName>
<ForeName>Laurie</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ludwig</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Toxicology, RWTH Aachen University, 52074 Aachen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wrana</LastName>
<ForeName>Jeffrey L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, M5G 1X5, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kislinger</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khokha</LastName>
<ForeName>Rama</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Cell Biol</MedlineTA>
<NlmUniqueID>100890575</NlmUniqueID>
<ISSNLinking>1465-7392</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.81</RegistryNumber>
<NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051722">ADAM Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053829">Amyloid Precursor Protein Secretases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008666">Metalloendopeptidases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019714">Tissue Inhibitor of Metalloproteinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25173977</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4679</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature cell biology</Title>
<ISOAbbreviation>Nat. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prostaglandin signalling regulates ciliogenesis by modulating intraflagellar transport.</ArticleTitle>
<Pagination>
<MedlinePgn>841-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb3029</ELocationID>
<Abstract>
<AbstractText>Cilia are microtubule-based organelles that mediate signal transduction in a variety of tissues. Despite their importance, the signalling cascades that regulate cilium formation remain incompletely understood. Here we report that prostaglandin signalling affects ciliogenesis by regulating anterograde intraflagellar transport (IFT). Zebrafish leakytail (lkt) mutants show ciliogenesis defects, and the lkt locus encodes an ATP-binding cassette transporter (ABCC4). We show that Lkt/ABCC4 localizes to the cell membrane and exports prostaglandin E2 (PGE2), a function that is abrogated by the Lkt/ABCC4(T804M) mutant. PGE2 synthesis enzyme cyclooxygenase-1 and its receptor, EP4, which localizes to the cilium and activates the cyclic-AMP-mediated signalling cascade, are required for cilium formation and elongation. Importantly, PGE2 signalling increases anterograde but not retrograde velocity of IFT and promotes ciliogenesis in mammalian cells. These findings lead us to propose that Lkt/ABCC4-mediated PGE2 signalling acts through a ciliary G-protein-coupled receptor, EP4, to upregulate cAMP synthesis and increase anterograde IFT, thereby promoting ciliogenesis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Daqing</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Genetic Engineering, Department of Genetics, Fudan University School of Life Sciences, Shanghai 200433, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ni</LastName>
<ForeName>Terri T</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Vanderbilt University School of Medicine, Tennessee 37232, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Jianjian</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Genetic Engineering, Department of Genetics, Fudan University School of Life Sciences, Shanghai 200433, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wan</LastName>
<ForeName>Haiyan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Vanderbilt University School of Medicine, Tennessee 37232, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Amack</LastName>
<ForeName>Jeffrey D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell &amp;Developmental Biology, State University of New York Upstate Medical University, New York 13210, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Guangju</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Genetic Engineering, Department of Genetics, Fudan University School of Life Sciences, Shanghai 200433, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fleming</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell &amp;Developmental Biology, Vanderbilt University School of Medicine, Tennessee 37232, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chiang</LastName>
<ForeName>Chin</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell &amp;Developmental Biology, Vanderbilt University School of Medicine, Tennessee 37232, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Wenyan</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Genetic Engineering, Department of Genetics, Fudan University School of Life Sciences, Shanghai 200433, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Papierniak</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>MRC Centre for Developmental and Biomedical Genetics, The University of Sheffield, Sheffield S10 2TN, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheepala</LastName>
<ForeName>Satish</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmaceutical Science, St Jude Children's Research Hospital, Tennessee 38163, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Conseil</LastName>
<ForeName>Gwenaëlle</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cole</LastName>
<ForeName>Susan P C</ForeName>
<Initials>SP</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Bin</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Institute for Nutritional Sciences, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Drummond</LastName>
<ForeName>Iain A</ForeName>
<Initials>IA</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Massachusetts 02148, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schuetz</LastName>
<ForeName>John D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmaceutical Science, St Jude Children's Research Hospital, Tennessee 38163, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malicki</LastName>
<ForeName>Jarema</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>MRC Centre for Developmental and Biomedical Genetics, The University of Sheffield, Sheffield S10 2TN, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Tao P</ForeName>
<Initials>TP</Initials>
<AffiliationInfo>
<Affiliation>1] State Key Laboratory of Genetic Engineering, Department of Genetics, Fudan University School of Life Sciences, Shanghai 200433, China [2] Department of Medicine, Vanderbilt University School of Medicine, Tennessee 37232, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP106513</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>R01 HL073348</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Cell Biol</MedlineTA>
<NlmUniqueID>100890575</NlmUniqueID>
<ISSNLinking>1465-7392</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592651">Abcc4 protein, zebrafish</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D027425">Multidrug Resistance-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K7Q1JQR04M</RegistryNumber>
<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Cell Biol. 2014 Sep;16(9):826-7</RefSource>
<PMID Version="1">25174819</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002923">Cilia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007728">Kupffer Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027425">Multidrug Resistance-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022161">Transport Vesicles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029961">Zebrafish Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS614412 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4154319 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25176369</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1011-601X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>27</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Pakistan journal of pharmaceutical sciences</Title>
<ISOAbbreviation>Pak J Pharm Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Prostate cancer: leading and misleading routes to TRAIL of death.</ArticleTitle>
<Pagination>
<MedlinePgn>1371-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Prostate cancer is a multifaceted disease that arises because of misrepresentation of linear and integrated signaling cascades that regulate gene network in normal and cancer cells. Programmed cell death is modulated by intracellular regulators within each cell and various lines of evidence suggest that there is under- expression and over-expression of pro-apoptotic and anti-apoptotic gene subsets respectively. Apoptosis is a response to the cellular microenvironment, and the cell microenvironment can be regulated by multiple signaling cascades at a higher organizational level by suppressing survival signals notably at genetic, epigenetic, transcriptional and post-transcriptional level. Unquestionably, drug-discovery approaches over the last decade aiming at neutralizing anti-apoptotic proteins, over-expressing pro-apoptotic proteins and enhancing the cell surface appearance of TRAIL receptors have revolutionized our current information about inducing and maximizing TRAIL mediated signaling in resistant prostate cancer phenotype. In this mini-review we outline outstanding developments in the field of prostate cancer that have played a role in understanding the underlying mechanisms that control TRAIL mediated apoptosis in prostate cancer cells, which may be helpful in the development of cancer therapies based on the apoptotic pathway. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Farooqi</LastName>
<ForeName>Ammad Ahmad</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, 35 Km Ferozepur Road, Lahore, Pakistan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qureshi</LastName>
<ForeName>Muhammad Zahid</ForeName>
<Initials>MZ</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, GC University, Lahore, Pakistan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rehman</LastName>
<ForeName>Abdur</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Rashid Latif Medical College, 35 Km Ferozepur Road, Lahore, Pakistan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nogueira</LastName>
<ForeName>Daniele Rubert</ForeName>
<Initials>DR</Initials>
<AffiliationInfo>
<Affiliation>Departament of Industrial Pharmacy, Federal University of Santa Maria, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Awan</LastName>
<ForeName>Imrana Iftikhar</ForeName>
<Initials>II</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Rashid Latif Medical College, 35 Km Ferozepur Road, Lahore, Pakistan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shahid</LastName>
<ForeName>Adeela</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Shalamar Medical and Dental College, Lahore, Pakistan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Pakistan</Country>
<MedlineTA>Pak J Pharm Sci</MedlineTA>
<NlmUniqueID>9426356</NlmUniqueID>
<ISSNLinking>1011-601X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505653">TNFSF10 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053221">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24965592</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1563</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Cell physiology</Title>
<ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Global discovery of high-NaCl-induced changes of protein phosphorylation.</ArticleTitle>
<Pagination>
<MedlinePgn>C442-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpcell.00379.2013</ELocationID>
<Abstract>
<AbstractText>High extracellular NaCl, such as in the renal medulla, can perturb and even kill cells, but cells mount protective responses that enable them to survive and function. Many high-NaCl-induced perturbations and protective responses are known, but the signaling pathways involved are less clear. Change in protein phosphorylation is a common mode of cell signaling, but there was no unbiased survey of protein phosphorylation in response to high NaCl. We used stable isotopic labeling of amino acids in cell culture coupled to mass spectrometry to identify changes in protein phosphorylation in human embryonic kidney (HEK 293) cells exposed to high NaCl. We reproducibly identify &gt;8,000 unique phosphopeptides in 4 biological replicate samples with a 1% false discovery rate. High NaCl significantly changed phosphorylation of 253 proteins. Western analysis and targeted ion selection mass spectrometry confirm a representative sample of the phosphorylation events. We analyze the affected proteins by functional category to infer how altered protein phosphorylation might signal cellular responses to high NaCl, including alteration of cell cycle, cyto/nucleoskeletal organization, DNA double-strand breaks, transcription, proteostasis, metabolism of mRNA, and cell death. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Rong</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferraris</LastName>
<ForeName>Joan D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Izumi</LastName>
<ForeName>Yuichiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dmitrieva</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ramkissoon</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Guanghui</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gucek</LastName>
<ForeName>Marjan</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burg</LastName>
<ForeName>Maurice B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo>
<Affiliation>Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland maurice_burg@nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
<NlmUniqueID>100901225</NlmUniqueID>
<ISSNLinking>0363-6143</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7647-14-5</RegistryNumber>
<NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002853">Chromatography, Liquid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045604">Extracellular Fluid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012965">Sodium Chloride</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053719">Tandem Mass Spectrometry</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4154074 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">organic osmolytes</Keyword>
<Keyword MajorTopicYN="N">phosphorylation</Keyword>
<Keyword MajorTopicYN="N">renal medulla</Keyword>
<Keyword MajorTopicYN="N">stable isotopic labeling of amino acids in cell culture</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25015964</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1539</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Heart and circulatory physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Urocortin 2 stimulates nitric oxide production in ventricular myocytes via Akt- and PKA-mediated phosphorylation of eNOS at serine 1177.</ArticleTitle>
<Pagination>
<MedlinePgn>H689-700</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00694.2013</ELocationID>
<Abstract>
<AbstractText>Urocortin 2 (Ucn2) is a cardioactive peptide exhibiting beneficial effects in normal and failing heart. In cardiomyocytes, it elicits cAMP- and Ca(2+)-dependent positive inotropic and lusitropic effects. We tested the hypothesis that, in addition, Ucn2 activates cardiac nitric oxide (NO) signaling and elucidated the underlying signaling pathways and mechanisms. In isolated rabbit ventricular myocytes, Ucn2 caused concentration- and time-dependent increases in phosphorylation of Akt (Ser473, Thr308), endothelial NO synthase (eNOS) (Ser1177), and ERK1/2 (Thr202/Tyr204). ERK1/2 phosphorylation, but not Akt and eNOS phosphorylation, was suppressed by inhibition of MEK1/2. Increased Akt phosphorylation resulted in increased Akt kinase activity and was mediated by corticotropin-releasing factor 2 (CRF2) receptors (astressin-2B sensitive). Inhibition of phosphatidylinositol 3-kinase (PI3K) diminished both Akt as well as eNOS phosphorylation mediated by Ucn2. Inhibition of protein kinase A (PKA) reduced Ucn2-induced phosphorylation of eNOS but did not affect the increase in phosphorylation of Akt. Conversely, direct receptor-independent elevation of cAMP via forskolin increased phosphorylation of eNOS but not of Akt. Ucn2 increased intracellular NO concentration ([NO]i), [cGMP], [cAMP], and cell shortening. Inhibition of eNOS suppressed the increases in [NO]i and cell shortening. When both PI3K-Akt and cAMP-PKA signaling were inhibited, the Ucn2-induced increases in [NO]i and cell shortening were attenuated. Thus, in rabbit ventricular myocytes, Ucn2 causes activation of cAMP-PKA, PI3K-Akt, and MEK1/2-ERK1/2 signaling. The MEK1/2-ERK1/2 pathway is not required for stimulation of NO signaling in these cells. The other two pathways, cAMP-PKA and PI3K-Akt, converge on eNOS phosphorylation at Ser1177 and result in pronounced and sustained cellular NO production with subsequent stimulation of cGMP signaling. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Walther</LastName>
<ForeName>Stefanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, Illinois;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pluteanu</LastName>
<ForeName>Florentina</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Clinical Pharmacy, Biochemical and Pharmacological Centre Marburg, Philipps-University of Marburg, Marburg, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Renz</LastName>
<ForeName>Susanne</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiology and Pneumology, University Medicine Göttingen, Göttingen, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nikonova</LastName>
<ForeName>Yulia</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Clinical Pharmacy, Biochemical and Pharmacological Centre Marburg, Philipps-University of Marburg, Marburg, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maxwell</LastName>
<ForeName>Joshua T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, Illinois;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Li-Zhen</ForeName>
<Initials>LZ</Initials>
<AffiliationInfo>
<Affiliation>Molecular Neuroendocrinology Group of the Max Planck Institute for Experimental Medicine, Göttingen, Germany, and Specialized Neuroscience Research Program 2, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii; Division of Endocrinology, Department of Internal Medicine, Shanghai Ninth People's Hospital of Shanghai Jiaotong University, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schmidt</LastName>
<ForeName>Kurt</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmaceutical Sciences, Pharmacology and Toxicology, Karl-Franzens-University of Graz, Graz, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Edwards</LastName>
<ForeName>Joshua N</ForeName>
<Initials>JN</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, Illinois;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wakula</LastName>
<ForeName>Paulina</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Division of Cardiology, Medical University of Graz, Graz, Austria;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Groschner</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Ludwig-Boltzmann-Institute for Translational Heart Failure Research, Graz, Austria; Institute of Biophysics, Medical University of Graz, Graz, Austria;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maier</LastName>
<ForeName>Lars S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiology and Pneumology, University Medicine Göttingen, Göttingen, Germany; Clinic and Policlinic for Internal Medicine II, University Clinics Regensburg, Regensburg, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spiess</LastName>
<ForeName>Joachim</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Molecular Neuroendocrinology Group of the Max Planck Institute for Experimental Medicine, Göttingen, Germany, and Specialized Neuroscience Research Program 2, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii; Sanford Burnham Medical Research Institute, La Jolla, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blatter</LastName>
<ForeName>Lothar A</ForeName>
<Initials>LA</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, Illinois;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pieske</LastName>
<ForeName>Burkert</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Division of Cardiology, Medical University of Graz, Graz, Austria; Ludwig-Boltzmann-Institute for Translational Heart Failure Research, Graz, Austria;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kockskämper</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Clinical Pharmacy, Biochemical and Pharmacological Centre Marburg, Philipps-University of Marburg, Marburg, Germany; jens.kockskaemper@staff.uni-marburg.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01-HL-080101</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-HL-062231</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-HL-101235</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
<NlmUniqueID>100901228</NlmUniqueID>
<ISSNLinking>0363-6135</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C101531">CRF receptor type 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018019">Receptors, Corticotropin-Releasing Hormone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054832">Urocortins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>31C4KY9ESH</RegistryNumber>
<NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>452VLY9402</RegistryNumber>
<NameOfSubstance UI="D012694">Serine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.13.39</RegistryNumber>
<NameOfSubstance UI="D052250">Nitric Oxide Synthase Type III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.11</RegistryNumber>
<NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>H2D2X058MU</RegistryNumber>
<NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017868">Cyclic AMP-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006152">Cyclic GMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006352">Heart Ventricles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019950">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048052">Mitogen-Activated Protein Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032383">Myocytes, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052250">Nitric Oxide Synthase Type III</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018019">Receptors, Corticotropin-Releasing Hormone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012694">Serine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054832">Urocortins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187402 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cardiac myocyte</Keyword>
<Keyword MajorTopicYN="N">eNOS phosphorylation</Keyword>
<Keyword MajorTopicYN="N">nitric oxide</Keyword>
<Keyword MajorTopicYN="N">urocortin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24920728</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Toll-like receptors and hypertension.</ArticleTitle>
<Pagination>
<MedlinePgn>R501-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00194.2014</ELocationID>
<Abstract>
<AbstractText>Hypertension and associated inflammatory processes that accelerate cardiovascular damage are regulated by the innate immune system. Toll-like receptors (TLR) are major components of the innate immune system that recognize endogenous damage-associated molecular patterns to activate prominent inflammatory signaling including activation of nuclear factor-κB (NF-κB). However, the role of TLR in the etiology of hypertension is not well understood. TLR signaling is dependent on adaptor proteins that, along with the TLR expression patterns, confer specificity of the inflammatory response and its pathological targets. Here we review the conceptual framework of how TLR and their adaptor proteins may differentially affect hypertension and cardiac hypertrophy by different stimuli. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Madhu V</ForeName>
<Initials>MV</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa; Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa; and madhu-singh@uiowa.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abboud</LastName>
<ForeName>François M</ForeName>
<Initials>FM</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa; Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa; and Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, Iowa.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HL-14388</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4214832 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">MyD88</Keyword>
<Keyword MajorTopicYN="N">hypertension</Keyword>
<Keyword MajorTopicYN="N">innate immune system</Keyword>
<Keyword MajorTopicYN="N">toll-like receptors</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24920734</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Modulation of sheep ruminal urea transport by ammonia and pH.</ArticleTitle>
<Pagination>
<MedlinePgn>R558-70</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00107.2014</ELocationID>
<Abstract>
<AbstractText>Ruminal fermentation products such as short-chain fatty acids (SCFA) and CO2 acutely stimulate urea transport across the ruminal epithelium in vivo, whereas ammonia has inhibitory effects. Uptake and signaling pathways remain obscure. The ruminal expression of SLC14a1 (UT-B) was studied using polymerase chain reaction (PCR). The functional short-term effects of ammonia on cytosolic pH (pHi) and ruminal urea transport across native epithelia were investigated using pH-sensitive microelectrodes and via flux measurements in Ussing chambers. Two variants (UT-B1 and UT-B2) could be fully sequenced from ovine ruminal cDNA. Functionally, transport was passive and modulated by luminal pH in the presence of SCFA and CO2, rising in response to luminal acidification to a peak value at pH 5.8 and dropping with further acidification, resulting in a bell-shaped curve. Presence of ammonia reduced the amplitude, but not the shape of the relationship between urea flux and pH, so that urea flux remained maximal at pH 5.8. Effects of ammonia were concentration dependent, with saturation at 5 mmol/l. Clamping the transepithelial potential altered the inhibitory potential of ammonia on urea flux. Ammonia depolarized the apical membrane and acidified pHi, suggesting that, at physiological pH (&lt; 7), uptake of NH4 (+) into the cytosol may be a key signaling event regulating ruminal urea transport. We conclude that transport of urea across the ruminal epithelium involves proteins subject to rapid modulation by manipulations that alter pHi and the cytosolic concentration of NH4 (+). Implications for epithelial and ruminal homeostasis are discussed. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Zhongyan</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stumpff</LastName>
<ForeName>Friederike</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deiner</LastName>
<ForeName>Carolin</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rosendahl</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Braun</LastName>
<ForeName>Hannah</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abdoun</LastName>
<ForeName>Khalid</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>College of Food and Agriculture Science, King Saud University, Riyadh, Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aschenbach</LastName>
<ForeName>Jörg R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martens</LastName>
<ForeName>Holger</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Veterinary Physiology, Freie Universität Berlin, Berlin, Germany; and Holger.Martens@fu-berlin.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011522">Protons</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C083800">urea transporter</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>142M471B3J</RegistryNumber>
<NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7664-41-7</RegistryNumber>
<NameOfSubstance UI="D000641">Ammonia</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8W8T17847W</RegistryNumber>
<NameOfSubstance UI="D014508">Urea</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000641">Ammonia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001692">Biological Transport</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002245">Carbon Dioxide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005232">Fatty Acids, Volatile</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006863">Hydrogen-Ion Concentration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026901">Membrane Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011522">Protons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012417">Rumen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012756">Sheep</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014508">Urea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ammonia</Keyword>
<Keyword MajorTopicYN="N">ion-selective microelectrode</Keyword>
<Keyword MajorTopicYN="N">recycling</Keyword>
<Keyword MajorTopicYN="N">rumen</Keyword>
<Keyword MajorTopicYN="N">urea</Keyword>
<Keyword MajorTopicYN="N">urea transporter B</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24920735</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Renal neurohormonal regulation in heart failure decompensation.</ArticleTitle>
<Pagination>
<MedlinePgn>R493-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00178.2014</ELocationID>
<Abstract>
<AbstractText>Decompensation in heart failure occurs when the heart fails to balance venous return with cardiac output, leading to fluid congestion and contributing to mortality. Decompensated heart failure can cause acute kidney injury (AKI), which further increases mortality. Heart failure activates signaling systems that are deleterious to kidneys such as renal sympathetic nerve activity (RSNA), renin-angiotensin-aldosterone system, and vasopressin secretion. All three reduce renal blood flow (RBF) and increase tubular sodium reabsorption, which may increase renal oxygen consumption causing AKI through renal tissue hypoxia. Vasopressin contributes to venous congestion through aquaporin-mediated water retention. Additional water retention may be mediated through vasopressin-induced medullary urea transport and hyaluronan but needs further study. In addition, there are several systems that could protect the kidneys and reduce fluid retention such as natriuretic peptides, prostaglandins, and nitric oxide. However, the effect of natriuretic peptides and nitric oxide are blunted in decompensation, partly due to oxidative stress. This review considers how neurohormonal signaling in heart failure drives fluid retention by the kidneys and thus exacerbates decompensation. It further identifies areas where there is limited data, such as signaling systems 20-HETE, purines, endothelin, the role of renal water retention mechanisms for congestion, and renal hypoxia in AKI during heart failure. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jönsson</LastName>
<ForeName>Sofia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Unit for Integrative Physiology, Department of Medical Cellbiology, Uppsala University, Uppsala, Sweden; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Agic</LastName>
<ForeName>Mediha Becirovic</ForeName>
<Initials>MB</Initials>
<AffiliationInfo>
<Affiliation>Unit for Integrative Physiology, Department of Medical Cellbiology, Uppsala University, Uppsala, Sweden; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Narfström</LastName>
<ForeName>Fredrik</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Unit for Anaesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Melville</LastName>
<ForeName>Jacqueline M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Unit for Integrative Physiology, Department of Medical Cellbiology, Uppsala University, Uppsala, Sweden; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hultström</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Unit for Integrative Physiology, Department of Medical Cellbiology, Uppsala University, Uppsala, Sweden; and Unit for Anaesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden michael.hultstrom@mcb.uu.se.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002302">Cardiac Output</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000294">innervation</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018377">Neurotransmitter Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013564">Sympathetic Nervous System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014882">Water-Electrolyte Balance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ADHF</Keyword>
<Keyword MajorTopicYN="N">GFR</Keyword>
<Keyword MajorTopicYN="N">acute renal failure</Keyword>
<Keyword MajorTopicYN="N">cardiorenal syndrome</Keyword>
<Keyword MajorTopicYN="N">glomerular filtration rate</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24944251</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Renin release: role of SNAREs.</ArticleTitle>
<Pagination>
<MedlinePgn>R484-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00175.2014</ELocationID>
<Abstract>
<AbstractText>Little is known about the molecular mechanism mediating renin granule exocytosis and the identity of proteins involved. We previously showed that soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNAREs), a family of proteins required for exocytosis, mediate the stimulated release of renin from juxtaglomerular cells. This minireview focuses on the current knowledge of the proteins that facilitate renin-granule exocytosis. We discuss the identity of potential candidates that mediate the signaling and final steps of exocytosis of the renin granule. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mendez</LastName>
<ForeName>Mariela</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan mmendez1@hfhs.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.23.15</RegistryNumber>
<NameOfSubstance UI="D012083">Renin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005089">Exocytosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007606">Juxtaglomerular Apparatus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008561">Membrane Fusion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012083">Renin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050600">SNARE Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">SNAREs</Keyword>
<Keyword MajorTopicYN="N">cAMP</Keyword>
<Keyword MajorTopicYN="N">exocytosis</Keyword>
<Keyword MajorTopicYN="N">hypertension</Keyword>
<Keyword MajorTopicYN="N">renin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24990855</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Intrafetal glucose infusion alters glucocorticoid signaling and reduces surfactant protein mRNA expression in the lung of the late-gestation sheep fetus.</ArticleTitle>
<Pagination>
<MedlinePgn>R538-45</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00053.2014</ELocationID>
<Abstract>
<AbstractText>Increased circulating fetal glucose and insulin concentrations are potential inhibitors of fetal lung maturation and may contribute to the pathogenesis of respiratory distress syndrome (RDS) in infants of diabetic mothers. In this study, we examined the effect of intrafetal glucose infusion on mRNA expression of glucose transporters, insulin-like growth factor signaling, glucocorticoid regulatory genes, and surfactant proteins in the lung of the late-gestation sheep fetus. The numerical density of the cells responsible for producing surfactant was determined using immunohistochemistry. Glucose infusion for 10 days did not affect mRNA expression of glucose transporters or IGFs but did decrease IGF-1R expression. There was reduced mRNA expression of the glucocorticoid-converting enzyme HSD11B-1 and the glucocorticoid receptor, potentially reducing glucocorticoid responsiveness in the fetal lung. Furthermore, surfactant protein (SFTP) mRNA expression was reduced in the lung following glucose infusion, while the number of SFTP-B-positive cells remained unchanged. These findings suggest the presence of a glucocorticoid-mediated mechanism regulating delayed maturation of the surfactant system in the sheep fetus following glucose infusion and provide evidence for the link between abnormal glycemic control during pregnancy and the increased risk of RDS in infants of uncontrolled diabetic mothers. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>McGillick</LastName>
<ForeName>Erin V</ForeName>
<Initials>EV</Initials>
<AffiliationInfo>
<Affiliation>Early Origins of Adult Health Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia; and Molecular and Evolutionary Physiology of the Lung Laboratory, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morrison</LastName>
<ForeName>Janna L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Early Origins of Adult Health Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McMillen</LastName>
<ForeName>I Caroline</ForeName>
<Initials>IC</Initials>
<AffiliationInfo>
<Affiliation>Early Origins of Adult Health Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Orgeig</LastName>
<ForeName>Sandra</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Molecular and Evolutionary Physiology of the Lung Laboratory, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia sandra.orgeig@unisa.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011663">Pulmonary Surfactants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.1.1.146</RegistryNumber>
<NameOfSubstance UI="D043205">11-beta-Hydroxysteroid Dehydrogenase Type 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043205">11-beta-Hydroxysteroid Dehydrogenase Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001784">Blood Gas Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005333">Fetus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023421">Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011270">Pregnancy, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011663">Pulmonary Surfactants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017526">Receptor, IGF Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011965">Receptors, Glucocorticoid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012756">Sheep</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">diabetes</Keyword>
<Keyword MajorTopicYN="N">glucose</Keyword>
<Keyword MajorTopicYN="N">obesity</Keyword>
<Keyword MajorTopicYN="N">surfactant</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25037564</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1460-2075</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The EMBO journal</Title>
<ISOAbbreviation>EMBO J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Location, location, and location: compartmentalization of Hedgehog signaling at primary cilia.</ArticleTitle>
<Pagination>
<MedlinePgn>1852-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.201489294</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pusapati</LastName>
<ForeName>Ganesh V</ForeName>
<Initials>GV</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine and Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rohatgi</LastName>
<ForeName>Rajat</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine and Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>EMBO J</MedlineTA>
<NlmUniqueID>8208664</NlmUniqueID>
<ISSNLinking>0261-4189</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="D016547">Kinesin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Nat Cell Biol. 2014 Jul;16(7):663-72</RefSource>
<PMID Version="1">24952464</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002923">Cilia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016547">Kinesin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4195781 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093272</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1520-5851</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>48</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Environmental science &amp; technology</Title>
<ISOAbbreviation>Environ. Sci. Technol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of lipidomic biomarkers for coexposure to subtoxic doses of benzo[a]pyrene and cadmium: the toxicological cascade biomarker approach.</ArticleTitle>
<Pagination>
<MedlinePgn>10423-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/es502419w</ELocationID>
<Abstract>
<AbstractText>The search for model bioassay systems indicating activation of different toxicological signaling pathways is one of the paramount goals of modern toxicology. Especially coexposure scenarios need to be investigated with respect to synergistic and interdependent effects for the activation of toxicological signaling pathways. The present study introduces an experimental in vitro model system for nontoxic and low-dose coexposures of human mammary carcinoma MCF-7 cells against polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BP) and heavy metals such as cadmium. For the first time, a multivariate model that identifies 18 metabolic biomarkers has been shown to be sufficient to separate BP-treated cells from coexposed or control cells. A "toxicological pathway color code model" is introduced to visualize the results. Different biomarker subsets can be associated with specific HER2 signaling steps. A tiered cascade biomarker approach is proposed that could be used to identify profiles associated with tumorigenic potency of environmental toxicants in coexposure scenarios, including possible synergistic or additive effects. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jungnickel</LastName>
<ForeName>Harald</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Product Safety, German Federal Institute for Risk Assessment (BfR) , Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Potratz</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baumann</LastName>
<ForeName>Sven</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tarnow</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>von Bergen</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luch</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Environ Sci Technol</MedlineTA>
<NlmUniqueID>0213155</NlmUniqueID>
<ISSNLinking>0013-936X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013109">Sphingomyelins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>00BH33GNGH</RegistryNumber>
<NameOfSubstance UI="D002104">Cadmium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3417WMA06D</RegistryNumber>
<NameOfSubstance UI="D001564">Benzo(a)pyrene</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001564">Benzo(a)pyrene</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002104">Cadmium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010713">Phosphatidylcholines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013109">Sphingomyelins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25154396</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-8140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>206</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of cell biology</Title>
<ISOAbbreviation>J. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>BMP-regulated exosomes from Drosophila male reproductive glands reprogram female behavior.</ArticleTitle>
<Pagination>
<MedlinePgn>671-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.201401072</ELocationID>
<Abstract>
<AbstractText>Male reproductive glands secrete signals into seminal fluid to facilitate reproductive success. In Drosophila melanogaster, these signals are generated by a variety of seminal peptides, many produced by the accessory glands (AGs). One epithelial cell type in the adult male AGs, the secondary cell (SC), grows selectively in response to bone morphogenetic protein (BMP) signaling. This signaling is involved in blocking the rapid remating of mated females, which contributes to the reproductive advantage of the first male to mate. In this paper, we show that SCs secrete exosomes, membrane-bound vesicles generated inside late endosomal multivesicular bodies (MVBs). After mating, exosomes fuse with sperm (as also seen in vitro for human prostate-derived exosomes and sperm) and interact with female reproductive tract epithelia. Exosome release was required to inhibit female remating behavior, suggesting that exosomes are downstream effectors of BMP signaling. Indeed, when BMP signaling was reduced in SCs, vesicles were still formed in MVBs but not secreted as exosomes. These results demonstrate a new function for the MVB-exosome pathway in the reproductive tract that appears to be conserved across evolution. </AbstractText>
<CopyrightInformation>© 2014 Corrigan et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Corrigan</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Redhai</LastName>
<ForeName>Siamak</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Leiblich</LastName>
<ForeName>Aaron</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Shih-Jung</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perera</LastName>
<ForeName>Sumeth M W</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Patel</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gandy</LastName>
<ForeName>Carina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wainwright</LastName>
<ForeName>S Mark</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morris</LastName>
<ForeName>John F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hamdy</LastName>
<ForeName>Freddie</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Goberdhan</LastName>
<ForeName>Deborah C I</ForeName>
<Initials>DC</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>Clive</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Anatomy and Genetics and Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 3QX, England, UK clive.wilson@dpag.ox.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>092927/Z/10/Z</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>BB/K017462/1</GrantID>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>C38302/A12278</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cell Biol</MedlineTA>
<NlmUniqueID>0375356</NlmUniqueID>
<ISSNLinking>0021-9525</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060149">Antigens, CD63</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060149">Antigens, CD63</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019485">Bone Morphogenetic Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029721">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004331">Drosophila melanogaster</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005836">Genitalia, Female</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005837">Genitalia, Male</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008247">Lysosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008561">Membrane Fusion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021962">Membrane Microdomains</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057146">Multivesicular Bodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022142">Secretory Vesicles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012726">Sexual Behavior, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013094">Spermatozoa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014617">Vacuoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4151142 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25012120</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-8421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>274</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of neuroimmunology</Title>
<ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Involvement of JAK/STAT signaling in the effect of cornel iridoid glycoside on experimental autoimmune encephalomyelitis amelioration in rats.</ArticleTitle>
<Pagination>
<MedlinePgn>28-37</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2014.06.022</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0165-5728(14)00193-3</ELocationID>
<Abstract>
<AbstractText>In the present study, we investigated the therapeutic benefit of cornel iridoid glycoside (CIG), the main component extracted from Cornus officinalis, in experimental autoimmune encephalomyelitis (EAE) rats. CIG was intragastrically administered daily after EAE initiation for 20days and reduced disease severity, incidence, disease onset and ongoing paralysis. Histopathological staining showed that CIG could reduce T cell entry to the central nervous system and microglia activation, increased brain-derived neurotrophic factor (BDNF) expression and mature oligodendrocytes, and decreased oligodendrocyte progenitor cells (OPCs). Also, CIG treatment inhibited brain JAK/STAT1/3 and reduced proinflammatory cytokines. CIG might be a novel potential therapeutic agent for multiple sclerosis (MS). </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Linlin</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Xuan Wu Hospital of Capital Medical University, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, 45 Changchun Street, Beijing 100053, PR China. Electronic address: yinll913@126.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yongyan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>School of Pharmaceutical Sciences, Zhengzhou University, 100 Science Avenue, Zhengzhou, Henan Province 450001, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qu</LastName>
<ForeName>Zhao</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou, Guangdong Province 510405, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Xuan Wu Hospital of Capital Medical University, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, 45 Changchun Street, Beijing 100053, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qi</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou, Guangdong Province 510405, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Qi</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>School of Pharmaceutical Sciences, Zhengzhou University, 100 Science Avenue, Zhengzhou, Henan Province 450001, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Xuan Wu Hospital of Capital Medical University, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, 45 Changchun Street, Beijing 100053, PR China. Electronic address: linli97@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Neuroimmunol</MedlineTA>
<NlmUniqueID>8109498</NlmUniqueID>
<ISSNLinking>0165-5728</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057888">Iridoid Glucosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507936">Jak3 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050794">STAT1 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494081">Stat1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494088">Stat3 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C507906">Jak1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053616">Janus Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019208">Brain-Derived Neurotrophic Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004681">Encephalomyelitis, Autoimmune, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057888">Iridoid Glucosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053613">Janus Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053616">Janus Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009103">Multiple Sclerosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009186">Myelin Sheath</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009836">Oligodendroglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011917">Rats, Inbred Lew</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050794">STAT1 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013116">Spinal Cord</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cornel iridoid glycoside</Keyword>
<Keyword MajorTopicYN="N">Experimental autoimmune encephalomyelitis</Keyword>
<Keyword MajorTopicYN="N">JAK/STAT signaling</Keyword>
<Keyword MajorTopicYN="N">Multiple sclerosis</Keyword>
<Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25081505</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-8421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>274</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of neuroimmunology</Title>
<ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation.</ArticleTitle>
<Pagination>
<MedlinePgn>125-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2014.07.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0165-5728(14)00225-2</ELocationID>
<Abstract>
<AbstractText>Inflammation is a pathological hallmark of traumatic brain injury (TBI). Recent evidence suggests that immune cells such as lymphocytes are of particular relevance for lesion development after TBI. FTY720, a sphingosine-1-phosphate (S1P) receptor modulator, sequesters T lymphocytes in lymphoid organs and has been shown to improve outcome in a variety of neurological disease models. We investigated the mode of FTY720 action in models of TBI. Focal cortical cryolesion was induced in C57BL/6 mice treated with FTY720 (1mg/kg) or vehicle immediately before injury. Lesion size was assessed 24h later. Immune cells in the blood and brain were counted by flow cytometry and immunocytochemistry. The integrity of the blood-brain barrier was analyzed using Evans Blue dye. To validate the findings in a diffuse brain trauma model, FTY720-treated mice and controls were subjected to weight drop contusion injury and neurological deficits were assessed until day 7. As expected FTY720 significantly lowered the numbers of circulating lymphocytes and attenuated the invasion of immune cells into the damaged brain parenchyma. However, FTY720 was unable to improve lesion size or functional outcome in both trauma models at either stage, i.e. acute vs chronic. Accordingly, the extent of blood-brain barrier disruption and neuronal apoptosis was similar between FTY720-treated mice and controls. We conclude that pharmacological S1P receptor modulation is an unfavorable strategy to combat TBI. Moreover, our findings put into perspective the pathophysiological relevance of inflammatory cells in traumatic neurodegeneration. </AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mencl</LastName>
<ForeName>Stine</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University Hospital Würzburg, Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hennig</LastName>
<ForeName>Nelli</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hopp</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University Hospital Würzburg, Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schuhmann</LastName>
<ForeName>Michael K</ForeName>
<Initials>MK</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University Hospital Würzburg, Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Albert-Weissenberger</LastName>
<ForeName>Christiane</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University Hospital Würzburg, Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sirén</LastName>
<ForeName>Anna-Leena</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kleinschnitz</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Electronic address: christoph.kleinschnitz@uni-wuerzburg.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Neuroimmunol</MedlineTA>
<NlmUniqueID>8109498</NlmUniqueID>
<ISSNLinking>0165-5728</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011409">Propylene Glycols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3QN8BYN5QF</RegistryNumber>
<NameOfSubstance UI="C098720">fingolimod</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>NGZ37HRE42</RegistryNumber>
<NameOfSubstance UI="D013110">Sphingosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001929">Brain Edema</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001930">Brain Injuries</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004660">Encephalitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008231">Lymphopenia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011409">Propylene Glycols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013110">Sphingosine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Blood–brain barrier</Keyword>
<Keyword MajorTopicYN="N">Edema</Keyword>
<Keyword MajorTopicYN="N">FTY720</Keyword>
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Lymphocytes</Keyword>
<Keyword MajorTopicYN="N">Traumatic brain injury</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24978642</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1530-0307</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>94</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Laboratory investigation; a journal of technical methods and pathology</Title>
<ISOAbbreviation>Lab. Invest.</ISOAbbreviation>
</Journal>
<ArticleTitle>Erythropoietin protects against hemorrhagic blood-brain barrier disruption through the effects of aquaporin-4.</ArticleTitle>
<Pagination>
<MedlinePgn>1042-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/labinvest.2014.84</ELocationID>
<Abstract>
<AbstractText>Erythropoietin (EPO) has protective effects against many neurological diseases, including intracerebral hemorrhage (ICH). Here, we aimed to test EPO's effects on blood-brain barrier (BBB) disruption morphologically and functionally following ICH, which has not been well investigated. We also examined whether the effects were dependent on aquaporin-4 (AQP4). We detected the expression of perihematomal AQP4 and EPO receptor (EPOR) induced by EPO injection at 1, 3 and 7 days after ICH. We also examined the effects of EPO on BBB disruption by ICH in wild-type mice, and tested whether such effects were AQP4 dependent by using AQP4 knock-out mice. Furthermore, we assessed the related signal transduction pathways via astrocyte cultures. We found that EPO highly increased perihematomal AQP4 and EPOR expression. Specifically, EPO led to BBB protection in both types of mice by functionally reducing brain edema and BBB permeability, as well as morphologically suppressing tight junction (TJ) opening and endothelial cell swelling, and increasing expression of the TJ proteins occludin and zonula occluden-1 (ZO-1). Statistical analysis indicated that AQP4 was required for these effects. In addition, EPO upregulated phosphorylation of C-Jun amino-terminal kinase (JNK) and p38-mitogen-activated protein kinase (MAPK) as well as EPOR and AQP4 proteins in cultured astrocytes. The latter was inhibited by JNK and p38-MAPK inhibitors. Our data suggest that EPO protects BBB from disruption after ICH and that the main targets are the TJ proteins occludin and ZO-1. The effects of EPO are associated with increased levels of AQP4, and may occur through activation of JNK and p38-MAPK pathways after binding to EPOR. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chu</LastName>
<ForeName>Heling</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Hongyan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Yuping</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Qiang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Lab Invest</MedlineTA>
<NlmUniqueID>0376617</NlmUniqueID>
<ISSNLinking>0023-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11096-26-7</RegistryNumber>
<NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051401">Aquaporin 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004921">Erythropoietin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008854">Microscopy, Electron</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019108">Tight Junctions</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25046436</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1530-0307</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>94</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Laboratory investigation; a journal of technical methods and pathology</Title>
<ISOAbbreviation>Lab. Invest.</ISOAbbreviation>
</Journal>
<ArticleTitle>MicroRNA-29b inhibits peritoneal fibrosis in a mouse model of peritoneal dialysis.</ArticleTitle>
<Pagination>
<MedlinePgn>978-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/labinvest.2014.91</ELocationID>
<Abstract>
<AbstractText>TGF-β/Smad3 signaling plays a pivotal role in the pathogenesis of peritoneal fibrosis associated with peritoneal dialysis (PD). MicroRNA-29 (miR-29) is known as a potent downstream inhibitor of TGF-β/Smad3 in renal fibrosis. In this study, we examined the therapeutic potential for miR-29b on PD-related peritoneal fibrosis in a mouse model of PD induced by daily infusion of 4.25% dextrose-containing PD fluid (PDF). MiR-29b-expressing plasmid was delivered into the peritoneum via an ultrasound-microbubble-mediated system before and at day 14 after PDF. We found that mice on PD developed peritoneal fibrosis with impaired peritoneal function, which was associated with a loss of miR-29b. In contrast, overexpression of miR-29b before the PDF infusion showed a protective effect on peritoneal fibrosis including EMT and prevented peritoneal dysfunction. Moreover, delayed miR-29b treatment until peritoneal fibrosis was established at day 14 also halted the progression of peritoneal fibrosis at day 28. Further studies identified that blockade of the Sp1-TGF-β/Smad3 pathway may be a mechanism by which miR-29b inhibited peritoneal fibrosis. In conclusion, treatment with miR-29b may represent a novel and effective therapy for PD-associated peritoneal fibrosis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Jian-Wen</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Nephrology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China [2] Li Ka Shing Institute of Health Sciences and Department of Medicine &amp; Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Duan</LastName>
<ForeName>Wen-Juan</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Nephrology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China [2] Li Ka Shing Institute of Health Sciences and Department of Medicine &amp; Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Xiao-Ru</ForeName>
<Initials>XR</Initials>
<AffiliationInfo>
<Affiliation>1] Li Ka Shing Institute of Health Sciences and Department of Medicine &amp; Therapeutics, The Chinese University of Hong Kong, Hong Kong, China [2] Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meng</LastName>
<ForeName>Xiao-Ming</ForeName>
<Initials>XM</Initials>
<AffiliationInfo>
<Affiliation>Li Ka Shing Institute of Health Sciences and Department of Medicine &amp; Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Xue-Qing</ForeName>
<Initials>XQ</Initials>
<AffiliationInfo>
<Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lan</LastName>
<ForeName>Hui-Yao</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>1] Li Ka Shing Institute of Health Sciences and Department of Medicine &amp; Therapeutics, The Chinese University of Hong Kong, Hong Kong, China [2] Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Lab Invest</MedlineTA>
<NlmUniqueID>0376617</NlmUniqueID>
<ISSNLinking>0023-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015342">DNA Probes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C547014">MIRN29 microRNA, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015342">DNA Probes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D023421">Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010530">Peritoneal Dialysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056627">Peritoneal Fibrosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051785">Smad Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016329">Sp1 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25068658</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1530-0307</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>94</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Laboratory investigation; a journal of technical methods and pathology</Title>
<ISOAbbreviation>Lab. Invest.</ISOAbbreviation>
</Journal>
<ArticleTitle>The microbiota regulates susceptibility to Fas-mediated acute hepatic injury.</ArticleTitle>
<Pagination>
<MedlinePgn>938-49</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/labinvest.2014.93</ELocationID>
<Abstract>
<AbstractText>Whereas a significant role for intestinal microbiota in affecting the pathogenesis and progression of chronic hepatic diseases is well documented, the contribution of the intestinal flora to acute liver injury has not been extensively addressed. Elucidating the influence of the intestinal microbiota on acute liver inflammation would be important for better understanding the transition from acute injury to chronic liver disease. Using the Concanavalin A (ConA)-induced liver injury model in laboratory mice, we show that the severity of acute hepatic damage varies greatly among genetically identical mice raised in different environments and harboring distinct microbiota. Through reconstitution of germ-free (GF) mice, and the co-housing of conventional mice, we provide direct evidence that manipulation of the intestinal flora alters susceptibility to ConA-induced liver injury. Through deep sequencing of the fecal microbiome, we observe that the relative abundance of Ruminococcaceae, a Gram(+) family within the class Clostridia, but distinct from segmented filamentous bacteria, is positively associated with the degree of liver damage. Searching for the underlying mechanism(s) that regulate susceptibility to ConA, we provide evidence that the extent of liver injury following triggering of the death receptor Fas varies greatly as a function of the microbiota. We demonstrate that the extent of Fas-induced liver injury increases in GF mice after microbiota reconstitution, and decreases in conventionally raised mice following reduction in intestinal bacterial load, by antibiotic treatment. We also show that the regulation of sensitivity to Fas-induced liver injury is dependent upon the toll-like receptor signaling molecule MyD88. In conclusion, the status and composition of the intestinal microbiota determine the susceptibility to ConA-induced acute liver injury. The microbiota acts as a rheostat, actively modulating the extent of liver damage in response to Fas triggering. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Celaj</LastName>
<ForeName>Stela</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gleeson</LastName>
<ForeName>Michael W</ForeName>
<Initials>MW</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deng</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Toole</LastName>
<ForeName>George A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hampton</LastName>
<ForeName>Thomas H</ForeName>
<Initials>TH</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Toft</LastName>
<ForeName>Martin F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo>
<Affiliation>Taconic Farms Inc., One Hudson City Center, Hudson, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morrison</LastName>
<ForeName>Hilary G</ForeName>
<Initials>HG</Initials>
<AffiliationInfo>
<Affiliation>Josephine Bay Paul Center for Comparative Molecular Biology and Evolution, Marine Biological Laboratory, Woods Hole, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sogin</LastName>
<ForeName>Mitchell L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo>
<Affiliation>Josephine Bay Paul Center for Comparative Molecular Biology and Evolution, Marine Biological Laboratory, Woods Hole, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Putra</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suriawinata</LastName>
<ForeName>Arief A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gorham</LastName>
<ForeName>James D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA [2] Department of Pathology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 GM103415</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30GM103415</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AI078195</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AI078195</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 AI083256</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37AI83256</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32AI007363</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Lab Invest</MedlineTA>
<NlmUniqueID>0376617</NlmUniqueID>
<ISSNLinking>0023-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019014">Antigens, CD95</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507780">Myd88 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019014">Antigens, CD95</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004198">Disease Susceptibility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008107">Liver Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D064307">Microbiota</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053594">Myeloid Differentiation Factor 88</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS606704 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4152405 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25068659</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1530-0307</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>94</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Laboratory investigation; a journal of technical methods and pathology</Title>
<ISOAbbreviation>Lab. Invest.</ISOAbbreviation>
</Journal>
<ArticleTitle>TRPA1 is required for TGF-β signaling and its loss blocks inflammatory fibrosis in mouse corneal stroma.</ArticleTitle>
<Pagination>
<MedlinePgn>1030-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/labinvest.2014.85</ELocationID>
<Abstract>
<AbstractText>We examined whether the loss of transient receptor potential ankyrin 1 (TRPA1), an irritant-sensing ion channel, or TRPA1 antagonist treatment affects the severity inflammation and scarring during tissue wound healing in a mouse cornea injury model. In addition, the effects of the absence of TRPA1 on transforming growth factor β1 (TGF-β1)-signaling activation were studied in cell culture. The lack of TRPA1 in cultured ocular fibroblasts attenuated expression of TGF-β1, interleukin-6, and α-smooth muscle actin, a myofibroblast the marker, but suppressed the activation of Smad3, p38 MAPK, ERK, and JNK. Stroma of the healing corneas of TRPA1(-/-) knockout (KO) mice appeared more transparent compared with those of wild-type mice post-alkali burn. Eye globe diameters were measured from photographs. An examination of the corneal surface and eye globes suggested the loss of TRPA1 suppressed post-alkali burn inflammation and fibrosis/scarring, which was confirmed by histology, immunohistochemistry, and gene expression analysis. Reciprocal bone marrow transplantation between mice showed that KO corneal tissue resident cells, but not KO bone marrow-derived cells, are responsible for KO mouse wound healing with reduced inflammation and fibrosis. Systemic TRPA1 antagonists reproduced the KO phenotype of healing. In conclusion, a loss or blocking of TRPA1 in mice reduces inflammation and fibrosis/scarring in the corneal stroma during wound healing following an alkali burn. The responsible mechanism may include the inhibition of TGF-β1-signaling cascades in fibroblasts by attenuated TRPA1 signaling. Inflammatory cells are considered to have a minimum involvement in the exhibition of the KO phenotype after injury. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Yuka</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Wakayama Medical University, Wakayama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shirai</LastName>
<ForeName>Kumi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Wakayama Medical University, Wakayama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reinach</LastName>
<ForeName>Peter S</ForeName>
<Initials>PS</Initials>
<AffiliationInfo>
<Affiliation>Wenzhou Medical University School of Ophthalmology and Optometry, Wenzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kitano-Izutani</LastName>
<ForeName>Ai</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Wakayama Medical University, Wakayama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miyajima</LastName>
<ForeName>Masayasu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory Animal Center, Wakayama Medical University, Wakayama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Flanders</LastName>
<ForeName>Kathleen C</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jester</LastName>
<ForeName>James V</ForeName>
<Initials>JV</Initials>
<AffiliationInfo>
<Affiliation>University of California, Irvine, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tominaga</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Signaling, Okazaki Institute for Integrative Bioscience, National Institute of Natural Science, Okazaki, Aichi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saika</LastName>
<ForeName>Shizuya</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Wakayama Medical University, Wakayama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Lab Invest</MedlineTA>
<NlmUniqueID>0376617</NlmUniqueID>
<ISSNLinking>0023-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050051">Transient Receptor Potential Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C475685">Trpa1 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003316">Corneal Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005126">Eye Burns</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005355">Fibrosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050051">Transient Receptor Potential Channels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014945">Wound Healing</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25183503</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0231-424X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>101</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Acta physiologica Hungarica</Title>
<ISOAbbreviation>Acta Physiol Hung</ISOAbbreviation>
</Journal>
<ArticleTitle>Different signal pathways regulate IL-1β-induced mature and primary miRNA-146a expression in human alveolar epithelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>282-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1556/APhysiol.101.2014.3.3</ELocationID>
<Abstract>
<AbstractText>It was known that IL-1β-induced rapid expression of miR-146a, which regulated the secretion of inflammatory chemokines in human A549 alveolar epithelial cells. However, little is known about the level of primary miR-146a and the downstream biogenesis of miR-146a in A549 cells. We examined the levels of primary miR-146a and mature miR-146a in A549 cells following treatment with pharmacological inhibitors of IKK-2 (TPCA-1), MEK-1/2 (PD098059), JNK-1/2 (SP600125), p38 MAPK (SB 203580) and PI-3k (LY294002). Our studies showed that exposure to PD98059, TPCA-1 and LY294002 resulted in a dose-dependent reduction in the expression of mature miR-146a while the primary miR-146a expression was not changed by any inhibitor. Western blot showed that IL-1β induced an increase of TRBP at 30 min, following by an extended expression at 24 h compared to the non-IL-1β controls in A549 cells. In conclusion, our studies indicated that miR-146a expression in alveolar epithelial cells was regulated at the post-transcriptional level via a MEK-1/2 and IKK2 pathway, and also for the first time via PI-3k pathway. The longer expression of TRBP following stimulation with IL-1β suggests that TRBP might play a role in the process of regulating the processing of primary miR-146a to mature miR-146a in human alveolar epithelial cells. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Xiaoying</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Xi'an Jiaotong University Department of Genetics and Molecular Biology, School of Medicine 76 Yanta West Road Xi'an, Shaanxi 710061 China University of Manchester NIHR Translational Research Facility in Respiratory Medicine Group, School of Translational Medicine Manchester UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Hungary</Country>
<MedlineTA>Acta Physiol Hung</MedlineTA>
<NlmUniqueID>8309201</NlmUniqueID>
<ISSNLinking>0231-424X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060565">Argonaute Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C466422">EIF2C2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C542542">MIRN146 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486559">NCOA6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056918">Nuclear Receptor Coactivators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C408087">DICER1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C517918">DROSHA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="D043244">Ribonuclease III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060565">Argonaute Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056918">Nuclear Receptor Coactivators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011650">Pulmonary Alveoli</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043244">Ribonuclease III</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">alveolar epithelial cells</Keyword>
<Keyword MajorTopicYN="N">inflammation</Keyword>
<Keyword MajorTopicYN="N">lung</Keyword>
<Keyword MajorTopicYN="N">miR-146a</Keyword>
<Keyword MajorTopicYN="N">miRNA</Keyword>
<Keyword MajorTopicYN="N">miRNAs biogenesis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25182392</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1428-345X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>18</Volume>
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 Jul-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Developmental period medicine</Title>
<ISOAbbreviation>Dev Period Med</ISOAbbreviation>
</Journal>
<ArticleTitle>The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.</ArticleTitle>
<Pagination>
<MedlinePgn>285-96</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The RASopathies are a class of developmental syndromes. Each of them exhibits distinctive phenotypic features, although there are numerous overlapping clinical manifestations that include: dysmorphic craniofacial features, congenital cardiac defects, skin abnormalities, varying degrees of intellectual disability and increased risk of malignancies. These disorders include: Noonan syndrome, Costello syndrome, LEOPARD syndrome, cardio-facio-cutaneous syndrome (CFC), capillary malformation-arteriovenous malformation syndrome (CM-AVM), Legius syndrome and neurofibromatosis type 1 (NF1). The RASopathies are associated with the presence of germline mutation in genes encoding specific proteins of the RAS/mitogen - activated protein kinase (MAPK) pathway that plays a crucial role in embryonic and postnatal development. In this review, we present the clinical and molecular features of selected syndromes from the RASopathies group.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bezniakow</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Genetics, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland, tel. (+48 22) 32-77-361, tel. (+48) 504-125-360, e-mail: natalia.bezniakow@imid.med.pl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gos</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Obersztyn</LastName>
<ForeName>Ewa</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Dev Period Med</MedlineTA>
<NlmUniqueID>101636421</NlmUniqueID>
<ISSNLinking>1428-345X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C564254">Capillary Malformation-Arteriovenous Malformation</SupplMeshName>
<SupplMeshName Type="Disease" UI="C535579">Cardiofaciocutaneous syndrome</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001165">Arteriovenous Malformations</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002196">Capillaries</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000002">abnormalities</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056685">Costello Syndrome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019465">Craniofacial Abnormalities</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004476">Ectodermal Dysplasia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019066">Facies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005183">Failure to Thrive</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018095">Germ-Line Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006330">Heart Defects, Congenital</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044542">LEOPARD Syndrome</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009456">Neurofibromatosis 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009634">Noonan Syndrome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019339">Port-Wine Stain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25182393</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1428-345X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>18</Volume>
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 Jul-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Developmental period medicine</Title>
<ISOAbbreviation>Dev Period Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.</ArticleTitle>
<Pagination>
<MedlinePgn>297-306</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Neurofibromatosis type I (NF1) is a disease associated with the presence of benign neurofibromas and malignant tumours of the central and peripheral nervous system, that are accompanied by characteristic changes in the skin, such as café-au-lait spots or axillary freckling. In 50% of NF1 patients, the clinical symptoms become apparent below 1st year and in 97%, before the age of 8 years. The disease is mainly caused by the presence of mutation in the NF1 gene that encodes neurofibromin - a protein involved in the regulation of several cellular signaling pathways responsible for cell proliferation and differentiation. Neurofibromin is necessary for embryonic development and involved mainly in the differentiation of neural crest derived cells, mesenchymal cells, neural cells, melanocytes and bone cells. Type I neurofibromatosis is inherited in autosomal dominant manner, nevertheless about 50% of detected mutations are de novo ones. The mutations have full penetrance, although they also have significant pleiotropic effect. Over 1485 different mutations have been identified in the NF1 gene so far, most of which lead to a synthesis of truncated, non-functional protein. It is estimated that the point mutations are responsible for approximately 90% of cases of NF1. The remaining 5-7% of NF1 cases are associated with the presence of a single exon or whole NF1 gene deletion (17q11.2 microdeletion syndrome). The article discusses the role of neurofibromin in cell signaling with the special attention to RAS/MAPK pathway regulation as well as in organism development. Also the basic methods of molecular analysis of NF1 gene are presented in the context of their application in the diagnosis and clinical differentiation of the disease. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Abramowicz</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Genetic, Institute of Mother and Child, 01-211 Warsaw, str. Kasprzaka 17A, phone: 48 22 32 77 176, e-mail: anna.abramowicz@imid.med.pl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gos</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Dev Period Med</MedlineTA>
<NlmUniqueID>101636421</NlmUniqueID>
<ISSNLinking>1428-345X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025542">Neurofibromin 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019080">Cafe-au-Lait Spots</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017353">Gene Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009456">Neurofibromatosis 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025542">Neurofibromin 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017354">Point Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25183867</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>141</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Roles for Hedgehog signaling in adult organ homeostasis and repair.</ArticleTitle>
<Pagination>
<MedlinePgn>3445-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.083691</ELocationID>
<Abstract>
<AbstractText>The hedgehog (HH) pathway is well known for its mitogenic and morphogenic functions during development, and HH signaling continues in discrete populations of cells within many adult mammalian tissues. Growing evidence indicates that HH regulates diverse quiescent stem cell populations, but the exact roles that HH signaling plays in adult organ homeostasis and regeneration remain poorly understood. Here, we review recently identified functions of HH in modulating the behavior of tissue-specific adult stem and progenitor cells during homeostasis, regeneration and disease. We conclude that HH signaling is a key factor in the regulation of adult tissue homeostasis and repair, acting via multiple different routes to regulate distinct cellular outcomes, including maintenance of plasticity, in a context-dependent manner. </AbstractText>
<CopyrightInformation>© 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Petrova</LastName>
<ForeName>Ralitsa</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Developmental Biology Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA BCMB Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Joyner</LastName>
<ForeName>Alexandra L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>Developmental Biology Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA BCMB Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA joynera@mskcc.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053687">Adult Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005855">Germ Layers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006706">Homeostasis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4197719 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adult stem cells</Keyword>
<Keyword MajorTopicYN="N">Hedgehog signaling</Keyword>
<Keyword MajorTopicYN="N">Homeostasis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25183873</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>141</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>NRP1-mediated Sema3A signals coordinate laminar formation in the developing chick optic tectum.</ArticleTitle>
<Pagination>
<MedlinePgn>3572-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.110205</ELocationID>
<Abstract>
<AbstractText>The optic tectum comprises multiple layers, which are formed by radial and tangential migration during development. Here, we report that Neuropilin 1 (NRP1)-mediated Sema3A signals are involved in the process of tectal laminar formation, which is elaborated by tangential migration. In the developing chick tectum, NRP1, a receptor for Sema3A, is expressed in microtubule-associated protein 2 (MAP2)-positive intermediate layers IV and V. Sema3A itself is a diffusible guidance factor and is expressed in the overlying layer VI. Using stable fluorescent labeling of tectal cells, we show that MAP2-positive intermediate layers are formed by the neurons that have been dispersed by tangential migration along the tectal efferent axons. When Sema3A was mis-expressed during laminar formation, local Sema3A repelled the tangential migrants, thus eliminating MAP2-positive neurons that expressed NRP1. Furthermore, in the absence of the MAP2-positive neurons, tectal layers were disorganized into an undulated form, indicating that MAP2-positive intermediate layers are required for proper laminar formation. These results suggest that NRP1-mediated Sema3A signals provide repulsive signals for MAP2-positive neurons to segregate tectal layers, which is important in order to coordinate laminar organization of the optic tectum. </AbstractText>
<CopyrightInformation>© 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Watanabe</LastName>
<ForeName>Yuji</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Neurobiology, Graduate School of Life Sciences, Tohoku University, Aoba-ku, Sendai 980-8575, Japan Institute of Development, Aging &amp; Cancer, Tohoku University, Sendai 980-8575, Japan Department of Neuroanatomy and Embryology, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan yuji-w@fmu.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sakuma</LastName>
<ForeName>Chie</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroanatomy and Embryology, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yaginuma</LastName>
<ForeName>Hiroyuki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroanatomy and Embryology, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D040121">Semaphorin-3A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>144713-63-3</RegistryNumber>
<NameOfSubstance UI="D039942">Neuropilin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>G34N38R2N1</RegistryNumber>
<NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001973">Bromodeoxyuridine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002642">Chick Embryo</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018274">Electroporation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005453">Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017403">In Situ Hybridization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018613">Microscopy, Confocal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039942">Neuropilin-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038081">Organogenesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040121">Semaphorin-3A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013477">Superior Colliculi</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cell migration</Keyword>
<Keyword MajorTopicYN="N">Chick</Keyword>
<Keyword MajorTopicYN="N">Laminar formation</Keyword>
<Keyword MajorTopicYN="N">NRP1</Keyword>
<Keyword MajorTopicYN="N">Optic tectum</Keyword>
<Keyword MajorTopicYN="N">Sema3A</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25097240</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1552-5783</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Investigative ophthalmology &amp; visual science</Title>
<ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Retinal ischemia/reperfusion injury is mediated by Toll-like receptor 4 activation of NLRP3 inflammasomes.</ArticleTitle>
<Pagination>
<MedlinePgn>5466-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.14-14380</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Retinal ischemia/reperfusion (IR) is common in eye disorders. Pattern-recognition receptors (PRRs) are reported to initiate sterile inflammatory response. The role of PRRs in retinal IR injury is currently unknown. Thus, we investigated the expression and function of membrane and cytoplasmic PRRs during retinal IR.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Retinal IR was induced in adult Brown Norway rats by clipping the retinal vessels for 30 minutes. RNA and proteins were extracted during the course of reperfusion, and the expression levels of the following proteins were determined: Toll-like receptor 2 (TLR2), TLR4, myeloid differentiation factor 88 (MyD88), TNF receptor-associated factor 6 (TRAF6), nuclear factor-κB (NF-κB), nucleotide-binding oligomerization domain-like receptor with pyrin domain protein 1 (NLRP1), NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, IL-1β, and IL-18. TLR4 expression in the retina was studied using immunohistochemistry. In addition, a TLR4 inhibitor was injected into the vitreous body as a therapeutic agent. After the treatment of TLR4 inhibitors, the levels of the above factors were evaluated, the apoptosis of cells in the retina, expression of cleaved-caspase-3 (c-casp-3), death of retinal ganglion cells, and the retina electroretinography was assessed.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">After releasing the artery clamp, the retinal vessels were reperfused in 5 minutes. During the reperfusion, TLR4, MyD88, TRAF6, NF-κB, NLRP1, NLRP3, mature IL-1β, and IL-18 were upregulated, but not TLR2. In the IR model, TLR4 was highly expressed in ganglion cell and glia cell. Additionally, the inhibition of TLR4 significantly downregulated the activation of NLRP3, but not NLRP1, and the secretion of mature IL-1β and IL-18 also were inhibited. Moreover, the TLR4 inhibitor partially attenuated the injury of the retina, including alleviated retina apoptosis, downregulated c-casp-3 expression, rescued retinal ganglion cells death, and restored retina function.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that TLR4-signaling activation, triggered by damage-associated molecular patterns, regulates the activation of the NLRP3 inflammasomes and is responsible for the function of the retina in retinal IR injury.</AbstractText>
<CopyrightInformation>Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>Yun</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>Yujing</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Lvzhen</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Wenzhen</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bian</LastName>
<ForeName>Zongmei</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Mingwei</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xiaoxin</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People's Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
<NlmUniqueID>7703701</NlmUniqueID>
<ISSNLinking>0146-0404</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C573346">NOD-like receptor 3, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051192">Receptors, Pattern Recognition</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003593">Cytoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058847">Inflammasomes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018160">Receptors, Cytoplasmic and Nuclear</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051192">Receptors, Pattern Recognition</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015427">Reperfusion Injury</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012164">Retinal Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">IL-18</Keyword>
<Keyword MajorTopicYN="N">IL-1β</Keyword>
<Keyword MajorTopicYN="N">Toll-like receptor 4</Keyword>
<Keyword MajorTopicYN="N">inflammasomes</Keyword>
<Keyword MajorTopicYN="N">ischemia-reperfusion</Keyword>
<Keyword MajorTopicYN="N">retina</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24518205</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>G-CSF regulates hematopoietic stem cell activity, in part, through activation of Toll-like receptor signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>1851-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.68</ELocationID>
<Abstract>
<AbstractText>Recent studies demonstrate that inflammatory signals regulate hematopoietic stem cells (HSCs). Granulocyte colony-stimulating factor (G-CSF) is often induced with infection and has a key role in the stress granulopoiesis response. However, its effects on HSCs are less clear. Herein, we show that treatment with G-CSF induces expansion and increased quiescence of phenotypic HSCs, but causes a marked, cell-autonomous HSC repopulating defect associated with induction of Toll-like receptor (TLR) expression and signaling. The G-CSF-mediated expansion of HSCs is reduced in mice lacking TLR2, TLR4 or the TLR signaling adaptor MyD88. Induction of HSC quiescence is abrogated in mice lacking MyD88 or in mice treated with antibiotics to suppress intestinal flora. Finally, loss of TLR4 or germ-free conditions mitigates the G-CSF-mediated HSC repopulating defect. These data suggest that low-level TLR agonist production by commensal flora contributes to the regulation of HSC function and that G-CSF negatively regulates HSCs, in part, by enhancing TLR signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schuettpelz</LastName>
<ForeName>L G</ForeName>
<Initials>LG</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borgerding</LastName>
<ForeName>J N</ForeName>
<Initials>JN</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christopher</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gopalan</LastName>
<ForeName>P K</ForeName>
<Initials>PK</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Romine</LastName>
<ForeName>M P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Herman</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Woloszynek</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Greenbaum</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Link</LastName>
<ForeName>D C</ForeName>
<Initials>DC</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K12-HD076224</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA91842</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL060772</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL60772</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507780">Myd88 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016188">Receptors, Granulocyte Colony-Stimulating Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>143011-72-7</RegistryNumber>
<NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C497971">Flt3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D051941">fms-Like Tyrosine Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016179">Granulocyte Colony-Stimulating Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006412">Hematopoietic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053594">Myeloid Differentiation Factor 88</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016188">Receptors, Granulocyte Colony-Stimulating Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051941">fms-Like Tyrosine Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS571508 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4130805 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24552990</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>1819-27</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.78</ELocationID>
<Abstract>
<AbstractText>Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphoblasts through poorly defined mechanisms. Normal T-cell progenitors are hypersensitive to mitochondrial apoptosis, a phenotype that is dependent on the expression of proapoptotic BIM. In a conditional zebrafish model, MYC downregulation induced BIM expression in T-lymphoblasts, an effect that was blunted by expression of constitutively active AKT. In human T-ALL cell lines and treatment-resistant patient samples, treatment with MYC or PI3K-AKT pathway inhibitors each induced BIM upregulation and apoptosis, indicating that BIM is repressed downstream of MYC and PI3K-AKT in high-risk T-ALL. Restoring BIM function in human T-ALL cells using a stapled peptide mimetic of the BIM BH3 domain had therapeutic activity, indicating that BIM repression is required for T-ALL viability. In the zebrafish model, where MYC downregulation induces T-ALL regression via mitochondrial apoptosis, T-ALL persisted despite MYC downregulation in 10% of bim wild-type zebrafish, 18% of bim heterozygotes and in 33% of bim homozygous mutants (P=0.017). We conclude that downregulation of BIM represents a key survival signal downstream of oncogenic MYC and PI3K-AKT signaling in treatment-resistant T-ALL. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Reynolds</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roderick</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>LaBelle</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [3] Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bird</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mathieu</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bodaar</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Colon</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pyati</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stevenson</LastName>
<ForeName>K E</ForeName>
<Initials>KE</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Harris</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Silverman</LastName>
<ForeName>L B</ForeName>
<Initials>LB</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sallan</LastName>
<ForeName>S E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bradner</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Neuberg</LastName>
<ForeName>D S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Look</LastName>
<ForeName>A T</ForeName>
<Initials>AT</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Walensky</LastName>
<ForeName>L D</ForeName>
<Initials>LD</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kelliher</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gutierrez</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000000202499007</Identifier>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA167124</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08 CA151450</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA096899</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA167124</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C110430">Bcl-2-like protein 11</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C549214">MIRN19 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489427">MYC protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>RUJ6Z9Y0DT</RegistryNumber>
<NameOfSubstance UI="C531198">dactolisib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054218">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016271">Proto-Oncogene Proteins c-myc</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011804">Quinolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS566969 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4139485 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24569779</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.</ArticleTitle>
<Pagination>
<MedlinePgn>1872-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.84</ELocationID>
<Abstract>
<AbstractText>Transforming growth factor beta (TGF-β) has an important role in mediating T-cell suppression in B-cell non-Hodgkin lymphoma (NHL). However, the underlying mechanism responsible for TGF-β-mediated inhibition of effector memory T (Tm) cells is largely unknown. As reported here, we show that exhaustion is a major mechanism by which TGF-β inhibits Tm cells, and TGF-β mediated exhaustion is associated with upregulation of CD70. We found that TGF-β upregulates CD70 expression on effector Tm cells while it preferentially induces Foxp3 expression in naive T cells. CD70 induction by TGF-β is Smad3-dependent and involves IL-2/Stat5 signaling. CD70+ T cells account for TGF-β-induced exhaustion of effector Tm cells. Both TGF-β-induced and preexisting intratumoral CD70+ effector Tm cells from B-cell NHL have an exhausted phenotype and express higher levels of PD-1 and TIM-3 compared with CD70- T cells. Signaling transduction, proliferation and cytokine production are profoundly decreased in these cells, and they are highly susceptible to apoptosis. Clinically, intratumoral CD70-expressing T cells are prevalent in follicular B-cell lymphoma (FL) biopsy specimens, and increased numbers of intratumoral CD70+ T cells correlate with an inferior patient outcome. These findings confirm TGF-β-mediated effector Tm cell exhaustion as an important mechanism of immune suppression in B-cell NHL.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Z-Z</ForeName>
<Initials>ZZ</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grote</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xiu</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Tongji Hospital, Tongji University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ziesmer</LastName>
<ForeName>S C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Price-Troska</LastName>
<ForeName>T L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hodge</LastName>
<ForeName>L S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yates</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Novak</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ansell</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA015083</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA097274</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA97274</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018127">Antigens, CD27</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053282">Antigens, CD70</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505771">CD70 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C448908">HAVCR2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050799">STAT5 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>J Pharmacol Exp Ther. 1998 Dec;287(3):1105-12</RefSource>
<PMID Version="1">9864299</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Gene Ther. 1999 May 1;10(7):1095-103</RefSource>
<PMID Version="1">10340542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunol. 2005 Jan;17(1):35-44</RefSource>
<PMID Version="1">15557315</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2005 May 15;174(10):6212-9</RefSource>
<PMID Version="1">15879118</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2005 Jun 15;65(12):5428-38</RefSource>
<PMID Version="1">15958592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2005 Aug;41(12):1794-801</RefSource>
<PMID Version="1">16043348</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lupus. 2005;14(8):598-606</RefSource>
<PMID Version="1">16175931</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2006 Jun 15;176(12):7726-35</RefSource>
<PMID Version="1">16751420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2006 Sep;25(3):455-71</RefSource>
<PMID Version="1">16973386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2006 Sep;25(3):441-54</RefSource>
<PMID Version="1">16973387</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2006 Sep 21;443(7109):350-4</RefSource>
<PMID Version="1">16921384</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2006 Nov;80(22):11398-403</RefSource>
<PMID Version="1">16956940</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 May 15;109(10):4368-75</RefSource>
<PMID Version="1">17227828</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Jun 1;109(11):4810-5</RefSource>
<PMID Version="1">17311995</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2007 Aug 1;179(3):1979-87</RefSource>
<PMID Version="1">17641065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2007 Aug 15;179(4):2609-15</RefSource>
<PMID Version="1">17675524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Oct 1;110(7):2537-44</RefSource>
<PMID Version="1">17615291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2008 Mar;82(6):3154-60</RefSource>
<PMID Version="1">18160439</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2009 Jan 1;182(1):718-25</RefSource>
<PMID Version="1">19109206</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2009 May 1;182(9):5352-62</RefSource>
<PMID Version="1">19380782</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Rev. 2009 May;229(1):216-31</RefSource>
<PMID Version="1">19426224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2009 Jul 1;69(13):5522-30</RefSource>
<PMID Version="1">19509224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2009 Jul 17;31(1):145-57</RefSource>
<PMID Version="1">19604493</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Aug 20;114(8):1528-36</RefSource>
<PMID Version="1">19420358</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Aug 20;114(8):1537-44</RefSource>
<PMID Version="1">19423728</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Histochem Cytochem. 2009 Oct;57(10):899-905</RefSource>
<PMID Version="1">19365090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Immunol. 2010 Apr;40(4):1107-17</RefSource>
<PMID Version="1">20140903</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Neurosurg. 2010 Aug;113(2):280-5</RefSource>
<PMID Version="1">19961309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2010 Sep 27;207(10):2175-86</RefSource>
<PMID Version="1">20819923</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2010 Sep 27;207(10):2187-94</RefSource>
<PMID Version="1">20819927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2011 Jul;85(13):6168-74</RefSource>
<PMID Version="1">21507976</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Immunol. 2012 Apr;143(1):39-44</RefSource>
<PMID Version="1">22306512</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2012 Apr 2;122(4):1271-82</RefSource>
<PMID Version="1">22426209</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2012 Jul 15;72(14):3664-76</RefSource>
<PMID Version="1">22628427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(3):e59456</RefSource>
<PMID Version="1">23555036</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Chromosomes Cancer. 2013 Aug;52(8):764-74</RefSource>
<PMID Version="1">23716461</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunopharmacology. 2000 Jul 20;48(2):101-15</RefSource>
<PMID Version="1">10936508</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Surg Pathol. 2000 May;24(5):742-6</RefSource>
<PMID Version="1">10800994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2007 Jun;7(6):443-53</RefSource>
<PMID Version="1">17525753</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Gene Ther. 2000 Dec;7(12):1543-56</RefSource>
<PMID Version="1">11228533</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2002 Jan;3(1):83-90</RefSource>
<PMID Version="1">11743585</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2002 May 1;62(9):2592-9</RefSource>
<PMID Version="1">11980654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2003 Jan 1;170(1):33-40</RefSource>
<PMID Version="1">12496380</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2003 Jan;4(1):49-54</RefSource>
<PMID Version="1">12469117</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunopharmacol. 2003 Feb;3(2):233-45</RefSource>
<PMID Version="1">12586604</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Immunol. 2003 Mar;33(3):806-14</RefSource>
<PMID Version="1">12616501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hepatology. 2003 May;37(5):1189-98</RefSource>
<PMID Version="1">12717401</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2004 May 15;172(10):6039-46</RefSource>
<PMID Version="1">15128787</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2004 Jun 7;199(11):1595-605</RefSource>
<PMID Version="1">15184507</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2004 Jun;50(6):1850-60</RefSource>
<PMID Version="1">15188362</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Gene Ther. 2004 Jul;11(7):497-507</RefSource>
<PMID Version="1">15153937</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1986 May 1;163(5):1037-50</RefSource>
<PMID Version="1">2871125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1998 May 4;187(9):1383-93</RefSource>
<PMID Version="1">9565631</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Gene Ther. 1998 May-Jun;5(3):163-75</RefSource>
<PMID Version="1">9622100</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1998 Dec 21;188(12):2205-13</RefSource>
<PMID Version="1">9858507</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018127">Antigens, CD27</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053282">Antigens, CD70</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007156">Immunologic Memory</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007376">Interleukin-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016393">Lymphoma, B-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050799">STAT5 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS574897</OtherID>
<OtherID Source="NLM">PMC4145058</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24727675</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>An aberrant microRNA signature in childhood T-cell lymphoblastic lymphoma affecting CDKN1B expression, NOTCH1 and growth factor signaling pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>1909-12</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.134</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mussolin</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Istituto di Ricerca Pediatrico Fondazione Citta' della Speranza, Padova, Italy [2] Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera-Universita' di Padova, Padova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Holmes</LastName>
<ForeName>A B</ForeName>
<Initials>AB</Initials>
<AffiliationInfo>
<Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Romualdi</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, University of Padova, Padova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sales</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, University of Padova, Padova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Amore</LastName>
<ForeName>E S G</ForeName>
<Initials>ES</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, San Bortolo Hospital, Vicenza, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghisi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pillon</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera-Universita' di Padova, Padova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rosolen</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>1] Istituto di Ricerca Pediatrico Fondazione Citta' della Speranza, Padova, Italy [2] Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera-Universita' di Padova, Padova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Basso</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Institute for Cancer Genetics, Columbia University, New York, NY, USA [2] Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C436291">CDKN1B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010982">Platelet-Derived Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147604-94-2</RegistryNumber>
<NameOfSubstance UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010982">Platelet-Derived Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054218">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051881">Receptor, Notch1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24940988</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0894-0282</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>27</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular plant-microbe interactions : MPMI</Title>
<ISOAbbreviation>Mol. Plant Microbe Interact.</ISOAbbreviation>
</Journal>
<ArticleTitle>Clavibacter michiganensis subsp. michiganensis Vatr1 and Vatr2 transcriptional regulators are required for virulence in tomato.</ArticleTitle>
<Pagination>
<MedlinePgn>1035-47</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1094/MPMI-02-14-0061-R</ELocationID>
<Abstract>
<AbstractText>The plant pathogen Clavibacter michiganensis subsp. michiganensis is a gram-positive bacterium responsible for wilt and canker disease of tomato. Although disease development is well characterized and diagnosed, molecular mechanisms of C. michiganensis subsp. michiganensis virulence are poorly understood. Here, we identified and characterized two C. michiganensis subsp. michiganensis transcriptional regulators, Vatr1 and Vatr2, that are involved in pathogenicity of C. michiganensis subsp. michiganensis. Vatr1 and Vatr2 belong to TetR and MocR families of transcriptional regulators, respectively. Mutations in their corresponding genes caused attenuated virulence, with the Δvatr2 mutant showing a more dramatic effect than Δvatr1. Although both mutants grew well in vitro and reached a high titer in planta, they caused reduced wilting and canker development in infected plants compared with the wild-type bacterium. They also led to a reduced expression of the ethylene-synthesizing tomato enzyme ACC-oxidase compared with wild-type C. michiganensis subsp. michiganensis and to reduced ethylene production in the plant. Transcriptomic analysis of wild-type C. michiganensis subsp. michiganensis and the two mutants under infection-mimicking conditions revealed that Vatr1 and Vatr2 regulate expression of virulence factors, membrane and secreted proteins, and signal-transducing proteins. A 70% overlap between the sets of genes positively regulated by Vatr1 and Vatr2 suggests that these transcriptional regulators are on the same molecular pathway responsible for C. michiganensis subsp. michiganensis virulence.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Savidor</LastName>
<ForeName>Alon</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chalupowicz</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Teper</LastName>
<ForeName>Doron</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gartemann</LastName>
<ForeName>Karl-Heinz</ForeName>
<Initials>KH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eichenlaub</LastName>
<ForeName>Rudolf</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manulis-Sasson</LastName>
<ForeName>Shulamit</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barash</LastName>
<ForeName>Isaac</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sessa</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Plant Microbe Interact</MedlineTA>
<NlmUniqueID>9107902</NlmUniqueID>
<ISSNLinking>0894-0282</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005030">Ethylenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010937">Plant Growth Regulators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010940">Plant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037521">Virulence Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>91GW059KN7</RegistryNumber>
<NameOfSubstance UI="C036216">ethylene</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.4.-</RegistryNumber>
<NameOfSubstance UI="D000594">Amino Acid Oxidoreductases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.4.3.-</RegistryNumber>
<NameOfSubstance UI="C059460">1-aminocyclopropane-1-carboxylic acid oxidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000192">Actinomycetales</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000594">Amino Acid Oxidoreductases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001426">Bacterial Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005030">Ethylenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015723">Gene Library</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018551">Lycopersicon esculentum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010935">Plant Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010937">Plant Growth Regulators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010940">Plant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017423">Sequence Analysis, RNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017384">Sequence Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014774">Virulence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D037521">Virulence Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25185422</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1433-6510</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>60</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Clinical laboratory</Title>
<ISOAbbreviation>Clin. Lab.</ISOAbbreviation>
</Journal>
<ArticleTitle>C-reactive protein induces pulmonary artery smooth cell proliferation via modulation of ERK1/2, Akt and NF-kappaB pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>1357-63</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">C-reactive protein (CRP) is a biomarker of systemic inflammation, which is also associated with pulmonary artery disease. However, the impact of CRP on cell proliferation of the pulmonary arterial wall has been investigated less. We, therefore, examined the effects and potential mechanisms of CRP on proliferation in human pulmonary artery smooth muscle cells (hPASMC).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">HPASMCs were cultured and stimulated by different concentrations of CRP (5 - 200 microg/mL) for 24 hours. The effects of CRP on proliferation of hPASMCs were examined using the BrDU incorporation assay, and the potential signal pathways including ERK1/2, Akt and NF-kappaB involved in hPASMCs' proliferation were evaluated by the Western blot and electrophoretic mobility shift assays.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">CRP significantly increased proliferation of hPASMCs with a dose-dependent fashion (1.13-fold increase in CRP 5 microg/mL, and 1.84-fold increase in CRP 200 microg/mL versus controls, p &lt; 0.05 and 0.01, respectively). Additionally, CRP could enhance the expression of Akt and ERK1/2 phosphorylation, but had no effects on total protein. Moreover, CRP resulted in the activation of NF-kappaB significantly, which was diminished by PI3K inhibitor wortmannin. The increased expression of phosphorylated ERK1/2 was inhibited by MEK inhibitor PD98095, whereas no such effects of NF-kappaB inhibitor Bay117082 on the expression of Akt and ERK1/2 was found.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The data suggest that CRP directly impacts proliferation of hPASMCs via modulation of Akt, ERK1/2, and NF-kappaB pathways, which may have important implications for treating pulmonary arterial disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Song-Hui</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jian-Jun</ForeName>
<Initials>JJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Clin Lab</MedlineTA>
<NlmUniqueID>9705611</NlmUniqueID>
<ISSNLinking>1433-6510</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C093973">2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C434003">3-(4-methylphenylsulfonyl)-2-propenenitrile</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052002">NF-kappa B p50 Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489548">NFKB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-41-4</RegistryNumber>
<NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="C535150">MAPK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002097">C-Reactive Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005419">Flavonoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019950">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048052">Mitogen-Activated Protein Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032389">Myocytes, Smooth Muscle</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052002">NF-kappa B p50 Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011651">Pulmonary Artery</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013450">Sulfones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">22772426</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1537-453X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>37</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>American journal of clinical oncology</Title>
<ISOAbbreviation>Am. J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.</ArticleTitle>
<Pagination>
<MedlinePgn>289-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/COC.0b013e318248dc1e</ELocationID>
<Abstract>
<AbstractText>Until recently, docetaxel-based chemotherapy was the only established treatment for patients with metastatic hormone refractory prostate cancer (mHRPC). In 2010 to 2011, 3 more agents were shown to be associated with a survival benefit in mHRPC, including the dendritic cell vaccine sipuleucel-T, the 17,20 lyase inhibitor abiraterone, and the taxane cabazitaxel. The improved understanding of prostate cancer biology in recent years led to the development of drugs directed against precise tumorigenesis-associated molecular pathways. Molecular pathways involved in the progression of mHRPC include the androgen receptor, angiogenesis, endothelin receptor, tyrosine kinases (SRC, MET, vascular endothelial growth factor receptor, RET), and the receptor activator of nuclear factor-kB-ligand. This review will focus on recent advances in the standard treatments paradigm, and promising new targeted agents that are being investigated, in mHRPC. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Keizman</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maimon</LastName>
<ForeName>Natalie</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gottfried</LastName>
<ForeName>Maya</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Clin Oncol</MedlineTA>
<NlmUniqueID>8207754</NlmUniqueID>
<ISSNLinking>0277-3732</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000737">Androstenols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053245">RANK Ligand</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017466">Receptors, Endothelin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014020">Tissue Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C511774">sipuleucel-T</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>15H5577CQD</RegistryNumber>
<NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51F690397J</RegistryNumber>
<NameOfSubstance UI="C552428">cabazitaxel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.38</RegistryNumber>
<NameOfSubstance UI="D056657">Cathepsin K</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>G819A456D0</RegistryNumber>
<NameOfSubstance UI="C089740">abiraterone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000726">Androgen Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000737">Androstenols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019496">Cancer Vaccines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056657">Cathepsin K</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053245">RANK Ligand</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017466">Receptors, Endothelin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040262">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043823">Taxoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014020">Tissue Extracts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24737735</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-3699</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>239</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Experimental biology and medicine (Maywood, N.J.)</Title>
<ISOAbbreviation>Exp. Biol. Med. (Maywood)</ISOAbbreviation>
</Journal>
<ArticleTitle>Microscale technologies for regulating human stem cell differentiation.</ArticleTitle>
<Pagination>
<MedlinePgn>1255-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1535370214530369</ELocationID>
<Abstract>
<AbstractText>During development and regeneration, tissues emerge from coordinated sequences of stem cell renewal, specialization, and assembly that are orchestrated by cascades of regulatory factors. This complex in vivo milieu, while necessary to fully recapitulate biology and to properly engineer progenitor cells, is difficult to replicate in vitro. We are just starting to fully realize the importance of the entire context of cell microenvironment-the other cells, three-dimensional matrix, molecular and physical signals. Bioengineered environments that combine tissue-specific transport and signaling are critical to study cellular responses at biologically relevant scales and in settings predictive of human condition. We therefore developed microbioreactors that couple the application of fast dynamic changes in environmental signals with versatile, high-throughput operation and imaging capability. Our base device is a microfluidic platform with an array of microwells containing cells or tissue constructs that are exposed to stable concentration gradients. Mathematical modeling of flow and mass transport can predict the shape of these gradients and the kinetic changes in local concentrations. A single platform, the size of a microscope slide, contains up to 120 biological samples. As an example of application, we describe studies of cell fate specification and mesodermal lineage commitment in human embryonic stem cells and induced pluripotent stem cells. The embryoid bodies formed from these cells were subjected to single and multiple concentration gradients of Wnt3a, Activin A, bone morphogenic protein 4 (BMP4), and their inhibitors, and the gene expression profiles were correlated to the concentration gradients of morphogens to identify the exact conditions for mesodermal differentiation.</AbstractText>
<CopyrightInformation>© 2014 by the Society for Experimental Biology and Medicine.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cimetta</LastName>
<ForeName>Elisa</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vunjak-Novakovic</LastName>
<ForeName>Gordana</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA gv2131@columbia.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>EB002520</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HL076485</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UH2 EB17103</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Biol Med (Maywood)</MedlineTA>
<NlmUniqueID>100973463</NlmUniqueID>
<ISSNLinking>1535-3699</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018929">Cell Culture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058732">Embryoid Bodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055153">Stem Cell Niche</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Human stem cells</Keyword>
<Keyword MajorTopicYN="N">cardiac differentiation</Keyword>
<Keyword MajorTopicYN="N">flow</Keyword>
<Keyword MajorTopicYN="N">gradients</Keyword>
<Keyword MajorTopicYN="N">microscale platforms</Keyword>
<Keyword MajorTopicYN="N">transport</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25040622</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1742-4658</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>281</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The FEBS journal</Title>
<ISOAbbreviation>FEBS J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Proline-serine-threonine phosphatase interacting protein 1 inhibition of T-cell receptor signaling depends on its SH3 domain.</ArticleTitle>
<Pagination>
<MedlinePgn>3844-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.12912</ELocationID>
<Abstract>
<AbstractText>Proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) is an adaptor protein associated with the cytoskeleton that is mainly expressed in hematopoietic cells. Mutations in PSTPIP1 cause the rare autoinflammatory disease called pyogenic arthritis, pyoderma gangrenosum, and acne. We carried out this study to further our knowledge on PSTPIP1 function in T cells, particularly in relation to the phosphatase lymphoid phosphatase (LYP), which is involved in several autoimmune diseases. LYP-PSTPIP1 binding occurs through the C-terminal homology domain of LYP and the F-BAR domain of PSTPIP1. PSTPIP1 inhibits T-cell activation upon T-cell receptor (TCR) and CD28 engagement, regardless of CD2 costimulation. This function of PSTPIP1 depends on the presence of an intact SH3 domain rather than on the F-BAR domain, indicating that ligands of the F-BAR domain, such as the PEST phosphatases LYP and PTP-PEST, are not critical for its negative regulatory role in TCR signaling. Additionally, PSTPIP1 mutations that cause the pyogenic arthritis, pyoderma gangrenosum and acne syndrome do not affect PSTPIP1 function in T-cell activation through the TCR.</AbstractText>
<CopyrightInformation>© 2014 FEBS.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Marcos</LastName>
<ForeName>Tamara</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Biología y Genética Molecular (IBGM), CSIC-Universidad de Valladolid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ruiz-Martín</LastName>
<ForeName>Virginia</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de la Puerta</LastName>
<ForeName>María Luisa</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trinidad</LastName>
<ForeName>Antonio G</ForeName>
<Initials>AG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rodríguez</LastName>
<ForeName>María del Carmen</ForeName>
<Initials>Mdel C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de la Fuente</LastName>
<ForeName>Miguel Angel</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sánchez Crespo</LastName>
<ForeName>Mariano</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alonso</LastName>
<ForeName>Andrés</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bayón</LastName>
<ForeName>Yolanda</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>FEBS J</MedlineTA>
<NlmUniqueID>101229646</NlmUniqueID>
<ISSNLinking>1742-464X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018106">Antigens, CD28</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017252">Antigens, CD3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486382">PSTPIP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D054596">Protein Tyrosine Phosphatase, Non-Receptor Type 22</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C536253">Pyogenic arthritis, pyoderma gangrenosum, and acne</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000152">Acne Vulgaris</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018106">Antigens, CD28</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017252">Antigens, CD3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001170">Arthritis, Infectious</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003598">Cytoskeletal Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054596">Protein Tyrosine Phosphatase, Non-Receptor Type 22</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017511">Pyoderma Gangrenosum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011948">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018909">src Homology Domains</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">PTPN22</Keyword>
<Keyword MajorTopicYN="N">T-cell receptor</Keyword>
<Keyword MajorTopicYN="N">T cell</Keyword>
<Keyword MajorTopicYN="N">proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1)</Keyword>
<Keyword MajorTopicYN="N">pyogenic arthritis, pyoderma gangrenosum and acne (PAPA)</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25040843</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1742-4658</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>281</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The FEBS journal</Title>
<ISOAbbreviation>FEBS J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Functional analysis of the fractalkine gene promoter in human aortic smooth muscle cells exposed to proinflammatory conditions.</ArticleTitle>
<Pagination>
<MedlinePgn>3869-81</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.12921</ELocationID>
<Abstract>
<AbstractText>Fractalkine (Fk) and its receptor CX3C receptor 1 contribute effectively to the atherosclerotic process, mediating the recruitment of leukocytes and promoting the interactions between monocytes/macrophages and smooth muscle cells (SMCs). As Fk expression is significantly increased in SMCs during atherogenesis, we aimed to uncover the detailed molecular mechanisms of transcriptional regulation of the Fk gene. For this purpose, we cloned and characterized the human Fk promoter, and studied the specific roles of different transcription factors in its regulation in human aortic SMCs activated by interferon-γ. In silico analysis of the Fk promoter indicated the presence of binding sites for various inflammatory modulators, such as nuclear factor-κB (NF-κB), signal transducer and activator of transcription (STAT)1/STAT3, and activator protein-1. Using a luciferase reporter plasmid, we identified a 2046-bp region spanning the transcriptional start point of the Fk gene, which has strong constitutive promoter activity in SMCs. The effects of interferon-γ on both Fk reporter activity and endogenous transcription were abolished by silencing NF-κB, STAT1, and STAT3. Transient overexpression of p65/NF-κB and STAT1/STAT3 increased Fk promoter activity, whereas c-Jun/activator protein-1 overexpression had no effect. The results obtained with chromatin immunoprecipitation assays revealed the existence of physical interactions of p65 and STAT1/STAT3 with the predicted elements of the Fk promoter. Moreover, Fk-promoted monocyte chemotaxis was dependent on the janus kinase-STAT pathway. Investigation of the detailed molecular mechanisms by cloning and characterizing potential transcriptional response elements has identified the Fk regulatory mechanism in activated human SMCs. </AbstractText>
<CopyrightInformation>© 2014 FEBS.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gan</LastName>
<ForeName>Ana-Maria</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Butoi</LastName>
<ForeName>Elena</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manea</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pirvulescu</LastName>
<ForeName>Monica Madalina</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stan</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Simion</LastName>
<ForeName>Viorel</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Calin</LastName>
<ForeName>Manuela</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Simionescu</LastName>
<ForeName>Maya</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manduteanu</LastName>
<ForeName>Ileana</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>FEBS J</MedlineTA>
<NlmUniqueID>101229646</NlmUniqueID>
<ISSNLinking>1742-464X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054428">Chemokine CX3CL1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050794">STAT1 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494079">STAT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001011">Aorta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054428">Chemokine CX3CL1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032389">Myocytes, Smooth Muscle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050794">STAT1 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018808">Transcription Factor AP-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">fractalkine promoter</Keyword>
<Keyword MajorTopicYN="N">interferon-γ</Keyword>
<Keyword MajorTopicYN="N">nuclear factor-κB (NF-κB)</Keyword>
<Keyword MajorTopicYN="N">signal transducer and activator of transcription (STAT)1/STAT3</Keyword>
<Keyword MajorTopicYN="N">smooth muscle cells</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25051991</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1742-4658</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>281</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The FEBS journal</Title>
<ISOAbbreviation>FEBS J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mitochondrial dynamics and the innate antiviral immune response.</ArticleTitle>
<Pagination>
<MedlinePgn>3791-802</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.12940</ELocationID>
<Abstract>
<AbstractText>The innate immune system has a key role in the mammalian immune response. In the cytosol, RNA viruses are sensed by the retinoic acid-inducible gene-I-like receptors, which trigger a complex signaling cascade in which mitochondrial antiviral signaling protein plays a central role in mediating the innate host response through the induction of antiviral and inflammatory responses. Hence, the mitochondrion is now emerging as a fundamental hub for innate antiviral immunity beyond its known roles in metabolic processes and the control of programmed cell death. This review summarizes the findings related to mitochondrial antiviral signaling protein, and mitochondria and their dynamics, in the innate immune response to RNA viruses. </AbstractText>
<CopyrightInformation>© 2014 FEBS.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pourcelot</LastName>
<ForeName>Marie</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR_S 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud P11, Orsay, France; Equipe Labellisée Ligue contre le Cancer, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arnoult</LastName>
<ForeName>Damien</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>FEBS J</MedlineTA>
<NlmUniqueID>101229646</NlmUniqueID>
<ISSNLinking>1742-464X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505371">VISA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C452820">DDX58 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D063154">Mitochondrial Dynamics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012328">RNA Viruses</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">innate immunity</Keyword>
<Keyword MajorTopicYN="N">mitochondria</Keyword>
<Keyword MajorTopicYN="N">mitochondrial antiviral signaling protein</Keyword>
<Keyword MajorTopicYN="N">mitochondrial dynamics</Keyword>
<Keyword MajorTopicYN="N">retinoic acid-inducible gene-I (RIG-I)-like receptors</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25184676</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1549-5477</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Genes &amp; development</Title>
<ISOAbbreviation>Genes Dev.</ISOAbbreviation>
</Journal>
<ArticleTitle>Pax6-dependent, but β-catenin-independent, function of Bcl9 proteins in mouse lens development.</ArticleTitle>
<Pagination>
<MedlinePgn>1879-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1101/gad.246140.114</ELocationID>
<Abstract>
<AbstractText>Bcl9 and Bcl9l (Bcl9/9l) encode Wnt signaling components that mediate the interaction between β-catenin and Pygopus (Pygo) via two evolutionarily conserved domains, HD1 and HD2, respectively. We generated mouse strains lacking these domains to probe the β-catenin-dependent and β-catenin-independent roles of Bcl9/9l and Pygo during mouse development. While lens development is critically dependent on the presence of the HD1 domain, it is not affected by the lack of the HD2 domain, indicating that Bcl9/9l act in this context in a β-catenin-independent manner. Furthermore, we uncover a new regulatory circuit in which Pax6, the master regulator of eye development, directly activates Bcl9/9l transcription. </AbstractText>
<CopyrightInformation>© 2014 Cantù et al.; Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cantù</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zimmerli</LastName>
<ForeName>Dario</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hausmann</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Valenta</LastName>
<ForeName>Tomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moor</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne, School of Life Sciences, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aguet</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne, School of Life Sciences, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Basler</LastName>
<ForeName>Konrad</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland; basler@imls.uzh.ch.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Genes Dev</MedlineTA>
<NlmUniqueID>8711660</NlmUniqueID>
<ISSNLinking>0890-9369</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C111180">BCL9 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C568071">BCL9L protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C086056">PAX6 protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051761">Paired Box Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495570">pygopus 2 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005136">Eye Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055879">Gene Knock-In Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007908">Lens, Crystalline</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051761">Paired Box Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051153">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4197948 [Available on 03/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Bcl9</Keyword>
<Keyword MajorTopicYN="N">Pax6</Keyword>
<Keyword MajorTopicYN="N">Pygopus</Keyword>
<Keyword MajorTopicYN="N">Wnt</Keyword>
<Keyword MajorTopicYN="N">lens induction</Keyword>
<Keyword MajorTopicYN="N">mouse</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25184679</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1549-5477</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Genes &amp; development</Title>
<ISOAbbreviation>Genes Dev.</ISOAbbreviation>
</Journal>
<ArticleTitle>The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2.</ArticleTitle>
<Pagination>
<MedlinePgn>1929-39</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1101/gad.243717.114</ELocationID>
<Abstract>
<AbstractText>Cell type-specific conditional activation of oncogenic K-Ras is a powerful tool for investigating the cell of origin of adenocarcinomas in the mouse lung. Our previous studies showed that K-Ras activation with a CC10(Scgb1a1)-CreER driver leads to adenocarcinoma in a subset of alveolar type II cells and hyperplasia in the bronchioalveolar duct region. However, no tumors develop in the bronchioles, although recombination occurs throughout this region. To explore underlying mechanisms, we simultaneously modulated either Notch signaling or Sox2 levels in the CC10+ cells along with activation of K-Ras. Inhibition of Notch strongly inhibits adenocarcinoma formation but promotes squamous hyperplasia in the alveoli. In contrast, activation of Notch leads to widespread Sox2+, Sox9+, and CC10+ papillary adenocarcinomas throughout the bronchioles. Chromatin immunoprecipitation demonstrates Sox2 binding to NOTCH1 and NOTCH2 regulatory regions. In transgenic mouse models, overexpression of Sox2 leads to a significant reduction of Notch1 and Notch2 transcripts, while a 50% reduction in Sox2 leads to widespread papillary adenocarcinoma in the bronchioles. Taken together, our data demonstrate that the cell of origin of K-Ras-induced tumors in the lung depends on levels of Sox2 expression affecting Notch signaling. In addition, the subtype of tumors arising from type II cells is determined in part by Notch activation or suppression.</AbstractText>
<CopyrightInformation>© 2014 Xu et al.; Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Xia</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Duke Medicine, Durham, North Carolina 27710, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Lingling</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Duke Medicine, Durham, North Carolina 27710, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Futtner</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Duke Medicine, Durham, North Carolina 27710, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schwab</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Duke Medicine, Durham, North Carolina 27710, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rampersad</LastName>
<ForeName>Rishi R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Duke Medicine, Durham, North Carolina 27710, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Yun</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Tsingua University, Beijing 100084, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sporn</LastName>
<ForeName>Thomas A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Duke Medicine, Durham, North Carolina 27710, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hogan</LastName>
<ForeName>Brigid L M</ForeName>
<Initials>BL</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Duke Medicine, Durham, North Carolina 27710, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Onaitis</LastName>
<ForeName>Mark W</ForeName>
<Initials>MW</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Duke Medicine, Durham, North Carolina 27710, USA; mark.onaitis@dm.duke.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Genes Dev</MedlineTA>
<NlmUniqueID>8711660</NlmUniqueID>
<ISSNLinking>0890-9369</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527783">Sox2 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011905">Genes, ras</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011650">Pulmonary Alveoli</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051880">Receptors, Notch</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055748">SOXB1 Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4197950 [Available on 03/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">K-Ras</Keyword>
<Keyword MajorTopicYN="N">Notch</Keyword>
<Keyword MajorTopicYN="N">Sox2</Keyword>
<Keyword MajorTopicYN="N">lung cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24938400</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1559-7016</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</Title>
<ISOAbbreviation>J. Cereb. Blood Flow Metab.</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice.</ArticleTitle>
<Pagination>
<MedlinePgn>1531-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/jcbfm.2014.113</ELocationID>
<Abstract>
<AbstractText>Akt (protein kinase B) and mammalian target of rapamycin (mTOR) have been implicated in the pathogenesis of cell death and cognitive outcome after cerebral contusion in mice; however, a role for Akt/mTOR in concussive brain injury has not been well characterized. In a mouse closed head injury (CHI) concussion traumatic brain injury (TBI) model, phosphorylation of Akt (p-Akt), mTOR (p-mTOR), and S6RP (p-S6RP) was increased by 24 hours in cortical and hippocampal brain homogenates (P&lt;0.05 versus sham for each), and p-S6RP was robustly induced in IBA-1+ microglia and glial fibrillary acidic protein-positive (GFAP+) astrocytes. Pretreatment with inhibitors of Akt or mTOR individually by the intracerebroventricular route reduced phosphorylation of their respective direct substrates FOXO1 (P&lt;0.05) or S6RP (P&lt;0.05) after CHI, confirming the activity of inhibitors. Rapamycin pretreatment significantly worsened hidden platform (P&lt;0.01) and probe trial (P&lt;0.05) performance in CHI mice. Intracerebroventricular administration of necrostatin-1 (Nec-1) before CHI increased hippocampal Akt and S6RP phosphorylation and improved place learning (probe trials, P&lt;0.001 versus vehicle), whereas co-administration of rapamycin or Akt inhibitor with Nec-1 eliminated improved probe trial performance. These data suggest a beneficial role for Akt/mTOR signaling after concussion TBI independent of cell death that may contribute to improved outcome by Nec-1. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Xiaoxia</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [3] Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Juyeon</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Golinski</LastName>
<ForeName>Julianne</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qiu</LastName>
<ForeName>Jianhua</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khuman</LastName>
<ForeName>Jugta</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Christopher C H</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lo</LastName>
<ForeName>Eng H</ForeName>
<Initials>EH</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Degterev</LastName>
<ForeName>Alexei</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Developmental, Molecular and Chemical Biology, Tufts University, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Whalen</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1UL1 TR001102-01</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5R01NS047447</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 TR001102</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cereb Blood Flow Metab</MedlineTA>
<NlmUniqueID>8112566</NlmUniqueID>
<ISSNLinking>0271-678X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467200">Foxo1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507699">necrostatin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001924">Brain Concussion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003071">Cognition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4158669 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25186749</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1529-2401</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
<ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>BMP2-SMAD signaling represses the proliferation of embryonic neural stem cells through YAP.</ArticleTitle>
<Pagination>
<MedlinePgn>12039-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0486-14.2014</ELocationID>
<Abstract>
<AbstractText>Previous studies have shown that the Hippo pathway effector yes-associated protein (YAP) plays an important role in maintaining stem cell proliferation. However, the precise molecular mechanism of YAP in regulating murine embryonic neural stem cells (NSCs) remains largely unknown. Here, we show that bone morphogenetic protein-2 (BMP2) treatment inhibited the proliferation of mouse embryonic NSCs, that YAP was critical for mouse NSC proliferation, and that BMP2 treatment-induced inhibition of mouse NSC proliferation was abrogated by YAP knockdown, indicating that the YAP protein mediates the inhibitory effect of BMP2 signaling. Additionally, we found that BMP2 treatment reduced YAP nuclear translocation, YAP-TEAD interaction, and YAP-mediated transactivation. BMP2 treatment inhibited YAP/TEAD-mediated Cyclin D1 (ccnd1) expression, and knockdown of ccnd1 abrogated the BMP2-mediated inhibition of mouse NSC proliferation. Mechanistically, we found that Smad1/4, effectors of BMP2 signaling, competed with YAP for the interaction with TAED1 and inhibited YAP's cotranscriptional activity. Our data reveal mechanistic cross talk between BMP2 signaling and the Hippo-YAP pathway in murine NSC proliferation, which may be exploited as a therapeutic target in neurodegenerative diseases and aging. </AbstractText>
<CopyrightInformation>Copyright © 2014 the authors 0270-6474/14/3412039-10$15.00/0.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yao</LastName>
<ForeName>Minghui</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics, State Key Laboratory of Developmental Biology, Institute of Genetic and Developmental Biology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yadong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Peng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Zhiheng</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Developmental Biology, Institute of Genetic and Developmental Biology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiao</LastName>
<ForeName>Jianwei</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-7893-0721</Identifier>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Zengqiang</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics, zqyuan@ibp.ac.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosci</MedlineTA>
<NlmUniqueID>8102140</NlmUniqueID>
<ISSNLinking>0270-6474</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055396">Bone Morphogenetic Protein 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530105">Ccnd1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051898">Smad1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497401">Smad1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051901">Smad4 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490810">Smad4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C083215">Tead1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486223">Yap protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055396">Bone Morphogenetic Protein 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053595">Embryonic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058953">Neural Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010750">Phosphoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051898">Smad1 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051901">Smad4 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BMP2</Keyword>
<Keyword MajorTopicYN="N">YAP</Keyword>
<Keyword MajorTopicYN="N">hippo</Keyword>
<Keyword MajorTopicYN="N">neural stem cell</Keyword>
<Keyword MajorTopicYN="N">proliferation</Keyword>
<Keyword MajorTopicYN="N">transcription</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25186765</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1529-2401</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
<ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.</ArticleTitle>
<Pagination>
<MedlinePgn>12230-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1694-14.2014</ELocationID>
<Abstract>
<AbstractText>The AMP-activated protein kinase (AMPK) is a Ser/Thr kinase that is activated in response to low-energy states to coordinate multiple signaling pathways to maintain cellular energy homeostasis. Dysregulation of AMPK signaling has been observed in Alzheimer's disease (AD), which is associated with abnormal neuronal energy metabolism. In the current study we tested the hypothesis that aberrant AMPK signaling underlies AD-associated synaptic plasticity impairments by using pharmacological and genetic approaches. We found that amyloid β (Aβ)-induced inhibition of long-term potentiation (LTP) and enhancement of long-term depression were corrected by the AMPK inhibitor compound C (CC). Similarly, LTP impairments in APP/PS1 transgenic mice that model AD were improved by CC treatment. In addition, Aβ-induced LTP failure was prevented in mice with genetic deletion of the AMPK α2-subunit, the predominant AMPK catalytic subunit in the brain. Furthermore, we found that eukaryotic elongation factor 2 (eEF2) and its kinase eEF2K are key downstream effectors that mediate the detrimental effects of hyperactive AMPK in AD pathophysiology. Our findings describe a previously unrecognized role of aberrant AMPK signaling in AD-related synaptic pathophysiology and reveal a potential therapeutic target for AD. </AbstractText>
<CopyrightInformation>Copyright © 2014 the authors 0270-6474/14/3412230-09$15.00/0.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Center for Neural Science, New York University, New York, New York 10003.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yiran</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Center for Neural Science, New York University, New York, New York 10003.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vingtdeux</LastName>
<ForeName>Valerie</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research, Manhasset, New York 11030.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Haitian</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research, Manhasset, New York 11030.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Viollet</LastName>
<ForeName>Benoit</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Institut Cochin, INSERM U1016, Paris 75014, France, CNRS, UMR 8104, Paris 75014, France, and Université Paris Descartes, Sorbonne Paris Cité, Paris 75014, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marambaud</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research, Manhasset, New York 11030.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klann</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Center for Neural Science, New York University, New York, New York 10003, eklann@cns.nyu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K99 AG044469</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NS034007</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NS047834</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AG042508</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosci</MedlineTA>
<NlmUniqueID>8102140</NlmUniqueID>
<ISSNLinking>0270-6474</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C516138">(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020652">Peptide Elongation Factor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.17</RegistryNumber>
<NameOfSubstance UI="D054736">Elongation Factor 2 Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055372">AMP-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000544">Alzheimer Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016564">Amyloid beta-Protein Precursor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054736">Elongation Factor 2 Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019706">Excitatory Postsynaptic Potentials</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017774">Long-Term Potentiation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036881">Long-Term Synaptic Depression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020652">Peptide Elongation Factor 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053764">Presenilin-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4152616 [Available on 03/03/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
<Keyword MajorTopicYN="N">long-term potentiation</Keyword>
<Keyword MajorTopicYN="N">neurodegeneration</Keyword>
<Keyword MajorTopicYN="N">protein synthesis</Keyword>
<Keyword MajorTopicYN="N">signaling</Keyword>
<Keyword MajorTopicYN="N">translation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079330</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7516</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.</ArticleTitle>
<Pagination>
<MedlinePgn>105-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13572</ELocationID>
<Abstract>
<AbstractText>In BRAF(V600)-mutant tumours, most mechanisms of resistance to drugs that target the BRAF and/or MEK kinases rely on reactivation of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway, on activation of the alternative, PI(3)K-AKT-mTOR, pathway (which is ERK independent) or on modulation of the caspase-dependent apoptotic cascade. All three pathways converge to regulate the formation of the eIF4F eukaryotic translation initiation complex, which binds to the 7-methylguanylate cap (m(7)G) at the 5' end of messenger RNA, thereby modulating the translation of specific mRNAs. Here we show that the persistent formation of the eIF4F complex, comprising the eIF4E cap-binding protein, the eIF4G scaffolding protein and the eIF4A RNA helicase, is associated with resistance to anti-BRAF, anti-MEK and anti-BRAF plus anti-MEK drug combinations in BRAF(V600)-mutant melanoma, colon and thyroid cancer cell lines. Resistance to treatment and maintenance of eIF4F complex formation is associated with one of three mechanisms: reactivation of MAPK signalling, persistent ERK-independent phosphorylation of the inhibitory eIF4E-binding protein 4EBP1 or increased pro-apoptotic BCL-2-modifying factor (BMF)-dependent degradation of eIF4G. The development of an in situ method to detect the eIF4E-eIF4G interactions shows that eIF4F complex formation is decreased in tumours that respond to anti-BRAF therapy and increased in resistant metastases compared to tumours before treatment. Strikingly, inhibiting the eIF4F complex, either by blocking the eIF4E-eIF4G interaction or by targeting eIF4A, synergizes with inhibiting BRAF(V600) to kill the cancer cells. eIF4F not only appears to be an indicator of both innate and acquired resistance but also is a promising therapeutic target. Combinations of drugs targeting BRAF (and/or MEK) and eIF4F may overcome most of the resistance mechanisms arising in BRAF(V600)-mutant cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Boussemart</LastName>
<ForeName>Lise</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France [4].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malka-Mahieu</LastName>
<ForeName>Hélène</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Girault</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Allard</LastName>
<ForeName>Delphine</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR981, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hemmingsson</LastName>
<ForeName>Oskar</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Department of Surgical and Perioperative Sciences, Umeå University, Umeå SE-90187, Sweden (O.H.); CNRS UMR3348, Institut Curie, Orsay F-91405, France (S.V.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tomasic</LastName>
<ForeName>Gorana</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Pathology Department, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Basmadjian</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ribeiro</LastName>
<ForeName>Nigel</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thuaud</LastName>
<ForeName>Frédéric</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mateus</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Routier</LastName>
<ForeName>Emilie</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kamsu-Kom</LastName>
<ForeName>Nyam</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR981, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Agoussi</LastName>
<ForeName>Sandrine</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR981, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eggermont</LastName>
<ForeName>Alexander M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>1] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [2] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Désaubry</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Robert</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vagner</LastName>
<ForeName>Stéphan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France [4] Department of Surgical and Perioperative Sciences, Umeå University, Umeå SE-90187, Sweden (O.H.); CNRS UMR3348, Institut Curie, Orsay F-91405, France (S.V.).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039561">Eukaryotic Initiation Factor-4E</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039562">Eukaryotic Initiation Factor-4F</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039603">Eukaryotic Initiation Factor-4G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551177">PLX4032</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489897">silvestrol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D039601">Eukaryotic Initiation Factor-4A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039601">Eukaryotic Initiation Factor-4A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039561">Eukaryotic Initiation Factor-4E</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039562">Eukaryotic Initiation Factor-4F</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039603">Eukaryotic Initiation Factor-4G</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24166502</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>4531-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.442</ELocationID>
<Abstract>
<AbstractText>Desmosomal cadherins mediate cell-cell adhesion in epithelial tissues and have been known to be altered in cancer. We have previously shown that one of the two intestinal epithelial desmosomal cadherins, desmocollin-2 (Dsc2) loss promotes colonic epithelial carcinoma cell proliferation and tumor formation. In this study we show that loss of the other intestinal desmosomal cadherin, desmoglein-2 (Dsg2) that pairs with Dsc2, results in decreased epithelial cell proliferation and suppressed xenograft tumor growth in mice. Dsg2-deficient cells demonstrated a compensatory increase in Dsc2 expression, and small interfering RNA-mediated loss of Dsc2 restored proliferation in Dsg2-deficient cells. Dsg2 downregulation inhibited epidermal growth factor receptor (EGFR) signaling and cell proliferation through altered phosphorylation of EGFR and downstream extracellular signal-regulated kinase activation in parallel with inhibited EGFR receptor internalization. Additionally, we demonstrated a central role of Dsc2 in controlling EGFR signaling and cell proliferation in intestinal epithelial cells. Consistent with these findings, analyses of human colon cancers demonstrated increased Dsg2 protein expression. Taken together, these data demonstrate that partner desmosomal cadherins Dsg2 and Dsc2 play opposing roles in controlling colonic carcinoma cell proliferation through differential effects on EGFR signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kamekura</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kolegraff</LastName>
<ForeName>K N</ForeName>
<Initials>KN</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nava</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Biophysics and Neuroscience, Center for Research and Advanced Studies (CINVESTAV), Mexico DF, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hilgarth</LastName>
<ForeName>R S</ForeName>
<Initials>RS</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parkos</LastName>
<ForeName>C A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nusrat</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK055679</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK059888</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK061379</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK064399</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK072564</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK059888</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK061379</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK072564</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK079392</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 DK007771</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051187">Desmocollins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051182">Desmogleins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2003 Nov 20;22(52):8509-18</RefSource>
<PMID Version="1">14627991</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2001 Jul;117(1):26-35</RefSource>
<PMID Version="1">11442746</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8064-9</RefSource>
<PMID Version="1">9653140</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1999 Mar 19;274(12):8335-43</RefSource>
<PMID Version="1">10075741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Differentiation. 2004 Oct;72(8):419-33</RefSource>
<PMID Version="1">15606501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2005 Apr;16(4):1744-55</RefSource>
<PMID Version="1">15689490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2005 May;5(5):341-54</RefSource>
<PMID Version="1">15864276</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Pathol. 2005 Oct;207(2):199-206</RefSource>
<PMID Version="1">16025435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2007 Jan 18;26(3):467-76</RefSource>
<PMID Version="1">16878157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2007 Mar 1;120(Pt 5):758-71</RefSource>
<PMID Version="1">17284515</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2007 Nov;18(11):4565-78</RefSource>
<PMID Version="1">17804817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Rev Cytol. 2007;264:65-163</RefSource>
<PMID Version="1">17964922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Adh Migr. 2009 Apr-Jun;3(2):148-54</RefSource>
<PMID Version="1">19458482</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2009 Jun 29;185(7):1243-58</RefSource>
<PMID Version="1">19546243</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G774-83</RefSource>
<PMID Version="1">20224006</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Jan 14;286(2):1499-507</RefSource>
<PMID Version="1">21071449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2011 Apr 15;22(8):1121-34</RefSource>
<PMID Version="1">21325624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Prolif. 2011 Aug;44(4):301-10</RefSource>
<PMID Version="1">21702856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Adh Migr. 2011 Jul-Aug;5(4):306-14</RefSource>
<PMID Version="1">21715983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 2012 Oct;43(10):1745-54</RefSource>
<PMID Version="1">22521077</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(11):e50024</RefSource>
<PMID Version="1">23185521</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1989 Apr 15;49(8):2128-33</RefSource>
<PMID Version="1">2702654</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051187">Desmocollins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051182">Desmogleins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS575287</OtherID>
<OtherID Source="NLM">PMC4061272</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24608434</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis.</ArticleTitle>
<Pagination>
<MedlinePgn>4496-507</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.10</ELocationID>
<Abstract>
<AbstractText>Metastasis is the predominant cause of death in breast cancer patients. Several lines of evidence have shown that microRNAs (miRs) can have an important role in cancer metastasis. Using isogenic pairs of low and high metastatic lines derived from a human breast cancer line, we have identified miR-149 to be a suppressor of breast cancer cell invasion and metastasis. We also identified GIT1 (G-protein-coupled receptor kinase-interacting protein 1) as a direct target of miR-149. Knockdown of GIT1 reduced migration/invasion and metastasis of highly invasive cells. Re-expression of GIT1 significantly rescued miR-149-mediated inhibition of cell migration/invasion and metastasis. Expression of miR-149 impaired fibronectin-induced focal adhesion formation and reduced phosphorylation of focal adhesion kinase and paxillin, which could be restored by re-expression of GIT1. Inhibition of GIT1 led to enhanced protein degradation of paxillin and α5β1 integrin via proteasome and lysosome pathways, respectively. Moreover, we found that GIT1 depletion in metastatic breast cancer cells greatly reduced α5β1-integrin-mediated cell adhesion to fibronectin and collagen. Low level of miR-149 and high level of GIT1 was significantly associated with advanced stages of breast cancer, as well as with lymph node metastasis. We conclude that miR-149 suppresses breast cancer cell migration/invasion and metastasis by targeting GIT1, suggesting potential applications of the miR-149-GIT1 pathway in clinical diagnosis and therapeutics. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>S-H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>W-C</ForeName>
<Initials>WC</Initials>
<AffiliationInfo>
<Affiliation>1] Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan [2] Department of Life Science, National Central University, Taoyuan, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>J-W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>K-J</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuo</LastName>
<ForeName>W-H</ForeName>
<Initials>WH</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>M-Y</ForeName>
<Initials>MY</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>K-Y</ForeName>
<Initials>KY</Initials>
<AffiliationInfo>
<Affiliation>Chi Mei Medical Center, Department of Medical Research, Tainan, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uen</LastName>
<ForeName>Y-H</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Chi Mei Medical Center, Department of Medical Research, Tainan, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hou</LastName>
<ForeName>M-F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>C-M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jang</LastName>
<ForeName>T-H</ForeName>
<Initials>TH</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tu</LastName>
<ForeName>C-W</ForeName>
<Initials>CW</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Chiayi Christian Hospital, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Y-R</ForeName>
<Initials>YR</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Research, Chiayi Christian Hospital, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Y-H</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tien</LastName>
<ForeName>M-T</ForeName>
<Initials>MT</Initials>
<AffiliationInfo>
<Affiliation>Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>L-H</ForeName>
<Initials>LH</Initials>
<AffiliationInfo>
<Affiliation>1] Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan [2] Department of Life Science, National Central University, Taoyuan, Taiwan [3] Department of Microbiology, Mount Sinai School of Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485647">GIT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016023">Integrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551557">MIRN149 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2002 Feb;2(2):91-100</RefSource>
<PMID Version="1">12635172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Pathol. 2002 Aug;55(8):613-5</RefSource>
<PMID Version="1">12147657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2002 Apr 1;115(Pt 7):1497-510</RefSource>
<PMID Version="1">11896197</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2001 Jul;7(7):2124-33</RefSource>
<PMID Version="1">11448932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2000 Oct;113 ( Pt 20):3563-71</RefSource>
<PMID Version="1">11017872</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2013 Jul 8;202(1):163-77</RefSource>
<PMID Version="1">23836933</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(10):e41693</RefSource>
<PMID Version="1">23144691</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Metastasis Rev. 2012 Dec;31(3-4):653-62</RefSource>
<PMID Version="1">22684369</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2012 Jun 15;72(12):3000-9</RefSource>
<PMID Version="1">22659453</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Med Genomics. 2012;5:3</RefSource>
<PMID Version="1">22260379</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>OMICS. 2011 Oct;15(10):673-82</RefSource>
<PMID Version="1">21978395</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2010 Sep;11(9):633-43</RefSource>
<PMID Version="1">20729930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2010 Mar 28;289(2):127-39</RefSource>
<PMID Version="1">19643531</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2010 Jan;10(1):9-22</RefSource>
<PMID Version="1">20029421</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 2009 Feb 20;386(2):280-9</RefSource>
<PMID Version="1">19136011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res. 2008;10(2):203</RefSource>
<PMID Version="1">18373886</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Metastasis Rev. 2007 Dec;26(3-4):567-78</RefSource>
<PMID Version="1">17786537</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Protoc. 2007;2(10):2520-8</RefSource>
<PMID Version="1">17947994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2007 Oct;9(10):1121</RefSource>
<PMID Version="1">17909523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Methods. 2007 Sep;4(9):721-6</RefSource>
<PMID Version="1">17694064</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):135-42</RefSource>
<PMID Version="1">17602286</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Signal. 2007 Aug;19(8):1733-44</RefSource>
<PMID Version="1">17467235</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Nov 17;127(4):679-95</RefSource>
<PMID Version="1">17110329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2006 Aug;12(8):895-904</RefSource>
<PMID Version="1">16892035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2005 Jul 29;280(30):27705-12</RefSource>
<PMID Version="1">15923189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 1996 Nov 21;228(3):662-8</RefSource>
<PMID Version="1">8941336</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioessays. 1996 May;18(5):379-89</RefSource>
<PMID Version="1">8639161</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26</RefSource>
<PMID Version="1">15459662</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2003 Dec 5;302(5651):1704-9</RefSource>
<PMID Version="1">14657486</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016023">Integrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4155808</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662833</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.</ArticleTitle>
<Pagination>
<MedlinePgn>4521-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.25</ELocationID>
<Abstract>
<AbstractText>Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation. Androgen deprivation or treatment with androgen receptor (AR) signaling inhibitor (ARSI), Enzalutamide (MDV-3100, ENZA) or bicalutamide induced autophagy in androgen-dependent and in castration-resistant CaP (castration-resistant prostate cancer (CRPC)) cell lines. The autophagic cascade triggered by AR blockage, correlated with the increased light chain 3-II/I ratio and ATG-5 expression. Autophagy was observed in a subpopulation of C4-2B cells that developed insensitivity to ENZA after sustained exposure in culture. Using flow cytometry and clonogenic assays, we showed that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased apoptosis and significantly impaired cell viability. This autophagic process was mediated by AMP-dependent protein kinase (AMPK) activation and the suppression of mammalian target of rapamycin (mTOR) through Raptor phosphorylation (Serine 792). Furthermore, small interfering RNA targeting AMPK significantly inhibited autophagy and promoted cell death in CaP cells acutely or chronically exposed to ENZA or androgen deprivation, suggesting that autophagy is an important survival mechanism in CRPC. Lastly, in vivo studies with mice orthotopically implanted with ENZA-resistant cells demonstrated that the combination of ENZA and autophagy modulators, CMI or metformin significantly reduced tumor growth when compared with control groups (P&lt;0.005). In conclusion, autophagy is as an important mechanism of resistance to ARSI in CRPC. Antiandrogen-induced autophagy is mediated through the activation of AMPK pathway and the suppression of mTOR pathway. Blocking autophagy pharmacologically or genetically significantly impairs prostate cancer cell survival in vitro and in vivo, implying the therapeutics potential of autophagy inhibitors in the antiandrogen-resistance setting. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>H G</ForeName>
<Initials>HG</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kung</LastName>
<ForeName>H-J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>X-B</ForeName>
<Initials>XB</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tilki</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lara</LastName>
<ForeName>P N</ForeName>
<Initials>PN</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo>
<Affiliation>UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>DeVere White</LastName>
<ForeName>R W</ForeName>
<Initials>RW</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA 165263</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D059002">Androgen Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C540278">MDV 3100</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2010-15-3</RegistryNumber>
<NameOfSubstance UI="D010669">Phenylthiohydantoin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>NUV44L116D</RegistryNumber>
<NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2008 Jan;4(1):54-60</RefSource>
<PMID Version="1">17993778</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2010;5(11):e15394</RefSource>
<PMID Version="1">21072212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2008 Apr 25;30(2):214-26</RefSource>
<PMID Version="1">18439900</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2009 May;5(4):567-8</RefSource>
<PMID Version="1">19276647</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2009 Aug;23(8):2741-8</RefSource>
<PMID Version="1">19332642</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Pharmacol. 2007 Jul;151(6):737-48</RefSource>
<PMID Version="1">17471183</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2007 Feb;117(2):326-36</RefSource>
<PMID Version="1">17235397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Intern Med. 2006 Mar 7;144(5):337-43</RefSource>
<PMID Version="1">16520474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2005 Jun;25(12):4977-92</RefSource>
<PMID Version="1">15923616</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2003 Nov 26;115(5):577-90</RefSource>
<PMID Version="1">14651849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2003 May 13;13(10):797-806</RefSource>
<PMID Version="1">12747827</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2003 May 2;278(18):15461-4</RefSource>
<PMID Version="1">12604610</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2010 Jul;6(5):670-1</RefSource>
<PMID Version="1">20559023</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Discov. 2013 Sep;3(9):1030-43</RefSource>
<PMID Version="1">23842682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2013 Aug;12(8):1629-37</RefSource>
<PMID Version="1">23699654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Urol. 2013 Aug;64(2):339-40</RefSource>
<PMID Version="1">23830228</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Prostate. 2013 Jul;73(10):1090-102</RefSource>
<PMID Version="1">23532738</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2013 May 23;153(5):1064-79</RefSource>
<PMID Version="1">23706743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BJU Int. 2013 Apr;111(4):672-82</RefSource>
<PMID Version="1">22897391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Jan 15;73(2):483-9</RefSource>
<PMID Version="1">23117885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2012 Sep 27;367(13):1187-97</RefSource>
<PMID Version="1">22894553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Urol. 2012 Oct;188(4):1361-8</RefSource>
<PMID Version="1">22906664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2012 Apr;8(4):445-544</RefSource>
<PMID Version="1">22966490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Res. 2012 May;32(5):1627-37</RefSource>
<PMID Version="1">22593441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2012 Apr 1;72(7):1773-83</RefSource>
<PMID Version="1">22447568</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Dis. 2012;3:e275</RefSource>
<PMID Version="1">22378068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Dis. 2011;2:e199</RefSource>
<PMID Version="1">21881601</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Horm Cancer. 2011 Feb;2(1):38-46</RefSource>
<PMID Version="1">21350583</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Signal. 2011 Sep;23(9):1466-72</RefSource>
<PMID Version="1">21554950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2011 Jun 14;19(6):792-804</RefSource>
<PMID Version="1">21620777</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2011 May 17;19(5):575-86</RefSource>
<PMID Version="1">21575859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Med Oncol. 2011 Mar;28(1):105-11</RefSource>
<PMID Version="1">20041317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2009 Sep 15;122(Pt 18):3330-9</RefSource>
<PMID Version="1">19706685</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Mar 15;70(6):2465-75</RefSource>
<PMID Version="1">20215500</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2008 Mar 1;68(5):1485-94</RefSource>
<PMID Version="1">18316613</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059002">Androgen Receptor Antagonists</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002738">Chloroquine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002997">Clomipramine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008687">Metformin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010669">Phenylthiohydantoin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064129">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4155805</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043756</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0045</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>74</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The Prostate</Title>
<ISOAbbreviation>Prostate</ISOAbbreviation>
</Journal>
<ArticleTitle>Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>1240-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/pros.22841</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We aimed to evaluate STAT5 expression and cell proliferation change after dihydrotestosterone (DHT) treatment in castration-resistant prostate cancer (CRPC) cells to elucidate the mechanism in relation to different androgen receptor (AR) expression status.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Using DU145, PC3, and LNCaP cells, cell viability assay and Western blot for phosphorylated STAT5 (p-STAT5) were done after DHT treatment at various concentrations. Endogenous levels of nuclear hormone receptor mRNA and protein were identified using real-time RT-PCR and Western blot. We treated the cells with RU486 and then glucocorticoid receptor (GR)-specific small interfering RNA (siRNA), to assess change in DHT-induced STAT5 activation. Immunofluorescence staining of DU145 cells with anti-GR and anti-pSTAT5 Ab before and after DHT treatment was done and visualized.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">DHT treatment enhanced STAT5 phosphorylation and promoted proliferation of all CRPC cells. Endogenous GR was identified strongly in DU145, weakly in PC3 but not in LNCaP cells. AR was identified strongly in LNCaP but not in DU145 cells. RU486 treatment abolished DHT-induced cell proliferation and STAT5 activation in both DU145 and PC3 cells but not in LNCaP cells. Similarly, GR-specific siRNA completely suppressed STAT5 activation. On immunofluorescence, activation of STAT5 and GR translocating into the nucleus after DHT treatment was confirmed. Immunoprecipitation confirmed direct complex formation between the GR and pSTAT5.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In CRPC cells, DHT activated STAT5 enhancing cell proliferation. Activation was induced regardless of presence of AR and in cells devoid of AR, DHT used GR which formed direct complex with p-STAT5.</AbstractText>
<CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Cheryn</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Yunlim</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Min</LastName>
<ForeName>Gyeong Eun</ForeName>
<Initials>GE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Hanjong</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Prostate</MedlineTA>
<NlmUniqueID>8101368</NlmUniqueID>
<ISSNLinking>0270-4137</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050799">STAT5 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>08J2K08A3Y</RegistryNumber>
<NameOfSubstance UI="D013196">Dihydrotestosterone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013196">Dihydrotestosterone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064129">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011965">Receptors, Glucocorticoid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050799">STAT5 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">STAT5</Keyword>
<Keyword MajorTopicYN="N">androgen receptor</Keyword>
<Keyword MajorTopicYN="N">castration-resistant</Keyword>
<Keyword MajorTopicYN="N">dihydrotestosterone</Keyword>
<Keyword MajorTopicYN="N">glucocorticoid receptor</Keyword>
<Keyword MajorTopicYN="N">prostate neoplasm</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25189027</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0017-7768</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>153</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Harefuah</Title>
<ISOAbbreviation>Harefuah</ISOAbbreviation>
</Journal>
<ArticleTitle>[Erdheim-Chester disease].</ArticleTitle>
<Pagination>
<MedlinePgn>389-91, 434, 433</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Erdheim-Chester disease is an orphan condition which involves the ongoing proliferation, migration and infiltration of the typical CD68(+), CD1a(-) histiocytes to various target foci. Consequently, both the infiltrating and fibrosing elements of the disease promote end organ damage and ultimately, failure. Presentation of the Erdheim-Chester disease typically involves longstanding diabetes insipidus in conjunction with intensifying bone pain that classically affects the femurs and tibiae. Alternatively, the disease may present with neurological deterioration of cerebellar nature. Thus, a high index of clinical suspicion is required when facing a patient with the combination of longstanding diabetes insipidus in conjunction with bone pain or cerebellar dysfunction. Typical symmetric, bilateral increased tracer uptake on a 99mTc bone scintigraphy invoLving the femurs and tibiae, is strongly suggestive of the Erdheim-Chester disease. interferon alpha is considered as the first line of treatment. Nevertheless, recent accumulated data suggests that this disease heavily relies on the Ras/Raf/MEK/ERK signal transduction pathway as inhibition of the V600E mutant BRAF by the small molecule vemurafenib among patients who are carriers of this mutation, yielded dramatic clinical responses.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mazor</LastName>
<ForeName>Roei D</ForeName>
<Initials>RD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shoenfeld</LastName>
<ForeName>Yehuda</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>heb</Language>
<PublicationTypeList>
<PublicationType UI="D016421">Editorial</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Israel</Country>
<MedlineTA>Harefuah</MedlineTA>
<NlmUniqueID>0034351</NlmUniqueID>
<ISSNLinking>0017-7768</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551177">PLX4032</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D031249">Erdheim-Chester Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24990888</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1528-0020</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>124</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Blood</Title>
<ISOAbbreviation>Blood</ISOAbbreviation>
</Journal>
<ArticleTitle>Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.</ArticleTitle>
<Pagination>
<MedlinePgn>1637-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-03-559591</ELocationID>
<Abstract>
<AbstractText>Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic leukemia (CLL), even though it is not cytotoxic for primary CLL cells in vitro. We examined the direct effect of lenalidomide on CLL-cell proliferation induced by CD154-expressing accessory cells in media containing interleukin-4 and -10. Treatment with lenalidomide significantly inhibited CLL-cell proliferation, an effect that was associated with the p53-independent upregulation of the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1) (p21). Silencing p21 with small interfering RNA impaired the capacity of lenalidomide to inhibit CLL-cell proliferation. Silencing cereblon, a known molecular target of lenalidomide, impaired the capacity of lenalidomide to induce expression of p21, inhibit CD154-induced CLL-cell proliferation, or enhance the degradation of Ikaros family zinc finger proteins 1 and 3. We isolated CLL cells from the blood of patients before and after short-term treatment with low-dose lenalidomide (5 mg per day) and found the leukemia cells were also induced to express p21 in vivo. These results indicate that lenalidomide can directly inhibit proliferation of CLL cells in a cereblon/p21-dependent but p53-independent manner, at concentrations achievable in vivo, potentially contributing to the capacity of this drug to inhibit disease-progression in patients with CLL. </AbstractText>
<CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fecteau</LastName>
<ForeName>Jessie-F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Corral</LastName>
<ForeName>Laura G</ForeName>
<Initials>LG</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghia</LastName>
<ForeName>Emanuela M</ForeName>
<Initials>EM</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gaidarova</LastName>
<ForeName>Svetlana</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Futalan</LastName>
<ForeName>Diahnn</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bharati</LastName>
<ForeName>Ila Sri</ForeName>
<Initials>IS</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cathers</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schwaederlé</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Bing</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lopez-Girona</LastName>
<ForeName>Antonia</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Messmer</LastName>
<ForeName>Davorka</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kipps</LastName>
<ForeName>Thomas J</ForeName>
<Initials>TJ</Initials>
<AffiliationInfo>
<Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA; and.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01-CA081534</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Blood</MedlineTA>
<NlmUniqueID>7603509</NlmUniqueID>
<ISSNLinking>0006-4971</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4Z8R6ORS6L</RegistryNumber>
<NameOfSubstance UI="D013792">Thalidomide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="C502543">CRBN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>F0P408N6V4</RegistryNumber>
<NameOfSubstance UI="C467567">lenalidomide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Blood. 2014 Sep 4;124(10):1545-6</RefSource>
<PMID Version="1">25190749</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015451">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010447">Peptide Hydrolases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013792">Thalidomide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4155272 [Available on 09/04/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25006124</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1528-0020</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>124</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Blood</Title>
<ISOAbbreviation>Blood</ISOAbbreviation>
</Journal>
<ArticleTitle>PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.</ArticleTitle>
<Pagination>
<MedlinePgn>1626-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-01-548800</ELocationID>
<Abstract>
<AbstractText>The aim of this study was to assess the efficiency of p53 reactivation and induction of massive apoptosis (PRIMA-1(Met)) in inducing myeloma cell death, using 27 human myeloma cell lines (HMCLs) and 23 primary samples. Measuring the lethal dose (LD50) of HMCLs revealed that HMCLs displayed heterogeneous sensitivity, with an LD50 ranging from 4 μM to more than 200 μM. The sensitivity of HMCLs did not correlate with myeloma genomic heterogeneity or TP53 status, and PRIMA-1(Met) did not induce or increase expression of the p53 target genes CDKN1A or TNFRSF10B/DR5. However, PRIMA-1(Met) increased expression of NOXA in a p53-independent manner, and NOXA silencing decreased PRIMA1(Met)-induced cell death. PRIMA-1(Met) depleted glutathione (GSH) content and induced reactive oxygen species production. The expression of GSH synthetase correlated with PRIMA-1(Met) LD50 values, and we showed that a GSH decrease mediated by GSH synthetase silencing or by and L-buthionine sulphoximine, an irreversible inhibitor of γ-glutamylcysteine synthetase, increased PRIMA-1(Met)-induced cell death and overcame PRIMA-1(Met) resistance. PRIMA-1(Met) (10 μM) induced cell death in 65% of primary cells independent of the presence of del17p; did not increase DR5 expression, arguing against an activation of p53 pathway; and synergized with L-buthionine sulphoximine in all samples. Finally, we showed in mouse TP53(neg) JJN3-xenograft model that PRIMA-1(Met) inhibited myeloma growth and synergized with L-buthionine sulphoximine in vivo. </AbstractText>
<CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tessoulin</LastName>
<ForeName>Benoît</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France; Service d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Descamps</LastName>
<ForeName>Géraldine</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moreau</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France; Service d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maïga</LastName>
<ForeName>Sophie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lodé</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France; Laboratoire d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Godon</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratoire d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marionneau-Lambot</LastName>
<ForeName>Séverine</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Plate-forme in vivo, Cancéropôle Grand Ouest, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oullier</LastName>
<ForeName>Thibauld</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Plate-forme in vivo, Cancéropôle Grand Ouest, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Le Gouill</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France; Service d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Amiot</LastName>
<ForeName>Martine</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France; Service d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pellat-Deceunynck</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>INSERM, Unité Mixte de Recherche 892, Nantes, France; Université de Nantes, Nantes, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6299, Nantes, France; Service d'Hématologie, Centre Hospitalo-Universitaire Nantes, Nantes, France;</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Blood</MedlineTA>
<NlmUniqueID>7603509</NlmUniqueID>
<ISSNLinking>0006-4971</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C533410">2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011812">Quinuclidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>GAN16C9B8O</RegistryNumber>
<NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005978">Glutathione</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011812">Quinuclidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25006126</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1528-0020</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>124</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Blood</Title>
<ISOAbbreviation>Blood</ISOAbbreviation>
</Journal>
<ArticleTitle>Ncor2 is required for hematopoietic stem cell emergence by inhibiting Fos signaling in zebrafish.</ArticleTitle>
<Pagination>
<MedlinePgn>1578-85</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2013-11-541391</ELocationID>
<Abstract>
<AbstractText>Nuclear receptor corepressors (Ncors) are important for developmental and homeostatic processes in vertebrates, which exert transcriptional repression by coordinating with histone deacetylases. However, little is known about their roles in definitive hematopoiesis. In this study, we show that in zebrafish, ncor2 is required for hematopoietic stem cell (HSC) development by repressing fos-vegfd signaling. ncor2 is specifically expressed in the aorta-gonad-mesonephros (AGM) region in zebrafish embryos. ncor2 deficiency reduced the population of HSCs in both the AGM region and T cells in the thymus. Mechanistically, ncor2 knockdown upregulated fos transcription by modulating the acetylation level in the fos promoter region, which then enhanced Vegfd signaling. Consequently, the augmented Vegfd signaling induced Notch signaling to promote the arterial endothelial fate, therefore, possibly repressing the hemogenic endothelial specification, which is a prerequisite for HSC emergence. Thus, our findings identify a novel regulatory mechanism for Ncor2 through Fos-Vegfd-Notch signaling cascade during HSC development in zebrafish embryos. </AbstractText>
<CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Yonglong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Dongyuan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Ya</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Chunxia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Blood</MedlineTA>
<NlmUniqueID>7603509</NlmUniqueID>
<ISSNLinking>0006-4971</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056985">Nuclear Receptor Co-Repressor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016761">Oncogene Proteins v-fos</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042643">Vascular Endothelial Growth Factor D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000590871">vascular endothelial growth factor D, zebrafish</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Blood. 2014 Sep 4;124(10):1541-2</RefSource>
<PMID Version="1">25190746</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030801">Animals, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004625">Embryo, Nonmammalian</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006410">Hematopoiesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006412">Hematopoietic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056985">Nuclear Receptor Co-Repressor 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016761">Oncogene Proteins v-fos</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042643">Vascular Endothelial Growth Factor D</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015027">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029961">Zebrafish Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25030064</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1528-0020</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>124</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Blood</Title>
<ISOAbbreviation>Blood</ISOAbbreviation>
</Journal>
<ArticleTitle>COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse.</ArticleTitle>
<Pagination>
<MedlinePgn>1610-21</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-03-559658</ELocationID>
<Abstract>
<AbstractText>Cyclooxygenases (COXs) and their prostanoid products play important roles in a diverse range of physiological processes, including in the immune system. Here, we provide evidence that COX-1 is an essential regulator in early stages of B-cell development. COX-1-deficient mice displayed systematic reduction in total B cells, which was attributed to the arrest of early B-cell development from pro-B to pre-B stage. We further demonstrated that this defect was mediated through downregulation of the Janus kinase/signal transducer and activator of transcription 5 (JAK/STAT5) signaling and its target genes, including Pax5, in COX-1(-/-) mice. Mechanistic studies revealed that COX-1-derived thromboxane A2 (TxA2) could regulate JAK3/STAT5 signaling through the cyclic adenosine monophosphate-protein kinase A pathway, via binding with its receptor thromboxane A2 receptor (TP). Administration of the TP agonist could rescue the defective B-cell development and JAK/STAT5 signaling activity in COX-1-deficient mice. Moreover, administration of low-dose aspirin caused a significant reduction in total B cells in peripheral blood of healthy human volunteers, coincidentally with reduced TxA2 production and downregulation of JAK/STAT5 signaling. Taken together, our results demonstrate that COX-1-derived TxA2 plays a critical role in the stage transition of early B-cell development through regulation of JAK/STAT5 signaling and indicate a potential immune-suppressive effect of low-dose aspirin in humans. </AbstractText>
<CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Qiong</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Maohua</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Yujun</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Yingjiao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zuo</LastName>
<ForeName>Shengkai</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zuo</LastName>
<ForeName>Caojian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China; Key Laboratory of Tropical Disease Control (Sun Yat-Sen University), Chinese Ministry of Education, Guangzhou, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gabrilovich</LastName>
<ForeName>Dmitry I</ForeName>
<Initials>DI</Initials>
<AffiliationInfo>
<Affiliation>Translational Tumor Immunology, The Wistar Institute, Philadelphia, PA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China; Key Laboratory of Tropical Disease Control (Sun Yat-Sen University), Chinese Ministry of Education, Guangzhou, China; and.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Blood</MedlineTA>
<NlmUniqueID>7603509</NlmUniqueID>
<ISSNLinking>0006-4971</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050799">STAT5 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>57576-52-0</RegistryNumber>
<NameOfSubstance UI="D013928">Thromboxane A2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051545">Cyclooxygenase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="C496512">Ptgs1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Blood. 2014 Sep 4;124(10):1543-4</RefSource>
<PMID Version="1">25190748</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051545">Cyclooxygenase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053612">Janus Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019891">Leukopoiesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050799">STAT5 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013928">Thromboxane A2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25190799</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>345</Volume>
<Issue>6201</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Intracellular sensing of complement C3 activates cell autonomous immunity.</ArticleTitle>
<Pagination>
<MedlinePgn>1256070</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1256070</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">1256070</ELocationID>
<Abstract>
<AbstractText>Pathogens traverse multiple barriers during infection, including cell membranes. We found that during this transition, pathogens carried covalently attached complement C3 into the cell, triggering immediate signaling and effector responses. Sensing of C3 in the cytosol activated mitochondrial antiviral signaling (MAVS)-dependent signaling cascades and induced proinflammatory cytokine secretion. C3 also flagged viruses for rapid proteasomal degradation, preventing their replication. This system could detect both viral and bacterial pathogens but was antagonized by enteroviruses, such as rhinovirus and poliovirus, which cleave C3 using their 3C protease. The antiviral rupintrivir inhibited 3C protease and prevented C3 cleavage, rendering enteroviruses susceptible to intracellular complement sensing. Thus, complement C3 allows cells to detect and disable pathogens that have invaded the cytosol. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tam</LastName>
<ForeName>Jerry C H</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bidgood</LastName>
<ForeName>Susanna R</ForeName>
<Initials>SR</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McEwan</LastName>
<ForeName>William A</ForeName>
<Initials>WA</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>James</LastName>
<ForeName>Leo C</ForeName>
<Initials>LC</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK. lcj@mrc-lmb.cam.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>U105181010</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003176">Complement C3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C035401">SS-A antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000256">Adenoviridae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000258">Adenovirus Infections, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000914">Antibodies, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003176">Complement C3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050835">Interferon Regulatory Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012261">Ribonucleoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018808">Transcription Factor AP-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">EMS60318 [Available on 03/05/15]</OtherID>
<OtherID Source="NLM">PMC4172439 [Available on 03/05/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24931396</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-5835</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>38</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia research</Title>
<ISOAbbreviation>Leuk. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Are we altering the natural history of primary myelofibrosis?</ArticleTitle>
<Pagination>
<MedlinePgn>1004-12</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2014.04.012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0145-2126(14)00123-4</ELocationID>
<Abstract>
<AbstractText>Primary myelofibrosis (PMF) is a clonal hematologic malignancy with a variable disease course; survival ranges from months to years. Historically, only allogeneic hematopoietic stem cell transplantation (alloHSCT) has demonstrated an ability to alter the natural history of PMF, but high treatment-related mortality risks limit the utility of alloHSCT to a minority of patients with PMF or myelofibrosis secondary to other myeloproliferative neoplasms. The recent development of therapies that regulate the Janus kinase-signal transducer and activator of transcription signaling pathway has changed the treatment landscape from primarily palliative treatment to potential disease modification. </AbstractText>
<CopyrightInformation>Copyright © 2014 The Author. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Savona</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: michael.savona@vanderbilt.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leuk Res</MedlineTA>
<NlmUniqueID>7706787</NlmUniqueID>
<ISSNLinking>0145-2126</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C507924">JAK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Leuk Res. 2014 Sep;38(9):1013-5</RefSource>
<PMID Version="1">25073660</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055728">Primary Myelofibrosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050791">STAT Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">JAK inhibitors</Keyword>
<Keyword MajorTopicYN="N">Myelofibrosis</Keyword>
<Keyword MajorTopicYN="N">Proinflammatory cytokines</Keyword>
<Keyword MajorTopicYN="N">Spleen volume</Keyword>
<Keyword MajorTopicYN="N">Targeted therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25022756</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>HUWE1 is a molecular link controlling RAF-1 activity supported by the Shoc2 scaffold.</ArticleTitle>
<Pagination>
<MedlinePgn>3579-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00811-14</ELocationID>
<Abstract>
<AbstractText>Scaffold proteins play a critical role in controlling the activity of the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway. Shoc2 is a leucine-rich repeat scaffold protein that acts as a positive modulator of ERK1/2 signaling. However, the precise mechanism by which Shoc2 modulates the activity of the ERK1/2 pathway is unclear. Here we report the identification of the E3 ubiquitin ligase HUWE1 as a binding partner and regulator of Shoc2 function. HUWE1 mediates ubiquitination and, consequently, the levels of Shoc2. Additionally, we show that both Shoc2 and HUWE1 are necessary to control the levels and ubiquitination of the Shoc2 signaling partner, RAF-1. Depletion of HUWE1 abolishes RAF-1 ubiquitination, with corresponding changes in ERK1/2 pathway activity occurring. Our results indicate that the HUWE1-mediated ubiquitination of Shoc2 is the switch that regulates the transition from an active to an inactive state of the RAF-1 kinase. Taken together, our results demonstrate that HUWE1 is a novel player involved in regulating ERK1/2 signal transmission through the Shoc2 scaffold complex. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jang</LastName>
<ForeName>Eun Ryoung</ForeName>
<Initials>ER</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Ping</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bryant</LastName>
<ForeName>Jamal</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dukhande</LastName>
<ForeName>Vikas</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gentry</LastName>
<ForeName>Matthew S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jang</LastName>
<ForeName>HyeIn</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jeoung</LastName>
<ForeName>Myoungkun</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Galperin</LastName>
<ForeName>Emilia</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA emilia.galperin@uky.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20GM103486</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103486)</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R00CA126161</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01NS070899</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C112913">SHOC2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D019908">Proto-Oncogene Proteins c-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C502830">HUWE1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019556">COS Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002522">Cercopithecus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054730">Protein Interaction Domains and Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019908">Proto-Oncogene Proteins c-raf</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D054875">Ubiquitination</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187736 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047839</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.</ArticleTitle>
<Pagination>
<MedlinePgn>3642-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00814-14</ELocationID>
<Abstract>
<AbstractText>One outcome of activation of the phosphatidylinositol 3-kinase (PI3K) pathway is increased aerobic glycolysis, but the upstream signaling events that regulate the PI3K pathway, and thus the Warburg effect, are elusive. Increasing evidence suggests that Plk1, a cell cycle regulator, is also involved in cellular events in addition to mitosis. To test whether Plk1 contributes to activation of the PI3K pathway, and thus aerobic glycolysis, we examined potential targets of Plk1 and identified PTEN as a Plk1 substrate. We hypothesize that Plk1 phosphorylation of PTEN leads to its inactivation, activation of the PI3K pathway, and the Warburg effect. Our data show that overexpression of Plk1 leads to activation of the PI3K pathway and enhanced aerobic glycolysis. In contrast, inhibition of Plk1 causes markedly reduced glucose metabolism in mice. Mechanistically, we show that Plk1 phosphorylation of PTEN and Nedd4-1, an E3 ubiquitin ligase of PTEN, results in PTEN inactivation. Finally, we show that Plk1 phosphorylation of PTEN promotes tumorigenesis in both its phosphatase-dependent and -independent pathways, revealing potentially new drug targets to arrest tumor cell growth. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zhiguo</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bi</LastName>
<ForeName>Pengpeng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burcham</LastName>
<ForeName>Grant</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Elzey</LastName>
<ForeName>Bennett D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo>
<Affiliation>Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ratliff</LastName>
<ForeName>Timothy</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Konieczny</LastName>
<ForeName>Stephen F</ForeName>
<Initials>SF</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahmad</LastName>
<ForeName>Nihal</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, University of Wisconsin, Madison, Wisconsin, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuang</LastName>
<ForeName>Shihuan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Xiaoqi</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA liu8@purdue.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA023168</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA124586</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA157429</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA176748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C518477">BI 2536</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056827">Endosomal Sorting Complexes Required for Transport</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006574">Heterocyclic Compounds, 2-Ring</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011621">Pteridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.137</RegistryNumber>
<NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C090134">polo-like kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C099897">Nedd4 ubiquitin protein ligases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SH1WY3R615</RegistryNumber>
<NameOfSubstance UI="D015739">Nocodazole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2010 Jan 15;16(2):384-9</RefSource>
<PMID Version="1">20068088</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 2010 Mar;138(3):1012-21.e1-5</RefSource>
<PMID Version="1">19962984</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Drug Discov. 2010 Aug;9(8):643-60</RefSource>
<PMID Version="1">20671765</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Sep 1;29(17):2953-65</RefSource>
<PMID Version="1">20664522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18868-73</RefSource>
<PMID Version="1">20921411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19135-6</RefSource>
<PMID Version="1">21041650</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2011 Jan;10(1):M110.004457</RefSource>
<PMID Version="1">20860994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2011 Jan 21;144(2):187-99</RefSource>
<PMID Version="1">21241890</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4129-34</RefSource>
<PMID Version="1">21325052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2011 Jun;13(6):728-33</RefSource>
<PMID Version="1">21532586</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2011;2:395</RefSource>
<PMID Version="1">21772266</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Metab. 2011 Oct 5;14(4):443-51</RefSource>
<PMID Version="1">21982705</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2011 Nov;10(11):M111.008540</RefSource>
<PMID Version="1">21857030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2011 Dec;31(23):4844-56</RefSource>
<PMID Version="1">21947279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2011 Dec 9;44(5):721-33</RefSource>
<PMID Version="1">22152476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2012 Jan 9;196(1):29-36</RefSource>
<PMID Version="1">22213801</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 Mar 30;149(1):49-62</RefSource>
<PMID Version="1">22401813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2012 May;13(5):283-96</RefSource>
<PMID Version="1">22473468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2012 Jun 15;444(3):457-64</RefSource>
<PMID Version="1">22413754</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2012 Jun 8;287(24):20088-99</RefSource>
<PMID Version="1">22511782</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2012 Sep;11(9):629-39</RefSource>
<PMID Version="1">22593177</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2013 Apr;23(4):552-64</RefSource>
<PMID Version="1">23419514</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2014 May 16;289(20):14066-74</RefSource>
<PMID Version="1">24706748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2000 Jul;20(14):5010-8</RefSource>
<PMID Version="1">10866658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2000 Oct 13;103(2):253-62</RefSource>
<PMID Version="1">11057898</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2000 Nov;157(5):1623-31</RefSource>
<PMID Version="1">11073822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2001 Jan 12;276(2):993-8</RefSource>
<PMID Version="1">11035045</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2001 Dec 28;276(52):48627-30</RefSource>
<PMID Version="1">11707428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94</RefSource>
<PMID Version="1">12732729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1990 Sep 15;50(18):6075-86</RefSource>
<PMID Version="1">1975513</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 1997 Jun;18(6):1215-23</RefSource>
<PMID Version="1">9214605</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1998 May 29;273(22):13375-8</RefSource>
<PMID Version="1">9593664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5</RefSource>
<PMID Version="1">10200246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene Ther. 1999 Jul;6(7):1258-66</RefSource>
<PMID Version="1">10455434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2006 Mar;26(6):2093-108</RefSource>
<PMID Version="1">16507989</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Jan 12;128(1):129-39</RefSource>
<PMID Version="1">17218260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Jan 12;128(1):141-56</RefSource>
<PMID Version="1">17218261</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2007 Feb 20;17(4):304-15</RefSource>
<PMID Version="1">17291761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1919-24</RefSource>
<PMID Version="1">18250300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2008 Mar 7;283(10):6209-21</RefSource>
<PMID Version="1">18171681</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2008 May 2;133(3):403-14</RefSource>
<PMID Version="1">18455982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ther. 2008 Jun;16(6):1073-80</RefSource>
<PMID Version="1">18414476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2008 Jun 1;68(11):4077-85</RefSource>
<PMID Version="1">18519666</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2008 Jun 26;27(28):3935-43</RefSource>
<PMID Version="1">18297112</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056827">Endosomal Sorting Complexes Required for Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006574">Heterocyclic Compounds, 2-Ring</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015739">Nocodazole</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051059">PTEN Phosphohydrolase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058539">Phosphatidylinositol 3-Kinase</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011621">Pteridines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187734</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25071152</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.</ArticleTitle>
<Pagination>
<MedlinePgn>3689-701</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00341-14</ELocationID>
<Abstract>
<AbstractText>Breast cancers are stratified into distinct subtypes, which influence therapeutic responsiveness and patient outcome. Patients with luminal breast cancers are often associated with a better prognosis relative to that with other subtypes. However, subsets of patients with luminal disease remain at increased risk of cancer-related death. A critical process that increases the malignant potential of breast cancers is the epithelial-to-mesenchymal transition (EMT). The p66ShcA adaptor protein stimulates the formation of reactive oxygen species in response to stress stimuli. In this paper, we report a novel role for p66ShcA in inducing an EMT in HER2(+) luminal breast cancers. p66ShcA increases the migratory properties of breast cancer cells and enhances signaling downstream of the Met receptor tyrosine kinase in these tumors. Moreover, Met activation is required for a p66ShcA-induced EMT in luminal breast cancer cells. Finally, elevated p66ShcA levels are associated with the acquisition of an EMT in primary breast cancers spanning all molecular subtypes, including luminal tumors. This is of high clinical relevance, as the luminal and HER2 subtypes together comprise 80% of all newly diagnosed breast cancers. This study identifies p66ShcA as one of the first prognostic biomarkers for the identification of more aggressive tumors with mesenchymal properties, regardless of molecular subtype. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hudson</LastName>
<ForeName>Jesse</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ha</LastName>
<ForeName>Jacqueline R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sabourin</LastName>
<ForeName>Valerie</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Ryuhjin</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>La Selva</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Livingstone</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Podmore</LastName>
<ForeName>Lauren</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Knight</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Forrest</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada Goodman Cancer Research Centre, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beauchemin</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada Department of Oncology, McGill University, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hallett</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Morag</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada Department of Oncology, McGill University, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ursini-Siegel</LastName>
<ForeName>Josie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada Department of Oncology, McGill University, Montreal, Quebec, Canada giuseppina.ursini-siegel@mcgill.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C528024">SHC1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055765">Shc Signaling Adaptor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C491743">MET protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019859">Proto-Oncogene Proteins c-met</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055765">Shc Signaling Adaptor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187732 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25106425</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-0111</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>86</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular pharmacology</Title>
<ISOAbbreviation>Mol. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?</ArticleTitle>
<Pagination>
<MedlinePgn>430-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/mol.114.094649</ELocationID>
<Abstract>
<AbstractText>The past decades have seen an exponential rise in our understanding of the endocannabinoid system, comprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes that synthesize and degrade endocannabinoids. The primary focus of this review is the CB2 receptor. CB2 receptors have been the subject of considerable attention, primarily due to their promising therapeutic potential for treating various pathologies while avoiding the adverse psychotropic effects that can accompany CB1 receptor-based therapies. With the appreciation that CB2-selective ligands show marked functional selectivity, there is a renewed opportunity to explore this promising area of research from both a mechanistic as well as a therapeutic perspective. In this review, we summarize our present knowledge of CB2 receptor signaling, localization, and regulation. We discuss the availability of genetic tools (and their limitations) to study CB2 receptors and also provide an update on preclinical data on CB2 agonists in pain models. Finally, we suggest possible reasons for the failure of CB2 ligands in clinical pain trials and offer possible ways to move the field forward in a way that can help reconcile the inconsistencies between preclinical and clinical data. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dhopeshwarkar</LastName>
<ForeName>Amey</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychological and Brain Sciences and Gill Center, Indiana University, Bloomington, Indiana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mackie</LastName>
<ForeName>Ken</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychological and Brain Sciences and Gill Center, Indiana University, Bloomington, Indiana kmackie@indiana.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Pharmacol</MedlineTA>
<NlmUniqueID>0035623</NlmUniqueID>
<ISSNLinking>0026-895X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D063386">Cannabinoid Receptor Agonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043885">Receptor, Cannabinoid, CB2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063386">Cannabinoid Receptor Agonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043885">Receptor, Cannabinoid, CB2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4164977 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25194176</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1916</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Best practice &amp; research. Clinical gastroenterology</Title>
<ISOAbbreviation>Best Pract Res Clin Gastroenterol</ISOAbbreviation>
</Journal>
<ArticleTitle>Bile acids, obesity, and the metabolic syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>573-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bpg.2014.07.004</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6918(14)00082-1</ELocationID>
<Abstract>
<AbstractText>Bile acids are increasingly recognized as key regulators of systemic metabolism. While bile acids have long been known to play important and direct roles in nutrient absorption, bile acids also serve as signalling molecules. Bile acid interactions with the nuclear hormone receptor farnesoid X receptor (FXR) and the membrane receptor G-protein-coupled bile acid receptor 5 (TGR5) can regulate incretin hormone and fibroblast growth factor 19 (FGF19) secretion, cholesterol metabolism, and systemic energy expenditure. Bile acid levels and distribution are altered in type 2 diabetes and increased following bariatric procedures, in parallel with reduced body weight and improved insulin sensitivity and glycaemic control. Thus, modulation of bile acid levels and signalling, using bile acid binding resins, TGR5 agonists, and FXR agonists, may serve as a potent therapeutic approach for the treatment of obesity, type 2 diabetes, and other components of the metabolic syndrome in humans. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Huijuan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Endocrinology and Metabolism, Hebei General Hospital, Shijiazhuang, Hebei 050051, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Patti</LastName>
<ForeName>Mary Elizabeth</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, MA 02215, USA. Electronic address: Mary.Elizabeth.Patti@joslin.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 DK036836</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30DK036836</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Best Pract Res Clin Gastroenterol</MedlineTA>
<NlmUniqueID>101120605</NlmUniqueID>
<ISSNLinking>1521-6918</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117476">FGF19 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C473772">GPBAR1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C091671">XCR1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62031-54-3</RegistryNumber>
<NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001647">Bile Acids and Salts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004734">Energy Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005346">Fibroblast Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024821">Metabolic Syndrome X</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618338 [Available on 08/01/15]</OtherID>
<OtherID Source="NLM">PMC4159616 [Available on 08/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Bile acids</Keyword>
<Keyword MajorTopicYN="N">FXR</Keyword>
<Keyword MajorTopicYN="N">Insulin resistance</Keyword>
<Keyword MajorTopicYN="N">Obesity</Keyword>
<Keyword MajorTopicYN="N">TGR5</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24995813</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1470-8728</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>463</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Biochemical journal</Title>
<ISOAbbreviation>Biochem. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>cAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products.</ArticleTitle>
<Pagination>
<MedlinePgn>75-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1042/BJ20140084</ELocationID>
<Abstract>
<AbstractText>Clarification of the roles of PAMPs (pathogen-associated molecular patterns) and DAMPs (damage-associated molecular patterns) is indispensable for therapeutic strategies against various inflammatory diseases. RAGE (receptor for advanced glycation end-products) is one of the PRRs (pattern recognition receptors) and has been implicated in autoimmune and inflammatory diseases. Effective remedies targeting RAGE are required for the diseases. In the present study, we show that cAMP-induced modulation of the RAGE isoform in macrophages can control the inflammatory state in both in vitro and in vivo experimental conditions. The RAGE ligand S100B stimulated MCP-1 (monocyte chemoattractant protein-1) secretion from peritoneal macrophages, but cAMP elevation suppressed it by converting the RAGE isoform from a membrane-bound into a soluble form. This shedding is the result of ectodomain cleavage of mRAGE (membrane-bound RAGE) by MMP9 (matrix metalloproteinase 9). Furthermore, forskolin significantly inhibited peritoneal macrophage accumulation in a mouse S100B-induced peritonitis model. These results suggest that cAMP serves as a negative regulator of ligand-RAGE signalling and macrophage recruitment by mRAGE down-regulation and formation of decoys as soluble receptors. The present study should deepen our understanding of the pathogenesis of RAGE-mediated tissue derangement and provide new clues for overcoming RAGE-related inflammatory diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Motoyoshi</LastName>
<ForeName>So</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Yasuhiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Munesue</LastName>
<ForeName>Seiichi</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Igawa</LastName>
<ForeName>Hirobumi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Harashima</LastName>
<ForeName>Ai</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saito</LastName>
<ForeName>Hidehito</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Dong</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Watanabe</LastName>
<ForeName>Takuo</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>†Department of Molecular Virology and Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 920-8640, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem J</MedlineTA>
<NlmUniqueID>2984726R</NlmUniqueID>
<ISSNLinking>0264-6021</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491768">Ccl2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C579159">S100b protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C068348">advanced glycosylation end-product receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="C501830">Mmp9 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.35</RegistryNumber>
<NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018932">Chemokine CCL2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017737">Macrophages, Peritoneal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020780">Matrix Metalloproteinase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011971">Receptors, Immunologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064568">S100 Calcium Binding Protein beta Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25195735</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1470-8728</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>463</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Biochemical journal</Title>
<ISOAbbreviation>Biochem. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>157-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1042/BJ20140680</ELocationID>
<Abstract>
<AbstractText>ATX (autotaxin) is a secreted lysophospholipase capable of catalysing the formation of the bioactive lipid mediator LPA (lysophosphatidate) from LPC (lysophosphatidylcholine). The ATX-LPA signalling axis plays an important role in both normal physiology and disease pathogenesis, including cancer. In a number of different human cancers, expression of ATX and the G-protein-coupled LPARs (lysophosphatidic acid receptors) have been shown to be elevated and their activation regulates many processes central to tumorigenesis, including proliferation, invasion, migration and angiogenesis. The present review provides an overview of the ATX-LPA signalling axis and collates current knowledge regarding its specific role in breast cancer. The potential manipulation of this pathway to facilitate diagnosis and treatment is also discussed. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Teo</LastName>
<ForeName>Katy</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brunton</LastName>
<ForeName>Valerie G</ForeName>
<Initials>VG</Initials>
<AffiliationInfo>
<Affiliation>*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>101911</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>C157/A15703</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem J</MedlineTA>
<NlmUniqueID>2984726R</NlmUniqueID>
<ISSNLinking>0264-6021</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008246">Lysophospholipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>22002-87-5</RegistryNumber>
<NameOfSubstance UI="C032881">lysophosphatidic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.4.-</RegistryNumber>
<NameOfSubstance UI="D010727">Phosphoric Diester Hydrolases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.4.39</RegistryNumber>
<NameOfSubstance UI="C052949">alkylglycerophosphoethanolamine phosphodiesterase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008246">Lysophospholipids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010727">Phosphoric Diester Hydrolases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23362215</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-7278</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>29</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Environmental toxicology</Title>
<ISOAbbreviation>Environ. Toxicol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Wogonin attenuates endotoxin-induced prostaglandin E2 and nitric oxide production via Src-ERK1/2-NFκB pathway in BV-2 microglial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1162-70</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/tox.21847</ELocationID>
<Abstract>
<AbstractText>Microglia are the major component of intrinsic brain immune system in neuroinflammation. Although wogonin expresses anti-inflammatory function in microglia, little is known about the molecular mechanisms of the protective effect of wogonin against microglia activation. The aim of this study was to evaluate how wogonin exerts its anti-inflammatory function in BV2 microglial cells after LPS/INFγ administration. Wogonin not only inhibited LPS/ INFγ-induced PGE2 and NO production without affecting cell viability but also exhibited parallel inhibition on LPS/INFγ-induced expression of iNOS and COX-2 in the same concentration range. While LPS/INFγ-induced expression of P-p65 and P-IκB was inhibited by wogonin-only weak inhibition on P-p38 and P-JNK were observed, whereas it significantly attenuated the P-ERK1/2 and its upstream activators P-MEK1/2 and P-Src in a parallel concentration-dependent manner. These results indicated that the blockade of PGE2 and NO production by wogonin in LPS/INFγ-stimulated BV2 cells is attributed mainly to interference in the Src-MEK1/2-ERK1/2-NFκB-signaling pathway.</AbstractText>
<CopyrightInformation>Copyright © 2013 Wiley Periodicals, Inc., a Wiley company.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yeh</LastName>
<ForeName>Chung-Hsin</ForeName>
<Initials>CH</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Show Chwan Memorial Hospital, Changhua, Taiwan, Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Ming-Ling</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Chien-Ying</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Ching-Ping</ForeName>
<Initials>CP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yi-Ching</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Chun-Jung</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuan</LastName>
<ForeName>Yu-Hsiang</ForeName>
<Initials>YH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>01</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Environ Toxicol</MedlineTA>
<NlmUniqueID>100885357</NlmUniqueID>
<ISSNLinking>1520-4081</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044950">Flavanones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>31C4KY9ESH</RegistryNumber>
<NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>632-85-9</RegistryNumber>
<NameOfSubstance UI="C085514">wogonin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K7Q1JQR04M</RegistryNumber>
<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044950">Flavanones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">MEK1/2-ERK1/2</Keyword>
<Keyword MajorTopicYN="N">NFκB</Keyword>
<Keyword MajorTopicYN="N">Src</Keyword>
<Keyword MajorTopicYN="N">microglia</Keyword>
<Keyword MajorTopicYN="N">wogonin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24697328</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>L-Arginine modulates neonatal lymphocyte proliferation through an interleukin-2 independent pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>184-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12300</ELocationID>
<Abstract>
<AbstractText>In cases of arginine depletion, lymphocyte proliferation, cytokine production and CD3ζ chain expression are all diminished. In addition to myeloid suppressor cells, polymorphonuclear cells (PMN) also exert T-cell immune suppressive effects through arginase-induced l-arginine depletion, especially during pregnancy. In this study, we investigated how arginase/l-arginine modulates neonatal lymphocyte proliferation. Results showed that the neonatal plasma l-arginine level was lower than in adults (48·1 ± 11·3 versus 86·5 ± 14·6 μm; P = 0·003). Neonatal PMN had a greater abundance of arginase I protein than adult PMN. Both transcriptional regulation and post-transcriptional regulation were responsible for the higher arginase I expression of neonatal PMN. Exogenous l-arginine enhanced neonate lymphocyte proliferation but not that of adult cells. The RNA-binding protein HuR was important but was not the only modulation factor in l-arginine-regulated neonatal T-cell proliferation. l-Arginine-mediated neonatal lymphocyte proliferation could not be blocked by interleukin-2 receptor blocking antibodies. These results suggest that the altered arginase/l-arginine cascade may be one of the mechanisms that contribute to altered neonatal immune responses. Exogenous l-arginine could enhance neonate lymphocyte proliferation through an interleukin-2-independent pathway.</AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Hong-Ren</ForeName>
<Initials>HR</Initials>
<AffiliationInfo>
<Affiliation>Department of Paediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Centre, Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Kaohsiug, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuo</LastName>
<ForeName>Ho-Chang</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Li-Tung</ForeName>
<Initials>LT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Chih-Cheng</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tain</LastName>
<ForeName>You-Lin</ForeName>
<Initials>YL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sheen</LastName>
<ForeName>Jiunn-Ming</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tiao</LastName>
<ForeName>Mao-Meng</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Hsin-Chun</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Kuender D</ForeName>
<Initials>KD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ou</LastName>
<ForeName>Chia-Yo</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hsu</LastName>
<ForeName>Te-Yao</ForeName>
<Initials>TY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051959">Hu Paraneoplastic Encephalomyelitis Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508594">IL2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>94ZLA3W45F</RegistryNumber>
<NameOfSubstance UI="D001120">Arginine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.3.1</RegistryNumber>
<NameOfSubstance UI="D001119">Arginase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.3.1</RegistryNumber>
<NameOfSubstance UI="C574619">arginase I, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001119">Arginase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001120">Arginine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005312">Fetal Blood</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051959">Hu Paraneoplastic Encephalomyelitis Antigens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007376">Interleukin-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009504">Neutrophils</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015375">Receptors, Interleukin-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172135 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">arginase</Keyword>
<Keyword MajorTopicYN="N">interleukin-2</Keyword>
<Keyword MajorTopicYN="N">l-arginine</Keyword>
<Keyword MajorTopicYN="N">lymphocyte proliferation</Keyword>
<Keyword MajorTopicYN="N">neonate</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24766459</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice.</ArticleTitle>
<Pagination>
<MedlinePgn>202-18</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12304</ELocationID>
<Abstract>
<AbstractText>Differentiation of CD4(+) T cells into type 1 or type 2 subsets is mediated by the expression of the opposing lineage defining transcription factors T-bet and GATA-3. However, the existence of GATA-3(+) T-bet(+) CD4(+) T cells in mice suggests functional plasticity of these subsets. Little is known about type 1 and type 2 plasticity of human T-cell subsets in vivo. Here, we show that in the xenogeneic environment of humanized mice, which lacks a functional immune-regulatory network, human CD4(+) and, notably, CD8(+) T cells preferentially differentiate into interleukin (IL)-4(+) GATA-3(+) and IL-4(+) interferon-γ(+) GATA-3(+) T-bet(+) subsets. Treatment with recombinant human IL-12 or expansion of IL-12-producing human dendritic cells in vivo reverted this phenotype and led to the down-regulation of GATA-3 expression. These changes also correlated with improved antiviral immune responses in humanized mice. In conclusion, our study shows the capacity of human CD4(+) and CD8(+) T cells for stable co-expression of GATA-3 and T-bet in humanized mice and reveals a critical role for IL-12 in regulating this phenotype.</AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Billerbeck</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Labitt</LastName>
<ForeName>Rachael N</ForeName>
<Initials>RN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vega</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frias-Staheli</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dorner</LastName>
<ForeName>Marcus</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Jing W</ForeName>
<Initials>JW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rice</LastName>
<ForeName>Charles M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ploss</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01DK085713</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U19AI057266</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1RR024143</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050990">GATA3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494749">GATA3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C573415">IFNG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508598">IL4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020825">T-Box Domain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C406820">T-box transcription factor TBX21</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>187348-17-0</RegistryNumber>
<NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>207137-56-2</RegistryNumber>
<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000256">Adenoviridae</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019070">Cell Lineage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050990">GATA3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007274">Injections, Intraperitoneal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018664">Interleukin-12</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015847">Interleukin-4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007700">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020825">T-Box Domain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016176">T-Lymphocyte Subsets</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014183">Transplantation, Heterologous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172137 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">T-cell plasticity</Keyword>
<Keyword MajorTopicYN="N">humanized mice</Keyword>
<Keyword MajorTopicYN="N">interleukin-12</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24766487</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Wogonin prevents lipopolysaccharide-induced acute lung injury and inflammation in mice via peroxisome proliferator-activated receptor gamma-mediated attenuation of the nuclear factor-kappaB pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>241-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12305</ELocationID>
<Abstract>
<AbstractText>Acute lung injury (ALI) from a variety of clinical disorders, characterized by diffuse inflammation, is a cause of acute respiratory failure that develops in patients of all ages. Previous studies reported that wogonin, a flavonoid-like chemical compound which was found in Scutellaria baicalensis, has anti-inflammatory effects in several inflammation models, but not in ALI. Here, the in vivo protective effect of wogonin in the amelioration of lipopolysaccharide (LPS) -induced lung injury and inflammation was assessed. In addition, the in vitro effects and mechanisms of wogonin were studied in the mouse macrophage cell lines Ana-1 and RAW264.7. In vivo results indicated that wogonin attenuated LPS-induced histological alterations. Peripheral blood leucocytes decreased in the LPS-induced group, which was ameliorated by wogonin. In addition, wogonin inhibited the production of several inflammatory cytokines, including tumour necrosis factor-α, interleukin-1β (IL-1β) and IL-6, in the bronchoalveolar lavage fluid and lung tissues after LPS challenge, while the peroxisome proliferator-activated receptor γ (PPARγ) inhibitor GW9662 reversed these effects. In vitro results indicated that wogonin significantly decreased the secretion of IL-6, IL-1β and tumour necrosis factor-α in Ana-1 and RAW264.7 cells, which was suppressed by transfection of PPARγ small interfering RNA and GW9662 treatment. Moreover, wogonin activated PPARγ, induced PPARγ-mediated attenuation of the nuclear translocation and the DNA-binding activity of nuclear factor-κB in vivo and in vitro. In conclusion, all of these results showed that wogonin may serve as a promising agent for the attenuation of ALI-associated inflammation and pathology by regulating the PPARγ-involved nuclear factor-κB pathway.</AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yao</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China; School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Di</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>You</LastName>
<ForeName>Qi-Dong</ForeName>
<Initials>QD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xi</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Qing-Long</ForeName>
<Initials>QL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Na</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044950">Flavanones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C482199">lipopolysaccharide, E coli O55-B5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>632-85-9</RegistryNumber>
<NameOfSubstance UI="C085514">wogonin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055371">Acute Lung Injury</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044950">Flavanones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018836">Inflammation Mediators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008070">Lipopolysaccharides</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047495">PPAR gamma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011014">Pneumonia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172140 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">acute lung injury</Keyword>
<Keyword MajorTopicYN="N">lipopolysaccharide</Keyword>
<Keyword MajorTopicYN="N">nuclear factor-κB</Keyword>
<Keyword MajorTopicYN="N">peroxisome proliferator-activated receptor γ</Keyword>
<Keyword MajorTopicYN="N">wogonin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24766519</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner.</ArticleTitle>
<Pagination>
<MedlinePgn>258-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12306</ELocationID>
<Abstract>
<AbstractText>Mycobacterium indicus pranii (MIP) is an atypical mycobacterial species possessing strong immunomodulatory properties. It is a potent vaccine candidate against tuberculosis, promotes Th1 immune response and protects mice from tumours. In previous studies, we demonstrated higher protective efficacy of MIP against experimental tuberculosis as compared with bacillus Calmette-Guérin (BCG). Since macrophages play an important role in the pathology of mycobacterial diseases and cancer, in the present study, we evaluated the MIP in live and killed form for macrophage activation potential, compared it with BCG and investigated the underlying mechanisms. High levels of tumour necrosis factor-α, interleukin-12p40 (IL-12p40), IL-6 and nitric oxide were produced by MIP-stimulated macrophages as compared with BCG-stimulated macrophages. Prominent up-regulation of co-stimulatory molecules CD40, CD80 and CD86 was also observed in response to MIP. Loss of response in MyD88-deficient macrophages showed that both MIP and BCG activate the macrophages in a MyD88-dependent manner. MyD88 signalling pathway culminates in nuclear factor-κB/activator protein-1 (NF-κB/AP-1) activation and higher activation of NF-κB/AP-1 was observed in response to MIP. With the help of pharmacological inhibitors and Toll-like receptor (TLR) -deficient macrophages, we observed the role of TLR2, TLR4 and intracellular TLRs in MIP-mediated macrophage activation. Stimulation of HEK293 cells expressing TLR2 in homodimeric or heterodimeric form showed that MIP has a distinctly higher level of TLR2 agonist activity compared with BCG. Further experiments suggested that TLR2 ligands are well exposed in MIP whereas they are obscured in BCG. Our findings establish the higher macrophage activation potential of MIP compared with BCG and delineate the underlying mechanism.</AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Pawan</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>National Institute of Immunology, New Delhi, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tyagi</LastName>
<ForeName>Rohit</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Das</LastName>
<ForeName>Gobardhan</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhaskar</LastName>
<ForeName>Sangeeta</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053762">Interleukin-12 Subunit p40</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507780">Myd88 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493486">Tlr2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>31C4KY9ESH</RegistryNumber>
<NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018836">Inflammation Mediators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016753">Interleukin-10</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053762">Interleukin-12 Subunit p40</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008262">Macrophage Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017737">Macrophages, Peritoneal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009163">Mycobacterium bovis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053594">Myeloid Differentiation Factor 88</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009170">Nontuberculous Mycobacteria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051195">Toll-Like Receptor 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018808">Transcription Factor AP-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172141 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Toll-like receptors</Keyword>
<Keyword MajorTopicYN="N">bacterial</Keyword>
<Keyword MajorTopicYN="N">cytokines</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24766550</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Nod2 and Rip2 contribute to innate immune responses in mouse neutrophils.</ArticleTitle>
<Pagination>
<MedlinePgn>269-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12307</ELocationID>
<Abstract>
<AbstractText>Nod-like receptors are a family of innate immune receptors that link cytosolic sensing of microbial and danger stimuli to the activation of immune responses. Two Nod-like receptor family members, Nod1 and Nod2, recognize bacterial peptidoglycan and activate immune responses via nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK). The function of Nod1 and Nod2 has been largely studied in macrophages, but the role of these receptors in other innate immune cells remains unclear. In this study, we examined the function of Nod1 and Nod2 in innate immune responses of neutrophils. Mice were injected intraperitoneally with thioglycollate, and then peritoneal neutrophils were isolated 4 hr after injection. Tri-DAP and muramyl-dipeptide (MDP) were used as Nod1 and Nod2 agonists, respectively. The level of cytokines [interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α)] and chemokines (CXCL1 and CCL2) was increased by MDP, but not Tri-DAP in wild-type (WT) neutrophils. Increased production of cytokines and chemokines with MDP was abolished in Nod2- and Rip2-deficient neutrophils. MDP also induced the activation of NF-κB and MAPK in WT neutrophils, but not in Nod2- and Rip2-deficient cells. Flow cytometry analysis showed that L-selectin shedding was induced by MDP in WT neutrophils, but not in Nod2- and Rip2-deficient cells. MDP and Toll-like receptor (TLR) agonists (Pam3 CSK4 and lipopolysaccharide) exerted synergistic effects on the production of IL-6 and CXCL1 in neutrophils. Moreover, Nod2 and TLR4 cooperated to produce IL-6, TNF-α, CXCL1 and CCL2 in neutrophils in response to Gram-negative bacteria. Our findings suggest that the Nod2-Rip2 axis may contribute to the innate immune response of neutrophils against bacterial infection.</AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jeong</LastName>
<ForeName>Yu-Jin</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, College of Medicine, Konyang University, Daejeon, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Min-Jung</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Sang-Jin</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chang-Hwan</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jee-Cheon</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Tae-Hyoun</ForeName>
<Initials>TH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Dong-Jae</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Donghyun</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Núñez</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Jong-Hwan</ForeName>
<Initials>JH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK61707</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495945">Card15 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507873">Card4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491768">Ccl2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054360">Chemokine CXCL1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C475895">Cxcl1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C555437">L-Ala-gamma-D-Glu-meso-diaminopimelic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053474">Nod1 Signaling Adaptor Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053473">Nod2 Signaling Adaptor Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C440499">lipopolysaccharide, Escherichia coli 0111 B4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>126880-86-2</RegistryNumber>
<NameOfSubstance UI="D019041">L-Selectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53678-77-6</RegistryNumber>
<NameOfSubstance UI="D000119">Acetylmuramyl-Alanyl-Isoglutamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>583-93-7</RegistryNumber>
<NameOfSubstance UI="D003960">Diaminopimelic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="C506255">Ripk2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000119">Acetylmuramyl-Alanyl-Isoglutamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018932">Chemokine CCL2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054360">Chemokine CXCL1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003960">Diaminopimelic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019041">L-Selectin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008089">Listeria monocytogenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018375">Neutrophil Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009504">Neutrophils</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053474">Nod1 Signaling Adaptor Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053473">Nod2 Signaling Adaptor Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009842">Oligopeptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015011">Yersinia pseudotuberculosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172142 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Nod2</Keyword>
<Keyword MajorTopicYN="N">Rip2</Keyword>
<Keyword MajorTopicYN="N">immune response</Keyword>
<Keyword MajorTopicYN="N">muramyl dipeptide</Keyword>
<Keyword MajorTopicYN="N">neutrophils</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24890927</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Regulation of immune responses by proton channels.</ArticleTitle>
<Pagination>
<MedlinePgn>131-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12326</ELocationID>
<Abstract>
<AbstractText>The identification of the HVCN1 gene, encoding the only mammalian voltage-gated proton channel, prompted a number of studies on how proton channels affect cellular functions. As their expression is mainly restricted to immune cells, it is not surprising that proton channels regulate different aspects of immune responses. In this review, I will examine the current knowledge of voltage-gated proton channels in both innate and adaptive responses and assess the remaining outstanding questions.</AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Capasso</LastName>
<ForeName>Melania</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C510235">Hv1 channel, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011522">Protons</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D056704">Adaptive Immunity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015640">Ion Channel Gating</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007473">Ion Channels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007962">Leukocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011522">Protons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172129 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HVCN1</Keyword>
<Keyword MajorTopicYN="N">Hv1</Keyword>
<Keyword MajorTopicYN="N">leucocytes</Keyword>
<Keyword MajorTopicYN="N">lymphocyte activation</Keyword>
<Keyword MajorTopicYN="N">proton channel</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24912917</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>143</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Transplantation and inflammation: implications for the modification of chemokine function.</ArticleTitle>
<Pagination>
<MedlinePgn>138-45</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12332</ELocationID>
<Abstract>
<AbstractText>Oxidative stress is a major and recurring cause of damage during inflammation, especially following organ transplantation. Initial ischaemia-reperfusion injury causes the production of many reactive oxygen and nitrogen species, and subsequent recruitment and activation of inflammatory cells can lead to further oxidative stress. This stress is well known to cause damage at the cellular level, for example by induction of senescence leading to the production of a characteristic senescence-associated secretory phenotype. Chemokines are an important component of the senescence-associated secretory phenotype, recruiting further leucocytes and reinforcing the stress and senescence responses. As well as inducing the production of proteins, including chemokines, oxidative stress can alter proteins themselves, both directly and by induction of enzymes capable of modification. These alterations can lead to important modifications to their biological activity and also alter detection by some antibodies, potentially limiting the biological relevance of some immunochemical and proteomic biomarkers. Peroxynitrite, a reactive nitrogen species generated during inflammation and ischaemia, can cause such modifications by nitrating chemokines. Matrix metalloproteinases, released by many stressed cells, can cleave chemokines, altering function, while peptidylarginine deiminases can inactivate certain chemokines by citrullination. This review discusses the relationship between inflammation and post-translational modification, focusing on the functional modulation of transplant-relevant pro-inflammatory chemokines.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Immunology Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barker</LastName>
<ForeName>Catriona E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo>
<Affiliation>Applied Immunobiology and Transplantation Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ali</LastName>
<ForeName>Simi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Boyle</LastName>
<ForeName>Graeme</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kirby</LastName>
<ForeName>John A</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018925">Chemokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018836">Inflammation Mediators</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016377">Organ Transplantation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172130 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">chemokines</Keyword>
<Keyword MajorTopicYN="N">inflammation</Keyword>
<Keyword MajorTopicYN="N">post-translational modification</Keyword>
<Keyword MajorTopicYN="N">stress</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24436106</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.</ArticleTitle>
<Pagination>
<MedlinePgn>2294-304</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.28726</ELocationID>
<Abstract>
<AbstractText>Protease activated receptor (PAR)-1 expression in tumor cells is associated with disease progression and overall survival in a variety of cancers of epithelial origin; however, the importance of PAR-1 in the tumor microenvironment remains unexplored. Utilizing an orthotopic pancreatic cancer model in which tumor cells are PAR-1 positive whereas stromal cells are PAR-1 negative, we show that PAR-1 expression in the microenvironment drives progression and induces chemoresistance of pancreatic cancer. PAR-1 enhances monocyte recruitment into the tumor microenvironment by regulating monocyte migration and fibroblast dependent chemokine production thereby inducing chemoresistance. Overall, our data identify a novel role of PAR-1 in the pancreatic tumor microenvironment and suggest that PAR-1 may be an attractive target to reduce drug resistance in pancreatic cancer. </AbstractText>
<CopyrightInformation>© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Queiroz</LastName>
<ForeName>Karla C S</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Kun</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Duitman</LastName>
<ForeName>JanWillem</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aberson</LastName>
<ForeName>Hella L</ForeName>
<Initials>HL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilmink</LastName>
<ForeName>Johanna W</ForeName>
<Initials>JW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>van Noesel</LastName>
<ForeName>Carel J M</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Richel</LastName>
<ForeName>Dick J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Spek</LastName>
<ForeName>C Arnold</ForeName>
<Initials>CA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044463">Receptor, PAR-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B76N6SBZ8R</RegistryNumber>
<NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007124">Immunoenzyme Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044463">Receptor, PAR-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017154">Stromal Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">chemoresistance</Keyword>
<Keyword MajorTopicYN="N">macrophage</Keyword>
<Keyword MajorTopicYN="N">microenvironment</Keyword>
<Keyword MajorTopicYN="N">protease activated receptors</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24706440</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>2305-16</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.28879</ELocationID>
<Abstract>
<AbstractText>MET is a master gene controlling a genetic program driving proliferation, apoptosis protection and invasion. The ROR1 pseudokinase acts as a MET substrate. However, its contribution to MET signaling and MET-dependent biological outcomes remains to be elucidated. By structure-function analysis of ROR1 mutants, we show that ROR1 encompasses two major substrate regions: one is located in the proline-rich domain and is directly phosphorylated by MET; the other resides in the pseudokinase domain and is phosphorylated through intermediate activation of SRC. Differential phosphorylation of these two regions dictates the execution of specific responses: phosphorylation of the ROR1 proline-rich domain by MET-but not phosphorylation of the pseudokinase domain by SRC-is necessary and sufficient to control MET-driven proliferation and protection from apoptosis. Differently, both the proline-rich and the pseudokinase domains mediate cell invasion. Consistent with the role of ROR1 in specifying the functional consequences of MET-dependent signals, ROR1 silencing leads to selective attenuation of only some of the signal transduction pathways sustained by MET. These data enlighten the so far elusive function(s) of pseudokinases and identify a mechanism of biological diversification, based on substrate specificity of oncogenic kinases. </AbstractText>
<CopyrightInformation>© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gentile</LastName>
<ForeName>Alessandra</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>ECMO, Experimental Clinical Molecular Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo (Torino), Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lazzari</LastName>
<ForeName>Luca</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benvenuti</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trusolino</LastName>
<ForeName>Livio</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Comoglio</LastName>
<ForeName>Paolo Maria</ForeName>
<Initials>PM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C491743">MET protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C078716">ROR1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D057050">Receptor Tyrosine Kinase-like Orphan Receptors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019556">COS Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002522">Cercopithecus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047468">Immunoprecipitation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016086">Lentivirus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010957">Plasmids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019859">Proto-Oncogene Proteins c-met</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011544">Pseudogenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057050">Receptor Tyrosine Kinase-like Orphan Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">RTK</Keyword>
<Keyword MajorTopicYN="N">oncogene addiction</Keyword>
<Keyword MajorTopicYN="N">pseudokinase</Keyword>
<Keyword MajorTopicYN="N">receptor tyrosine kinase</Keyword>
<Keyword MajorTopicYN="N">transphosphorylation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130873</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>135</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer. Journal international du cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>2262-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.29081</ELocationID>
<Abstract>
<AbstractText>Inevitably fatal some 40 years, acute promyelocytic leukemia (APL) can now be cured in more than 95% of cases. This clinical success story is tightly linked to tremendous progress in our understanding of retinoic acid (RA) signaling. The discovery of retinoic acid receptor alpha (RARA) was followed by the cloning of the chromosomal translocations driving APL, all of which involve RARA. Since then, new findings on the biology of nuclear receptors have progressively enlightened the basis for the clinical efficacy of RA in APL. Reciprocally, the disease offered a range of angles to approach the cellular and molecular mechanisms of RA action. This virtuous circle contributed to make APL one of the best-understood cancers from both clinical and biological standpoints. Yet, some important questions remain unanswered including how lessons learnt from RA-triggered APL cure can help design new therapies for other malignancies. </AbstractText>
<CopyrightInformation>© 2014 UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ablain</LastName>
<ForeName>Julien</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Université Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, Paris Cedex 10, France; INSERM U 944, Equipe labellisée par la Ligue Nationale contre le Cancer, Institut Universitaire d'Hématologie, Hôpital St. Louis, Paris Cedex 10, France; CNRS UMR 7212, Hôpital St. Louis, Paris Cedex 10, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Thé</LastName>
<ForeName>Hugues</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>5688UTC01R</RegistryNumber>
<NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015473">Leukemia, Promyelocytic, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">degradation</Keyword>
<Keyword MajorTopicYN="N">differentiation</Keyword>
<Keyword MajorTopicYN="N">leukemia</Keyword>
<Keyword MajorTopicYN="N">retinoic acid</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25134838</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1759-4820</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Urology</Title>
<ISOAbbreviation>Nat Rev Urol</ISOAbbreviation>
</Journal>
<ArticleTitle>NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>499-507</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrurol.2014.195</ELocationID>
<Abstract>
<AbstractText>Prostate cancer is among the most prevalent life-threatening cancers diagnosed in the male population today. Various methods have been exploited in an attempt to treat this disease but these treatments, alongside preventative tactics, have been insufficient to control mortality rates and have usually resulted in detrimental adverse events. An opportunity to devise more-specific and potentially more-effective approaches for the eradication of prostate tumours can be found by targeting specific biological pathways. NUMB (protein numb homologue), a key regulator of cell fate, represents an attractive, actionable target in prostate cancer. NUMB participates in the observed deregulation of NOTCH (neurogenic locus notch homologue protein) signalling in prostate tumours, and the NUMB-NOTCH interaction regulates cell fate. NUMB has potential both as a target for control of prostate tumorigenesis and as a biomarker for identification of patients with prostate cancer who are likely to benefit from NOTCH inhibition. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Flores</LastName>
<ForeName>Angela N</ForeName>
<Initials>AN</Initials>
<AffiliationInfo>
<Affiliation>Division of International Health, Mount Sinai School of Medicine, New York, NY 10029, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McDermott</LastName>
<ForeName>Niamh</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Radiation and Urologic Oncology, Applied Radiation Therapy Trinity and Prostate Molecular Oncology Research Group, Trinity College Dublin, Trinity Centre for Health Sciences, James's Street, Dublin 8, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meunier</LastName>
<ForeName>Armelle</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Radiation and Urologic Oncology, Applied Radiation Therapy Trinity and Prostate Molecular Oncology Research Group, Trinity College Dublin, Trinity Centre for Health Sciences, James's Street, Dublin 8, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marignol</LastName>
<ForeName>Laure</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Radiation and Urologic Oncology, Applied Radiation Therapy Trinity and Prostate Molecular Oncology Research Group, Trinity College Dublin, Trinity Centre for Health Sciences, James's Street, Dublin 8, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MD001452</GrantID>
<Acronym>MD</Acronym>
<Agency>NIMHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Rev Urol</MedlineTA>
<NlmUniqueID>101500082</NlmUniqueID>
<ISSNLinking>1759-4812</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C113026">Numb protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051880">Receptors, Notch</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24611805</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-3024</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>36</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Parasite immunology</Title>
<ISOAbbreviation>Parasite Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunoregulatory networks in human Chagas disease.</ArticleTitle>
<Pagination>
<MedlinePgn>377-87</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/pim.12107</ELocationID>
<Abstract>
<AbstractText>Chagas disease, caused by the infection with Trypanosoma cruzi, is endemic in all Latin America. Due to the increase in population migration, Chagas disease has spread worldwide and is now considered a health issue not only in endemic countries. While most chronically infected individuals remain asymptomatic, approximately 30% of the patients develop a potentially deadly cardiomyopathy. The exact mechanisms that underlie the establishment and maintenance of the cardiac pathology are not clear. However, there is consistent evidence that immunoregulatory cytokines are critical for orchestrating the immune response and thus influence disease development or control. While the asymptomatic (indeterminate) form represents a state of balance between the host and the parasite, the establishment of the cardiac form represents the loss of this balance. Analysis of data obtained from several studies has led to the hypothesis that the indeterminate form is associated with an anti-inflammatory cytokine profile, represented by high expression of IL-10, while cardiac form is associated with a high production of IFN-gamma and TNF-alpha in relation to IL-10, leading to an inflammatory profile. Here, we discuss the immunoregulatory events that might influence disease outcome, as well as the mechanisms that influence the establishment of these complex immunoregulatory networks. </AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dutra</LastName>
<ForeName>W O</ForeName>
<Initials>WO</Initials>
<AffiliationInfo>
<Affiliation>Laboratório de Biologia das Interações Celulares, Departamento de Morfologia, Instituto de Ciências Biológicas, Belo Horizonte, MG, Brazil; Instituto Nacional de Ciência e Tecnologia - Doenças Tropicais - INCT-DT, Belo Horizonte, MG, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Menezes</LastName>
<ForeName>C A S</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Magalhães</LastName>
<ForeName>L M D</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gollob</LastName>
<ForeName>K J</ForeName>
<Initials>KJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI06604403</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R03 AI066044</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Parasite Immunol</MedlineTA>
<NlmUniqueID>7910948</NlmUniqueID>
<ISSNLinking>0141-9838</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014355">Chagas Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006790">Host-Parasite Interactions</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014349">Trypanosoma cruzi</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS571915 [Available on 08/01/15]</OtherID>
<OtherID Source="NLM">PMC4143493 [Available on 08/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chagas disease</Keyword>
<Keyword MajorTopicYN="N">Trypanosoma cruzi</Keyword>
<Keyword MajorTopicYN="N">cytokines</Keyword>
<Keyword MajorTopicYN="N">immunoregulation</Keyword>
<Keyword MajorTopicYN="N">neuroendocrine</Keyword>
<Keyword MajorTopicYN="N">pathology</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25071204</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>E3689-98</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1405801111</ELocationID>
<Abstract>
<AbstractText>Nitrogen-containing heterocyclic compounds are an important class of molecules that are commonly used for the synthesis of candidate drugs. Phosphatidylinositol-4-phosphate 5-kinase-α (PIP5Kα) is a lipid kinase, similar to PI3K. However, the role of PIP5K1α in oncogenic processes and the development of inhibitors that selectively target PIP5K1α have not been reported. In the present study we report that overexpression of PIP5K1α is associated with poor prognosis in prostate cancer and correlates with an elevated level of the androgen receptor. Overexpression of PIP5K1α in PNT1A nonmalignant cells results in an increased AKT activity and an increased survival, as well as invasive malignant phenotype, whereas siRNA-mediated knockdown of PIP5K1α in aggressive PC-3 cells leads to a reduced AKT activity and an inhibition in tumor growth in xenograft mice. We further report a previously unidentified role for PIP5K1α as a druggable target for our newly developed compound ISA-2011B using a high-throughput KINOMEscan platform. ISA-2011B was discovered during our synthetic studies of C-1 indol-3-yl substituted 1,2,3,4-tetrahydroisoquinolines via a Pictet-Spengler approach. ISA-2011B significantly inhibits growth of tumor cells in xenograft mice, and we show that this is mediated by targeting PIP5K1α-associated PI3K/AKT and the downstream survival, proliferation, and invasion pathways. Further, siRNA-mediated knockdown of PIP5K1α exerts similar effects on PC3 cells as ISA-2011B treatment, significantly inhibiting AKT activity, increasing apoptosis and reducing invasion. Thus, PIP5K1α has high potential as a drug target, and compound ISA-2011B is interesting for further development of targeted cancer therapy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Semenas</LastName>
<ForeName>Julius</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Cancer Research, Department of Laboratory Medicine, Clinical Research Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hedblom</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Cancer Research, Department of Laboratory Medicine, Clinical Research Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miftakhova</LastName>
<ForeName>Regina R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Cancer Research, Department of Laboratory Medicine, Clinical Research Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sarwar</LastName>
<ForeName>Martuza</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Cancer Research, Department of Laboratory Medicine, Clinical Research Center.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Larsson</LastName>
<ForeName>Rikard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Center for Analysis and Synthesis, Lund University, 22100, Lund, Sweden; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shcherbina</LastName>
<ForeName>Liliya</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Cancer Research, Department of Laboratory Medicine, Clinical Research Center, Division of Neuroendocrine Cell Biology, Department of Clinical Science, Clinical Research Center, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Johansson</LastName>
<ForeName>Martin E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Department of Laboratory Medicine, Lund University, 20502, Malmö, Sweden;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Härkönen</LastName>
<ForeName>Pirkko</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biomedicine, Department of Cell Biology and Anatomy, University of Turku, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sterner</LastName>
<ForeName>Olov</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Center for Analysis and Synthesis, Lund University, 22100, Lund, Sweden; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Persson</LastName>
<ForeName>Jenny L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Cancer Research, Department of Laboratory Medicine, Clinical Research Center, jenny_l.persson@med.lu.se.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054659">Diketopiperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592937">ISA-2011B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044005">Tetrahydroisoquinolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>91-21-4</RegistryNumber>
<NameOfSubstance UI="C014843">1,2,3,4-tetrahydroisoquinoline</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.68</RegistryNumber>
<NameOfSubstance UI="C020077">1-phosphatidylinositol-4-phosphate 5-kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Drug Discov. 2014 Oct;13(10):723</RefSource>
<PMID Version="1">25270953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12578-9</RefSource>
<PMID Version="1">25118275</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054659">Diketopiperazines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055808">Drug Discovery</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007546">Isoquinolines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044005">Tetrahydroisoquinolines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156761 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cancer metastasis</Keyword>
<Keyword MajorTopicYN="N">drug discovery</Keyword>
<Keyword MajorTopicYN="N">kinase inhibitor</Keyword>
<Keyword MajorTopicYN="N">targeted therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136113</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>IL-6/STAT3 promotes regeneration of airway ciliated cells from basal stem cells.</ArticleTitle>
<Pagination>
<MedlinePgn>E3641-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1409781111</ELocationID>
<Abstract>
<AbstractText>The pseudostratified airway epithelium of the lung contains a balanced proportion of multiciliated and secretory luminal cells that are maintained and regenerated by a population of basal stem cells. However, little is known about how these processes are modulated in vivo, and about the potential role of cytokine signaling between stem and progenitor cells and their niche. Using a clonal 3D organoid assay, we found that IL-6 stimulated, and Stat3 inhibitors reduced, the generation of ciliated vs. secretory cells from basal cells. Gain-of-function and loss-of-function studies with cultured mouse and human basal cells suggest that IL-6/Stat3 signaling promotes ciliogenesis at multiple levels, including increases in multicilin gene and forkhead box protein J1 expression and inhibition of the Notch pathway. To test the role of IL-6 in vivo genetically, we followed the regeneration of mouse tracheal epithelium after ablation of luminal cells by inhaled SO2. Stat3 is activated in basal cells and their daughters early in the repair process, correlating with an increase in Il-6 expression in platelet-derived growth factor receptor alpha(+) mesenchymal cells in the stroma. Conditional deletion in basal cells of suppressor of cytokine signaling 3, encoding a negative regulator of the Stat3 pathway, results in an increase in multiciliated cells at the expense of secretory and basal cells. By contrast, Il-6 null mice regenerate fewer ciliated cells and an increased number of secretory cells after injury. The results support a model in which IL-6, produced in the reparative niche, functions to enhance the differentiation of basal cells, and thereby acts as a "friend" to promote airway repair rather than a "foe." </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tadokoro</LastName>
<ForeName>Tomomi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Duke University Medical Center, Durham, NC 27710; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, and Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barak</LastName>
<ForeName>Larry S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Duke University Medical Center, Durham, NC 27710; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>Yushi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Duke University Medical Center, Durham, NC 27710; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Randell</LastName>
<ForeName>Scott H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, and Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hogan</LastName>
<ForeName>Brigid L M</ForeName>
<Initials>BL</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Duke University Medical Center, Durham, NC 27710; and brigid.hogan@dm.duke.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DA029925</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK065988</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 HL111018</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01-HL111018</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-22-9</RegistryNumber>
<NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2000 Mar;22(3):289-95</RefSource>
<PMID Version="1">10696065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2008 Dec;40(12):1445-53</RefSource>
<PMID Version="1">19011630</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2009 Jul;136(13):2297-307</RefSource>
<PMID Version="1">19502490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2009 Jun 26;137(7):1343-55</RefSource>
<PMID Version="1">19563763</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12771-5</RefSource>
<PMID Version="1">19625615</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2010 Jan 15;123(Pt 2):213-24</RefSource>
<PMID Version="1">20048339</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Cell Biol. 2010 Feb;2(1):37-49</RefSource>
<PMID Version="1">19797317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):219-31</RefSource>
<PMID Version="1">20695774</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dis Model Mech. 2010 Sep-Oct;3(9-10):545-56</RefSource>
<PMID Version="1">20699479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2011 May;1813(5):878-88</RefSource>
<PMID Version="1">21296109</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Stem Cell. 2011 Jun 3;8(6):639-48</RefSource>
<PMID Version="1">21624809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2011 Jun;13(6):693-9</RefSource>
<PMID Version="1">21602795</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2011 Aug;25(8):2659-68</RefSource>
<PMID Version="1">21518851</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2011 Sep 10;378(9795):1006-14</RefSource>
<PMID Version="1">21907864</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Mol Genet. 2011 Nov 1;20(21):4143-54</RefSource>
<PMID Version="1">21821671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2011 Nov 10;479(7372):189-93</RefSource>
<PMID Version="1">21983963</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2011 Dec;45(6):1133-41</RefSource>
<PMID Version="1">21642586</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2012 Feb;14(2):140-7</RefSource>
<PMID Version="1">22231168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2012 Apr;24(2):225-31</RefSource>
<PMID Version="1">22296770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Allergy Clin Immunol. 2012 Aug;130(2):510-5.e1</RefSource>
<PMID Version="1">22554704</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2012 Dec 1;139(23):4365-73</RefSource>
<PMID Version="1">23132245</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Biol Sci. 2012;8(9):1248-53</RefSource>
<PMID Version="1">23136553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Biol Sci. 2012;8(9):1281-90</RefSource>
<PMID Version="1">23136556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20035-40</RefSource>
<PMID Version="1">23169653</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Dyn. 2013 Jun;242(6):678-86</RefSource>
<PMID Version="1">23526493</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2013 Oct;140(20):4277-86</RefSource>
<PMID Version="1">24048590</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2014 Apr;141(7):1427-41</RefSource>
<PMID Version="1">24644260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2014 Jun 5;510(7503):115-20</RefSource>
<PMID Version="1">24899310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2014 Jul 1;28(13):1461-71</RefSource>
<PMID Version="1">24934224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2851-7</RefSource>
<PMID Version="1">24982181</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2001 Jun;24(6):662-70</RefSource>
<PMID Version="1">11415930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2001 Dec;108(12):1817-24</RefSource>
<PMID Version="1">11748265</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Lung Cell Mol Physiol. 2002 Dec;283(6):L1315-21</RefSource>
<PMID Version="1">12388377</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2003 Jun;23(11):4013-25</RefSource>
<PMID Version="1">12748302</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2003 Jun;4(6):540-5</RefSource>
<PMID Version="1">12754505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ther. 2003 Oct;8(4):637-45</RefSource>
<PMID Version="1">14529837</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Dev Biol. 2001;1:4</RefSource>
<PMID Version="1">11299042</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2004 Jan;113(1):28-37</RefSource>
<PMID Version="1">14702106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L650-7</RefSource>
<PMID Version="1">12818891</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods Mol Med. 2005;107:183-206</RefSource>
<PMID Version="1">15492373</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Respir Med. 1993 Aug;87 Suppl B:9-11</RefSource>
<PMID Version="1">8234974</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1995 Jul 28;82(2):241-50</RefSource>
<PMID Version="1">7543024</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1997 Jun 1;25(11):2062-7</RefSource>
<PMID Version="1">9153303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 1998 Sep 15;102(6):1077-82</RefSource>
<PMID Version="1">9739041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Aug 25;126(4):663-76</RefSource>
<PMID Version="1">16904174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Am Thorac Soc. 2006 Nov;3(8):718-25</RefSource>
<PMID Version="1">17065380</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):410-7</RefSource>
<PMID Version="1">17194755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2007 Sep;37(3):339-46</RefSource>
<PMID Version="1">17541011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2008 Apr;28(4):477-87</RefSource>
<PMID Version="1">18400190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2008 Jun;172(6):1542-54</RefSource>
<PMID Version="1">18467707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2009 May;136(10):1751-9</RefSource>
<PMID Version="1">19369400</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001980">Bronchi</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002923">Cilia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049452">Green Fluorescent Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061251">Primary Cell Culture</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012038">Regeneration</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020545">Respiratory Mucosa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014132">Trachea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156689</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cell fate</Keyword>
<Keyword MajorTopicYN="N">epithelial repair</Keyword>
<Keyword MajorTopicYN="N">mucociliary epithelium</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136120</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses.</ArticleTitle>
<Pagination>
<MedlinePgn>12835-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1406908111</ELocationID>
<Abstract>
<AbstractText>Group 3 innate lymphoid cells (ILC3s) have emerged as important cellular players in tissue repair and innate immunity. Whether these cells meaningfully regulate adaptive immune responses upon activation has yet to be explored. Here we show that upon IL-1β stimulation, peripheral ILC3s become activated, secrete cytokines, up-regulate surface MHC class II molecules, and express costimulatory molecules. ILC3s can take up latex beads, process protein antigen, and consequently prime CD4(+) T-cell responses in vitro. The cognate interaction of ILC3s and CD4(+) T cells leads to T-cell proliferation both in vitro and in vivo, whereas its disruption impairs specific T-cell and T-dependent B-cell responses in vivo. In addition, the ILC3-CD4(+) T-cell interaction is bidirectional and leads to the activation of ILC3s. Taken together, our data reveal a novel activation-dependent function of peripheral ILC3s in eliciting cognate CD4(+) T-cell immune responses. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>von Burg</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedicine, University of Basel, 4058 Basel, Switzerland; University Children's Hospital of Basel, 4056 Basel, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chappaz</LastName>
<ForeName>Stéphane</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedicine, University of Basel, 4058 Basel, Switzerland; Australian Cancer Research Foundation Chemical Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baerenwaldt</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedicine, University of Basel, 4058 Basel, Switzerland; University Children's Hospital of Basel, 4056 Basel, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Horvath</LastName>
<ForeName>Edit</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedicine, University of Basel, 4058 Basel, Switzerland; University Children's Hospital of Basel, 4056 Basel, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bose Dasgupta</LastName>
<ForeName>Somdeb</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Biozentrum, University of Basel, 4056 Basel, Switzerland; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ashok</LastName>
<ForeName>Devika</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pieters</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Biozentrum, University of Basel, 4056 Basel, Switzerland; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tacchini-Cottier</LastName>
<ForeName>Fabienne</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and World Health Organization Immunology Research and Training Centre, University of Lausanne, 1066 Epalinges, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rolink</LastName>
<ForeName>Antonius</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedicine, University of Basel, 4058 Basel, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Acha-Orbea</LastName>
<ForeName>Hans</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Finke</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedicine, University of Basel, 4058 Basel, Switzerland; University Children's Hospital of Basel, 4056 Basel, Switzerland; Daniela.Finke@unibas.ch.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017951">Antigen Presentation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000949">Histocompatibility Antigens Class II</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007111">Immunity, Cellular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156721 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">T-cell activation</Keyword>
<Keyword MajorTopicYN="N">antigen presentation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136127</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>A sharp T-cell antigen receptor signaling threshold for T-cell proliferation.</ArticleTitle>
<Pagination>
<MedlinePgn>E3679-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1413726111</ELocationID>
<Abstract>
<AbstractText>T-cell antigen receptor (TCR) signaling is essential for activation, proliferation, and effector function of T cells. Modulation of both intensity and duration of TCR signaling can regulate these events. However, it remains unclear how individual T cells integrate such signals over time to make critical cell-fate decisions. We have previously developed an engineered mutant allele of the critical T-cell kinase zeta-chain-associated protein kinase 70 kDa (Zap70) that is catalytically inhibited by a small molecule inhibitor, thereby blocking TCR signaling specifically and efficiently. We have also characterized a fluorescent reporter Nur77-eGFP transgenic mouse line in which T cells up-regulate GFP uniquely in response to TCR stimulation. The combination of these technologies unmasked a sharp TCR signaling threshold for commitment to cell division both in vitro and in vivo. Further, we demonstrate that this threshold is independent of both the magnitude of the TCR stimulus and Interleukin 2. Similarly, we identify a temporal threshold of TCR signaling that is required for commitment to proliferation, after which T cells are able to proliferate in a Zap70 kinase-independent manner. Taken together, our studies reveal a sharp threshold for the magnitude and duration of TCR signaling required for commitment of T cells to proliferation. These results have important implications for understanding T-cell responses to infection and optimizing strategies for immunomodulatory drug delivery. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Au-Yeung</LastName>
<ForeName>Byron B</ForeName>
<Initials>BB</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zikherman</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mueller</LastName>
<ForeName>James L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ashouri</LastName>
<ForeName>Judith F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matloubian</LastName>
<ForeName>Mehrdad</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>Debra A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yiling</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shokat</LastName>
<ForeName>Kevan M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cellular and Molecular Pharmacology, and Howard Hughes Medical Institute, University of California, San Francisco, CA 94143.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weiss</LastName>
<ForeName>Arthur</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Rosalind Russell and Ephraim P. Engleman Arthritis Research Center, Division of Rheumatology, Department of Medicine, Howard Hughes Medical Institute, University of California, San Francisco, CA 94143 aweiss@medicine.ucsf.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI091580</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08 AR059723</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC2AR058947</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C539818">Nr4a1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-22-9</RegistryNumber>
<NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D051746">ZAP-70 Protein-Tyrosine Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C497262">Zap70 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019264">Adoptive Transfer</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049452">Green Fluorescent Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007376">Interleukin-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011948">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051746">ZAP-70 Protein-Tyrosine Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156735 [Available on 03/02/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136128</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>A lipid zipper triggers bacterial invasion.</ArticleTitle>
<Pagination>
<MedlinePgn>12895-900</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1402637111</ELocationID>
<Abstract>
<AbstractText>Glycosphingolipids are important structural constituents of cellular membranes. They are involved in the formation of nanodomains ("lipid rafts"), which serve as important signaling platforms. Invasive bacterial pathogens exploit these signaling domains to trigger actin polymerization for the bending of the plasma membrane and the engulfment of the bacterium--a key process in bacterial uptake. However, it is unknown whether glycosphingolipids directly take part in the membrane invagination process. Here, we demonstrate that a "lipid zipper," which is formed by the interaction between the bacterial surface lectin LecA and its cellular receptor, the glycosphingolipid Gb3, triggers plasma membrane bending during host cell invasion of the bacterium Pseudomonas aeruginosa. In vitro experiments with Gb3-containing giant unilamellar vesicles revealed that LecA/Gb3-mediated lipid zippering was sufficient to achieve complete membrane engulfment of the bacterium. In addition, theoretical modeling elucidated that the adhesion energy of the LecA-Gb3 interaction is adequate to drive the engulfment process. In cellulo experiments demonstrated that inhibition of the LecA/Gb3 lipid zipper by either lecA knockout, Gb3 depletion, or application of soluble sugars that interfere with LecA binding to Gb3 significantly lowered P. aeruginosa uptake by host cells. Of note, membrane engulfment of P. aeruginosa occurred independently of actin polymerization, thus corroborating that lipid zippering alone is sufficient for this crucial first step of bacterial host-cell entry. Our study sheds new light on the impact of glycosphingolipids in the cellular invasion of bacterial pathogens and provides a mechanistic explication of the initial uptake processes.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eierhoff</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies, thorsten.eierhoff@bioss.uni-freiburg.de christian.fleck@wur.nl winfried.roemer@bioss.uni-freiburg.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bastian</LastName>
<ForeName>Björn</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Centre for Biological Systems Analysis, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thuenauer</LastName>
<ForeName>Roland</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Madl</LastName>
<ForeName>Josef</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Audfray</LastName>
<ForeName>Aymeric</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Centre de Recherches sur les Macromolécules Végétales, Université Grenoble Alpes and Centre National de la Recherche Scientifique, F38000 Grenoble, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aigal</LastName>
<ForeName>Sahaja</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies, International Max Planck Research School for Molecular and Cellular Biology, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Juillot</LastName>
<ForeName>Samuel</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies, Spemann Graduate School of Biology and Medicine, Albert Ludwigs University Freiburg, 79104 Freiburg, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rydell</LastName>
<ForeName>Gustaf E</ForeName>
<Initials>GE</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, Section for Clinical Virology, University of Gothenburg, S-413 46 Gothenburg, Sweden;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Müller</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Bentzmann</LastName>
<ForeName>Sophie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratoire d'Ingénierie des Systèmes Macromoléculaires, UMR7255 Centre National de la Recherche Scientifique and Aix Marseille University, Institut de Microbiologie de la Méditerranée, 13402 Marseille, France; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Imberty</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Centre de Recherches sur les Macromolécules Végétales, Université Grenoble Alpes and Centre National de la Recherche Scientifique, F38000 Grenoble, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fleck</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Centre for Biological Systems Analysis, and Laboratory for Systems and Synthetic Biology, Wageningen University, 6703 HB, Wageningen, The Netherlands thorsten.eierhoff@bioss.uni-freiburg.de christian.fleck@wur.nl winfried.roemer@bioss.uni-freiburg.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Römer</LastName>
<ForeName>Winfried</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Biology, BIOSS Centre for Biological Signalling Studies, Spemann Graduate School of Biology and Medicine, Albert Ludwigs University Freiburg, 79104 Freiburg, Germany; thorsten.eierhoff@bioss.uni-freiburg.de christian.fleck@wur.nl winfried.roemer@bioss.uni-freiburg.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018829">Adhesins, Bacterial</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006017">Glycolipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006028">Glycosphingolipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102929">LecA protein, bacteria</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013107">Sphingolipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>126550-86-5</RegistryNumber>
<NameOfSubstance UI="C063288">globotriaosyl lysosphingolipid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018829">Adhesins, Bacterial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001422">Bacterial Adhesion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006017">Glycolipids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006028">Glycosphingolipids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008051">Lipid Bilayers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021962">Membrane Microdomains</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011552">Pseudomonas Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011550">Pseudomonas aeruginosa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013107">Sphingolipids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156737 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">glycolipid</Keyword>
<Keyword MajorTopicYN="N">infection</Keyword>
<Keyword MajorTopicYN="N">membrane curvature</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136132</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.</ArticleTitle>
<Pagination>
<MedlinePgn>12853-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1407358111</ELocationID>
<Abstract>
<AbstractText>SET domain containing (lysine methyltransferase) 7 (SETD7) is implicated in multiple signaling and disease related pathways with a broad diversity of reported substrates. Here, we report the discovery of (R)-PFI-2-a first-in-class, potent (Ki (app) = 0.33 nM), selective, and cell-active inhibitor of the methyltransferase activity of human SETD7-and its 500-fold less active enantiomer, (S)-PFI-2. (R)-PFI-2 exhibits an unusual cofactor-dependent and substrate-competitive inhibitory mechanism by occupying the substrate peptide binding groove of SETD7, including the catalytic lysine-binding channel, and by making direct contact with the donor methyl group of the cofactor, S-adenosylmethionine. Chemoproteomics experiments using a biotinylated derivative of (R)-PFI-2 demonstrated dose-dependent competition for binding to endogenous SETD7 in MCF7 cells pretreated with (R)-PFI-2. In murine embryonic fibroblasts, (R)-PFI-2 treatment phenocopied the effects of Setd7 deficiency on Hippo pathway signaling, via modulation of the transcriptional coactivator Yes-associated protein (YAP) and regulation of YAP target genes. In confluent MCF7 cells, (R)-PFI-2 rapidly altered YAP localization, suggesting continuous and dynamic regulation of YAP by the methyltransferase activity of SETD7. These data establish (R)-PFI-2 and related compounds as a valuable tool-kit for the study of the diverse roles of SETD7 in cells and further validate protein methyltransferases as a druggable target class. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barsyte-Lovejoy</LastName>
<ForeName>Dalia</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7; carrow@uhnres.utoronto.ca m.vedadi@utoronto.ca d.barsyte@utoronto.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Fengling</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oudhoff</LastName>
<ForeName>Menno J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T1Z3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tatlock</LastName>
<ForeName>John H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, San Diego, CA 92121;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Aiping</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zeng</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Freeman</LastName>
<ForeName>Spencer A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada V6T1Z3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schapira</LastName>
<ForeName>Matthieu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada M5S 1A8;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Senisterra</LastName>
<ForeName>Guillermo A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuznetsova</LastName>
<ForeName>Ekaterina</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marcellus</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada M5G 0A3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Allali-Hassani</LastName>
<ForeName>Abdellah</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kennedy</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lambert</LastName>
<ForeName>Jean-Philippe</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada M5G 1X5;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Couzens</LastName>
<ForeName>Amber L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada M5G 1X5;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aman</LastName>
<ForeName>Ahmed</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada M5G 0A3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gingras</LastName>
<ForeName>Anne-Claude</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada M5G 1X5; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada M5S 1A8;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Al-Awar</LastName>
<ForeName>Rima</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada M5S 1A8; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada M5G 0A3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fish</LastName>
<ForeName>Paul V</ForeName>
<Initials>PV</Initials>
<AffiliationInfo>
<Affiliation>Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gerstenberger</LastName>
<ForeName>Brian S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, CT 06340;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>Lee</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Benn</LastName>
<ForeName>Caroline L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo>
<Affiliation>Neusentis Research Unit, Pfizer Worldwide Research and Development, Cambridge CB21 6GS, United Kingdom;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grimley</LastName>
<ForeName>Rachel L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo>
<Affiliation>Neusentis Research Unit, Pfizer Worldwide Research and Development, Cambridge CB21 6GS, United Kingdom;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Braam</LastName>
<ForeName>Mitchell J S</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T1Z3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rossi</LastName>
<ForeName>Fabio M V</ForeName>
<Initials>FM</Initials>
<AffiliationInfo>
<Affiliation>Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T1Z3; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada V6T1Z3;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sudol</LastName>
<ForeName>Marius</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Weis Center for Research, Geisinger Clinic, Danville, PA 17821;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>Peter J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bunnage</LastName>
<ForeName>Mark E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Owen</LastName>
<ForeName>Dafydd R</ForeName>
<Initials>DR</Initials>
<AffiliationInfo>
<Affiliation>Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zaph</LastName>
<ForeName>Colby</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T1Z3; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada V6T1Z3; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vedadi</LastName>
<ForeName>Masoud</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada M5S 1A8; carrow@uhnres.utoronto.ca m.vedadi@utoronto.ca d.barsyte@utoronto.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arrowsmith</LastName>
<ForeName>Cheryl H</ForeName>
<Initials>CH</Initials>
<AffiliationInfo>
<Affiliation>Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, ON, Canada M5G 1L7 carrow@uhnres.utoronto.ca m.vedadi@utoronto.ca d.barsyte@utoronto.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>4JLG</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>092809/Z/10/Z</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>MOP-106623</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP-123322</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP-89773</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MSH-95368</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592938">(R)-PFI-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044005">Tetrahydroisoquinolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C088374">YAP1 (Yes-associated) protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.-</RegistryNumber>
<NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="D011495">Histone-Lysine N-Methyltransferase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="C540312">SETD7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C585165">Hippo protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011495">Histone-Lysine N-Methyltransferase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008780">Methyltransferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010750">Phosphoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011759">Pyrrolidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044005">Tetrahydroisoquinolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156762 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">chemical biology</Keyword>
<Keyword MajorTopicYN="N">chemical probe</Keyword>
<Keyword MajorTopicYN="N">epigenetics</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136137</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates.</ArticleTitle>
<Pagination>
<MedlinePgn>12865-70</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1408472111</ELocationID>
<Abstract>
<AbstractText>The PI3K/Akt pathway is necessary for several key endothelial cell (EC) functions, including cell growth, migration, survival, and vascular tone. However, existing literature supports the idea that Akt can be either pro- or antiangiogenic, possibly due to compensation by multiple isoforms in the EC when a single isoform is deleted. Thus, biochemical, genetic, and proteomic studies were conducted to examine isoform-substrate specificity for Akt1 vs. Akt2. In vitro, Akt1 preferentially phosphorylates endothelial nitric oxide synthase (eNOS) and promotes NO release, whereas nonphysiological overexpression of Akt2 can bypass the loss of Akt1. Conditional deletion of Akt1 in the EC, in the absence or presence of Akt2, retards retinal angiogenesis, implying that Akt1 exerts a nonredundant function during physiological angiogenesis. Finally, proteomic analysis of Akt substrates isolated from Akt1- or Akt2-deficient ECs documents that phosphorylation of multiple Akt substrates regulating angiogenic signaling is reduced in Akt1-deficient, but not Akt2-deficient, ECs, including eNOS and Forkhead box proteins. Therefore, Akt1 promotes angiogenesis largely due to phosphorylation and regulation of important downstream effectors that promote aspects of angiogenic signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Monica Y</ForeName>
<Initials>MY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520; Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luciano</LastName>
<ForeName>Amelia K</ForeName>
<Initials>AK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520; Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ackah</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rodriguez-Vita</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Barcelona, Spain; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bancroft</LastName>
<ForeName>Tara A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo>
<Affiliation>Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Departments of Pathology and Biomedical Engineering and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eichmann</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simons</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kyriakides</LastName>
<ForeName>Themis R</ForeName>
<Initials>TR</Initials>
<AffiliationInfo>
<Affiliation>Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Departments of Pathology and Biomedical Engineering and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morales-Ruiz</LastName>
<ForeName>Manuel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Barcelona, Spain; and Biochemistry and Molecular Genetics, Hospital Clinic of Barcelona, Networked Biomedical Research Center of Hepatic and Digestive Diseases (CIBERehd), 08036 Barcelona, Spain morales@clinic.ub.es william.sessa@yale.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sessa</LastName>
<ForeName>William C</ForeName>
<Initials>WC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520; Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520; morales@clinic.ub.es william.sessa@yale.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 HL70295</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL081190</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL61371</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01HL64793</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32GM007324</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009588">Nitrogen Mustard Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>54940-95-3</RegistryNumber>
<NameOfSubstance UI="C008634">nitrocaphane</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.13.39</RegistryNumber>
<NameOfSubstance UI="D052250">Nitric Oxide Synthase Type III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.13.39</RegistryNumber>
<NameOfSubstance UI="C496315">Nos3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C514862">Akt1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494922">Akt2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002461">Cell Line, Transformed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004730">Endothelium, Vascular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018919">Neovascularization, Physiologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052250">Nitric Oxide Synthase Type III</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009588">Nitrogen Mustard Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040901">Proteomics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012160">Retina</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012171">Retinal Vessels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013379">Substrate Specificity</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156707 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">development</Keyword>
<Keyword MajorTopicYN="N">kinase</Keyword>
<Keyword MajorTopicYN="N">phosphoproteomics</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25139986</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Phospholipase A2 regulates eicosanoid class switching during inflammasome activation.</ArticleTitle>
<Pagination>
<MedlinePgn>12746-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1404372111</ELocationID>
<Abstract>
<AbstractText>Initiation and resolution of inflammation are considered to be tightly connected processes. Lipoxins (LX) are proresolution lipid mediators that inhibit phlogistic neutrophil recruitment and promote wound-healing macrophage recruitment in humans via potent and specific signaling through the LXA4 receptor (ALX). One model of lipoxin biosynthesis involves sequential metabolism of arachidonic acid by two cell types expressing a combined transcellular metabolon. It is currently unclear how lipoxins are efficiently formed from precursors or if they are directly generated after receptor-mediated inflammatory commitment. Here, we provide evidence for a pathway by which lipoxins are generated in macrophages as a consequence of sequential activation of toll-like receptor 4 (TLR4), a receptor for endotoxin, and P2X7, a purinergic receptor for extracellular ATP. Initial activation of TLR4 results in accumulation of the cyclooxygenase-2-derived lipoxin precursor 15-hydroxyeicosatetraenoic acid (15-HETE) in esterified form within membrane phospholipids, which can be enhanced by aspirin (ASA) treatment. Subsequent activation of P2X7 results in efficient hydrolysis of 15-HETE from membrane phospholipids by group IVA cytosolic phospholipase A2, and its conversion to bioactive lipoxins by 5-lipoxygenase. Our results demonstrate how a single immune cell can store a proresolving lipid precursor and then release it for bioactive maturation and secretion, conceptually similar to the production and inflammasome-dependent maturation of the proinflammatory IL-1 family cytokines. These findings provide evidence for receptor-specific and combinatorial control of pro- and anti-inflammatory eicosanoid biosynthesis, and potential avenues to modulate inflammatory indices without inhibiting downstream eicosanoid pathways. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Norris</LastName>
<ForeName>Paul C</ForeName>
<Initials>PC</Initials>
<AffiliationInfo>
<Affiliation>Departments of Chemistry/Biochemistry and Pharmacology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gosselin</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reichart</LastName>
<ForeName>Donna</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Glass</LastName>
<ForeName>Christopher K</ForeName>
<Initials>CK</Initials>
<AffiliationInfo>
<Affiliation>Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dennis</LastName>
<ForeName>Edward A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Departments of Chemistry/Biochemistry and Pharmacology, and edennis@ucsd.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>T32 GM007752</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54GM069338</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016861">Cyclooxygenase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015777">Eicosanoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006893">Hydroxyeicosatetraenoic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058486">Receptors, Purinergic P2X7</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>169590-42-5</RegistryNumber>
<NameOfSubstance UI="C105934">celecoxib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>73151-66-3</RegistryNumber>
<NameOfSubstance UI="C027356">11-hydroxy-5,8,12,14-eicosatetraenoic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>73945-47-8</RegistryNumber>
<NameOfSubstance UI="C025984">15-hydroxy-5,8,11,13-eicosatetraenoic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.1.4</RegistryNumber>
<NameOfSubstance UI="D054513">Group IV Phospholipases A2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>R16CO5Y76E</RegistryNumber>
<NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002461">Cell Line, Transformed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052246">Cyclooxygenase 2 Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016861">Cyclooxygenase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015777">Eicosanoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054513">Group IV Phospholipases A2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006893">Hydroxyeicosatetraenoic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058847">Inflammasomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007375">Interleukin-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008064">Lipidoses</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058486">Receptors, Purinergic P2X7</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156727 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">enzyme coupling</Keyword>
<Keyword MajorTopicYN="N">lipidomics</Keyword>
<Keyword MajorTopicYN="N">membrane remodeling</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202042</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis.</ArticleTitle>
<Pagination>
<MedlinePgn>4665-72</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The intercellular cell-adhesion molecule-1 (ICAM-1) is a transmembrane molecule and a distinguished member of the Immunoglobulin superfamily of proteins that participates in many important processes, including leukocyte endothelial transmigration, cell signaling, cell-cell interaction, cell polarity and tissue stability. ICAM-1and its soluble part are highly expressed in inflammatory conditions, chronic diseases and a number of malignancies. In the present article we present the implications of ICAM-1 in the progression and prognosis of one of the major global killers of our era: lung cancer. </AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kotteas</LastName>
<ForeName>Elias A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Oncology Unit GPP, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boulas</LastName>
<ForeName>Panagiotis</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Oncology Unit GPP, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gkiozos</LastName>
<ForeName>Ioannis</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Oncology Unit GPP, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsagkouli</LastName>
<ForeName>Sofia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Oncology Unit GPP, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsoukalas</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Oncology Unit GPP, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Syrigos</LastName>
<ForeName>Konstantinos N</ForeName>
<Initials>KN</Initials>
<AffiliationInfo>
<Affiliation>Oncology Unit GPP, Athens School of Medicine, Sotiria General Hospital, Athens, Greece ksyrigos@med.uoa.gr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>126547-89-5</RegistryNumber>
<NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001980">Bronchi</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018799">Intercellular Adhesion Molecule-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020545">Respiratory Mucosa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Intercellular cell-adhesion molecule</Keyword>
<Keyword MajorTopicYN="N">cell polarity</Keyword>
<Keyword MajorTopicYN="N">cell signaling</Keyword>
<Keyword MajorTopicYN="N">cell-cell interaction</Keyword>
<Keyword MajorTopicYN="N">immunoglobulin</Keyword>
<Keyword MajorTopicYN="N">lung cancer</Keyword>
<Keyword MajorTopicYN="N">prognosis</Keyword>
<Keyword MajorTopicYN="N">review</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202044</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4677-83</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The kinase inhibitor sorafenib is the only approved drug which is effective against late-stage hepatocellular carcinoma (HCC). However, the mean survival of patients is still less than one year, making new approaches for tumor treatment essential. Oncogenic signaling through β-catenin is frequently overactivated in HCC and therefore a potential target for a combination therapy with sorafenib.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Two hepatoma cell lines were treated with non-cytotoxic concentrations of sorafenib and different β-catenin inhibitors. The tumor-relevant end-points of proliferation, apoptosis, cell migration, and colony formation were assessed in vitro along with the activity of the Wingless/Int-1(WNT)/β-catenin and mitogen-activated protein kinase pathways.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Combined treatment with sorafenib and β-catenin inhibitors synergized in the inhibition of cell proliferation, migration, colony formation ability, and induction of apoptosis.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In vitro data suggest that the combination of sorafenib and β-catenin inhibition might be a promising approach for HCC treatment.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Muche</LastName>
<ForeName>Sylvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kirschnick</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schwarz</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Braeuning</LastName>
<ForeName>Albert</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany albert.braeuning@uni-tuebingen.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25X51I8RD4</RegistryNumber>
<NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9ZOQ3TZI87</RegistryNumber>
<NameOfSubstance UI="C471405">sorafenib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009536">Niacinamide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010671">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
<Keyword MajorTopicYN="N">MAPK signaling</Keyword>
<Keyword MajorTopicYN="N">Wnt signaling</Keyword>
<Keyword MajorTopicYN="N">liver tumor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202048</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of light irradiation by light emitting diode on colon cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4709-16</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Recent studies have demonstrated the efficacy of irradiation from light emitting diodes (LED) for wound healing, anti-inflammation and anticancer therapies. However, little is known about the effects of visible light in colon cancer cells. The purpose of this study was to evaluate the biological response (including gene expression changes) of human colon cancer cells to different wavelengths of LED irradiation.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Human colon cancer cells (HT29 or HCT116) were seeded onto laboratory dishes that were then put on LED irradiation equipment with a 465 nm-, 525 nm-, or 635 nm-LED. Irradiation at 15 or 30 mW was performed 10 min/day, each day for 5 days. The cell counting kit8 was then used to measure cell viability. Apoptosis and expression of several mRNAs (caspase, MAPK and autophagy pathway) in HT29 cultures irradiated with 465 nm LED were evaluated via AnnexinV/PI and RT-PCR, respectively.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Viability of HT29 and HCT116 cells was lower in 465 nm-LED irradiated cultures than in control cultures, but viability of HT29 cells did not differ between control cultures and 525 nm-LED or 635 nm-LED irradiated cultures. Moreover, the expression of FAS, caspase-3, capase-8, and JUK were significantly higher in 465 nm-LED irradiated cultures than in control cultures, and expression of ERK1/2 and LC3 was lower in blue-irradiated cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LED irradiation at 465 nm inhibited the proliferation of HT29 cells and of HCT116 cells. Notably, LED irradiation at 465 nm promoted apoptosis inHT29 cultures via the extrinsic apoptosis pathway and the MAPK pathway.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matsumoto</LastName>
<ForeName>Noriko</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshikawa</LastName>
<ForeName>Kozo</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan yoshikawa.kozo@tokushima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimada</LastName>
<ForeName>Mitsuo</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurita</LastName>
<ForeName>Nobuhiro</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Hirohiko</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwata</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Higashijima</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chikakiyo</LastName>
<ForeName>Motoya</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishi</LastName>
<ForeName>Masaaki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kashihara</LastName>
<ForeName>Hideya</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takasu</LastName>
<ForeName>Chie</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eto</LastName>
<ForeName>Shohei</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Preventive Environment and Nutrition, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akutagawa</LastName>
<ForeName>Masatake</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Life system, Institute of Technology and Science, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Emoto</LastName>
<ForeName>Takahiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Life system, Institute of Technology and Science, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004307">Dose-Response Relationship, Radiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019073">HT29 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D054023">Lasers, Semiconductor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008027">Light</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HCT116 cells</Keyword>
<Keyword MajorTopicYN="N">HT29</Keyword>
<Keyword MajorTopicYN="N">Light-emitting diode</Keyword>
<Keyword MajorTopicYN="N">colon cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202050</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4723-31</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Activation of the c-JUN N-terminal kinase (JNK) signaling pathway has been associated with poor survival of ovarian cancer patients, but the role(s) and significance of JNK signaling in ovarian cancer cells remain poorly understood. In the present study, we aimed to investigate the role of JNK specifically in ovarian cancer stem cells (CSCs).</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The effect of JNK inhibition on the self-renewal (CSC marker expression, sphere-forming ability) and tumor-initiating capacity was examined in CSCs derived from the A2780 human ovarian cancer cell line. JNK inhibition was achieved either pharmacologically or genetically by use of RNA interference.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Both pharmacological and genetic targeting of JNK resulted in loss of self-renewal and tumor-initiating capacity of A2780 CSCs.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings demonstrate, to our knowledge for the first time, that JNK has a pivotal role in the maintenance of ovarian CSCs.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Seino</LastName>
<ForeName>Manabu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Masashi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shibuya</LastName>
<ForeName>Keita</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seino</LastName>
<ForeName>Shizuka</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Shuhei</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan Department of Regional Cancer Network, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohta</LastName>
<ForeName>Tsuyoshi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurachi</LastName>
<ForeName>Hirohisa</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kitanaka</LastName>
<ForeName>Chifumi</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata, Japan ckitanak@med.id.yamagata-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C432165">anthra(1,9-cd)pyrazol-6(2H)-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000873">Anthracenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048031">JNK Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018874">Spheroids, Cellular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
<Keyword MajorTopicYN="N">cancer initiating cells</Keyword>
<Keyword MajorTopicYN="N">tumorigenicity</Keyword>
<Keyword MajorTopicYN="N">xenograft analysis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202064</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hsp70 inhibition potentiates radicicol-induced cell death in anaplastic thyroid carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4829-37</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The aim of the present study was to evaluate the effect of radicicol, an inhibitor of heat shock protein (hsp) 90, alone or in combination with hsp70 inhibition on survival of anaplastic thyroid carcinoma (ATC) cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Antitumor activity of radicicol-alone or in combination with the hsp70 inhibitor VER155008 was investigated in 8505C and CAL62 cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Radicicol decreased cell viability and Akt protein levels, and increased the percentage of dead cells and hsp70 protein levels. In PIK3CA plasmid-transfected cells, compared to cells treated with radicicol-alone, cell viability increased and cellular death decreased. In cells treated with both radicicol and VER155008, compared to cells treated with radicicol-alone, cell viability further decreased and the percentage of dead cells further increased, with a parallel decrease of the protein levels of heat shock cognate 70, Akt and survivin.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that radicicol induces cell death mediated through PI3K/Akt signaling with modulation of hsp90 client proteins and hsp70 inhibition enhances radicicol-induced cell death with suppression of survivin in ATC cells.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Si Hyoung</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Jun Goo</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chul Sik</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ihm</LastName>
<ForeName>Sung-Hee</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Moon Gi</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoo</LastName>
<ForeName>Hyung Joon</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Seong Jin</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea leesj@hallym.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011684">Purine Nucleosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C550733">VER 155008</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>12772-57-5</RegistryNumber>
<NameOfSubstance UI="C035359">monorden</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018840">HSP70 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018942">Macrolides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011684">Purine Nucleosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065646">Thyroid Carcinoma, Anaplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Akt</Keyword>
<Keyword MajorTopicYN="N">Anaplastic thyroid carcinoma</Keyword>
<Keyword MajorTopicYN="N">hsp70</Keyword>
<Keyword MajorTopicYN="N">hsp90</Keyword>
<Keyword MajorTopicYN="N">radicicol</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202081</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Equol induces mitochondria-mediated apoptosis of human cervical cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4985-92</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The present study aimed to investigate anticancer properties of equol and demonstrate its underlying mechanisms of action in human cervical cancer HeLa cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Inhibition of cell viability was examined by 3-(4,5-dimethylthiazoly-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was evaluated by observation of apoptotic cell morphology, and an increase of annexin-V(+) cells. Western blotting was used to examine apoptosis-related proteins. Flow cytometry was used to measure mitochondrial membrane potential (MMP) and reactive oxygen species (ROS).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Equol treatment inhibited HeLa cell proliferation in dose- and time-dependent manner. Equol-induced apoptotic cell death was accompanied by the activation of caspases, and alteration of MMP and mitochondrial membrane proteins; equol also rapidly triggered ROS production. Pre-treatment with N-acetylcysteine blocked loss of MMP, caused increase of Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, caspase-8 activation, and apoptosis induced by equol.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Equol is a potential anticancer agent against HeLa, with possible mechanisms involved in ROS generation and mitochondrial membrane alteration.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Eun Young</ForeName>
<Initials>EY</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Jin Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Young-Ja</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>An Keun</ForeName>
<Initials>AK</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea akkim@sookmyung.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>531-95-3</RegistryNumber>
<NameOfSubstance UI="D060754">Equol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060754">Equol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002583">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Equol</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">caspase</Keyword>
<Keyword MajorTopicYN="N">cervical cancer cells</Keyword>
<Keyword MajorTopicYN="N">mitochondria</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24982127</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1524-4539</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>130</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>Circulation</Title>
<ISOAbbreviation>Circulation</ISOAbbreviation>
</Journal>
<ArticleTitle>PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>902-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.114.009683</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Regulation of vascular endothelial growth factor receptor-2 (VEGFR2) signaling is a control point that determines the extent of vascular tree formation. Recent studies demonstrated an important role played by VEGFR2 endothelial trafficking in control of its activity and suggested the involvement of a phosphotyrosine phosphatase 1b (PTP1b) in this process. This study was designed to define the role of PTP1b in endothelial VEGFR2 signaling and its role in regulation of angiogenesis and arteriogenesis.</AbstractText>
<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We generated mice carrying an endothelial-specific deletion of PTP1b and examined the effect of this knockout on VEGF signaling, angiogenesis, and arteriogenesis in vitro and in vivo. PTP1b knockout endothelial cells had increased VEGF-dependent activation of extracellular signal-regulated kinase signaling, sprouting, migration, and proliferation compared with controls. Endothelial PTP1b null mice had increased retinal and Matrigel implant angiogenesis and accelerated wound healing, pointing to enhanced angiogenesis. Increased arteriogenesis was demonstrated by observations of faster recovery of arterial blood flow and large numbers of newly formed arterioles in the hindlimb ischemia mouse model. PTP1b endothelial knockout also rescued impaired blood flow recovery after common femoral artery ligation in synectin null mice.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PTP1b is a key regulator of endothelial VEGFR2 signaling and plays an important role in regulation of the extent of vascular tree formation.</AbstractText>
<CopyrightInformation>© 2014 American Heart Association, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lanahan</LastName>
<ForeName>Anthony A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lech</LastName>
<ForeName>Diana</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dubrac</LastName>
<ForeName>Alexandre</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jiasheng</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhuang</LastName>
<ForeName>Zhen W</ForeName>
<Initials>ZW</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eichmann</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simons</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT. michael.simons@yale.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Circulation</MedlineTA>
<NlmUniqueID>0147763</NlmUniqueID>
<ISSNLinking>0009-7322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592875">VEGFR2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467480">vascular endothelial growth factor A, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000588866">vascular endothelial growth factor receptor-2, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C516607">PTPN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C516609">Ptpn1 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001011">Aorta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006614">Hindlimb</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007511">Ischemia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008817">Mice, Mutant Strains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018919">Neovascularization, Physiologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061251">Primary Cell Culture</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040301">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">PTP1b</Keyword>
<Keyword MajorTopicYN="N">VEGF</Keyword>
<Keyword MajorTopicYN="N">VEGF receptor-2</Keyword>
<Keyword MajorTopicYN="N">angiogenesis</Keyword>
<Keyword MajorTopicYN="N">arteriogenesis</Keyword>
<Keyword MajorTopicYN="N">extracellular signal-regulated kinases</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25008924</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>HIV-1 gp120 activates the STAT3/interleukin-6 axis in primary human monocyte-derived dendritic cells.</ArticleTitle>
<Pagination>
<MedlinePgn>11045-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00307-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Dendritic cells (DCs) are fundamental for the initiation of immune responses and are important players in AIDS immunopathogenesis. The modulation of DC functional activities represents a strategic mechanism for HIV-1 to evade immune surveillance. Impairment of DC function may result from bystander effects of HIV-1 envelope proteins independently of direct HIV-1 infection. In this study, we report that exposure of immature monocyte-derived DCs (MDDCs) to HIV-1 R5 gp120 resulted in the CCR5-dependent production of interleukin-6 (IL-6) via mitogen-activated protein kinase (MAPK)/NF-κB pathways. IL-6 in turn activated STAT3 by an autocrine loop. Concomitantly, gp120 promoted an early activation of STAT3 that further contributed to IL-6 induction. This activation paralleled a concomitant upregulation of the STAT3 inhibitor PIAS3. Notably, STAT3/IL-6 pathway activation was not affected by the CCR5-specific ligand CCL4. These results identify STAT3 as a key signaling intermediate activated by gp120 in MDDCs and highlight the existence of a virus-induced dysregulation of the IL-6/STAT3 axis. HIV-1 gp120 signaling through STAT3 may provide an explanation for the impairment of DC function observed upon HIV exposure.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">This study provides new evidence for the molecular mechanisms and signaling pathways triggered by HIV-1 gp120 in human DCs in the absence of productive infection, emphasizing a role of aberrant signaling in early virus-host interaction, contributing to viral pathogenesis. We identified STAT3 as a key component in the gp120-mediated signaling cascade involving MAPK and NF-κB components and ultimately leading to IL-6 secretion. STAT3 now is recognized as a key regulator of DC functions. Thus, the identification of this transcription factor as a signaling molecule mediating some of gp120's biological effects unveils a new mechanism by which HIV-1 may deregulate DC functions and contribute to AIDS pathogenesis.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Del Cornò</LastName>
<ForeName>Manuela</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Donninelli</LastName>
<ForeName>Gloria</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Varano</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Da Sacco</LastName>
<ForeName>Letizia</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Gene Expression-Microarrays Laboratory, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Masotti</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Gene Expression-Microarrays Laboratory, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gessani</LastName>
<ForeName>Sandra</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy sandra.gessani@iss.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C584933">CCR5 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054407">Chemokine CCL4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015699">HIV Envelope Protein gp120</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C484745">PIAS3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050828">Protein Inhibitors of Activated STAT</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C514793">gp120 protein, Human immunodeficiency virus 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019898">Autocrine Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054407">Chemokine CCL4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015699">HIV Envelope Protein gp120</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057131">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018832">Molecular Chaperones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050828">Protein Inhibitors of Activated STAT</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019713">Receptors, CCR5</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178808 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25008939</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>New small-molecule inhibitors effectively blocking picornavirus replication.</ArticleTitle>
<Pagination>
<MedlinePgn>11091-107</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01877-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Few drugs targeting picornaviruses are available, making the discovery of antivirals a high priority. Here, we identified and characterized three compounds from a library of kinase inhibitors that block replication of poliovirus, coxsackievirus B3, and encephalomyocarditis virus. Using an in vitro translation-replication system, we showed that these drugs inhibit different stages of the poliovirus life cycle. A4(1) inhibited both the formation and functioning of the replication complexes, while E5(1) and E7(2) were most effective during the formation but not the functioning step. Neither of the compounds significantly inhibited VPg uridylylation. Poliovirus resistant to E7(2) had a G5318A mutation in the 3A protein. This mutation was previously found to confer resistance to enviroxime-like compounds, which target a phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ)-dependent step in viral replication. Analysis of host protein recruitment showed that E7(2) reduced the amount of GBF1 on the replication complexes; however, the level of PI4KIIIβ remained intact. E7(2) as well as another enviroxime-like compound, GW5074, interfered with viral polyprotein processing affecting both 3C- and 2A-dependent cleavages, and the resistant G5318A mutation partially rescued this defect. Moreover, E7(2) induced abnormal recruitment to membranes of the viral proteins; thus, enviroxime-like compounds likely severely compromise the interaction of the viral polyprotein with membranes. A4(1) demonstrated partial protection from paralysis in a murine model of poliomyelitis. Multiple attempts to isolate resistant mutants in the presence of A4(1) or E5(1) were unsuccessful, showing that effective broad-spectrum antivirals could be developed on the basis of these compounds.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Diverse picornaviruses can trigger multiple human maladies, yet currently, only hepatitis A virus and poliovirus can be controlled with vaccination. The development of antipicornavirus therapeutics is also facing significant difficulties because these viruses readily generate resistance to compounds targeting either viral or cellular factors. Here, we describe three novel compounds that effectively block replication of distantly related picornaviruses with minimal toxicity to cells. The compounds prevent viral RNA replication after the synthesis of the uridylylated VPg primer. Importantly, two of the inhibitors are strongly refractory to the emergence of resistant mutants, making them promising candidates for further broad-spectrum therapeutic development. Evaluation of one of the compounds in an in vivo model of poliomyelitis demonstrated partial protection from the onset of paralysis.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ford Siltz</LastName>
<ForeName>Lauren A</ForeName>
<Initials>LA</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Medicine, University of Maryland, and Virginia-Maryland Regional College of Veterinary Medicine, College Park, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Viktorova</LastName>
<ForeName>Ekaterina G</ForeName>
<Initials>EG</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Medicine, University of Maryland, and Virginia-Maryland Regional College of Veterinary Medicine, College Park, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Ben</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kouiavskaia</LastName>
<ForeName>Diana</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA, Rockville, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dragunsky</LastName>
<ForeName>Eugenia</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA, Rockville, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chumakov</LastName>
<ForeName>Konstantin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA, Rockville, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Isaacs</LastName>
<ForeName>Lyle</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Belov</LastName>
<ForeName>George A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Medicine, University of Maryland, and Virginia-Maryland Regional College of Veterinary Medicine, College Park, Maryland, USA gbelov@umd.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA-168365</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020815">Polyproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.67</RegistryNumber>
<NameOfSubstance UI="D019870">1-Phosphatidylinositol 4-Kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019870">1-Phosphatidylinositol 4-Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002474">Cell-Free System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004686">Encephalomyocarditis virus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029822">Enterovirus B, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011051">Poliomyelitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017955">Poliovirus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020815">Polyproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054852">Small Molecule Libraries</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014764">Viral Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178779 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031336</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules.</ArticleTitle>
<Pagination>
<MedlinePgn>11229-39</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00727-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Mammalian cells produce many proteins, such as IFITM3, ISG15, MxA, and viperin, that inhibit influenza A virus (IAV) infection. Here, we show that a new class of host protein, histone deacetylase 6 (HDAC6), inhibits IAV infection. We found that HDAC6-overexpressing cells release about 3-fold less IAV progeny, whereas HDAC6-depleted cells release about 6-fold more IAV progeny. The deacetylase activity of HDAC6 played a role in its anti-IAV function as tubacin, a specific small-molecule inhibitor of HDAC6, increased the release of IAV progeny in a dose-dependent manner. Further, as visualized by electron microscopy, tubacin-treated cells showed an increase in IAV budding at the plasma membrane, the site of IAV assembly. Tubacin is a domain-specific inhibitor and binds to one of the two HDAC6 catalytic domains possessing tubulin deacetylase activity. This indicated the potential involvement of acetylated microtubules in the trafficking of viral components to the plasma membrane. Indeed, as quantified by flow cytometry, there was about a 2.0- to 2.5-fold increase and about a 2.0-fold decrease in the amount of viral envelope protein hemagglutinin present on the plasma membrane of tubacin-treated/HDAC6-depleted and HDAC6-overexpressing cells, respectively. In addition, the viral ribonucleoprotein complex was colocalized with acetylated microtubule filaments, and viral nucleoprotein coimmunoprecipitated with acetylated tubulin. Together, our findings indicate that HDAC6 is an anti-IAV host factor and exerts its anti-IAV function by negatively regulating the trafficking of viral components to the host cell plasma membrane via its substrate, acetylated microtubules.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Host cells produce many proteins that have the natural ability to restrict influenza virus infection. Here, we discovered that another host protein, histone deacetylase 6 (HDAC6), inhibits influenza virus infection. We demonstrate that HDAC6 exerts its anti-influenza virus function by negatively regulating the trafficking of viral components to the site of influenza virus assembly via its substrate, acetylated microtubules. HDAC6 is a multisubstrate enzyme and regulates multiple cellular pathways, including the ones leading to various cancers, neurodegenerative diseases, and inflammatory disorders. Therefore, several drugs targeting HDAC6 are under clinical development for the treatment of a wide range of diseases. Influenza virus continues to be a major global public health problem due to regular emergence of drug-resistant and novel influenza virus strains in humans. As an alternative antiviral strategy, HDAC6 modulators could be employed to stimulate the anti-influenza virus potential of endogenous HDAC6 to inhibit influenza virus infection.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Husain</LastName>
<ForeName>Matloob</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand matloob.husain@otago.ac.nz.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheung</LastName>
<ForeName>Chen-Yi</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000813">Anilides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C474316">tubacin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000107">Acetylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000813">Anilides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006877">Hydroxamic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053118">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008870">Microtubules</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012261">Ribonucleoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014771">Virion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057074">Virus Release</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178787 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031338</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of antiviral innate immunity by birnavirus VP3 protein via blockage of viral double-stranded RNA binding to the host cytoplasmic RNA detector MDA5.</ArticleTitle>
<Pagination>
<MedlinePgn>11154-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01115-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Chicken MDA5 (chMDA5), the sole known pattern recognition receptor for cytoplasmic viral RNA in chickens, initiates type I interferon (IFN) production. Infectious bursal disease virus (IBDV) evades host innate immunity, but the mechanism is unclear. We report here that IBDV inhibited antiviral innate immunity via the chMDA5-dependent signaling pathway. IBDV infection did not induce efficient type I interferon (IFN) production but antagonized the antiviral activity of beta interferon (IFN-β) in DF-1 cells pretreated with IFN-α/β. Dual-luciferase assays and inducible expression systems demonstrated that IBDV protein VP3 significantly inhibited IFN-β expression stimulated by naked IBDV genomic double-stranded RNA (dsRNA). The VP3 protein competed strongly with chMDA5 to bind IBDV genomic dsRNA in vitro and in vivo, and VP3 from other birnaviruses also bound dsRNA. Site-directed mutagenesis confirmed that deletion of the VP3 dsRNA binding domain restored IFN-β expression. Our data demonstrate that VP3 inhibits antiviral innate immunity by blocking binding of viral genomic dsRNA to MDA5.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">MDA5, a known pattern recognition receptor and cytoplasmic viral RNA sensor, plays a critical role in host antiviral innate immunity. Many pathogens escape or inhibit the host antiviral immune response, but the mechanisms involved are unclear for most pathogens. We report here that birnaviruses inhibit host antiviral innate immunity via the MDA5-dependent signaling pathway. The antiviral innate immune system involving IFN-β did not function effectively during birnavirus infection, and the viral protein VP3 significantly inhibited IFN-β expression stimulated by naked viral genomic dsRNA. We also show that VP3 blocks MDA5 binding to viral genomic dsRNA in vitro and in vivo. Our data reveal that birnavirus-encoded viral protein VP3 is an inhibitor of the antiviral innate immune response and inhibits the antiviral innate immune response via the MDA5-dependent signaling pathway.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ye</LastName>
<ForeName>Chengjin</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jia</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Yanting</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Boli</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Lun</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Xingmeng</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Jiyong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, People's Republic of China College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, People's Republic of China jyzhou@zju.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D030161">Avian Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C478244">VP3 protein, infectious bursal disease virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030161">Avian Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001667">Binding, Competitive</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002645">Chickens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057131">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007243">Infectious bursal disease virus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016899">Interferon-beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012330">RNA, Double-Stranded</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012367">RNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015678">Viral Structural Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178823 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031339</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.</ArticleTitle>
<Pagination>
<MedlinePgn>11166-77</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01785-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">The EBNA1 protein of Epstein-Barr virus (EBV) plays multiple roles in EBV latent infection, including altering cellular pathways relevant for cancer. Here we used microRNA (miRNA) cloning coupled with high-throughput sequencing to identify the effects of EBNA1 on cellular miRNAs in two nasopharyngeal carcinoma cell lines. EBNA1 affected a small percentage of cellular miRNAs in both cell lines, in particular, upregulating multiple let-7 family miRNAs, including let-7a. The effects of EBNA1 on let-7a were verified by demonstrating that EBNA1 silencing in multiple EBV-positive carcinomas downregulated let-7a. Accordingly, the let-7a target, Dicer, was found to be partially downregulated by EBNA1 expression (at the mRNA and protein levels) and upregulated by EBNA1 silencing in EBV-positive cells. Reporter assays based on the Dicer 3' untranslated region with and without let-7a target sites indicated that the effects of EBNA1 on Dicer were mediated by let-7a. EBNA1 was also found to induce the expression of let-7a primary RNAs in a manner dependent on the EBNA1 transcriptional activation region, suggesting that EBNA1 induces let-7a by transactivating the expression of its primary transcripts. Consistent with previous reports that Dicer promotes EBV reactivation, we found that a let-7a mimic inhibited EBV reactivation to the lytic cycle, while a let-7 sponge increased reactivation. The results provide a mechanism by which EBNA1 could promote EBV latency by inducing let-7 miRNAs.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The EBNA1 protein of Epstein-Barr virus (EBV) contributes in multiple ways to the latent mode of EBV infection that leads to lifelong infection. In this study, we identify a mechanism by which EBNA1 helps to maintain EBV infection in a latent state. This involves induction of a family of microRNAs (let-7 miRNAs) that in turn decreases the level of the cellular protein Dicer. We demonstrate that let-7 miRNAs inhibit the reactivation of latent EBV, providing an explanation for our previous observation that EBNA1 promotes latency. In addition, since decreased levels of Dicer have been associated with metastatic potential, EBNA1 may increase metastases by downregulating Dicer.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mansouri</LastName>
<ForeName>Sheila</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Qun</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Banting and Best Department of Medical Research and Donnelly Centre, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blencowe</LastName>
<ForeName>Benjamin J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada Banting and Best Department of Medical Research and Donnelly Centre, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Claycomb</LastName>
<ForeName>Julie M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Frappier</LastName>
<ForeName>Lori</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada lori.frappier@utoronto.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>12477</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C417029">EBV-encoded nuclear antigen 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019309">Epstein-Barr Virus Nuclear Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C487931">mirnlet7 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.13.12.-</RegistryNumber>
<NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C408087">DICER1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="D043244">Ribonuclease III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019309">Epstein-Barr Virus Nuclear Antigens</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017930">Genes, Reporter</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004854">Herpesvirus 4, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008156">Luciferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043244">Ribonuclease III</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017735">Virus Latency</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178782 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031344</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Annexin V incorporated into influenza virus particles inhibits gamma interferon signaling and promotes viral replication.</ArticleTitle>
<Pagination>
<MedlinePgn>11215-28</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01405-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">During the budding process, influenza A viruses (IAVs) incorporate multiple host cell membrane proteins. However, for most of them, their significance in viral morphogenesis and infectivity remains unknown. We demonstrate here that the expression of annexin V (A5) is upregulated at the cell surface upon IAV infection and that a substantial proportion of the protein is present in lipid rafts, the site of virus budding. Western blotting and immunogold analysis of highly purified IAV particles showed the presence of A5 in the virion. Significantly, gamma interferon (IFN-γ)-induced Stat phosphorylation and IFN-γ-induced 10-kDa protein (IP-10) production in macrophage-derived THP-1 cells was inhibited by purified IAV particles. Disruption of the IFN-γ signaling pathway was A5 dependent since downregulation of its expression or its blockage reversed the inhibition and resulted in decreased viral replication in vitro. The functional significance of these results was also observed in vivo. Thus, IAVs can subvert the IFN-γ antiviral immune response by incorporating A5 into their envelope during the budding process.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Many enveloped viruses, including influenza A viruses, bud from the plasma membrane of their host cells and incorporate cellular surface proteins into viral particles. However, for the vast majority of these proteins, only the observation of their incorporation has been reported. We demonstrate here that the host protein annexin V is specifically incorporated into influenza virus particles during the budding process. Importantly, we showed that packaged annexin V counteracted the antiviral activity of gamma interferon in vitro and in vivo. Thus, these results showed that annexin V incorporated in the viral envelope of influenza viruses allow viral escape from immune surveillance. Understanding the role of host incorporated protein into virions may reveal how enveloped RNA viruses hijack the host cell machinery for their own purposes.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Berri</LastName>
<ForeName>Fatma</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Haffar</LastName>
<ForeName>Ghina</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lê</LastName>
<ForeName>Vuong Ba</ForeName>
<Initials>VB</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sadewasser</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paki</LastName>
<ForeName>Katharina</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lina</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolff</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Riteau</LastName>
<ForeName>Béatrice</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France INRA, Tours, France beatrice.riteau@laposte.net.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017304">Annexin A5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C114753">CXCL10 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017304">Annexin A5</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054357">Chemokine CXCL10</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009980">Influenza A virus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021962">Membrane Microdomains</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050791">STAT Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014771">Virion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057074">Virus Release</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178827 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25056888</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis.</ArticleTitle>
<Pagination>
<MedlinePgn>11430-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00682-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">The effects of heightened microbial translocation on B cells during HIV infection are unknown. We examined the in vitro effects of HIV and lipopolysaccharide (LPS) on apoptosis of CD27+ IgD- memory B (mB) cells from healthy controls. In vivo analysis was conducted on a cohort of 82 HIV+ donors and 60 healthy controls. In vitro exposure of peripheral blood mononuclear cells (PBMCs) to LPS and HIV led to mB cell death via the Fas/Fas ligand (FasL) pathway. Plasmacytoid dendritic cells (pDCs) produced FasL in response to HIV via binding to CD4 and chemokine coreceptors. HIV and LPS increased Fas expression on mB cells in PBMCs, which was dependent on the presence of pDCs and monocytes. Furthermore, mB cells purified from PBMCs and pretreated with both HIV and LPS were more sensitive to apoptosis when cocultured with HIV-treated pDCs. Blocking the interferon receptor (IFNR) prevented HIV-stimulated FasL production in pDCs, HIV-plus-LPS-induced Fas expression, and apoptosis of mB cells. In vivo or ex vivo, HIV+ donors have higher levels of plasma LPS, Fas expression on mB cells, and mB cell apoptosis than controls. Correspondingly, in HIV+ donors, but not in controls, a positive correlation was found between plasma FasL and HIV RNA levels and between Fas expression on mB cells and plasma LPS levels. This work reveals a novel mechanism of mB cell apoptosis mediated by LPS and HIV through the Fas/FasL pathway, with key involvement of pDCs and type I IFN, suggesting a role for microbial translocation in HIV pathogenesis.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">This study demonstrates that lipopolysaccharide (LPS) and type I interferon (IFN) play an important role in memory B cell apoptosis in HIV infection. It reveals a previously unrecognized role of microbial translocation in HIV pathogenesis.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Lumin</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Zhenwu</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sieg</LastName>
<ForeName>Scott F</ForeName>
<Initials>SF</Initials>
<AffiliationInfo>
<Affiliation>Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Funderburg</LastName>
<ForeName>Nicholas T</ForeName>
<Initials>NT</Initials>
<AffiliationInfo>
<Affiliation>School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, The Ohio State University, Columbus, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Xiaocong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Pingfu</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Center for Infectious Diseases, Beijing You-An Hospital, Capital Medical University, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiao</LastName>
<ForeName>Yanmei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Center for Infectious Diseases, Beijing You-An Hospital, Capital Medical University, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Greenspan</LastName>
<ForeName>Neil S</ForeName>
<Initials>NS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Harding</LastName>
<ForeName>Clifford V</ForeName>
<Initials>CV</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kilby</LastName>
<ForeName>J Michael</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zihai</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lederman</LastName>
<ForeName>Michael M</ForeName>
<Initials>MM</Initials>
<AffiliationInfo>
<Affiliation>Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA jianw@musc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI034343</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI36219</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI91526</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30GM103331</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018127">Antigens, CD27</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019014">Antigens, CD95</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491901">FAS protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505661">FASLG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007072">Immunoglobulin D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018127">Antigens, CD27</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019014">Antigens, CD95</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001419">Bacteria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018988">Bacterial Translocation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002469">Cell Separation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053222">Fas Ligand Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007072">Immunoglobulin D</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007156">Immunologic Memory</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007370">Interferon Type I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178795 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25056896</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Kaposi's sarcoma-associated herpesvirus ORF18 and ORF30 are essential for late gene expression during lytic replication.</ArticleTitle>
<Pagination>
<MedlinePgn>11369-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00793-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with several human malignances. As saliva is likely the major vehicle for KSHV transmission, we studied in vitro KSHV infection of oral epithelial cells. Through infection of two types of oral epithelial cells, normal human oral keratinocytes (NHOKs) and papilloma-immortalized human oral keratinocyte (HOK16B) cells, we found that KSHV can undergo robust lytic replication in oral epithelial cells. By employing de novo lytic infection of HOK16B cells, we studied the functions of two previously uncharacterized genes, ORF18 and ORF30, during the KSHV lytic cycle. For this purpose, an ORF18-deficient virus and an ORF30-deficient virus were generated using a mutagenesis strategy based on bacterial artificial chromosome (BAC) technology. We found that neither ORF18 nor ORF30 is required for immediately early or early gene expression or viral DNA replication, but each is essential for late gene expression during both de novo lytic replication and reactivation. This critical role of ORF18 and ORF30 in late gene expression was also observed during KSHV reactivation. In addition, global analysis of viral transcripts by RNA sequencing indicated that ORF18 and ORF30 control the same set of viral genes. Therefore, we suggest that these two viral ORFs are involved in the same mechanism or pathway that coregulates the viral late genes as a group.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">While KSHV can infect multiple cell types in vitro, only a few can support a full lytic replication cycle with progeny virions produced. Consequently, KSHV lytic replication is mostly studied through reactivation, which requires chemicals to induce the lytic cycle or overexpression of the viral transcriptional activator, RTA. In this study, we present a robust de novo lytic infection system based on oral epithelial cells. Using this system, we demonstrate the role of two viral ORFs, ORF18 and ORF30, in regulating viral gene expression during KSHV lytic replication. As the major route of KSHV transmission is thought to be via saliva, this new KSHV lytic replication system will have important utility in the field.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gong</LastName>
<ForeName>Danyang</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Nicholas C</ForeName>
<Initials>NC</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Yafang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tong</LastName>
<ForeName>Leming</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brulois</LastName>
<ForeName>Kevin F</ForeName>
<Initials>KF</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luan</LastName>
<ForeName>Harding</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Du</LastName>
<ForeName>Yushen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>Jae U</ForeName>
<Initials>JU</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Cun-yu</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>School of Dentistry, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Mo Kwan</ForeName>
<Initials>MK</Initials>
<AffiliationInfo>
<Affiliation>School of Dentistry, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>No-Hee</ForeName>
<Initials>NH</Initials>
<AffiliationInfo>
<Affiliation>School of Dentistry, University of California, Los Angeles, California, USA Department of Medicine, University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Ren</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA rsun@mednet.ucla.edu twu@mednet.ucla.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Ting-Ting</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA rsun@mednet.ucla.edu twu@mednet.ucla.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI078133</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA91791</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DE15752</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022202">Chromosomes, Artificial, Bacterial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019288">Herpesvirus 8, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015603">Keratinocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009061">Mouth Mucosa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016366">Open Reading Frames</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017384">Sequence Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014764">Viral Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014775">Virus Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178812 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25056899</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism.</ArticleTitle>
<Pagination>
<MedlinePgn>11529-39</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01712-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Resting CD4+ T lymphocytes resist human immunodeficiency virus (HIV) infection. Here, we provide evidence that exosomes from HIV-1-infected cells render resting human primary CD4+ T lymphocytes permissive to HIV-1 replication. These results were obtained with transwell cocultures of HIV-1-infected cells with quiescent CD4+ T lymphocytes in the presence of inhibitors of exosome release and were confirmed using exosomes purified from supernatants of HIV-1-infected primary CD4+ T lymphocytes. We found that the expression of HIV-1 Nef in exosome-producing cells is both necessary and sufficient for cell activation as well as HIV-1 replication in target CD4+ T lymphocytes. We also identified a Nef domain important for the effects we observed, i.e., the 62EEEE65 acidic cluster domain. In addition, we observed that ADAM17, i.e., a disintegrin and metalloprotease converting pro-tumor necrosis factor alpha (TNF-α) in its mature form, associates with exosomes from HIV-1-infected cells, and plays a key role in the HIV-1 replication in quiescent CD4+ T lymphocytes. Treatment with an inhibitor of ADAM17 abolished both activation and HIV-1 replication in resting CD4+ T lymphocytes. TNF-α is the downstream effector of ADAM17 since the treatment of resting lymphocytes with anti-TNF-α antibodies blocked the HIV-1 replication. The data presented here are consistent with a model where Nef induces intercellular communication through exosomes to activate bystander quiescent CD4+ T lymphocytes, thus stimulating viral spread.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Overall, our findings support the idea that HIV evolved to usurp the exosome-based intercellular communication network to favor its spread in infected hosts.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Arenaccio</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>National AIDS Center, Istituto Superiore di Sanità, Rome, Italy Department of Science, University Roma Tre, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chiozzini</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>National AIDS Center, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Columba-Cabezas</LastName>
<ForeName>Sandra</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Manfredi</LastName>
<ForeName>Francesco</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>National AIDS Center, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Affabris</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Science, University Roma Tre, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baur</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Federico</LastName>
<ForeName>Maurizio</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>National AIDS Center, Istituto Superiore di Sanità, Rome, Italy maurizio.federico@iss.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054311">nef Gene Products, Human Immunodeficiency Virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C514837">nef protein, Human immunodeficiency virus 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="C101146">tumor necrosis factor-alpha convertase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051722">ADAM Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000906">Antibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015194">Diffusion Chambers, Culture</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054311">nef Gene Products, Human Immunodeficiency Virus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178784 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25056900</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of phosphorylated-STAT1 nuclear translocation and antiviral protein expression in human brain vascular adventitial fibroblasts infected with varicella-zoster virus.</ArticleTitle>
<Pagination>
<MedlinePgn>11634-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01945-14</ELocationID>
<Abstract>
<AbstractText>In varicella-zoster virus (VZV)-infected primary human brain vascular adventitial fibroblasts (BRAFs), levels of beta interferon (IFN-β,) STAT1, and STAT2 transcripts as well as STAT1 and STAT2 protein were decreased. IFN-α transcript levels were increased but not secreted IFN-α protein levels. Compared to IFN-α-treated control results, in VZV-infected BRAFs, phosphorylated STAT1 did not translocate to the nucleus, resulting in impaired downstream expression of interferon-inducible antiviral Mx1. Overall, VZV interference with the type I interferon pathway may promote virus persistence in cerebral arteries. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nagel</LastName>
<ForeName>Maria A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA Maria.nagel@ucdenver.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>James</LastName>
<ForeName>Stephanie F</ForeName>
<Initials>SF</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Traktinskiy</LastName>
<ForeName>Igor</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wyborny</LastName>
<ForeName>Ann</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choe</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rempel</LastName>
<ForeName>April</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baird</LastName>
<ForeName>Nicholas L</ForeName>
<Initials>NL</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gilden</LastName>
<ForeName>Don</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA Department of Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AG006127</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AG032958</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NS 067070</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NS007321</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C579071">MX1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064547">Myxovirus Resistance Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050794">STAT1 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494079">STAT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050795">STAT2 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494084">STAT2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063194">Adventitia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001808">Blood Vessels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014645">Herpesvirus 3, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016899">Interferon-beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064547">Myxovirus Resistance Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061251">Primary Cell Culture</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050794">STAT1 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050795">STAT2 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178816 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25056901</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response.</ArticleTitle>
<Pagination>
<MedlinePgn>11356-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01400-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Retinoic acid-inducible gene I (RIG-I) is an intracellular RNA virus sensor that induces type I interferon-mediated host-protective innate immunity against viral infection. Although cylindromatosis (CYLD) has been shown to negatively regulate innate antiviral response by removing K-63-linked polyubiquitin from RIG-I, the regulation of its expression and the underlying regulatory mechanisms are still incompletely understood. Here we show that RIG-I activity is regulated by inhibition of CYLD expression mediated by the microRNA miR-526a. We found that viral infection specifically upregulates miR-526a expression in macrophages via interferon regulatory factor (IRF)-dependent mechanisms. In turn, miR-526a positively regulates virus-triggered type I interferon (IFN-I) production, thus suppressing viral replication, the underlying mechanism of which is the enhancement of RIG-I K63-linked ubiquitination by miR-526a via suppression of the expression of CYLD. Remarkably, virus-induced miR-526a upregulation and CYLD downregulation are blocked by enterovirus 71 (EV71) 3C protein, while ectopic miR-526a expression inhibits the replication of EV71 virus. The collective results of this study suggest a novel mechanism of the regulation of RIG-I activity during RNA virus infection by miR-526a and suggest a novel mechanism for the evasion of the innate immune response controlled by EV71.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">RNA virus infection upregulates the expression of miR-526a in macrophages through IRF-dependent pathways. In turn, miR-526a positively regulates virus-triggered type I IFN production and inhibits viral replication, the underlying mechanism of which is the enhancement of RIG-I K-63 ubiquitination by miR-526a via suppression of the expression of CYLD. Remarkably, virus-induced miR-526a upregulation and CYLD downregulation are blocked by enterovirus 71 (EV71) 3C protein; cells with overexpressed miR-526a were highly resistant to EV71 infection. The collective results of this study suggest a novel mechanism of the regulation of RIG-I activity during RNA virus infection by miR-526a and propose a novel mechanism for the evasion of the innate immune response controlled by EV71.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Changzhi</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Zirui</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Zhe</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Congwen</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guan</LastName>
<ForeName>Kai</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hou</LastName>
<ForeName>Lihua</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Buchang</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Yuan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Laboratory Medicine, General Hospital of Jinan Military Region, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yanhong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Ye</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Shengli</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Penghao</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Pingping</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China Department of Laboratory Medicine, General Hospital of Jinan Military Region, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Quanbin</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ling</LastName>
<ForeName>Youguo</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Xiao</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China xyang@nic.bmi.ac.cn towall@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Beijing Institute of Biotechnology, Beijing, China xyang@nic.bmi.ac.cn towall@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C409984">CYLD protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>120904-94-1</RegistryNumber>
<NameOfSubstance UI="D025821">Polyubiquitin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.28</RegistryNumber>
<NameOfSubstance UI="C052731">3C proteases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C452820">DDX58 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002522">Cercopithecus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003546">Cysteine Endopeptidases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029821">Enterovirus A, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057131">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007370">Interferon Type I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025821">Polyubiquitin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014709">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014764">Viral Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178780 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25078688</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Murine gammaherpesvirus 68 reactivation from B cells requires IRF4 but not XBP-1.</ArticleTitle>
<Pagination>
<MedlinePgn>11600-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01876-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Gammaherpesviruses display tropism for B cells and, like all known herpesviruses, exhibit distinct lytic and latent life cycles. One well-established observation among members of the gammaherpesvirus family is the link between viral reactivation from latently infected B cells and plasma cell differentiation. Importantly, a number of studies have identified a potential role for a CREB/ATF family member, X-box binding protein 1 (XBP-1), in trans-activating the immediate early BZLF-1 or BRLF1/gene 50 promoters of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), respectively. XBP-1 is required for the unfolded protein response and has been identified as a critical transcription factor in plasma cells. Here, we demonstrate that XBP-1 is capable of trans-activating the murine gammaherpesvirus 68 (MHV68) RTA promoter in vitro, consistent with previous observations for EBV and KSHV. However, we show that in vivo there does not appear to be a requirement for XBP-1 expression in B cells for virus reactivation. The MHV68 M2 gene product under some experimental conditions plays an important role in virus reactivation from B cells. M2 has been shown to drive B cell differentiation to plasma cells, as well as interleukin-10 (IL-10) production, both of which are dependent on M2 induction of interferon regulatory factor 4 (IRF4) expression. IRF4 is required for plasma cell differentiation, and consistent with a role for plasma cells in MHV68 reactivation from B cells, we show that IRF4 expression in B cells is required for efficient reactivation of MHV68 from splenocytes. Thus, the latter analyses are consistent with previous studies linking plasma cell differentiation to MHV68 reactivation from B cells. The apparent independence of MHV68 reactivation from XBP-1 expression in plasma cells may reflect redundancy among CREB/ATF family members or the involvement of other plasma cell-specific transcription factors. Regardless, these findings underscore the importance of in vivo studies in assessing the relevance of observations made in tissue culture models.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">All known herpesviruses establish a chronic infection of their respective host, persisting for the life of the individual. A critical feature of these viruses is their ability to reactivate from a quiescent form of infection (latency) and generate progeny virus. In the case of gammaherpesviruses, which are associated with the development of lymphoproliferative disorders, including lymphomas, reactivation from latently infected B lymphocytes occurs upon terminal differentiation of these cells to plasma cells-the cell type that produces antibodies. A number of studies have linked a plasma cell transcription factor, XBP-1, to the induction of gammaherpesvirus reactivation, and we show here that indeed in tissue culture models this cellular transcription factor can trigger expression of the murine gammaherpesvirus gene involved in driving virus reactivation. However, surprisingly, when we examined the role of XBP-1 in the setting of infection of mice-using mice that lack a functional XBP-1 gene in B cells-we failed to observe a role for XBP-1 in virus reactivation. However, we show that another cellular factor essential for plasma cell differentiation, IRF4, is critical for virus reactivation. Thus, these studies point out the importance of studies in animal models to validate findings from studies carried out in cell lines passaged in vitro.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matar</LastName>
<ForeName>Caline G</ForeName>
<Initials>CG</Initials>
<AffiliationInfo>
<Affiliation>Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, Georgia, USA Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rangaswamy</LastName>
<ForeName>Udaya Shankari</ForeName>
<Initials>US</Initials>
<AffiliationInfo>
<Affiliation>Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, Georgia, USA Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wakeman</LastName>
<ForeName>Brian S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, Georgia, USA Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwakoshi</LastName>
<ForeName>Neal</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Division of Transplantation, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Speck</LastName>
<ForeName>Samuel H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA Emory Vaccine Center, Emory University, Atlanta, Georgia, USA sspeck@emory.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577263">M2 protein, murine gammaherpesvirus 68</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C094531">interferon regulatory factor-4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C056311">regulatory factor X transcription factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006566">Herpesviridae Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050835">Interferon Regulatory Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010950">Plasma Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018144">Rhadinovirus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013154">Spleen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014764">Viral Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014775">Virus Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017735">Virus Latency</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178818 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24246800</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-9142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>62</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Molecular immunology</Title>
<ISOAbbreviation>Mol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Calcium signaling in B cells: regulation of cytosolic Ca2+ increase and its sensor molecules, STIM1 and STIM2.</ArticleTitle>
<Pagination>
<MedlinePgn>339-43</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molimm.2013.10.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0161-5890(13)00532-4</ELocationID>
<Abstract>
<AbstractText>Calcium signals are crucial for diverse cellular functions including adhesion, differentiation, proliferation, effector functions and gene expression. After engagement of the B cell receptor, the intracellular calcium ion (Ca(2+)) concentration is increased promoting the activation of various signaling cascades. While elevated Ca(2+) in the cytosol initially comes from the endoplasmic reticulum (ER), a continuous influx of extracellular Ca(2+) is required to maintain the increased level of cytosolic Ca(2+). Store-operated Ca(2+) entry manages this process, which is regulated by an ER calcium sensor, stromal interaction molecule (STIM). STIM proteins sense changes in the levels of Ca(2+) stored within the ER lumen and regulates the Ca(2+)-release activated Ca(2+) channel in the plasma membrane. This review focuses on the signaling pathways leading to Ca(2+) influx and the role of Ca(2+) signals in B cell functions. </AbstractText>
<CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Baba</LastName>
<ForeName>Yoshihiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Laboratory for Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Osaka 565-0871, Japan; Laboratory for Lymphocyte Differentiation, RIKEN Research Center for Integrative Medical Sciences (IMS-RCAI), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsumoto</LastName>
<ForeName>Masanori</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory for Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Osaka 565-0871, Japan; Laboratory for Lymphocyte Differentiation, RIKEN Research Center for Integrative Medical Sciences (IMS-RCAI), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurosaki</LastName>
<ForeName>Tomohiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Laboratory for Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Osaka 565-0871, Japan; Laboratory for Lymphocyte Differentiation, RIKEN Research Center for Integrative Medical Sciences (IMS-RCAI), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan. Electronic address: kurosaki@ifrec.osaka-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>11</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Mol Immunol</MedlineTA>
<NlmUniqueID>7905289</NlmUniqueID>
<ISSNLinking>0161-5890</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020013">Calcium Signaling</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003600">Cytosol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011947">Receptors, Antigen, B-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Ca(2+) signal</Keyword>
<Keyword MajorTopicYN="N">IL-10</Keyword>
<Keyword MajorTopicYN="N">Store-operated Ca(2+) entry (SOCE)</Keyword>
<Keyword MajorTopicYN="N">Stromal interaction molecule 1 (STIM1)</Keyword>
<Keyword MajorTopicYN="N">regulatory B cell</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24970737</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-9142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>62</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Molecular immunology</Title>
<ISOAbbreviation>Mol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>IL-10 production by B cells is differentially regulated by immune-mediated and infectious stimuli and requires p38 activation.</ArticleTitle>
<Pagination>
<MedlinePgn>266-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molimm.2014.05.018</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0161-5890(14)00130-8</ELocationID>
<Abstract>
<AbstractText>IL-10 is an immune suppressive cytokine with pleiotropic effects on B cell biology. IL-10 production has a pivotal role for the regulatory suppressive functions that B cells exert in many physiological and pathological settings. Several exogenous stimuli and endogenous immune mediators can trigger IL-10-producing B cell maturation. To clarify and gain a better insight into the mechanisms of IL-10 production by B cells, we first compared the effects of LPS, CpG, agonistic CD40 mAb and BAFF on IL-10 production, and then we investigated the signal transduction mechanisms responsible for these responses. While infectious/danger stimuli determine the rapid production and release of IL-10 by B cells, a limited subset of CD40-poised, IL-10-competent B cells produce IL-10 in response to a later antigenic or infectious signal. Although BAFF is able to induce a similar subset of IL-10-competent B cells, these cells do not similarly respond to the same antigenic or infectious signals. Importantly, by using specific inhibitors of the MAP kinase pathways, we found that while il-10 gene expression triggered by the TLR agonists LPS and CpG is strongly dependent on p38 activity, the induction of IL-10 competence in CD40-activated B cells does not depend on ERK1/2, p38 or JNK pathways. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mion</LastName>
<ForeName>Francesca</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical and Biological Sciences, University of Udine, P.le M. Kolbe, 4, 33100 Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tonon</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical and Biological Sciences, University of Udine, P.le M. Kolbe, 4, 33100 Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Toffoletto</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical and Biological Sciences, University of Udine, P.le M. Kolbe, 4, 33100 Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cesselli</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical and Biological Sciences, University of Udine, P.le M. Kolbe, 4, 33100 Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pucillo</LastName>
<ForeName>Carlo E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical and Biological Sciences, University of Udine, P.le M. Kolbe, 4, 33100 Udine, Italy. Electronic address: carlo.pucillo@uniud.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vitale</LastName>
<ForeName>Gaetano</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical and Biological Sciences, University of Udine, P.le M. Kolbe, 4, 33100 Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Mol Immunol</MedlineTA>
<NlmUniqueID>7905289</NlmUniqueID>
<ISSNLinking>0161-5890</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016753">Interleukin-10</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">B cells</Keyword>
<Keyword MajorTopicYN="N">CD40</Keyword>
<Keyword MajorTopicYN="N">IL-10</Keyword>
<Keyword MajorTopicYN="N">MyD88</Keyword>
<Keyword MajorTopicYN="N">TLR</Keyword>
<Keyword MajorTopicYN="N">p38</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25108526</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1546-170X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>20</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature medicine</Title>
<ISOAbbreviation>Nat. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB.</ArticleTitle>
<Pagination>
<MedlinePgn>1009-17</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3586</ELocationID>
<Abstract>
<AbstractText>Aging-related bone loss and osteoporosis affect millions of people worldwide. Chronic inflammation associated with aging promotes bone resorption and impairs bone formation. Here we show that Wnt4 attenuates bone loss in osteoporosis and skeletal aging mouse models by inhibiting nuclear factor-κB (NF-κB) via noncanonical Wnt signaling. Transgenic mice expressing Wnt4 from osteoblasts were significantly protected from bone loss and chronic inflammation induced by ovariectomy, tumor necrosis factor or natural aging. In addition to promoting bone formation, Wnt4 inhibited osteoclast formation and bone resorption. Mechanistically, Wnt4 inhibited NF-κB activation mediated by transforming growth factor-β-activated kinase-1 (Tak1) in macrophages and osteoclast precursors independently of β-catenin. Moreover, recombinant Wnt4 alleviated bone loss and inflammation by inhibiting NF-κB in vivo in mouse models of bone disease. Given its dual role in promoting bone formation and inhibiting bone resorption, our results suggest that Wnt4 signaling could be an attractive therapeutic target for treating osteoporosis and preventing skeletal aging. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>1] Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California Los Angeles (UCLA), Los Angeles, California, USA. [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Jia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California Los Angeles (UCLA), Los Angeles, California, USA. [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yunsong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Prosthodontics, School and Hospital of Stomatology, Peking University, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jiong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California Los Angeles (UCLA), Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kevork</LastName>
<ForeName>Kareena</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California Los Angeles (UCLA), Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Al-Hezaimi</LastName>
<ForeName>Khalid</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Eng. A.B. Research Center for Growth Factors and Bone Regeneration, Division of Periodontology, College of Dentistry, King Saud University, Riyadh, Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Graves</LastName>
<ForeName>Dana T</ForeName>
<Initials>DT</Initials>
<AffiliationInfo>
<Affiliation>Department of Periodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>No-Hee</ForeName>
<Initials>NH</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Diagnostic and Surgical Sciences, School of Dentistry, UCLA, Los Angeles, California, USA. [2] Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Cun-Yu</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>1] Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California Los Angeles (UCLA), Los Angeles, California, USA. [2] Broad Stem Cell Research Center, UCLA, Los Angeles, California, USA. [3] Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, UCLA, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AR63089</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DE16513</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DE19412</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AR063089</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DE016513</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DE019412</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Med</MedlineTA>
<NlmUniqueID>9502015</NlmUniqueID>
<ISSNLinking>1078-8956</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004967">Estrogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060528">Wnt4 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C555582">Wnt4 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Rheumatol. 2014 Oct;10(10):575</RefSource>
<PMID Version="1">25155580</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001842">Bone and Bones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004967">Estrogens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010024">Osteoporosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010052">Ovariectomy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060528">Wnt4 Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS593685 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4159424 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25108527</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1546-170X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>20</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature medicine</Title>
<ISOAbbreviation>Nat. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>An acetate switch regulates stress erythropoiesis.</ArticleTitle>
<Pagination>
<MedlinePgn>1018-26</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3587</ELocationID>
<Abstract>
<AbstractText>The hormone erythropoietin (EPO), which is synthesized in the kidney or liver of adult mammals, controls erythrocyte production and is regulated by the stress-responsive transcription factor hypoxia-inducible factor-2 (HIF-2). We previously reported that the lysine acetyltransferase CREB-binding protein (CBP) is required for HIF-2α acetylation and efficient HIF-2-dependent EPO induction during hypoxia. We now show that these processes require acetate-dependent acetyl CoA synthetase 2 (ACSS2). In human Hep3B hepatoma cells and in EPO-generating organs of hypoxic or acutely anemic mice, acetate levels rise and ACSS2 is required for HIF-2α acetylation, CBP-HIF-2α complex formation, CBP-HIF-2α recruitment to the EPO enhancer and efficient induction of EPO gene expression. In acutely anemic mice, acetate supplementation augments stress erythropoiesis in an ACSS2-dependent manner. Moreover, in acquired and inherited chronic anemia mouse models, acetate supplementation increases EPO expression and the resting hematocrit. Thus, a mammalian stress-responsive acetate switch controls HIF-2 signaling and EPO induction during pathophysiological states marked by tissue hypoxia. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nagati</LastName>
<ForeName>Jason S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Jian</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jiwen</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Walters</LastName>
<ForeName>Holly</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moon</LastName>
<ForeName>Young-Ah</ForeName>
<Initials>YA</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gerard</LastName>
<ForeName>Robert D</ForeName>
<Initials>RD</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Chou-Long</ForeName>
<Initials>CL</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Comerford</LastName>
<ForeName>Sarah A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hammer</LastName>
<ForeName>Robert E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Horton</LastName>
<ForeName>Jay D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Rui</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garcia</LastName>
<ForeName>Joseph A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. [2] Department of Medicine, VA North Texas Health Care System, Dallas, Texas, USA. [3].</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK79328</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HL108104</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HL20948</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 DK079328</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Med</MedlineTA>
<NlmUniqueID>9502015</NlmUniqueID>
<ISSNLinking>1078-8956</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485502">HIF-2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11096-26-7</RegistryNumber>
<NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000107">Acetylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015687">Cell Hypoxia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004920">Erythropoiesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004921">Erythropoietin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D013312">Stress, Physiological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS594557 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4159437 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25150496</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1546-170X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>20</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature medicine</Title>
<ISOAbbreviation>Nat. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma.</ArticleTitle>
<Pagination>
<MedlinePgn>1035-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3666</ELocationID>
<Abstract>
<AbstractText>Medulloblastoma, the most common malignant childhood brain tumor, exhibits distinct molecular subtypes and cellular origins. Genetic alterations driving medulloblastoma initiation and progression remain poorly understood. Herein, we identify GNAS, encoding the G protein Gαs, as a potent tumor suppressor gene that, when expressed at low levels, defines a subset of aggressive Sonic hedgehog (SHH)-driven human medulloblastomas. Ablation of the single Gnas gene in anatomically distinct progenitors in mice is sufficient to induce Shh-associated medulloblastomas, which recapitulate their human counterparts. Gαs is highly enriched at the primary cilium of granule neuron precursors and suppresses Shh signaling by regulating both the cAMP-dependent pathway and ciliary trafficking of Hedgehog pathway components. Elevation in levels of a Gαs effector, cAMP, effectively inhibits tumor cell proliferation and progression in Gnas-ablated mice. Thus, our gain- and loss-of-function studies identify a previously unrecognized tumor suppressor function for Gαs that can be found consistently across Shh-group medulloblastomas of disparate cellular and anatomical origins, highlighting G protein modulation as a potential therapeutic avenue. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Xuelian</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Forensic Medicine, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, School of Preclinical and Forensic Medicine, West China Second Hospital, Sichuan University, Chengdu, China. [2] Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Liguo</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences, Xiamen University, Fujian, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Remke</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shih</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Fanghui</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Haibo</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deng</LastName>
<ForeName>Yaqi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xia</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Xiaochong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ramaswamy</LastName>
<ForeName>Vijay</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Tom</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Fan</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Forensic Medicine, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, School of Preclinical and Forensic Medicine, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Wenhao</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burns</LastName>
<ForeName>Dennis K</ForeName>
<Initials>DK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Se Hoon</ForeName>
<Initials>SH</Initials>
<Identifier Source="ORCID">0000000175167372</Identifier>
<AffiliationInfo>
<Affiliation>Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kool</LastName>
<ForeName>Marcel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pfister</LastName>
<ForeName>Stefan M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weinstein</LastName>
<ForeName>Lee S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pomeroy</LastName>
<ForeName>Scott L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gilbertson</LastName>
<ForeName>Richard J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rubin</LastName>
<ForeName>Joshua B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hou</LastName>
<ForeName>Yiping</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Forensic Medicine, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, School of Preclinical and Forensic Medicine, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wechsler-Reya</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Tumor Development Program, Sanford-Burnham Medical Research Institute, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Taylor</LastName>
<ForeName>Michael D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Q Richard</ForeName>
<Initials>QR</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. [2] Department of Pediatrics, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Second Hospital, Sichuan University, Chengdu, China. [3] Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE53248</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 NS072427</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS075243</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS075243</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS078092</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS078092</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Med</MedlineTA>
<NlmUniqueID>9502015</NlmUniqueID>
<ISSNLinking>1078-8956</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.1</RegistryNumber>
<NameOfSubstance UI="D019205">GTP-Binding Protein alpha Subunits, Gs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019205">GTP-Binding Protein alpha Subunits, Gs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008527">Medulloblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058953">Neural Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24615848</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Insulin-sensitizing and beneficial lipid-metabolic effects of the water-soluble melanin complex extracted from Inonotus obliquus.</ArticleTitle>
<Pagination>
<MedlinePgn>1320-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ptr.5131</ELocationID>
<Abstract>
<AbstractText>Inonotus obliquus has been traditionally used for treatment of metabolic diseases; however, the mechanism remains to be elucidated. In this study, we found that the water-soluble melanin complex extracted from I. obliquus improved insulin sensitivity and reduced adiposity in high fat (HF)-fed obese mice. When the melanin complex was treated to 3T3-L1 adipocytes, insulin-stimulated glucose uptake was increased significantly, and its phosphoinositide 3-kinase-dependent action was proven with wortmannin treatment. Additionally, dose-dependent increases in Akt phosphorylation and glucose transporter 4 translocation into the plasma membrane were observed in melanin complex-treated cells. Adiponectin gene expression in 3T3-L1 cells incubated with melanin complex increased which was corroborated by increased AMP-activated protein kinase phosphorylation in HepG2 and C2C12 cells treated with conditioned media from the 3T3-L1 culture. Melanin complex-treated 3T3-L1 cells showed no significant change in expression of several lipogenic genes, whereas enhanced expressions of fatty acid oxidative genes were observed. Similarly, the epididymal adipose tissue of melanin complex-treated HF-fed mice had higher expression of fatty acid oxidative genes without significant change in lipogenic gene expression. Together, these results suggest that the water-soluble melanin complex of I. obliquus exerts antihyperglycemic and beneficial lipid-metabolic effects, making it a candidate for promising antidiabetic agent.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jung-Han</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>School of Life Science, Handong Global University, Pohang, Gyungbuk, 791-708, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hyun</LastName>
<ForeName>Chang-Kee</ForeName>
<Initials>CK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052242">Adiponectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008543">Melanins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D041721">3T3-L1 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052242">Adiponectin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050154">Adiposity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001487">Basidiomycota</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059305">Diet, High-Fat</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007333">Insulin Resistance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008543">Melanins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008820">Mice, Obese</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">3T3-L1 adipocytes</Keyword>
<Keyword MajorTopicYN="N">GLUT4</Keyword>
<Keyword MajorTopicYN="N">Inonotus obliquus</Keyword>
<Keyword MajorTopicYN="N">PI 3-K</Keyword>
<Keyword MajorTopicYN="N">antidiabetic</Keyword>
<Keyword MajorTopicYN="N">fatty acid oxidation</Keyword>
<Keyword MajorTopicYN="N">glucose uptake</Keyword>
<Keyword MajorTopicYN="N">high fat-fed mice</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24623679</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Luteolin inhibits hyperglycemia-induced proinflammatory cytokine production and its epigenetic mechanism in human monocytes.</ArticleTitle>
<Pagination>
<MedlinePgn>1383-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ptr.5141</ELocationID>
<Abstract>
<AbstractText>Hyperglycemia is a key feature in diabetes. Hyperglycemia has been implicated as a major contributor to several complications of diabetes. High glucose levels induce the release of proinflammatory cytokines. Luteolin is a flavone isolated from celery, green pepper, perilla leaf, and chamomile tea. Luteolin has been reported to possess antimutagenic, antitumorigenic, antioxidant, and anti-inflammatory properties. In this study, we investigated the effects of luteolin on proinflammatory cytokine secretion and its underlying epigenetic regulation in high-glucose-induced human monocytes. Human monocytic (THP-1) cells were cultured under controlled (14.5 mM mannitol), normoglycemic (NG, 5.5 mM glucose), or hyperglycemic (HG, 20 mM glucose) conditions, in the absence or presence of luteolin. Luteolin (3-10 μM) was added for 48 h. While hyperglycemic conditions significantly induced histone acetylation, NF-κB activation, and proinflammatory cytokine (IL-6 and TNF-α) release from THP-1 cells, luteolin suppressed NF-κB activity and cytokine release. Luteolin also significantly reduced CREB-binding protein/p300 (CBP/p300) gene expression, as well as the levels of acetylation and histone acetyltransferase (HAT) activity of the CBP/p300 protein, which is a known NF-κB coactivator. These results suggest that luteolin inhibits HG-induced cytokine production in monocytes, through epigenetic changes involving NF-κB. We therefore suggest that luteolin may be a potential candidate for the treatment and prevention of diabetes and its complications.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Hye Joo</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Pharmacology Research Center, Korea Research Institute of Chemical Technology, Daejeon, 305-600, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Wooje</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yun</LastName>
<ForeName>Jung-Mi</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003470">Culture Media</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="D050881">E1A-Associated p300 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="C494360">EP300 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="D051548">Histone Acetyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>KUX1ZNC9J2</RegistryNumber>
<NameOfSubstance UI="D047311">Luteolin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000107">Acetylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003470">Culture Media</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050881">E1A-Associated p300 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051548">Histone Acetyltransferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006943">Hyperglycemia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047311">Luteolin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">NF-κB</Keyword>
<Keyword MajorTopicYN="N">acetylation</Keyword>
<Keyword MajorTopicYN="N">deacetylation</Keyword>
<Keyword MajorTopicYN="N">luteolin</Keyword>
<Keyword MajorTopicYN="N">p300</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093615</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-3169</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>230</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology letters</Title>
<ISOAbbreviation>Toxicol. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hexachlorobenzene induces TGF-β1 expression, which is a regulator of p27 and cyclin D1 modifications.</ArticleTitle>
<Pagination>
<MedlinePgn>1-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2014.08.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0378-4274(14)01207-7</ELocationID>
<Abstract>
<AbstractText>Hexachlorobenzene (HCB) is an organochlorine pesticide widely distributed in the environment. In this study we have demonstrated that HCB induced loss of cell viability and alterations in cell cycle regulation in FRTL-5 rat thyroid cells. Analysis of cell cycle distribution by flow cytometric analysis demonstrated that HCB induced cell cycle arrest at G2/M and at G0/G1 phase, inhibiting cell cycle progression at the G1/S phase, after 24 h and 72 h of treatment. HCB-treatment resulted in an increase in transforming growth factor-beta (TGF-β1) mRNA levels, a negative regulator of cell growth in thyroid epithelial cells. Time-dependent studies showed that both cytosolic and nuclear p27 protein levels were increased by 5 μM HCB. After 24 h of treatment, total p27 in whole cells lysate was increased. Dose-dependent studies, demonstrated that HCB (0.005, 0.05, 0.5 and 5 μM) increased p27, both in the cytosol and nucleus. HCB (5 μM) induced a concomitant decrease in nuclear cyclin D1 protein levels, in a time-dependent manner. We have also demonstrated that TGF-β1 Smad signaling is involved in HCB-induced alterations of p27 and cyclin D1 protein levels. On the other hand, ERK1/2 activation is not involved in the alteration of cell cycle regulatory proteins.</AbstractText>
<CopyrightInformation>Copyright © 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chiappini</LastName>
<ForeName>Florencia</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pontillo</LastName>
<ForeName>Carolina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Randi</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alvarez</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kleiman de Pisarev</LastName>
<ForeName>Diana L</ForeName>
<Initials>DL</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos, Buenos Aires, Argentina. Electronic address: dianakleiman@yahoo.com.ar.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Toxicol Lett</MedlineTA>
<NlmUniqueID>7709027</NlmUniqueID>
<ISSNLinking>0378-4274</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530106">Ccnd1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493962">Cdkn1b protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010575">Pesticides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508962">Tgfb1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147604-94-2</RegistryNumber>
<NameOfSubstance UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4Z87H0LKUY</RegistryNumber>
<NameOfSubstance UI="D006581">Hexachlorobenzene</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="C535149">Mapk1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016192">G0 Phase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059585">G1 Phase Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059565">G2 Phase Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006581">Hexachlorobenzene</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019950">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048052">Mitogen-Activated Protein Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010575">Pesticides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051785">Smad Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013961">Thyroid Gland</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053773">Transforming Growth Factor beta1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cell cycle</Keyword>
<Keyword MajorTopicYN="N">Cyclin D1</Keyword>
<Keyword MajorTopicYN="N">ERK1/2</Keyword>
<Keyword MajorTopicYN="N">FRTL-5 cells</Keyword>
<Keyword MajorTopicYN="N">Hexachlorobenzene</Keyword>
<Keyword MajorTopicYN="N">TGF-β1</Keyword>
<Keyword MajorTopicYN="N">p27</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24905940</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-3185</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>324</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology</Title>
<ISOAbbreviation>Toxicology</ISOAbbreviation>
</Journal>
<ArticleTitle>Involvement of CaM-CaMKII-ERK in bisphenol A-induced Sertoli cell apoptosis.</ArticleTitle>
<Pagination>
<MedlinePgn>27-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2014.06.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0300-483X(14)00113-9</ELocationID>
<Abstract>
<AbstractText>Bisphenol A (BPA), one of the most prevalent chemicals for daily use, has been reported as a xenoestrogen to induce reproductive toxicity, but its mechanism is poorly understood. In the present study, we aimed to explore whether CaM-CaMKII-ERK1/2 signaling pathway was involved in BPA-induced Sertoli cells injury via the mitochondrial apoptotic pathway. TM4 cells were cultured with 0, 0.02, 0.2, 2.0, 20μM BPA, and cell viability, mitochondrial function and CaM-CaMKII-ERK1/2 signal pathway were examined. With the MTT assay, BPA was found to suppress cell viability in a dose- and time-dependent manner. Moreover, mitochondrial mass loss, membrane potential decrease, cytochrome c release, Bcl-2 family members down-regulation and caspases-3 up-regulation were obviously observed when the TM4 cells were exposed to BPA. Additionally, the expression of calmodulin (CaM) and phosphorylation of calcium/calmodulin dependent kinase II (CaMKII) significantly increased, and pretreatment with 10μM antagonist of CaM (W-7) or CaMKII (KN62) prevented cell damage through mitochondrial apoptotic pathway. In parallel, ERK1/2 pathway was proved to participate in BPA-induced cell damage, since W-7 and KN62 partially suppressed ERK1/2 activation, and PD98059, the ERK1/2 antagonist, significantly attenuated BPA-induced cell damage. These data, taken together, indicated that CaM-CaMKII-ERK axis might transmit apoptotic signals to the mitochondria during BPA-induced cell apoptosis. By exploring the mechanisms of the Ca(2+) homeostasis and the corresponding proteins, our study provides new insight into BPA-induced reproductive toxicity. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Wenyi</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Jingying</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mao</LastName>
<ForeName>Changfei</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China; Department of Oncology, Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jingli</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China; Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yixin</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qiang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Preventive Medicine, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang 212013, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yanqing</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Rong</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Hang</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 210029, China. Electronic address: wangjun@njmu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Toxicology</MedlineTA>
<NlmUniqueID>0361055</NlmUniqueID>
<ISSNLinking>0300-483X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002147">Calmodulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052244">Endocrine Disruptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-43-6</RegistryNumber>
<NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="C535148">Mapk1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>MLT3645I99</RegistryNumber>
<NameOfSubstance UI="C006780">bisphenol A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001559">Benzhydryl Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002147">Calmodulin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052244">Endocrine Disruptors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019950">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048052">Mitogen-Activated Protein Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010636">Phenols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012708">Sertoli Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Bisphenol A</Keyword>
<Keyword MajorTopicYN="N">Calcium/calmodulin dependent protein kinase II</Keyword>
<Keyword MajorTopicYN="N">Calmodulin</Keyword>
<Keyword MajorTopicYN="N">ERK1/2</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25089838</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-3185</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>324</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology</Title>
<ISOAbbreviation>Toxicology</ISOAbbreviation>
</Journal>
<ArticleTitle>The novel regulations of MEF2A, CAMKK2, CALM3, and TNNI3 in ventricular hypertrophy induced by arsenic exposure in rats.</ArticleTitle>
<Pagination>
<MedlinePgn>123-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2014.07.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0300-483X(14)00150-4</ELocationID>
<Abstract>
<AbstractText>Arsenic is a ubiquitous toxic compound that exists naturally in many sources such as soil, groundwater, and food; in which vast majority forms are arsenite (As(3+)) or arsenate (As(5+)). The mechanism of arsenic detoxification in humans still remains obscured. Epidemiologic studies documented that arsenic pollution caused black foot disease, cardiovascular diseases (hypertension, hypotension, cardiomyopathy), bladder cancer and skin cancer in many countries in which Taiwan is considered as high arsenic exposure country for long time ago. However, the effects of arsenic to cardiac functions still lacked of investigation while some studies mainly focus on inflammatory and cancer mechanisms. In the present study, we found cardiac hypertrophy signaling may be the most significant pathway for up regulated genes in arsenic exposed patients via bioinformatics approach. To verify our bioinformatics prediction, arsenic was fed orally to rats at different concentration based on previous studies in Taiwan. Using hemodynamic method as the main tool to measure the changes in blood pressure, left ventricular pressure and left ventricular contractility index, the findings suggest that highly exposure to arsenic lead to hypertension; elevated left ventricular diastolic pressure and alteration in cardiac contractility which are supposed to be the interaction between arsenic and cardiac nerves activity via the changing in calcium homeostasis. Collectively, based on our real-time PCR and western blot data strongly suggest that calcium homeostasis may also go through MEF2A, TNNI3, CAMKK2, CALM3 and cardiac hypertrophy relative signaling pathway. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Phan</LastName>
<ForeName>Nam Nhut</ForeName>
<Initials>NN</Initials>
<AffiliationInfo>
<Affiliation>Graduate Institute of Biotechnology, Chinese Culture University, 55 Hwa-Kang Road, Yang-Ming-Shan, Taipei 11114, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Chih-Yang</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, University of California, San Francisco, CA, USA; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Yen-Chang</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>Graduate Institute of Biotechnology, Chinese Culture University, 55 Hwa-Kang Road, Yang-Ming-Shan, Taipei 11114, Taiwan. Electronic address: lycnthu@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Toxicology</MedlineTA>
<NlmUniqueID>0361055</NlmUniqueID>
<ISSNLinking>0300-483X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018053">Arsenites</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002147">Calmodulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064326">MEF2 Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578037">MEF2A protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017670">Sodium Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019210">Troponin I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>48OVY2OC72</RegistryNumber>
<NameOfSubstance UI="C017947">sodium arsenite</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance UI="D054737">Calcium-Calmodulin-Dependent Protein Kinase Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance UI="C517702">Camkk2 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018053">Arsenites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054737">Calcium-Calmodulin-Dependent Protein Kinase Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002147">Calmodulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006352">Heart Ventricles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017379">Hypertrophy, Left Ventricular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064326">MEF2 Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009200">Myocardial Contraction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017670">Sodium Compounds</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019210">Troponin I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016277">Ventricular Function, Left</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017725">Ventricular Pressure</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Arsenic</Keyword>
<Keyword MajorTopicYN="N">Cardiac function</Keyword>
<Keyword MajorTopicYN="N">Hypertension</Keyword>
<Keyword MajorTopicYN="N">Ventricular hypertrophy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25207369</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0065-2598</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>810</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in experimental medicine and biology</Title>
<ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Molecular biology of basal and squamous cell carcinomas.</ArticleTitle>
<Pagination>
<MedlinePgn>234-52</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The prevalent keratinocyte-derived neoplasms of the skin are basal cell carcinoma and squamous cell carcinoma. Both so called nonmelanoma skin cancers comprise the most common cancers in humans by far. Common risk factors for both tumor entities include sun-exposure, DNA repair deficiencies leading to chromosomal instability, or immunosuppression. Yet, fundamental differences in the development of the two different entities have been and are currently unveiled. The constitutive activation of the sonic hedgehog signaling pathway by acquired mutations in the PTCH and SMO genes appears to represent the early basal cell carcinoma developmental determinant. Although other signaling pathways are also affected, small hedgehog inhibitory molecules evolve as the most promising basal cell carcinoma treatment options systemically as well as topically in current clinical trials. For squamous cell carcinoma development mutations in the p53 gene, especially UV-induced mutations, have been identified as early events. Yet, other signaling pathways including epidermal growth factor receptor, RAS, Fyn, or p16INK4a signaling may play significant roles in squamous cell carcinoma development. The improved understanding of the molecular events leading to different tumor entities by de-differentiation of the same cell type have begun to pave the way for modulating new molecular targets therapeutically with small molecules.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Emmert</LastName>
<ForeName>Steffen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schön</LastName>
<ForeName>Michael P</ForeName>
<Initials>MP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haenssle</LastName>
<ForeName>Holger A</ForeName>
<Initials>HA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Exp Med Biol</MedlineTA>
<NlmUniqueID>0121103</NlmUniqueID>
<ISSNLinking>0065-2598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491023">SMO protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099744">patched receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C494957">FYN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D051076">Proto-Oncogene Proteins c-fyn</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002280">Carcinoma, Basal Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009928">Organ Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051076">Proto-Oncogene Proteins c-fyn</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25207372</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0065-2598</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>810</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in experimental medicine and biology</Title>
<ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The vitamin D receptor: a tumor suppressor in skin.</ArticleTitle>
<Pagination>
<MedlinePgn>282-302</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Cutaneous malignancies including melanomas and non melanoma skin cancers (NMSC) are the most common types of cancer, occurring at a rate of over 1 million per year in the United States. The major cell in the epidermis, the keratinocyte, not only produces vitamin D but contains the enzymatic machinery to metabolize vitamin D to its active metabolite, 1,25(OH)2D, and expresses the receptor for this metabolite, the vitamin D receptor (VDR), allowing the cell to respond to the 1,25(OH)2D that it produces. In vitro, 1,25(OH)2D stimulates the differentiation and inhibits the proliferation of these cells and so would be expected to be tumor suppressive. However, epidemiologic evidence demonstrating a negative relationship between circulating levels of the substrate for CYP27B1, 25OHD, and the incidence of these malignancies is mixed, raising the question whether vitamin D is protective in the in vivo setting. UV radiation (UV), both UVB and UVA, as occurs with sunlight exposure is generally regarded as causal for these malignancies, but UVB is also required for vitamin D synthesis in the skin. This complicates conclusions reached from epidemiologic studies in that UVB is associated with higher 25OHD levels as well as increased incidence of cutaneous malignancies. Based on our own data and that reported in the literature we hypothesize that vitamin D signaling in the skin suppresses UVR induced epidermal tumor formation. In this chapter we will first discuss recent data regarding potential mechanisms by which vitamin D signaling suppresses tumor formation, then focus on three general mechanisms that mediate tumor suppression by VDR in the skin: inhibition of proliferation and stimulation of differentiation, immune regulation, and stimulation of DNA damage repair (DDR).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bikle</LastName>
<ForeName>Daniel D</ForeName>
<Initials>DD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA110338</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 AR39448</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Exp Med Biol</MedlineTA>
<NlmUniqueID>0121103</NlmUniqueID>
<ISSNLinking>0065-2598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018167">Receptors, Calcitriol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1406-16-2</RegistryNumber>
<NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>66772-14-3</RegistryNumber>
<NameOfSubstance UI="C097949">1,25-dihydroxyvitamin D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.-</RegistryNumber>
<NameOfSubstance UI="D015090">25-Hydroxyvitamin D3 1-alpha-Hydroxylase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015090">25-Hydroxyvitamin D3 1-alpha-Hydroxylase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015603">Keratinocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018167">Receptors, Calcitriol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014807">Vitamin D</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25207373</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0065-2598</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>810</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in experimental medicine and biology</Title>
<ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Protection from ultraviolet damage and photocarcinogenesis by vitamin D compounds.</ArticleTitle>
<Pagination>
<MedlinePgn>303-28</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Vitamin D is primarily produced by a photochemical reaction in skin, using the energy of ultraviolet B radiation. Ultraviolet radiation in sunlight is also responsible for several types of DNA damage, immunosuppression and photoaging. A number of adaptive responses are known to occur in skin to increasing UV exposure, including increased pigmentation, increased thickness of the cornified layer of skin and upregulation of DNA repair pathways. In addition to these known responses, there is now sufficient evidence to suggest that the local vitamin D system in skin, which includes local production of the active hormone, 1,25 dihydroxyvitamin D, together with metabolites of over-irradiation products, and vitamin D receptor(s), also provide an adaptive response to UV. The vitamin D system in skin reduces DNA damage, inflammation and photocarcinogenesis. Because vitamin D is made in skin, sun damage is less than it would be otherwise.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gordon-Thomson</LastName>
<ForeName>Clare</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tongkao-on</LastName>
<ForeName>Wannit</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Eric J</ForeName>
<Initials>EJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carter</LastName>
<ForeName>Sally E</ForeName>
<Initials>SE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dixon</LastName>
<ForeName>Katie M</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mason</LastName>
<ForeName>Rebecca S</ForeName>
<Initials>RS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Exp Med Biol</MedlineTA>
<NlmUniqueID>0121103</NlmUniqueID>
<ISSNLinking>0065-2598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018167">Receptors, Calcitriol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1406-16-2</RegistryNumber>
<NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>66772-14-3</RegistryNumber>
<NameOfSubstance UI="C097949">1,25-dihydroxyvitamin D</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018167">Receptors, Calcitriol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015595">Skin Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012880">Skin Pigmentation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014807">Vitamin D</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25207374</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0065-2598</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>810</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in experimental medicine and biology</Title>
<ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.</ArticleTitle>
<Pagination>
<MedlinePgn>329-41</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Basal Cell Carcinomas (BCCs) are the most commonly diagnosed tumors among people in the western world. Most BCCs are caused by mutational inactivation of the tumor suppressor Patched (PTCH), which results in activation of Smoothened (SMO) and of the Hedgehog (HH) signaling pathway. Recent studies indicate that BCC progression involves a crosstalk between Hh signaling, vitamin D derivatives and the vitamin D receptor (Vdr) signaling pathway. This has been demonstrated in BCC-bearing Ptch mutant mice and BCC cell lines, in which both vitamin D3 and its active metabolite calcitriol (1alpha-25(OH)2D3) exert antitumor effects. Interestingly, the antitumor effects are mainly ascribed to an inhibition of Hh signaling. Furthermore, as evident from studies in Vdr deficient mice, calcitriol may also repress the activity of Hh signaling in a Vdr-dependent fashion thereby establishing an additional inhibitory feedback on Hh signaling activity. In this chapter, we discuss the current understanding and controversial findings of the inhibition of Hh signaling by vitamin D derivatives and the implication of these findings for BCC carcinogenesis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Albert</LastName>
<ForeName>Benedikt</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hahn</LastName>
<ForeName>Heidi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Exp Med Biol</MedlineTA>
<NlmUniqueID>0121103</NlmUniqueID>
<ISSNLinking>0065-2598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018167">Receptors, Calcitriol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491023">SMO protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099744">patched receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1406-16-2</RegistryNumber>
<NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>66772-14-3</RegistryNumber>
<NameOfSubstance UI="C097949">1,25-dihydroxyvitamin D</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002280">Carcinoma, Basal Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018167">Receptors, Calcitriol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014807">Vitamin D</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203887</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1528-1140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>260</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Annals of surgery</Title>
<ISOAbbreviation>Ann. Surg.</ISOAbbreviation>
</Journal>
<ArticleTitle>X chromosome-linked IRAK-1 polymorphism is a strong predictor of multiple organ failure and mortality postinjury.</ArticleTitle>
<Pagination>
<MedlinePgn>698-703; discussion 703-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0000000000000918</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE(S)" NlmCategory="OBJECTIVE">Clinical research characterizing the mechanisms responsible for sex-based outcome differences postinjury remain conflicting. We sought to characterize an X chromosome-linked IRAK-1 (IL-1 receptor-associated kinase) polymorphism as an alternative mechanism responsible for sex differences postinjury. IRAK-1 is key intermediate in the toll-like receptor (TLR) pathway thought to drive inflammation postinjury.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A prospective cohort study was performed over a 24-month period. Bluntly injured patients requiring intensive care unit admission were enrolled, whereas patients with isolated brain and spinal cord injuries were excluded. Outcomes of interest included multiple organ failure (MOF, Marshall MOD score &gt; 5) and mortality. Logistic regression was utilized to determine the independent risk of poor outcome associated with the IRAK-1 variant after controlling for important differences.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In an enrolled cohort of 321 patients, the IRAK-1 variant was common (12.5%). Patients with and without the variant were similar in age, injury severity, and 24hr blood transfusion. After controlling for important confounders, the IRAK1 variant was independently associated with more than eightfold (OR = 8.4, P = 0.005, 95% CI: 1.9-37.1) and 11-fold (OR = 11.8, P = 0.037, 95% CI: 1.1-121) greater risk of MOF and mortality, respectively. These differences were most prominent in men, whereas women heterozygous for the variant demonstrated worse outcome in a dose-dependent fashion.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The IRAK1 polymorphism is a strong independent predictor of MOF and mortality postinjury and represents a common variant with prognostic potential. These data demonstrate the importance of TLR signaling postinjury and supports that a genetic mechanism may drive sex outcome differences postinjury.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sperry</LastName>
<ForeName>Jason L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>From the Division of Trauma and General Surgery, Department of Surgery, University of Pittsburgh, PA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zolin</LastName>
<ForeName>Samuel</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zuckerbraun</LastName>
<ForeName>Brian S</ForeName>
<Initials>BS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vodovotz</LastName>
<ForeName>Yoram</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Namas</LastName>
<ForeName>Rami</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neal</LastName>
<ForeName>Matthew D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferrell</LastName>
<ForeName>Robert E</ForeName>
<Initials>RE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rosengart</LastName>
<ForeName>Matthew R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peitzman</LastName>
<ForeName>Andrew B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Billiar</LastName>
<ForeName>Timothy R</ForeName>
<Initials>TR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K23 GM093032</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K23GM093032</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Ann Surg</MedlineTA>
<NlmUniqueID>0372354</NlmUniqueID>
<ISSNLinking>0003-4932</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C507768">IRAK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D053592">Interleukin-1 Receptor-Associated Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D041321">Chromosomes, Human, X</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053592">Interleukin-1 Receptor-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009102">Multiple Organ Failure</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018805">Sepsis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014949">Wounds, Nonpenetrating</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS615701 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4159729 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25186638</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Tanshinone IIA pretreatment protects free flaps against hypoxic injury by upregulating stem cell-related biomarkers in epithelial skin cells.</ArticleTitle>
<Pagination>
<MedlinePgn>331</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-331</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Partial or total flap necrosis after flap transplantation is sometimes encountered in reconstructive surgery, often as a result of a period of hypoxia that exceeds the tolerance of the flap tissue. The purpose of this study was to determine whether Tanshinone IIA (TSA) pretreatment can protect flap tissue against hypoxic injury and improve its viability.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Primary epithelial cells isolated from the dorsal skin of mice were pretreated with TSA for 2 weeks. Cell Counting Kit-8 and Trypan Blue assays were carried out to examine the proliferation of TSA-pretreated cells after exposure to cobalt chloride. Polymerase chain reaction and western blot analysis were used to assess the expression of β-catenin, vascular endothelial growth factor (VEGF), sex determining region Y-box 2 (SOX2), OCT4 (also known as POU domain class 5 transcription factor 1), Nanog, and glycogen synthase kinase-3 beta (GSK-3β) in TSA-treated cells. In other experiments, after mice were pretreated with TSA for 2 weeks, a reproducible ischemic flap model was implemented, and the area of surviving tissue in the transplanted flaps was measured. Immunohistochemistry was conducted to examine Wnt signaling as well as stem cell- and angiogenesis-related biomarkers in epithelial tissue in vivo.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Epidermal cells, pretreated with TSA, showed enhanced resistance to hypoxia. Activation of the Wnt signaling pathway in TSA-pretreated cells was characterized by the upregulation of β-catenin and the downregulation of GSK-3β. The expression of SOX2, Nanog, and OCT4 were also higher in TSA-pretreated epithelial cells than in control cells. In the reproducible ischemic flap model, pretreatment with TSA enhanced resistance to hypoxia and increased the area of surviving tissue in transplanted flaps. The expression of Wnt signaling pathway components, stem-cell related biomarkers, and VEGF and CD34, which are involved in the regeneration of blood vessels, was also upregulated in TSA-pretreated flap tissue.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TSA pretreatment protects free flaps against hypoxic injury and increases the area of surviving tissue by activating Wnt signaling and upregulating stem cell-related biomarkers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Zihan</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Lijun</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Yaowen</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Yadong</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>Gaoping</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mu</LastName>
<ForeName>Shengzhi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Ronghui</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Benfeng</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Zhenxin</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Burns and Plastic Surgery, Shaanxi Provincial People's Hospital, 256 West Youyi Road, Xi'an 710068, China. zzsxa2006@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045784">Diterpenes, Abietane</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>568-73-0</RegistryNumber>
<NameOfSubstance UI="C021751">tanshinone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C448280">glycogen synthase kinase 3 beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Mutat Res. 1999 Dec 17;431(2):351-9</RefSource>
<PMID Version="1">10636000</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Aviat Space Environ Med. 2000 Feb;71(2):119-24</RefSource>
<PMID Version="1">10685584</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2002 Jan;109(1):45-52</RefSource>
<PMID Version="1">11786790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2002 Oct;119(4):888-99</RefSource>
<PMID Version="1">12406335</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2003 May 22;423(6938):448-52</RefSource>
<PMID Version="1">12717451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11830-5</RefSource>
<PMID Version="1">12913119</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2004 Jul;114(1):74-82</RefSource>
<PMID Version="1">15220572</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 1974 Aug;63(2):187-93</RefSource>
<PMID Version="1">4602091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Oct 6;127(1):171-83</RefSource>
<PMID Version="1">17018284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Plast Reconstr Aesthet Surg. 2007;60(3):272-8</RefSource>
<PMID Version="1">17293285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Mar 8;446(7132):185-9</RefSource>
<PMID Version="1">17330052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Vascul Pharmacol. 2007 Jun;46(6):427-38</RefSource>
<PMID Version="1">17337361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 May 17;447(7142):316-20</RefSource>
<PMID Version="1">17507982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2007 Jun 20;25(18):2586-93</RefSource>
<PMID Version="1">17577038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Pharmacol. 2007 Jul 30;568(1-3):213-21</RefSource>
<PMID Version="1">17537428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Nov 30;131(5):861-72</RefSource>
<PMID Version="1">18035408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2007 Dec 21;318(5858):1917-20</RefSource>
<PMID Version="1">18029452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2008 Jan 18;319(5861):323-7</RefSource>
<PMID Version="1">18063757</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2008 Mar;121(3):860-77</RefSource>
<PMID Version="1">18317135</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Biochem Sci. 2008 Dec;33(12):583-91</RefSource>
<PMID Version="1">18848452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Microsurgery. 2009;29(1):72-9</RefSource>
<PMID Version="1">18946882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Jul 9;114(2):371-9</RefSource>
<PMID Version="1">19417213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17061-6</RefSource>
<PMID Version="1">19805089</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pharm Biol. 2010 May;48(5):484-7</RefSource>
<PMID Version="1">20645787</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 2010 Sep;139(3):718-22</RefSource>
<PMID Version="1">20659460</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tohoku J Exp Med. 2010 Oct;222(2):131-40</RefSource>
<PMID Version="1">20944441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Plast Reconstr Aesthet Surg. 2010 Dec;63(12):2152-9</RefSource>
<PMID Version="1">20359971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytomedicine. 2010 Dec 15;18(1):58-64</RefSource>
<PMID Version="1">20638255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2011 Jan;127 Suppl 1:131S-141S</RefSource>
<PMID Version="1">21200283</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Orthop. 2011 Apr;82(2):125-30</RefSource>
<PMID Version="1">21438671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15858-63</RefSource>
<PMID Version="1">21911394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Atherosclerosis. 2012 Jan;220(1):3-10</RefSource>
<PMID Version="1">21774934</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(6):e40165</RefSource>
<PMID Version="1">22768247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jul 5;487(7405):57-63</RefSource>
<PMID Version="1">22722858</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Transl Res. 2012 Aug;160(2):114-24</RefSource>
<PMID Version="1">22677363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cold Spring Harb Perspect Biol. 2012 Aug;4(8):a008078</RefSource>
<PMID Version="1">22723493</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cell Rev. 2012 Sep;8(3):854-62</RefSource>
<PMID Version="1">22529016</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Brain Res. 2012 Dec 7;1488:81-91</RefSource>
<PMID Version="1">23063715</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Fitoterapia. 2012 Dec;83(8):1666-74</RefSource>
<PMID Version="1">23022532</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Expert Opin Ther Pat. 2013 Feb;23(2):149-53</RefSource>
<PMID Version="1">23231009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Physiol Biochem. 2012;30(4):843-52</RefSource>
<PMID Version="1">22890296</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 2013 May 15;319(9):1317-23</RefSource>
<PMID Version="1">23291327</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000860">Anoxia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045784">Diterpenes, Abietane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058752">Free Tissue Flaps</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016038">Skin Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4162953</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093491</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1168-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.421</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple lines of evidence support that the Hedgehog (Hh) signalling has a role in the maintenance and progression of different human cancers. Therefore, inhibition of the Hh pathway represents a valid anticancer therapeutic approach for renal cell carcinoma (RCC) patients. NVP-LDE225 is a Smoothened (Smo) antagonist that induces dose-related inhibition of Hh and Smo-dependent tumour growth.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We assayed the effects of NVP-LDE225 alone or in combination with everolimus or sunitinib on the growth and invasion of human RCC models both in vitro and in vivo. To this aim, we used a panel of human RCC models, comprising cells with acquired resistance to sunitinib - a multiple tyrosine kinase inhibitor approved as a first-line treatment for RCC.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">NVP-LDE225 cooperated with either everolimus or sunitinib to inhibit proliferation, migration, and invasion of RCC cells even in sunitinib-resistant (SuR) cells. Some major transducers involved in tumour cell motility, including paxillin, were also efficiently inhibited by the combination therapy, as demonstrated by western blot and confocal microscopy assays. Moreover, these combined treatments inhibited tumour growth and increased animal survival in nude mice xenografted with SuR RCC cells. Finally, lung micrometastasis formation was reduced when mice were treated with NVP-LDE225 plus everolimus or sunitinib, as evidenced by artificial metastatic assays.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hedgehog inhibition by NVP-LDE225 plus sunitinib or everolimus bolsters antitumour activity by interfering with tumour growth and metastatic spread, even in SuR cells. Thus, this new evidence puts forward a new promising therapeutic approach for RCC patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>D'Amato</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rosa</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marciano</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Amato</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Formisano</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nappi</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raimondo</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Di Mauro</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Servetto</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fulciniti</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Anatomia Patologica e Citopatologia, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cipolletta</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Anatomia Patologica e Citopatologia, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bianco</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Radioterapia, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ciardiello</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', II Universitá degli Studi di Napoli, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Veneziani</LastName>
<ForeName>B M</ForeName>
<Initials>BM</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>De Placido</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bianco</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C400551">GLI1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C082593">GLI2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C561435">LDE225</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051419">Paxillin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491023">SMO protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C473478">sunitinib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9HW64Q8G6G</RegistryNumber>
<NameOfSubstance UI="C107135">everolimus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001713">Biphenyl Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051741">Kruppel-Like Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061206">Neoplasm Micrometastasis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051419">Paxillin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011758">Pyrroles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25132496</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development.</ArticleTitle>
<Pagination>
<MedlinePgn>331-43</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00277-3</ELocationID>
<Abstract>
<AbstractText>Endoplasmic reticulum (ER) stress has been implicated in the pathogenesis of viral hepatitis, insulin resistance, hepatosteatosis, and nonalcoholic steatohepatitis (NASH), disorders that increase risk of hepatocellular carcinoma (HCC). To determine whether and how ER stress contributes to obesity-driven hepatic tumorigenesis we fed wild-type (WT) and MUP-uPA mice, in which hepatocyte ER stress is induced by plasminogen activator expression, with high-fat diet. Although both strains were equally insulin resistant, the MUP-uPA mice exhibited more liver damage, more immune infiltration, and increased lipogenesis and, as a result, displayed classical NASH signs and developed typical steatohepatitic HCC. Both NASH and HCC development were dependent on TNF produced by inflammatory macrophages that accumulate in the MUP-uPA liver in response to hepatocyte ER stress. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nakagawa</LastName>
<ForeName>Hayato</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA; Department of Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Umemura</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Taniguchi</LastName>
<ForeName>Koji</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Font-Burgada</LastName>
<ForeName>Joan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dhar</LastName>
<ForeName>Debanjan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ogata</LastName>
<ForeName>Hisanobu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Zhenyu</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Valasek</LastName>
<ForeName>Mark A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seki</LastName>
<ForeName>Ekihiro</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hidalgo</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autonoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Koike</LastName>
<ForeName>Kazuhiko</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kaufman</LastName>
<ForeName>Randal J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo>
<Affiliation>Program in Degenerative Diseases, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Karin</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA; Department of Pathology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA. Electronic address: karinoffice@ucsd.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA118165-06</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA155120-02</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK042394-18</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK088227-06</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HL052173-16</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P42 ES010337</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P42ES010337</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA118165</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA155120</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047888">Receptors, Tumor Necrosis Factor, Type I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506236">Tnfrsf1a protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C048690">molecular chaperone GRP78</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.73</RegistryNumber>
<NameOfSubstance UI="D014568">Urokinase-Type Plasminogen Activator</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Cancer Cell. 2014 Sep 8;26(3):301-3</RefSource>
<PMID Version="1">25203316</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059305">Diet, High-Fat</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059865">Endoplasmic Reticulum Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005234">Fatty Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006360">Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050155">Lipogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008114">Liver Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044343">Overnutrition</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047888">Receptors, Tumor Necrosis Factor, Type I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014568">Urokinase-Type Plasminogen Activator</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS625073 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4165611 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25155755</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>402-13</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00299-2</ELocationID>
<Abstract>
<AbstractText>Numerous oncogenic mutations occur within the BRAF kinase domain (BRAF(KD)). Here we show that stable BRAF-MEK1 complexes are enriched in BRAF(WT) and KRAS mutant (MT) cells but not in BRAF(MT) cells. The crystal structure of the BRAF(KD) in a complex with MEK1 reveals a face-to-face dimer sensitive to MEK1 phosphorylation but insensitive to BRAF dimerization. Structure-guided studies reveal that oncogenic BRAF mutations function by bypassing the requirement for BRAF dimerization for activity or weakening the interaction with MEK1. Finally, we show that conformation-specific BRAF inhibitors can sequester a dormant BRAF-MEK1 complex resulting in pathway inhibition. Taken together, these findings reveal a regulatory role for BRAF in the MAPK pathway independent of its kinase activity but dependent on interaction with MEK. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Haling</LastName>
<ForeName>Jacob R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sudhamsu</LastName>
<ForeName>Jawahar</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yen</LastName>
<ForeName>Ivana</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sideris</LastName>
<ForeName>Steve</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sandoval</LastName>
<ForeName>Wendy</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Protein Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phung</LastName>
<ForeName>Wilson</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Protein Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bravo</LastName>
<ForeName>Brandon J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Giannetti</LastName>
<ForeName>Anthony M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Peck</LastName>
<ForeName>Ariana</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Masselot</LastName>
<ForeName>Alexandre</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Bioinformatics, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morales</LastName>
<ForeName>Tony</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Structural Biology, Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Darin</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Structural Biology, Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brandhuber</LastName>
<ForeName>Barbara J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Structural Biology, Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hymowitz</LastName>
<ForeName>Sarah G</ForeName>
<Initials>SG</Initials>
<AffiliationInfo>
<Affiliation>Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: hymowitz.sarah@gene.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malek</LastName>
<ForeName>Shiva</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: malek.shiva@gene.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>4MNE</AccessionNumber>
<AccessionNumber>4MNF</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="C482125">MAP2K1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D048369">MAP Kinase Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020134">Catalytic Domain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018360">Crystallography, X-Ray</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048369">MAP Kinase Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020125">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017354">Point Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020836">Protein Structure, Quaternary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017433">Protein Structure, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25175707</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1878-1551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Developmental cell</Title>
<ISOAbbreviation>Dev. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential apicobasal VEGF signaling at vascular blood-neural barriers.</ArticleTitle>
<Pagination>
<MedlinePgn>541-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.devcel.2014.06.027</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1534-5807(14)00416-X</ELocationID>
<Abstract>
<AbstractText>The vascular endothelium operates in a highly polarized environment, but to date there has been little exploration of apicobasal polarization of its signaling. We show that VEGF-A, histamine, IGFBP3, and LPA trigger unequal endothelial responses when acting from the circulation or the parenchymal side at blood-neural barriers. For VEGF-A, highly polarized receptor distribution contributed to distinct signaling patterns: VEGFR2, which was found to be predominantly abluminal, mediated increased permeability via p38; in contrast, luminal VEGFR1 led to Akt activation and facilitated cytoprotection. Importantly, such differential apicobasal signaling and VEGFR distribution were found in the microvasculature of brain and retina but not lung, indicating that endothelial cells at blood-neural barriers possess specialized signaling compartments that assign different functions depending on whether an agonist is tissue or blood borne.</AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hudson</LastName>
<ForeName>Natalie</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Powner</LastName>
<ForeName>Michael B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sarker</LastName>
<ForeName>Mosharraf H</ForeName>
<Initials>MH</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK; Cardiovascular Division, King's College London, 150 Stamford Street, London SE1 9NH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burgoyne</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Campbell</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Neurovascular Genetics Laboratory, Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College, Dublin 2, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ockrim</LastName>
<ForeName>Zoe K</ForeName>
<Initials>ZK</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martinelli</LastName>
<ForeName>Roberta</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Futter</LastName>
<ForeName>Clare E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grant</LastName>
<ForeName>Maria B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo>
<Affiliation>Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, 1160 West Michigan Street, Indianapolis, IN 46202, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fraser</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Cardiovascular Division, King's College London, 150 Stamford Street, London SE1 9NH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shima</LastName>
<ForeName>David T</ForeName>
<Initials>DT</Initials>
<AffiliationInfo>
<Affiliation>Department of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Greenwood</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Turowski</LastName>
<ForeName>Patric</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK. Electronic address: p.turowski@ucl.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>PG/11/62/29010</GrantID>
<Agency>British Heart Foundation</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Cell</MedlineTA>
<NlmUniqueID>101120028</NlmUniqueID>
<ISSNLinking>1534-5807</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040281">Vascular Endothelial Growth Factor Receptor-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Circ Res. 2000 Sep 15;87(6):434-9</RefSource>
<PMID Version="1">10988233</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuropharmacology. 2013 Feb;65:74-82</RefSource>
<PMID Version="1">22960442</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2012;3:972</RefSource>
<PMID Version="1">22828632</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2002 Jun 15;115(Pt 12):2559-67</RefSource>
<PMID Version="1">12045226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2002 Oct 1;367(Pt 1):145-55</RefSource>
<PMID Version="1">12084011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2002 Dec 4;532(1-2):67-9</RefSource>
<PMID Version="1">12459464</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2003 Feb;17(2):262-4</RefSource>
<PMID Version="1">12490545</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2003 Apr 11;278(15):12605-8</RefSource>
<PMID Version="1">12538598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2003 May 12;161(3):653-60</RefSource>
<PMID Version="1">12743111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 2013 May 15;319(9):1247-54</RefSource>
<PMID Version="1">23567183</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 1999 Nov 15;13(22):2905-27</RefSource>
<PMID Version="1">10579998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2013 Apr;182(4):1379-90</RefSource>
<PMID Version="1">23416159</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ophthalmology. 2013 Jan;120(1):106-14</RefSource>
<PMID Version="1">23031671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Diabetes. 2003 Dec;52(12):2959-68</RefSource>
<PMID Version="1">14633857</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2786-94</RefSource>
<PMID Version="1">15277505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anat Embryol (Berl). 1989;180(1):1-15</RefSource>
<PMID Version="1">2571310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Physiol. 1990 Oct;429:47-62</RefSource>
<PMID Version="1">2277354</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 1991 Apr;113(1):123-35</RefSource>
<PMID Version="1">2007617</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 1992 Sep;103 ( Pt 1):23-37</RefSource>
<PMID Version="1">1429907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Physiol. 1994 Feb 15;475(1):147-57</RefSource>
<PMID Version="1">8189387</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol. 1995 Feb;268(2 Pt 2):F285-95</RefSource>
<PMID Version="1">7864168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol. 1996 Dec;271(6 Pt 2):H2520-8</RefSource>
<PMID Version="1">8997313</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Physiol. 1997 Sep 15;503 ( Pt 3):613-23</RefSource>
<PMID Version="1">9379415</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Physiol. 1998 Mar 15;507 ( Pt 3):909-18</RefSource>
<PMID Version="1">9508849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1998 Nov 13;273(46):30336-43</RefSource>
<PMID Version="1">9804796</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1999 Mar;126(6):1149-59</RefSource>
<PMID Version="1">10021335</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1999 Apr;126(7):1407-15</RefSource>
<PMID Version="1">10068634</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2005 Apr;132(8):1855-62</RefSource>
<PMID Version="1">15790963</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Circ Res. 2005 Jun 24;96(12):1257-65</RefSource>
<PMID Version="1">15920019</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Sci (Lond). 2005 Sep;109(3):227-41</RefSource>
<PMID Version="1">16104843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2005 Sep 22;437(7058):497-504</RefSource>
<PMID Version="1">16177780</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2005 Nov;11(11):1188-96</RefSource>
<PMID Version="1">16227992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Neurosurg. 2005 Nov;103(5):853-68</RefSource>
<PMID Version="1">16304990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Med. 2007;58:491-504</RefSource>
<PMID Version="1">17052163</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Brain Res. 2007 May 30;1150:1-13</RefSource>
<PMID Version="1">17434463</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biophys Chem. 2007 Jul;128(2-3):125-39</RefSource>
<PMID Version="1">17442480</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Microvasc Res. 2007 Sep-Nov;74(2-3):100-13</RefSource>
<PMID Version="1">17532010</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Angiogenesis. 2008;11(2):109-19</RefSource>
<PMID Version="1">18293091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Physiol. 2008 Oct;217(1):13-22</RefSource>
<PMID Version="1">18543272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2008;3(11):e3554</RefSource>
<PMID Version="1">18978936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2009 Feb;20(3):995-1005</RefSource>
<PMID Version="1">19073885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2009;4(4):e5149</RefSource>
<PMID Version="1">19340291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Clin Oncol. 2009 Aug;6(8):465-77</RefSource>
<PMID Version="1">19581909</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neurobiol Dis. 2010 Jan;37(1):13-25</RefSource>
<PMID Version="1">19664713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Microcirculation. 2010 Jan;17(1):39-46</RefSource>
<PMID Version="1">20141599</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Differ. 2010 Mar;17(3):499-512</RefSource>
<PMID Version="1">19834490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2010 Mar;12(3):267-72</RefSource>
<PMID Version="1">20118922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2010 Mar;20(3):142-9</RefSource>
<PMID Version="1">20061152</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Glia. 2010 Aug;58(10):1177-85</RefSource>
<PMID Version="1">20544853</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Diabetes. 2010 Sep;59(9):2297-305</RefSource>
<PMID Version="1">20530741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ophthalmology. 2010 Dec;117(12):2407-16</RefSource>
<PMID Version="1">20678804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2011 Jul 15;437(2):169-83</RefSource>
<PMID Version="1">21711246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2012 Feb 15;125(Pt 4):831-43</RefSource>
<PMID Version="1">22399811</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2012;3:849</RefSource>
<PMID Version="1">22617289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2012 Jul 2;122(7):2454-68</RefSource>
<PMID Version="1">22653056</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2012 Jul 2;209(7):1363-77</RefSource>
<PMID Version="1">22689825</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004730">Endothelium, Vascular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008833">Microcirculation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010539">Permeability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011917">Rats, Inbred Lew</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040281">Vascular Endothelial Growth Factor Receptor-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040301">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4160345</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203207</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-1551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Developmental cell</Title>
<ISOAbbreviation>Dev. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development.</ArticleTitle>
<Pagination>
<MedlinePgn>528-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.devcel.2014.07.012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1534-5807(14)00454-7</ELocationID>
<Abstract>
<AbstractText>Atypical 7-transmembrane receptors, often called decoy receptors, act promiscuously as molecular sinks to regulate ligand bioavailability and consequently temper the signaling of canonical G protein-coupled receptor (GPCR) pathways. Loss of mammalian CXCR7, the most recently described decoy receptor, results in postnatal lethality due to aberrant cardiac development and myocyte hyperplasia. Here, we provide the molecular underpinning for this proliferative phenotype by demonstrating that the dosage and signaling of adrenomedullin (Adm, gene; AM, protein)-a mitogenic peptide hormone required for normal cardiovascular development-is tightly controlled by CXCR7. To this end, Cxcr7(-/-) mice exhibit gain-of-function cardiac and lymphatic vascular phenotypes that can be reversed upon genetic depletion of adrenomedullin ligand. In addition to identifying a biological ligand accountable for the phenotypes of Cxcr7(-/-) mice, these results reveal a previously underappreciated role for decoy receptors as molecular rheostats in controlling the timing and extent of GPCR-mediated cardiac and vascular development. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Klein</LastName>
<ForeName>Klara R</ForeName>
<Initials>KR</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Karpinich</LastName>
<ForeName>Natalie O</ForeName>
<Initials>NO</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Espenschied</LastName>
<ForeName>Scott T</ForeName>
<Initials>ST</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Willcockson</LastName>
<ForeName>Helen H</ForeName>
<Initials>HH</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dunworth</LastName>
<ForeName>William P</ForeName>
<Initials>WP</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hoopes</LastName>
<ForeName>Samantha L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kushner</LastName>
<ForeName>Erich J</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bautch</LastName>
<ForeName>Victoria L</ForeName>
<Initials>VL</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, The University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Caron</LastName>
<ForeName>Kathleen M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA; Department of Genetics, The University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: kathleen_caron@med.unc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE59938</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK099156</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F30 HL118932</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F30HL118932</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM008719</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HD060860</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HL069768</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK099156</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HD060860</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM008719</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 HL069768</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Cell</MedlineTA>
<NlmUniqueID>101120028</NlmUniqueID>
<ISSNLinking>1534-5807</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501897">Cmkor1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054387">Receptors, CXCR</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>148498-78-6</RegistryNumber>
<NameOfSubstance UI="D053607">Adrenomedullin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Dev Cell. 2014 Sep 8;30(5):490-1</RefSource>
<PMID Version="1">25203203</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053607">Adrenomedullin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042601">Lymphatic Vessels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032342">Muscle Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054387">Receptors, CXCR</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS626144 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4166507 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24615293</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>152-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4341</ELocationID>
<Abstract>
<AbstractText>Morgana/CHP-1 is a ubiquitously expressed protein able to inhibit ROCK II kinase activity. We have previously demonstrated that morgana haploinsufficiency leads to multiple centrosomes, genomic instability, and higher susceptibility to tumour development. While a large fraction of human cancers has shown morgana down-regulation, a small subset of tumours was shown to express high morgana levels. Here we demonstrate that high morgana expression in different breast cancer subtypes correlates with high tumour grade, mitosis number, and lymph node positivity. Moreover, morgana overexpression induces transformation in NIH-3T3 cells and strongly protects them from various apoptotic stimuli. From a mechanistic point of view, we demonstrate that morgana causes PTEN destabilization, by inhibiting ROCK activity, hence triggering the PI3K/AKT survival pathway. In turn, morgana down-regulation in breast cancer cells that express high morgana levels increases PTEN expression and leads to sensitization of cells to chemotherapy.</AbstractText>
<CopyrightInformation>Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fusella</LastName>
<ForeName>Federica</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology and Health Sciences, University of Torino, Torino, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferretti</LastName>
<ForeName>Roberta</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Recupero</LastName>
<ForeName>Daniele</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rocca</LastName>
<ForeName>Stefania</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Di Savino</LastName>
<ForeName>Augusta</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tornillo</LastName>
<ForeName>Giusy</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Silengo</LastName>
<ForeName>Lorenzo</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Turco</LastName>
<ForeName>Emilia</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cabodi</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Provero</LastName>
<ForeName>Paolo</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pandolfi</LastName>
<ForeName>Pier Paolo</ForeName>
<Initials>PP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sapino</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tarone</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brancaccio</LastName>
<ForeName>Mara</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C469743">CHP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C478383">Chp-1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C487757">Pten protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002135">Calcium-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018385">Centrosome</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051059">PTEN Phosphohydrolase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054460">rho-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">PTEN</Keyword>
<Keyword MajorTopicYN="N">ROCK</Keyword>
<Keyword MajorTopicYN="N">breast cancer</Keyword>
<Keyword MajorTopicYN="N">chemoresistance</Keyword>
<Keyword MajorTopicYN="N">morgana</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24931423</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential activation of placental unfolded protein response pathways implies heterogeneity in causation of early- and late-onset pre-eclampsia.</ArticleTitle>
<Pagination>
<MedlinePgn>262-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4394</ELocationID>
<Abstract>
<AbstractText>Based on gestational age at diagnosis and/or delivery, pre-eclampsia (PE) is commonly divided into early-onset (&lt;34 weeks) and late-onset (≥34 weeks) forms. Recently, the distinction between 'placental' and 'maternal' causation has been proposed, with 'placental' cases being more frequently associated with early-onset and intrauterine growth restriction. To test whether molecular placental pathology varies according to clinical presentation, we investigated stress-signalling pathways, including unfolded protein response (UPR) pathways, MAPK stress pathways, heat-shock proteins and AMPKα in placentae delivered by caesarean section for clinical indications at different gestational ages. Controls included second-trimester, pre-term and normal-term placentae. BeWo cells were used to investigate how these pathways react to different severities of hypoxia-reoxygenation (H/R) and pro-inflammatory cytokines. Activation of placental UPR and stress-response pathways, including P-IRE1α, ATF6, XBP-1, GRP78 and GRP94, P-p38/p38 and HSP70, was higher in early-onset PE than in both late-onset PE and normotensive controls (NTCs), with a clear inflection around 34 weeks. Placentae from ≥ 34 weeks PE and NTC were indistinguishable. Levels of UPR signalling were similar between second-trimester and term controls, but were significantly higher in pre-term 'controls' delivered vaginally for chorioamnionitis and other conditions. Severe H/R (1/20% O2 ) induced equivalent activation of UPR pathways, including P-eIF2α, ATF6, P-IRE1α, GRP78 and GRP94, in BeWo cells. By contrast, the pro-inflammatory cytokines TNFα and IL-1β induced only mild activation of P-eIF2α and GRP78. AKT, a central regulator of cell proliferation, was reduced in the &lt; 34 weeks PE placentae and severe H/R-treated cells, but not in other conditions. These findings provide the first molecular evidence that placental stress may contribute to the pathophysiology of early-onset pre-eclampsia, whereas that is unlikely to be the case in the late-onset form of the syndrome.</AbstractText>
<CopyrightInformation>© 2014 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yung</LastName>
<ForeName>Hong Wa</ForeName>
<Initials>HW</Initials>
<AffiliationInfo>
<Affiliation>Centre for Trophoblast Research, University of Cambridge, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Atkinson</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Campion-Smith</LastName>
<ForeName>Tim</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olovsson</LastName>
<ForeName>Matts</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Charnock-Jones</LastName>
<ForeName>D Stephen</ForeName>
<Initials>DS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Burton</LastName>
<ForeName>Graham J</ForeName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>084804/2/08/Z</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C018551">glucose-regulated proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005317">Fetal Growth Retardation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005865">Gestational Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018840">HSP70 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010920">Placenta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011225">Pre-Eclampsia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056811">Unfolded Protein Response</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cell stress responses</Keyword>
<Keyword MajorTopicYN="N">growth restriction</Keyword>
<Keyword MajorTopicYN="N">placenta</Keyword>
<Keyword MajorTopicYN="N">pre-eclampsia</Keyword>
<Keyword MajorTopicYN="N">pregnancy</Keyword>
<Keyword MajorTopicYN="N">unfolded protein response</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23625726</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>Up-regulated cten by FGF2 contributes to FGF2-mediated cell migration.</ArticleTitle>
<Pagination>
<MedlinePgn>787-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22034</ELocationID>
<Abstract>
<AbstractText>Cten is a focal adhesion molecule that is expressed at very low levels in most normal tissues. Nonetheless, its expression has been found to increase dramatically in many types of cancer including colorectal, breast, gastric, and pancreatic cancer, suggesting that cten may play a critical role during tumorigenesis. To study the mechanisms that induce cten expression and the function of up-regulated cten, we examined the effects of several cancer-associated growth factors and cytokines on cten expression. We found that EGF, FGF2, NGF, PDGF, TGF-β, IGF-1, IL-6, and IL-13 were able to induce cten expression in a dose- and time-dependent manner. The Mek-Erk and PI3K-Akt pathways were two main signaling cascades responsible for cten up-regulation, whereas the Jak-Stat pathway could contribute to the increase in some conditions. Since many of these factors are known to promote cell migration, we hypothesized that up-regulated cten might contribute to this process. This hypothesis was investigated in FGF2-mediated cell migration. Silencing of cten not only reduced regular cell motility but also FGF2-mediated cell migration. Overexpression of cten promoted cell migration and FGF2 treatment failed to further enhance cell migration. Our findings that (1) cten is a common downstream molecule of these cancer-associated growth factors and cytokines; and that (2) up-regulated cten modulates cell migration induced by FGF2 and likely other growth factors as well, strongly suggest that cten could be a potential downstream therapeutic target for treating cancers associated with aberrant signaling of these growth factors and cytokines.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hung</LastName>
<ForeName>Shih-Ya</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>Center for Tissue Regeneration and Repair, Department of Biochemistry and Molecular Medicine, University of California-Davis, Sacramento, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shih</LastName>
<ForeName>Yi-Ping</ForeName>
<Initials>YP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Michelle</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lo</LastName>
<ForeName>Su Hao</ForeName>
<Initials>SH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA102537</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C074700">tensins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>103107-01-3</RegistryNumber>
<NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016222">Fibroblast Growth Factor 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008840">Microfilament Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FGF2</Keyword>
<Keyword MajorTopicYN="N">cell migration</Keyword>
<Keyword MajorTopicYN="N">cten</Keyword>
<Keyword MajorTopicYN="N">focal adhesion</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23765383</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>β-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase.</ArticleTitle>
<Pagination>
<MedlinePgn>793-806</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22035</ELocationID>
<Abstract>
<AbstractText>Constitutive activation of STAT3 is frequently observed and closely linked with proliferation, survival, invasion, metastasis and angiogenesis in tumor cells. In the present study, we investigated whether β-caryophyllene oxide (CPO), a sesquiterpene isolated primarily from the essential oils of medicinal plants such as guava (Psidium guajava), and oregano (Origanum vulgare L.), can mediate its effect through interference with the STAT3 activation pathway in cancer cells. The effect of CPO on STAT3 activation, associated protein kinases and phosphatase, STAT3-regulated gene products and apoptosis was investigated using both functional proteomics tumor pathway technology platform and different tumor cell lines. We found that CPO suppressed constitutive STAT3 activation in multiple myeloma (MM), breast and prostate cancer cell lines, with a significant dose- and time-dependent effects observed in MM cells. The suppression was mediated through the inhibition of activation of upstream kinases c-Src and JAK1/2. Also, vanadate treatment reversed CPO-induced down-regulation of STAT3, suggesting the involvement of a tyrosine phosphatase. Indeed, we found that CPO induced the expression of tyrosine phosphatase SHP-1 that correlated with the down-regulation of constitutive STAT3 activation. Interestingly, deletion of SHP-1 gene by siRNA abolished the ability of CPO to inhibit STAT3 activation. The inhibition of STAT3 activation by CPO inhibited proliferation, induced apoptosis and abrogated the invasive potential of tumor cells. Our results suggest for the first time that CPO is a novel blocker of STAT3 signaling cascade and thus has an enormous potential for the treatment of various cancers harboring constitutively activated STAT3.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chulwon</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, Seoul, Republic of, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Somi K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kapoor</LastName>
<ForeName>Shweta</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Ansu</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vali</LastName>
<ForeName>Shireen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abbasi</LastName>
<ForeName>Taher</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hoon</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sethi</LastName>
<ForeName>Gautam</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kwang Seok</ForeName>
<Initials>KS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>06</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C507924">JAK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C509249">PTPN6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S2XU9K448U</RegistryNumber>
<NameOfSubstance UI="C515179">caryophyllene oxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004790">Enzyme Induction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012717">Sesquiterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">SHP-1</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">β-caryophyllene oxide</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25127718</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB.</ArticleTitle>
<Pagination>
<MedlinePgn>299</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-299</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Annona muricata leaves have been reported to have antiproliferative effects against various cancer cell lines. However, the detailed mechanism has yet to be defined. The current study was designed to evaluate the molecular mechanisms of A. muricata leaves ethyl acetate extract (AMEAE) against lung cancer A549 cells.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The effect of AMEAE on cell proliferation of different cell lines was analyzed by MTT assay. High content screening (HCS) was applied to investigate the suppression of NF-κB translocation, cell membrane permeability, mitochondrial membrane potential (MMP) and cytochrome c translocation from mitochondria to cytosol. Reactive oxygen species (ROS) formation, lactate dehydrogenase (LDH) release and activation of caspase-3/7, -8 and -9 were measured while treatment. The western blot analysis also carried out to determine the protein expression of cleaved caspase-3 and -9. Flow cytometry analysis was used to determine the cell cycle distribution and phosphatidylserine externalization. Quantitative PCR analysis was performed to measure the gene expression of Bax and Bcl-2 proteins.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Cell viability analysis revealed the selective cytotoxic effect of AMEAE towards lung cancer cells, A549, with an IC50 value of 5.09 ± 0.41 μg/mL after 72 h of treatment. Significant LDH leakage and phosphatidylserine externalization were observed in AMEAE treated cells by fluorescence analysis. Treatment of A549 cells with AMEAE significantly elevated ROS formation, followed by attenuation of MMP via upregulation of Bax and downregulation of Bcl-2, accompanied by cytochrome c release to the cytosol. The incubation of A549 cells with superoxide dismutase and catalase significantly attenuated the cytotoxicity caused by AMEAE, indicating that intracellular ROS plays a pivotal role in cell death. The released cytochrome c triggered the activation of caspase-9 followed by caspase-3. In addition, AMEAE-induced apoptosis was accompanied by cell cycle arrest at G0/G1 phase. Moreover, AMEAE suppressed the induced translocation of NF-κB from cytoplasm to nucleus.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data showed for the first time that the ethyl acetate extract of Annona muricata inhibited the proliferation of A549 cells, leading to cell cycle arrest and programmed cell death through activation of the mitochondrial-mediated signaling pathway with the involvement of the NF-kB signalling pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moghadamtousi</LastName>
<ForeName>Soheil Zorofchian</ForeName>
<Initials>SZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kadir</LastName>
<ForeName>Habsah Abdul</ForeName>
<Initials>HA</Initials>
<AffiliationInfo>
<Affiliation>Biomolecular Research Group, Biochemistry Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia. habsah@um.edu.my.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paydar</LastName>
<ForeName>Mohammadjavad</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rouhollahi</LastName>
<ForeName>Elham</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karimian</LastName>
<ForeName>Hamed</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-43-6</RegistryNumber>
<NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D031041">Annona</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053453">Caspase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018515">Plant Leaves</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051028">bcl-2-Associated X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25069040</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of oxidized ATM in the regulation of oxidative stress-induced energy metabolism reprogramming of CAFs.</ArticleTitle>
<Pagination>
<MedlinePgn>133-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.028</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00375-9</ELocationID>
<Abstract>
<AbstractText>Cancer-associated fibroblasts (CAFs) are the predominant cell type in tumor microenvironment (TM) and featured with the distinct energy metabolism reprogramming (EMR) phenotype caused by many factors such as hypoxia and growth factors. The EMR of CAFs plays a key role in biological behaviors of cancer cells including proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). Recently, accumulative evidence indicates that oxidative stress (OS) mediates the EMR of CAFs under conditions of various stimuli. However, the precise mechanism by which OS causes the EMR of CAFs is not clear. Interestingly, our previous work suggested that ataxia-telangiectasia mutated (ATM) signaling is activated independent of DNA double strand breaks (DSBs) in CAFs derived from human breast cancers compared with paired normal fibroblasts (NFs). Recent studies have shown that ATM protein kinase, as a redox sensor, is closely associated with cellular energy metabolism. Thus, it is very possible that ATM protein kinase regulates the EMR of CAFs. So, it is necessary to perform an integral study on how oxidized ATM regulates the EMR of CAFs in response to various stimuli evoking OS. This will facilitate to develop a new powerful strategy of preventing and treating cancers. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Shifu</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Xi</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Manran</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China. Electronic address: mliu-hncq@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C576324">ATM protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064007">Ataxia Telangiectasia Mutated Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004734">Energy Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010084">Oxidation-Reduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018384">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer-associated fibroblasts</Keyword>
<Keyword MajorTopicYN="N">Energy metabolism reprogramming</Keyword>
<Keyword MajorTopicYN="N">Oxidative stress</Keyword>
<Keyword MajorTopicYN="N">Oxidized ATM</Keyword>
<Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079688</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>194-200</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.034</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00399-1</ELocationID>
<Abstract>
<AbstractText>The invasiveness of glioblastoma is a major cause of poor prognosis and relapse. However, the molecular mechanism controlling glioma cell invasion is poorly understood. Here, we report that receptor activator of nuclear factor kappa-B (NFκB) ligand (RANKL) promotes glioma cell invasion in vivo, but not in vitro. Unlike the invasiveness under in vitro culture conditions, in vivo xenograft studies revealed that LN229 cells expressing high endogenous RANKL generated more invasive tumors than U87MG cells expressing relatively low endogenous RANKL. Consistently, RANKL-overexpressing U87MG resulted in invasive tumors, whereas RANKL-depleted LN229 generated rarely invasive tumors. We found that the number of activated astrocytes was markedly increased in the periphery of RANKL-high invasive tumors. RANKL activated astrocytes through NFκB signaling and these astrocytes in turn secreted various factors which regulate glioma cell invasion. Among them, transforming growth factor β (TGF-β) signaling was markedly increased in glioblastoma specimens and xenograft tumors expressing high levels of RANKL. These results indicate that RANKL contributes to glioma invasion by modulating the peripheral microenvironment of the tumor, and that targeting RANKL signaling has important implications for the prevention of highly invasive glioblastoma. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jun-Kyum</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Xiong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sohn</LastName>
<ForeName>Young-Woo</ForeName>
<Initials>YW</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Xun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jeon</LastName>
<ForeName>Hee-Young</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Eun-Jung</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ham</LastName>
<ForeName>Seok Won</ForeName>
<Initials>SW</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jeon</LastName>
<ForeName>Hye-Min</ForeName>
<Initials>HM</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>So-Young</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Se-Yeong</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Jinlong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Specific Organs Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hak</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Jong Bae</ForeName>
<Initials>JB</Initials>
<AffiliationInfo>
<Affiliation>Specific Organs Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakano</LastName>
<ForeName>Ichiro</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Hyunggee</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea. Electronic address: hg-kim@korea.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053245">RANK Ligand</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505688">TNFSF11 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053245">RANK Ligand</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Astrocyte</Keyword>
<Keyword MajorTopicYN="N">Glioblastoma</Keyword>
<Keyword MajorTopicYN="N">RANKL signaling</Keyword>
<Keyword MajorTopicYN="N">Tumor-invasive microenvironment</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24794629</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.</ArticleTitle>
<Pagination>
<MedlinePgn>3685-710</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1633-0</ELocationID>
<Abstract>
<AbstractText>The erythropoietin-producing hepatocellular (Eph) receptors comprise the largest family of receptor tyrosine kinases (RTKs). Initially regarded as axon-guidance and tissue-patterning molecules, Eph receptors have now been attributed with various functions during development, tissue homeostasis, and disease pathogenesis. Their ligands, ephrins, are synthesized as membrane-associated molecules. At least two properties make this signaling system unique: (1) the signal can be simultaneously transduced in the receptor- and the ligand-expressing cell, (2) the signaling outcome through the same molecules can be opposite depending on cellular context. Moreover, shedding of Eph and ephrin ectodomains as well as ligand-dependent and -independent receptor crosstalk with other RTKs, proteases, and adhesion molecules broadens the repertoire of Eph/ephrin functions. These integrated pathways provide plasticity to cell-microenvironment communication in varying tissue contexts. The complex molecular networks and dynamic cellular outcomes connected to the Eph/ephrin signaling in tumor-host communication and stem cell niche are the main focus of this review. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gucciardo</LastName>
<ForeName>Erika</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Research Programs Unit, Genome-Scale Biology, Biomedicum Helsinki, University of Helsinki, P.O.B. 63, 00014, Helsinki, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sugiyama</LastName>
<ForeName>Nami</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lehti</LastName>
<ForeName>Kaisa</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016023">Integrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016764">Cell Polarity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036342">Ephrins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016023">Integrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045726">Metalloproteases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036081">Receptors, Eph Family</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020741">rho GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24846395</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Moving towards a paradigm: common mechanisms of chemotactic signaling in Dictyostelium and mammalian leukocytes.</ArticleTitle>
<Pagination>
<MedlinePgn>3711-47</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1638-8</ELocationID>
<Abstract>
<AbstractText>Chemotaxis, or directed migration of cells along a chemical gradient, is a highly coordinated process that involves gradient sensing, motility, and polarity. Most of our understanding of chemotaxis comes from studies of cells undergoing amoeboid-type migration, in particular the social amoeba Dictyostelium discoideum and leukocytes. In these amoeboid cells the molecular events leading to directed migration can be conceptually divided into four interacting networks: receptor/G protein, signal transduction, cytoskeleton, and polarity. The signal transduction network occupies a central position in this scheme as it receives direct input from the receptor/G protein network, as well as feedback from the cytoskeletal and polarity networks. Multiple overlapping modules within the signal transduction network transmit the signals to the actin cytoskeleton network leading to biased pseudopod protrusion in the direction of the gradient. The overall architecture of the networks, as well as the individual signaling modules, is remarkably conserved between Dictyostelium and mammalian leukocytes, and the similarities and differences between the two systems are the subject of this review. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Artemenko</LastName>
<ForeName>Yulia</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Johns Hopkins University, School of Medicine, 725 N. Wolfe St., 114 WBSB, Baltimore, MD, 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lampert</LastName>
<ForeName>Thomas J</ForeName>
<Initials>TJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Devreotes</LastName>
<ForeName>Peter N</ForeName>
<Initials>PN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM28007</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM34933</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM028007</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM034933</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015800">Protozoan Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002634">Chemotaxis, Leukocyte</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004023">Dictyostelium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007962">Leukocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015800">Protozoan Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS597547 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4162842 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24972636</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Possible mechanisms and function of nuclear trafficking of the colony-stimulating factor-1 receptor.</ArticleTitle>
<Pagination>
<MedlinePgn>3627-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1668-2</ELocationID>
<Abstract>
<AbstractText>Receptor tyrosine kinases (RTK) have long being studied with respect to the "canonical" signaling. This includes ligand-induced activation of a receptor tyrosine kinase at the cell surface that leads to receptor dimerization, followed by its phosphorylation in the intracellular domain and activation. The activated receptor then recruits cytoplasmic signaling molecules including other kinases. Activation of the downstream signaling cascade frequently leads to changes in gene expression following nuclear translocation of downstream targets. However, RTK themselves may localize within the nucleus, as either full-length molecules or cleaved fragments, with or without their ligands. Significant differences in this mechanism have been reported depending on the individual RTK, cellular context or disease. Accumulating evidences indicate that the colony-stimulating factor-1 receptor (CSF-1R) may localize within the nucleus. To date, however, little is known about the mechanism of CSF-1R nuclear shuttling, as well as the functional role of nuclear CSF-1R. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rovida</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Biomediche Sperimentali e Cliniche "Mario Serio", Sezione di Patologia e Oncologia Sperimentali, Istituto Toscano Tumori, Università degli Studi di Firenze, Viale G.B. Morgagni 50, 50134, Florence, Italy, erovida@unifi.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dello Sbarba</LastName>
<ForeName>Persio</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>81627-83-0</RegistryNumber>
<NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D016186">Receptor, Macrophage Colony-Stimulating Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016173">Macrophage Colony-Stimulating Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016186">Receptor, Macrophage Colony-Stimulating Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23178582</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2430</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>260</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental neurology</Title>
<ISOAbbreviation>Exp. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of stem cells and progenitors in the genesis of medulloblastoma.</ArticleTitle>
<Pagination>
<MedlinePgn>69-73</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2012.11.014</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4886(12)00431-1</ELocationID>
<Abstract>
<AbstractText>Cancer results from dysregulation of growth and survival pathways in normal stem cells and progenitors. Identifying the cells from which a tumor arises can facilitate the development of animal models and point to novel targets for therapy. Medulloblastoma is an aggressive tumor of the cerebellum that occurs predominantly in children. Recent genomic studies suggest that medulloblastoma consists of 4 major subgroups, each with distinct mutations and signaling pathway deregulations, and each potentially arising from distinct populations of stem cells and progenitors. Here we review the major types of progenitor cells in the cerebellum and discuss their role in the genesis of medulloblastoma.</AbstractText>
<CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Tumor Development Program, NCI-Designated Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wechsler-Reya</LastName>
<ForeName>Robert J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo>
<Affiliation>Tumor Development Program, NCI-Designated Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA; Department of Pharmacology &amp; Cancer Biology, Duke University Medical Center, Durham, NC, USA. Electronic address: rwreya@sanfordburnham.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA159859</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA122759</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2012</Year>
<Month>11</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Neurol</MedlineTA>
<NlmUniqueID>0370712</NlmUniqueID>
<ISSNLinking>0014-4886</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002528">Cerebellar Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008527">Medulloblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS423730 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC3718859 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cell of origin</Keyword>
<Keyword MajorTopicYN="N">Medulloblastoma</Keyword>
<Keyword MajorTopicYN="N">Mouse models</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23376224</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2430</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>260</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental neurology</Title>
<ISOAbbreviation>Exp. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Signals that regulate the oncogenic fate of neural stem cells and progenitors.</ArticleTitle>
<Pagination>
<MedlinePgn>56-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2013.01.027</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4886(13)00040-X</ELocationID>
<Abstract>
<AbstractText>Brain tumors have frequently been associated with a neural stem cell (NSC) origin and contain stem-like tumor cells, so-called brain tumor stem cells (BTSCs) that share many features with normal NSCs. A stem cell state of BTSCs confers resistance to radiotherapy and treatment with alkylating agents. It is also a hallmark of aggressive brain tumors and is maintained by transcriptional networks that are also active in embryonic stem cells. Advances in reprogramming of somatic cells into induced pluripotent stem (iPS) cells have further identified genes that drive stemness. In this review, we will highlight the possible drivers of stemness in medulloblastoma and glioma, the most frequent types of primary malignant brain cancer in children and adults, respectively. Signals that drive expansion of developmentally defined neural precursor cells are also active in corresponding brain tumors. Transcriptomal subgroups of human medulloblastoma and glioma match features of NSCs but also more restricted progenitors. Lessons from genetically-engineered mouse (GEM) models show that temporally and regionally defined NSCs can give rise to distinct subgroups of medulloblastoma and glioma. We will further discuss how acquisition of stem cell features may drive brain tumorigenesis from a non-NSC origin. Genetic alterations, signaling pathways, and therapy-induced changes in the tumor microenvironment can drive reprogramming networks and induce stemness in brain tumors. Finally, we propose a model where dysregulation of microRNAs (miRNAs) that normally provide barriers against reprogramming plays an integral role in promoting stemness in brain tumors.</AbstractText>
<CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Swartling</LastName>
<ForeName>Fredrik J</ForeName>
<Initials>FJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bolin</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phillips</LastName>
<ForeName>Joanna J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, USA; Department of Pathology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Persson</LastName>
<ForeName>Anders I</ForeName>
<Initials>AI</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, USA; Department of Neurology, Sandler Neurosciences Center, University of California, San Francisco, USA. Electronic address: Anders.Persson@ucsf.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1R01 NS081117-01</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08 NS063456</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08NS063456</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS081117</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54 CA163155</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54CA163155-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>01</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Neurol</MedlineTA>
<NlmUniqueID>0370712</NlmUniqueID>
<ISSNLinking>0014-4886</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019070">Cell Lineage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058953">Neural Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS441682 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC3758390 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Brain tumor</Keyword>
<Keyword MajorTopicYN="N">Glioma</Keyword>
<Keyword MajorTopicYN="N">Medulloblastoma</Keyword>
<Keyword MajorTopicYN="N">Neural stem cell</Keyword>
<Keyword MajorTopicYN="N">Progenitor</Keyword>
<Keyword MajorTopicYN="N">Reprogramming</Keyword>
<Keyword MajorTopicYN="N">miRNA</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093298</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators.</ArticleTitle>
<Pagination>
<MedlinePgn>3382-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.07.029</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00578-X</ELocationID>
<Abstract>
<AbstractText>Understanding how single nucleotide polymorphisms (SNPs) lead to disease at a molecular level provides a starting point for improved therapeutic intervention. SNPs in the innate immune receptor nucleotide oligomerisation domain 2 (NOD2) can cause the inflammatory disorders Blau Syndrome (BS) and early onset sarcoidosis (EOS) through receptor hyperactivation. Here, we show that these polymorphisms cluster into two primary locations: the ATP/Mg(2+)-binding site and helical domain 1. Polymorphisms in these two locations may consequently dysregulate ATP hydrolysis and NOD2 autoinhibition, respectively. Complementary mutations in NOD1 did not mirror the NOD2 phenotype, which indicates that NOD1 and NOD2 are activated and regulated by distinct methods.</AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Parkhouse</LastName>
<ForeName>Rhiannon</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Cambridge, Cambridge, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boyle</LastName>
<ForeName>Joseph P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Cambridge, Cambridge, UK; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Monie</LastName>
<ForeName>Tom P</ForeName>
<Initials>TP</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Cambridge, Cambridge, UK; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. Electronic address: tpm22@cam.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>WT085090MA</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C119067">NOD1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C429018">NOD2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053474">Nod1 Signaling Adaptor Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053473">Nod2 Signaling Adaptor Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538157">Synovitis granulomatous with uveitis and cranial neuropathies</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2001 May 31;411(6837):599-603</RefSource>
<PMID Version="1">11385576</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2014 Aug 25;588(17):2830-6</RefSource>
<PMID Version="1">24960071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2003 Mar 14;278(11):8869-72</RefSource>
<PMID Version="1">12527755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3455-60</RefSource>
<PMID Version="1">12626759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2003 Nov 20;554(3):520-8</RefSource>
<PMID Version="1">14623123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2004;32(5):1792-7</RefSource>
<PMID Version="1">15034147</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 2004 Oct 8;343(1):1-28</RefSource>
<PMID Version="1">15381417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Hum Genet. 1996 Nov;59(5):1097-107</RefSource>
<PMID Version="1">8900239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 1999 Sep 18;354(9183):1035</RefSource>
<PMID Version="1">10501396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2005 Feb 1;105(3):1195-7</RefSource>
<PMID Version="1">15459013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2005 Jul 4;170(1):21-6</RefSource>
<PMID Version="1">15998797</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Infect Immun. 2006 Jun;74(6):3115-24</RefSource>
<PMID Version="1">16714539</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2007 May 18;282(20):15197-207</RefSource>
<PMID Version="1">17355968</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Microbiol. 2008 Feb;10(2):477-86</RefSource>
<PMID Version="1">17970764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2008;3(4):e2119</RefSource>
<PMID Version="1">18446235</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2009 Jan;60(1):242-50</RefSource>
<PMID Version="1">19116920</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Protoc. 2009;4(3):363-71</RefSource>
<PMID Version="1">19247286</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Scand J Rheumatol. 2009 May-Jun;38(3):190-7</RefSource>
<PMID Version="1">19169908</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Rheumatology (Oxford). 2009 Jun;48(6):706-7</RefSource>
<PMID Version="1">19359344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2009 Jun;60(6):1797-803</RefSource>
<PMID Version="1">19479837</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Mol Immunol. 2011 Mar;8(2):135-45</RefSource>
<PMID Version="1">21258359</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Hematol. 2011 Jun;93(6):771-8</RefSource>
<PMID Version="1">21573891</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Innate Immun. 2012 Feb;18(1):100-11</RefSource>
<PMID Version="1">21310790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2012 Jun 29;287(27):23057-67</RefSource>
<PMID Version="1">22549783</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Biochem Sci. 2013 Mar;38(3):131-9</RefSource>
<PMID Version="1">23394939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2013 Jul 12;341(6142):172-5</RefSource>
<PMID Version="1">23765277</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Ophthalmol. 2013 Sep-Nov;28(5-6):327-32</RefSource>
<PMID Version="1">24010719</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2014 Jan;14(1):9-23</RefSource>
<PMID Version="1">24336102</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2014 Apr 10;54(1):17-29</RefSource>
<PMID Version="1">24657167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2014 May 8;509(7499):240-4</RefSource>
<PMID Version="1">24695226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Host Microbe. 2014 May 14;15(5):623-35</RefSource>
<PMID Version="1">24746552</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2001 Sep;29(1):19-20</RefSource>
<PMID Version="1">11528384</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019943">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003389">Cranial Nerve Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056726">Genetic Association Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006868">Hydrolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053474">Nod1 Signaling Adaptor Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053473">Nod2 Signaling Adaptor Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017433">Protein Structure, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013585">Synovitis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014605">Uveitis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4158908</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Blau syndrome</Keyword>
<Keyword MajorTopicYN="N">Innate immunity</Keyword>
<Keyword MajorTopicYN="N">NACHT</Keyword>
<Keyword MajorTopicYN="N">Nucleotide oligomerisation domain containing 2</Keyword>
<Keyword MajorTopicYN="N">Nucleotide-binding, leucine-rich repeat containing receptor</Keyword>
<Keyword MajorTopicYN="N">Single nucleotide polymorphisms</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24676428</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-1335</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cancer research and clinical oncology</Title>
<ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.</ArticleTitle>
<Pagination>
<MedlinePgn>1629-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-014-1653-z</ELocationID>
<Abstract>
<AbstractText>The receptor for hyaluronan (HA)-mediated motility (RHAMM) is a HA-binding protein located in the cytoskeleton and centrosome. RHAMM has multiple functions that manifest with different cellular localizations, for example, modulation of growth factor receptor, regulation of cell signaling pathways, and mitotic spindle assembly. In addition, its increased expression has major roles in tumorigenesis and can induce genomic instability and cancer progression. In head and neck cancers, increased expression of RHAMM is associated with high proliferation of cancer cells and decreased survival. CD44, a cell-adhesion molecule and HA receptor, can modulate intracellular signaling by forming complexes with RHAMM to promote invasion and metastasis of cancer cells. In this review, we provide an overview of the biological functions of RHAMM in non-neoplastic cells and cancer cells, as well as its association with CD44, and also introduce studies that particularly implicate RHAMM in the pathogenesis of head and neck cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shigeishi</LastName>
<ForeName>Hideo</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral and Maxillofacial Surgery, Division of Cervico-Gnathostomatology, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan, shige@hiroshima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Higashikawa</LastName>
<ForeName>Koichiro</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takechi</LastName>
<ForeName>Masaaki</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
<NlmUniqueID>7902060</NlmUniqueID>
<ISSNLinking>0171-5216</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018960">Antigens, CD44</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C122167">TPX2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C098946">hyaluronan-mediated motility receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9004-61-9</RegistryNumber>
<NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018960">Antigens, CD44</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018385">Centrosome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003599">Cytoskeleton</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016326">Extracellular Matrix Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006820">Hyaluronic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24828199</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1520-6025</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>77</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Journal of natural products</Title>
<ISOAbbreviation>J. Nat. Prod.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plumbagin downregulates Wnt signaling independent of p53 in human colorectal cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1130-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/np4010085</ELocationID>
<Abstract>
<AbstractText>Plumbagin (1), a naphthoquinone, induces cell death and affects various signaling pathways in cancer cells. Wnt signaling is active constitutively in colorectal cancer and plays an important role in its progression and pathogenesis. It was hypothesized that 1 is likely to modulate Wnt signaling, and this compound was studied for its effect on this pathway in human colorectal cancer cells. Plumbagin (1) was found to downregulate Wnt signaling when assessed by a TOPFlash/FOPFlash reporter activity assay and also decreased the expression of several coactivators and downstream targets of Wnt signaling such as β-catenin, TCF7L2, p300, Bcl9l, c-Myc, vimentin, and cyclinD1 in SW620 colorectal cancer cells. Using isogenic HCT116p53+/+ and HCT116p53-/- colorectal cancer cells, it was found that compound 1-mediated downregulation of Wnt signaling is p53-independent. Interestingly, treatment with 1 upregulated the expression of HBP1 (a negative regulator of Wnt signaling) in these cells. The results obtained show for the first time that downregulation of Wnt signaling could be one of the molecular mechanisms by which plumbagin exerts its inhibitory effects in human colorectal cancer cells. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Raghu</LastName>
<ForeName>Dinesh</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Indian Institute of Technology Madras , Chennai, India 600036.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Karunagaran</LastName>
<ForeName>Devarajan</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Nat Prod</MedlineTA>
<NlmUniqueID>7906882</NlmUniqueID>
<ISSNLinking>0163-3864</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>YAS4TBQ4OQ</RegistryNumber>
<NameOfSubstance UI="C014758">plumbagin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009285">Naphthoquinones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051153">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24828286</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1520-6025</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>77</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Journal of natural products</Title>
<ISOAbbreviation>J. Nat. Prod.</ISOAbbreviation>
</Journal>
<ArticleTitle>Rhapontigenin suppresses cell migration and invasion by inhibiting the PI3K-dependent Rac1 signaling pathway in MDA-MB-231 human breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1135-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/np401078g</ELocationID>
<Abstract>
<AbstractText>The invasive behavior of cancer cells resulting in metastasis is the major cause of cancer-related deaths. Rhapontigenin (1) has various biological activities including anticancer activities. However, whether and how 1 affects cancer invasion has never been explored. Here, we examined the anti-invasive effects of 1 and its underlying molecular mechanisms in the highly invasive human breast cancer cell line designated MDA-MB-231. At noncytotoxic concentrations, 1 strongly suppressed serum-induced cell migration and invasion as judged by Boyden chamber analysis and wound-healing assays, respectively. Compound 1 strikingly reduced Rac1 activity as judged by both absorbance-based and pull-down assays. In addition, its downstream effectors such as WASP-family verprolin homologous proteins 2 (WAVE-2) and p21-activated kinase 1 (PAK1) signaling cascades were attenuated after treatment with 1. Immunofluorescence staining showed that 1 diminished lamellipodia formation at the leading edge of cells. Finally, 1 decreased the phosphorylation of phosphoinisitide-3-kinase (PI3K) and AKT. Rac1 activity was inhibited by the PI3K inhibitor wortmannin. Taken together, these results suggest that 1 suppresses breast cancer cell migration and invasion, which is involved in inhibiting the PI3K-dependent Rac1 signaling pathway. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Ji Sung</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Cancer Preventive Material Development Research Center, College of Korean Medicine, Kyung Hee University , 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Chi Gu</ForeName>
<Initials>CG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hoon</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Eun-Ok</ForeName>
<Initials>EO</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Nat Prod</MedlineTA>
<NlmUniqueID>7906882</NlmUniqueID>
<ISSNLinking>0163-3864</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C431126">rhapontigenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>19545-26-7</RegistryNumber>
<NameOfSubstance UI="C009687">wortmannin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000730">Androstadienes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013267">Stilbenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25207766</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>371</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>1005-15</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1403088</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR-ABL1-positive ALL, alterations of lymphoid transcription factor genes, and a poor outcome. The frequency and spectrum of genetic alterations in Ph-like ALL and its responsiveness to tyrosine kinase inhibition are undefined, especially in adolescents and adults.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed genomic profiling of 1725 patients with precursor B-cell ALL and detailed genomic analysis of 154 patients with Ph-like ALL. We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Ph-like ALL increased in frequency from 10% among children with standard-risk ALL to 27% among young adults with ALL and was associated with a poor outcome. Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common. Expression of ABL1, ABL2, CSF1R, JAK2, and PDGFRB fusions resulted in cytokine-independent proliferation and activation of phosphorylated STAT5. Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the American Lebanese Syrian Associated Charities and others.).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>Kathryn G</ForeName>
<Initials>KG</Initials>
<AffiliationInfo>
<Affiliation>From the Departments of Pathology (K.G.R., D.P.-T., Y.-L.Y., K. McCastlain, G.S., J.M., S.-C.C., J.C., N.S.-M., I.I., J.W., J.R.D., C.G.M.), Computational Biology and Bioinformatics (Y.L., J.B., M.R., E.H., P.G., P.N., G.W., X.C., J.Z.), Biostatistics (D.P., C.C.), Pharmaceutical Sciences (S.W.P., M.V.R., W.E.E.), and Oncology (C.-H.P., S.J.), the Pediatric Cancer Genome Project (Y.L., L.D., C.L., M.R., J.E., J.C., K.B., R.S.F., E.H., P.G., P.N., G.W., X.C., D.Y., B.V., H.M., M.V.R., W.E.E., E.M., R.K.W., J.R.D., J.Z., C.G.M.), and Cytogenetics Shared Resource (M.V.), St. Jude Children's Research Hospital, Memphis, TN; the University of New Mexico Cancer Center and School of Medicine, Albuquerque (R.C.H., I-M.C., C.L.W.); the Genome Institute at Washington University (L.D., C.L., R.S.F., E.M., R.K.W.), the Department of Genetics, Washington University School of Medicine (L.D., C.L., R.S.F., E.M., R.K.W.), and Siteman Cancer Center, Washington University (E.M., R.K.W.) - all in St. Louis; Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville (M.D.); the Research Institute at Nationwide Children's Hospital (S.R., A.S., J.M.G.-F.), the Department of Pathology, College of Medicine, Ohio State University (N.A.H.), and Ohio State University Comprehensive Cancer Center (G.M., C.D.B., K. Mrózek, J.K.) - all in Columbus, OH; the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas (N.J.W.), Scott and White Hospitals and Clinics and Texas A&amp;M Health Science Center, Temple (G.G.), the University of Texas Health Science Center San Antonio, San Antonio (M.F.-J.), and the Departments of Leukemia and Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (S.M.K., M.K.) - all in Texas; Maine Children's Cancer Program, Scarborough (E.C.L.); New York University Cancer Institute, New York (W.L.C.), and the Department of Medicine (Oncology), Albert Einstein</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yongjin</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Payne-Turner</LastName>
<ForeName>Debbie</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harvey</LastName>
<ForeName>Richard C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Yung-Li</ForeName>
<Initials>YL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pei</LastName>
<ForeName>Deqing</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McCastlain</LastName>
<ForeName>Kelly</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Guangchun</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Becksfort</LastName>
<ForeName>Jared</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rusch</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Shann-Ching</ForeName>
<Initials>SC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Easton</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>Jinjun</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boggs</LastName>
<ForeName>Kristy</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santiago-Morales</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iacobucci</LastName>
<ForeName>Ilaria</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fulton</LastName>
<ForeName>Robert S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wen</LastName>
<ForeName>Ji</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Valentine</LastName>
<ForeName>Marcus</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paugh</LastName>
<ForeName>Steven W</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Devidas</LastName>
<ForeName>Meenakshi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>I-Ming</ForeName>
<Initials>IM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reshmi</LastName>
<ForeName>Shalini</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Amy</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hedlund</LastName>
<ForeName>Erin</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Pankaj</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nagahawatte</LastName>
<ForeName>Panduka</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Gang</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yergeau</LastName>
<ForeName>Donald</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vadodaria</LastName>
<ForeName>Bhavin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mulder</LastName>
<ForeName>Heather</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Winick</LastName>
<ForeName>Naomi J</ForeName>
<Initials>NJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Larsen</LastName>
<ForeName>Eric C</ForeName>
<Initials>EC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carroll</LastName>
<ForeName>William L</ForeName>
<Initials>WL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heerema</LastName>
<ForeName>Nyla A</ForeName>
<Initials>NA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carroll</LastName>
<ForeName>Andrew J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grayson</LastName>
<ForeName>Guy</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tasian</LastName>
<ForeName>Sarah K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moore</LastName>
<ForeName>Andrew S</ForeName>
<Initials>AS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Keller</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frei-Jones</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Whitlock</LastName>
<ForeName>James A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raetz</LastName>
<ForeName>Elizabeth A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>White</LastName>
<ForeName>Deborah L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hughes</LastName>
<ForeName>Timothy P</ForeName>
<Initials>TP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guidry Auvil</LastName>
<ForeName>Jaime M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Malcolm A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marcucci</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bloomfield</LastName>
<ForeName>Clara D</ForeName>
<Initials>CD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mrózek</LastName>
<ForeName>Krzysztof</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kohlschmidt</LastName>
<ForeName>Jessica</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stock</LastName>
<ForeName>Wendy</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kornblau</LastName>
<ForeName>Steven M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Konopleva</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paietta</LastName>
<ForeName>Elisabeth</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pui</LastName>
<ForeName>Ching-Hon</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jeha</LastName>
<ForeName>Sima</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Relling</LastName>
<ForeName>Mary V</ForeName>
<Initials>MV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>William E</ForeName>
<Initials>WE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gerhard</LastName>
<ForeName>Daniela S</ForeName>
<Initials>DS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gastier-Foster</LastName>
<ForeName>Julie M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mardis</LastName>
<ForeName>Elaine</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>Richard K</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Loh</LastName>
<ForeName>Mignon L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Downing</LastName>
<ForeName>James R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hunger</LastName>
<ForeName>Stephen P</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Willman</LastName>
<ForeName>Cheryl L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jinghui</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mullighan</LastName>
<ForeName>Charles G</ForeName>
<Initials>CG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA 21765</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA145707</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA14958</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F32 CA141762</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F32 CA141762</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN261200800001E</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NIGMS 92666</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA021765</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 CA036401</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 CA36401</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC1 CA145707</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC2 CA148529</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA157937</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA157937-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 GM092666</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA014958</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA021115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA098543</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA101140</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA101140</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA21115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA98413</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA98543</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24 CA114737</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24 CA114766</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24 CA114766</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24-CA114737</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C498762">CRLF2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018121">Receptors, Cytokine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2014 Sep 11;371(11):1064-6</RefSource>
<PMID Version="1">25207770</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004273">DNA, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010677">Philadelphia Chromosome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015452">Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011505">Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018121">Receptors, Cytokine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS632485 [Available on 03/11/15]</OtherID>
<OtherID Source="NLM">PMC4191900 [Available on 03/11/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043023</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7517</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Carbonic anhydrases, EPF2 and a novel protease mediate CO2 control of stomatal development.</ArticleTitle>
<Pagination>
<MedlinePgn>246-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13452</ELocationID>
<Abstract>
<AbstractText>Environmental stimuli, including elevated carbon dioxide levels, regulate stomatal development; however, the key mechanisms mediating the perception and relay of the CO2 signal to the stomatal development machinery remain elusive. To adapt CO2 intake to water loss, plants regulate the development of stomatal gas exchange pores in the aerial epidermis. A diverse range of plant species show a decrease in stomatal density in response to the continuing rise in atmospheric CO2 (ref. 4). To date, one mutant that exhibits deregulation of this CO2-controlled stomatal development response, hic (which is defective in cell-wall wax biosynthesis, ref. 5), has been identified. Here we show that recently isolated Arabidopsis thaliana β-carbonic anhydrase double mutants (ca1 ca4) exhibit an inversion in their response to elevated CO2, showing increased stomatal development at elevated CO2 levels. We characterized the mechanisms mediating this response and identified an extracellular signalling pathway involved in the regulation of CO2-controlled stomatal development by carbonic anhydrases. RNA-seq analyses of transcripts show that the extracellular pro-peptide-encoding gene EPIDERMAL PATTERNING FACTOR 2 (EPF2), but not EPF1 (ref. 9), is induced in wild-type leaves but not in ca1 ca4 mutant leaves at elevated CO2 levels. Moreover, EPF2 is essential for CO2 control of stomatal development. Using cell-wall proteomic analyses and CO2-dependent transcriptomic analyses, we identified a novel CO2-induced extracellular protease, CRSP (CO2 RESPONSE SECRETED PROTEASE), as a mediator of CO2-controlled stomatal development. Our results identify mechanisms and genes that function in the repression of stomatal development in leaves during atmospheric CO2 elevation, including the carbonic-anhydrase-encoding genes CA1 and CA4 and the secreted protease CRSP, which cleaves the pro-peptide EPF2, in turn repressing stomatal development. Elucidation of these mechanisms advances the understanding of how plants perceive and relay the elevated CO2 signal and provides a framework to guide future research into how environmental challenges can modulate gas exchange in plants. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Engineer</LastName>
<ForeName>Cawas B</ForeName>
<Initials>CB</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Sciences, University of California San Diego, La Jolla, California 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghassemian</LastName>
<ForeName>Majid</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Anderson</LastName>
<ForeName>Jeffrey C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Missouri-Columbia, Columbia, Missouri 65211, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Peck</LastName>
<ForeName>Scott C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Missouri-Columbia, Columbia, Missouri 65211, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Honghong</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Biological Sciences, University of California San Diego, La Jolla, California 92093, USA [2] College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schroeder</LastName>
<ForeName>Julian I</ForeName>
<Initials>JI</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Sciences, University of California San Diego, La Jolla, California 92093, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>BioProject</DataBankName>
<AccessionNumberList>
<AccessionNumber>PRJNA218542</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>ES010337</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM060396</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029681">Arabidopsis Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C542689">EPF2 protein, Arabidopsis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>142M471B3J</RegistryNumber>
<NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="C000591840">CRSP protein, Arabidopsis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.2.1.1</RegistryNumber>
<NameOfSubstance UI="D002256">Carbonic Anhydrases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017360">Arabidopsis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029681">Arabidopsis Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002245">Carbon Dioxide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002256">Carbonic Anhydrases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018506">Gene Expression Regulation, Plant</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010447">Peptide Hydrolases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054046">Plant Stomata</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096478</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis.</ArticleTitle>
<Pagination>
<MedlinePgn>4558-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.404</ELocationID>
<Abstract>
<AbstractText>Characteristically, prostate cancer (PCa) cells exhibit marked decrease in intracellular zinc; however, the mechanism responsible is not clearly understood. HOXB13 is involved in PCa progression and is overexpressed in castration-resistant PCa. DNA microarray analysis of LNCaP Pca cells showed that ZnT zinc output transporters were strikingly upregulated among androgen-independent HOXB13 target genes. Furthermore, exogenous HOXB13 caused intracellular zinc concentrations to fall in PCa cells, stimulated NF-κB-mediated signaling by reducing inhibitor of NF-κB alpha (IκBα) and enhanced the nuclear translocation of RelA/p65. Human prostate tumors also exhibited strong inverse correlation between the protein expressions of HOXB13 and IκBα. Consequently, HOXB13 stimulated PCa cell invasion, and this was inhibited by the suppression of ZnT4. In addition, studies in a PC3 orthotopic mouse model of PCa metastasis showed that HOXB13 is a strong metastatic stimulator. Taken together, these results show that HOXB13 promotes PCa invasion and metastasis by decreasing intracellular zinc levels, thus stimulating NF-κB signals, and suggest that HOXB13 acts as a modulator of intracellular zinc levels that promotes the malignant characteristics of PCa. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Y-R</ForeName>
<Initials>YR</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>I-J</ForeName>
<Initials>IJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>T W</ForeName>
<Initials>TW</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>K K</ForeName>
<Initials>KK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Statistics, College of Natural Sciences, Chonnam National University, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>K I</ForeName>
<Initials>KI</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C484414">HOXB13 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020672">I-kappa B Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052002">NF-kappa B p50 Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489548">NFKB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>139874-52-5</RegistryNumber>
<NameOfSubstance UI="C069722">NF-kappaB inhibitor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J41CSQ7QDS</RegistryNumber>
<NameOfSubstance UI="D015032">Zinc</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020672">I-kappa B Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052002">NF-kappa B p50 Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015032">Zinc</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096482</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression.</ArticleTitle>
<Pagination>
<MedlinePgn>4548-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.402</ELocationID>
<Abstract>
<AbstractText>Although epidemiological and preclinical studies have shown the preventative effects of n-3 polyunsaturated fatty acids (PUFAs) on breast cancer, inconsistencies still remain in the data and the underlying mechanisms remain unclear. In this study, we identified mammalian target of rapamycin (mTOR) signaling, which plays an essential role in cell proliferation and breast tumorigenesis, as a target of n-3 PUFAs. In breast cancer cell lines, n-3 PUFAs rapidly and efficiently suppress both mTOR complex 1 (mTORC1) and mTORC2 and their downstream signaling, and subsequently inhibit cell proliferation and angiogenesis while promoting apoptosis. Further study indicates that stabilization of the mTOR-raptor complex by n-3 PUFAs may contribute to their inhibitory effect on mTORC1. Importantly, four complementary and well-controlled animal models were utilized to identify the role and molecular target of n-3 PUFAs in the prevention of breast carcinogenesis and progression, namely: (1) chemically induced mammary tumor rats with a high dietary intake of n-3 PUFAs; (2) nude mice implanted with mammary tumor cell lines stably expressing fat-1, a desaturase that catalyzes the conversion of n-6 to n-3 PUFAs and produces n-3 PUFAs endogenously; (3) fat-1 transgenic severe combined immune deficiency mice implanted with breast tumor cells; and (4) the fat-1 transgenic mouse mammary tumor virus-polyoma virus middle T oncogene double-hybrid mice, a model of aggressive breast cancer. In summary, dietary and endogenous n-3 PUFAs abrogate the activity of mTORC1/2 pathways in vitro and in vivo and prevent breast carcinogenesis, tumor growth and metastasis. Taken together, our findings convincingly clarify the causal relationship between n-3 PUFAs and breast cancer prevention and establish mTORC1/2 as a target of n-3 PUFAs. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jia</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lai</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ren</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>College of Life Sciences, Nankai University, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wan</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy and Neurobiology, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dai</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576554">TOR complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576553">mechanistic target of rapamycin complex 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>684-93-5</RegistryNumber>
<NameOfSubstance UI="D008770">Methylnitrosourea</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002273">Carcinogens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015525">Fatty Acids, Omega-3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015674">Mammary Neoplasms, Animal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008770">Methylnitrosourea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046912">Multiprotein Complexes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24121270</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>p21 suppresses inflammation and tumorigenesis on pRB-deficient stratified epithelia.</ArticleTitle>
<Pagination>
<MedlinePgn>4599-612</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.417</ELocationID>
<Abstract>
<AbstractText>The retinoblastoma gene product (pRb) controls proliferation and differentiation processes in stratified epithelia. Importantly, and in contrast to other tissues, Rb deficiency does not lead to spontaneous skin tumor formation. As the cyclin-dependent kinase inhibitor p21 regulates proliferation and differentiation in the absence of pRb, we analyzed the consequences of deleting p21 in pRb-ablated stratified epithelia (hereafter pRb(ΔEpi);p21-/-). These mice display an enhancement of the phenotypic abnormalities observed in pRb(ΔEpi) animals, indicating that p21 partially compensates pRb absence. Remarkably, pRb(ΔEpi);p21-/- mice show an acute skin inflammatory phenotype and develop spontaneous epithelial tumors, particularly affecting tongue and oral tissues. Biochemical analyses and transcriptome studies reveal changes affecting multiple pathways, including DNA damage and p53-dependent signaling responses. Comparative metagenomic analyses, together with the histopathological profiles, indicate that these mice constitute a faithful model for human head and neck squamous cell carcinomas. Collectively, our findings demonstrate that p21, in conjunction with pRb, has a central role in regulating multiple epithelial processes and orchestrating specific tumor suppressor functions. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Saiz-Ladera</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lara</LastName>
<ForeName>M F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garín</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematopoietic Innovative Therapies (HIT), Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ruiz</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Genomic Instability Group, Spanish National Cancer Research Center, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Santos</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lorz</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>García-Escudero</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<Identifier Source="ORCID">0000000156406542</Identifier>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martínez-Fernández</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bravo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Clinical Sciences, University of Santiago de Compostela, Lugo, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fernández-Capetillo</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Genomic Instability Group, Spanish National Cancer Research Center, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Segrelles</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paramio</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Unit (ed70A), Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016160">Retinoblastoma Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004848">Epithelium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007249">Inflammation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015603">Keratinocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016160">Retinoblastoma Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662831</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>4568-78</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.32</ELocationID>
<Abstract>
<AbstractText>Our goal in this work was to illustrate the Epstein-Barr virus (EBV)-modulated global biochemical profile and provide a novel metabolism-related target to improve the therapeutic regimen of nasopharyngeal carcinoma (NPC). We used a metabolomics approach to investigate EBV-modulated metabolic changes, and found that the exogenous overexpression of the EBV-encoded latent membrane protein 1 (LMP1) significantly increased glycolysis. The deregulation of several glycolytic genes, including hexokinase 2 (HK2), was determined to be responsible for the reprogramming of LMP1-mediated glucose metabolism in NPC cells. The upregulation of HK2 elevated aerobic glycolysis and facilitated proliferation by blocking apoptosis. More importantly, HK2 was positively correlated with LMP1 in NPC biopsies, and high HK2 levels were significantly associated with poor overall survival of NPC patients following radiation therapy. Knockdown of HK2 effectively enhanced the sensitivity of LMP1-overexpressing NPC cells to irradiation. Finally, c-Myc was demonstrated to be required for LMP1-induced upregulation of HK2. The LMP1-mediated attenuation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis resulted in the stabilization of c-Myc. These findings indicate a close relationship between EBV and glycolysis in NPC. Notably, LMP1 is the key regulator of the reprogramming of EBV-mediated glycolysis in NPC cells. Given the importance of EBV-mediated deregulation of glycolysis, anti-glycolytic therapy might represent a worthwhile avenue of exploration in the treatment of EBV-related cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Z-Y</ForeName>
<Initials>ZY</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] The First Hospital of Changsha City, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] Metabolic Syndrome Research Center, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] Center For Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tao</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yi</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Clinical Biochemical Laboratory, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Pathology Department, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Pathology Department, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>You</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Radiation Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA [2] Endocrinology Department, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deng</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Metabolic Syndrome Research Center, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Metabolic Syndrome Research Center, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bode</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>The Hormel Institute, University of Minnesota, Austin, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>The Hormel Institute, University of Minnesota, Austin, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>L-Q</ForeName>
<Initials>LQ</Initials>
<AffiliationInfo>
<Affiliation>Center For Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C037662">EBV-associated membrane antigen, Epstein-Barr virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011838">Radiation-Sensitizing Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D006593">Hexokinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538339">Nasopharyngeal carcinoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Dec 1;71(23):7291-300</RefSource>
<PMID Version="1">21987722</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2012 Jan;11(1):14-23</RefSource>
<PMID Version="1">22234809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):561-6</RefSource>
<PMID Version="1">21300483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Cancer Biol. 2012 Apr;22(2):144-53</RefSource>
<PMID Version="1">22249143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 Mar 30;149(1):49-62</RefSource>
<PMID Version="1">22401813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9593-8</RefSource>
<PMID Version="1">22647604</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11818-23</RefSource>
<PMID Version="1">22752304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(7):e42072</RefSource>
<PMID Version="1">22848707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 Aug 17;150(4):685-96</RefSource>
<PMID Version="1">22901803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2012 Dec;1826(2):370-84</RefSource>
<PMID Version="1">22750268</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2013 Feb;87(3):1301-11</RefSource>
<PMID Version="1">23152522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2013 Aug 10;31(23):2861-9</RefSource>
<PMID Version="1">23857969</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2013 Aug 12;24(2):213-28</RefSource>
<PMID Version="1">23911236</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Virology. 2013 Sep;444(1-2):301-9</RefSource>
<PMID Version="1">23876457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2002 Mar 1;277(9):7610-8</RefSource>
<PMID Version="1">11751859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2004 Jun;24(12):5223-34</RefSource>
<PMID Version="1">15169887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2004 Oct;4(10):757-68</RefSource>
<PMID Version="1">15510157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2004 Dec 3;16(5):819-30</RefSource>
<PMID Version="1">15574336</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2005 Jul 1;11(13):4658-65</RefSource>
<PMID Version="1">16000558</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2005 Oct 20;24(46):6917-24</RefSource>
<PMID Version="1">16007144</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402</RefSource>
<PMID Version="1">16798876</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cold Spring Harb Symp Quant Biol. 2005;70:363-74</RefSource>
<PMID Version="1">16869773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Oct 15;66(20):9870-7</RefSource>
<PMID Version="1">17047048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Mol Immunol. 2007 Jun;4(3):185-96</RefSource>
<PMID Version="1">17601372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Exp Med Biol. 2007;597:173-87</RefSource>
<PMID Version="1">17633026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2007 Nov;27(21):7381-93</RefSource>
<PMID Version="1">17785433</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Pathog. 2007 Nov;3(11):e166</RefSource>
<PMID Version="1">17997602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2008 Feb;8(2):83-93</RefSource>
<PMID Version="1">18094723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2008 Jul 8;265(2):226-38</RefSource>
<PMID Version="1">18353539</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2008 Aug;22(8):2809-20</RefSource>
<PMID Version="1">18381814</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2008 Oct;82(20):10175-87</RefSource>
<PMID Version="1">18684838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2009 Jan 30;284(5):3001-11</RefSource>
<PMID Version="1">19033437</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Pathog. 2010 Jan;6(1):e1000719</RefSource>
<PMID Version="1">20062526</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10696-701</RefSource>
<PMID Version="1">20498071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Neuroimmune Pharmacol. 2010 Sep;5(3):271-7</RefSource>
<PMID Version="1">20369303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2010 Dec 3;330(6009):1340-4</RefSource>
<PMID Version="1">21127244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2011 Jan 18;19(1):17-30</RefSource>
<PMID Version="1">21251613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5</RefSource>
<PMID Version="1">21289278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource>
<PMID Version="1">21376230</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Apr 15;71(8):2815-20</RefSource>
<PMID Version="1">21487041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2011 May;11(5):325-37</RefSource>
<PMID Version="1">21508971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Pathog. 2011 Jul;7(7):e1002124</RefSource>
<PMID Version="1">21779165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Aug 26;286(34):29872-81</RefSource>
<PMID Version="1">21690090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2011 Aug 26;333(6046):1154-7</RefSource>
<PMID Version="1">21798897</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(11):e24647</RefSource>
<PMID Version="1">22096476</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006019">Glycolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004854">Herpesvirus 4, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006593">Hexokinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055432">Metabolomics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009303">Nasopharyngeal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016271">Proto-Oncogene Proteins c-myc</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011838">Radiation-Sensitizing Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014763">Viral Matrix Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4162460</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25118816</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1532-0979</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>38</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of surgical pathology</Title>
<ISOAbbreviation>Am. J. Surg. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.</ArticleTitle>
<Pagination>
<MedlinePgn>1349-59</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/PAS.0000000000000309</ELocationID>
<Abstract>
<AbstractText>Despite the immunologic functions of T-cell receptor signaling molecules being extensively investigated, their potential as immunohistochemical markers has been poorly explored. With this background, we evaluated the expression of 5 intracellular proteins-GADS, DOK2, SKAP55, ITK, and PKCα-involved in T-cell receptor signaling in normal and neoplastic hematologic tissue samples, using antibodies raised against fixation-resistant epitopes of the 5 molecules. All 5 antibodies were associated with normal T-cell differentiation. GADS, DOK2, SKAP55, and ITK turned out to be T-cell lineage-specific markers in the setting of lymphoid and myeloid precursor neoplasms but showed differential expression in peripheral T-cell lymphoma (PTCL) subtypes, being detected in PTCL/not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma but negative in anaplastic large cell lymphoma (ALCL). Peripheral B-cell lymphomas were consistently negative for ITK, with occasional cases showing expression of DOK2 and SKAP55, and a proportion (47%) of hairy cell leukemias were GADS. Notably, PKCα highlighted a defective antigen in both PTCL/NOS (6%) and angioimmunoblastic T-cell lymphoma (10%), mostly negative in ALCL, and was aberrantly expressed in classical Hodgkin lymphoma (65%), Burkitt lymphoma (48%), and plasma cell myeloma (48%). In conclusion, all five molecules evaluated play a role in T-cell differentiation in normal and neoplastic tissues. They can be applied confidently to routine sections contributing primarily to assignment of T-lineage differentiation in the setting of hematopoietic precursor neoplasms (GADS/DOK2/SKAP55/ITK) and for the differential diagnosis between ALCL and PTCL/NOS (GADS/DOK2/SKAP55/ITK) or classical Hodgkin lymphoma (PKCα). Finally, association with specific tumor subtypes may have therapeutic potential. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Agostinelli</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>*Section of Haematopathology, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Italy †Department of Pathology, University College of London, London, UK ‡Department of Immunology, University of Washington, Seattle, WA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rizvi</LastName>
<ForeName>Hasan</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paterson</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shende</LastName>
<ForeName>Vishvesh</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akarca</LastName>
<ForeName>Ayse U</ForeName>
<Initials>AU</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Agostini</LastName>
<ForeName>Elena</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fuligni</LastName>
<ForeName>Fabio</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Righi</LastName>
<ForeName>Simona</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Spagnolo</LastName>
<ForeName>Sebastiano</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piccaluga</LastName>
<ForeName>Pier Paolo</ForeName>
<Initials>PP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>Edward A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pileri</LastName>
<ForeName>Stefano A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marafioti</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Surg Pathol</MedlineTA>
<NlmUniqueID>7707904</NlmUniqueID>
<ISSNLinking>0147-5185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C115089">DOK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C409587">GRAP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C108336">SKAP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C080813">emt protein-tyrosine kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="C496628">PRKCA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="D051571">Protein Kinase C-alpha</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019070">Cell Lineage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005060">Europe</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008223">Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010750">Phosphoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051571">Protein Kinase C-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011505">Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011948">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014861">Washington</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25125602</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1552-5783</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Investigative ophthalmology &amp; visual science</Title>
<ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Constitutive and LPS-induced expression of MCP-1 and IL-8 by human uveal melanocytes in vitro and relevant signal pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>5760-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.14-14685</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Melanocytes are one of the major cellular components in the uvea. Interleukin-8/CXCL8 and monocyte chemoattractant protein-1 (MCP-1/CCL2) are the two most important proinflammatory chemokines. We studied the constitutive and lipopolysaccharide (LPS)-induced expression of IL-8 and MCP-1 in cultured human uveal melanocytes (UM) and explored the relevant signal pathways.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Conditioned media and cells were collected from UM cultured in medium with and without stimulation of LPS. Interleukin-8 and MCP-1 proteins and mRNAs were measured using an ELISA kit and RT-PCR, respectively. Nuclear factor (NF)-κB in nuclear extracts and phosphorylated p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases1/2 (ERK1/2), and c-Jun N-terminal kinase1/2 (JNK1/2) in cells cultured with and without LPS were measured by ELISA kits. Inhibitors of p38 (SB203580), ERK1/2 (UO1026), JNK1/2 (SP600125), and NF-κB (BAY11-7082) were added to the cultures to evaluate their effects.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Low levels of IL-8 and MCP-1 proteins were detected in the conditioned media in UM cultured without serum. Lipopolysaccharide (0.01-1 μg/mL) increased IL-8 and MCP-1 mRNAs and proteins levels in a dose- and time-dependent manner, accompanied by a significant increase of phosphorylated JNK1/2 in cell lysates and NF-κB in nuclear extracts. Nuclear factor-κB and JNK1/2 inhibitors significantly blocked LPS-induced expression of IL-8 and MCP-1.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first report on the expression and secretion of chemokines by UM. The data suggest that UM may play a role in the pathogenesis of ocular inflammatory diseases.</AbstractText>
<CopyrightInformation>Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Dan-Ning</ForeName>
<Initials>DN</Initials>
<AffiliationInfo>
<Affiliation>Tissue Culture Center, New York Eye and Ear Infirmary at Mount Sinai Health Center, New York, New York, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bi</LastName>
<ForeName>Mingchao</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Tissue Culture Center, New York Eye and Ear Infirmary at Mount Sinai Health Center, New York, New York, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>David Y</ForeName>
<Initials>DY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Mount Sinai Hospital, New York, New York, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ye</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Mount Sinai Hospital, New York, New York, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McCormick</LastName>
<ForeName>Steven A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, New York Eye and Ear Infirmary at Mount Sinai Health Center, New York, New York, United States Department of Ophthalmology, New York Eye and Ear Infirmary at Mount Sinai Health Center, New York, New York, United States; New York Medical College, Valhalla, New York, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Chi-Chao</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Immunopathology Section, Laboratory of Immunology, National Eye Institute, Bethesda, Maryland, United States.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
<NlmUniqueID>7703701</NlmUniqueID>
<ISSNLinking>0146-0404</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018932">Chemokine CCL2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016209">Interleukin-8</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008544">Melanocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014602">Uvea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4161485 [Available on 03/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">IL-8</Keyword>
<Keyword MajorTopicYN="N">JNK</Keyword>
<Keyword MajorTopicYN="N">LPS</Keyword>
<Keyword MajorTopicYN="N">MCP-1</Keyword>
<Keyword MajorTopicYN="N">NF-κB</Keyword>
<Keyword MajorTopicYN="N">p38 MAPK</Keyword>
<Keyword MajorTopicYN="N">uveal melanocyte</Keyword>
<Keyword MajorTopicYN="N">uveitis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25201528</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-4172</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>158</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Cell</Title>
<ISOAbbreviation>Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Reelin signaling specifies the molecular identity of the pyramidal neuron distal dendritic compartment.</ArticleTitle>
<Pagination>
<MedlinePgn>1335-47</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.07.035</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00985-4</ELocationID>
<Abstract>
<AbstractText>The apical dendrites of many neurons contain proximal and distal compartments that receive synaptic inputs from different brain regions. These compartments also contain distinct complements of ion channels that enable the differential processing of their respective synaptic inputs, making them functionally distinct. At present, the molecular mechanisms that specify dendritic compartments are not well understood. Here, we report that the extracellular matrix protein Reelin, acting through its downstream, intracellular Dab1 and Src family tyrosine kinase signaling cascade, is essential for establishing and maintaining the molecular identity of the distal dendritic compartment of cortical pyramidal neurons. We find that Reelin signaling is required for the striking enrichment of HCN1 and GIRK1 channels in the distal tuft dendrites of both hippocampal CA1 and neocortical layer 5 pyramidal neurons, where the channels actively filter inputs targeted to these dendritic domains. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kupferman</LastName>
<ForeName>Justine V</ForeName>
<Initials>JV</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA; Department of Neuroscience, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Basu</LastName>
<ForeName>Jayeeta</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Russo</LastName>
<ForeName>Marco J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guevarra</LastName>
<ForeName>Jenieve</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheung</LastName>
<ForeName>Stephanie K</ForeName>
<Initials>SK</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Siegelbaum</LastName>
<ForeName>Steven A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA; Department of Pharmacology, Kavli Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA; Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: sas8@columbia.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 NS036658</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS036658</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM008798</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell</MedlineTA>
<NlmUniqueID>0413066</NlmUniqueID>
<ISSNLinking>0092-8674</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C103773">Dab1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051676">G Protein-Coupled Inwardly-Rectifying Potassium Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578666">Hcn1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064428">Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="C093091">reelin protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015816">Cell Adhesion Molecules, Neuronal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003712">Dendrites</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016326">Extracellular Matrix Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051676">G Protein-Coupled Inwardly-Rectifying Potassium Channels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064428">Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008818">Mice, Neurologic Mutants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015221">Potassium Channels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012697">Serine Endopeptidases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618294 [Available on 09/11/15]</OtherID>
<OtherID Source="NLM">PMC4183142 [Available on 09/11/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25076485</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-7035</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>154</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Toll-like receptor signaling directly increases functional IL-17RA expression in neuroglial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>127-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2014.07.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6616(14)00173-9</ELocationID>
<Abstract>
<AbstractText>IL-17, the hallmark cytokine of Th17 cells, plays a pivotal role in the pathogenesis of autoimmune diseases, including encephalomyelitis. In the central nervous system, neuroglial cells are the main residents that express IL-17R and respond to IL-17 by producing chemokines/cytokines and boosting local inflammation. Factors that influence the IL-17R expression in neuroglial cells can also exert their impacts on the outbreak, progression and outcome of encephalomyelitis. Here, we reported that Toll-like receptor signaling has its bias for promoting the IL-17RA, but not the IL-17RC, expression in mouse neuroglial cells in a T cell infiltration independent manner. Elevated IL-17R functionally responded to IL-17 by secreting more chemokines and accelerating CD4 cell migration. First, real-time PCR confirmed that the expression of Il-17ra, but not Il-17rc, was significantly increased in the brain and spinal cord of EAE-induced mice. This effect was elicited by something in complete Freund's adjuvant (CFA), because markedly increased IL-17R was detected in mice immunized with CFA only, even though no evidence of EAE was found. Furthermore, in Rag1(-/-) mice, it was confirmed that CFA could augment the IL-17RA expression in the CNS in the absence of T cell infiltration. In vivo immunization with TLR ligands and in vitro treatment of purified neuroglial cells demonstrated that TLR ligands directly and effectively evoke the IL-17RA expression in the CNS and in cultured astrocytes, microglia and oligodendrocytes. LPS was the most effective inducer of the IL-17RA expression in astrocytes, and polyIC was superior to LPS for microglia and oligodendrocytes. Activated CD4 cells can also promote the secretion of chemokines by LPS pre-treated astrocytes, and hence accelerate the migration of CD4 cells, which was blocked by the neutralization of IL-17RA on the surface of the astrocyte. Taken together, we concluded that TLR signaling can directly stimulate the expression of IL-17RA, but not IL-17RC, in neuroglial cells, which functionally respond to IL-17A by secreting chemokines, accelerating CD4 cell migration, and contributing to the pathogenesis of encephalomyelitis.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Guoping</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Tianjin First Central Hospital, Tianjin 300192, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Tianjin First Central Hospital, Tianjin 300192, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Tianjin First Central Hospital, Tianjin 300192, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Zhiyun</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Tianjin First Central Hospital, Tianjin 300192, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Dongchun</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Doheny Eye Institute, University of Southern California, CA 90033, USA. Electronic address: dongchun.liang@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>128559-51-3</RegistryNumber>
<NameOfSubstance UI="C064658">RAG-1 protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018925">Chemokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004681">Encephalomyelitis, Autoimmune, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020381">Interleukin-17</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009457">Neuroglia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Astrocytes</Keyword>
<Keyword MajorTopicYN="N">Expression</Keyword>
<Keyword MajorTopicYN="N">IL-17RA</Keyword>
<Keyword MajorTopicYN="N">Toll-like receptor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24997360</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of RHO-ROCK signaling enhances ICM and suppresses TE characteristics through activation of Hippo signaling in the mouse blastocyst.</ArticleTitle>
<Pagination>
<MedlinePgn>142-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.06.023</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00319-4</ELocationID>
<Abstract>
<AbstractText>Specification of the trophectoderm (TE) and inner cell mass (ICM) lineages in the mouse blastocyst correlates with cell position, as TE derives from outer cells whereas ICM from inner cells. Differences in position are reflected by cell polarization and Hippo signaling. Only in outer cells, the apical-basal cell polarity is established, and Hippo signaling is inhibited in such a manner that LATS1 and 2 (LATS1/2) kinases are prevented from phosphorylating YAP, a key transcriptional co-activator of the TE-specifying gene Cdx2. However, the molecular mechanisms that regulate these events are not fully understood. Here, we showed that inhibition of RHO-ROCK signaling enhances ICM and suppresses TE characteristics through activation of Hippo signaling and disruption of apical-basal polarity. Embryos treated with ROCK inhibitor Y-27632 exhibited elevated expression of ICM marker NANOG and reduced expression of CDX2 at the blastocyst stage. Y-27632-treated embryos failed to accumulate YAP in the nucleus, although it was rescued by concomitant inhibition of LATS1/2. Segregation between apical and basal polarity regulators, namely PARD6B, PRKCZ, SCRIB, and LLGL1, was dampened by Y-27632 treatment, whereas some of the polarization events at the late 8-cell stage such as compaction and apical localization of p-ERM and tyrosinated tubulin occurred normally. Similar abnormalities of Hippo signaling and apical-basal polarization were also observed in embryos that were treated with RHO GTPases inhibitor. These results suggest that RHO-ROCK signaling plays an essential role in regulating Hippo signaling and cell polarization to enable proper specification of the ICM and TE lineages.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kono</LastName>
<ForeName>Kanako</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tamashiro</LastName>
<ForeName>Dana Ann A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alarcon</LastName>
<ForeName>Vernadeth B</ForeName>
<Initials>VB</Initials>
<AffiliationInfo>
<Affiliation>Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA. Electronic address: vernadet@hawaii.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20 GM103457</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103457</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000577">Amides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C487514">Cdx2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C082939">Llgl1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C475540">Nanog protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486223">Yap protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508433">scribble protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>138381-45-0</RegistryNumber>
<NameOfSubstance UI="C108830">Y 27632</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="C490501">Lats1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C578495">Hippo protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C522633">LATS2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C088238">protein kinase C zeta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000577">Amides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053624">Blastocyst Inner Cell Mass</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019070">Cell Lineage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016764">Cell Polarity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004475">Ectoderm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008811">Mice, Inbred DBA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010750">Phosphoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011493">Protein Kinase C</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020741">rho GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054460">rho-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CDX2</Keyword>
<Keyword MajorTopicYN="N">Cell lineage</Keyword>
<Keyword MajorTopicYN="N">Cell polarity</Keyword>
<Keyword MajorTopicYN="N">Inner cell mass</Keyword>
<Keyword MajorTopicYN="N">Trophectoderm</Keyword>
<Keyword MajorTopicYN="N">YAP</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25072627</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The contrasting roles of primary cilia and cytonemes in Hh signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>1-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.07.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00351-0</ELocationID>
<Abstract>
<AbstractText>Hedgehog (Hh) is a paracrine signaling protein with major roles in development and disease. In vertebrates and invertebrates, Hh signal transduction is carried out almost entirely by evolutionarily conserved components, and in both, intercellular movement of Hh is mediated by cytonemes - specialized filopodia that serve as bridges that bring distant cells into contact. A significant difference is the role of the primary cilium, a slender, tubulin-based protuberance of many vertebrate cells. Although the primary cilium is essential for Hh signaling in cells that have one, most Drosophila cells lack a primary cilium. This perspective addresses the roles of primary cilia and cytonemes, and proposes that for Hh signaling, the role of primary cilia is to provide a specialized hydrophobic environment that hosts lipid-modified Hh and other components of Hh signal transduction after Hh has traveled from elsewhere in the cell. Implicit in this model is the idea that initial binding and uptake of Hh is independent of and segregated from the processes of signal transduction and activation.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kornberg</LastName>
<ForeName>Thomas B</ForeName>
<Initials>TB</Initials>
<AffiliationInfo>
<Affiliation>Cardiovascular Research Institute, University of California, San Francisco, CA 94158, United States. Electronic address: tkornberg@ucsf.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM030637</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM105987</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM030637</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM105987</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>149291-21-4</RegistryNumber>
<NameOfSubstance UI="C077245">hedgehog protein, Drosophila</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002923">Cilia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004330">Drosophila</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029721">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057927">Hydrophobic and Hydrophilic Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008870">Microtubules</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011554">Pseudopodia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS617842 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4163518 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cytoneme</Keyword>
<Keyword MajorTopicYN="N">Hedgehog</Keyword>
<Keyword MajorTopicYN="N">Lipid raft</Keyword>
<Keyword MajorTopicYN="N">Primary cilium</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093968</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Steroid signaling promotes stem cell maintenance in the Drosophila testis.</ArticleTitle>
<Pagination>
<MedlinePgn>129-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.07.016</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00352-2</ELocationID>
<Abstract>
<AbstractText>Stem cell regulation by local signals is intensely studied, but less is known about the effects of hormonal signals on stem cells. In Drosophila, the primary steroid twenty-hydroxyecdysone (20E) regulates ovarian germline stem cells (GSCs) but was considered dispensable for testis GSC maintenance. Male GSCs reside in a microenvironment (niche) generated by somatic hub cells and adjacent cyst stem cells (CySCs). Here, we show that depletion of 20E from adult males by overexpressing a dominant negative form of the Ecdysone receptor (EcR) or its heterodimeric partner ultraspiracle (usp) causes GSC and CySC loss that is rescued by 20E feeding, uncovering a requirement for 20E in stem cell maintenance. EcR and USP are expressed, activated and autonomously required in the CySC lineage to promote CySC maintenance, as are downstream genes ftz-f1 and E75. In contrast, GSCs non-autonomously require ecdysone signaling. Global inactivation of EcR increases cell death in the testis that is rescued by expression of EcR-B2 in the CySC lineage, indicating that ecdysone signaling supports stem cell viability primarily through a specific receptor isoform. Finally, EcR genetically interacts with the NURF chromatin-remodeling complex, which we previously showed maintains CySCs. Thus, although 20E levels are lower in males than females, ecdysone signaling acts through distinct cell types and effectors to ensure both ovarian and testis stem cell maintenance.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yijie</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, 725 N. Wolfe Street, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, 725 N. Wolfe Street, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cherry</LastName>
<ForeName>Christopher M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, 725 N. Wolfe Street, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matunis</LastName>
<ForeName>Erika L</ForeName>
<Initials>EL</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, 725 N. Wolfe Street, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: matunis@jhmi.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HD040307</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HD052937</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HD040307</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002868">Chromosomal Proteins, Non-Histone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011987">Receptors, Steroid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C055469">ecdysone receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C437989">enhancer of bithorax protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499712">nuclear hormone receptor FTZ-F1, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C066030">ultraspiracle protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>126968-14-7</RegistryNumber>
<NameOfSubstance UI="C061375">Eip75B protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5289-74-7</RegistryNumber>
<NameOfSubstance UI="D004441">Ecdysterone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030801">Animals, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002868">Chromosomal Proteins, Non-Histone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004330">Drosophila</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029721">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004441">Ecdysterone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053595">Embryonic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005854">Germ Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011987">Receptors, Steroid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013737">Testis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS619187 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4165524 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Drosophila spermatogenesis</Keyword>
<Keyword MajorTopicYN="N">Ecdysone</Keyword>
<Keyword MajorTopicYN="N">NURF</Keyword>
<Keyword MajorTopicYN="N">Stem cell niche</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25106852</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Stem-loop binding protein is required for retinal cell proliferation, neurogenesis, and intraretinal axon pathfinding in zebrafish.</ArticleTitle>
<Pagination>
<MedlinePgn>94-109</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.07.020</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00356-X</ELocationID>
<Abstract>
<AbstractText>In the developing retina, neurogenesis and cell differentiation are coupled with cell proliferation. However, molecular mechanisms that coordinate cell proliferation and differentiation are not fully understood. In this study, we found that retinal neurogenesis is severely delayed in the zebrafish stem-loop binding protein (slbp) mutant. SLBP binds to a stem-loop structure at the 3'-end of histone mRNAs, and regulates a replication-dependent synthesis and degradation of histone proteins. Retinal cell proliferation becomes slower in the slbp1 mutant, resulting in cessation of retinal stem cell proliferation. Although retinal stem cells cease proliferation by 2 days postfertilization (dpf) in the slbp mutant, retinal progenitor cells in the central retina continue to proliferate and generate neurons until at least 5dpf. We found that this progenitor proliferation depends on Notch signaling, suggesting that Notch signaling maintains retinal progenitor proliferation when faced with reduced SLBP activity. Thus, SLBP is required for retinal stem cell maintenance. SLBP and Notch signaling are required for retinal progenitor cell proliferation and subsequent neurogenesis. We also show that SLBP1 is required for intraretinal axon pathfinding, probably through morphogenesis of the optic stalk, which expresses attractant cues. Taken together, these data indicate important roles of SLBP in retinal development.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Imai</LastName>
<ForeName>Fumiyasu</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshizawa</LastName>
<ForeName>Asuka</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsuzaki</LastName>
<ForeName>Ayako</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oguri</LastName>
<ForeName>Eri</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Araragi</LastName>
<ForeName>Masato</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishiwaki</LastName>
<ForeName>Yuko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Masai</LastName>
<ForeName>Ichiro</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna, Okinawa 904-0495, Japan. Electronic address: masai@oist.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C579453">CXCL12 protein, zebrafish</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C584140">SLBP protein, zebrafish</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-22-9</RegistryNumber>
<NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C471932">mind bomb protein, zebrafish</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054377">Chemokine CXCL12</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049452">Green Fluorescent Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055495">Neurogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051880">Receptors, Notch</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012160">Retina</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029961">Zebrafish Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Neurogenesis</Keyword>
<Keyword MajorTopicYN="N">Notch</Keyword>
<Keyword MajorTopicYN="N">Proliferation</Keyword>
<Keyword MajorTopicYN="N">Retina</Keyword>
<Keyword MajorTopicYN="N">Stem-loop binding protein</Keyword>
<Keyword MajorTopicYN="N">Zebrafish</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25127992</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The Fog signaling pathway: insights into signaling in morphogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>6-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.08.003</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00379-0</ELocationID>
<Abstract>
<AbstractText>Epithelia form the building blocks of many tissue and organ types. Epithelial cells often form a contiguous 2-dimensional sheet that is held together by strong adhesions. The mechanical properties conferred by these adhesions allow the cells to undergo dramatic three-dimensional morphogenetic movements while maintaining cell-cell contacts during embryogenesis and post-embryonic development. The Drosophila Folded gastrulation pathway triggers epithelial cell shape changes that drive gastrulation and tissue folding and is one of the most extensively studied examples of epithelial morphogenesis. This pathway has yielded key insights into the signaling mechanisms and cellular machinery involved in epithelial remodeling. In this review, we discuss principles of morphogenesis and signaling that have been discovered through genetic and cell biological examination of this pathway. We also consider various regulatory mechanisms and the system׳s relevance to mammalian development. We propose future directions that will continue to broaden our knowledge of morphogenesis across taxa.</AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Manning</LastName>
<ForeName>Alyssa J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Box 357350, The University of Washington, Seattle, WA 98195-7350, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rogers</LastName>
<ForeName>Stephen L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, The University of North Carolina at Chapel Hill, CB ♯3280, Fordham Hall, South Road, Chapel Hill, NC 27599-3280, USA; Lineberger Comprehensive Cancer Center, USA; Carolina Center for Genome Sciences, USA. Electronic address: srogers@bio.unc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R03 HD077523</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491313">dimmed protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508614">folded gastrulation protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 1998 Jan 15;12(2):274-84</RefSource>
<PMID Version="1">9436986</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2001 Oct 19;107(2):183-94</RefSource>
<PMID Version="1">11672526</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2003 Aug 19;13(16):1365-77</RefSource>
<PMID Version="1">12932320</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Oct 6;29(19):3222-35</RefSource>
<PMID Version="1">20802461</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2010 Nov;137(22):3801-11</RefSource>
<PMID Version="1">20929950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2011 Jan;39(Database issue):D283-8</RefSource>
<PMID Version="1">20972218</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene Expr Patterns. 2011 Jan-Feb;11(1-2):93-104</RefSource>
<PMID Version="1">20920606</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Genet. 2011 Mar;7(3):e1001335</RefSource>
<PMID Version="1">21437272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phys Biol. 2011 Dec;8(6):066007</RefSource>
<PMID Version="1">22120059</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2012 Mar 9;335(6073):1232-5</RefSource>
<PMID Version="1">22323741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Apr 19;484(7394):390-3</RefSource>
<PMID Version="1">22456706</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Growth Differ. 2012 Apr;54(3):266-76</RefSource>
<PMID Version="1">22524600</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Growth Differ. 2012 Apr;54(3):306-16</RefSource>
<PMID Version="1">22524603</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Biomed Eng. 2012;14:129-54</RefSource>
<PMID Version="1">22524386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2013 Jan;1831(1):213-22</RefSource>
<PMID Version="1">22986288</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19298-303</RefSource>
<PMID Version="1">23134725</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mech Dev. 2013 Feb;130(2-3):132-42</RefSource>
<PMID Version="1">23085574</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2013 Jun 10;201(6):887-901</RefSource>
<PMID Version="1">23751496</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2013 Aug;15(8):926-36</RefSource>
<PMID Version="1">23831726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2013 Oct;140(20):4246-55</RefSource>
<PMID Version="1">24026125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2013 Nov;24(21):3460-71</RefSource>
<PMID Version="1">24006487</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Signal. 2013 Nov 12;6(301):ra98</RefSource>
<PMID Version="1">24222713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2013;4:2821</RefSource>
<PMID Version="1">24281726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2014 Apr 17;508(7496):392-6</RefSource>
<PMID Version="1">24590071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2004 Mar 1;164(5):729-38</RefSource>
<PMID Version="1">14981094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2004 Sep;7(3):413-24</RefSource>
<PMID Version="1">15363415</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2004 Oct 11;167(1):135-47</RefSource>
<PMID Version="1">15479740</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2004 Oct 26;14(20):1822-6</RefSource>
<PMID Version="1">15498489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2004 Oct 26;14(20):1827-33</RefSource>
<PMID Version="1">15498490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 1983 Jan;143(1):103-14</RefSource>
<PMID Version="1">6825714</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 1984 Oct;105(2):257-72</RefSource>
<PMID Version="1">6479439</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genetics. 1989 Jan;121(1):101-17</RefSource>
<PMID Version="1">2492966</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1989 May 19;57(4):645-58</RefSource>
<PMID Version="1">2566386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1989 Dec 22;59(6):1189-202</RefSource>
<PMID Version="1">2688897</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann N Y Acad Sci. 1990;582:233-51</RefSource>
<PMID Version="1">2192598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1990 Nov 22;348(6299):308-12</RefSource>
<PMID Version="1">1979146</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1991 Jan 25;64(2):447-58</RefSource>
<PMID Version="1">1899050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1990 Sep;110(1):73-84</RefSource>
<PMID Version="1">2081472</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 1991 Sep;5(9):1568-76</RefSource>
<PMID Version="1">1884999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1991 Jul;112(3):775-89</RefSource>
<PMID Version="1">1935689</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11067-70</RefSource>
<PMID Version="1">1662381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 1992 Aug;6(8):1518-30</RefSource>
<PMID Version="1">1644293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 1993 Sep;159(1):311-26</RefSource>
<PMID Version="1">8365569</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 1994 Feb;124(3):325-40</RefSource>
<PMID Version="1">8294516</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1994 Mar 25;76(6):1075-89</RefSource>
<PMID Version="1">8137424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 1996 Jul;134(1):133-48</RefSource>
<PMID Version="1">8698810</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 1996 Jul;134(1):149-63</RefSource>
<PMID Version="1">8698811</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Pharmacol Toxicol. 1997;37:167-203</RefSource>
<PMID Version="1">9131251</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1997 Jul;124(13):2591-602</RefSource>
<PMID Version="1">9217001</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1997 Dec 26;91(7):905-15</RefSource>
<PMID Version="1">9428514</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1998 Feb;125(4):589-97</RefSource>
<PMID Version="1">9435280</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 1998 Dec 1;204(1):151-64</RefSource>
<PMID Version="1">9851849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuron. 1998 Dec;21(6):1259-72</RefSource>
<PMID Version="1">9883720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2005 Mar;132(5):1009-20</RefSource>
<PMID Version="1">15689371</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2005 Feb 14;168(4):575-85</RefSource>
<PMID Version="1">15699213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2005 Sep;132(18):4165-78</RefSource>
<PMID Version="1">16123312</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2005 Aug 29;170(5):813-23</RefSource>
<PMID Version="1">16129788</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2005 Dec 29;123(7):1323-35</RefSource>
<PMID Version="1">16377571</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2005 Nov;7(11):1091-8</RefSource>
<PMID Version="1">16228012</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2006 Nov;133(21):4257-67</RefSource>
<PMID Version="1">17021037</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Pharmacol Toxicol. 2007;47:53-87</RefSource>
<PMID Version="1">17029567</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2007 Feb;134(3):567-78</RefSource>
<PMID Version="1">17202187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2007 Jan 19;315(5810):384-6</RefSource>
<PMID Version="1">17234948</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Physiol. 2007;69:511-34</RefSource>
<PMID Version="1">17305472</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mech Dev. 2007 Mar;124(3):167-79</RefSource>
<PMID Version="1">17267182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 2007 Aug 1;308(1):158-68</RefSource>
<PMID Version="1">17560973</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2007 Nov;13(5):609-22</RefSource>
<PMID Version="1">17981131</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2008 Mar;135(6):1005-18</RefSource>
<PMID Version="1">18256194</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2008 Mar;1778(3):614-30</RefSource>
<PMID Version="1">18005931</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Protoc. 2008;3(4):606-11</RefSource>
<PMID Version="1">18388942</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phys Biol. 2008;5(1):015005</RefSource>
<PMID Version="1">18403824</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2008 Aug;135(14):2435-44</RefSource>
<PMID Version="1">18550716</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 2008 Sep 1;321(1):88-100</RefSource>
<PMID Version="1">18585373</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2008 Sep;15(3):470-7</RefSource>
<PMID Version="1">18804441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Jan 22;457(7228):495-9</RefSource>
<PMID Version="1">19029882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neurosignals. 2009;17(1):55-70</RefSource>
<PMID Version="1">19212140</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Pharmacol Toxicol. 2009;49:31-56</RefSource>
<PMID Version="1">18834311</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Signal. 2009;2(66):ra16</RefSource>
<PMID Version="1">19366994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2009 Jun 5;324(5932):1338-40</RefSource>
<PMID Version="1">19498173</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2009 Jun 26;137(7):1331-42</RefSource>
<PMID Version="1">19563762</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2009;4(10):e7437</RefSource>
<PMID Version="1">19823683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Pathol. 2010 Jan;220(2):217-30</RefSource>
<PMID Version="1">19918803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2010 Mar 8;188(5):735-49</RefSource>
<PMID Version="1">20194639</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2010 Feb;1803(2):183-90</RefSource>
<PMID Version="1">18977250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 2010 May 1;341(1):5-19</RefSource>
<PMID Version="1">19751720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14217-22</RefSource>
<PMID Version="1">20660765</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cytoskeleton (Hoboken). 2010 Sep;67(9):545-54</RefSource>
<PMID Version="1">20803696</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1999 Dec;126(23):5353-64</RefSource>
<PMID Version="1">10556060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene. 1999 Oct 1;238(2):437-44</RefSource>
<PMID Version="1">10570971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Physiol. 2000 Jan 15;522 Pt 2:177-85</RefSource>
<PMID Version="1">10639096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2000 May;127(9):1887-97</RefSource>
<PMID Version="1">10751177</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genetics. 2000 Jul;155(3):1253-65</RefSource>
<PMID Version="1">10880486</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genetics. 2000 Jul;155(3):1281-95</RefSource>
<PMID Version="1">10880488</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2000 Oct;127(19):4217-26</RefSource>
<PMID Version="1">10976053</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051792">Basic Helix-Loop-Helix Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004330">Drosophila</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029721">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D054262">Gastrulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020741">rho GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS630522</OtherID>
<OtherID Source="NLM">PMC4182926</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Actin</Keyword>
<Keyword MajorTopicYN="N">Apical constriction</Keyword>
<Keyword MajorTopicYN="N">Cell signaling</Keyword>
<Keyword MajorTopicYN="N">Folded gastrulation</Keyword>
<Keyword MajorTopicYN="N">Morphogenesis</Keyword>
<Keyword MajorTopicYN="N">Myosin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25127993</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Retinoic acid plays an evolutionarily conserved and biphasic role in pancreas development.</ArticleTitle>
<Pagination>
<MedlinePgn>83-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.07.021</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00372-8</ELocationID>
<Abstract>
<AbstractText>As the developing zebrafish pancreas matures, hormone-producing endocrine cells differentiate from pancreatic Notch-responsive cells (PNCs) that reside within the ducts. These new endocrine cells form small clusters known as secondary (2°) islets. We use the formation of 2° islets in the pancreatic tail of the larval zebrafish as a model of β-cell neogenesis. Pharmacological inhibition of Notch signaling leads to precocious endocrine differentiation and the early appearance of 2° islets in the tail of the pancreas. Following a chemical screen, we discovered that blocking the retinoic acid (RA)-signaling pathway also leads to the induction of 2° islets. Conversely, the addition of exogenous RA blocks the differentiation caused by Notch inhibition. In this report we characterize the interaction of these two pathways. We first verified that signaling via both RA and Notch ligands act together to regulate pancreatic progenitor differentiation. We produced a transgenic RA reporter, which demonstrated that PNCs directly respond to RA signaling through the canonical transcriptional pathway. Next, using a genetic lineage tracing approach, we demonstrated these progenitors produce endocrine cells following inhibition of RA signaling. Lastly, inhibition of RA signaling using a cell-type specific inducible cre/lox system revealed that RA signaling acts cell-autonomously in PNCs to regulate their differentiation. Importantly, the action of RA inhibition on endocrine formation is evolutionarily conserved, as shown by the differentiation of human embryonic stem cells in a model of human pancreas development. Together, these results revealed a biphasic function for RA in pancreatogenesis. As previously shown by others, RA initially plays an essential role during embryogenesis as it patterns the endoderm and specifies the pancreatic field. We reveal here that later in development RA is involved in negatively regulating the further differentiation of pancreatic progenitors and expands upon the developmental mechanisms by which this occurs.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, and McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, 470 Miller Research Building, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Guangliang</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, and McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, 470 Miller Research Building, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Delaspre</LastName>
<ForeName>Fabien</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, and McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, 470 Miller Research Building, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vitery</LastName>
<ForeName>Maria Del Carmen</ForeName>
<Initials>Mdel C</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, and McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, 470 Miller Research Building, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beer</LastName>
<ForeName>Rebecca L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, and McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, 470 Miller Research Building, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parsons</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, and McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, 470 Miller Research Building, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1F32DK101289</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F32 DK101289</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30DK079637</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01DK080730</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01HD058530</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5688UTC01R</RegistryNumber>
<NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030801">Animals, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019070">Cell Lineage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055098">Endocrine Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050417">Insulin-Secreting Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038081">Organogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051880">Receptors, Notch</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029961">Zebrafish Proteins</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Differentiation</Keyword>
<Keyword MajorTopicYN="N">Pancreas</Keyword>
<Keyword MajorTopicYN="N">Progenitors</Keyword>
<Keyword MajorTopicYN="N">Retinoic acid</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128586</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-564X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>394</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The small GTPases RhoA and Rac1 regulate cerebellar development by controlling cell morphogenesis, migration and foliation.</ArticleTitle>
<Pagination>
<MedlinePgn>39-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ydbio.2014.08.004</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0012-1606(14)00380-7</ELocationID>
<Abstract>
<AbstractText>The small GTPases RhoA and Rac1 are key cytoskeletal regulators that function in a mutually antagonistic manner to control the migration and morphogenesis of a broad range of cell types. However, their role in shaping the cerebellum, a unique brain structure composed of an elaborate set of folia separated by fissures of different lengths, remains largely unexplored. Here we show that dysregulation of both RhoA and Rac1 signaling results in abnormal cerebellar ontogenesis. Ablation of RhoA from neuroprogenitor cells drastically alters the timing and placement of fissure formation, the migration and positioning of granule and Purkinje cells, the alignment of Bergmann glia, and the integrity of the basement membrane, primarily in the anterior lobules. Furthermore, in the absence of RhoA, granule cell precursors located at the base of fissures fail to undergo cell shape changes required for fissure initiation. Many of these abnormalities can be recapitulated by deleting RhoA specifically from granule cell precursors but not postnatal glia, indicating that RhoA functions in granule cell precursors to control cerebellar morphogenesis. Notably, mice with elevated Rac1 activity due to loss of the Rac1 inhibitors Bcr and Abr show similar anterior cerebellar deficits, including ectopic neurons and defects in fissure formation, Bergmann glia organization and basement membrane integrity. Together, our results suggest that RhoA and Rac1 play indispensable roles in patterning cerebellar morphology.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mulherkar</LastName>
<ForeName>Shalaka</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uddin</LastName>
<ForeName>Mohammad Danish</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>University of Houston, Houston, TX 77004, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Couvillon</LastName>
<ForeName>Anthony D</ForeName>
<Initials>AD</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sillitoe</LastName>
<ForeName>Roy V</ForeName>
<Initials>RV</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute, Texas Children׳s Hospital, Houston, TX 77030, USA; Department of Pathology &amp; Immunology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tolias</LastName>
<ForeName>Kimberley F</ForeName>
<Initials>KF</Initials>
<AffiliationInfo>
<Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA; Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, M.S. BCM 295, Houston, TX 77030, USA. Electronic address: tolias@bcm.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5P30HD024064</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS062829</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01NS062829</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C484145">Abr protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004965">Estrogen Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C484602">Rac1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>094ZI81Y45</RegistryNumber>
<NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C496614">Bcr protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051562">Proto-Oncogene Proteins c-bcr</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="C526380">RhoA protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020830">rac1 GTP-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001485">Basement Membrane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019521">Body Patterning</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002531">Cerebellum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004965">Estrogen Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020690">GTPase-Activating Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009024">Morphogenesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009457">Neuroglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009479">Neuropeptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051562">Proto-Oncogene Proteins c-bcr</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013629">Tamoxifen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020830">rac1 GTP-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020741">rho GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS622557 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4163514 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Bergmann glia</Keyword>
<Keyword MajorTopicYN="N">Cell shape changes</Keyword>
<Keyword MajorTopicYN="N">Foliation</Keyword>
<Keyword MajorTopicYN="N">Granule cell precursors</Keyword>
<Keyword MajorTopicYN="N">Granule cells</Keyword>
<Keyword MajorTopicYN="N">Rho GTPases</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25027205</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2568</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>59</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Digestive diseases and sciences</Title>
<ISOAbbreviation>Dig. Dis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>2367-80</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-014-3190-7</ELocationID>
<Abstract>
<AbstractText>A high-fat diet coincides with increased levels of bile acids. This increase in bile acids, particularly deoxycholic acid (DCA), has been strongly associated with the development of colon cancer. Conversely, ursodeoxycholic acid (UDCA) may have chemopreventive properties. Although structurally similar, DCA and UDCA present different biological and pathological effects in colon cancer progression. The differential regulation of cancer by these two bile acids is not yet fully understood. However, one possible explanation for their diverging effects is their ability to differentially regulate signaling pathways involved in the multistep progression of colon cancer, such as the epidermal growth factor receptor (EGFR)-mitogen-activated protein kinase (MAPK) pathway. This review will examine the biological effects of DCA and UDCA on colon cancer development, as well as the diverging effects of these bile acids on the oncogenic signaling pathways that play a role in colon cancer development, with a particular emphasis on bile acid regulation of the EGFR-MAPK pathway. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Centuori</LastName>
<ForeName>Sara M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cellular and Molecular Medicine, The University of Arizona Cancer Center, 1515 N. Campbell Ave., PO Box 245024, Tucson, AZ, 85724-5024, USA, smb4@email.arizona.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martinez</LastName>
<ForeName>Jesse D</ForeName>
<Initials>JD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA129688 S1</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA129688</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA129688</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dig Dis Sci</MedlineTA>
<NlmUniqueID>7902782</NlmUniqueID>
<ISSNLinking>0163-2116</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>005990WHZZ</RegistryNumber>
<NameOfSubstance UI="D003840">Deoxycholic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>724L30Y2QR</RegistryNumber>
<NameOfSubstance UI="D014580">Ursodeoxycholic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003840">Deoxycholic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014580">Ursodeoxycholic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS603992 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4163523 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25219119</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1000-0607</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Zhen ci yan jiu = Acupuncture research / [Zhongguo yi xue ke xue yuan Yi xue qing bao yan jiu suo bian ji]</Title>
<ISOAbbreviation>Zhen Ci Yan Jiu</ISOAbbreviation>
</Journal>
<ArticleTitle>[Effect of elongated-needle penetration intervention on spinal apoptosis and cell signal transduction in acute spinal cord injury rabbits].</ArticleTitle>
<Pagination>
<MedlinePgn>259-66, 277</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effect of elongated-needle penetration (ENP) stimulation of "Zhibian" (BL 54), "Shuidao" (ST 28), "Qihai" (CV 6) and "Zhongji" (CV 3) on spinal nerve cell apoptosis and cellular signal transduction in spinal cord injury rabbits, so as to reveal its mechanism underlying improvement of spinal injury.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A total of 80 adult Newzealand rabbits were randomized to control, model, ENP, ENP + LY 294002 (PI3K antagonist), ENP + PD 98059 (MEK antagonist) groups, with 16 rabbits in each group. The spinal cord injury model was established by using modified Allen's method (Gravity-drop device). Elongated-needle penetration was applied to bilateral BL 54, ST 28, CV 3 and CV 6, once daily for 3 times. For rabbits of the ENP+ LY 294002 and ENP+ PD 98059 groups, LY 294002 (10 microg, 20 microL), PD 98059 (3 microg, 20 microL) were separately given by intrathecal injection. Pathomorphological changes of the injured spinal cord (T13-L1) were observed after H.E. stain. Spinal cell apoptosis was detected by TUNEL,and phosphorylated (p)-Akt and p-ERK1/2 immunoactivity was detected by immunohistochemistry, and the expression levels of p-Akt, p-ERK1/2, cytochrome C (Cyt C) and Caspase-3 proteins were determined by Western blot (WB), and serum TNF-alpha content was assayed by ELISA.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">H. E. staining showed apparent structural changes as hemmorrhage, inflammatory cell infiltration, cellular edema and necrosis, and formation of vacuolation in the spinal cord in the model group, which was marked milder in the ENP group. TUNEL assay showed that the rate of apoptotic cells was notably increased in the model group than in the control group (P &lt; 0.05), obviously decreased in the ENP group when compared with the model group (P &lt; 0.05). Immunohistochemistry, WB and ELISA results showed that compared with the control group, spinal p-Akt and p-ERK1/2 protein expression levels in the model group were significantly decreased (P &lt; 0.05), and Cyt C and Caspase-3 expression levels and serum TNF-a content were significantly increased in the model group (P &lt; 0.05). Compared with the model group, the expression levels of p-Akt, p-ERK1/2 were significantly increased in the ENP group (P &lt; 0.05), while Cyt C and Caspase-3 expression levels and TNF-alpha content were significantly down-regulated in the ENP group (P &lt; 0.05). After intrathecal injection of PI3K and MEK antagonists, the effects of ENP were significantly weakened in reducing apoptosis rate, upregulating p-Akt and p-ERK1/2 expression and in down-regulating Cyt C and Caspase-3 expression and TNF-alpha content (P &lt; 0.05), suggesting important roles of ERK1/2 mediated extracellular and PI3K/Akt mediated intracellular apoptotic signal transduction pathways in ENP induced repair of the traumatic tissues.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ENP stimulation can decrease spinal injury and cell apoptosis in spinal injury rabbits, which may be closely related to its effects in up-regulating p-Akt and p-ERK1/2 and down-regulating Cyt C and Caspase-3 expression levels in the spinal cord and serum TNF-alpha content.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Rong-Liang</ForeName>
<Initials>RL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Quan</LastName>
<ForeName>Ren-Fu</ForeName>
<Initials>RF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Shi-Chao</ForeName>
<Initials>SC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ni</LastName>
<ForeName>Yue-Ming</ForeName>
<Initials>YM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Xuan</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Shang-Ju</ForeName>
<Initials>SJ</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhen Ci Yan Jiu</MedlineTA>
<NlmUniqueID>8507710</NlmUniqueID>
<ISSNLinking>1000-0607</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015670">Acupuncture Therapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009339">Needles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013119">Spinal Cord Injuries</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25178654</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-2148</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC evolutionary biology</Title>
<ISOAbbreviation>BMC Evol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of differentially expressed genes in female Drosophila antonietae and Drosophila meridionalis in response to host cactus odor.</ArticleTitle>
<Pagination>
<MedlinePgn>191</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12862-014-0191-2</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies of insect-plant interactions have provided critical insights into the ecology and evolution of adaptive processes within and among species. Cactophilic Drosophila species have received much attention because larval development occurs in the necrotic tissues of cacti, and both larvae and adults feed on these tissues. Such Drosophila-cactus interactions include effects of the host plant on the physiology and behavior of the flies, especially so their nutritional status, mating condition and reproduction. The aim of this work was to compare the transcriptional responses of two species, Drosophila antonietae and Drosophila meridionalis, and identify genes potentially related to responses to odors released by their host cactus, Cereus hildmannianus. The two fly species are sympatric in most of their populations and use this same host cactus in nature.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We obtained 47 unique sequences (USs) for D. antonietae in a suppression subtractive hybridization screen, 30 of these USs had matches with genes predicted for other Drosophila species. For D. meridionalis we obtained 81 USs, 46 of which were orthologous with genes from other Drosophila species. Functional information (Gene Ontology) revealed that these differentially expressed genes are related to metabolic processes, detoxification mechanisms, signaling, response to stimuli, and reproduction. The expression of 13 genes from D. meridionalis and 12 from D. antonietae were further analyzed by quantitative real time-PCR, showing that four genes were significantly overexpressed in D. antonietae and six in D. meridionalis.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results revealed the differential expression of genes related to responses to odor stimuli by a cactus, in two associated fly species. Although the majority of activated genes were similar between the two species, we also observed that certain metabolic pathways were specifically activated, especially those related to signaling pathways and detoxification mechanisms. The activation of these genes may reflect different metabolic pathways used by these flies in their interaction with this host cactus. Our findings provide insight into how the use of C. hildmannianus may have arisen independently in the two fly species, through genetic differentiation in metabolic pathways to effectively explore this cactus as a host.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Borgonove</LastName>
<ForeName>Camila M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Biologia, Faculdade de Filosofia Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av, Bandeirantes 3900, Ribeirão Preto 14049-900, Brazil. cmborgonove@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cavallari</LastName>
<ForeName>Carla B</ForeName>
<Initials>CB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santos</LastName>
<ForeName>Mateus H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rossetti</LastName>
<ForeName>Rafaela</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hartfelder</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manfrin</LastName>
<ForeName>Maura H</ForeName>
<Initials>MH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Evol Biol</MedlineTA>
<NlmUniqueID>100966975</NlmUniqueID>
<ISSNLinking>1471-2148</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1999 Oct 22;286(5440):720-3</RefSource>
<PMID Version="1">10531050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1999 Oct 22;286(5440):741-6</RefSource>
<PMID Version="1">10531053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Pharmacol Sci. 2001 Jul;22(7):368-76</RefSource>
<PMID Version="1">11431032</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Biochem. 2001;70:503-33</RefSource>
<PMID Version="1">11395416</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2002 Feb;3(2):121-6</RefSource>
<PMID Version="1">11812988</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2002 Apr 1;16(7):846-58</RefSource>
<PMID Version="1">11937492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2002 May 1;30(9):e36</RefSource>
<PMID Version="1">11972351</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neurosci Lett. 2003 Mar 13;339(1):62-6</RefSource>
<PMID Version="1">12618301</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEMS Yeast Res. 2003 Jun;3(4):441-8</RefSource>
<PMID Version="1">12748055</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2003 Aug 5;13(15):1348-54</RefSource>
<PMID Version="1">12906797</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Neurosci Res. 2003 Nov 15;74(4):577-88</RefSource>
<PMID Version="1">14598302</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Heredity (Edinb). 2004 Mar;92(3):235-41</RefSource>
<PMID Version="1">14710171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1993 Sep 15;268(26):19188-91</RefSource>
<PMID Version="1">8366071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6025-30</RefSource>
<PMID Version="1">8650213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Crit Rev Biochem Mol Biol. 1995;30(6):445-600</RefSource>
<PMID Version="1">8770536</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10797-802</RefSource>
<PMID Version="1">9380713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1999 Apr 30;284(5415):770-6</RefSource>
<PMID Version="1">10221902</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Res. 1999 Sep;9(9):868-77</RefSource>
<PMID Version="1">10508846</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Insect Mol Biol. 2005 Jan;14(1):3-8</RefSource>
<PMID Version="1">15663770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2005 Jun 15;21(12):2812-3</RefSource>
<PMID Version="1">15814554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Braz J Biol. 2005 May;65(2):299-304</RefSource>
<PMID Version="1">16097733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Insect Mol Biol. 2006 Feb;15(1):33-44</RefSource>
<PMID Version="1">16469066</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genetica. 2006 Jan;126(1-2):57-75</RefSource>
<PMID Version="1">16502085</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Biochem. 2006;75:243-69</RefSource>
<PMID Version="1">16756492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2006 Sep;20(11):1826-35</RefSource>
<PMID Version="1">16940154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ecol. 2006 Dec;15(14):4635-43</RefSource>
<PMID Version="1">17107489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neurochem Res. 2006 Dec;31(12):1425-32</RefSource>
<PMID Version="1">17086442</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biol Lett. 2005 Sep 22;1(3):299-302</RefSource>
<PMID Version="1">17148192</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Evol Biol. 2007;7:77</RefSource>
<PMID Version="1">17504529</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Brain Res. 2007 Oct 31;1178:28-37</RefSource>
<PMID Version="1">17888892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Nov 8;450(7167):203-18</RefSource>
<PMID Version="1">17994087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genetics. 2008 Feb;178(2):1061-72</RefSource>
<PMID Version="1">18245367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Feb 12;457(7231):837-42</RefSource>
<PMID Version="1">19212402</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Evolution. 2009 Jul;63(7):1712-30</RefSource>
<PMID Version="1">19228188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Neuropsychopharmacol. 2009 Oct;19(10):718-25</RefSource>
<PMID Version="1">19586755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2010;5(1):e8735</RefSource>
<PMID Version="1">20090945</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2010 Feb;196(2):97-109</RefSource>
<PMID Version="1">20033746</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Genomics. 2010;11:29</RefSource>
<PMID Version="1">20074338</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Neurosci. 2011 Jan;33(1):1-8</RefSource>
<PMID Version="1">21073552</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genetics. 2011 Apr;187(4):1193-205</RefSource>
<PMID Version="1">21270389</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Insect Physiol. 2011 Jun;57(6):840-50</RefSource>
<PMID Version="1">21435341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ecol. 2012 May;21(10):2428-39</RefSource>
<PMID Version="1">22512269</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Funct Integr Genomics. 2012 Jun;12(2):305-15</RefSource>
<PMID Version="1">22430022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Phylogenet Evol. 2012 Sep;64(3):533-44</RefSource>
<PMID Version="1">22634936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Rep. 2013 Jun 27;3(6):1857-65</RefSource>
<PMID Version="1">23791523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Evolution. 2013 Jul;67(7):1950-63</RefSource>
<PMID Version="1">23815652</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(7):e70027</RefSource>
<PMID Version="1">23936137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Exp Med Biol. 2014;781:233-47</RefSource>
<PMID Version="1">24277303</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029421">Cactaceae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004330">Drosophila</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019143">Evolution, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007814">Larva</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009812">Odors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012098">Reproduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4161902</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25124665</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Nascent histamine induces α-synuclein and caspase-3 on human cells.</ArticleTitle>
<Pagination>
<MedlinePgn>580-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.08.022</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01437-5</ELocationID>
<Abstract>
<AbstractText>Histamine (Hia) is the most multifunctional biogenic amine. It is synthetized by histidine decarboxylase (HDC) in a reduced set of mammalian cell types. Mast cells and histaminergic neurons store Hia in specialized organelles until the amine is extruded by exocytosis; however, other immune and cancer cells are able to produce but not store Hia. The intracellular effects of Hia are still not well characterized, in spite of its physiopathological relevance. Multiple functional relationships exist among Hia metabolism/signaling elements and those of other biogenic amines, including growth-related polyamines. Previously, we obtained the first insights for an inhibitory effect of newly synthetized Hia on both growth-related polyamine biosynthesis and cell cycle progression of non-fully differentiated mammalian cells. In this work, we describe progress in this line. HEK293 cells were transfected to express active and inactive versions of GFP-human HDC fusion proteins and, after cell sorting by flow cytometry, the relative expression of a large number of proteins associated with cell signaling were measured using an antibody microarray. Experimental results were analyzed in terms of protein-protein and functional interaction networks. Expression of active HDC induced a cell cycle arrest through the alteration of the levels of several proteins such as cyclin D1, cdk6, cdk7 and cyclin A. Regulation of α-synuclein and caspase-3 was also observed. The analyses provide new clues on the molecular mechanisms underlying the regulatory effects of intracellular newly synthetized Hia on cell proliferation/survival, cell trafficking and protein turnover. This information is especially interesting for emergent and orphan immune and neuroinflammatory diseases. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Caro-Astorga</LastName>
<ForeName>Joaquín</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga - Andalucia Tech, 29071 Málaga, Spain; CIBER de Enfermedades Raras (CIBERER), 29071 Málaga, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fajardo</LastName>
<ForeName>Ignacio</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga - Andalucia Tech, 29071 Málaga, Spain; CIBER de Enfermedades Raras (CIBERER), 29071 Málaga, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ruiz-Pérez</LastName>
<ForeName>María Victoria</ForeName>
<Initials>MV</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga - Andalucia Tech, 29071 Málaga, Spain; CIBER de Enfermedades Raras (CIBERER), 29071 Málaga, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sánchez-Jiménez</LastName>
<ForeName>Francisca</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga - Andalucia Tech, 29071 Málaga, Spain; CIBER de Enfermedades Raras (CIBERER), 29071 Málaga, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Urdiales</LastName>
<ForeName>José Luis</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga - Andalucia Tech, 29071 Málaga, Spain; CIBER de Enfermedades Raras (CIBERER), 29071 Málaga, Spain. Electronic address: jlurdial@uma.es.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>820484N8I3</RegistryNumber>
<NameOfSubstance UI="D006632">Histamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.1.1.22</RegistryNumber>
<NameOfSubstance UI="D006640">Histidine Decarboxylase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006632">Histamine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006640">Histidine Decarboxylase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051844">alpha-Synuclein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Cell cycle</Keyword>
<Keyword MajorTopicYN="N">Histamine</Keyword>
<Keyword MajorTopicYN="N">Histidine decarboxylase</Keyword>
<Keyword MajorTopicYN="N">Synuclein</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128825</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Modulation of cytokine expression in human macrophages by endocrine-disrupting chemical Bisphenol-A.</ArticleTitle>
<Pagination>
<MedlinePgn>592-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.08.031</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01446-6</ELocationID>
<Abstract>
<AbstractText>Exposure to environmental endocrine-disrupting chemical Bisphenol-A (BPA) is often associated with dysregulated immune homeostasis, but the mechanisms remain unclear. In the present study, the effects of BPA on the cytokines responses of human macrophages were investigated. Treatment with BPA increased pro-inflammation cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production, but decreased anti-inflammation cytokines interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) production in THP1 macrophages, as well as in primary human macrophages. BPA effected cytokines expression through estrogen receptor α/β (ERα/β)-dependent mechanism with the evidence of ERα/β antagonist reversed the expression of cytokines. We also identified that activation of extracellular regulated protein kinases (ERK)/nuclear factor κB (NF-κB) signal cascade marked the effects of BPA on cytokines expression. Our results indicated that BPA effected inflammatory responses of macrophages via modulating of cytokines expression, and provided a new insight into the link between exposure to BPA and human health. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yanzhen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mei</LastName>
<ForeName>Chenfang</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, Guangzhou 510095, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hongsheng</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zeng</LastName>
<ForeName>Guoqu</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Jianhui</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Meiying</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China. Electronic address: xumy@gdim.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506487">estrogen receptor alpha, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>MLT3645I99</RegistryNumber>
<NameOfSubstance UI="C006780">bisphenol A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001559">Benzhydryl Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047628">Estrogen Receptor alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016753">Interleukin-10</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010636">Phenols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Bisphenol-A</Keyword>
<Keyword MajorTopicYN="N">Cytokine</Keyword>
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Macrophage</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24846540</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-4141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>44</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>European journal of immunology</Title>
<ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus.</ArticleTitle>
<Pagination>
<MedlinePgn>2659-66</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.201344134</ELocationID>
<Abstract>
<AbstractText>NK cells are important for the control of vaccinia virus (VV) in vivo. Recent studies have shown that multiple pathways are required for effective activation of NK cells. These include both TLR-dependent and -independent pathways, as well as the NKG2D activating receptor that recognizes host stress-induced NKG2D ligands. However, it remains largely unknown what controls the upregulation of NKG2D ligands in response to VV infection. In this study using C57BL/6 mice, we first showed that IL-18 is critical for NK-cell activation and viral clearance. We then demonstrated that IL-18 signaling on both NK cells and DCs is required for efficient NK-cell activation upon VV infection in vitro. We further showed in vivo that efficient NK-cell activation in response to VV is dependent on DCs and IL-18 signaling in non-NK cells, suggesting an essential role for NK cell-extrinsic IL-18 signaling in NK-cell activation. Mechanistically, IL-18 signaling in DCs promotes expression of Rae-1, an NKG2D ligand. Collectively, our data reveal a previously unrecognized role for NK cell-extrinsic IL-18 signaling in NK-cell activation through upregulation of NKG2D ligands. These observations may provide insights into the design of effective NK-cell-based therapies for viral infections and cancer. </AbstractText>
<CopyrightInformation>© 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Brandstadter</LastName>
<ForeName>Joshua D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Molecular Cancer Biology Program, Duke University Medical Center, Durham, North Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Xiaopei</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Yiping</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI083000</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA047741</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA136934</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA047741</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA136934</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM007171</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32CA009111</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32GM00717</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 AI083000</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Eur J Immunol</MedlineTA>
<NlmUniqueID>1273201</NlmUniqueID>
<ISSNLinking>0014-2980</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020382">Interleukin-18</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527086">Klrk1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034521">Nuclear Matrix-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029543">Nucleocytoplasmic Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490521">Rae1 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020382">Interleukin-18</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034521">Nuclear Matrix-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029543">Nucleocytoplasmic Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014615">Vaccinia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014616">Vaccinia virus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS600528 [Available on 09/01/15]</OtherID>
<OtherID Source="NLM">PMC4165707 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">IL-18</Keyword>
<Keyword MajorTopicYN="N">NK cells</Keyword>
<Keyword MajorTopicYN="N">NKG2D</Keyword>
<Keyword MajorTopicYN="N">Rae-1</Keyword>
<Keyword MajorTopicYN="N">Vaccinia virus</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24935715</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-4141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>44</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>European journal of immunology</Title>
<ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Fli-1 regulates the DN2 to DN3 thymocyte transition and promotes γδ T-cell commitment by enhancing TCR signal strength.</ArticleTitle>
<Pagination>
<MedlinePgn>2617-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.201444442</ELocationID>
<Abstract>
<AbstractText>Friend leukemia integration 1 (Fli-1) is a member of the Ets transcription factor family and is expressed during T-cell development; however, the role Fli-1 plays in early T-cell differentiation has not been elucidated. In this report, we demonstrate that in mouse, Fli-1 overexpression retards the CD4(-) CD8(-) double-negative (DN) to CD4(+) CD8(+) double-positive (DP) transition by deregulating normal DN thymocyte development. Specifically, Fli-1 expression moderates the DN2 and DN3 developmental transitions. We further show that Fli-1 overexpression partially mimics strong TCR signals in developing DN thymocytes and thereby enhances γδ T-cell development. Conversely, Fli-1 knockdown by small hairpin RNA reverses the lineage bias from γδ T cells and directs DN cells to the αβ lineage by attenuating TCR signaling. Therefore, Fli-1 plays a critical role in both the DN2 to DN3 transition and αβ/γδ lineage commitment. </AbstractText>
<CopyrightInformation>© 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Smeets</LastName>
<ForeName>Monique F M A</ForeName>
<Initials>MF</Initials>
<AffiliationInfo>
<Affiliation>Haematology and Leukaemia Unit, St. Vincent's Institute, Fitzroy, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wiest</LastName>
<ForeName>David L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Izon</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Eur J Immunol</MedlineTA>
<NlmUniqueID>1273201</NlmUniqueID>
<ISSNLinking>0014-2980</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497426">Fli1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051789">Proto-Oncogene Protein c-fli-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016693">Receptors, Antigen, T-Cell, alpha-beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016692">Receptors, Antigen, T-Cell, gamma-delta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051789">Proto-Oncogene Protein c-fli-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016693">Receptors, Antigen, T-Cell, alpha-beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016692">Receptors, Antigen, T-Cell, gamma-delta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060168">Thymocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Fli-1</Keyword>
<Keyword MajorTopicYN="N">T cells</Keyword>
<Keyword MajorTopicYN="N">Thymic selection</Keyword>
<Keyword MajorTopicYN="N">Transcription factors</Keyword>
<Keyword MajorTopicYN="N">γδ T cells</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25066089</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-4141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>44</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>European journal of immunology</Title>
<ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mast cell activation: a complex interplay of positive and negative signaling pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>2558-66</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.201444546</ELocationID>
<Abstract>
<AbstractText>Mast cells regulate the immunological responses causing allergy and autoimmunity, and contribute to the tumor microenvironment through generation and secretion of a broad array of preformed, granule-stored and de novo synthesized bioactive compounds. The release and production of mast cell mediators is the result of a coordinated signaling machinery, followed by the FcεRI and FcγR antigen ligation. In this review, we present the latest understanding of FcεRI and FcγR signaling, required for the canonical mast cell activation during allergic responses and anaphylaxis. We then describe the cooperation between the signaling of FcR and other recently characterized membrane-bound receptors (i.e., IL-33R and thymic stromal lymphopoietin receptor) and their role in the chronic settings, where mast cell activation is crucial for the development and the sustainment of chronic diseases, such as asthma or airway inflammation. Finally, we report how the FcR activation could be used as a therapeutic approach to treat allergic and atopic diseases by mast cell inactivation. Understanding the magnitude and the complexity of mast cell signaling is necessary to identify the mechanisms underlying the potential effector and regulatory roles of mast cells in the biology and pathology of those disease settings in which mast cells are activated. </AbstractText>
<CopyrightInformation>© 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sibilano</LastName>
<ForeName>Riccardo</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, CCSR 3255, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Frossi</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pucillo</LastName>
<ForeName>Carlo E</ForeName>
<Initials>CE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>UL1 RR025744</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Eur J Immunol</MedlineTA>
<NlmUniqueID>1273201</NlmUniqueID>
<ISSNLinking>0014-2980</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017455">Receptors, IgE</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018123">Receptors, Interleukin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000707">Anaphylaxis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008407">Mast Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017455">Receptors, IgE</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017452">Receptors, IgG</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018123">Receptors, Interleukin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FcγR</Keyword>
<Keyword MajorTopicYN="N">FcεRI</Keyword>
<Keyword MajorTopicYN="N">IL-33</Keyword>
<Keyword MajorTopicYN="N">TSLP</Keyword>
<Keyword MajorTopicYN="N">mast cells</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24798100</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2422</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>327</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Experimental cell research</Title>
<ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The nuclear factor kappa B (NF-κB) activation is required for phagocytosis of staphylococcus aureus by RAW 264.7 cells.</ArticleTitle>
<Pagination>
<MedlinePgn>256-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2014.04.018</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4827(14)00176-1</ELocationID>
<Abstract>
<AbstractText>Nuclear factor kappa B (NF-κB) is a ubiquitous transcription factor which controls the expression of various genes involved in immune responses. However, it is not clear whether NF-κB activation is critical for phagocytosis when Staphylococcus aureus is the pathogen. Using oligonucleotide microarrays, we investigated whether NF-κB cascade genes are altered in a mouse leukemic monocyte macrophage cell line (RAW 264.7) when the cells were stimulated to activate a host innate immune response against live S. aureus or heat-inactivated S. aureus (HISA). NF-κB cascade genes such as Nfκb1, Nfκbiz, Nfκbie, Rel, Traf1 and Tnfaip3 were up-regulated by all treatments at one hour after incubation. NF-κB play an important role in activating phagocytosis in RAW 264.7 cells infected with S. aureus. Inhibition of NF-κB significantly blocked phagocytosis of fluorescently labeled S. aureus and decreased the expression of NFκB1, IL1α, IL1β and TLR2 in this cell line. Our results demonstrate that S. aureus may activate the NF-κB pathway and that NF-κB activation is required for phagocytosis of S. aureus by macrophages.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>College of Animal Science and Technology, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China. Electronic address: zhufei@zju.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yue</LastName>
<ForeName>Wanfu</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>College of Animal Science and Technology, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yongxia</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>College of Animal Science and Technology, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Cell Res</MedlineTA>
<NlmUniqueID>0373226</NlmUniqueID>
<ISSNLinking>0014-4827</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018613">Microscopy, Confocal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046529">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010587">Phagocytosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013203">Staphylococcal Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013211">Staphylococcus aureus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">NF-κB</Keyword>
<Keyword MajorTopicYN="N">Phagocytosis</Keyword>
<Keyword MajorTopicYN="N">RAW 264.7 cells</Keyword>
<Keyword MajorTopicYN="N">Staphylococcus aureus</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25064462</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2422</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>327</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Experimental cell research</Title>
<ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>RhoA/rho kinase signaling reduces connexin43 expression in high glucose-treated glomerular mesangial cells with zonula occludens-1 involvement.</ArticleTitle>
<Pagination>
<MedlinePgn>276-86</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2014.07.019</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4827(14)00299-7</ELocationID>
<Abstract>
<AbstractText>RhoA/Rho kinase (ROCK) signaling has been suggested to be involved in diabetic nephropathy (DN) pathogenesis. Altered expression of connexin43 (Cx43) has been found in kidneys of diabetic animals. Both of them have been found to regulate nuclear factor kappa-B (NF-κB) activation in high glucose-treated glomerular mesangial cells (GMCs). The aim of this study was to investigate the relationship between RhoA/ROCK signaling and Cx43 in the DN pathogenesis. We found that upregulation of Cx43 expression inhibited NF-κB p65 nuclear translocation induced by RhoA/ROCK signaling in GMCs. Inhibition of RhoA/ROCK signaling attenuated the high glucose-induced decrease in Cx43. F-actin accumulation and an enhanced interaction between zonula occludens-1 (ZO-1) and Cx43 were observed in high glucose-treated GMCs. ZO-1 depletion or disruption of F-actin formation also inhibited the reduction in Cx43 protein levels induced by high glucose. In conclusion, activated RhoA/ROCK signaling induces Cx43 degradation in GMCs cultured in high glucose, depending on F-actin regulation. Increased F-actin induced by RhoA/ROCK signaling promotes the association between ZO-1 and Cx43, which possibly triggered Cx43 endocytosis, a mechanism of NF-κB activation in high glucose-treated GMCs.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Xi</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Department of Pharmaceutical Engineering, Ocean College, Hainan University, Haikou 570228, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Kaipeng</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Shaogui</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hao</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Junying</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Heqing</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Pharmacology &amp; Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Electronic address: huangheq@mail.sysu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Cell Res</MedlineTA>
<NlmUniqueID>0373226</NlmUniqueID>
<ISSNLinking>0014-4827</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018031">Connexin 43</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013549">Sweetening Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C569044">Tjp1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D062826">Zonula Occludens-1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C580592">connexin 43 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020742">rhoA GTP-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018031">Connexin 43</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047468">Immunoprecipitation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050527">Mesangial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013549">Sweetening Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062826">Zonula Occludens-1 Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054460">rho-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020742">rhoA GTP-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Connexin43</Keyword>
<Keyword MajorTopicYN="N">F-actin</Keyword>
<Keyword MajorTopicYN="N">RhoA/Rho kinase</Keyword>
<Keyword MajorTopicYN="N">Zonula occludens-1</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128150</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2422</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>327</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Experimental cell research</Title>
<ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>A syndecan-4 binding peptide derived from laminin 5 uses a novel PKCε pathway to induce cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells.</ArticleTitle>
<Pagination>
<MedlinePgn>171-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2014.07.035</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4827(14)00326-7</ELocationID>
<Abstract>
<AbstractText>In this study, we examined the role(s) of syndecan-4 in regulating the formation of an actin geodesic dome structure called a cross-linked actin network (CLAN) in which syndecan-4 has previously been localized. CLANs have been described in several different cell types, but they have been most widely studied in human trabecular meshwork (HTM) cells where they may play a key role in controlling intraocular pressure by regulating aqueous humor outflow from the eye. In this study we show that a loss of cell surface synedcan-4 significantly reduces CLAN formation in HTM cells. Analysis of HTM cultures treated with or without dexamethasone shows that laminin 5 deposition within the extracellular matrix is increased by glucocorticoid treatment and that a laminin 5-derived, syndecan-4-binding peptide (PEP75), induces CLAN formation in TM cells. This PEP75-induced CLAN formation was inhibited by heparin and the broad spectrum PKC inhibitor Ro-31-7549. In contrast, the more specific PKCα inhibitor Gö 6976 had no effect, thus excluding PKCα as a downstream effector of syndecan-4 signaling. Analysis of PKC isozyme expression showed that HTM cells also expressed both PKCγ and PKCε. Cells treated with a PKCε agonist formed CLANs while a PKCα/γ agonist had no effect. These data suggest that syndecan-4 is essential for CLAN formation in HTM cells and that a novel PKCε-mediated signaling pathway can regulate formation of this unique actin structure.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Filla</LastName>
<ForeName>Mark S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology &amp; Visual Sciences, Medical Science Center, 1300 University Avenue, Madison, WI 53706, United States. Electronic address: msfilla@wisc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>Ross</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Laboratory Medicine, Medical Science Center, 1300 University Avenue, Madison, WI 53706, United States. Electronic address: rclark2@wisc.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Peters</LastName>
<ForeName>Donna M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology &amp; Visual Sciences, Medical Science Center, 1300 University Avenue, Madison, WI 53706, United States; Department of Pathology &amp; Laboratory Medicine, Medical Science Center, 1300 University Avenue, Madison, WI 53706, United States. Electronic address: dmpeter2@wisc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>EY0020490</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY017006</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 EY016665</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 EY016665</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY017006</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY020490</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Cell Res</MedlineTA>
<NlmUniqueID>0373226</NlmUniqueID>
<ISSNLinking>0014-4827</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003432">Cross-Linking Reagents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053671">Syndecan-4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C076524">kalinin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7S5I7G3JQL</RegistryNumber>
<NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="D051744">Protein Kinase C-epsilon</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003432">Cross-Linking Reagents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003907">Dexamethasone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005128">Eye Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051744">Protein Kinase C-epsilon</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053671">Syndecan-4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014129">Trabecular Meshwork</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS622477 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4164596 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CLANs</Keyword>
<Keyword MajorTopicYN="N">Cytoskeleton</Keyword>
<Keyword MajorTopicYN="N">Laminin 5</Keyword>
<Keyword MajorTopicYN="N">Protein kinase C</Keyword>
<Keyword MajorTopicYN="N">Syndecan-4</Keyword>
<Keyword MajorTopicYN="N">Trabecular meshwork</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128810</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2422</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>327</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Experimental cell research</Title>
<ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The protective effect of hispidin against hydrogen peroxide-induced apoptosis in H9c2 cardiomyoblast cells through Akt/GSK-3β and ERK1/2 signaling pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>264-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2014.07.037</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4827(14)00328-0</ELocationID>
<Abstract>
<AbstractText>Hispidin, a phenolic compound from Phellinus linteus (a medicinal mushroom), has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties. However, the cardioprotective efficacy of hispidin has not yet been investigated. In the present study, we investigated the protective effect of hispidin against oxidative stress-induced apoptosis in H9c2 cardiomyoblast cells and neonatal rat ventricular myocytes. While the treatment of H9c2 cardiomyoblast cells with hydrogen peroxide caused a loss of cell viability and an increase in the number of apoptotic cells, hispidin significantly protected the cells against hydrogen peroxide-induced cell death without any cytotoxicity as determined by XTT assay, LDH release assay, Hoechst 33342 assay, and Western blotting of apoptosis proteins such as caspase-3, Bax, and Bcl-2. Our data also shows that hispidin significantly scavenged intracellular ROS, and markedly enhanced the expression of antioxidant enzymes such as heme oxygenase-1 and catalase, which was accompanied by the concomitant activation of Akt/GSK-3β and ERK1/2 phosphorylation in H9c2 cardiomyoblast cells. The effects of hispidin on Akt and ERK phosphorylation were abrogated by LY294002 (a PI3K/Akt inhibitor) and U0126 (an ERK1/2 inhibitor). The effect of hispidin on GSK-3b activities was also blocked by LY294002. Furthermore, inhibiting the Akt/GSK-3β and ERK1/2 pathway by these inhibitors significantly reversed the hispidin-induced Bax and Bcl-2 expression, apoptosis induction, and ROS production. These findings indicate that hispidin protects against apoptosis in H9c2 cardiomyoblast cells exposed to hydrogen peroxide through reducing intracellular ROS production, regulating apoptosis-related proteins, and the activation of the Akt/GSK-3β and ERK1/2 signaling pathways.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Dae-Eun</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomaterials Science and Engineering, Translational Research Center for Protein Function Control, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea; Department of Biomedical Laboratory Science, Kyungbok University, Sinbuk-myeon, Pochen, Gyeonggi 487-717, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Bokyung</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Institute of Functional Genomics, Konkuk University School of Medicine, Chungju, Chungbuk 380-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Hwa-Sup</ForeName>
<Initials>HS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Chemistry, Konkuk University, Chungju, Chungbuk 380-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kwon</LastName>
<ForeName>Ho Jeong</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomaterials Science and Engineering, Translational Research Center for Protein Function Control, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea; Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea; Department of Internal Medicine, College of Medicine, Yonsei University, Seoul 120-752, Republic of Korea. Electronic address: kwonhj@yonsei.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Eun-Seok</ForeName>
<Initials>ES</Initials>
<AffiliationInfo>
<Affiliation>Department of Biomedical Laboratory Science, Kyungbok University, Sinbuk-myeon, Pochen, Gyeonggi 487-717, Republic of Korea. Electronic address: eunspark@kbu.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Cell Res</MedlineTA>
<NlmUniqueID>0373226</NlmUniqueID>
<ISSNLinking>0014-4827</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016877">Oxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011753">Pyrones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>555-55-5</RegistryNumber>
<NameOfSubstance UI="C007946">hispidin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BBX060AN9V</RegistryNumber>
<NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C448280">glycogen synthase kinase 3 beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006861">Hydrogen Peroxide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019950">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048052">Mitogen-Activated Protein Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032383">Myocytes, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016877">Oxidants</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011753">Pyrones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hispidin</Keyword>
<Keyword MajorTopicYN="N">Myocardial apoptosis</Keyword>
<Keyword MajorTopicYN="N">Oxidative stress</Keyword>
<Keyword MajorTopicYN="N">PKC inhibitor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24966026</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-8652</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>89</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>American journal of hematology</Title>
<ISOAbbreviation>Am. J. Hematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.</ArticleTitle>
<Pagination>
<MedlinePgn>954-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.23786</ELocationID>
<Abstract>
<AbstractText>Ineffective erythropoiesis is observed in many erythroid disorders including β-thalassemia and anemia of chronic disease in which increased production of erythroblasts that fail to mature exacerbate the underlying anemias. As loss of the transcription factor FOXO3 results in erythroblast abnormalities similar to the ones observed in ineffective erythropoiesis, we investigated the underlying mechanisms of the defective Foxo3(-/-) erythroblast cell cycle and maturation. Here we show that loss of Foxo3 results in overactivation of the JAK2/AKT/mTOR signaling pathway in primary bone marrow erythroblasts partly mediated by redox modulation. We further show that hyperactivation of mTOR signaling interferes with cell cycle progression in Foxo3 mutant erythroblasts. Importantly, inhibition of mTOR signaling, in vivo or in vitro enhances significantly Foxo3 mutant erythroid cell maturation. Similarly, in vivo inhibition of mTOR remarkably improves erythroid cell maturation and anemia in a model of β-thalassemia. Finally we show that FOXO3 and mTOR are likely part of a larger metabolic network in erythroblasts as together they control the expression of an array of metabolic genes some of which are implicated in erythroid disorders. These combined findings indicate that a metabolism-mediated regulatory network centered by FOXO3 and mTOR control the balanced production and maturation of erythroid cells. They also highlight physiological interactions between these proteins in regulating erythroblast energy. Our results indicate that alteration in the function of this network might be implicated in the pathogenesis of ineffective erythropoiesis.</AbstractText>
<CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xin</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Campreciós</LastName>
<ForeName>Genís</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rimmelé</LastName>
<ForeName>Pauline</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Raymond</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yalcin</LastName>
<ForeName>Safak</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mungamuri</LastName>
<ForeName>Sathish Kumar</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barminko</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>D'Escamard</LastName>
<ForeName>Valentina</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baron</LastName>
<ForeName>Margaret H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brugnara</LastName>
<ForeName>Carlo</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Papatsenko</LastName>
<ForeName>Dmitri</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rivella</LastName>
<ForeName>Stefano</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ghaffari</LastName>
<ForeName>Saghi</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 DK077174</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK077174</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL094283</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL116365</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL116365</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Hematol</MedlineTA>
<NlmUniqueID>7610369</NlmUniqueID>
<ISSNLinking>0361-8609</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C474033">FoxO3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004900">Erythroblasts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004920">Erythropoiesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006706">Homeostasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017086">beta-Thalassemia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS605017 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4201594 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031020</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1563</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Cell physiology</Title>
<ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Reduced endoplasmic reticulum stress-induced apoptosis and impaired unfolded protein response in TRPC3-deficient M1 macrophages.</ArticleTitle>
<Pagination>
<MedlinePgn>C521-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpcell.00369.2013</ELocationID>
<Abstract>
<AbstractText>Endoplasmic reticulum (ER) stress is a prominent mechanism of macrophage apoptosis in advanced atherosclerotic lesions. Recent studies from our laboratory showed that advanced atherosclerotic plaques in Apoe(-/-) mice with bone marrow deficiency of the calcium-permeable channel Transient Receptor Potential Canonical 3 (TRPC3) are characterized by reduced areas of necrosis and fewer apoptotic macrophages than animals transplanted with Trpc3(+/+) bone marrow. In vitro, proinflammatory M1 but not anti-inflammatory M2 macrophages derived from Trpc3(-/-)Apoe(-/-) animals exhibited reduced ER stress-induced apoptosis. However, whether this was due to a specific effect of TRPC3 deficiency on macrophage ER stress signaling remained to be determined. In the present work we used polarized macrophages derived from mice with macrophage-specific deficiency of TRPC3 to examine the expression level of ER stress markers and the activation status of some typical mediators of macrophage apoptosis. We found that the reduced susceptibility of TRPC3-deficient M1 macrophages to ER stress-induced apoptosis correlates with an impaired unfolded protein response (UPR), reduced mitochondrion-dependent apoptosis, and reduced activation of the proapoptotic molecules calmodulin-dependent protein kinase II and signal transducer and activator of transcription 1. Notably, none of these pathways was altered in TRPC3-deficient M2 macrophages. These findings show for the first time an obligatory requirement for a member of the TRPC family of cation channels in ER stress-induced apoptosis in macrophages, underscoring a rather selective role of the TRPC3 channel on mechanisms related to the UPR signaling in M1 macrophages. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Solanki</LastName>
<ForeName>Sumeet</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pharmacology and Center for Diabetes and Endocrine Research, University of Toledo Health Science Campus, Toledo, Ohio; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dube</LastName>
<ForeName>Prabhatchandra R</ForeName>
<Initials>PR</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pharmacology and Center for Diabetes and Endocrine Research, University of Toledo Health Science Campus, Toledo, Ohio; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tano</LastName>
<ForeName>Jean-Yves</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pharmacology and Center for Diabetes and Endocrine Research, University of Toledo Health Science Campus, Toledo, Ohio; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Birnbaumer</LastName>
<ForeName>Lutz</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Membrane Signaling, Department of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vazquez</LastName>
<ForeName>Guillermo</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pharmacology and Center for Diabetes and Endocrine Research, University of Toledo Health Science Campus, Toledo, Ohio; and guillermo.vazquez@utoledo.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 HL-111877-01</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL111877</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>Z01-ES-101864</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
<NlmUniqueID>100901225</NlmUniqueID>
<ISSNLinking>0363-6143</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050794">STAT1 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494080">Stat1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050052">TRPC Cation Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C104603">TRPC3 cation channel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004721">Endoplasmic Reticulum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059865">Endoplasmic Reticulum Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057507">Mice, 129 Strain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050794">STAT1 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050052">TRPC Cation Channels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D056811">Unfolded Protein Response</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166736 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">TRPC channels</Keyword>
<Keyword MajorTopicYN="N">endoplasmic reticulum stress</Keyword>
<Keyword MajorTopicYN="N">macrophage apoptosis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031022</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1563</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Cell physiology</Title>
<ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Uroguanylin inhibits H-ATPase activity and surface expression in renal distal tubules by a PKG-dependent pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>C532-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpcell.00392.2013</ELocationID>
<Abstract>
<AbstractText>Cumulative evidence suggests that guanylin peptides play an important role on electrolyte homeostasis. We have previously reported that uroguanylin (UGN) inhibits bicarbonate reabsorption in a renal distal tubule. In the present study, we tested the hypothesis that the bicarbonaturic effect of UGN is at least in part attributable to inhibition of H(+)-ATPase-mediated hydrogen secretion in the distal nephron. By in vivo stationary microperfusion experiments, we were able to show that UGN inhibits H(+)-ATPase activity by a PKG-dependent pathway because KT5823 (PKG inhibitor) abolished the UGN effect on distal bicarbonate reabsorption and H89 (PKA inhibitor) was unable to prevent it. The in vivo results were confirmed by the in vitro experiments, where we used fluorescence microscopy to measure intracellular pH (pHi) recovery after an acid pulse with NH4Cl. By this technique, we observed that UGN and 8 bromoguanosine-cGMP (8Br-cGMP) inhibited H(+)-ATPase-dependent pHi recovery and that the UGN inhibitory effect was abolished in the presence of the PKG inhibitor. In addition, by using RT-PCR technique, we verified that Madin-Darby canine kidney (MDCK)-C11 cells express guanylate cyclase-C. Besides, UGN stimulated an increase of both cGMP content and PKG activity but was unable to increase the production of cellular cAMP content and PKA activity. Furthermore, we found that UGN reduced cell surface abundance of H+-ATPase B1 subunit in MDCK-C11 and that this effect was abolished by the PKG inhibitor. Taken together, our data suggest that UGN inhibits H(+)-ATPase activity and surface expression in renal distal cells by a cGMP/PKG-dependent pathway. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>da Silva Lima</LastName>
<ForeName>Vanessa</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Superior Institute of Biomedical Sciences, State University of Ceará, Fortaleza, Ceará, Brazil;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Crajoinas</LastName>
<ForeName>Renato O</ForeName>
<Initials>RO</Initials>
<AffiliationInfo>
<Affiliation>Heart Institute (InCor), and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carraro-Lacroix</LastName>
<ForeName>Luciene R</ForeName>
<Initials>LR</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Biophysics, Biomedical Sciences Institute, University of São Paulo, São Paulo, São Paulo, Brazil;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Godinho</LastName>
<ForeName>Alana N</ForeName>
<Initials>AN</Initials>
<AffiliationInfo>
<Affiliation>Superior Institute of Biomedical Sciences, State University of Ceará, Fortaleza, Ceará, Brazil;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dias</LastName>
<ForeName>João L G</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Superior Institute of Biomedical Sciences, State University of Ceará, Fortaleza, Ceará, Brazil;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dariolli</LastName>
<ForeName>Rafael</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Heart Institute (InCor), and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Girardi</LastName>
<ForeName>Adriana C C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Heart Institute (InCor), and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fonteles</LastName>
<ForeName>Manassés C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Superior Institute of Biomedical Sciences, State University of Ceará, Fortaleza, Ceará, Brazil; Mackenzie University, São Paulo, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malnic</LastName>
<ForeName>Gerhard</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Biophysics, Biomedical Sciences Institute, University of São Paulo, São Paulo, São Paulo, Brazil;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lessa</LastName>
<ForeName>Lucília M A</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>Superior Institute of Biomedical Sciences, State University of Ceará, Fortaleza, Ceará, Brazil; lucilialessa17@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
<NlmUniqueID>100901225</NlmUniqueID>
<ISSNLinking>0363-6143</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001639">Bicarbonates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045265">Natriuretic Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>152175-68-3</RegistryNumber>
<NameOfSubstance UI="C084362">uroguanylin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.12</RegistryNumber>
<NameOfSubstance UI="D017869">Cyclic GMP-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.3.14</RegistryNumber>
<NameOfSubstance UI="D006180">Proton-Translocating ATPases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.6.1.2</RegistryNumber>
<NameOfSubstance UI="D050705">Receptors, Guanylate Cyclase-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>H2D2X058MU</RegistryNumber>
<NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001639">Bicarbonates</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006152">Cyclic GMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017869">Cyclic GMP-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006863">Hydrogen-Ion Concentration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007686">Kidney Tubules, Distal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045265">Natriuretic Peptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010477">Perfusion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006180">Proton-Translocating ATPases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050705">Receptors, Guanylate Cyclase-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166739 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">H+-ATPase</Keyword>
<Keyword MajorTopicYN="N">PKG</Keyword>
<Keyword MajorTopicYN="N">cGMP</Keyword>
<Keyword MajorTopicYN="N">distal tubule</Keyword>
<Keyword MajorTopicYN="N">renal microperfusion</Keyword>
<Keyword MajorTopicYN="N">uroguanylin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25055824</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1563</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Cell physiology</Title>
<ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Epidermal growth factor-induced proliferation of collecting duct cells from Oak Ridge polycystic kidney mice involves activation of Na+/H+ exchanger.</ArticleTitle>
<Pagination>
<MedlinePgn>C554-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpcell.00188.2014</ELocationID>
<Abstract>
<AbstractText>Epidermal growth factor (EGF) is linked to the pathogenesis of polycystic kidney disease (PKD). We explored signaling pathways activated by EGF in orpk cilia (-) collecting duct cell line derived from a mouse model of PKD (hypomorph of the Tg737/Ift88 gene) with severely stunted cilia, and in a control orpk cilia (+) cell line with normal cilia. RT-PCR demonstrated mRNAs for EGF receptor subunits ErbB1, ErbB2, ErbB3, ErbB4, and mRNAs for Na(+)/H(+) exchangers (NHE), NHE-1, NHE-2, NHE-3, NHE-4, and NHE-5 in both cell lines. EGF stimulated proton efflux in both cell lines. This effect was significantly attenuated by MIA, 5-(n-methyl-N-isobutyl) amiloride, a selective inhibitor of NHE-1 and NHE-2, and orpk cilia (-) cells were more sensitive to MIA than control cells (P &lt; 0.01). EGF significantly induced extracellular signal-regulated kinase (ERK) phosphorylation in both cilia (+) and cilia (-) cells (63.3 and 123.6%, respectively), but the effect was more pronounced in orpk cilia (-) cells (P &lt; 0.01). MIA significantly attenuated EGF-induced ERK phosphorylation only in orpk cilia (-) cells (P &lt; 0.01). EGF increased proliferation of orpk cilia (+) cells and orpk cilia (-) cells, respectively, and MIA at 1-5 μM attenuated EGF-induced proliferation in orpk cilia (-) cells without affecting proliferation of orpk cilia (+) cells. EGF-induced proliferation of both cell lines was significantly decreased by the EGFR tyrosine kinase inhibitor AG1478 and MEK inhibitor PD98059. These results suggest that EGF exerts mitogenic effects in the orpk cilia (-) cells via activation of growth-associated amiloride-sensitive NHEs and ERK. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Coaxum</LastName>
<ForeName>Sonya D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blanton</LastName>
<ForeName>Mary G</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Joyner</LastName>
<ForeName>Alisha</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>College of Medicine, Medical University of South Carolina, Charleston, South Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akter</LastName>
<ForeName>Tanjina</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bell</LastName>
<ForeName>P Darwin</ForeName>
<Initials>PD</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina; Medical and Research Services of the Ralph H. Johnson VAMC, Charleston, Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luttrell</LastName>
<ForeName>Louis M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Endocrinology, Medical University of South Carolina, Charleston, South Carolina; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raymond</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
<Suffix>Sr</Suffix>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical College of Wisconsin and the Medical Service of the Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Mi-Hye</ForeName>
<Initials>MH</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Endocrinology, Medical University of South Carolina, Charleston, South Carolina; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blichmann</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garnovskaya</LastName>
<ForeName>Maria N</ForeName>
<Initials>MN</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saigusa</LastName>
<ForeName>Takamitsu</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina; saigusa@musc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K01 HL-092606</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK-52448</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
<NlmUniqueID>100901225</NlmUniqueID>
<ISSNLinking>0363-6143</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017923">Sodium-Hydrogen Antiporter</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490898">Tg737Rpw protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002923">Cilia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048049">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007527">Isoenzymes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007685">Kidney Tubules, Collecting</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007690">Polycystic Kidney Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017923">Sodium-Hydrogen Antiporter</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166740 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AG1478</Keyword>
<Keyword MajorTopicYN="N">cytosensor microphysiometer</Keyword>
<Keyword MajorTopicYN="N">phosphorylation</Keyword>
<Keyword MajorTopicYN="N">polycystic kidney disease</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25080488</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1563</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Cell physiology</Title>
<ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibitors of the 5-lipoxygenase pathway activate pannexin1 channels in macrophages via the thromboxane receptor.</ArticleTitle>
<Pagination>
<MedlinePgn>C571-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpcell.00087.2014</ELocationID>
<Abstract>
<AbstractText>A multitude of environmental signaling molecules influence monocyte and macrophage innate and adaptive immune responses, including ATP and prostanoids. Interestingly, purinergic (P2) and eicosanoid receptor signaling interact such that the activation of P2 receptors leads to prostanoid production, which can then interfere with P2Y-mediated macrophage migration. Recent studies suggest that blockade of 5-lipoxygenase (5-LOX) in macrophages can activate a permeation pathway involved in the influx of dye and the release of ATP. Here, we provide evidence that pannexin1 (Panx1) is a component of this pathway and present the intracellular signaling molecules linking the thromboxane (TP) receptor to Panx1-mediated dye influx and ATP release. Using pharmacological tools and transgenic mice deficient in Panx1, we show that two 5-LOX pathway inhibitors induce ATP release and influx of dye in a Panx1-dependent manner. Electrophysiological recordings performed in wild-type and Panx1-deficient macrophages confirmed that these 5-LOX pathway inhibitors activate currents characteristic of Panx1 channels. We found that the mechanism by which Panx1 channels are activated under this condition involves activation of the TP receptor that is mediated by the cAMP/PKA pathway. This is to our knowledge the first evidence for the involvement of Panx1 in the TP receptor signaling pathway. Future studies aimed to clarify the contribution of this TP-Panx1 signaling network to macrophage immune responses are likely to be important for targeting inflammatory and autoimmune diseases. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>da Silva-Souza</LastName>
<ForeName>Hercules A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Instituto Nacional de Ciência e Tecnologia de Pesquisa Translacional em Saúde e Ambiente da Região Amazônica-INPeTAm, Rio de Janeiro, Brazil; and Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Lira</LastName>
<ForeName>Maria Nathália</ForeName>
<Initials>MN</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Patel</LastName>
<ForeName>Naman K</ForeName>
<Initials>NK</Initials>
<AffiliationInfo>
<Affiliation>Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spray</LastName>
<ForeName>David C</ForeName>
<Initials>DC</Initials>
<AffiliationInfo>
<Affiliation>Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Persechini</LastName>
<ForeName>Pedro Muanis</ForeName>
<Initials>PM</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Instituto Nacional de Ciência e Tecnologia de Pesquisa Translacional em Saúde e Ambiente da Região Amazônica-INPeTAm, Rio de Janeiro, Brazil; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scemes</LastName>
<ForeName>Eliana</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York eliana.scemes@einstein.yu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
<NlmUniqueID>100901225</NlmUniqueID>
<ISSNLinking>0363-6143</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017630">Connexins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016859">Lipoxygenase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C503631">Panx1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017482">Receptors, Thromboxane</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8L70Q75FXE</RegistryNumber>
<NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.11</RegistryNumber>
<NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000255">Adenosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017630">Connexins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017868">Cyclic AMP-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016859">Lipoxygenase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017737">Macrophages, Peritoneal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008564">Membrane Potentials</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017482">Receptors, Thromboxane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ATP release</Keyword>
<Keyword MajorTopicYN="N">dye uptake</Keyword>
<Keyword MajorTopicYN="N">macrophages</Keyword>
<Keyword MajorTopicYN="N">pannexin</Keyword>
<Keyword MajorTopicYN="N">prostanoids</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25074986</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1555</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Endocrinology and metabolism</Title>
<ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
</Journal>
<ArticleTitle>(Pro)renin receptor in skeletal muscle is involved in the development of insulin resistance associated with postinfarct heart failure in mice.</ArticleTitle>
<Pagination>
<MedlinePgn>E503-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpendo.00449.2013</ELocationID>
<Abstract>
<AbstractText>We previously reported that insulin resistance was induced by the impairment of insulin signaling in the skeletal muscle from heart failure (HF) via NAD(P)H oxidase-dependent oxidative stress. (Pro)renin receptor [(P)RR] is involved in the activation of local renin-angiotensin system and subsequent oxidative stress. We thus examined whether (P)RR inhibitor, handle region peptide (HRP), could ameliorate insulin resistance in HF after myocardial infarction (MI) by improving oxidative stress and insulin signaling in the skeletal muscle. C57BL6J mice were divided into four groups: sham operated (Sham, n = 10), Sham treated with HRP (Sham+HRP, 0.1 mg·kg(-1)·day(-1), n = 10), MI operated (MI, n = 10), and MI treated with HRP (MI+HRP, 0.1 mg/kg/day, n = 10). After 4 wk, MI mice showed left ventricular dysfunction, which was not affected by HRP. (P)RR was upregulated in the skeletal muscle after MI (149% of sham, P &lt; 0.05). The decrease in plasma glucose after insulin load was smaller in MI than in Sham (21 ± 2 vs. 44 ± 3%, P &lt; 0.05), and was greater in MI+HRP (38 ± 2%, P &lt; 0.05) than in MI. Insulin-stimulated serine phosphorylation of Akt and glucose transporter 4 translocation were decreased in the skeletal muscle from MI by 48 and 49% of Sham, both of which were ameliorated in MI+HRP. Superoxide production and NAD(P)H oxidase activities were increased in MI, which was inhibited in MI+HRP. HRP ameliorated insulin resistance associated with HF by improving insulin signaling via the inhibition of NAD(P)H oxidase-induced superoxide production in the skeletal muscle. The (P)RR pathway is involved in the development of insulin resistance, at least in part, via the impairment of insulin signaling in the skeletal muscle from HF. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fukushima</LastName>
<ForeName>Arata</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kinugawa</LastName>
<ForeName>Shintaro</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan; tuckahoe@med.hokudai.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takada</LastName>
<ForeName>Shingo</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsushima</LastName>
<ForeName>Shouji</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sobirin</LastName>
<ForeName>Mochamad Ali</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Diponegoro University, Semarang, Indonesia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ono</LastName>
<ForeName>Taisuke</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Masashige</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suga</LastName>
<ForeName>Tadashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Homma</LastName>
<ForeName>Tsuneaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Masaki</LastName>
<ForeName>Yoshihiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Furihata</LastName>
<ForeName>Takaaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kadoguchi</LastName>
<ForeName>Tomoyasu</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yokota</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okita</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Graduate School of Program in Lifelong Learning Studies, Hokusho University, Ebetsu, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsutsui</LastName>
<ForeName>Hiroyuki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan;</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
<NlmUniqueID>100901226</NlmUniqueID>
<ISSNLinking>0193-1849</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C458320">prorenin receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11002-13-4</RegistryNumber>
<NameOfSubstance UI="D000808">Angiotensinogen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.6.3.1</RegistryNumber>
<NameOfSubstance UI="D019255">NADPH Oxidase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000808">Angiotensinogen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018485">Muscle Fibers, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019255">NADPH Oxidase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051058">Oncogene Protein v-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010101">Oxygen Consumption</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012084">Renin-Angiotensin System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">(pro)renin receptor</Keyword>
<Keyword MajorTopicYN="N">heart failure</Keyword>
<Keyword MajorTopicYN="N">insulin resistance</Keyword>
<Keyword MajorTopicYN="N">oxidative stress</Keyword>
<Keyword MajorTopicYN="N">renin-angiotensin system</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25035109</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1547</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Gastrointestinal and liver physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Gastrointest. Liver Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Heme oxygenase-1 upregulation modulates tone and fibroelastic properties of internal anal sphincter.</ArticleTitle>
<Pagination>
<MedlinePgn>G595-601</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpgi.00159.2014</ELocationID>
<Abstract>
<AbstractText>A compromise in the internal anal sphincter (IAS) tone and fibroelastic properties (FEP) plays an important role in rectoanal incontinence. Herein, we examined the effects of heme oxygenase (HO)-1 upregulation on these IAS characteristics in young rats. We determined the effect of HO-1 upregulator hemin on HO-1 mRNA and protein expressions and on basal IAS tone and its FEP before and after HO-1 inhibitor tin protoporphyrin IX. For FEP, we determined the kinetics of the IAS smooth muscle responses, by the velocities of relaxation, and recovery of the IAS tone following 0 Ca(2+) and electrical field stimulation. To characterize the underlying signal transduction for these changes, we determined the effects of hemin on RhoA-associated kinase (RhoA)/Rho kinase (ROCK) II, myosin-binding subunit of myosin light chain phosphatase 1, fibronectin, and elastin expression levels. Hemin increased HO-1 mRNA and protein similar to the increases in the basal tone, and in the FEP of the IAS. Underlying mechanisms in the IAS characteristics are associated with increases in the genetic and translational expressions of RhoA/ROCKII, and elastin. Fibronectin expression levels on the other hand were found to be decreased following HO-1 upregulation. The results of our study show that the hemin/HO-1 system regulates the tone and FEP of IAS. The hemin/HO-1 system thus provides a potential target for the development of new interventions aimed at treatment of gastrointestinal motility disorders, specifically the age-related IAS dysfunction. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Krishna</LastName>
<ForeName>Chadalavada Vijay</ForeName>
<Initials>CV</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Jagmohan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Sumit</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rattan</LastName>
<ForeName>Satish</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania satish.rattan@jefferson.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01-DK-035385</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Gastrointest Liver Physiol</MedlineTA>
<NlmUniqueID>100901227</NlmUniqueID>
<ISSNLinking>0193-1857</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008665">Metalloporphyrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011524">Protoporphyrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>14325-05-4</RegistryNumber>
<NameOfSubstance UI="C032628">tin protoporphyrin IX</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>743LRP9S7N</RegistryNumber>
<NameOfSubstance UI="D006427">Hemin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-58-3</RegistryNumber>
<NameOfSubstance UI="D004549">Elastin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.3</RegistryNumber>
<NameOfSubstance UI="D006419">Heme Oxygenase (Decyclizing)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.3</RegistryNumber>
<NameOfSubstance UI="C491523">Hmox1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C580818">ROCK2 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="C499850">Ppp1r12a protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="D054645">Protein Phosphatase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001003">Anal Canal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000294">innervation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004548">Elasticity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004549">Elastin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004558">Electric Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005353">Fibronectins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006419">Heme Oxygenase (Decyclizing)</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006427">Hemin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007700">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008665">Metalloporphyrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009119">Muscle Contraction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009126">Muscle Relaxation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054645">Protein Phosphatase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011524">Protoporphyrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054460">rho-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166724 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">rectoanal incontinence</Keyword>
<Keyword MajorTopicYN="N">smooth muscle tone</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25035111</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1547</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Gastrointestinal and liver physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Gastrointest. Liver Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential cell growth/apoptosis behavior of 13-hydroxyoctadecadienoic acid enantiomers in a colorectal cancer cell line.</ArticleTitle>
<Pagination>
<MedlinePgn>G664-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpgi.00064.2014</ELocationID>
<Abstract>
<AbstractText>Cyclooxygenases (COXs) and lipoxygenases (LOXs) are important enzymes that metabolize arachidonic and linoleic acids. Various metabolites generated by the arachidonic acid cascade regulate cell proliferation, apoptosis, differentiation, and senescence. Hydroxyoctadecadienoic acids (HODEs) are synthesized from linoleic acid, giving two enantiomeric forms for each metabolite. The aim was to investigate the effect of 13-HODE enantiomers on nondifferentiated Caco-2 cell growth/apoptosis. Our results indicate that 13(S)-HODE decreases cell growth and DNA synthesis of nondifferentiated Caco-2 cells cultured with 10% fetal bovine serum (FBS). Moreover, 13(S)-HODE showed an apoptotic effect that was reduced in the presence of a specific peroxisome proliferator-activated receptor-γ (PPARγ) antagonist. In addition, we observed that 13(S)-HODE but not 13(R)-HODE is a ligand to PPARγ, confirming the implication of this nuclear receptor in 13(S)-HODE actions. In contrast, 13(R)-HODE increases cell growth and DNA synthesis in the absence of FBS. 13(R)-HODE interaction with BLT receptors activates ERK and CREB signaling pathways, as well as PGE2 synthesis. These results suggest that the proliferative effect of 13(R)-HODE could be due, at least in part, to COX pathway activation. Thus both enantiomers use different receptors and have contrary effects. We also found these differential effects of 9-HODE enantiomers on cell growth/apoptosis. Therefore, the balance between (R)-HODEs and (S)-HODEs in the intestinal epithelium could be important to its cell growth/apoptosis homeostasis. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cabral</LastName>
<ForeName>Marisol</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martín-Venegas</LastName>
<ForeName>Raquel</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moreno</LastName>
<ForeName>Juan José</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain jjmoreno@ub.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Gastrointest Liver Physiol</MedlineTA>
<NlmUniqueID>100901227</NlmUniqueID>
<ISSNLinking>0193-1857</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C115163">CREB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008041">Linoleic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5204-88-6</RegistryNumber>
<NameOfSubstance UI="C024348">13-hydroxy-9,11-octadecadienoic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K7Q1JQR04M</RegistryNumber>
<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018938">Caco-2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017362">Cyclic AMP Response Element-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004261">DNA Replication</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048049">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007413">Intestinal Mucosa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007536">Isomerism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008041">Linoleic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047495">PPAR gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">PPARγ</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">cell growth</Keyword>
<Keyword MajorTopicYN="N">cyclooxygenase</Keyword>
<Keyword MajorTopicYN="N">lipoxygenase</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24944246</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene.</ArticleTitle>
<Pagination>
<MedlinePgn>R608-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00085.2014</ELocationID>
<Abstract>
<AbstractText>Inducible gene expression, which requires chromatin remodeling on gene promoters, underlies the epigenetically inherited differentiation program of most immune cells. However, chromatin-mediated mechanisms that underlie these events in T regulatory cells remain to be fully characterized. Here, we report that inducibility of FOXP3, a key transcription factor for the development of T regulatory cells, depends upon Kruppel-like factor 10 (KLF10) interacting with two antagonistic histone-modifying systems. We utilized chromatin immunoprecipitation, genome-integrated reporter assays, and functional domain KLF10 mutant proteins, to characterize reciprocal interactions between this transcription factor and either the Sin3-histone deacetylase complex or the histone acetyltransferase, p300/CBP-associated factor (PCAF). We characterize a Sin3-interacting repressor domain on the NH2 terminus of KLF10, which works to limit the activating function of this transcription factor. Indeed, inactivation of this Sin3-interacting domain renders KLF10 able to physically associate with PCAF as to induce FOXP3 gene transcription. We show that this biochemical data derived from studying our genome-integrated reporter cell system are recapitulated in primary murine lymphocytes. Collectively, these results advance our understanding of how a single transcription factor, namely KLF10, functions as a toggle to integrate antagonistic signals regulating FOXP3 and, thus, immune activation. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xiong</LastName>
<ForeName>Yuning</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Svingen</LastName>
<ForeName>Phyllis A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sarmento</LastName>
<ForeName>Olga O</ForeName>
<Initials>OO</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smyrk</LastName>
<ForeName>Thomas C</ForeName>
<Initials>TC</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dave</LastName>
<ForeName>Maneesh</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khanna</LastName>
<ForeName>Sahil</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lomberk</LastName>
<ForeName>Gwen A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Translational Epigenomic Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Urrutia</LastName>
<ForeName>Raul A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Translational Epigenomic Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Faubion</LastName>
<ForeName>William A</ForeName>
<Initials>WA</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo>
<Affiliation>Epigenetics and Chromatin Dynamics Laboratory, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Translational Epigenomic Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; and faubion.william@mayo.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI89714-R01</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NIDDK-52913</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30DK-084567</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051765">Early Growth Response Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C418974">FOXP3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C498833">Foxp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C098111">KLF10 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C569958">KLF10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9042-14-2</RegistryNumber>
<NameOfSubstance UI="D016264">Dextran Sulfate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="D050880">p300-CBP Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="C100367">p300-CBP-associated factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D056264">Sin3 Histone Deacetylase and Corepressor Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042002">Chromatin Assembly and Disassembly</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003106">Colon</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016264">Dextran Sulfate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051765">Early Growth Response Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051741">Kruppel-Like Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011487">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054730">Protein Interaction Domains and Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056264">Sin3 Histone Deacetylase and Corepressor Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050880">p300-CBP Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166759 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FOXP3</Keyword>
<Keyword MajorTopicYN="N">KLF10</Keyword>
<Keyword MajorTopicYN="N">PCAF</Keyword>
<Keyword MajorTopicYN="N">Sin3</Keyword>
<Keyword MajorTopicYN="N">T regulatory cell</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24990862</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis.</ArticleTitle>
<Pagination>
<MedlinePgn>R585-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00096.2014</ELocationID>
<Abstract>
<AbstractText>The gut-brain axis plays a key role in the control of energy balance and glucose homeostasis. In response to luminal stimulation of macronutrients and microbiota-derived metabolites (secondary bile acids and short chain fatty acids), glucagon-like peptides (GLP-1 and -2) are cosecreted from endocrine L cells in the gut and coreleased from preproglucagonergic neurons in the brain stem. Glucagon-like peptides are proposed as key mediators for bariatric surgery-improved glycemic control and energy balance. Little is known about the GLP-2 receptor (Glp2r)-mediated physiological roles in the control of food intake and glucose homeostasis, yet Glp1r has been studied extensively. This review will highlight the physiological relevance of the central nervous system (CNS) Glp2r in the control of energy balance and glucose homeostasis and focuses on cellular mechanisms underlying the CNS Glp2r-mediated neural circuitry and intracellular PI3K signaling pathway. New evidence (obtained from Glp2r tissue-specific KO mice) indicates that the Glp2r in POMC neurons is essential for suppressing feeding behavior, gastrointestinal motility, and hepatic glucose production. Mice with Glp2r deletion selectively in POMC neurons exhibit hyperphagic behavior, accelerated gastric emptying, glucose intolerance, and hepatic insulin resistance. GLP-2 differentially modulates postsynaptic membrane excitability of hypothalamic POMC neurons in Glp2r- and PI3K-dependent manners. GLP-2 activates the PI3K-Akt-FoxO1 signaling pathway in POMC neurons by Glp2r-p85α interaction. Intracerebroventricular GLP-2 augments glucose tolerance, suppresses glucose production, and enhances insulin sensitivity, which require PI3K (p110α) activation in POMC neurons. Thus, the CNS Glp2r plays a physiological role in the control of food intake and glucose homeostasis. This review will also discuss key questions for future studies. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Guan</LastName>
<ForeName>Xinfu</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>U.S. Department of Agriculture/Agricultural Research Service, Children's Nutrition Research Center, Department of Pediatrics; and Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas xguan@bcm.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK-075489</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK-084125</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK-56338</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499894">GLP-2 receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018027">Receptors, Glucagon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>66796-54-1</RegistryNumber>
<NameOfSubstance UI="D011333">Pro-Opiomelanocortin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.137</RegistryNumber>
<NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004435">Eating</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004734">Energy Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005247">Feeding Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005746">Gastric Emptying</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D041981">Gastrointestinal Tract</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000294">innervation</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006706">Homeostasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009434">Neural Pathways</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058539">Phosphatidylinositol 3-Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011333">Pro-Opiomelanocortin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018027">Receptors, Glucagon</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166762 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">central nervous system</Keyword>
<Keyword MajorTopicYN="N">food intake</Keyword>
<Keyword MajorTopicYN="N">gastric emptying</Keyword>
<Keyword MajorTopicYN="N">glucagon-like peptides</Keyword>
<Keyword MajorTopicYN="N">glucose homeostasis</Keyword>
<Keyword MajorTopicYN="N">gut-brain axis</Keyword>
<Keyword MajorTopicYN="N">insulin sensitivity</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25009216</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Somatostatin-28 inhibitory action on somatolactin-α and -β gene expression in goldfish.</ArticleTitle>
<Pagination>
<MedlinePgn>R755-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00193.2014</ELocationID>
<Abstract>
<AbstractText>Somatostain (SS) is known to inhibit growth hormone (GH) and prolactin (PRL) secretion. Somatolactin (SL) is a member of the GH/PRL family, but its regulation by goldfish brain somatostatin-28 (gbSS-28) has not been examined. To this end, the structural identity of goldfish SLα was established by 5'/3'-rapid amplification of cDNA ends. As revealed by in situ hybridization and immunohistochemical staining, the expression of SL isoforms was detected in pituitary cells located in the neurointermediate lobe (NIL). The transcripts of goldfish SS receptor 5a (Sst5a) but not Sst1b, Sst2, or Sst3a were detected in the goldfish NIL cells by RT-PCR. In goldfish pituitary cells, gbSS-28 not only had an inhibitory effect on basal SLα and SLβ mRNA levels but also could abolish insulin-like growth factor-stimulated SL gene expression. In primary cultures of goldfish NIL cells, gbSS-28 reduced forskolin-stimulated total cAMP production. With the use of a pharmacological approach, the adenylate cyclase (AC)/cAMP and phospholipase C (PLC)/inositol trisphosphate (IP3)/protein kinase C (PKC) cascades were shown to be involved in gbSS-28-inhibited SLα mRNA expression. Similar postreceptor signaling cascades were also observed for gbSS-28-reduced SLβ mRNA expression, except that PKC coupling to PLC was not involved. These results provide evidence that gbSS-28 can inhibit SLα and SLβ gene expression at the goldfish pituitary level via Sst5 through differential coupling of AC/cAMP and PLC/IP3/PKC cascades. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Quan</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Bio-resources and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, Peoples Republic of China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Anderson O L</ForeName>
<Initials>AO</Initials>
<AffiliationInfo>
<Affiliation>School of Biological Sciences, The University of Hong Kong, Hong Kong, China olwong@hku.hk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029941">Fish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010907">Pituitary Hormones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017481">Receptors, Somatostatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C064448">somatolactin protein, fish</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C094573">somatostatin receptor 5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>75037-27-3</RegistryNumber>
<NameOfSubstance UI="D053561">Somatostatin-28</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>85166-31-0</RegistryNumber>
<NameOfSubstance UI="D015544">Inositol 1,4,5-Trisphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.4.-</RegistryNumber>
<NameOfSubstance UI="D010738">Type C Phospholipases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.6.1.1</RegistryNumber>
<NameOfSubstance UI="D000262">Adenylate Cyclase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000262">Adenylate Cyclase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003001">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029941">Fish Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006023">Glycoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006054">Goldfish</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015544">Inositol 1,4,5-Trisphosphate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010902">Pituitary Gland</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010907">Pituitary Hormones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061251">Primary Cell Culture</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011493">Protein Kinase C</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017481">Receptors, Somatostatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053561">Somatostatin-28</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010738">Type C Phospholipases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">goldfish brain somatostatin-28</Keyword>
<Keyword MajorTopicYN="N">goldfish pituitary cells</Keyword>
<Keyword MajorTopicYN="N">signaling pathways</Keyword>
<Keyword MajorTopicYN="N">somatolactin</Keyword>
<Keyword MajorTopicYN="N">somatostatin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25009217</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>ANG II receptor subtype 1a gene knockdown in the subfornical organ prevents increased drinking behavior in bile duct-ligated rats.</ArticleTitle>
<Pagination>
<MedlinePgn>R597-607</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00163.2014</ELocationID>
<Abstract>
<AbstractText>Bile duct ligation (BDL) causes congestive liver failure that initiates hemodynamic changes, resulting in dilutional hyponatremia due to increased water intake and vasopressin release. This project tested the hypothesis that angiotensin signaling at the subfornical organ (SFO) augments drinking behavior in BDL rats. A genetically modified adeno-associated virus containing short hairpin RNA (shRNA) for ANG II receptor subtype 1a (AT1aR) gene was microinjected into the SFO of rats to knock down expression. Two weeks later, BDL or sham surgery was performed. Rats were housed in metabolic chambers for measurement of fluid and food intake and urine output. The rats were euthanized 28 days after BDL surgery for analysis. A group of rats was perfused for immunohistochemistry, and a second group was used for laser-capture microdissection for analysis of SFO AT1aR gene expression. BDL rats showed increased water intake that was attenuated in rats that received SFO microinjection of AT1aR shRNA. Among BDL rats treated with scrambled (control) and AT1aR shRNA, we observed an increased number of vasopressin-positive cells in the supraoptic nucleus that colocalized with ΔFosB staining, suggesting increased vasopressin release in both groups. These results indicate that angiotensin signaling through the SFO contributes to increased water intake, but not dilutional hyponatremia, during congestive liver failure. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Walch</LastName>
<ForeName>Joseph D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Anatomy and the Cardiovascular Research Institute, University of North Texas Health Science Centre at Fort Worth, Fort Worth, Texas; and Department of Pharmacology and Neuroscience, University of Texas Health Science Center at San Antonio, San Antonio, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nedungadi</LastName>
<ForeName>T Prashant</ForeName>
<Initials>TP</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Anatomy and the Cardiovascular Research Institute, University of North Texas Health Science Centre at Fort Worth, Fort Worth, Texas; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cunningham</LastName>
<ForeName>J Thomas</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Anatomy and the Cardiovascular Research Institute, University of North Texas Health Science Centre at Fort Worth, Fort Worth, Texas; and Tom.Cunningham@unthsc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>F32 DK-083884</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R56 HL-62569</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C544067">Agtr1a protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C483820">Fosb protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016760">Proto-Oncogene Proteins c-fos</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044140">Receptor, Angiotensin, Type 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11000-17-2</RegistryNumber>
<NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9NEZ333N27</RegistryNumber>
<NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001522">Behavior, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001652">Bile Ducts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000229">Dependovirus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004327">Drinking Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005822">Genetic Vectors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007010">Hyponatremia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008026">Ligation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017093">Liver Failure</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016760">Proto-Oncogene Proteins c-fos</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044140">Receptor, Angiotensin, Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012964">Sodium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013356">Subfornical Organ</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014161">Transduction, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014667">Vasopressins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166751 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">angiotensin</Keyword>
<Keyword MajorTopicYN="N">supraoptic</Keyword>
<Keyword MajorTopicYN="N">vasopressin</Keyword>
<Keyword MajorTopicYN="N">water intake</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25009220</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The unfolded protein response is triggered following a single, unaccustomed resistance-exercise bout.</ArticleTitle>
<Pagination>
<MedlinePgn>R664-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00511.2013</ELocationID>
<Abstract>
<AbstractText>Endoplasmic reticulum (ER) stress results from an imbalance between the abundance of synthesized proteins and the folding capacity of the ER. In response, the unfolded protein response (UPR) attempts to restore ER function by attenuating protein synthesis and inducing chaperone expression. Resistance exercise (RE) stimulates protein synthesis; however, a postexercise accumulation of unfolded proteins may activate the UPR. Aging may impair protein folding, and the accumulation of oxidized and misfolded proteins may stimulate the UPR at rest in aged muscle. Eighteen younger (n = 9; 21 ± 3 yr) and older (n = 9; 70 ± 4 yr) untrained men completed a single, unilateral bout of RE using the knee extensors (four sets of 10 repetitions at 75% of one repetition maximum on the leg press and leg extension) to determine whether the UPR is increased in resting, aged muscle and whether RE stimulates the UPR. Muscle biopsies were taken from the nonexercised and exercised vastus lateralis at 3, 24, and 48 h postexercise. Age did not affect any of the proteins and transcripts related to the UPR. Glucose-regulated protein 78 (GRP78) and protein kinase R-like ER protein kinase (PERK) proteins were increased at 48 h postexercise, whereas inositol-requiring enzyme 1 alpha (IRE1α) was elevated at 24 h and 48 h. Despite elevated protein, GRP78 and PERK mRNA was unchanged; however, IRE1α mRNA was increased at 24 h postexercise. Activating transcription factor 6 (ATF6) mRNA increased at 24 h and 48 h, whereas ATF4, CCAAT/enhancer-binding protein homologous protein (CHOP), and growth arrest and DNA damage protein 34 mRNA were unchanged. These data suggest that RE activates specific pathways of the UPR (ATF6/IRE1α), whereas PERK/eukaryotic initiation factor 2 alpha/CHOP does not. In conclusion, acute RE results in UPR activation, irrespective of age. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ogborn</LastName>
<ForeName>Daniel I</ForeName>
<Initials>DI</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McKay</LastName>
<ForeName>Bryon R</ForeName>
<Initials>BR</Initials>
<AffiliationInfo>
<Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Crane</LastName>
<ForeName>Justin D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parise</LastName>
<ForeName>Gianni</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tarnopolsky</LastName>
<ForeName>Mark A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada tarnopol@mcmaster.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>112223</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497109">ATF4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497111">ATF6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051702">Activating Transcription Factor 6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497249">DDIT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C460640">EIF2AK3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C048690">molecular chaperone GRP78</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>145891-90-3</RegistryNumber>
<NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-12-7</RegistryNumber>
<NameOfSubstance UI="D051742">Transcription Factor CHOP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C528229">ERN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.-</RegistryNumber>
<NameOfSubstance UI="D004722">Endoribonucleases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051701">Activating Transcription Factor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051702">Activating Transcription Factor 6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004721">Endoplasmic Reticulum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059865">Endoplasmic Reticulum Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004722">Endoribonucleases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006360">Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009119">Muscle Contraction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052097">Quadriceps Muscle</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055070">Resistance Training</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051742">Transcription Factor CHOP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D056811">Unfolded Protein Response</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019892">eIF-2 Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">aging</Keyword>
<Keyword MajorTopicYN="N">endoplasmic reticulum</Keyword>
<Keyword MajorTopicYN="N">resistance exercise</Keyword>
<Keyword MajorTopicYN="N">skeletal muscle</Keyword>
<Keyword MajorTopicYN="N">unfolded protein response</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25171143</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1520-4995</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>Biochemistry</Title>
<ISOAbbreviation>Biochemistry</ISOAbbreviation>
</Journal>
<ArticleTitle>Intrapolypeptide interactions between the GTPase effector domain (GED) and the GTPase domain form the bundle signaling element in dynamin dimers.</ArticleTitle>
<Pagination>
<MedlinePgn>5724-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/bi500998s</ELocationID>
<Abstract>
<AbstractText>Biochemical and structural studies of dynamin have shown that the C-terminus of the GTPase effector domain (GED) folds back and docks onto a platform created by the N- and C-terminal α-helices of the GTPase domain to form a three-helix bundle. While cross-linking studies suggested that insect cell-expressed dynamin existed as a domain-swapped dimer, X-ray structures of protein expressed in Escherichia coli failed to detect evidence of this domain swap. Here, by cross-linking several cysteine pair replacements and analyzing cross-linked species by matrix-assisted laser desorption ionization Mega time of flight, we conclude that dynamin is not domain-swapped and that GED-GTPase domain interactions occur in cis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Srinivasan</LastName>
<ForeName>Saipraveen</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, University of Texas Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mattila</LastName>
<ForeName>Juha-Pekka</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schmid</LastName>
<ForeName>Sandra L</ForeName>
<Initials>SL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01GM42455</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochemistry</MedlineTA>
<NlmUniqueID>0370623</NlmUniqueID>
<ISSNLinking>0006-2960</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.5</RegistryNumber>
<NameOfSubstance UI="D034281">Dynamins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019281">Dimerization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034281">Dynamins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004591">Electrophoresis, Polyacrylamide Gel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020558">GTP Phosphohydrolases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166026 [Available on 08/29/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24975213</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>167</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>British journal of haematology</Title>
<ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>69-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.13013</ELocationID>
<Abstract>
<AbstractText>PIM kinases (PIM1, 2 and 3) are involved in cell proliferation and survival signalling and are emerging targets for the therapy of various malignancies. We found that a significant proportion of primary acute myeloid leukaemia (AML) samples showed PIM1 and PIM2 expression by quantitative reverse transcription polymerase chain reaction. Therefore, we investigated the effects of a novel ATP-competitive pan-PIM inhibitor, AZD1897, on AML cell growth and survival. PIM inhibition showed limited single agent activity in AML cell lines and primary AML cells, including those with or without FLT3-internal tandem duplication (ITD) mutation. However, significant synergy was seen when AZD1897 was combined with the Akt inhibitor AZD5363, a compound that is in early-phase clinical trials. AML cells from putative leukaemia stem cell subsets, including CD34+38- and CD34+38+ fractions, were equivalently affected by dual PIM/Akt inhibition when compared with bulk tumour cells. Analysis of downstream signalling pathways showed that combined PIM/Akt inhibition downregulated mTOR outputs (phosphorylation of 4EBP1 and S6) and markedly reduced levels of the anti-apoptotic protein MCL1. The combination of PIM and Akt inhibition holds promise for the treatment of AML. </AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Meja</LastName>
<ForeName>Koremu</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Haematology, University College London Cancer Institute, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stengel</LastName>
<ForeName>Chloe</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sellar</LastName>
<ForeName>Rob</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huszar</LastName>
<ForeName>Dennis</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Davies</LastName>
<ForeName>Barry R</ForeName>
<Initials>BR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gale</LastName>
<ForeName>Rosemary E</ForeName>
<Initials>RE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Linch</LastName>
<ForeName>David C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khwaja</LastName>
<ForeName>Asim</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Haematol</MedlineTA>
<NlmUniqueID>0372544</NlmUniqueID>
<ISSNLinking>0007-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051573">Proto-Oncogene Proteins c-pim-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C406031">proto-oncogene proteins pim</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051573">Proto-Oncogene Proteins c-pim-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">kinase</Keyword>
<Keyword MajorTopicYN="N">leukaemia</Keyword>
<Keyword MajorTopicYN="N">oncogenes</Keyword>
<Keyword MajorTopicYN="N">therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25100567</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>167</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>British journal of haematology</Title>
<ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.</ArticleTitle>
<Pagination>
<MedlinePgn>19-32</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.13065</ELocationID>
<Abstract>
<AbstractText>Targeted therapy represents a transformation in oncology, a field that has relied primarily on non-selective cytotoxic therapies. Phosphatidylinositol 3-kinase (PI3K) is a family of ubiquitous signalling molecules involved in a wide variety of cellular processes and likewise, in a broad selection of human cancers. The discovery that the p110-δ form of PI3K is differentially expressed in normal and malignant lymphocytes has led to the development of specific inhibitors that are currently in clinical trials for lymphoma. Downstream effectors of PI3K, including v-akt murine thymoma viral oncogene homolog 1 (AKT; also termed AKT1) and mechanistic target of rapamycin (serine/threonine kinase) (mTOR) are similarly important in lymphoma, and agents targeting these components of the PI3K-AKT-mTOR axis are also underway, although at earlier stages of development. In this review we examine the role of PI3K-AKT-mTOR in normal and malignant lymphocytes, as well as the preclinical and clinical status of a number of inhibitors of this pathway. </AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Blachly</LastName>
<ForeName>James S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Department of Internal Medicine and The Ohio State University James Comprehensive Cancer, The Ohio State University, Columbus, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baiocchi</LastName>
<ForeName>Robert A</ForeName>
<Initials>RA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Haematol</MedlineTA>
<NlmUniqueID>0372544</NlmUniqueID>
<ISSNLinking>0007-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008223">Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008228">Lymphoma, Non-Hodgkin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AKT</Keyword>
<Keyword MajorTopicYN="N">PI3K</Keyword>
<Keyword MajorTopicYN="N">lymphoma</Keyword>
<Keyword MajorTopicYN="N">mTOR</Keyword>
<Keyword MajorTopicYN="N">targeted-therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25113558</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation.</ArticleTitle>
<Pagination>
<MedlinePgn>3911-25</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00980-14</ELocationID>
<Abstract>
<AbstractText>Neuroinflammation and endoplasmic reticulum (ER) stress are associated with many neurological diseases. Here, we have examined the interaction between ER stress and JAK/STAT-dependent inflammation in glial cells. We show that ER stress is present in the central nervous system (CNS) concomitant with inflammation and astrogliosis in the multiple sclerosis (MS) mouse model of experimental autoimmune encephalomyelitis (EAE). Astrocytes do not easily succumb to ER stress but rather activate an inflammatory program involving activation of STAT3 in a JAK1-dependent fashion. ER stress-induced activation of the JAK1/STAT3 axis leads to expression of interleukin 6 (IL-6) and several chemokines. Moreover, the activation of STAT3 signaling is dependent on PERK, a central component of the ER stress response, which we show is phosphorylated by JAK1. Disruption of PERK abrogates ER stress-induced activation of STAT3 and subsequent gene expression. Additionally, ER-stressed astrocytes, via paracrine signaling, can stimulate activation of microglia, leading to production of IL-6 and oncostatin M (OSM). These IL-6 cytokines can then synergize with ER stress in astrocytes to drive inflammation. Together, this work describes a new PERK/JAK1/STAT3 signaling pathway that elicits a feed-forward inflammatory loop involving astrocytes and microglia to drive neuroinflammation, which may be relevant in diseases such as MS. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Meares</LastName>
<ForeName>Gordon P</ForeName>
<Initials>GP</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell, Developmental, and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA mearegp@uab.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yudong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell, Developmental, and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rajbhandari</LastName>
<ForeName>Rajani</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell, Developmental, and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>Hongwei</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell, Developmental, and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nozell</LastName>
<ForeName>Susan E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell, Developmental, and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mobley</LastName>
<ForeName>James A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Corbett</LastName>
<ForeName>John A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>The Medical College of Wisconsin, Department of Biochemistry, Milwaukee, Wisconsin, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Benveniste</LastName>
<ForeName>Etty N</ForeName>
<Initials>EN</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell, Developmental, and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA158534</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NS57563</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30CA13148-38</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507905">Jak1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.-</RegistryNumber>
<NameOfSubstance UI="C117035">PERK kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004681">Encephalomyelitis, Autoimmune, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059865">Endoplasmic Reticulum Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025461">Feedback, Physiological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053613">Janus Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009103">Multiple Sclerosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019892">eIF-2 Kinase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187715 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25113560</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plakophilin-2 promotes tumor development by enhancing ligand-dependent and -independent epidermal growth factor receptor dimerization and activation.</ArticleTitle>
<Pagination>
<MedlinePgn>3843-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00758-14</ELocationID>
<Abstract>
<AbstractText>Epidermal growth factor (EGF) receptor (EGFR) has been implicated in tumor development and invasion. Dimerization and autophosphorylation of EGFR are the critical events for EGFR activation. However, the regulation of EGF-dependent and EGF-independent dimerization and phosphorylation of EGFR has not been fully understood. Here, we report that cytoplasmic protein plakophilin-2 (PKP2) is a novel positive regulator of EGFR signaling. PKP2 specifically interacts with EGFR via its N-terminal head domain. Increased PKP2 expression enhances EGF-dependent and EGF-independent EGFR dimerization and phosphorylation. Moreover, PKP2 knockdown reduces EGFR phosphorylation and attenuates EGFR-mediated signal activation, resulting in a significant decrease in proliferation and migration of cancer cells and tumor development. Our results indicate that PKP2 is a novel activator of the EGFR signaling pathway and a potential new drug target for inhibiting tumor growth. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Arimoto</LastName>
<ForeName>Kei-ichiro</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA karimoto@ucsd.edu d7zhang@ucsd.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burkart</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Ming</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ran</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weng</LastName>
<ForeName>Stephanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Dong-Er</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA Department of Pathology and Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA karimoto@ucsd.edu d7zhang@ucsd.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01CA177305</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01HL091549</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495337">PKP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051191">Plakophilins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Mol Cell Biol. 2014 Oct;34(20):3778-9</RefSource>
<PMID Version="1">25113561</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051191">Plakophilins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055503">Protein Multimerization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187709 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25027872</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1941-3297</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>7</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Circulation. Heart failure</Title>
<ISOAbbreviation>Circ Heart Fail</ISOAbbreviation>
</Journal>
<ArticleTitle>Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.</ArticleTitle>
<Pagination>
<MedlinePgn>814-21</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCHEARTFAILURE.113.000885</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The endocrine balance between atrial natriuretic peptide (ANP) and the renin-angiotensin-aldosterone system is critical for the maintenance of arterial blood pressure and volume homeostasis. This study investigated whether a cardiac imbalance between ANP and aldosterone, toward increased mineralocorticoid receptor (MR) signaling, contributes to adverse left ventricular remodeling in response to pressure overload.</AbstractText>
<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We used the MR-selective antagonist eplerenone to test the role of MRs in mediating pressure overload-induced dilatative cardiomyopathy of mice with abolished local, cardiac ANP activity. In response to 21 days of transverse aortic constriction, mice with cardiomyocyte-restricted inactivation (knockout) of the ANP receptor (guanylyl cyclase [GC]-A) or the downstream cGMP-dependent protein kinase I developed enhanced left ventricular hypertrophy and fibrosis together with contractile dysfunction. Treatment with eplerenone (100 mg/kg/d) attenuated left ventricular hypertrophy and fully prevented fibrosis, dilatation, and failure. Transverse aortic constriction induced the cardiac expression of profibrotic connective tissue growth factor and attenuated the expression of SERCA2a (sarcoplasmic reticulum Ca(2+)-ATPase) in knockout mice, but not in controls. These genotype-dependent molecular changes were similarly prevented by eplerenone. ANP attenuated the aldosterone-induced nuclear translocation of MRs via GC-A/cGMP-dependent protein kinase I in transfected HEK 293 (human embryonic kidney) cells. Coimmunoprecipitation and fluorescence resonance energy transfer experiments demonstrated that a population of MRs were membrane associated in close interaction with GC-A and cGMP-dependent protein kinase I and, moreover, that aldosterone caused a conformational change of this membrane MR/GC-A protein complex which was prevented by ANP.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ANP counter-regulates cardiac MR activation in hypertensive heart disease. An imbalance in cardiac ANP/GC-A (inhibition) and aldosterone/MR signaling (augmentation) favors adverse cardiac remodeling in chronic pressure overload.</AbstractText>
<CopyrightInformation>© 2014 American Heart Association, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nakagawa</LastName>
<ForeName>Hitoshi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oberwinkler</LastName>
<ForeName>Heike</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nikolaev</LastName>
<ForeName>Viacheslav O</ForeName>
<Initials>VO</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gaßner</LastName>
<ForeName>Birgit</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Umbenhauer</LastName>
<ForeName>Sandra</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>Helga</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saito</LastName>
<ForeName>Yoshihiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baba</LastName>
<ForeName>Hideo A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Frantz</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuhn</LastName>
<ForeName>Michaela</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>From the Institute of Physiology (H.N., H.O., B.G., M.K.) and Comprehensive Heart Failure Center (H.N., S.F., M.K.), University Würzburg, Würzburg, Germany; Emmy Noether Group of the Deutsche Forschungsgemeinschaft, Department of Cardiology and Pneumology, University Göttingen, Göttingen, Germany (V.O.N.); Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (S.U., H.W, S.F.); First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.); and Institute of Pathology, University Duisburg-Essen, Essen, Germany (H.A.B.). michaela.kuhn@mail.uni-wuerzburg.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Circ Heart Fail</MedlineTA>
<NlmUniqueID>101479941</NlmUniqueID>
<ISSNLinking>1941-3289</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000451">Mineralocorticoid Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018161">Receptors, Mineralocorticoid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>139568-91-5</RegistryNumber>
<NameOfSubstance UI="D055513">Connective Tissue Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>27O7W4T232</RegistryNumber>
<NameOfSubstance UI="D013148">Spironolactone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6995V82D0B</RegistryNumber>
<NameOfSubstance UI="C414690">eplerenone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>85637-73-6</RegistryNumber>
<NameOfSubstance UI="D009320">Atrial Natriuretic Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.3.8</RegistryNumber>
<NameOfSubstance UI="C506950">Atp2a3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.3.8</RegistryNumber>
<NameOfSubstance UI="D053498">Sarcoplasmic Reticulum Calcium-Transporting ATPases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009320">Atrial Natriuretic Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002311">Cardiomyopathy, Dilated</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055513">Connective Tissue Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004247">DNA</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018613">Microscopy, Confocal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000451">Mineralocorticoid Receptor Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032383">Myocytes, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018161">Receptors, Mineralocorticoid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053498">Sarcoplasmic Reticulum Calcium-Transporting ATPases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013148">Spironolactone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020257">Ventricular Remodeling</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">aldosterone</Keyword>
<Keyword MajorTopicYN="N">angiotensins</Keyword>
<Keyword MajorTopicYN="N">atrial natriuretic factor</Keyword>
<Keyword MajorTopicYN="N">heart failure</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25232100</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1529-2401</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
<ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>BDNF signaling potentiates transmission of information from the basolateral amygdala to infralimbic prefrontal cortex during conditioned taste aversion extinction.</ArticleTitle>
<Pagination>
<MedlinePgn>12617-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2882-14.2014</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kimbrough</LastName>
<ForeName>Adam</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-9434-4987</Identifier>
<AffiliationInfo>
<Affiliation>Department of Biological Science, Program in Neuroscience, Florida State University, Tallahassee, Florida 32306 akimbrough@neuro.fsu.edu lbiggs@neuro.fsu.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Biggs</LastName>
<ForeName>Lindsey M</ForeName>
<Initials>LM</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-7700-6599</Identifier>
<AffiliationInfo>
<Affiliation>Department of Biological Science, Program in Neuroscience, Florida State University, Tallahassee, Florida 32306 akimbrough@neuro.fsu.edu lbiggs@neuro.fsu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>T32-00044</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosci</MedlineTA>
<NlmUniqueID>8102140</NlmUniqueID>
<ISSNLinking>0270-6474</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>J Neurosci. 2014 May 21;34(21):7302-13</RefSource>
<PMID Version="1">24849362</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000679">Amygdala</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001362">Avoidance Learning</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019208">Brain-Derived Neurotrophic Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005108">Extinction, Psychological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017397">Prefrontal Cortex</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013649">Taste</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166152 [Available on 03/17/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25232115</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1529-2401</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
<ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Survival of neural stem cell grafts in the lesioned spinal cord is enhanced by a combination of treadmill locomotor training via insulin-like growth factor-1 signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>12788-800</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5359-13.2014</ELocationID>
<Abstract>
<AbstractText>Combining cell transplantation with activity-based rehabilitation is a promising therapeutic approach for spinal cord repair. The present study was designed to investigate potential interactions between the transplantation (TP) of neural stem cells (NSCs) obtained at embryonic day 14 and treadmill training (TMT) in promoting locomotor recovery and structural repair in rat contusive injury model. Combination of TMT with NSC TP at 1 week after injury synergistically improved locomotor function. We report here that combining TMT increased the survival of grafted NSCs by &gt;3-fold and &gt;5-fold at 3 and 9 weeks after injury, respectively. The number of surviving NSCs was significantly correlated with the extent of locomotor recovery. NSCs grafted into the injured spinal cord were under cellular stresses induced by reactive nitrogen or oxygen species, which were markedly attenuated by TMT. TMT increased the concentration of insulin-like growth factor-1 (IGF-1) in the CSF. Intrathecal infusion of neutralizing IGF-1 antibodies, but not antibodies against either BDNF or Neurotrophin-3 (NT-3), abolished the enhanced survival of NSC grafts by TMT. The combination of TP and TMT also resulted in tissue sparing, increased myelination, and restoration of serotonergic fiber innervation to the lumbar spinal cord to a larger extent than that induced by either TP or TMT alone. Therefore, we have discovered unanticipated beneficial effects of TMT in modulating the survival of grafted NSCs via IGF-1. Our study identifies a novel neurobiological basis for complementing NSC-based spinal cord repair with activity-based neurorehabilitative approaches. </AbstractText>
<CopyrightInformation>Copyright © 2014 the authors 0270-6474/14/3412788-13$15.00/0.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hwang</LastName>
<ForeName>Dong Hoon</ForeName>
<Initials>DH</Initials>
<AffiliationInfo>
<Affiliation>Department of Brain Science.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Hae Young</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>Department of Brain Science, Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 443-721, Republic of Korea, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kwon</LastName>
<ForeName>Min Jung</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Brain Science, Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 443-721, Republic of Korea, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Jun Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Brain Science, Department of Neurology, and Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 443-721, Republic of Korea, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ryu</LastName>
<ForeName>Buom-Yong</ForeName>
<Initials>BY</Initials>
<AffiliationInfo>
<Affiliation>Department of Animal Science and Technology, Chung-Ang University, Ansung, 456-756, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Byung Gon</ForeName>
<Initials>BG</Initials>
<AffiliationInfo>
<Affiliation>Department of Brain Science, Department of Neurology, and Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 443-721, Republic of Korea, and kimbg@ajou.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosci</MedlineTA>
<NlmUniqueID>8102140</NlmUniqueID>
<ISSNLinking>0270-6474</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020933">Neurotrophin 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026361">Reactive Nitrogen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>67763-96-6</RegistryNumber>
<NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057134">Antibodies, Neutralizing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019208">Brain-Derived Neurotrophic Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007278">Injections, Spinal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007334">Insulin-Like Growth Factor I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008161">Lumbosacral Region</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000294">innervation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009186">Myelin Sheath</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058953">Neural Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000637">transplantation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020933">Neurotrophin 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026361">Reactive Nitrogen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020127">Recovery of Function</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059326">Serotonergic Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013119">Spinal Cord Injuries</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000534">rehabilitation</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058630">Spinal Cord Regeneration</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">insulin-like growth factor-1</Keyword>
<Keyword MajorTopicYN="N">neural stem cell</Keyword>
<Keyword MajorTopicYN="N">spinal cord injury</Keyword>
<Keyword MajorTopicYN="N">transplantation</Keyword>
<Keyword MajorTopicYN="N">treadmill</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25232121</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1529-2401</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
<ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hey1 and Hey2 control the spatial and temporal pattern of mammalian auditory hair cell differentiation downstream of Hedgehog signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>12865-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1494-14.2014</ELocationID>
<Abstract>
<AbstractText>Mechano-sensory hair cells (HCs), housed in the inner ear cochlea, are critical for the perception of sound. In the mammalian cochlea, differentiation of HCs occurs in a striking basal-to-apical and medial-to-lateral gradient, which is thought to ensure correct patterning and proper function of the auditory sensory epithelium. Recent studies have revealed that Hedgehog signaling opposes HC differentiation and is critical for the establishment of the graded pattern of auditory HC differentiation. However, how Hedgehog signaling interferes with HC differentiation is unknown. Here, we provide evidence that in the murine cochlea, Hey1 and Hey2 control the spatiotemporal pattern of HC differentiation downstream of Hedgehog signaling. It has been recently shown that HEY1 and HEY2, two highly redundant HES-related transcriptional repressors, are highly expressed in supporting cell (SC) and HC progenitors (prosensory cells), but their prosensory function remained untested. Using a conditional double knock-out strategy, we demonstrate that prosensory cells form and proliferate properly in the absence of Hey1 and Hey2 but differentiate prematurely because of precocious upregulation of the pro-HC factor Atoh1. Moreover, we demonstrate that prosensory-specific expression of Hey1 and Hey2 and its subsequent graded downregulation is controlled by Hedgehog signaling in a largely FGFR-dependent manner. In summary, our study reveals a critical role for Hey1 and Hey2 in prosensory cell maintenance and identifies Hedgehog signaling as a novel upstream regulator of their prosensory function in the mammalian cochlea. The regulatory mechanism described here might be a broadly applied mechanism for controlling progenitor behavior in the central and peripheral nervous system. </AbstractText>
<CopyrightInformation>Copyright © 2014 the authors 0270-6474/14/3412865-12$15.00/0.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Benito-Gonzalez</LastName>
<ForeName>Ana</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, and Center for Sensory Biology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Doetzlhofer</LastName>
<ForeName>Angelika</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, and Center for Sensory Biology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205 adoetzlhofer@jhmi.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DC 005211</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F32DC013477</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosci</MedlineTA>
<NlmUniqueID>8102140</NlmUniqueID>
<ISSNLinking>0270-6474</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C500943">Atoh1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C120420">Hey1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485778">Hey2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051792">Basic Helix-Loop-Helix Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003051">Cochlea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006198">Hair Cells, Auditory</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062211">Spatio-Temporal Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046509">Tissue Culture Techniques</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4166165 [Available on 03/17/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Atoh1</Keyword>
<Keyword MajorTopicYN="N">Hedgehog signaling</Keyword>
<Keyword MajorTopicYN="N">Hey1</Keyword>
<Keyword MajorTopicYN="N">Hey2</Keyword>
<Keyword MajorTopicYN="N">hair cells</Keyword>
<Keyword MajorTopicYN="N">inner ear cochlea</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043031</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7518</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Coordinated regulation of protein synthesis and degradation by mTORC1.</ArticleTitle>
<Pagination>
<MedlinePgn>440-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13492</ELocationID>
<Abstract>
<AbstractText>Eukaryotic cells coordinately control anabolic and catabolic processes to maintain cell and tissue homeostasis. Mechanistic target of rapamycin complex 1 (mTORC1) promotes nutrient-consuming anabolic processes, such as protein synthesis. Here we show that as well as increasing protein synthesis, mTORC1 activation in mouse and human cells also promotes an increased capacity for protein degradation. Cells with activated mTORC1 exhibited elevated levels of intact and active proteasomes through a global increase in the expression of genes encoding proteasome subunits. The increase in proteasome gene expression, cellular proteasome content, and rates of protein turnover downstream of mTORC1 were all dependent on induction of the transcription factor nuclear factor erythroid-derived 2-related factor 1 (NRF1; also known as NFE2L1). Genetic activation of mTORC1 through loss of the tuberous sclerosis complex tumour suppressors, TSC1 or TSC2, or physiological activation of mTORC1 in response to growth factors or feeding resulted in increased NRF1 expression in cells and tissues. We find that this NRF1-dependent elevation in proteasome levels serves to increase the intracellular pool of amino acids, which thereby influences rates of new protein synthesis. Therefore, mTORC1 signalling increases the efficiency of proteasome-mediated protein degradation for both quality control and as a mechanism to supply substrate for sustained protein synthesis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yinan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nicholatos</LastName>
<ForeName>Justin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dreier</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Translational Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ricoult</LastName>
<ForeName>Stéphane J H</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Widenmaier</LastName>
<ForeName>Scott B</ForeName>
<Initials>SB</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hotamisligil</LastName>
<ForeName>Gökhan S</ForeName>
<Initials>GS</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kwiatkowski</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Translational Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Manning</LastName>
<ForeName>Brendan D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA120964</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA122617</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051266">Nuclear Respiratory Factor 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051780">Sterol Regulatory Element Binding Protein 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576553">mechanistic target of rapamycin complex 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000596">Amino Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046912">Multiprotein Complexes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051266">Nuclear Respiratory Factor 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014176">Protein Biosynthesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011506">Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051780">Sterol Regulatory Element Binding Protein 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096486</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.</ArticleTitle>
<Pagination>
<MedlinePgn>4664-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.405</ELocationID>
<Abstract>
<AbstractText>Increased microRNA-10b (miR-10b) expression in the cancer cells in pancreatic ductal adenocarcinoma (PDAC) is a marker of disease aggressiveness. In the present study, we determined that plasma miR-10b levels are significantly increased in PDAC patients by comparison with normal controls. By gene profiling, we identified potential targets downregulated by miR-10b, including Tat-interacting protein 30 (TIP30). Immunoblotting and luciferase reporter assays confirmed that TIP30 was a direct miR-10b target. Downregulation of TIP30 by miR-10b or siRNA-mediated silencing of TIP30 enhanced epidermal growth factor (EGF)-dependent invasion. The actions of miR-10b were abrogated by expressing a modified TIP30 cDNA resistant to miR-10b. EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extracellular signal-regulated kinase phosphorylation were enhanced by miR-10b, and these effects were mimicked by TIP30 silencing. The actions of EGF in the presence of miR-10b were blocked by EGFR kinase inhibition with erlotinib and by dual inhibition of PI3K (phosphatidylinositol 3'-kinase) and MEK. Moreover, miR-10b, EGF and transforming growth factor-beta (TGF-β) combined to markedly increase cell invasion, and this effect was blocked by the combination of erlotinib and SB505124, a type I TGF-β receptor inhibitor. miR-10b also enhanced the stimulatory effects of EGF and TGF-β on cell migration and epithelial-mesenchymal transition (EMT) and decreased the expression of RAP2A, EPHB2, KLF4 and NF1. Moreover, miR-10b overexpression accelerated pancreatic cancer cell (PCC) proliferation and tumor growth in an orthotopic model. Thus, plasma miR-10b levels may serve as a diagnostic marker in PDAC, whereas intra-tumoral miR-10b promotes PCC proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF-TGF-β cross-talk and enhances the expression of EMT-promoting genes, whereas decreasing the expression of several metastasis-suppressing genes. Therefore, therapeutic targeting of miR-10b in PDAC may interrupt growth-promoting deleterious EGF-TGF-β interactions and antagonize the metastatic process at various levels. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ouyang</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gore</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deitz</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Korc</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R37 CA075059</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37-CA-075059</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C547183">MIRN10 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.-</RegistryNumber>
<NameOfSubstance UI="D000123">Acetyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="C111246">HTATIP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J4T82NDH7E</RegistryNumber>
<NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Chem. 2008 Oct;54(10):1716-24</RefSource>
<PMID Version="1">18719196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2008 Dec 1;14(23):7614-23</RefSource>
<PMID Version="1">19047086</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2009 Jan;19(1):89-102</RefSource>
<PMID Version="1">19050696</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2009 Feb 27;284(9):5731-41</RefSource>
<PMID Version="1">19073608</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 2009 Feb 15;315(4):683-96</RefSource>
<PMID Version="1">19278030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2009 Mar 15;69(6):2195-200</RefSource>
<PMID Version="1">19276373</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2009 May;174(5):1931-9</RefSource>
<PMID Version="1">19349353</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2009 Jul 1;421(1):119-31</RefSource>
<PMID Version="1">19356148</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2009 Jun 12;324(5933):1457-61</RefSource>
<PMID Version="1">19460966</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90</RefSource>
<PMID Version="1">19597153</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2009 Aug;19(8):385-94</RefSource>
<PMID Version="1">19648010</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Prev Res (Phila). 2009 Sep;2(9):807-13</RefSource>
<PMID Version="1">19723895</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2010 Jan 1;126(1):73-80</RefSource>
<PMID Version="1">19551852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2009 Dec 1;27(34):5848-56</RefSource>
<PMID Version="1">19884536</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2010 Mar 12;285(11):7986-94</RefSource>
<PMID Version="1">20075075</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Chem. 2010 Apr;56(4):603-12</RefSource>
<PMID Version="1">20093556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 2010 Apr;28(4):341-7</RefSource>
<PMID Version="1">20351690</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2011;2:513</RefSource>
<PMID Version="1">22027593</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(10):e26815</RefSource>
<PMID Version="1">22053213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Crit Rev Eukaryot Gene Expr. 2011;21(2):115-29</RefSource>
<PMID Version="1">22077151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</RefSource>
<PMID Version="1">22237781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(5):e36753</RefSource>
<PMID Version="1">22586492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2012 Sep 15;131(6):E884-96</RefSource>
<PMID Version="1">22573479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2012 Aug;14(8):793-801</RefSource>
<PMID Version="1">22797597</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg Oncol. 2012 Sep;19(9):3065-71</RefSource>
<PMID Version="1">22322955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2012 Sep 11;22(3):304-17</RefSource>
<PMID Version="1">22975374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2012 Sep 11;22(3):318-30</RefSource>
<PMID Version="1">22975375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS J. 2012 Oct;279(20):3800-12</RefSource>
<PMID Version="1">22883469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Dis. 2012;3:e398</RefSource>
<PMID Version="1">23034333</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2004 Aug;16(4):400-6</RefSource>
<PMID Version="1">15261672</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1986 Jul;83(14):5141-4</RefSource>
<PMID Version="1">3014534</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 1992 Oct;90(4):1352-60</RefSource>
<PMID Version="1">1401070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 1993 Oct;24(10):1127-34</RefSource>
<PMID Version="1">8104858</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 1993 Dec;105(6):1846-56</RefSource>
<PMID Version="1">8253361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surg Oncol Clin N Am. 1998 Jan;7(1):25-41</RefSource>
<PMID Version="1">9443985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 1995 Nov;1(11):1413-20</RefSource>
<PMID Version="1">9815939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biochem. 2005 Aug 1;95(5):918-31</RefSource>
<PMID Version="1">15861394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2006 Mar 1;20(5):515-24</RefSource>
<PMID Version="1">16510870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2006 Apr;6(4):259-69</RefSource>
<PMID Version="1">16557279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2006 May 15;20(10):1218-49</RefSource>
<PMID Version="1">16702400</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 2007 Feb;38(2):293-8</RefSource>
<PMID Version="1">17097132</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Colorectal Dis. 2010 Jun;25(6):687-94</RefSource>
<PMID Version="1">20339854</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2010 Jul 2;285(27):20541-6</RefSource>
<PMID Version="1">20444703</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13450-5</RefSource>
<PMID Version="1">20624982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2010 Sep;10(9):618-29</RefSource>
<PMID Version="1">20720570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Nov 1;70(21):8822-31</RefSource>
<PMID Version="1">20978205</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Sci. 2010 Sep;101(9):1997-2004</RefSource>
<PMID Version="1">20550523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Dec 15;70(24):10224-33</RefSource>
<PMID Version="1">21159643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cancer Res Clin Oncol. 2011 Jan;137(1):73-80</RefSource>
<PMID Version="1">20238226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Mar 18;286(11):9373-81</RefSource>
<PMID Version="1">21252234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 May 1;17(9):2725-33</RefSource>
<PMID Version="1">21220473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 2011 Jul;13(7):601-10</RefSource>
<PMID Version="1">21750654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Exp Med Biol. 2011;700:15-27</RefSource>
<PMID Version="1">21755469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Biol Ther. 2011 Aug 1;12(3):198-207</RefSource>
<PMID Version="1">21613822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 2011 Sep;141(3):1091-101</RefSource>
<PMID Version="1">21699781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2012 Oct;11(10):2138-48</RefSource>
<PMID Version="1">22869556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tumour Biol. 2012 Oct;33(5):1455-65</RefSource>
<PMID Version="1">22528944</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Nov 15;491(7424):399-405</RefSource>
<PMID Version="1">23103869</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Oncol. 2013 Jan;25(1):76-84</RefSource>
<PMID Version="1">23197193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2013 May 2;32(18):2273-81, 2281e.1-12</RefSource>
<PMID Version="1">22733137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2013 May 16;497(7449):383-7</RefSource>
<PMID Version="1">23636329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Signal. 2013 Jul 16;6(284):ra58</RefSource>
<PMID Version="1">23861540</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2013 Oct;23(10):1157-8</RefSource>
<PMID Version="1">23835474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2002 Oct 1;62(19):5611-7</RefSource>
<PMID Version="1">12359775</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2002 Jan;1(3):161-7</RefSource>
<PMID Version="1">12467210</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg. 2003 Jan;237(1):74-85</RefSource>
<PMID Version="1">12496533</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2003 Dec 15;63(24):8763-7</RefSource>
<PMID Version="1">14695192</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Gastroenterol. 2003;38(12):1162-6</RefSource>
<PMID Version="1">14714254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32</RefSource>
<PMID Version="1">15040445</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 Sep 1;17(17):5812-21</RefSource>
<PMID Version="1">21652542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 Sep 1;17(17):5527-9</RefSource>
<PMID Version="1">21816909</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surgery. 2011 Nov;150(5):916-22</RefSource>
<PMID Version="1">22018284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2007 Mar 1;120(5):1046-54</RefSource>
<PMID Version="1">17149698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2007 May 2;297(17):1901-8</RefSource>
<PMID Version="1">17473300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Aug 16;448(7155):807-10</RefSource>
<PMID Version="1">17676035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Surg. 2007 Oct;194(4 Suppl):S84-6</RefSource>
<PMID Version="1">17903452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Oct 11;449(7163):682-8</RefSource>
<PMID Version="1">17898713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2008 Aug 15;123(4):810-6</RefSource>
<PMID Version="1">18528861</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2008 Jul 3;454(7200):56-61</RefSource>
<PMID Version="1">18548003</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8</RefSource>
<PMID Version="1">18663219</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2008 Sep 26;321(5897):1801-6</RefSource>
<PMID Version="1">18772397</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000123">Acetyltransferases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021441">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS560246</OtherID>
<OtherID Source="NLM">PMC3979498</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662814</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>4675-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.69</ELocationID>
<Abstract>
<AbstractText>We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor β (TGFβ) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGFβ-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak(-/-) mouse model expressing middle T antigen in a mammary gland-specific manner (MMTV(Tg/+)Ahnak(-/-)), which showed significantly progressed hyperplasia of mammary glands compared with MMTV(Tg/+)Ahnak(+/+). Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGFβ signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>I H</ForeName>
<Initials>IH</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sohn</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>H J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoon</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Seoul National University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>S-H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Gachon University, Incheon, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>D K</ForeName>
<Initials>DK</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Noh</LastName>
<ForeName>D Y</ForeName>
<Initials>DY</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, School of Medicine, Seoul National University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bae</LastName>
<ForeName>D S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Samsung Hospital, SungKyunKwan University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seong</LastName>
<ForeName>J K</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Seoul National University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bae</LastName>
<ForeName>Y S</ForeName>
<Initials>YS</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences and GT5 program, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489572">Ahnak protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018125">Receptors, Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.11</RegistryNumber>
<NameOfSubstance UI="C091280">TGF-beta type I receptor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 1995 Apr;217(2):258-66</RefSource>
<PMID Version="1">7698224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30</RefSource>
<PMID Version="1">22992590</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1998 Sep 4;281(5382):1509-12</RefSource>
<PMID Version="1">9727977</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1999 May 14;274(20):13900-7</RefSource>
<PMID Version="1">10318799</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Metastasis Rev. 2012 Dec;31(3-4):553-68</RefSource>
<PMID Version="1">22714591</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Virology. 2013 Jan 20;435(2):425-32</RefSource>
<PMID Version="1">23084288</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cardiovasc Res. 2013 Feb 1;97(2):302-10</RefSource>
<PMID Version="1">23042471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2013 Mar 28;32(13):1609-15</RefSource>
<PMID Version="1">22614010</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):287-300</RefSource>
<PMID Version="1">22119658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2005 Mar 15;65(6):2296-302</RefSource>
<PMID Version="1">15781643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Jun 2;125(5):915-28</RefSource>
<PMID Version="1">16751101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2007 Jun;27(12):4488-99</RefSource>
<PMID Version="1">17438144</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2008 Mar 7;283(10):6312-20</RefSource>
<PMID Version="1">18174170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2008 Jul 25;134(2):215-30</RefSource>
<PMID Version="1">18662538</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2009 Apr;21(2):166-76</RefSource>
<PMID Version="1">19237272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2009 Aug;19(8):385-94</RefSource>
<PMID Version="1">19648010</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Cycle. 2011 Jan 1;10(1):57-67</RefSource>
<PMID Version="1">21200143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1112-9</RefSource>
<PMID Version="1">21527583</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Mol Pharmacol. 2011 Jun;4(2):141-53</RefSource>
<PMID Version="1">21222648</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Tissue Res. 2012 Jan;347(1):21-36</RefSource>
<PMID Version="1">21643690</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 1999 Dec;13(15):2161-72</RefSource>
<PMID Version="1">10593863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2000 Feb;24(2):144-52</RefSource>
<PMID Version="1">10655059</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2001 Jun 29;276(26):23253-61</RefSource>
<PMID Version="1">11312263</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2002 May 3;109(3):321-34</RefSource>
<PMID Version="1">12015982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2002 Aug;16(10):1205-16</RefSource>
<PMID Version="1">12153988</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2003 Feb;13(2):65-70</RefSource>
<PMID Version="1">12559756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2004 Jan 23;116(2):235-46</RefSource>
<PMID Version="1">14744434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2004 Jun 18;279(25):26645-53</RefSource>
<PMID Version="1">15033986</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 1987 Jan;6(1):139-44</RefSource>
<PMID Version="1">3034571</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 1992 Mar;12(3):954-61</RefSource>
<PMID Version="1">1312220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5472-6</RefSource>
<PMID Version="1">1608957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 1993 Feb;120(3):625-30</RefSource>
<PMID Version="1">8381120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Cycle. 2012 Jul 1;11(13):2443-51</RefSource>
<PMID Version="1">22659843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res. 2012;14(1):204</RefSource>
<PMID Version="1">22315972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 1996 Dec 5;13(11):2447-57</RefSource>
<PMID Version="1">8957087</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019556">COS Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002522">Cercopithecus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D041681">NIH 3T3 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018125">Receptors, Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051785">Smad Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4180639</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24681955</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4697-708</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.71</ELocationID>
<Abstract>
<AbstractText>Melanoma is one of the most aggressive types of human cancer, characterized by enhanced heterogeneity and resistance to conventional therapy at advanced stages. We and others have previously shown that HEDGEHOG-GLI (HH-GLI) signaling is required for melanoma growth and for survival and expansion of melanoma-initiating cells (MICs). Recent reports indicate that HH-GLI signaling regulates a set of genes typically expressed in embryonic stem cells, including SOX2 (sex-determining region Y (SRY)-Box2). Here we address the function of SOX2 in human melanomas and MICs and its interaction with HH-GLI signaling. We find that SOX2 is highly expressed in melanoma stem cells. Knockdown of SOX2 sharply decreases self-renewal in melanoma spheres and in putative melanoma stem cells with high aldehyde dehydrogenase activity (ALDH(high)). Conversely, ectopic expression of SOX2 in melanoma cells enhances their self-renewal in vitro. SOX2 silencing also inhibits cell growth and induces apoptosis in melanoma cells. In addition, depletion of SOX2 progressively abrogates tumor growth and leads to a significant decrease in tumor-initiating capability of ALDH(high) MICs upon xenotransplantation, suggesting that SOX2 is required for tumor initiation and for continuous tumor growth. We show that SOX2 is regulated by HH signaling and that the transcription factors GLI1 and GLI2, the downstream effectors of HH-GLI signaling, bind to the proximal promoter region of SOX2 in primary melanoma cells. In functional studies, we find that SOX2 function is required for HH-induced melanoma cell growth and MIC self-renewal in vitro. Thus SOX2 is a critical factor for self-renewal and tumorigenicity of MICs and an important mediator of HH-GLI signaling in melanoma. These findings could provide the basis for novel therapeutic strategies based on the inhibition of SOX2 for the treatment of a subset of human melanomas. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Santini</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pietrobono</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pandolfi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Montagnani</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Amico</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Penachioni</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vinci</LastName>
<ForeName>M C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borgognoni</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Plastic Surgery Unit, S.M. Annunziata Hospital-Regional Melanoma Referral Center, Istituto Toscano Tumori, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stecca</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C400551">GLI1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527782">SOX2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.2.1.3</RegistryNumber>
<NameOfSubstance UI="D000444">Aldehyde Dehydrogenase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2012 Oct;30(10):2100-13</RefSource>
<PMID Version="1">22887839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2012 Oct;44(10):1111-6</RefSource>
<PMID Version="1">22941189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 Nov 22;31(47):4898-911</RefSource>
<PMID Version="1">22286766</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mod Pathol. 2013 Jan;26(1):44-53</RefSource>
<PMID Version="1">22899289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2013 Mar;34(3):550-9</RefSource>
<PMID Version="1">23222817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Jun 15;73(12):3796-807</RefSource>
<PMID Version="1">23596255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(7):e69064</RefSource>
<PMID Version="1">23935925</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Sep 1;73(17):5544-55</RefSource>
<PMID Version="1">23867475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2013 Oct;32(40):4737-47</RefSource>
<PMID Version="1">23146903</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Signal. 2013 Dec;25(12):2734-42</RefSource>
<PMID Version="1">24036214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO Mol Med. 2014 Jan;6(1):66-79</RefSource>
<PMID Version="1">24178749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2013 Dec;31(12):2607-19</RefSource>
<PMID Version="1">23940081</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2014 Apr;35(4):942-50</RefSource>
<PMID Version="1">24325912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Aspects Med. 2014 Oct;39:33-49</RefSource>
<PMID Version="1">24145241</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Neurosci. 2003 Jan;6(1):21-7</RefSource>
<PMID Version="1">12469128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2003 Jan 1;17(1):126-40</RefSource>
<PMID Version="1">12514105</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuron. 2003 Aug 28;39(5):749-65</RefSource>
<PMID Version="1">12948443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuron. 2003 Sep 11;39(6):937-50</RefSource>
<PMID Version="1">12971894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1997 Jul;124(13):2537-52</RefSource>
<PMID Version="1">9216996</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2005 Jan 15;19(2):214-23</RefSource>
<PMID Version="1">15625189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2005 May 6;121(3):465-77</RefSource>
<PMID Version="1">15882627</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2005 May 15;65(10):4320-33</RefSource>
<PMID Version="1">15899824</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2005 Oct 15;65(20):9328-37</RefSource>
<PMID Version="1">16230395</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2006 May 12;281(19):13374-81</RefSource>
<PMID Version="1">16547000</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Aug 25;126(4):663-76</RefSource>
<PMID Version="1">16904174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2007 Mar;43(5):935-46</RefSource>
<PMID Version="1">17320377</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900</RefSource>
<PMID Version="1">17392427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2007 Jun;9(6):625-35</RefSource>
<PMID Version="1">17515932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Nov 30;131(5):861-72</RefSource>
<PMID Version="1">18035408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19879-84</RefSource>
<PMID Version="1">18077420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2007 Dec 21;318(5858):1917-20</RefSource>
<PMID Version="1">18029452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2008 Jan 17;451(7176):345-9</RefSource>
<PMID Version="1">18202660</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2009 Mar 18;28(6):663-76</RefSource>
<PMID Version="1">19214186</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2009 Jan;27(1):165-74</RefSource>
<PMID Version="1">18927476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2009 Jan;27(1):40-8</RefSource>
<PMID Version="1">18948646</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2009 Aug 15;347(1-2):70-8</RefSource>
<PMID Version="1">19567251</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2009 Sep;27(9):2175-84</RefSource>
<PMID Version="1">19591226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2009 Oct 1;122(Pt 19):3502-10</RefSource>
<PMID Version="1">19723802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Neurosci. 2009 Oct;12(10):1248-56</RefSource>
<PMID Version="1">19734891</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2009 Nov;41(11):1238-42</RefSource>
<PMID Version="1">19801978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Chromosomes Cancer. 2010 Jan;49(1):9-16</RefSource>
<PMID Version="1">19787784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2010 Feb;176(2):903-13</RefSource>
<PMID Version="1">20042675</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2010 Jul;130(7):1877-86</RefSource>
<PMID Version="1">20376064</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2010 Jul 1;466(7302):133-7</RefSource>
<PMID Version="1">20596026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Differ. 2010 Aug;17(8):1345-53</RefSource>
<PMID Version="1">20489730</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Aug 4;29(15):2659-74</RefSource>
<PMID Version="1">20581802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Aug 4;29(15):2646-58</RefSource>
<PMID Version="1">20581804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2010 Aug 4;102(15):1148-59</RefSource>
<PMID Version="1">20660365</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2010 Dec;130(12):2799-808</RefSource>
<PMID Version="1">20739950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2010 Dec;28(12):2141-50</RefSource>
<PMID Version="1">20945330</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Genomics. 2011;12:11</RefSource>
<PMID Version="1">21211035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9</RefSource>
<PMID Version="1">21282657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Dermatol. 2011 Apr;20(4):339-45</RefSource>
<PMID Version="1">21410764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Apr 15;71(8):3098-109</RefSource>
<PMID Version="1">21393506</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Invest. 2011 May;91(5):647-64</RefSource>
<PMID Version="1">21445060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(4):e18784</RefSource>
<PMID Version="1">21526207</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Stem Cell. 2011 May 6;8(5):552-65</RefSource>
<PMID Version="1">21549329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2011 Jun;43(6):607-11</RefSource>
<PMID Version="1">21532573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>ACS Chem Biol. 2011 Jun 17;6(6):573-81</RefSource>
<PMID Version="1">21344919</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Stem Cell. 2011 Oct 4;9(4):317-29</RefSource>
<PMID Version="1">21982232</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Invest. 2011 Dec;91(12):1796-804</RefSource>
<PMID Version="1">21931300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2012 Jan;139(2):397-410</RefSource>
<PMID Version="1">22186729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncotarget. 2012 Jan;3(1):22-30</RefSource>
<PMID Version="1">22289880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Invest. 2012 Mar;92(3):362-70</RefSource>
<PMID Version="1">22184093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO Mol Med. 2012 Mar;4(3):218-33</RefSource>
<PMID Version="1">22294553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 Mar 15;31(11):1354-65</RefSource>
<PMID Version="1">21822303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ther. 2012 May;20(5):1056-62</RefSource>
<PMID Version="1">22354376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 May 3;31(18):2270-82</RefSource>
<PMID Version="1">21927024</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(5):e36762</RefSource>
<PMID Version="1">22675422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2012 Aug;40(14):6725-40</RefSource>
<PMID Version="1">22561374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2012 Sep;30(9):1808-18</RefSource>
<PMID Version="1">22730244</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000444">Aldehyde Dehydrogenase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055748">SOXB1 Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4180644</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25062973</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-5028</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>86</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Plant molecular biology</Title>
<ISOAbbreviation>Plant Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The PSI family of nuclear proteins is required for growth in arabidopsis.</ArticleTitle>
<Pagination>
<MedlinePgn>289-302</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11103-014-0229-2</ELocationID>
<Abstract>
<AbstractText>PSI1 was identified as a gene that is co-expressed with the phytosulfokine (PSK) receptor genes PSKR1 and PSKR2 in Arabidopsis thaliana. It represents a plant-specific protein family of unknown function with six members in two clades. Clade 1 members PSI1, PSI2 and PSI3 were characterized in this study. All three are nuclear localized. A predicted N-terminal myristoylation site was functionally analyzed. psi1-1 seedlings have shorter roots and hypocotyls. This growth-retarded phenotype was restored by expression of either wildtype PSI1 or PSI1 G2A with a mutated myristate attachment site in the psi1-1 background suggesting that myristate attachment was not essential for PSI1 function. psi2-1 and psi3-1 seedlings have a wildtype phenotype but overexpression of PSI1 or PSI2 promoted seedling growth. PSI2 activity appears to be linked to PSK signaling as psi2-1 and psi2-1 psi3-1 roots are unresponsive to PSK. PSI3 functions in vegetative plant growth synergistic with PSI2. psi3-1 and particularly psi2-1 psi3-1 rosettes are small. Overexpression of PSI3 promoted plant growth indicating that PSI3 is limiting at the vegetative stage. Severe dwarfism of psi2-1 psi3-1 plants results from reduced cell growth and proliferation and premature leaf growth arrest. Plants further display reduced fertility and premature senescence revealing a crucial function of PSI proteins in vegetative growth and reproduction. Psi single and double knock-out plants have less and PSI3ox plants have more starch compared to wt and growth retardation is partially rescued by sucrose. Our studies reveal a crucial function of the nuclear-localized PSI proteins in growth possibly through metabolic control.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stührwohldt</LastName>
<ForeName>Nils</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Plant Developmental Biology and Plant Physiology, University of Kiel, Am Botanischen Garten 5, 24118, Kiel, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hartmann</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dahlke</LastName>
<ForeName>Renate I</ForeName>
<Initials>RI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oecking</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sauter</LastName>
<ForeName>Margret</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Plant Mol Biol</MedlineTA>
<NlmUniqueID>9106343</NlmUniqueID>
<ISSNLinking>0167-4412</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029681">Arabidopsis Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9005-25-8</RegistryNumber>
<NameOfSubstance UI="D013213">Starch</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017360">Arabidopsis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029681">Arabidopsis Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003001">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004843">Epistasis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018506">Gene Expression Regulation, Plant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055786">Gene Knockout Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013213">Starch</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25092201</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-5028</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>86</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Plant molecular biology</Title>
<ISOAbbreviation>Plant Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Transcriptomic profiling revealed an important role of cell wall remodeling and ethylene signaling pathway during salt acclimation in Arabidopsis.</ArticleTitle>
<Pagination>
<MedlinePgn>303-17</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11103-014-0230-9</ELocationID>
<Abstract>
<AbstractText>Plants can successfully improve their resistance to previously lethal salinity stress by a short exposure to low levels of salt stress, a process known as salt acclimation (SA). In spite of its fundamental significance in theoretical study and agricultural practice, the molecular mechanisms underlying plant SA remain elusive. In this study, we found that salt acclimated Arabidopsis young seedlings can survive subsequent 200 mM NaCl stress. RNA-seq was performed to analyze the genome-wide transcriptional response under SA conditions. Among 518 differentially expressed genes (DEGs) under SA, 366 up-regulated genes were enriched for cell wall biosynthesis, osmoregulation, oxidative stress, or transcription factors. Seven DEGs participate in the synthesis of lignin and 24 DEGs encode plant cell wall proteins, suggesting the importance of cell wall remodeling under SA. Furthermore, in comparison to non-acclimated salt stress, 228 of 245 DEGs were repressed by acclimated salt stress, including many genes related to ethylene biosynthesis and signaling pathway. In addition, MAPK6, a major component of the ethylene signaling pathway, was found to play a crucial role in SA. Our transcriptomic analysis has provided important insight on the roles of transcription factors, cell wall remodeling, and the ethylene biosynthesis and signaling pathways during SA in Arabidopsis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Xiaoyan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>College of Life Sciences, Shandong Normal University, Wenhua East Road 88, Jinan, 250014, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Zenglan</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Xiaofeng</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Jiajia</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Chunyun</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Yanxiu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Changle</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Plant Mol Biol</MedlineTA>
<NlmUniqueID>9106343</NlmUniqueID>
<ISSNLinking>0167-4412</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005030">Ethylenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7647-14-5</RegistryNumber>
<NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>91GW059KN7</RegistryNumber>
<NameOfSubstance UI="C036216">ethylene</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048053">Mitogen-Activated Protein Kinase 6</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000064">Acclimatization</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017360">Arabidopsis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053898">Biosynthetic Pathways</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002473">Cell Wall</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005030">Ethylenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048053">Mitogen-Activated Protein Kinase 6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009997">Osmotic Pressure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055049">Salt-Tolerance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012965">Sodium Chloride</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25139229</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-5028</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>86</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Plant molecular biology</Title>
<ISOAbbreviation>Plant Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Arabidopsis thaliana calmodulin-like protein CML24 regulates pollen tube growth by modulating the actin cytoskeleton and controlling the cytosolic Ca(2+) concentration.</ArticleTitle>
<Pagination>
<MedlinePgn>225-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11103-014-0220-y</ELocationID>
<Abstract>
<AbstractText>Cytosolic free calcium ([Ca(2+)]cyt), which is essential during pollen germination and pollen tube growth, can be sensed by calmodulin-like proteins (CMLs). The Arabidopsis thaliana genome encodes over 50 CMLs, the physiological role(s) of most of which are unknown. Here we show that the gene AtCML24 acts as a regulator of pollen germination and pollen tube extension, since the pollen produced by loss-of-function mutants germinated less rapidly than that of wild-type (WT) plants, the rate of pollen tube extension was slower, and the final length of the pollen tube was shorter. The [Ca(2+)]cyt within germinated pollen and extending pollen tubes produced by the cml24 mutant were higher than their equivalents in WT plants, and pollen tube extension was less sensitive to changes in external [K(+)] and [Ca(2+)]. The pollen and pollen tubes produced by cml24 mutants were characterized by a disorganized actin cytoskeleton and lowered sensitivity to the action of latrunculin B. The observations support an interaction between CML24 and [Ca(2+)]cyt and an involvement of CML24 in actin organization, thereby affecting pollen germination and pollen tube elongation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Xue</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Plant Cell Engineering and Germplasm Innovation, Ministry of Education, School of Life Science, Shandong University, Jinan, 250100, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Shuang-Shuang</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Mei</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qiao</LastName>
<ForeName>Zhu</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bao</LastName>
<ForeName>Chan-Chan</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Plant Mol Biol</MedlineTA>
<NlmUniqueID>9106343</NlmUniqueID>
<ISSNLinking>0167-4412</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029681">Arabidopsis Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C106145">TCH2 protein, Arabidopsis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017360">Arabidopsis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029681">Arabidopsis Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002135">Calcium-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003600">Cytosol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018525">Germination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053205">Pollen Tube</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25237743</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>08</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1543-3641</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>27</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology</Title>
<ISOAbbreviation>Cogn Behav Neurol</ISOAbbreviation>
</Journal>
<ArticleTitle>Impaired visuospatial transformation but intact sequence processing in Parkinson disease.</ArticleTitle>
<Pagination>
<MedlinePgn>130-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/WNN.0000000000000032</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We examined whether visuospatial deficits in Parkinson disease (PD) can be explained by a domain-general, nonspatial impairment in the sequencing or serial chaining of mental operations.</AbstractText>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">PD has been shown to be associated with impaired visuospatial processing, but the mechanisms of this impairment remain unclear.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Thirteen patients with PD and 20 age-matched, neurologically normal controls performed a visuospatial grid navigation task requiring sequential spatial transformations. The participants also performed a control task of serial number subtraction designed to assess their nonvisuospatial sequencing. The tasks were matched in structure and difficulty.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The patients were impaired on the visuospatial task but not in serial number subtraction. This finding suggests that visuospatial processing impairments in PD do not derive from a general impairment affecting sequencing or serial chaining.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We argue that visuospatial deficits in PD result from impairments to spatial transformation routines involved in the computation of mappings between spatial locations. These routines are mediated by dopaminergic pathways linking the basal ganglia, prefrontal cortex, supplementary motor area, and parietal cortex.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leek</LastName>
<ForeName>E Charles</ForeName>
<Initials>EC</Initials>
<AffiliationInfo>
<Affiliation>*Wolfson Centre for Clinical and Cognitive Neuroscience, School of Psychology ‡School of Medical Sciences, Bangor University, Bangor, United Kingdom †Department of Psychology, Swansea University, Swansea, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kerai</LastName>
<ForeName>Julie H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnston</LastName>
<ForeName>Stephen J</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hindle</LastName>
<ForeName>John V</ForeName>
<Initials>JV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bracewell</LastName>
<ForeName>R Martyn</ForeName>
<Initials>RM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cogn Behav Neurol</MedlineTA>
<NlmUniqueID>101167278</NlmUniqueID>
<ISSNLinking>1543-3633</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006113">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008570">Memory, Short-Term</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009044">Motor Cortex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010296">Parietal Lobe</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010364">Pattern Recognition, Visual</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017397">Prefrontal Cortex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011597">Psychomotor Performance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D013028">Space Perception</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013850">Thinking</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25220212</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination.</ArticleTitle>
<Pagination>
<MedlinePgn>478-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.08.009</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00303-3</ELocationID>
<Abstract>
<AbstractText>Systems biological analysis of immunity to the trivalent inactivated influenza vaccine (TIV) in humans revealed a correlation between early expression of TLR5 and the magnitude of the antibody response. Vaccination of Trl5(-/-) mice resulted in reduced antibody titers and lower frequencies of plasma cells, demonstrating a role for TLR5 in immunity to TIV. This was due to a failure to sense host microbiota. Thus, antibody responses in germ-free or antibiotic-treated mice were impaired, but restored by oral reconstitution with a flagellated, but not aflagellated, strain of E. coli. TLR5-mediated sensing of flagellin promoted plasma cell differentiation directly and by stimulating lymph node macrophages to produce plasma cell growth factors. Finally, TLR5-mediated sensing of the microbiota also impacted antibody responses to the inactivated polio vaccine, but not to adjuvanted vaccines or the live-attenuated yellow fever vaccine. These results reveal an unappreciated role for gut microbiota in promoting immunity to vaccination. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Jason Z</ForeName>
<Initials>JZ</Initials>
<AffiliationInfo>
<Affiliation>Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ravindran</LastName>
<ForeName>Rajesh</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chassaing</LastName>
<ForeName>Benoit</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Center for Inflammation, Immunity, and Infection, Georgia State University, Atlanta, GA 30302, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carvalho</LastName>
<ForeName>Frederic A</ForeName>
<Initials>FA</Initials>
<AffiliationInfo>
<Affiliation>Center for Inflammation, Immunity, and Infection, Georgia State University, Atlanta, GA 30302, USA; INSERM U1107, Universite d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maddur</LastName>
<ForeName>Mohan S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bower</LastName>
<ForeName>Maureen</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>National Gnotobiotic Rodent Resource Center, University of North Carolina, Chapel Hill, NC 27514, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hakimpour</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gill</LastName>
<ForeName>Kiran P</ForeName>
<Initials>KP</Initials>
<AffiliationInfo>
<Affiliation>Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakaya</LastName>
<ForeName>Helder I</ForeName>
<Initials>HI</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, School of Medicine, Emory University, Atlanta, GA 30329, USA; Department of Clinical and Toxicological Analyses, Institute of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yarovinsky</LastName>
<ForeName>Felix</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sartor</LastName>
<ForeName>R Balfour</ForeName>
<Initials>RB</Initials>
<AffiliationInfo>
<Affiliation>National Gnotobiotic Rodent Resource Center, University of North Carolina, Chapel Hill, NC 27514, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gewirtz</LastName>
<ForeName>Andrew T</ForeName>
<Initials>AT</Initials>
<AffiliationInfo>
<Affiliation>Center for Inflammation, Immunity, and Infection, Georgia State University, Atlanta, GA 30302, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pulendran</LastName>
<ForeName>Bali</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA; Department of Pathology, School of Medicine, Emory University, Atlanta, GA 30329, USA. Electronic address: bpulend@emory.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI085263</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI100663-02</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK083890</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK099071</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HHSN272201400004C</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 DK34987</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P40 OD010995</GrantID>
<Acronym>OD</Acronym>
<Agency>NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 AI048638</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 DK057665</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37AI48638</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37DK057665</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U19 AI057266</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U19 AI090023</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U19AI057266</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U19AI090023</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54AI057157</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051198">Toll-Like Receptor 5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022341">Yellow Fever Vaccine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>12777-81-0</RegistryNumber>
<NameOfSubstance UI="D005408">Flagellin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Immunity. 2014 Sep 18;41(3):349-51</RefSource>
<PMID Version="1">25238091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Immunol. 2014 Oct;14(10):650-1</RefSource>
<PMID Version="1">25234145</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000914">Antibodies, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000917">Antibody Formation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004926">Escherichia coli</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005408">Flagellin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007156">Immunologic Memory</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007252">Influenza Vaccines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007251">Influenza, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008198">Lymph Nodes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064307">Microbiota</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010950">Plasma Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011054">Poliovirus Vaccine, Inactivated</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051198">Toll-Like Receptor 5</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022341">Yellow Fever Vaccine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS626317 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4169736 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25238093</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>Development, differentiation, and diversity of innate lymphoid cells.</ArticleTitle>
<Pagination>
<MedlinePgn>354-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.09.005</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00316-1</ELocationID>
<Abstract>
<AbstractText>Recent years have witnessed the discovery of an unprecedented complexity in innate lymphocyte lineages, now collectively referred to as innate lymphoid cells (ILCs). ILCs are preferentially located at barrier surfaces and are important for protection against pathogens and for the maintenance of organ homeostasis. Inappropriate activation of ILCs has been linked to the pathogenesis of inflammatory and autoimmune disorders. Recent evidence suggests that ILCs can be grouped into two separate lineages, cytotoxic ILCs represented by conventional natural killer (cNK) cells and cytokine-producing helper-like ILCs (i.e., ILC1s, ILC2s, ILC3s). We will focus here on current work in humans and mice that has identified core transcriptional circuitry required for the commitment of lymphoid progenitors to the ILC lineage. The striking similarities in transcriptional control of ILC and T cell lineages reveal important insights into the evolution of transcriptional programs required to protect multicellular organisms against infections and to fortify barrier surfaces. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Diefenbach</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Research Centre for Immunology and Immunotherapy, University of Mainz Medical Centre, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany; Institute of Medical Microbiology and Hygiene, University of Mainz Medical Centre, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany. Electronic address: diefenbach@uni-mainz.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Colonna</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid, St. Louis, MO 63110, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Koyasu</LastName>
<ForeName>Shigeo</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory for Immune Cell Systems, RIKEN Research Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan; Department of Microbiology and Immunology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1U01AI095542</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DE021255</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01DE021255</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA167192</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21CA16719</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 AI095542</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019070">Cell Lineage</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006377">T-Lymphocytes, Helper-Inducer</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019108">Tight Junctions</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS627210 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4171710 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25238097</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression.</ArticleTitle>
<Pagination>
<MedlinePgn>427-39</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.08.012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00306-9</ELocationID>
<Abstract>
<AbstractText>Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead box protein P1 (Foxp1), which prevents CD8⁺ T cells from proliferating and upregulating Granzyme-B and interferon-γ in response to tumor antigens. Accordingly, Foxp1-deficient lymphocytes induced rejection of incurable tumors and promoted protection against tumor rechallenge. Mechanistically, Foxp1 interacted with the transcription factors Smad2 and Smad3 in preactivated CD8⁺ T cells in response to microenvironmental transforming growth factor-β (TGF-β), and was essential for its suppressive activity. Therefore, Smad2 and Smad3-mediated c-Myc repression requires Foxp1 expression in T cells. Furthermore, Foxp1 directly mediated TGF-β-induced c-Jun transcriptional repression, which abrogated T cell activity. Our results unveil a fundamental mechanism of T cell unresponsiveness different from anergy or exhaustion, driven by TGF-β signaling on tumor-associated lymphocytes undergoing Foxp1-dependent transcriptional regulation.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stephen</LastName>
<ForeName>Tom L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rutkowski</LastName>
<ForeName>Melanie R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Allegrezza</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perales-Puchalt</LastName>
<ForeName>Alfredo</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tesone</LastName>
<ForeName>Amelia J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Svoronos</LastName>
<ForeName>Nikolaos</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Jenny M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sarmin</LastName>
<ForeName>Fahmida</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borowsky</LastName>
<ForeName>Mark E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Helen F. Graham Cancer Center, Christiana Care Health System, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tchou</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104-1693, USA; Rena Rowan Breast Center, University of Pennsylvania, Philadelphia, PA 19104-1693, USA; Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-1693, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Conejo-Garcia</LastName>
<ForeName>Jose R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: jrconejo@wistar.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA010815</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA010815</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA124515</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA157664</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA178687</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA124515</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA157664</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32CA009171</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54 CA151662</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C432917">Foxp1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489428">Myc protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051899">Smad2 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497783">Smad2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051900">Smad3 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497791">Smad3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="D053804">Granzymes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Immunity. 2014 Sep 18;41(3):345-7</RefSource>
<PMID Version="1">25238089</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019264">Adoptive Transfer</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000951">Antigens, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053804">Granzymes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048031">JNK Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008213">Lymphocyte Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016271">Proto-Oncogene Proteins c-myc</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051899">Smad2 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051900">Smad3 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000637">transplantation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS626648 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4174366 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25143441</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The survival and differentiation of pro-B and pre-B cells in the bone marrow is dependent on IL-7Rα Tyr449.</ArticleTitle>
<Pagination>
<MedlinePgn>3446-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1302925</ELocationID>
<Abstract>
<AbstractText>IL-7 is critical for murine T and B cell development and survival and plays a significant role in lymphoblastic leukemia in both humans and mice. We evaluated the role of the IL-7Rα Tyr(449) cytoplasmic SH2-binding motif in IL-7-mediated B cell development using a knock-in mouse with a Tyr to Phe mutation (IL-7Rα(449F/449F) mouse). IL-7Rα(449F/449F) and IL-7Rα(-/-) mice showed no defect in the number of pre-pro-B cells, although IL-7Rα(449F/449F) mice had decreased Ebf1 in pre-pro-B cells and impairment in B cell-committed CLPs. We identified that IL-7Rα Tyr(449) was critical for both pro-B and pre-B stages of development in the bone marrow. IL-7Rα(449F/449F) and IL-7Rα(-/-) mice had comparable precursor B cell defects, indicating that signaling from the IL-7Rα required this motif. Although the defect in IL-7Rα(449F/449F) pro-B cells was associated with loss of STAT5 activation and diminished expression of Mcl1, this was not rescued by overexpression of Bcl-2. IL-7Rα(449F/449F) and IL-7Rα(-/-) pre-B cells also showed defective cyto-Igμ and CD25 expression, associated with reduced levels of Rag1, Rag2, and Irf4. Pre-B cells from IL-7Rα(449F/449F) mice also failed to proliferate, perhaps as a result of the failure to rearrange Igμ. Our data suggest that IL-7Rα Tyr(449) was essential for IL-7Rα signaling in bone marrow B cell development and survival. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Patton</LastName>
<ForeName>Daniel T</ForeName>
<Initials>DT</Initials>
<AffiliationInfo>
<Affiliation>Infection, Inflammation and Immunity Research Group, Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Plumb</LastName>
<ForeName>Adam W</ForeName>
<Initials>AW</Initials>
<AffiliationInfo>
<Affiliation>Infection, Inflammation and Immunity Research Group, Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abraham</LastName>
<ForeName>Ninan</ForeName>
<Initials>N</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-2747-1246</Identifier>
<AffiliationInfo>
<Affiliation>Infection, Inflammation and Immunity Research Group, Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; and Department of Zoology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada ninan@mail.ubc.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP-126060</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP-84532</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508018">Il2ra protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007148">Immunoglobulin mu-Chains</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053645">Interleukin-2 Receptor alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C579094">Mcl1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499308">Rag2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020395">Receptors, Interleukin-7</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050799">STAT5 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C094531">interferon regulatory factor-4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C415350">interleukin-7 receptor, alpha chain</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>114100-40-2</RegistryNumber>
<NameOfSubstance UI="C052617">Bcl2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>128559-51-3</RegistryNumber>
<NameOfSubstance UI="C064658">RAG-1 protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>42HK56048U</RegistryNumber>
<NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019943">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001853">Bone Marrow</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015322">Gene Rearrangement, B-Lymphocyte</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007148">Immunoglobulin mu-Chains</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050835">Interferon Regulatory Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053645">Interleukin-2 Receptor alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020125">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054448">Precursor Cells, B-Lymphoid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020395">Receptors, Interleukin-7</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050799">STAT5 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014443">Tyrosine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25156366</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.</ArticleTitle>
<Pagination>
<MedlinePgn>3278-87</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1400205</ELocationID>
<Abstract>
<AbstractText>Psoriasis is a chronic autoimmune disease affecting the skin and characterized by aberrant keratinocyte proliferation and function. Immune cells infiltrate the skin and release proinflammatory cytokines that play important roles in psoriasis. The Th17 network, including IL-23 and IL-22, has recently emerged as a critical component in the pathogenesis of psoriasis. IL-22 and IL-23 signaling is dependent on the JAK family of protein tyrosine kinases, making JAK inhibition an appealing strategy for the treatment of psoriasis. In this study, we report the activity of SAR-20347, a small molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members. In cellular assays, SAR-20347 dose dependently (1 nM-10 μM) inhibited JAK1- and/or TYK2-dependent signaling from the IL-12/IL-23, IL-22, and IFN-α receptors. In vivo, TYK2 mutant mice or treatment of wild-type mice with SAR-20347 significantly reduced IL-12-induced IFN-γ production and IL-22-dependent serum amyloid A to similar extents, indicating that, in these models, SAR-20347 is probably acting through inhibition of TYK2. In an imiquimod-induced psoriasis model, the administration of SAR-20347 led to a striking decrease in disease pathology, including reduced activation of keratinocytes and proinflammatory cytokine levels compared with both TYK2 mutant mice and wild-type controls. Taken together, these data indicate that targeting both JAK1- and TYK2-mediated cytokine signaling is more effective than TYK2 inhibition alone in reducing psoriasis pathogenesis. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Works</LastName>
<ForeName>Melissa G</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Fangfang</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Catherine C</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yiu</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shew</LastName>
<ForeName>Kenneth</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tran</LastName>
<ForeName>Thanh-Thuy</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dunlap</LastName>
<ForeName>Nahoko</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lam</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mitchell</LastName>
<ForeName>Tim</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Sareum, Cambridge CB22 3FX, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reader</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Sareum, Cambridge CB22 3FX, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stein</LastName>
<ForeName>Paul L</ForeName>
<Initials>PL</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Andrea</LastName>
<ForeName>Annalisa</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Biosciences Division, Center for Immunology and Infectious Diseases, SRI International, Menlo Park, CA 94025; and annalisa.dandrea@sri.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R21 AI095990</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 AI096042</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21A1095990</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21AI096042</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C573415">IFNG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507905">Jak1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000685">Serum Amyloid A Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C415368">interleukin-22</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>187348-17-0</RegistryNumber>
<NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.010.2</RegistryNumber>
<NameOfSubstance UI="C507904">JAK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053634">TYK2 Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C070139">TYK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C499356">Tyk2 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003872">Dermatitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018664">Interleukin-12</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020381">Interleukin-17</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053759">Interleukin-23</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007378">Interleukins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053613">Janus Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008817">Mice, Mutant Strains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011565">Psoriasis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000685">Serum Amyloid A Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053634">TYK2 Kinase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS616906 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170002 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172483</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation.</ArticleTitle>
<Pagination>
<MedlinePgn>3344-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1400534</ELocationID>
<Abstract>
<AbstractText>The Notch signaling pathway plays a substantial role in human NK cell development. However, the role of Notch on killer Ig-like receptor (KIR) upregulation and acquisition of effector function has not been explored. To evaluate how Notch influences terminal differentiation, cord blood-derived NK cells or sorted peripheral blood NK cells were cultured with IL-15 for 7 d with inhibitory or activating Notch signals. Inhibition of Notch signaling significantly decreased KIR expression, whereas activation enhanced it. Overexpression of activated Notch on cord blood-derived NK cells resulted in a 2-fold increase in KIR expression, indicating that Notch signaling plays a direct, cell-intrinsic role in KIR regulation. Moreover, Notch-mediated KIR expression on NK cells is regulated through cis inhibition by delta-like ligand 1. Notch signaling also enhances CD16 upregulation that precedes KIR expression. Concomitant with the upregulation of KIR and CD16, Notch signaling induces increased cytolytic effector capacity and cytokine secretion, even in posttransplant samples in which NK cell function is inherently defective. Given these attributes of Notch signaling, we propose that Notch agonists may enhance NK cell maturation and tumor killing in a posttransplant setting. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Felices</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ankarlo</LastName>
<ForeName>Dave E M</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lenvik</LastName>
<ForeName>Todd R</ForeName>
<Initials>TR</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nelson</LastName>
<ForeName>Heather H</ForeName>
<Initials>HH</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blazar</LastName>
<ForeName>Bruce R</ForeName>
<Initials>BR</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Verneris</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Jeffrey S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455 mille011@umn.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>2T32HL007062-36</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA111412</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA65493</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA065493</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA111412</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C512941">DLK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C428200">FCGR3B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054340">Receptors, KIR</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058851">GPI-Linked Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036341">Intercellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020014">K562 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017452">Receptors, IgG</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054340">Receptors, KIR</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051880">Receptors, Notch</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS619145 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170052 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172492</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cutting edge: CD8+ recent thymic emigrants exhibit increased responses to low-affinity ligands and improved access to peripheral sites of inflammation.</ArticleTitle>
<Pagination>
<MedlinePgn>3262-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1401870</ELocationID>
<Abstract>
<AbstractText>To explore the TCR sensitivity of recent thymic emigrants (RTEs), we triggered T cells with altered peptide ligands (APLs). Upon peptide stimulation in vitro, RTEs exhibited increased TCR signal transduction, and following infection in vivo with APL-expressing bacteria, CD8 RTEs expanded to a greater extent in response to low-affinity Ags than did their mature T cell counterparts. RTEs skewed to short-lived effector cells in response to all APLs but also were characterized by diminished cytokine production. RTEs responding to infection expressed increased levels of VLA-4, with consequent improved entry into inflamed tissue and pathogen clearance. These positive outcomes were offset by the capacity of RTEs to elicit autoimmunity. Overall, salient features of CD8 RTE biology should inform strategies to improve neonatal vaccination and therapies for cancer and HIV, because RTEs make up a large proportion of the T cells in lymphodepleted environments. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Berkley</LastName>
<ForeName>Amy M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, University of Washington, Seattle, WA 98109.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fink</LastName>
<ForeName>Pamela J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, University of Washington, Seattle, WA 98109 pfink@uw.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI06677</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AI064318</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AI064318</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 AI106677</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM007270</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM07270</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000941">Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039041">Integrin alpha4beta1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000941">Antigens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039041">Integrin alpha4beta1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011948">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013950">Thymus Gland</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS620360 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170019 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172494</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis.</ArticleTitle>
<Pagination>
<MedlinePgn>3755-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1302470</ELocationID>
<Abstract>
<AbstractText>Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with progressive fibrosis and death within 2-3 y of diagnosis. IPF incidence and prevalence rates are increasing annually with few effective treatments available. Inhibition of IL-6 results in the attenuation of pulmonary fibrosis in mice. It is unclear whether this is due to blockade of classical signaling, mediated by membrane-bound IL-6Rα, or trans signaling, mediated by soluble IL-6Rα (sIL-6Rα). Our study assessed the role of sIL-6Rα in IPF. We demonstrated elevations of sIL-6Rα in IPF patients and in mice during the onset and progression of fibrosis. We demonstrated that protease-mediated cleavage from lung macrophages was important in production of sIL-6Rα. In vivo neutralization of sIL-6Rα attenuated pulmonary fibrosis in mice as seen by reductions in myofibroblasts, fibronectin, and collagen in the lung. In vitro activation of IL-6 trans signaling enhanced fibroblast proliferation and extracellular matrix protein production, effects relevant in the progression of pulmonary fibrosis. Taken together, these findings demonstrate that the production of sIL-6Rα from macrophages in the diseased lung contributes to IL-6 trans signaling that in turn influences events crucial in pulmonary fibrosis. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Le</LastName>
<ForeName>Thanh-Thuy T</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Karmouty-Quintana</LastName>
<ForeName>Harry</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Melicoff</LastName>
<ForeName>Ernestina</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Le</LastName>
<ForeName>Thanh-Truc T</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weng</LastName>
<ForeName>Tingting</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Ning-Yuan</ForeName>
<Initials>NY</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pedroza</LastName>
<ForeName>Mesias</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030; Biology of Inflammation Center, Section of Immunology, Allergy and Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Davies</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Philip</LastName>
<ForeName>Kemly</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Molina</LastName>
<ForeName>Jose</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Fayong</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>George</LastName>
<ForeName>Anuh T</ForeName>
<Initials>AT</Initials>
<AffiliationInfo>
<Affiliation>Biology of Inflammation Center, Section of Immunology, Allergy and Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garcia-Morales</LastName>
<ForeName>Luis J</ForeName>
<Initials>LJ</Initials>
<AffiliationInfo>
<Affiliation>Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX 77030; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bunge</LastName>
<ForeName>Raquel R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo>
<Affiliation>Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX 77030; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bruckner</LastName>
<ForeName>Brian A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo>
<Affiliation>Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX 77030; and Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX 77030.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Loebe</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX 77030; and Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX 77030.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seethamraju</LastName>
<ForeName>Harish</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX 77030.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Agarwal</LastName>
<ForeName>Sandeep K</ForeName>
<Initials>SK</Initials>
<AffiliationInfo>
<Affiliation>Biology of Inflammation Center, Section of Immunology, Allergy and Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blackburn</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX 77030; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030; michael.r.blackburn@uth.tmc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 HL114457</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01-HL114457</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL070952</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-HL070952</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508603">IL6R protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-34-5</RegistryNumber>
<NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Lung Cell Mol Physiol. 2010 Jun;298(6):L715-31</RefSource>
<PMID Version="1">20363851</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Interferon Cytokine Res. 2009 Nov;29(11):711-8</RefSource>
<PMID Version="1">19642894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hypertension. 2010 Aug;56(2):225-31</RefSource>
<PMID Version="1">20606113</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Immunol. 2010 Oct;137(1):89-101</RefSource>
<PMID Version="1">20674506</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Biochem Cell Biol. 2011 Jan;43(1):154-62</RefSource>
<PMID Version="1">21044893</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2011 Jan 15;186(2):1097-106</RefSource>
<PMID Version="1">21149612</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pulm Pharmacol Ther. 2011 Apr;24(2):193-8</RefSource>
<PMID Version="1">20951825</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824</RefSource>
<PMID Version="1">21471066</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2011 May;1813(5):878-88</RefSource>
<PMID Version="1">21296109</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Biochem. 2000 May;267(9):2624-31</RefSource>
<PMID Version="1">10785383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2000 May;6(5):583-8</RefSource>
<PMID Version="1">10802717</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Biochem. 2001 Jan;268(1):160-7</RefSource>
<PMID Version="1">11121117</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Dermatol Sci. 2001 Oct;27(2):140-6</RefSource>
<PMID Version="1">11532378</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Immunol. 2003;21:425-56</RefSource>
<PMID Version="1">12615888</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1992 Jul 1;176(1):287-92</RefSource>
<PMID Version="1">1613462</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 1992 Dec 15;189(2):794-800</RefSource>
<PMID Version="1">1335247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1993 Jun 18;260(5115):1808-10</RefSource>
<PMID Version="1">8511589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1994 Jan 7;263(5143):92-5</RefSource>
<PMID Version="1">8272873</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1994 Apr 1;264(5155):95-8</RefSource>
<PMID Version="1">8140422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Immunol. 1995 Apr;25(4):1101-4</RefSource>
<PMID Version="1">7537672</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Lett. 1996 Dec;54(2-3):177-84</RefSource>
<PMID Version="1">9052874</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Rheumatol. 1998 Feb;25(2):308-13</RefSource>
<PMID Version="1">9489824</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 1998 Mar;152(3):821-8</RefSource>
<PMID Version="1">9502424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 1998 Sep 1;334 ( Pt 2):297-314</RefSource>
<PMID Version="1">9716487</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1998 Dec 1;161(11):6347-55</RefSource>
<PMID Version="1">9834125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Immunol. 1998 Nov;28(11):3514-22</RefSource>
<PMID Version="1">9842894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2005 Jan;32(1):2-8</RefSource>
<PMID Version="1">15472138</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2005 Jan;52(1):84-93</RefSource>
<PMID Version="1">15641051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Cell Mol Biol. 2005 Jul;33(1):9-13</RefSource>
<PMID Version="1">15964990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Immunol. 2006 Jan-Feb;67(1-2):27-32</RefSource>
<PMID Version="1">16698422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2006 Jul;27(7):1507-15</RefSource>
<PMID Version="1">16597643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Crit Care Med. 2006 Oct 1;174(7):810-6</RefSource>
<PMID Version="1">16809633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L199-206</RefSource>
<PMID Version="1">16936245</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Apr 29;286(17):14804-11</RefSource>
<PMID Version="1">21454673</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Soc Nephrol. 2011 May;22(5):890-901</RefSource>
<PMID Version="1">21511827</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cell Biol. 2011 Jun-Jul;90(6-7):484-94</RefSource>
<PMID Version="1">21145125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cytokine Growth Factor Rev. 2011 Apr;22(2):83-9</RefSource>
<PMID Version="1">21377916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>IUBMB Life. 2011 Jul;63(7):538-46</RefSource>
<PMID Version="1">21698758</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2011 Jul 4;208(7):1339-50</RefSource>
<PMID Version="1">21727191</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(7):e22667</RefSource>
<PMID Version="1">21799929</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Immunol. 2011 Aug;32(8):380-7</RefSource>
<PMID Version="1">21752713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2011 Sep;121(9):3375-83</RefSource>
<PMID Version="1">21881215</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2011 Dec 3;378(9807):1949-61</RefSource>
<PMID Version="1">21719092</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Pharmacol Toxicol. 2012;52:199-219</RefSource>
<PMID Version="1">21910626</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(2):e31299</RefSource>
<PMID Version="1">22363610</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mod Pathol. 2012 Mar;25(3):416-33</RefSource>
<PMID Version="1">22037258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2012 Apr;180(4):1398-412</RefSource>
<PMID Version="1">22322297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2012 Jun;26(6):2546-57</RefSource>
<PMID Version="1">22415303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Am Thorac Soc. 2012 Jul;9(3):177-82</RefSource>
<PMID Version="1">22802294</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO Mol Med. 2012 Sep;4(9):939-51</RefSource>
<PMID Version="1">22684844</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2013 Mar 1;123(3):1019-31</RefSource>
<PMID Version="1">23426178</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Leukoc Biol. 2013 Apr;93(4):499-510</RefSource>
<PMID Version="1">23159927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2013 May;133(5):1212-20</RefSource>
<PMID Version="1">23303450</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunol. 2007 Jun;19(6):685-93</RefSource>
<PMID Version="1">17496315</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Crit Care Med. 2007 Jul 1;176(1):78-89</RefSource>
<PMID Version="1">17431224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Respir Crit Care Med. 2007 Aug 1;176(3):277-84</RefSource>
<PMID Version="1">17478620</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S11-5</RefSource>
<PMID Version="1">17708739</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Sep 15;110(6):1748-55</RefSource>
<PMID Version="1">17567983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Respir Res. 2007;8:51</RefSource>
<PMID Version="1">17620132</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2007 Nov 16;282(46):33714-24</RefSource>
<PMID Version="1">17884817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2008 May;172(5):1209-21</RefSource>
<PMID Version="1">18403600</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2008 Jun 1;180(11):7102-6</RefSource>
<PMID Version="1">18490707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Pathol. 2008 Sep;216(1):1-14</RefSource>
<PMID Version="1">18680111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1332-43</RefSource>
<PMID Version="1">19299578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2010 Feb 1;184(3):1543-51</RefSource>
<PMID Version="1">20042582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2010;5(2):e9224</RefSource>
<PMID Version="1">20169073</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2010;5(3):e9683</RefSource>
<PMID Version="1">20300636</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2003 Jul;163(1):345-54</RefSource>
<PMID Version="1">12819039</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2003 Oct 3;278(40):38829-39</RefSource>
<PMID Version="1">12832423</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 1982 Jan;69(1):113-22</RefSource>
<PMID Version="1">7054232</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1987 Oct 1;166(4):967-81</RefSource>
<PMID Version="1">2821154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1989 Aug 11;58(3):573-81</RefSource>
<PMID Version="1">2788034</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1989 Nov 1;170(5):1537-49</RefSource>
<PMID Version="1">2809509</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005353">Fibronectins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054990">Idiopathic Pulmonary Fibrosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016676">Macrophages, Alveolar</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058628">Myofibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011658">Pulmonary Fibrosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019947">Receptors, Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS619142</OtherID>
<OtherID Source="NLM">PMC4169999</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172495</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunoregulation of dendritic cells by the receptor T cell Ig and mucin protein-3 via Bruton's tyrosine kinase and c-Src.</ArticleTitle>
<Pagination>
<MedlinePgn>3417-25</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1400395</ELocationID>
<Abstract>
<AbstractText>The receptor T cell Ig and mucin protein-3 (TIM-3) has emerged as an important regulator of innate immune responses. However, whether TIM-3-induced signaling promotes or inhibits the activation and maturation of dendritic cells (DCs) still remains uncertain. In addition, the TIM-3 signaling events involved in this immunoregulatory function are yet to be established. In this article, we report that TIM-3 crosslinking by anti-TIM-3 Ab inhibited DC activation and maturation by blocking the NF-κB pathway. After Ab-mediated crosslinking, TIM-3 became tyrosine phosphorylated, which then sequentially bound and activated the nonreceptor tyrosine kinases Bruton's tyrosine kinase (Btk) and c-Src. Activation of Btk-c-Src signaling in turn triggered the secretion of some inhibitory factor (or factors) from DCs that inhibited the NF-κB pathway and subsequent activation and maturation of DCs. Silencing of Btk or c-Src abrogated the inhibitory effects of TIM-3 on DCs. These results demonstrate an essential role for Btk-c-Src signaling in TIM-3-induced DC suppression. Thus, in addition to demonstrating an inhibitory role for TIM-3 signaling in DC activation, we define the molecular mechanism by which TIM-3 mediates this effect. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Maurya</LastName>
<ForeName>Neeraj</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Biology and Immunology, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gujar</LastName>
<ForeName>Ravindra</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Biology and Immunology, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Mamta</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Biology and Immunology, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yadav</LastName>
<ForeName>Vinod</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Biology and Immunology, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Verma</LastName>
<ForeName>Saurabh</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Biology and Immunology, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sen</LastName>
<ForeName>Pradip</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell Biology and Immunology, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India psen@imtech.res.in.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C442241">Havcr2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C082176">Agammaglobulinaemia tyrosine kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C073097">CSK tyrosine-protein kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011505">Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011991">Receptors, Virus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172496</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>GATA-3 dose-dependent checkpoints in early T cell commitment.</ArticleTitle>
<Pagination>
<MedlinePgn>3470-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1301663</ELocationID>
<Abstract>
<AbstractText>GATA-3 expression is crucial for T cell development and peaks during commitment to the T cell lineage, midway through the CD4(-)CD8(-) (double-negative [DN]) stages 1-3. We used RNA interference and conditional deletion to reduce GATA-3 protein acutely at specific points during T cell differentiation in vitro. Even moderate GATA-3 reduction killed DN1 cells, delayed progression to the DN2 stage, skewed DN2 gene regulation, and blocked appearance of the DN3 phenotype. Although a Bcl-2 transgene rescued DN1 survival and improved DN2 cell generation, it did not restore DN3 differentiation. Gene expression analyses (quantitative PCR, RNA sequencing) showed that GATA-3-deficient DN2 cells quickly upregulated genes, including Spi1 (PU.1) and Bcl11a, and downregulated genes, including Cpa3, Ets1, Zfpm1, Bcl11b, Il9r, and Il17rb with gene-specific kinetics and dose dependencies. These targets could mediate two distinct roles played by GATA-3 in lineage commitment, as revealed by removing wild-type or GATA-3-deficient early T lineage cells from environmental Notch signals. GATA-3 worked as a potent repressor of B cell potential even at low expression levels, so that only full deletion of GATA-3 enabled pro-T cells to reveal B cell potential. The ability of GATA-3 to block B cell development did not require T lineage commitment factor Bcl11b. In prethymic multipotent precursors, however, titration of GATA-3 activity using tamoxifen-inducible GATA-3 showed that GATA-3 inhibits B and myeloid developmental alternatives at different threshold doses. Furthermore, differential impacts of a GATA-3 obligate repressor construct imply that B and myeloid development are inhibited through distinct transcriptional mechanisms. Thus, the pattern of GATA-3 expression sequentially produces B lineage exclusion, T lineage progression, and myeloid-lineage exclusion for commitment. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Scripture-Adams</LastName>
<ForeName>Deirdre D</ForeName>
<Initials>DD</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Damle</LastName>
<ForeName>Sagar S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Long</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Elihu</LastName>
<ForeName>Koorosh J</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>Shuyang</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arias</LastName>
<ForeName>Alexandra M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Butler</LastName>
<ForeName>Robert R</ForeName>
<Initials>RR</Initials>
<Suffix>3rd</Suffix>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Champhekar</LastName>
<ForeName>Ameya</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jingli A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rothenberg</LastName>
<ForeName>Ellen V</ForeName>
<Initials>EV</Initials>
<AffiliationInfo>
<Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125 evroth@its.caltech.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE59215</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5T32 HD07257</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AI095943</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA090233</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA098925</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AI95943</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA90233</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA98925</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC2 CA148278</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC2CA148278</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C511143">Bcl11b protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050990">GATA3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494748">Gata3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>094ZI81Y45</RegistryNumber>
<NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>114100-40-2</RegistryNumber>
<NameOfSubstance UI="C052617">Bcl2 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018931">Antineoplastic Agents, Hormonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050990">GATA3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022423">Myeloid Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054504">Precursor Cells, T-Lymphoid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051880">Receptors, Notch</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013629">Tamoxifen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS620361 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170028 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172498</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>CD39 and CD161 modulate Th17 responses in Crohn's disease.</ArticleTitle>
<Pagination>
<MedlinePgn>3366-77</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1400346</ELocationID>
<Abstract>
<AbstractText>CD39 (ENTPD1) is expressed by subsets of pathogenic human CD4(+) T cells, such as Th17 cells. These Th17 cells are considered important in intestinal inflammation, such as seen in Crohn's disease (CD). Recently, CD161 (NKR-P1A) was shown to be a phenotypic marker of human Th17 cells. In this study, we report that coexpression of CD161 and CD39 not only identifies these cells but also promotes Th17 generation. We note that human CD4(+)CD39(+)CD161(+) T cells can be induced under stimulatory conditions that promote Th17 in vitro. Furthermore, CD4(+)CD39(+)CD161(+) cells purified from blood and intestinal tissues, from both healthy controls and patients with CD, are of the Th17 phenotype and exhibit proinflammatory functions. CD39 is coexpressed with CD161, and this association augments acid sphingomyelinase (ASM) activity upon stimulation of CD4(+) T cells. These pathways regulate mammalian target of rapamycin and STAT3 signaling to drive the Th17 phenotype. Inhibition of ASM activity by pharmacological blockers or knockdown of ASM abrogates STAT3 signaling, thereby limiting IL-17 production in CD4(+) T cells obtained from both controls and patients with active CD. Increased levels of CD39(+)CD161(+) CD4(+) T cells in blood or lamina propria are noted in patients with CD, and levels directly correlate with clinical disease activity. Hence, coexpression of CD39 and CD161 by CD4(+) T cells might serve as a biomarker to monitor Th17 responsiveness. Collectively, CD39 and CD161 modulate human Th17 responses in CD through alterations in purinergic nucleotide-mediated responses and ASM catalytic bioactivity, respectively. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>Aiping</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moss</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kokkotou</LastName>
<ForeName>Efi</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Usheva</LastName>
<ForeName>Anny</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Xiaofeng</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheifetz</LastName>
<ForeName>Adam</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Yi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Longhi</LastName>
<ForeName>Maria Serena</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Wenda</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Antagen Institute for Biomedical Research, Boston, MA 02118.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Robson</LastName>
<ForeName>Simon C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215; srobson@bidmc.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5T32DK007760-15</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DP1 CA174427</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>G0902288</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>P01 AI045897</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01-HL076540</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 DK043351</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL094400</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-HL094400</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA164970</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055651">NK Cell Lectin-Like Receptor Subfamily B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.4.12</RegistryNumber>
<NameOfSubstance UI="D013108">Sphingomyelin Phosphodiesterase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.5</RegistryNumber>
<NameOfSubstance UI="D001081">Apyrase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.5</RegistryNumber>
<NameOfSubstance UI="C067869">CD39 antigen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001081">Apyrase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003424">Crohn Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020381">Interleukin-17</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009092">Mucous Membrane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055651">NK Cell Lectin-Like Receptor Subfamily B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013108">Sphingomyelin Phosphodiesterase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058504">Th17 Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS620363 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170017 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172502</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>CD4+ T cells and CD40 participate in selection and homeostasis of peripheral B cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3492-502</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1400798</ELocationID>
<Abstract>
<AbstractText>Control of peripheral B cell development and homeostasis depends critically on coordinate signals received through the BAFFRs and BCRs. The extent to which other signals contribute to this process, however, remains undefined. We present data indicating that CD4(+) T cells directly influence naive B cell development via CD40 signaling. Loss of CD4(+) T cells or CD40-CD40L interaction leads to reduced B cell homeostatic proliferation and hindered B cell reconstitution posttransplantation. Furthermore, we demonstrate that in the absence of CD40 signals, these events are modulated by BCR self-reactivity. Strikingly, murine models lacking CD40 reveal a broadly altered BCR specificity and limited diversity by both single-cell cloning and high-throughput sequencing techniques. Collectively, our results imply that any setting of T cell lymphopenia or reduced CD40 function, including B cell recovery following transplantation, will impact the naive B cell repertoire. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schwartz</LastName>
<ForeName>Marc A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kolhatkar</LastName>
<ForeName>Nikita S</ForeName>
<Initials>NS</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thouvenel</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195; and Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khim</LastName>
<ForeName>Socheath</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195; and Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rawlings</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195; and Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101 drawling@u.washington.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 AI071163</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AI084457</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL075453</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AI071163</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AI084457</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01HL075453</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM007266</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019013">Antigens, CD40</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2001 Sep 14;293(5537):2111-4</RefSource>
<PMID Version="1">11509691</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunol. 1989;1(4):398-408</RefSource>
<PMID Version="1">2489036</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2002 Oct 15;169(8):4198-204</RefSource>
<PMID Version="1">12370349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2002 Dec 15;169(12):6795-805</RefSource>
<PMID Version="1">12471111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2003 Jun 15;170(12):5820-3</RefSource>
<PMID Version="1">12794106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1991 Jun 1;173(6):1357-71</RefSource>
<PMID Version="1">1903427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1991 Nov 1;174(5):1189-201</RefSource>
<PMID Version="1">1940797</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1992 Dec 1;149(11):3456-62</RefSource>
<PMID Version="1">1385525</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1993 Nov 1;151(9):4431-44</RefSource>
<PMID Version="1">8409411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1994 Aug 15;153(4):1441-8</RefSource>
<PMID Version="1">7519204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1995 Aug 1;182(2):541-8</RefSource>
<PMID Version="1">7629511</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1995 Sep 15;155(6):3223-33</RefSource>
<PMID Version="1">7673735</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1996 May 23;381(6580):325-8</RefSource>
<PMID Version="1">8692271</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunol. 1996 Nov;8(11):1675-85</RefSource>
<PMID Version="1">8943562</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunol. 1997 Mar;9(3):395-405</RefSource>
<PMID Version="1">9088978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2011 Sep 26;208(10):2033-42</RefSource>
<PMID Version="1">21875954</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Exp Immunol. 2012 Jan;167(1):15-25</RefSource>
<PMID Version="1">22132880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Sep 6;489(7414):160-4</RefSource>
<PMID Version="1">22902503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2013 Jan 14;210(1):125-42</RefSource>
<PMID Version="1">23267014</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2013 Mar 1;190(5):2090-101</RefSource>
<PMID Version="1">23335750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2013 Mar 21;38(3):475-88</RefSource>
<PMID Version="1">23453634</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Immunol. 1998 Nov;28(11):3738-48</RefSource>
<PMID Version="1">9842916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Immunol. 1998 Nov;10(11):1673-82</RefSource>
<PMID Version="1">9846696</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1999 Jul 2;285(5424):113-6</RefSource>
<PMID Version="1">10390361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1999 Jul 5;190(1):75-89</RefSource>
<PMID Version="1">10429672</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunology. 2005 Nov;116(3):308-17</RefSource>
<PMID Version="1">16236120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10717-22</RefSource>
<PMID Version="1">16815973</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2007 Mar 19;204(3):645-55</RefSource>
<PMID Version="1">17312005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2007 Jul 9;204(7):1583-93</RefSource>
<PMID Version="1">17562816</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2007 Aug 6;204(8):1959-71</RefSource>
<PMID Version="1">17664289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2008 Jan 21;205(1):155-68</RefSource>
<PMID Version="1">18180309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Immunol. 2008 May;28 Suppl 1:S62-6</RefSource>
<PMID Version="1">18246414</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Immunol. 2008 Apr;20(2):149-57</RefSource>
<PMID Version="1">18434123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Immunol. 2008 Apr;20(2):158-61</RefSource>
<PMID Version="1">18456486</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2008 Dec;9(12):1379-87</RefSource>
<PMID Version="1">18978795</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2009 Mar 1;182(5):2868-78</RefSource>
<PMID Version="1">19234182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2009 Jul;9(7):491-502</RefSource>
<PMID Version="1">19521398</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2009 Oct 31;350(1-2):183-93</RefSource>
<PMID Version="1">19716372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2009 Oct 30;139(3):573-86</RefSource>
<PMID Version="1">19879843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Immunol. 2010 Jul;136(1):105-15</RefSource>
<PMID Version="1">20381429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Rev. 2010 Sep;237(1):205-25</RefSource>
<PMID Version="1">20727038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Thromb Haemost. 2010 Oct;104(4):693-701</RefSource>
<PMID Version="1">20694278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2010 Oct 15;185(8):4570-81</RefSource>
<PMID Version="1">20861359</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2010 Nov 22;207(12):2767-78</RefSource>
<PMID Version="1">21078890</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2003 Sep 5;301(5638):1374-7</RefSource>
<PMID Version="1">12920303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2003 Dec 15;171(12):6381-8</RefSource>
<PMID Version="1">14662836</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Immunol. 2004 Apr;16(2):246-50</RefSource>
<PMID Version="1">15023420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1982 Mar 1;155(3):903-13</RefSource>
<PMID Version="1">6801182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 1991 Apr 15;146(8):2568-77</RefSource>
<PMID Version="1">1901880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2002 Jan 21;195(2):181-8</RefSource>
<PMID Version="1">11805145</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019013">Antigens, CD40</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006706">Homeostasis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008231">Lymphopenia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011947">Receptors, Antigen, B-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4170672</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25187653</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Negative self-regulation of TLR9 signaling by its N-terminal proteolytic cleavage product.</ArticleTitle>
<Pagination>
<MedlinePgn>3726-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1400210</ELocationID>
<Abstract>
<AbstractText>TLR signaling is essential to innate immunity against microbial invaders and must be tightly controlled. We have previously shown that TLR9 undergoes proteolytic cleavage processing by lysosomal proteases to generate two distinct fragments. The C-terminal cleavage product plays a critical role in activating TLR9 signaling; however, the precise role of the N-terminal fragment, which remains in lysosomes, in the TLR9 response is still unclear. In this article, we report that the N-terminal cleavage product negatively regulates TLR9 signaling. Notably, the N-terminal fragment promotes the aspartic protease-mediated degradation of the C-terminal fragment in endolysosomes. Furthermore, the N-terminal TLR9 fragment physically interacts with the C-terminal product, thereby inhibiting the formation of homodimers of the C-terminal fragment; this suggests that the monomeric C-terminal product is more susceptible to attack by aspartic proteases. Together, these results suggest that the N-terminal TLR9 proteolytic cleavage product is a negative self-regulator that prevents excessive TLR9 signaling activity. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Sungwook</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Dongju</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ra</LastName>
<ForeName>Eun A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Taeyun A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ploegh</LastName>
<ForeName>Hidde L</ForeName>
<Initials>HL</Initials>
<AffiliationInfo>
<Affiliation>Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02115.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Boyoun</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea; and bypark@yonsei.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495371">TLR9 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495370">Tlr9 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051217">Toll-Like Receptor 9</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D057055">Aspartic Acid Proteases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057055">Aspartic Acid Proteases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011992">Endosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008247">Lysosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055503">Protein Multimerization</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051217">Toll-Like Receptor 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25187659</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Systemic C3 modulates CD8+ T cell contraction after Listeria monocytogenes infection.</ArticleTitle>
<Pagination>
<MedlinePgn>3426-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1302763</ELocationID>
<Abstract>
<AbstractText>Ag-specific CD8(+) T cell contraction (contraction), which occurs after the resolution of infection, is critical for homeostasis of the immune system. Although complement components regulate the primary CD8(+) T cell response, there is insufficient evidence supporting their role in regulating contraction and memory. In this study, we show that C3-deficient (C3(-/-)) mice exhibited significantly less CD8(+) T cell contraction than did wild-type mice postinfection with recombinant Listeria monocytogenes expressing OVA. Kinetic analyses also revealed decreased contraction in mice treated with cobra venom factor to deplete C3, which was consistent with the results in C3(-/-) recipient mice transplanted with bone marrow cells from the same donors as wild-type recipient mice. The phenotypes of memory cells generated by C3(-/-) mice were not altered compared with those of wild-type mice. Further, C5aR signaling downstream of C3 was not involved in the regulation of contraction. Moreover, the regulation of contraction by C3 may be independent of the duration of antigenic stimulation or the functional avidity of effector CD8(+) T cells. However, reduced contraction in C3(-/-) mice was accompanied by a decrease in the proportion of KLRG-1(hi) (killer-cell lectin-like receptor G1) CD127(lo) short-lived effector cells at the peak of the response and correlated with a reduction in the levels of inflammatory cytokines, such as IL-12 and IFN-γ, produced early postinfection. These results provide new insights into the role of systemic C3 in regulating contraction following intracellular bacterial infection and may help to develop vaccines that are more effective. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Yulong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Third Military Medical University, Chongqing 400038, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yongsheng</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Xiaolan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Third Military Medical University, Chongqing 400038, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Third Military Medical University, Chongqing 400038, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Ping</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Third Military Medical University, Chongqing 400038, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jue</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Third Military Medical University, Chongqing 400038, China; and guobomail@gmail.com wuyuzhang@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Yuzhang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Third Military Medical University, Chongqing 400038, China; and guobomail@gmail.com wuyuzhang@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000591759">C5ar1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003040">Cobra Venoms</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003176">Complement C3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053699">Interleukin-7 Receptor alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C451496">Klrg1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044087">Receptor, Anaphylatoxin C5a</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>187348-17-0</RegistryNumber>
<NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003040">Cobra Venoms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003176">Complement C3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007156">Immunologic Memory</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018664">Interleukin-12</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053699">Interleukin-7 Receptor alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008089">Listeria monocytogenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008088">Listeriosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044087">Receptor, Anaphylatoxin C5a</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011971">Receptors, Immunologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25155613</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-4164</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Molecular cell</Title>
<ISOAbbreviation>Mol. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>SIRT1-mediated deacetylation of CRABPII regulates cellular retinoic acid signaling and modulates embryonic stem cell differentiation.</ArticleTitle>
<Pagination>
<MedlinePgn>843-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2014.07.011</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1097-2765(14)00604-2</ELocationID>
<Abstract>
<AbstractText>Retinoid homeostasis is critical for normal embryonic development. Both the deficiency and excess of these compounds are associated with congenital malformations. Here we demonstrate that SIRT1, the most conserved mammalian NAD⁺-dependent protein deacetylase, contributes to homeostatic retinoic acid (RA) signaling and modulates mouse embryonic stem cell (mESC) differentiation in part through deacetylation of cellular retinoic acid binding protein II (CRABPII). We show that RA-mediated acetylation of CRABPII at K102 is essential for its nuclear accumulation and subsequent activation of RA signaling. SIRT1 interacts with and deacetylates CRABPII, regulating its subcellular localization. Consequently, SIRT1 deficiency induces hyperacetylation and nuclear accumulation of CRABPII, enhancing RA signaling and accelerating mESC differentiation in response to RA. Consistently, SIRT1 deficiency is associated with elevated RA signaling and development defects in mice. Our findings reveal a molecular mechanism that regulates RA signaling and highlight the importance of SIRT1 in regulation of ESC pluripotency and embryogenesis.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Shuang</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China; Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Gang</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. Electronic address: huang2802@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Division of Medical Cell Biology, Institute for Anatomy and Cell Biology II, Justus Liebig University, Aulweg 123, 35385 Giessen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>The Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ward</LastName>
<ForeName>James M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Integrated Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Xiaojiang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Integrated Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Ashley</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA; NIEHS Scholars Connect Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McBurney</LastName>
<ForeName>Michael W</ForeName>
<Initials>MW</Initials>
<AffiliationInfo>
<Affiliation>Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada K1H 8L6.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fargo</LastName>
<ForeName>David C</ForeName>
<Initials>DC</Initials>
<AffiliationInfo>
<Affiliation>Integrated Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Guang</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baumgart-Vogt</LastName>
<ForeName>Eveline</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Division of Medical Cell Biology, Institute for Anatomy and Cell Biology II, Justus Liebig University, Aulweg 123, 35385 Giessen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Yingming</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>The Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xiaoling</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA. Electronic address: lix3@niehs.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE59140</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA160036</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM105933</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>Z01 ES102205</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>ZIA ES102205-08</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell</MedlineTA>
<NlmUniqueID>9802571</NlmUniqueID>
<ISSNLinking>1097-2765</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018168">Receptors, Retinoic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5688UTC01R</RegistryNumber>
<NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.-</RegistryNumber>
<NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000107">Acetylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053595">Embryonic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059647">Gene-Environment Interaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018168">Receptors, Retinoic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056564">Sirtuin 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS617239 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4228935 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25219500</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-4164</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Molecular cell</Title>
<ISOAbbreviation>Mol. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.</ArticleTitle>
<Pagination>
<MedlinePgn>904-15</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2014.08.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1097-2765(14)00643-1</ELocationID>
<Abstract>
<AbstractText>Most colorectal cancers (CRCs) containing activated BRAF (BRAF[V600E]) have a CpG island methylator phenotype (CIMP) characterized by aberrant hypermethylation of many genes, including the mismatch repair gene MLH1. MLH1 silencing results in microsatellite instability and a hypermutable phenotype. Through an RNAi screen, here we identify the transcriptional repressor MAFG as the pivotal factor required for MLH1 silencing and CIMP in CRCs containing BRAF(V600E). In BRAF-positive human CRC cell lines and tumors, MAFG is bound at the promoters of MLH1 and other CIMP genes, and recruits a corepressor complex that includes its heterodimeric partner BACH1, the chromatin remodeling factor CHD8, and the DNA methyltransferase DNMT3B, resulting in hypermethylation and transcriptional silencing. BRAF(V600E) increases BRAF/MEK/ERK signaling resulting in phosphorylation and elevated levels of MAFG, which drives DNA binding. Analysis of transcriptionally silenced CIMP genes in KRAS-positive CRCs indicates that different oncoproteins direct the assembly of distinct repressor complexes on common promoters. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Minggang</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA; Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ou</LastName>
<ForeName>Jianhong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hutchinson</LastName>
<ForeName>Lloyd</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Green</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA; Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA. Electronic address: michael.green@umassmed.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 GM033977</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01GM033977</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell</MedlineTA>
<NlmUniqueID>9802571</NlmUniqueID>
<ISSNLinking>1097-2765</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102108">BACH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050976">Basic-Leucine Zipper Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C523331">CHD8 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051856">Fanconi Anemia Complementation Group Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C103944">MAFG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501486">MLH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051259">MafG Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.37</RegistryNumber>
<NameOfSubstance UI="D004248">DNA (Cytosine-5-)-Methyltransferase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.37</RegistryNumber>
<NameOfSubstance UI="C120396">DNA methyltransferase 3B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050976">Basic-Leucine Zipper Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018899">CpG Islands</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004248">DNA (Cytosine-5-)-Methyltransferase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051856">Fanconi Anemia Complementation Group Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051259">MafG Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS627196 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4170521 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25239329</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1532-7361</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>156</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Surgery</Title>
<ISOAbbreviation>Surgery</ISOAbbreviation>
</Journal>
<ArticleTitle>Novel microRNA correlations in the severely injured.</ArticleTitle>
<Pagination>
<MedlinePgn>834-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.surg.2014.06.017</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0039-6060(14)00356-0</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Severe injury initiates an inflammatory response that can perpetuate immunological dysfunction, uncontrolled inflammation, and subsequent multisystem organ failure. MicroRNAs (miRNAs) have recently been identified as regulators of this inflammatory response. Our study sought to identify the differential expression of unique miRNAs and their correlations with genes of the Toll-like receptor (TLR) pathways, and clinical parameters in the severely injured.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Fourteen trauma patients requiring transfusion were prospectively enrolled in this institutional review board-approved study. Inclusion criteria consisted of adult patients deemed clinically to be in hemorrhagic shock necessitating transfusion in the acute phase of their injury care. Peripheral blood samples were obtained after admission to the surgical intensive care unit. Expression of circulating mature miRNA from each patient, as well as from 10 healthy, age-matched controls, was determined and compared using the HiSeq 2500 sequencing system and the R software system. Gene expression of TLR signaling pathways for each patient was examined using custom gene expression polymerase chain reaction arrays. Statistical analyses were performed using general linear models and empirical Bayes methods to determine differential expression and Spearman's nonparametric correlation analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects were 21-77 years old (mean, 42), 80% male, Injury Severity Score 11-43 (mean, 26), with 11 blunt and 3 penetrating injuries. Three were intubated and 5 received blood products before arrival. Base deficit upon hospital admission was 3 to 20 (mean, 9). All patients required blood transfusion secondary to blood loss sustained during injury. Survival to discharge was 93%. Controls were 27-64 years old (mean, 40) and 60% male. Sequencing analysis revealed 69 differentially expressed miRNAs (P &lt; .05) in the severely injured. Within the differentially expressed miRNAs, there were 12 direct and 6 indirect correlations with multiple genes involved in the TLR3 and TLR4 signaling pathways. The relationships between these same miRNAs and clinical parameters were also analyzed. We discovered 4 direct correlations with base deficit and HCO3, and 7 indirect correlations involving total fresh frozen plasma transfused, base deficit, HCO3, and PaCO2 levels.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Differential expression and correlations between miRNAs, genes of the TLR pathways, and clinical parameters are unique findings in the severely injured and may lead to a greater understanding of the regulation of sterile inflammation after severe injury.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Uhlich</LastName>
<ForeName>Rindi M</ForeName>
<Initials>RM</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, University of Missouri, Columbia, MO.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Konie</LastName>
<ForeName>Jared A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, University of Missouri, Columbia, MO.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Davis</LastName>
<ForeName>J Wade</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Health Management and Informatics, University of Missouri, Columbia, MO.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Misfeldt</LastName>
<ForeName>Michael L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nelson</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, University of Missouri, Columbia, MO.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Calaluce</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, University of Missouri, Columbia, MO.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barnes</LastName>
<ForeName>Stephen L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, University of Missouri, Columbia, MO. Electronic address: barnesste@health.missouri.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Surgery</MedlineTA>
<NlmUniqueID>0417347</NlmUniqueID>
<ISSNLinking>0039-6060</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495344">TLR3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Surgery. 2014 Oct;156(4):840-1</RefSource>
<PMID Version="1">25239330</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001803">Blood Transfusion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005819">Genetic Markers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015601">Injury Severity Score</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016014">Linear Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017423">Sequence Analysis, RNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012771">Shock, Hemorrhagic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051196">Toll-Like Receptor 3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014947">Wounds and Injuries</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25041791</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).</ArticleTitle>
<Pagination>
<MedlinePgn>2980-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28744</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to affect its natural history. We tested the hypothesis that simulataneous targeting of the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) pathways would significantly improve progression-free survival (PFS) by abrogating reciprocal signaling that promote drug resistance</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This was a phase Ib/II study testing cixutumumab, combined with erlotinib and gemcitabine (G) in patients with untreated metastatic PC. The control arm was erlotinib plus G. The primary end point was PFS. Eligibility included performance status 0/1 and normal fasting blood glucose. Polymorphisms in genes involved in G metabolism and in the EGFR pathway were also studied</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The phase I results (n = 10) established the safety of cixutumumab 6 mg/kg/week intravenously, erlotinib 100 mg/day orally, and G 1000 mg/m(2) intravenously on days 1, 8, and 15 of a 28-day cycle. In the RP2 portion (116 eligible patients; median age, 63), the median PFS and overall survival (OS) were 3.6 and 7.0 months, respectively, on the cixutumumab arm, and 3.6 and 6.7 months, respecively, on the control arm. Major grades 3 and 4 toxicities with cixutumumab and control were elevation of transaminases, 12% and 6%, respectively; fatigue, 16% and 12%, respectively; gastrointestinal, 35% and 28%, respectively; neutropenia, 21% and 10%, respectively; and thrombocytopenia, 16% and 7%, respecively. Grade 3/4 hyperglycemia was seen in 16% of patients on cixutumumab. Grade 3 or 4 skin toxicity was similar in both arms of the study (&lt; 5%). No significant differences in PFS by genotype were seen for any of the polymorphisms.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adding the IGF-1R inhibitor cixutumumab to erlotinib and G did not lead to longer PFS or OS in metastatic PC.</AbstractText>
<CopyrightInformation>© 2014 American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Philip</LastName>
<ForeName>Philip A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Wayne State University, Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Goldman</LastName>
<ForeName>Bryan</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ramanathan</LastName>
<ForeName>Ramesh K</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lenz</LastName>
<ForeName>Heinz-Josef</ForeName>
<Initials>HJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lowy</LastName>
<ForeName>Andrew M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Whitehead</LastName>
<ForeName>Robert P</ForeName>
<Initials>RP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wakatsuki</LastName>
<ForeName>Takeru</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iqbal</LastName>
<ForeName>Syma</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gaur</LastName>
<ForeName>Rakesh</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benedetti</LastName>
<ForeName>Jacqueline K</ForeName>
<Initials>JK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blanke</LastName>
<ForeName>Charles D</ForeName>
<Initials>CD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA073590</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA11083</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA128567</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA139519</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA14028</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA20319</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA22433</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA27057</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA32102</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA35176</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA35178</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA37981</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA38926</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA42777</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA4461</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA45450</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA45807</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA45808</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA46113</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA46368</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA46441</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA52654</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA58723</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA58861</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA58882</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA67575</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA74647</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA76447</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA76448</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA76462</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA86780</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA95860</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C557414">anti-IGF-1R antibody A12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>67763-96-6</RegistryNumber>
<NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B76N6SBZ8R</RegistryNumber>
<NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J4T82NDH7E</RegistryNumber>
<NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007334">Insulin-Like Growth Factor I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">IGF-1R</Keyword>
<Keyword MajorTopicYN="N">cixutumumab</Keyword>
<Keyword MajorTopicYN="N">erlotinib signaling</Keyword>
<Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
<Keyword MajorTopicYN="N">randomized phase II</Keyword>
<Keyword MajorTopicYN="N">targeted treatment</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24952340</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Time- and concentration-dependent genomic responses of the rat airway to inhaled nickel subsulfide.</ArticleTitle>
<Pagination>
<MedlinePgn>441-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00230-0</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To provide insights into the mode of action for Ni3S2 lung carcinogenicity by examining gene expression changes in target cells after inhalation exposure.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Gene expression changes were determined in micro-dissected lung broncho-alveolar cells from Fischer 344 rats following inhalation of Ni3S2 at 0.0, 0.04, 0.08, 0.15, and 0.60 mg/m(3) (0.03, 0.06, 0.11, and 0.44 mgNi/m(3)) for one and four weeks (6h/day, 5 days/week).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Broncho-alveolar lavage fluid evaluation and lung histopathology provided evidence of inflammation only at the two highest concentrations, which were similar to those tested in the 2-year bioassay. The number of statistically significant up- and down-regulated genes decreased markedly from one to four weeks of exposure, suggesting adaptation. Cell signal pathway enrichment at both time-points primarily reflected responses to toxicity, including inflammatory and proliferative signaling. While proliferative signaling was up-regulated at both time points, some inflammatory signaling reversed from down-regulation at 1 week to up-regulation at 4 weeks.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results support a mode of action for Ni3S2 carcinogenicity driven by chronic toxicity, inflammation and proliferation, leading to mis-replication, rather than by direct genotoxicity. Benchmark dose (BMD) analysis identified the lowest pathway transcriptional BMD exposure concentration as 0.026 mgNi/m(3), for apoptosis/survival signaling. When conducted on the basis of lung Ni concentration the lowest pathway BMD was 0.64 μgNi/g lung, for immune/inflammatory signaling.</AbstractText>
<AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">These highly conservative BMDs could be used to derive a point of departure in a nonlinear risk assessment for Ni3S2 toxicity and carcinogenicity.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Efremenko</LastName>
<ForeName>A Y</ForeName>
<Initials>AY</Initials>
<AffiliationInfo>
<Affiliation>The Hamner Institutes for Health Sciences, 6 Davis Drive, Research Triangle Park, NC 27709, USA. Electronic address: aefremenko@thehamner.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Campbell</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo>
<Affiliation>The Hamner Institutes for Health Sciences, 6 Davis Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dodd</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>The Hamner Institutes for Health Sciences, 6 Davis Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oller</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo>
<Affiliation>NiPERA, Inc., 2525 Meridian Parkway, Suite 240, Durham, NC 27713, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clewell</LastName>
<ForeName>H J</ForeName>
<Initials>HJ</Initials>
<Suffix>3rd</Suffix>
<AffiliationInfo>
<Affiliation>The Hamner Institutes for Health Sciences, 6 Davis Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>12035-72-2</RegistryNumber>
<NameOfSubstance UI="C017557">nickel subsulfide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7OV03QG267</RegistryNumber>
<NameOfSubstance UI="D009532">Nickel</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019985">Benchmarking</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001992">Bronchoalveolar Lavage Fluid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002273">Carcinogens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019570">Inhalation Exposure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046228">Microarray Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046529">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009153">Mutagens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009532">Nickel</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Carcinogenicity</Keyword>
<Keyword MajorTopicYN="N">Gene expression</Keyword>
<Keyword MajorTopicYN="N">Inhalation</Keyword>
<Keyword MajorTopicYN="N">Nickel subsulfide</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24978599</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Polychlorinated biphenyls (PCB 101, PCB 153 and PCB 180) alter leptin signaling and lipid metabolism in differentiated 3T3-L1 adipocytes.</ArticleTitle>
<Pagination>
<MedlinePgn>401-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.016</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00245-2</ELocationID>
<Abstract>
<AbstractText>Non-dioxin-like polychlorinated biphenyls (NDL-PCBs) are highly lipophilic environmental contaminants that accumulate in lipid-rich tissues, such as adipose tissue. Here, we reported the effects induced by PCBs 101, 153 and 180, three of the six NDL-PCBs defined as indicators, on mature 3T3-L1 adipocytes. We observed an increase in lipid content, in leptin gene expression and a reduction of leptin receptor expression and signaling, when cells were exposed to PCBs, alone or in combination. These modifications were consistent with the occurrence of "leptin-resistance" in adipose tissue, a typical metabolic alteration related to obesity. Therefore, we investigated how PCBs affect the expression of pivotal proteins involved in the signaling of leptin receptor. We evaluated the PCB effect on the intracellular pathway JAK/STAT, determining the phosphorylation of STAT3, a downstream activator of the transcription of leptin gene targets, and the expression of SOCS3 and PTP1B, two important regulators of leptin resistance. In particular, PCBs 153 and 180 or all PCB combinations induced a significant reduction in pSTAT3/STAT3 ratio and an increase in PTP1B and SOCS3, evidencing an additive effect. The impairment of leptin signaling was associated with the reduction of AMPK/ACC pathway activation, leading to the increase in lipid content. These pollutants were also able to increase the transcription of inflammatory cytokines (IL-6 and TNFα). It is worthy to note that the PCB concentrations used are comparable to levels detectable in human adipose tissue. Our data strongly support the hypothesis that NDL-PCBs may interfere with the lipid metabolism contributing to the development of obesity and related diseases. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ferrante</LastName>
<ForeName>Maria C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Medicine and Animal Productions, Federico II University of Naples, Via Delpino 1, 80137 Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Amero</LastName>
<ForeName>Paola</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, Federico II University of Naples, Via Montesano 49, 80131 Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Santoro</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, Federico II University of Naples, Via Montesano 49, 80131 Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Monnolo</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Medicine and Animal Productions, Federico II University of Naples, Via Delpino 1, 80137 Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simeoli</LastName>
<ForeName>Raffaele</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, Federico II University of Naples, Via Montesano 49, 80131 Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Di Guida</LastName>
<ForeName>Francesca</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, Federico II University of Naples, Via Montesano 49, 80131 Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mattace Raso</LastName>
<ForeName>Giuseppina</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, Federico II University of Naples, Via Montesano 49, 80131 Naples, Italy. Electronic address: mattace@unina.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meli</LastName>
<ForeName>Rosaria</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, Federico II University of Naples, Via Montesano 49, 80131 Naples, Italy. Electronic address: meli@unina.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001391">Azo Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004785">Environmental Pollutants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020738">Leptin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054411">Receptors, Leptin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491411">Socs3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050826">Suppressor of Cytokine Signaling Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1320-06-5</RegistryNumber>
<NameOfSubstance UI="C011049">oil red O</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DFC2HB4I0K</RegistryNumber>
<NameOfSubstance UI="D011078">Polychlorinated Biphenyls</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C516609">Ptpn1 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D041721">3T3-L1 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017667">Adipocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001391">Azo Compounds</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004396">Coloring Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004785">Environmental Pollutants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020738">Leptin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011078">Polychlorinated Biphenyls</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054411">Receptors, Leptin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050826">Suppressor of Cytokine Signaling Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AMPK/ACC pathway</Keyword>
<Keyword MajorTopicYN="N">Leptin receptor</Keyword>
<Keyword MajorTopicYN="N">Non-dioxin-like polychlorinated biphenyls</Keyword>
<Keyword MajorTopicYN="N">Pro-inflammatory cytokines</Keyword>
<Keyword MajorTopicYN="N">Signal transducer and activator of transcription 3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25018059</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Taurine protects HK-2 cells from oxidized LDL-induced cytotoxicity via the ROS-mediated mitochondrial and p53-related apoptotic pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>351-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.029</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00258-0</ELocationID>
<Abstract>
<AbstractText>Oxidized LDL (oxLDL) induces a pro-oxidative environment and promotes apoptosis, causing the progression of renal diseases in humans. Taurine is a semi-essential amino acid in mammals and has been shown to be a potent endogenous antioxidant. The kidney plays a pivotal role in maintaining the balance of taurine. However, the mechanisms underlying the protective effects of taurine against oxLDL-induced injury in renal epithelial cells have not been clarified. In the present study, we investigated the anti-apoptotic effects of taurine on human proximal tubular epithelial (HK-2) cells exposed to oxLDL and explored the related mechanisms. We observed that oxLDL increased the contents of ROS and of malondialdehyde (MDA), which is a lipid peroxidation by-product that acts as an indicator of the cellular oxidation status. In addition, oxLDL induced cell death and apoptosis in HK-2 cells. Pretreatment with taurine at 100 μM significantly attenuated the oxLDL-induced cytotoxicity. We determined that oxLDL triggered the phosphorylation of ERK and, in turn, the activation of p53 and other apoptosis-related events, including calcium accumulation, destabilization of the mitochondrial permeability and disruption of the balance between pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins. The malfunctions induced by oxLDL were effectively blocked by taurine. Thus, our results suggested that taurine exhibits potential therapeutic activity by preventing oxLDL-induced nephrotoxicity. The inhibition of oxLDL-induced epithelial apoptosis by taurine was at least partially due to its anti-oxidant activity and its ability to modulate the ERK and p53 apoptotic pathways.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Chun-Yu</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Graduate Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Chao-Yu</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>School of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung, Taiwan; Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Chao-Kai</ForeName>
<Initials>CK</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sher</LastName>
<ForeName>Yuh-Pyng</ForeName>
<Initials>YP</Initials>
<AffiliationInfo>
<Affiliation>Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sheu</LastName>
<ForeName>Wayne H-H</ForeName>
<Initials>WH</Initials>
<AffiliationInfo>
<Affiliation>Graduate Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan; Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; School of Medicine, National Yang Ming University, Taipei, Taiwan; School of Medicine, National Defense Medical Center, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Chia-Che</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Graduate Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan; Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan. Electronic address: chia_che@dragon.nchu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Tsung-Han</ForeName>
<Initials>TH</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan,; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan; Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan; Department of Biological Science and Technology, China Medical University, Taichung, Taiwan. Electronic address: thlee@email.nchu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099252">oxidized low density lipoprotein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1EQV5MLY3D</RegistryNumber>
<NameOfSubstance UI="D013654">Taurine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.15.1.1</RegistryNumber>
<NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000975">Antioxidants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020013">Calcium Signaling</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004247">DNA</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020287">In Situ Nick-End Labeling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008074">Lipoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008077">Lipoproteins, LDL</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018613">Microscopy, Confocal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013654">Taurine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">HK-2 cells</Keyword>
<Keyword MajorTopicYN="N">ROS</Keyword>
<Keyword MajorTopicYN="N">Taurine</Keyword>
<Keyword MajorTopicYN="N">oxLDL</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25108222</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0007</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>127</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental eye research</Title>
<ISOAbbreviation>Exp. Eye Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Aspergillus fumigatus triggers innate immune response via NOD1 signaling in human corneal epithelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>170-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exer.2014.07.025</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4835(14)00214-0</ELocationID>
<Abstract>
<AbstractText>Fungal keratitis is a serious vision-threatening disease caused by fungi after corneal epithelium damage. We have previously shown a role of cell surface TLRs in Aspergillus fumigatus (A. fumigatus) keratitis. In the present study we showed that Human telomerase-immortalized corneal epithelial cells (HCECs) exposed to A. fumigatus elicited an inflammatory response consisting in increased interleukin-6 (IL-6), IL-8 and tumor necrosis factor (TNF)-α expression and innate defense molecules hBD2 and LL37 in a time-dependent manner. In this study we further investigated the role of intracellular nucleotide-binding oligomerization domain-containing protein (NOD)-like receptors, NOD1 in innate immune and inflammatory response to A. fumigatus. We showed that NOD1 and its downstream signaling molecules RIP2 and NF-κB p65 are expressed in HCECs challenged with either NOD1 specific ligand iE-DAP or A. fumigatus. More importantly, NOD1 knockdown attenuated A. fumigatus-triggered the expression of NOD1, and downstream signaling effectors RIP2 and NF-κB p65, as well as the secretion of IL-6, IL-8 and TNF-α, and the production of hBD2 and LL37. In conclusion, our results demonstrated that NOD1 is a prominent factor of innate immune and inflammatory response in HCECs against A. fumigatus, suggesting that NOD1 might be a potential novel therapeutic target for the treatment of fungal keratitis. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yuting</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Qilu Hospital of Shandong University, Wenhua Xi Road 107, Jinan, Shandong Province, 250012, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Jiayin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Qilu Hospital of Shandong University, Wenhua Xi Road 107, Jinan, Shandong Province, 250012, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xin</LastName>
<ForeName>Zhaoting</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Qilu Hospital of Shandong University, Wenhua Xi Road 107, Jinan, Shandong Province, 250012, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Xinyi</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Qilu Hospital of Shandong University, Wenhua Xi Road 107, Jinan, Shandong Province, 250012, PR China. Electronic address: xywu8868@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Eye Res</MedlineTA>
<NlmUniqueID>0370707</NlmUniqueID>
<ISSNLinking>0014-4835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054804">Cathelicidins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C106641">DEFB4A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C119067">NOD1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053474">Nod1 Signaling Adaptor Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D023083">beta-Defensins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C106170">cathelicidin antimicrobial peptide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001232">Aspergillus fumigatus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054804">Cathelicidins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019573">Epithelium, Corneal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007378">Interleukins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053474">Nod1 Signaling Adaptor Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023083">beta-Defensins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Aspergillus fumigatus</Keyword>
<Keyword MajorTopicYN="N">HCECs</Keyword>
<Keyword MajorTopicYN="N">NOD1</Keyword>
<Keyword MajorTopicYN="N">inflammatory cytokine</Keyword>
<Keyword MajorTopicYN="N">innate immune</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25151301</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0007</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>127</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental eye research</Title>
<ISOAbbreviation>Exp. Eye Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Müller cells, lens, trabecular meshwork, cornea and lacrimal gland.</ArticleTitle>
<Pagination>
<MedlinePgn>270-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exer.2014.08.009</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4835(14)00230-9</ELocationID>
<Abstract>
<AbstractText>This review highlights recent findings that describ how purines modulate the physiological and pathophysiological responses of ocular tissues. For example, in lacrimal glands the cross-talk between P2X7 receptors and both M3 muscarinic receptors and α1D-adrenergic receptors can influence tear secretion. In the cornea, purines lead to post-translational modification of EGFR and structural proteins that participate in wound repair in the epithelium and influence the expression of matrix proteins in the stroma. Purines act at receptors on both the trabecular meshwork and ciliary epithelium to modulate intraocular pressure (IOP); ATP-release pathways of inflow and outflow cells differ, possibly permitting differential modulation of adenosine delivery. Modulators of trabecular meshwork cell ATP release include cell volume, stretch, extracellular Ca(2+) concentration, oxidation state, actin remodeling and possibly endogenous cardiotonic steroids. In the lens, osmotic stress leads to ATP release following TRPV4 activation upstream of hemichannel opening. In the anterior eye, diadenosine polyphosphates such as Ap4A act at P2 receptors to modulate the rate and composition of tear secretion, impact corneal wound healing and lower IOP. The Gq11-coupled P2Y1-receptor contributes to volume control in Müller cells and thus the retina. P2X receptors are expressed in neurons in the inner and outer retina and contribute to visual processing as well as the demise of retinal ganglion cells. In RPE cells, the balance between extracellular ATP and adenosine may modulate lysosomal pH and the rate of lipofuscin formation. In optic nerve head astrocytes, mechanosensitive ATP release via pannexin hemichannels, coupled with stretch-dependent upregulation of pannexins, provides a mechanism for ATP signaling in chronic glaucoma. With so many receptors linked to divergent functions throughout the eye, ensuring the transmitters remain local and stimulation is restricted to the intended target may be a key issue in understanding how physiological signaling becomes pathological in ocular disease. </AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sanderson</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>School of Pharmacy, University of East Anglia, Norwich, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dartt</LastName>
<ForeName>Darlene A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Trinkaus-Randall</LastName>
<ForeName>Vickery</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, MA, USA; Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pintor</LastName>
<ForeName>Jesus</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Faculty of Optometry, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Civan</LastName>
<ForeName>Mortimer M</ForeName>
<Initials>MM</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Delamere</LastName>
<ForeName>Nicholas A</ForeName>
<Initials>NA</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, University of Arizona, Tucson, AZ, USA; Department of Ophthalmology and Vision Science, University of Arizona, Tucson, AZ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fletcher</LastName>
<ForeName>Erica L</ForeName>
<Initials>EL</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy and of Neuroscience, University of Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Salt</LastName>
<ForeName>Thomas E</ForeName>
<Initials>TE</Initials>
<AffiliationInfo>
<Affiliation>Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grosche</LastName>
<ForeName>Antje</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Human Genetics, Franz-Josef-Strauß-Allee, Regensburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mitchell</LastName>
<ForeName>Claire H</ForeName>
<Initials>CH</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: chm@exchange.upenn.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>EY006177</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY009532</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY013434</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY013624</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY015537</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY01583</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY06000</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY06000S</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>EY06915</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY006000</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY006177</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY006915</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY009532</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY013434</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY013624</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EY015537</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Eye Res</MedlineTA>
<NlmUniqueID>0370707</NlmUniqueID>
<ISSNLinking>0014-4835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011684">Purine Nucleosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011685">Purine Nucleotides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003315">Cornea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063928">Ependymoglial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005123">Eye</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005128">Eye Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007765">Lacrimal Apparatus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007908">Lens, Crystalline</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011684">Purine Nucleosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011685">Purine Nucleotides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055351">Retinal Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055213">Retinal Pigment Epithelium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014129">Trabecular Meshwork</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS626351 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4175147 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ATP</Keyword>
<Keyword MajorTopicYN="N">P2X</Keyword>
<Keyword MajorTopicYN="N">P2Y</Keyword>
<Keyword MajorTopicYN="N">RPE</Keyword>
<Keyword MajorTopicYN="N">adenosine</Keyword>
<Keyword MajorTopicYN="N">cornea</Keyword>
<Keyword MajorTopicYN="N">diadenosine polyphosphates</Keyword>
<Keyword MajorTopicYN="N">eye</Keyword>
<Keyword MajorTopicYN="N">lacrimal gland</Keyword>
<Keyword MajorTopicYN="N">lens</Keyword>
<Keyword MajorTopicYN="N">neurotransmitter</Keyword>
<Keyword MajorTopicYN="N">retina</Keyword>
<Keyword MajorTopicYN="N">trabecular meshwork</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25180063</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-9538</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>211</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of experimental medicine</Title>
<ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Germinal center B cell maintenance and differentiation are controlled by distinct NF-κB transcription factor subunits.</ArticleTitle>
<Pagination>
<MedlinePgn>2103-18</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20132613</ELocationID>
<Abstract>
<AbstractText>Germinal centers (GCs) are the sites where memory B cells and plasma cells producing high-affinity antibodies are generated during T cell-dependent immune responses. The molecular control of GC B cell maintenance and differentiation remains incompletely understood. Activation of the NF-κB signaling pathway has been implicated; however, the distinct roles of the individual NF-κB transcription factor subunits are unknown. We report that GC B cell-specific deletion of the NF-κB subunits c-REL or RELA, which are both activated by the canonical NF-κB pathway, abolished the generation of high-affinity B cells via different mechanisms acting at distinct stages during the GC reaction. c-REL deficiency led to the collapse of established GCs immediately after the formation of dark and light zones at day 7 of the GC reaction and was associated with the failure to activate a metabolic program that promotes cell growth. Conversely, RELA was dispensable for GC maintenance but essential for the development of GC-derived plasma cells due to impaired up-regulation of BLIMP1. These results indicate that activation of the canonical NF-κB pathway in GC B cells controls GC maintenance and differentiation through distinct transcription factor subunits. Our findings have implications for the role of NF-κB in GC lymphomagenesis. </AbstractText>
<CopyrightInformation>© 2014 Heise et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Heise</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>De Silva</LastName>
<ForeName>Nilushi S</ForeName>
<Initials>NS</Initials>
<AffiliationInfo>
<Affiliation>Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Silva</LastName>
<ForeName>Kathryn</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carette</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simonetti</LastName>
<ForeName>Giorgia</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pasparakis</LastName>
<ForeName>Manolis</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Genetics, University of Cologne, 50674 Cologne, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klein</LastName>
<ForeName>Ulf</ForeName>
<Initials>U</Initials>
<AffiliationInfo>
<Affiliation>Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032 Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032 Herbert Irving Comprehensive Cancer Center, Department of Pathology and Cell Biology, and Department of Microbiology and Immunology, Columbia University, New York, NY 10032 uk30@columbia.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5T32-CA009503-26</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P60DK20541</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-CA157660</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Exp Med</MedlineTA>
<NlmUniqueID>2985109R</NlmUniqueID>
<ISSNLinking>0022-1007</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C087165">5-(6)-carboxyfluorescein diacetate succinimidyl ester</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005452">Fluoresceins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513258">Prdm1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020569">Proto-Oncogene Proteins c-rel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013388">Succinimides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051996">Transcription Factor RelA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005452">Fluoresceins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017353">Gene Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018858">Germinal Center</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015151">Immunoblotting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020569">Proto-Oncogene Proteins c-rel</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017423">Sequence Analysis, RNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013388">Succinimides</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051996">Transcription Factor RelA</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172226 [Available on 03/22/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25200027</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-9538</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>211</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of experimental medicine</Title>
<ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Regulation of proximal T cell receptor signaling and tolerance induction by deubiquitinase Usp9X.</ArticleTitle>
<Pagination>
<MedlinePgn>1947-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20140860</ELocationID>
<Abstract>
<AbstractText>The T cell hyperproliferation and autoimmune phenotypes that manifest in mice lacking E3 ubiquitin ligases such as Cbl, ITCH, or GRAIL highlight the importance of ubiquitination for the maintenance of peripheral T cell tolerance. Less is known, however, about the deubiquitinating enzymes that regulate T cell proliferation and effector function. Here, we define a cell intrinsic role for the deubiquitinase Usp9X during proximal TCR signaling. Usp9X-deficient T cells were hypoproliferative, yet mice with T cell-specific Usp9x deletion had elevated numbers of antigen-experienced T cells and expanded PD-1 and OX40-expressing populations consistent with immune hyperactivity. Aged Usp9x KO mice developed lupus-like autoimmunity and lymphoproliferative disease, indicating that ubiquitin ligases and deubiquitinases maintain the delicate balance between effective immunity and self-tolerance. </AbstractText>
<CopyrightInformation>© 2014 Naik et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Naik</LastName>
<ForeName>Edwina</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Department of Pathology, Department of Immunology, Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Webster</LastName>
<ForeName>Joshua D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Department of Pathology, Department of Immunology, Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>DeVoss</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Department of Pathology, Department of Immunology, Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jinfeng</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Department of Pathology, Department of Immunology, Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suriben</LastName>
<ForeName>Rowena</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Department of Pathology, Department of Immunology, Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dixit</LastName>
<ForeName>Vishva M</ForeName>
<Initials>VM</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Department of Pathology, Department of Immunology, Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080 dixit@gene.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Exp Med</MedlineTA>
<NlmUniqueID>2985109R</NlmUniqueID>
<ISSNLinking>0022-1007</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.99.-</RegistryNumber>
<NameOfSubstance UI="C404328">Usp9x protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015551">Autoimmunity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017931">DNA Primers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010450">Endopeptidases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008232">Lymphoproliferative Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011948">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017634">Self Tolerance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172213 [Available on 03/22/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25225457</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-9538</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>211</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of experimental medicine</Title>
<ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>IKK-induced NF-κB1 p105 proteolysis is critical for B cell antibody responses to T cell-dependent antigen.</ArticleTitle>
<Pagination>
<MedlinePgn>2085-101</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20132019</ELocationID>
<Abstract>
<AbstractText>The importance of IκB kinase (IKK)-induced proteolysis of NF-κB1 p105 in B cells was investigated using Nfkb1(SSAA/SSAA) mice, in which this NF-κB signaling pathway is blocked. Nfkb1(SSAA) mutation had no effect on the development and homeostasis of follicular mature (FM) B cells. However, analysis of mixed bone marrow chimeras revealed that Nfkb1(SSAA/SSAA) FM B cells were completely unable to mediate T cell-dependent antibody responses. Nfkb1(SSAA) mutation decreased B cell antigen receptor (BCR) activation of NF-κB in FM B cells, which selectively blocked BCR stimulation of cell survival and antigen-induced differentiation into plasmablasts and germinal center B cells due to reduced expression of Bcl-2 family proteins and IRF4, respectively. In contrast, the antigen-presenting function of FM B cells and their BCR-induced migration to the follicle T cell zone border, as well as their growth and proliferation after BCR stimulation, were not affected. All of the inhibitory effects of Nfkb1(SSAA) mutation on B cell functions were rescued by normalizing NF-κB activation genetically. Our study identifies critical B cell-intrinsic functions for IKK-induced NF-κB1 p105 proteolysis in the antigen-induced survival and differentiation of FM B cells, which are essential for T-dependent antibody responses. </AbstractText>
<CopyrightInformation>© 2014 Jacque et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jacque</LastName>
<ForeName>Emilie</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schweighoffer</LastName>
<ForeName>Edina</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Visekruna</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Papoutsopoulou</LastName>
<ForeName>Stamatia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Janzen</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zillwood</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tarlinton</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>The Walter and Eliza Hall Institute for Medical Research, Parkville, Victoria 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tybulewicz</LastName>
<ForeName>Victor L J</ForeName>
<Initials>VL</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ley</LastName>
<ForeName>Steven C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Division of Immune Cell Biology, MRC National Institute for Medical Research, London NW7 1AA, England, UK sley@nimr.mrc.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Exp Med</MedlineTA>
<NlmUniqueID>2985109R</NlmUniqueID>
<ISSNLinking>0022-1007</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052002">NF-kappa B p50 Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.10</RegistryNumber>
<NameOfSubstance UI="D051550">I-kappa B Kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000917">Antibody Formation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051550">I-kappa B Kinase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015151">Immunoblotting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008856">Microscopy, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052002">NF-kappa B p50 Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011947">Receptors, Antigen, B-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172221 [Available on 03/22/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25225460</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-9538</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>211</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of experimental medicine</Title>
<ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Selective and strain-specific NFAT4 activation by the Toxoplasma gondii polymorphic dense granule protein GRA6.</ArticleTitle>
<Pagination>
<MedlinePgn>2013-32</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20131272</ELocationID>
<Abstract>
<AbstractText>Toxoplasma gondii infection results in co-option and subversion of host cellular signaling pathways. This process involves discharge of T. gondii effector molecules from parasite secretory organelles such as rhoptries and dense granules. We report that the T. gondii polymorphic dense granule protein GRA6 regulates activation of the host transcription factor nuclear factor of activated T cells 4 (NFAT4). GRA6 overexpression robustly and selectively activated NFAT4 via calcium modulating ligand (CAMLG). Infection with wild-type (WT) but not GRA6-deficient parasites induced NFAT4 activation. Moreover, GRA6-deficient parasites failed to exhibit full virulence in local infection, and the treatment of WT mice with an NFAT inhibitor mitigated virulence of WT parasites. Notably, NFAT4-deficient mice displayed prolonged survival, decreased recruitment of CD11b(+) Ly6G(+) cells to the site of infection, and impaired expression of chemokines such as Cxcl2 and Ccl2. In addition, infection with type I parasites culminated in significantly higher NFAT4 activation than type II parasites due to a polymorphism in the C terminus of GRA6. Collectively, our data suggest that GRA6-dependent NFAT4 activation is required for T. gondii manipulation of host immune responses to maximize the parasite virulence in a strain-dependent manner. </AbstractText>
<CopyrightInformation>© 2014 Ma et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Ji Su</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan myamamoto@biken.osaka-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sasai</LastName>
<ForeName>Miwa</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohshima</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Youngae</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bando</LastName>
<ForeName>Hironori</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takeda</LastName>
<ForeName>Kiyoshi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Masahiro</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan Department of Immunoparasitology, Research Institute for Microbial Diseases, Laboratory of Immunoparasitology, Laboratory of Mucosal Immunology, WPI Immunology Frontier Research Center, Department of Microbiology and Immunology, Graduate School of Medicine, and Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan myamamoto@biken.osaka-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Exp Med</MedlineTA>
<NlmUniqueID>2985109R</NlmUniqueID>
<ISSNLinking>0022-1007</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000953">Antigens, Protozoan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490314">Caml protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C095047">GRA6 protein, Toxoplasma gondii</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050778">NFATC Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015800">Protozoan Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C054562">yellow fluorescent protein, Bacteria</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.13.12.-</RegistryNumber>
<NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Exp Med. 2014 Sep 22;211(10):1923</RefSource>
<PMID Version="1">25246389</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000953">Antigens, Protozoan</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001426">Bacterial Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047468">Immunoprecipitation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008156">Luciferases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008164">Luminescent Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008856">Microscopy, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050778">NFATC Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015800">Protozoan Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014122">Toxoplasma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014123">Toxoplasmosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172224 [Available on 03/22/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25225461</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-9538</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>211</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of experimental medicine</Title>
<ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.</ArticleTitle>
<Pagination>
<MedlinePgn>2033-45</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20140039</ELocationID>
<Abstract>
<AbstractText>In the present study, we have investigated the functional profile of CD4 T cells from patients with common variable immunodeficiency (CVID), including production of cytokines and proliferation in response to bacteria and virus-derived antigens. We show that the functional impairment of CD4 T cells, including the reduced capacity to proliferate and to produce IFN-γ and IL-2, was restricted to bacteria-specific and not virus-specific CD4 T cells. High levels of endotoxins were found in the plasma of patients with CVID, suggesting that CD4 T cell dysfunction might be caused by bacterial translocation. Of note, endotoxemia was associated with significantly higher expression of programmed death 1 (PD-1) on CD4 T cells. The blockade of the PD-1-PD-L1/2 axis in vitro restored CD4 T cell proliferation capacity, thus indicating that PD-1 signaling negatively regulates CD4 T cell functions. Finally, we showed that intravenous immunoglobulin G (IVIG) treatment significantly reduced endotoxemia and the percentage of PD-1(+) CD4 T cells, and restored bacteria-specific CD4 T cell cytokine production and proliferation. In conclusion, the present study demonstrates that the CD4 T cell exhaustion and functional impairment observed in CVID patients is associated with bacterial translocation and that IVIG treatment resolves bacterial translocation and restores CD4 T cell functions. </AbstractText>
<CopyrightInformation>© 2014 Perreau et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Perreau</LastName>
<ForeName>Matthieu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland matthieu.perreau@chuv.ch giuseppe.pantaleo@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vigano</LastName>
<ForeName>Selena</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bellanger</LastName>
<ForeName>Florence</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pellaton</LastName>
<ForeName>Céline</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Buss</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Comte</LastName>
<ForeName>Denis</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roger</LastName>
<ForeName>Thierry</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lacabaratz</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>INSERM U955, Université Paris Est Créteil, Groupe Henri-Mondor Albert-Chenevier, Immunologie Clinique, Vaccine Research Institute, 94010 Creteil, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bart</LastName>
<ForeName>Pierre-Alexandre</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Levy</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>INSERM U955, Université Paris Est Créteil, Groupe Henri-Mondor Albert-Chenevier, Immunologie Clinique, Vaccine Research Institute, 94010 Creteil, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pantaleo</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Service of Immunology and Allergy and Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland Swiss Vaccine Research Institute, 1011 Lausanne, Switzerland matthieu.perreau@chuv.ch giuseppe.pantaleo@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Exp Med</MedlineTA>
<NlmUniqueID>2985109R</NlmUniqueID>
<ISSNLinking>0022-1007</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061605">Administration, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000942">Antigens, Bacterial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000956">Antigens, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017074">Common Variable Immunodeficiency</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007963">Leukocytes, Mononuclear</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008033">Limulus Test</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172212 [Available on 03/22/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25246389</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1540-9538</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>211</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of experimental medicine</Title>
<ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Parasite uses host NFAT to co-opt immune response.</ArticleTitle>
<Pagination>
<MedlinePgn>1923</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.21110insight2</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hunter</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>University of Pennsylvania chunter@vet.upenn.edu dac2@vet.upenn.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christian</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>University of Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Exp Med</MedlineTA>
<NlmUniqueID>2985109R</NlmUniqueID>
<ISSNLinking>0022-1007</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000953">Antigens, Protozoan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C095047">GRA6 protein, Toxoplasma gondii</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050778">NFATC Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015800">Protozoan Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>J Exp Med. 2014 Sep 22;211(10):2013-32</RefSource>
<PMID Version="1">25225460</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000953">Antigens, Protozoan</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050778">NFATC Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015800">Protozoan Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014122">Toxoplasma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014123">Toxoplasmosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4172225 [Available on 03/22/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25044177</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8600</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Metabolism: clinical and experimental</Title>
<ISOAbbreviation>Metab. Clin. Exp.</ISOAbbreviation>
</Journal>
<ArticleTitle>The PI3K/p-Akt signaling pathway participates in calcitriol ameliorating podocyte injury in DN rats.</ArticleTitle>
<Pagination>
<MedlinePgn>1324-33</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metabol.2014.06.013</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0026-0495(14)00180-2</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The present study aimed to investigate the relationship between PI3K/p-Akt signaling pathway and podocyte impairment in DN rats as well as the protective effect of calcitriol.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">SD rats were randomly divided into four groups: normal control (NC), normal treated with calcitriol (NC+VD), diabetic nephropathy (DN) and DN treated with calcitriol (DN+VD); all VD rats were treated with 0.1 μg/kg/d calcitriol by gavage. DN model rats were established by intraperitoneal injections of streptozotocin (STZ). Rats were sacrificed after 18 weeks of treatments.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In the present study, increased albuminuria was observed as early as 3 weeks of diabetes and continued to increase more than six-fold throughout the length of the study (18 weeks). Expectedly, animals receiving the treatment with calcitriol was protected from this increase, lower about one third. Meanwhile, the expression of podocyte specific markers, including nephrin and podocin, together with PI3K/p-Akt was significantly decreased in DN rats, whereas calcitriol reversed these above changes accompanied by elevated the expression levels of VDR. Additionally, a positive correlation was observed between the expression levels of nephrin and VDR (r = 0.776, P &lt; 0.05). Likewise, the expression of nephrin was positively correlated with both PI3K-p85 and p-Akt (r = 0.736, P &lt; 0.05; r = 0.855, P &lt; 0.05, respectively).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PI3K/p-Akt signaling pathway participates in calcitriol ameliorating podocyte injury in DN rats. The manipulation of calcitriol might act as a promising therapeutic intervention for diabetic nephropathy.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Zhixia</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009 China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Yinfeng</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009 China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009 China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xiaoliang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009 China. Electronic address: tonyxlz@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Metabolism</MedlineTA>
<NlmUniqueID>0375267</NlmUniqueID>
<ISSNLinking>0026-0495</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003893">Desmin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018167">Receptors, Calcitriol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C113267">nephrin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>FXC9231JVH</RegistryNumber>
<NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000419">Albuminuria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002117">Calcitriol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003893">Desmin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003928">Diabetic Nephropathies</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050199">Podocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018167">Receptors, Calcitriol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Calcitriol</Keyword>
<Keyword MajorTopicYN="N">Diabetic nephropathy</Keyword>
<Keyword MajorTopicYN="N">PI3K/p-Akt signaling pathway</Keyword>
<Keyword MajorTopicYN="N">Podocyte</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25060689</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8600</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Metabolism: clinical and experimental</Title>
<ISOAbbreviation>Metab. Clin. Exp.</ISOAbbreviation>
</Journal>
<ArticleTitle>Leptin modulates autophagy in human CD4+CD25- conventional T cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1272-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metabol.2014.06.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0026-0495(14)00177-2</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this report we show that the adipocytokine leptin directly modulates autophagy in human CD4(+)CD25(-) conventional (Tconv) T cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In vitro treatment with recombinant human leptin determined an inhibition of autophagy during T cell receptor (TCR) stimulation, and this phenomenon was dose- and time-dependent. The events were secondary to the activation of the mammalian-target of rapamycin (mTOR)-pathway induced by leptin, as testified by its reversion induced by mTOR inhibition with rapamycin. At molecular level these phenomena associated with Bcl-2 up-regulation and its interaction with Beclin-1, whose complex exerts a negative effect on autophagy.</AbstractText>
<AbstractText Label="MATERIALS/METHODS" NlmCategory="METHODS">The impact of leptin on autophagy of Tconv cells was determined at biochemical level by western blotting and by flow cytometry; the interaction between BCL-2 and Beclin-1 by co-immunoprecipitation assays.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results, suggest that in unconditioned, freshly-isolated human Tconv cells, autophagy and proliferation are controlled by leptin during TCR-engagement, and that both phenomena occur alternatively indicating a balance between these processes during immune activation.</AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cassano</LastName>
<ForeName>Silvana</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pucino</LastName>
<ForeName>Valentina</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>La Rocca</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Procaccini</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>De Rosa</LastName>
<ForeName>Veronica</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Unità di NeuroImmunologia, IRCCS-Fondazione Santa Lucia, 00143 Roma, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marone</LastName>
<ForeName>Gianni</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Napoli, Italy; Centro Interdipartimentale di Ricerca in Scienze Immunologiche di Base e Cliniche (CISI), Università di Napoli "Federico II", 80131 Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matarese</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Medicina e Chirurgia, Facoltà di Medicina e Chirurgia, Università di Salerno, Baronissi Campus, 84081 Baronissi, Salerno, Italy; IRCCS-MultiMedica, 20138 Milano, Italy. Electronic address: gmatarese@unisa.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Metabolism</MedlineTA>
<NlmUniqueID>0375267</NlmUniqueID>
<ISSNLinking>0026-0495</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491997">BECN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508017">IL2RA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053645">Interleukin-2 Receptor alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020738">Leptin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1998 Aug 27;394(6696):897-901</RefSource>
<PMID Version="1">9732873</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Diabetologia. 2000 Jan;43(1):3-12</RefSource>
<PMID Version="1">10663211</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Diabetes. 2002 May;51(5):1356-61</RefSource>
<PMID Version="1">11978630</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2003 Jan;111(2):241-50</RefSource>
<PMID Version="1">12531880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2004 May;4(5):371-9</RefSource>
<PMID Version="1">15122202</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2004 Aug;7(2):167-78</RefSource>
<PMID Version="1">15296714</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1995 Dec 29;83(7):1263-71</RefSource>
<PMID Version="1">8548812</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1998 Feb 13;273(7):3963-6</RefSource>
<PMID Version="1">9461583</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1998 Oct 22;395(6704):763-70</RefSource>
<PMID Version="1">9796811</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Rheumatol. 1999;18(5):394-401</RefSource>
<PMID Version="1">10524554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2005 Sep 23;122(6):927-39</RefSource>
<PMID Version="1">16179260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2005 Oct;115(10):2679-88</RefSource>
<PMID Version="1">16200202</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2006 Oct 15;177(8):5163-8</RefSource>
<PMID Version="1">17015701</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2007 Jan;26(1):79-92</RefSource>
<PMID Version="1">17182262</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2007 Feb;26(2):241-55</RefSource>
<PMID Version="1">17307705</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2007 Jul;39(7):830-2</RefSource>
<PMID Version="1">17554261</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tissue Antigens. 2007 Aug;70(2):87-95</RefSource>
<PMID Version="1">17610413</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2008 Feb;40(2):204-10</RefSource>
<PMID Version="1">18204446</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Nutr. 2008;28:295-311</RefSource>
<PMID Version="1">18429698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2008 Sep 18;455(7211):396-400</RefSource>
<PMID Version="1">18701890</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2008 Dec;9(12):1004-10</RefSource>
<PMID Version="1">18971948</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2009 May;10(5):461-70</RefSource>
<PMID Version="1">19381141</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Differ. 2009 Jul;16(7):966-75</RefSource>
<PMID Version="1">19325568</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2009 Dec;41(12):1313-8</RefSource>
<PMID Version="1">19898481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2010 Apr 2;584(7):1287-95</RefSource>
<PMID Version="1">20083114</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Expert Rev Clin Immunol. 2010 Sep;6(5):801-8</RefSource>
<PMID Version="1">20828288</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2010 Oct 22;40(2):310-22</RefSource>
<PMID Version="1">20965424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2010 Dec 15;185(12):7474-9</RefSource>
<PMID Version="1">21078910</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2010 Dec 14;33(6):929-41</RefSource>
<PMID Version="1">21145759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2011 Feb;13(2):132-41</RefSource>
<PMID Version="1">21258367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2011 May 1;186(9):5313-22</RefSource>
<PMID Version="1">21421856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Rheumatol. 2011 Sep;7(9):528-36</RefSource>
<PMID Version="1">21808287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2011 Dec 19;208(13):2625-32</RefSource>
<PMID Version="1">22162830</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jan 26;481(7382):511-5</RefSource>
<PMID Version="1">22258505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2012 Sep 15;189(6):2941-53</RefSource>
<PMID Version="1">22904304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2012 Nov;8(11):1690-2</RefSource>
<PMID Version="1">22874554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2013 Apr 1;190(7):3054-8</RefSource>
<PMID Version="1">23447682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Med Chem. 2013;20(27):3416-25</RefSource>
<PMID Version="1">23746275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2013 Oct;13(10):722-37</RefSource>
<PMID Version="1">24064518</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2013 Nov;19(11):1478-88</RefSource>
<PMID Version="1">24141421</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunology. 2014 Jan;141(1):1-8</RefSource>
<PMID Version="1">23991647</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Cytokine Netw. 2000 Mar;11(1):7-14</RefSource>
<PMID Version="1">10705294</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol. 2001 May 15;166(10):5909-16</RefSource>
<PMID Version="1">11342605</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047468">Immunoprecipitation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053645">Interleukin-2 Receptor alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020738">Leptin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011948">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4180014</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Autophagy</Keyword>
<Keyword MajorTopicYN="N">Leptin</Keyword>
<Keyword MajorTopicYN="N">Metabolism</Keyword>
<Keyword MajorTopicYN="N">T cells</Keyword>
<Keyword MajorTopicYN="N">mTOR</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25108566</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8600</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Metabolism: clinical and experimental</Title>
<ISOAbbreviation>Metab. Clin. Exp.</ISOAbbreviation>
</Journal>
<ArticleTitle>Adiponectin stimulates Rho-mediated actin cytoskeleton remodeling and glucose uptake via APPL1 in primary cardiomyocytes.</ArticleTitle>
<Pagination>
<MedlinePgn>1363-73</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metabol.2014.07.005</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0026-0495(14)00200-5</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Adiponectin is known to confer its cardioprotective effects in obesity and type 2 diabetes, mainly by regulating glucose and fatty acid metabolism in cardiomyocytes. Dynamic actin cytoskeleton remodeling is involved in regulation of multiple biological functions, including glucose uptake. Here we investigated in neonatal cardiomyocytes whether adiponectin induced actin cytoskeleton remodeling and if this played a role in adiponectin-stimulated glucose uptake.</AbstractText>
<AbstractText Label="MATERIALS/METHODS" NlmCategory="METHODS">Primary cardiomyocytes were treated with full-length and globular adiponectin (fAd and gAd, respectively).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Both fAd and gAd increased RhoA activity, phosphorylation of the Rho/ROCK signaling target cofilin and actin polymerization to form filamentous actin as determined by rhodamine-phallodin immunofluorescence and quantitative analysis of filamentous to globular actin ratio. Scanning electron microscopy also demonstrated structural remodeling. Adiponectin stimulated glucose uptake, was significantly abrogated in the presence of inhibitors of actin cytoskeleton remodeling (cytochalasin D) and Rho/ROCK signaling (C3 transferase, Y27632). We showed that adiponectin increased colocalization of actin and APPL1 and that actin remodeling, phosphorylation of AMPK, p38MAPK and cofilin, glucose uptake and oxidation were all attenuated after siRNA-mediated knockdown of APPL1.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We show that adiponectin mediates Rho/ROCK-dependent actin cytoskeleton remodeling to increase glucose uptake and metabolism via APPL1 signaling.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Palanivel</LastName>
<ForeName>Rengasamy</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, York University, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ganguly</LastName>
<ForeName>Riya</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, York University, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Turdi</LastName>
<ForeName>Subat</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, York University, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Aimin</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Pharmaceutical Biotechnology, and Department of Medicine, the University of Hong Kong.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sweeney</LastName>
<ForeName>Gary</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, York University, Toronto, Canada. Electronic address: gsweeney@yorku.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Metabolism</MedlineTA>
<NlmUniqueID>0375267</NlmUniqueID>
<ISSNLinking>0026-0495</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052242">Adiponectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C515694">Appl1 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052242">Adiponectin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032383">Myocytes, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054460">rho-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">APPL1</Keyword>
<Keyword MajorTopicYN="N">Actin cytoskeleton</Keyword>
<Keyword MajorTopicYN="N">Adiponectin</Keyword>
<Keyword MajorTopicYN="N">Cardiomyocyte</Keyword>
<Keyword MajorTopicYN="N">Glucose uptake</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25101566</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1327-37</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.422</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Constitutive activation of signal transducer and activator of transcription signalling 3 (STAT3) has been linked with survival, proliferation and angiogenesis in a wide variety of malignancies including hepatocellular carcinoma (HCC).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the effect of lupeol on STAT3 signalling cascade and its regulated functional responses in HCC cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Lupeol suppressed constitutive activation of STAT3 phosphorylation at tyrosine 705 residue effectively in a dose- and time-dependent manner. The phosphorylation of Janus-activated kinases (JAKs) 1 and 2 and Src was also suppressed by lupeol. Pervanadate treatment reversed the downregulation of phospho-STAT3 induced by lupeol, thereby indicating the involvement of a phosphatase. Indeed, we observed that treatment with lupeol increased the protein and mRNA levels of SHP-2, and silencing of SHP-2 abolished the inhibitory effects of lupeol on STAT3 activation. Treatment with lupeol also downregulated the expression of diverse STAT3-regulated genes and decreased the binding of STAT3 to VEGF promoter. Moreover, the proliferation of various HCC cells was significantly suppressed by lupeol, being associated with substantial induction of apoptosis. Depletion of SHP-2 reversed the observed antiproliferative and pro-apoptotic effects of lupeol.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lupeol exhibited its potential anticancer effects in HCC through the downregulation of STAT3-induced pro-survival signalling cascade.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Siveen</LastName>
<ForeName>K S</ForeName>
<Initials>KS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>A H</ForeName>
<Initials>AH</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>S S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore [2] Cancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore [2] Cancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore [3] Biomedical Sciences, Faculty of Health Sciences, Curtin University, Perth, Western Australia 6009, Australia [4] Department of Biological Sciences, University of North Texas, Denton, TX 76203, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Low</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore [2] Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jha</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore [2] Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tergaonkar</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular and Cell Biology, A*STAR, Biopolis Drive Proteos, Singapore, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>K S</ForeName>
<Initials>KS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sethi</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore [2] Cancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.010.2</RegistryNumber>
<NameOfSubstance UI="C507904">JAK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C507924">JAK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>O268W13H3O</RegistryNumber>
<NameOfSubstance UI="C010480">lupeol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054377">Chemokine CXCL12</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053613">Janus Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053978">Pentacyclic Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183851 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25144626</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Eph receptors as therapeutic targets in glioblastoma.</ArticleTitle>
<Pagination>
<MedlinePgn>1255-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.73</ELocationID>
<Abstract>
<AbstractText>The dismal outlook for patients with the most aggressive and common form of adult brain cancer, glioblastoma (GBM), motivates a search for new therapeutic strategies and targets for this aggressive disease. Here we review the findings to date on the role of Eph family receptor tyrosine kinases and their ephrin ligands in brain cancer. Expression of the Eph family of cell surface proteins is generally downregulated to very low levels in normal adult tissues making them particularly attractive for directed therapeutic targeting. Recent Eph targeting studies in pre-clinical models of GBM have been very encouraging and may provide an avenue to treat these highly refractory aggressive tumours. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Day</LastName>
<ForeName>B W</ForeName>
<Initials>BW</Initials>
<AffiliationInfo>
<Affiliation>Brain Cancer &amp; Leukaemia Foundation Research Unit, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stringer</LastName>
<ForeName>B W</ForeName>
<Initials>BW</Initials>
<AffiliationInfo>
<Affiliation>Brain Cancer &amp; Leukaemia Foundation Research Unit, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boyd</LastName>
<ForeName>A W</ForeName>
<Initials>AW</Initials>
<AffiliationInfo>
<Affiliation>1] Brain Cancer &amp; Leukaemia Foundation Research Unit, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia [2] Department of Medicine, University of Queensland, Herston, Brisbane 4006, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 Dec 13;31(50):5132-43</RefSource>
<PMID Version="1">22310282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2012 Dec 11;22(6):765-80</RefSource>
<PMID Version="1">23238013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Jan 15;73(2):990-9</RefSource>
<PMID Version="1">23204229</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tumour Biol. 2013 Feb;34(1):379-85</RefSource>
<PMID Version="1">23138393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest New Drugs. 2013 Feb;31(1):77-84</RefSource>
<PMID Version="1">22370972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2013 Feb 11;23(2):238-48</RefSource>
<PMID Version="1">23410976</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2013 Oct 10;155(2):462-77</RefSource>
<PMID Version="1">24120142</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2004 May 1;64(9):3179-85</RefSource>
<PMID Version="1">15126357</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2000 Sep 1;60(17):4855-63</RefSource>
<PMID Version="1">10987298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Drug Discov. 2014 Jan;13(1):39-62</RefSource>
<PMID Version="1">24378802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2004 Jul 30;279(31):32643-50</RefSource>
<PMID Version="1">15145949</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ai Zheng. 2004 Oct;23(10):1161-5</RefSource>
<PMID Version="1">15473927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1995 Jan 27;80(2):179-85</RefSource>
<PMID Version="1">7834738</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 1996 Jul 17;67(2):275-82</RefSource>
<PMID Version="1">8760599</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1998 May 29;93(5):741-53</RefSource>
<PMID Version="1">9630219</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Brain Res. 1999 Mar 6;821(1):169-76</RefSource>
<PMID Version="1">10064801</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2004 Nov 15;64(22):8271-5</RefSource>
<PMID Version="1">15548694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2005 Feb 15;19(4):462-71</RefSource>
<PMID Version="1">15713841</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2005 Mar 10;352(10):987-96</RefSource>
<PMID Version="1">15758009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2005 Jun 16;24(26):4243-56</RefSource>
<PMID Version="1">15782114</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2005 Aug;167(2):565-76</RefSource>
<PMID Version="1">16049340</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 2005 Aug;7(8):717-22</RefSource>
<PMID Version="1">16207473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Res. 2005 Oct;3(10):541-51</RefSource>
<PMID Version="1">16254188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2006 Feb 8;25(3):628-41</RefSource>
<PMID Version="1">16424904</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2006 Jun;6(6):425-36</RefSource>
<PMID Version="1">16723989</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Sep 1;66(17):8492-500</RefSource>
<PMID Version="1">16951161</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Nov 15;66(22):10815-23</RefSource>
<PMID Version="1">17090523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 2007 Feb 1;302(1):66-79</RefSource>
<PMID Version="1">17046737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Oncol. 2007 Apr;30(4):865-71</RefSource>
<PMID Version="1">17332925</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tumour Biol. 2007;28(3):165-72</RefSource>
<PMID Version="1">17519535</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2024-36</RefSource>
<PMID Version="1">17673999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3208-18</RefSource>
<PMID Version="1">18089715</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Rep. 2008 Jan;19(1):151-6</RefSource>
<PMID Version="1">18097589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2008 Jan 1;14(1):199-208</RefSource>
<PMID Version="1">18172271</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Cancer. 2008;8:79</RefSource>
<PMID Version="1">18366728</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Rep. 2008 May;19(5):1277-83</RefSource>
<PMID Version="1">18425388</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2008 Jul 31;359(5):492-507</RefSource>
<PMID Version="1">18669428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2008 Sep;7(9):2768-78</RefSource>
<PMID Version="1">18790757</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Immunol Immunother. 2008 Dec;57(12):1861-9</RefSource>
<PMID Version="1">18438665</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2008 Dec 11;27(58):7260-73</RefSource>
<PMID Version="1">18794797</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2009 Feb 1;69(3):836-44</RefSource>
<PMID Version="1">19176381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2009 Apr 16;28(15):1759-68</RefSource>
<PMID Version="1">19270726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2009 Jul 7;16(1):9-20</RefSource>
<PMID Version="1">19573808</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Expert Rev Neurother. 2009 Oct;9(10):1519-27</RefSource>
<PMID Version="1">19831841</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2010 Mar 1;126(5):1155-65</RefSource>
<PMID Version="1">19728339</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2010 Jan 19;17(1):98-110</RefSource>
<PMID Version="1">20129251</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2010 Mar;10(3):165-80</RefSource>
<PMID Version="1">20179713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2010 May 27;465(7297):487-91</RefSource>
<PMID Version="1">20445540</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tumour Biol. 2010 Oct;31(5):477-88</RefSource>
<PMID Version="1">20571968</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2011 Jan 20;29(3):330-6</RefSource>
<PMID Version="1">21149657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(1):e16264</RefSource>
<PMID Version="1">21264258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Sep 15;71(18):6073-83</RefSource>
<PMID Version="1">21803743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Transl Oncol. 2012 Mar;14(3):214-20</RefSource>
<PMID Version="1">22374425</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 2012 Jul;14(7):666-9</RefSource>
<PMID Version="1">22904683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Onkologie. 2012;35(12):763-8</RefSource>
<PMID Version="1">23207622</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036342">Ephrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036081">Receptors, Eph Family</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183860</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24760138</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Liver-restricted Repin1 deficiency improves whole-body insulin sensitivity, alters lipid metabolism, and causes secondary changes in adipose tissue in mice.</ArticleTitle>
<Pagination>
<MedlinePgn>3295-309</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-0933</ELocationID>
<Abstract>
<AbstractText>Replication initiator 1 (Repin1) is a zinc finger protein highly expressed in liver and adipose tissue and maps within a quantitative trait locus (QTL) for body weight and triglyceride (TG) levels in the rat. The QTL has further been supported as a susceptibility locus for dyslipidemia and related metabolic disorders in congenic and subcongenic rat strains. Here, we elucidated the role of Repin1 in lipid metabolism in vivo. We generated a liver-specific Repin1 knockout mouse (LRep1(-/-)) and systematically characterized the consequences of Repin1 deficiency in the liver on body weight, glucose and lipid metabolism, liver lipid patterns, and protein/mRNA expression. Hyperinsulinemic-euglycemic clamp studies revealed significantly improved whole-body insulin sensitivity in LRep1(-/-) mice, which may be due to significantly lower TG content in the liver. Repin1 deficiency causes significant changes in potential downstream target molecules including Cd36, Pparγ, Glut2 protein, Akt phosphorylation, and lipocalin2, Vamp4, and Snap23 mRNA expression. Mice with hepatic deletion of Repin1 display secondary changes in adipose tissue function, which may be mediated by altered hepatic expression of lipocalin2 or chemerin. Our findings indicate that Repin1 plays a role in insulin sensitivity and lipid metabolism by regulating key genes of glucose and lipid metabolism. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kern</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kosacka</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hesselbarth</LastName>
<ForeName>Nico</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brückner</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Heiker</LastName>
<ForeName>John T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Flehmig</LastName>
<ForeName>Gesine</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>IFB AdiposityDiseases, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klöting</LastName>
<ForeName>Ingrid</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Laboratory Animal Science, University of Greifswald, Karlsburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kovacs</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>IFB AdiposityDiseases, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matz-Soja</LastName>
<ForeName>Madlen</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gebhardt</LastName>
<ForeName>Rolf</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Krohn</LastName>
<ForeName>Knut</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Interdisciplinary Center for Clinical Research, Core Unit DNA Technologies, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sales</LastName>
<ForeName>Susanne</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abshagen</LastName>
<ForeName>Kerstin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute for Experimental Surgery, Rostock University Medical School, Rostock, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shevchenko</LastName>
<ForeName>Andrej</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stumvoll</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany IFB AdiposityDiseases, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blüher</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany IFB AdiposityDiseases, University of Leipzig, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klöting</LastName>
<ForeName>Nora</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Leipzig, Leipzig, Germany IFB AdiposityDiseases, University of Leipzig, Leipzig, Germany nora.kloeting@medizin.uni-leipzig.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C552723">Repin1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000273">Adipose Tissue</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015309">Glucose Clamp Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24760140</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>BH3-only molecule Bim mediates β-cell death in IRS2 deficiency.</ArticleTitle>
<Pagination>
<MedlinePgn>3378-87</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1814</ELocationID>
<Abstract>
<AbstractText>Irs2-deficient mice develop type 2-like diabetes due to a reduction in β-cell mass and a failure of pancreatic islets to undergo compensatory hyperplasia in response to insulin resistance. In order to define the molecular mechanisms, we knocked down Irs2 gene expression in mouse MIN6 insulinoma cells. Insulin receptor substrate 2 (IRS2) suppression induced apoptotic cell death, which was associated with an increase in expression of the BH3-only molecule Bim. Knockdown (KD) of Bim reduced apoptotic β-cell death induced by IRS2 suppression. In Irs2-deficient mice, Bim ablation restored β-cell mass, decreased the number of TUNEL-positive cells, and restored normal glucose tolerance after glucose challenge. FoxO1 mediates Bim upregulation induced by IRS2 suppression, and FoxO1 KD partially inhibits β-cell death induced by IRS2 suppression. These results suggest that Bim plays an important role in mediating the increase in β-cell apoptosis and the reduction in β-cell mass that occurs in IRS2-deficient diabetes. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ren</LastName>
<ForeName>Decheng</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, The University of Chicago, Chicago, IL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, The University of Chicago, Chicago, IL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mao</LastName>
<ForeName>Liqun</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, The University of Chicago, Chicago, IL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ye</LastName>
<ForeName>Honggang</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, The University of Chicago, Chicago, IL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Polonsky</LastName>
<ForeName>Kenneth S</ForeName>
<Initials>KS</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, The University of Chicago, Chicago, IL polonsky@bsd.uchicago.edu decheng@uchicago.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 DK020595</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30-DK-020595</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK031842</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-DK-031842</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C110430">Bcl-2-like protein 11</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055504">Insulin Receptor Substrate Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C526298">Irs2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002452">Cell Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055504">Insulin Receptor Substrate Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050417">Insulin-Secreting Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007515">Islets of Langerhans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4171655 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24789920</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1α pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>3199-209</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1921</ELocationID>
<Abstract>
<AbstractText>Type 2 diabetes (T2D) is hallmarked by insulin resistance, impaired insulin secretion, and increased hepatic glucose production. The worldwide increasing prevalence of T2D calls for efforts to understand its pathogenesis in order to improve disease prevention and management. Recent genome-wide association studies have revealed strong associations between the CDKN2A/B locus and T2D risk. The CDKN2A/B locus contains genes encoding cell cycle inhibitors, including p16(Ink4a), which have not yet been implicated in the control of hepatic glucose homeostasis. Here, we show that p16(Ink4a) deficiency enhances fasting-induced hepatic glucose production in vivo by increasing the expression of key gluconeogenic genes. p16(Ink4a) downregulation leads to an activation of PKA-CREB-PGC1α signaling through increased phosphorylation of PKA regulatory subunits. Taken together, these results provide evidence that p16(Ink4a) controls fasting glucose homeostasis and could as such be involved in T2D development. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bantubungi</LastName>
<ForeName>Kadiombo</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hannou</LastName>
<ForeName>Sarah-Anissa</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Caron-Houde</LastName>
<ForeName>Sandrine</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vallez</LastName>
<ForeName>Emmanuelle</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baron</LastName>
<ForeName>Morgane</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lucas</LastName>
<ForeName>Anthony</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bouchaert</LastName>
<ForeName>Emmanuel</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paumelle</LastName>
<ForeName>Réjane</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tailleux</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Staels</LastName>
<ForeName>Bart</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Université Lille 2, Lille, France INSERM, U1011, Lille, France European Genomic Institute for Diabetes, Lille, France Institut Pasteur de Lille, Lille, France bart.staels@pasteur-lille.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485290">Ppargc1a protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.11</RegistryNumber>
<NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017362">Cyclic AMP Response Element-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017868">Cyclic AMP-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005215">Fasting</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005943">Gluconeogenesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24812425</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Catalase overexpression prevents nuclear factor erythroid 2-related factor 2 stimulation of renal angiotensinogen gene expression, hypertension, and kidney injury in diabetic mice.</ArticleTitle>
<Pagination>
<MedlinePgn>3483-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1830</ELocationID>
<Abstract>
<AbstractText>This study investigated the impact of catalase (Cat) overexpression in renal proximal tubule cells (RPTCs) on nuclear factor erythroid 2-related factor 2 (Nrf2) stimulation of angiotensinogen (Agt) gene expression and the development of hypertension and renal injury in diabetic Akita transgenic mice. Additionally, adult male mice were treated with the Nrf2 activator oltipraz with or without the inhibitor trigonelline. Rat RPTCs, stably transfected with plasmid containing either rat Agt or Nrf2 gene promoter, were also studied. Cat overexpression normalized systolic BP, attenuated renal injury, and inhibited RPTC Nrf2, Agt, and heme oxygenase-1 (HO-1) gene expression in Akita Cat transgenic mice compared with Akita mice. In vitro, high glucose level, hydrogen peroxide, and oltipraz stimulated Nrf2 and Agt gene expression; these changes were blocked by trigonelline, small interfering RNAs of Nrf2, antioxidants, or pharmacological inhibitors of nuclear factor-κB and p38 mitogen-activated protein kinase. The deletion of Nrf2-responsive elements in the rat Agt gene promoter abolished the stimulatory effect of oltipraz. Oltipraz administration also augmented Agt, HO-1, and Nrf2 gene expression in mouse RPTCs and was reversed by trigonelline. These data identify a novel mechanism, Nrf2-mediated stimulation of intrarenal Agt gene expression and activation of the renin-angiotensin system, by which hyperglycemia induces hypertension and renal injury in diabetic mice. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Abdo</LastName>
<ForeName>Shaaban</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Yixuan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Otoukesh</LastName>
<ForeName>Abouzar</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghosh</LastName>
<ForeName>Anindya</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lo</LastName>
<ForeName>Chao-Sheng</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chenier</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Filep</LastName>
<ForeName>Janos G</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ingelfinger</LastName>
<ForeName>Julie R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Pediatric Nephrology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Shao Ling</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>John S D</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Research Centre, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada john.chan@umontreal.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HL-48455</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>MOP 16088</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP 93650</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP-84363</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP-86450</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>MOP-97742</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495636">Nfe2l2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11002-13-4</RegistryNumber>
<NameOfSubstance UI="D000808">Angiotensinogen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6N510JUL1Y</RegistryNumber>
<NameOfSubstance UI="C026209">oltipraz</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.11.1.6</RegistryNumber>
<NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000808">Angiotensinogen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002374">Catalase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007687">Kidney Tubules, Proximal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051267">NF-E2-Related Factor 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011719">Pyrazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018894">Reverse Transcriptase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4171660 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24812431</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>IKKε is key to induction of insulin resistance in the hypothalamus, and its inhibition reverses obesity.</ArticleTitle>
<Pagination>
<MedlinePgn>3334-45</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1817</ELocationID>
<Abstract>
<AbstractText>IKK epsilon (IKKε) is induced by the activation of nuclear factor-κB (NF-κB). Whole-body IKKε knockout mice on a high-fat diet (HFD) were protected from insulin resistance and showed altered energy balance. We demonstrate that IKKε is expressed in neurons and is upregulated in the hypothalamus of obese mice, contributing to insulin and leptin resistance. Blocking IKKε in the hypothalamus of obese mice with CAYMAN10576 or small interfering RNA decreased NF-κB activation in this tissue, relieving the inflammatory environment. Inhibition of IKKε activity, but not TBK1, reduced IRS-1(Ser307) phosphorylation and insulin and leptin resistance by an improvement of the IR/IRS-1/Akt and JAK2/STAT3 pathways in the hypothalamus. These improvements were independent of body weight and food intake. Increased insulin and leptin action/signaling in the hypothalamus may contribute to a decrease in adiposity and hypophagia and an enhancement of energy expenditure accompanied by lower NPY and increased POMC mRNA levels. Improvement of hypothalamic insulin action decreases fasting glycemia, glycemia after pyruvate injection, and PEPCK protein expression in the liver of HFD-fed and db/db mice, suggesting a reduction in hepatic glucose production. We suggest that IKKε may be a key inflammatory mediator in the hypothalamus of obese mice, and its hypothalamic inhibition improves energy and glucose metabolism. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Weissmann</LastName>
<ForeName>Laís</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Quaresma</LastName>
<ForeName>Paula G F</ForeName>
<Initials>PG</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Santos</LastName>
<ForeName>Andressa C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Matos</LastName>
<ForeName>Alexandre H B</ForeName>
<Initials>AH</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pascoal</LastName>
<ForeName>Vínicius D'Ávila Bittencourt</ForeName>
<Initials>VD</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zanotto</LastName>
<ForeName>Tamires M</ForeName>
<Initials>TM</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Castro</LastName>
<ForeName>Gisele</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guadagnini</LastName>
<ForeName>Dioze</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>da Silva</LastName>
<ForeName>Joelcimar Martins</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Velloso</LastName>
<ForeName>Licio A</ForeName>
<Initials>LA</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bittencourt</LastName>
<ForeName>Jackson C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lopes-Cendes</LastName>
<ForeName>Iscia</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saad</LastName>
<ForeName>Mario J A</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Prada</LastName>
<ForeName>Patricia O</ForeName>
<Initials>PO</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil School of Applied Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil pprada@fcm.unicamp.br.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020738">Leptin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.10</RegistryNumber>
<NameOfSubstance UI="D051550">I-kappa B Kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059305">Diet, High-Fat</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007031">Hypothalamus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051550">I-kappa B Kinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020738">Leptin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008820">Mice, Obese</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24824430</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.</ArticleTitle>
<Pagination>
<MedlinePgn>3394-403</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1868</ELocationID>
<Abstract>
<AbstractText>In pancreatic β-cells, closure of the ATP-sensitive K(+) (K(ATP)) channel is an initial process triggering glucose-stimulated insulin secretion. In addition, constitutive opening of background nonselective cation channels (NSCCs) is essentially required to effectively evoke depolarization as a consequence of K(ATP) channel closure. Thus, it is hypothesized that further opening of NSCC facilitates membrane excitability. We identified a class of NSCC that was activated by exendin (ex)-4, GLP-1, and its analog liraglutide at picomolar levels. This NSCC was also activated by increasing the glucose concentration. NSCC activation by glucose and GLP-1 was a consequence of the activated cAMP/EPAC-mediated pathway and was attenuated in TRPM2-deficient mice. The NSCC was not activated by protein kinase A (PKA) activators and was activated by ex-4 in the presence of PKA inhibitors. These results suggest that glucose- and incretin-activated NSCC (TRPM2) works in concert with closure of the KATP channel to effectively induce membrane depolarization to initiate insulin secretion. The current study reveals a new mechanism for regulating electrical excitability in β-cells and for mediating the action of glucose and incretin to evoke insulin secretion, thereby providing an innovative target for the treatment of type 2 diabetes.</AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yosida</LastName>
<ForeName>Masashi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dezaki</LastName>
<ForeName>Katsuya</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Integrative Physiology, Jichi Medical University, Shimotsuke, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uchida</LastName>
<ForeName>Kunitoshi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>National Institute for Physiological Sciences, Okazaki, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kodera</LastName>
<ForeName>Shiho</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lam</LastName>
<ForeName>Nien V</ForeName>
<Initials>NV</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ito</LastName>
<ForeName>Kiyonori</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rita</LastName>
<ForeName>Rauza S</ForeName>
<Initials>RS</Initials>
<AffiliationInfo>
<Affiliation>Integrative Physiology, Jichi Medical University, Shimotsuke, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamada</LastName>
<ForeName>Hodaka</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimomura</LastName>
<ForeName>Kenju</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Integrative Physiology, Jichi Medical University, Shimotsuke, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ishikawa</LastName>
<ForeName>San-e</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sugawara</LastName>
<ForeName>Hitoshi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kawakami</LastName>
<ForeName>Masanobu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan Nerima Hikarigaoka Hospital, Nerima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tominaga</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>National Institute for Physiological Sciences, Okazaki, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yada</LastName>
<ForeName>Toshihiko</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Integrative Physiology, Jichi Medical University, Shimotsuke, Japan National Institute for Physiological Sciences, Okazaki, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kakei</LastName>
<ForeName>Masafumi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Internal Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan mkakei@jichi.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054795">Incretins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050053">TRPM Cation Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C544443">TRPM2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014688">Venoms</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63937KV33D</RegistryNumber>
<NameOfSubstance UI="D004917">Erythromycin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>84252-03-9</RegistryNumber>
<NameOfSubstance UI="C057513">erythromycin propionate-N-acetylcysteinate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9P1872D4OL</RegistryNumber>
<NameOfSubstance UI="C074031">exenatide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>WYQ7N0BPYC</RegistryNumber>
<NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000111">Acetylcysteine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004917">Erythromycin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054795">Incretins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050417">Insulin-Secreting Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050053">TRPM Cation Channels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014688">Venoms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24834975</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Palmitate induces mRNA translation and increases ER protein load in islet β-cells via activation of the mammalian target of rapamycin pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>3404-15</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db14-0105</ELocationID>
<Abstract>
<AbstractText>Saturated free fatty acids (FFAs) have complex effects on the islet β-cell, acutely promoting adaptive hyperplasia but chronically impairing insulin release. The acute effects of FFAs remain incompletely defined. To elucidate these early molecular events, we incubated mouse β-cells and islets with palmitate and then studied mRNA translation by polyribosomal profiling and analyzed signaling pathways by immunoblot analysis. We found that palmitate acutely increases polyribosome occupancy of total RNA, consistent with an increase in mRNA translation. This effect on translation was attributable to activation of mammalian target of rapamycin (mTOR) pathways via L-type Ca(2+) channels but was independent of insulin signaling. Longer incubations led to depletion of polyribosome-associated RNA, consistent with activation of the unfolded protein response (UPR). Pharmacologic inhibition of mTOR suppressed both the acute effects of palmitate on mRNA translation and the chronic effects on the UPR. Islets from mice fed a high-fat diet for 7 days showed increases in polyribosome-associated RNA and phosphorylation of S6K, both consistent with activation of mTOR. Our results suggest that palmitate acutely activates mRNA translation and that this increase in protein load contributes to the later UPR. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hatanaka</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maier</LastName>
<ForeName>Bernhard</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sims</LastName>
<ForeName>Emily K</ForeName>
<Initials>EK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Templin</LastName>
<ForeName>Andrew T</ForeName>
<Initials>AT</Initials>
<AffiliationInfo>
<Affiliation>Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kulkarni</LastName>
<ForeName>Rohit N</ForeName>
<Initials>RN</Initials>
<AffiliationInfo>
<Affiliation>Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Evans-Molina</LastName>
<ForeName>Carmella</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Indiana University School of Medicine, Indianapolis, IN Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mirmira</LastName>
<ForeName>Raghavendra G</ForeName>
<Initials>RG</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Indiana University School of Medicine, Indianapolis, IN Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN rmirmira@iu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 DK093954</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-DK-060581</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-DK-083583</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-DK-093954</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-DK-67536</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32-DK-065549</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2V16EO95H1</RegistryNumber>
<NameOfSubstance UI="D019308">Palmitic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059305">Diet, High-Fat</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004721">Endoplasmic Reticulum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050417">Insulin-Secreting Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019308">Palmitic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014176">Protein Biosynthesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4171659 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24848063</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Orally active osteoanabolic agent GTDF binds to adiponectin receptors, with a preference for AdipoR1, induces adiponectin-associated signaling, and improves metabolic health in a rodent model of diabetes.</ArticleTitle>
<Pagination>
<MedlinePgn>3530-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1619</ELocationID>
<Abstract>
<AbstractText>Adiponectin is an adipocytokine that signals through plasma membrane-bound adiponectin receptors 1 and 2 (AdipoR1 and -2). Plasma adiponectin depletion is associated with type 2 diabetes, obesity, and cardiovascular diseases. Adiponectin therapy, however, is yet unavailable owing to its large size, complex multimerization, and functional differences of the multimers. We report discovery and characterization of 6-C-β-D-glucopyranosyl-(2S,3S)-(+)-5,7,3',4'-tetrahydroxydihydroflavonol (GTDF) as an orally active adiponectin mimetic. GTDF interacted with both AdipoRs, with a preference for AdipoR1. It induced adiponectin-associated signaling and enhanced glucose uptake and fatty acid oxidation in vitro, which were augmented or abolished by AdipoR1 overexpression or silencing, respectively. GTDF improved metabolic health, characterized by elevated glucose clearance, β-cell survival, reduced steatohepatitis, browning of white adipose tissue, and improved lipid profile in an AdipoR1-expressing but not an AdipoR1-depleted strain of diabetic mice. The discovery of GTDF as an adiponectin mimetic provides a promising therapeutic tool for the treatment of metabolic diseases.</AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Abhishek Kumar</ForeName>
<Initials>AK</Initials>
<AffiliationInfo>
<Affiliation>Biochemistry Division, Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Joharapurkar</LastName>
<ForeName>Amit Arvind</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Zydus Research Center, Moraiya, Ahmedabad, Gujarat, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khan</LastName>
<ForeName>Mohd Parvez</ForeName>
<Initials>MP</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mishra</LastName>
<ForeName>Jay Sharan</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Biochemistry Division, Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Nidhi</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Biochemistry Division, Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yadav</LastName>
<ForeName>Manisha</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Biochemistry Division, Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hossain</LastName>
<ForeName>Zakir</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Division of Phramacokinetics, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khan</LastName>
<ForeName>Kainat</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Sudhir</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Medicinal and Process Chemistry, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dhanesha</LastName>
<ForeName>Nirav Anilkumar</ForeName>
<Initials>NA</Initials>
<AffiliationInfo>
<Affiliation>Zydus Research Center, Moraiya, Ahmedabad, Gujarat, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mishra</LastName>
<ForeName>Devendra Pratap</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>Division of Medicinal and Process Chemistry, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maurya</LastName>
<ForeName>Rakesh</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Medicinal and Process Chemistry, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sharma</LastName>
<ForeName>Sharad</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Toxicology, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jain</LastName>
<ForeName>Mukul Rameshchandra</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Zydus Research Center, Moraiya, Ahmedabad, Gujarat, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Trivedi</LastName>
<ForeName>Arun Kumar</ForeName>
<Initials>AK</Initials>
<AffiliationInfo>
<Affiliation>Biochemistry Division, Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Godbole</LastName>
<ForeName>Madan Madhav</ForeName>
<Initials>MM</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gayen</LastName>
<ForeName>Jiaur Rahaman</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Division of Phramacokinetics, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chattopadhyay</LastName>
<ForeName>Naibedya</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology, CSIR-CDRI, Lucknow, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sanyal</LastName>
<ForeName>Sabyasachi</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Biochemistry Division, Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh, India sanyal@cdri.res.in.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052242">Adiponectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054419">Receptors, Adiponectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9IKM0I5T1E</RegistryNumber>
<NameOfSubstance UI="D011794">Quercetin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052242">Adiponectin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005227">Fatty Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011794">Quercetin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054419">Receptors, Adiponectin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24848066</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Nardilysin-dependent proteolysis of cell-associated VTCN1 (B7-H4) marks type 1 diabetes development.</ArticleTitle>
<Pagination>
<MedlinePgn>3470-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db14-0213</ELocationID>
<Abstract>
<AbstractText>T-cell responses directed against insulin-secreting pancreatic β-cells are the key events highlighting type 1 diabetes (T1D). Therefore, a defective control of T-cell activation is thought to underlie T1D development. Recent studies implicated a B7-like negative costimulatory protein, V-set domain-containing T-cell activation inhibitor-1 (VTCN1), as a molecule capable of inhibiting T-cell activation and, potentially, an important constituent in experimental models of T1D. Here, we unravel a general deficiency within the VTCN1 pathway that is shared between diabetes-prone mice and a subset of T1D patients. Gradual loss of membrane-tethered VTCN1 from antigen-presenting cells combined with an increased release of soluble VTCN1 (sVTCN1) occurs in parallel to natural T1D development, potentiating hyperproliferation of diabetogenic T cells. Mechanistically, we demonstrate that the loss of membrane-tethered VTCN1 is linked to proteolytic cleavage mediated by the metalloproteinase nardilysin. The cleaved sVTCN1 fragment was detected at high levels in the peripheral blood of 53% T1D patients compared with only 9% of the healthy subjects. Elevated blood sVTCN1 levels appeared early in the disease progression and correlated with the aggressive pace of disease, highlighting the potential use of sVTCN1 as a new T1D biomarker, and identifying nardilysin as a potential therapeutic target. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Radichev</LastName>
<ForeName>Ilian A</ForeName>
<Initials>IA</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maneva-Radicheva</LastName>
<ForeName>Lilia V</ForeName>
<Initials>LV</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Amatya</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parker</LastName>
<ForeName>Camille</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ellefson</LastName>
<ForeName>Jacob</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wasserfall</LastName>
<ForeName>Clive</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Atkinson</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, University of Florida, Gainesville, FL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burn</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Savinov</LastName>
<ForeName>Alexei Y</ForeName>
<Initials>AY</Initials>
<AffiliationInfo>
<Affiliation>Sanford Project/Children's Health Research Center at Sanford Research, Sioux Falls, SD Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD alexei.savinov@sanfordhealth.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1P20RR024219</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060907">V-Set Domain-Containing T-Cell Activation Inhibitor 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C475826">VTCN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.61</RegistryNumber>
<NameOfSubstance UI="C087976">nardilysin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003922">Diabetes Mellitus, Type 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008666">Metalloendopeptidases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060907">V-Set Domain-Containing T-Cell Activation Inhibitor 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4171653 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24947355</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance.</ArticleTitle>
<Pagination>
<MedlinePgn>3279-94</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1751</ELocationID>
<Abstract>
<AbstractText>Mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) are functional domains between both organelles involved in Ca(2+) exchange, through the voltage-dependent anion channel (VDAC)-1/glucose-regulated protein 75 (Grp75)/inositol 1,4,5-triphosphate receptor (IP3R)-1 complex, and regulating energy metabolism. Whereas mitochondrial dysfunction, ER stress, and altered Ca(2+) homeostasis are associated with altered insulin signaling, the implication of MAM dysfunctions in insulin resistance is unknown. Here we validated an approach based on in situ proximity ligation assay to detect and quantify VDAC1/IP3R1 and Grp75/IP3R1 interactions at the MAM interface. We demonstrated that MAM integrity is required for insulin signaling and that induction of MAM prevented palmitate-induced alterations of insulin signaling in HuH7 cells. Disruption of MAM integrity by genetic or pharmacological inhibition of the mitochondrial MAM protein, cyclophilin D (CypD), altered insulin signaling in mouse and human primary hepatocytes and treatment of CypD knockout mice with metformin improved both insulin sensitivity and MAM integrity. Furthermore, ER-mitochondria interactions are altered in liver of both ob/ob and diet-induced insulin-resistant mice and improved by rosiglitazone treatment in the latter. Finally, increasing organelle contacts by overexpressing CypD enhanced insulin action in primary hepatocytes of diabetic mice. Collectively, our data reveal a new role of MAM integrity in hepatic insulin action and resistance, providing a novel target for the modulation of insulin action. </AbstractText>
<CopyrightInformation>© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tubbs</LastName>
<ForeName>Emily</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Theurey</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vial</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bendridi</LastName>
<ForeName>Nadia</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bravard</LastName>
<ForeName>Amélie</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chauvin</LastName>
<ForeName>Marie-Agnès</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ji-Cao</LastName>
<ForeName>Jingwei</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zoulim</LastName>
<ForeName>Fabien</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1052, Cancer Research Center of Lyon, Lyon 1 University, Hospices Civils de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bartosch</LastName>
<ForeName>Birke</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1052, Cancer Research Center of Lyon, Lyon 1 University, Hospices Civils de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ovize</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France Hospices Civils de Lyon, Louis Pradel Hospital, Cardiovascular Functional Explorations Service and CIC of Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vidal</LastName>
<ForeName>Hubert</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France Hospices Civils de Lyon, Lyon-Sud Hospital, Endocrinology, Diabetology, and Nutrition Service, Pierre-Bénite, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rieusset</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>INSERM UMR-1060, CarMeN Laboratory, Lyon 1 University, INRA U1235, INSA of Lyon, Rockefeller and Charles Merieux Lyon-Sud Medical Universities, Lyon, France Hospices Civils de Lyon, Lyon-Sud Hospital, Endocrinology, Diabetology, and Nutrition Service, Pierre-Bénite, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Diabetes. 2014 Oct;63(10):3163-5</RefSource>
<PMID Version="1">25249639</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004721">Endoplasmic Reticulum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007425">Intracellular Membranes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25249638</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1939-327X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes</Title>
<ISOAbbreviation>Diabetes</ISOAbbreviation>
</Journal>
<ArticleTitle>In this issue of diabetes.</ArticleTitle>
<Pagination>
<MedlinePgn>3161-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/db14-ti10</ELocationID>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016421">Editorial</PublicationType>
<PublicationType UI="D054711">Introductory Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes</MedlineTA>
<NlmUniqueID>0372763</NlmUniqueID>
<ISSNLinking>0012-1797</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052436">Adipose Tissue, White</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005943">Gluconeogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25248890</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0385-0684</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>41</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>
<ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>
</Journal>
<ArticleTitle>[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>1071-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Recent studies have revealed that tumor cells can acquire several mechanisms to evade host immunity in the tumor microenvironment, called cancer immune escape. One of the most important mechanisms in this system is an immunosuppressive co- signal, called immune checkpoint, in the programmed cell death-1(PD-1)/programmed death-ligand 1(PD-L1)pathway. PD-1 is mainly expressed on activated T cells, while PD-L1 is frequently expressed on tumor cells. Inhibition of the interaction between PD-1 and PD-L1 enhances T-cell response and mediates antitumor activity. Several clinical trials by several institutions and pharmaceutical companies in the world have shown the antitumor efficacy of PD-1/PD-L1 signal blockade in patients with some solid and hematological malignancies. Production of some drugs for use in anti-PD-1 therapies are on the verge of completion. Herein, we provide a background about the PD-1/PD-L1 signal and describe some previously performed foreign clinical trials, including a trial in our department.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hamanishi</LastName>
<ForeName>Junzo</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Dept. of Gynecology and Obstetrics, Graduate School of Medicine Kyoto University.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Konishi</LastName>
<ForeName>Ikuo</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gan To Kagaku Ryoho</MedlineTA>
<NlmUniqueID>7810034</NlmUniqueID>
<ISSNLinking>0385-0684</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060890">Antigens, CD274</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060890">Antigens, CD274</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057131">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24975163</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1212-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12470</ELocationID>
<Abstract>
<AbstractText>The alternative splicing of the extracellular domain of fibroblast growth factor receptor (FGFR)-2 generates the IIIb and IIIc isoforms. Expression of FGFR-2 IIIb correlates with vascular endothelial growth factor-A (VEGF-A) expression and venous invasion of pancreatic ductal adenocarcinoma (PDAC). By contrast, FGFR-2 IIIc expression correlates with faster development of liver metastasis after surgery, and increased proliferation rates and invasion of the cancer. In this study, we analyzed the expression and roles of total FGFR-2 (both isoforms) to determine the effectiveness of FGFR-2-targeting therapy for PDAC. Immunohistochemically, FGFR-2 was highly expressed in 25/48 (52.1%) PDAC cases, and correlated with advanced stage cancer. In FISH analysis, FGFR2 was amplified in 3/7 PDAC cell lines. We stably transfected an FGFR-2 shRNA targeting the IIIb and IIIc isoforms into FGFR2-amplified PDAC cells. The proliferation rates, migration, and invasion of FGFR-2-shRNA-transfected cells were lower than those of control cells in vitro. In response to FGF-2, FGFR-2-shRNA-transfected cells showed decreased phosphorylation of ERK compared with control cells. The FGFR-2-shRNA-transfected cells also expressed lower levels of vascular endothelial growth factor-A than control cells, and formed smaller s.c. tumors in nude mice. These findings suggest that FGFR-2 is a therapeutic target for inhibition in PDAC.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matsuda</LastName>
<ForeName>Yoko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshimura</LastName>
<ForeName>Hisashi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Taeko</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uchida</LastName>
<ForeName>Eiji</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Naito</LastName>
<ForeName>Zenya</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ishiwata</LastName>
<ForeName>Toshiyuki</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C496353">FGFR2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D051497">Receptor, Fibroblast Growth Factor, Type 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021441">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005784">Gene Amplification</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051497">Receptor, Fibroblast Growth Factor, Type 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FGFR-2 IIIb</Keyword>
<Keyword MajorTopicYN="N">FGFR-2 IIIc</Keyword>
<Keyword MajorTopicYN="N">fibroblast growth factor receptor-2 (FGFR-2)</Keyword>
<Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
<Keyword MajorTopicYN="N">short hairpin RNA</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24981766</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>1116-23</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12476</ELocationID>
<Abstract>
<AbstractText>The lymphatic system plays important roles not only in the physiological processes, such as maintenance of tissue fluid homeostasis, but also in pathological processes including the lymph node metastasis of tumor cells. Therefore, understanding of the molecular mechanisms underlying lymphatic vessel formation is crucial. Previous studies have shown that proliferation and migration of lymphatic endothelial cells (LECs) are activated by multiple types of signals mediated by tyrosine kinase receptors such as vascular endothelial growth factor receptor (VEGFR) 3. Although signals mediated by platelet-derived growth factor receptor β (PDGFRβ) have been implicated in lymphangiogenesis, the mechanisms explaining how PDGFRβ expression is maintained in LECs remain to be fully elucidated. In the present study, we show that PDGFRβ expression in LECs is maintained by Prox1 transcription factor. Knockdown of Prox1 expression in human dermal LECs decreased the expression of PDGFRβ, leading to the lowered migration of human dermal LECs towards PDGF-BB. Furthermore, we found that PDGF signals play important roles in inflammatory lymphangiogenesis in a chronic aseptic peritonitis model. Intraperitoneal administration of imatinib, a potent inhibitor of PDGFRβ, and transduction of PDGFRβ/Fc chimeric protein by an adenoviral system both reduced inflammatory lymphangiogenesis induced by thioglycollate in mice. We also found that the expression of PDGFRβ/Fc reduced tumor lymphangiogenesis in a BxPC3 human pancreatic cancer xenograft model. These findings suggest that PDGFRβ is one of the key mediators of lymphatic vessel formation acting downstream of Prox1.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Miyazaki</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Human Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshimatsu</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akatsu</LastName>
<ForeName>Yuichi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mishima</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fukayama</LastName>
<ForeName>Masashi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watabe</LastName>
<ForeName>Tetsuro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miyazono</LastName>
<ForeName>Kohei</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020574">Proto-Oncogene Proteins c-sis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C072194">platelet-derived growth factor BB</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102225">prospero-related homeobox 1 protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BKJ8M8G5HI</RegistryNumber>
<NameOfSubstance UI="C097613">imatinib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D020797">Receptor, Platelet-Derived Growth Factor beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042583">Lymphangiogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042601">Lymphatic Vessels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020574">Proto-Oncogene Proteins c-sis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020797">Receptor, Platelet-Derived Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Prox1</Keyword>
<Keyword MajorTopicYN="N">lymphangiogenesis</Keyword>
<Keyword MajorTopicYN="N">platelet-derived growth factor</Keyword>
<Keyword MajorTopicYN="N">tumor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24996003</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Epigenetic deregulation of Ellis Van Creveld confers robust Hedgehog signaling in adult T-cell leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>1160-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12480</ELocationID>
<Abstract>
<AbstractText>One of the hallmarks of cancer, global gene expression alteration, is closely associated with the development and malignant characteristics associated with adult T-cell leukemia (ATL) as well as other cancers. Here, we show that aberrant overexpression of the Ellis Van Creveld (EVC) family is responsible for cellular Hedgehog (HH) activation, which provides the pro-survival ability of ATL cells. Using microarray, quantitative RT-PCR and immunohistochemistry we have demonstrated that EVC is significantly upregulated in ATL and human T-cell leukemia virus type I (HTLV-1)-infected cells. Epigenetic marks, including histone H3 acetylation and Lys4 trimethylation, are specifically accumulated at the EVC locus in ATL samples. The HTLV-1 Tax participates in the coordination of EVC expression in an epigenetic fashion. The treatment of shRNA targeting EVC, as well as the transcription factors for HH signaling, diminishes the HH activation and leads to apoptotic death in ATL cell lines. We also showed that a HH signaling inhibitor, GANT61, induces strong apoptosis in the established ATL cell lines and patient-derived primary ATL cells. Therefore, our data indicate that HH activation is involved in the regulation of leukemic cell survival. The epigenetically deregulated EVC appears to play an important role for HH activation. The possible use of EVC as a specific cell marker and a novel drug target for HTLV-1-infected T-cells is implicated by these findings. The HH inhibitors are suggested as drug candidates for ATL therapy. Our findings also suggest chromatin rearrangement associated with active histone markers in ATL.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Ryutaro</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamagishi</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakano</LastName>
<ForeName>Kazumi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yamochi</LastName>
<ForeName>Toshiko</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yamochi</LastName>
<ForeName>Tadanori</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fujikawa</LastName>
<ForeName>Dai</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakashima</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>Yuetsu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uchimaru</LastName>
<ForeName>Kaoru</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Utsunomiya</LastName>
<ForeName>Atae</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watanabe</LastName>
<ForeName>Toshiki</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C406058">EVC protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551027">GANT 61</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C514970">tax protein, Human T-lymphotrophic virus 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018899">CpG Islands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015458">Leukemia, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011506">Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ATL</Keyword>
<Keyword MajorTopicYN="N">EVC</Keyword>
<Keyword MajorTopicYN="N">HTLV-1</Keyword>
<Keyword MajorTopicYN="N">Hedgehog</Keyword>
<Keyword MajorTopicYN="N">epigenetics</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24638095</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>4027-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1599-y</ELocationID>
<Abstract>
<AbstractText>The main pathological characteristic of glomerulonephritis is diffuse mesangial cell proliferation. MiR-34a is associated with the proliferation of various organs and cancer cells. However, the role of miR-34a in renal proliferation diseases is not clear. Therefore, this study aimed to elucidate the mechanism of miR-34a in the regulation of renal mesangial cell proliferation. The miR-34a expression level at different time points in an anti-Thy1 mesangial proliferative nephritis rat model was determined by qRT-PCR. The cell proliferation rate and cell cycle changes were measured in the in vitro cultured rat mesangial cells (RMCs). Our results suggested that miR-34a expression was negatively correlated with the degree of cell proliferation in the anti-Thy1 nephritis model. MiR-34a could extend the G0/G1 phase and block cell proliferation in RMCs. Dual-luciferase assay results showed that there were binding sites of miR-34a at 3'-UTR of platelet-derived growth factor receptor-β (PDGFR-β). MiR-34a can inhibit PDGFR-β protein expression at a post-transcriptional level, suppress Ras/MAPK signaling pathways, and down-regulate expression of cell cycle proteins at the G0/G1 phase, such as cyclin D1, CDK4/CDK6. In addition, miR-34a may also inhibit RMC proliferation by directly targeting cyclin E and CDK2. MiR-34a inhibits exogenous stimuli-induced proliferation of mesangial cells. Expression levels of phospho-PDGFR-β and phospho-MEK1 (an important downstream molecule in PDGFR-β-induced signaling pathway) were significantly increased in the anti-Thy-1 nephritis rat model. These results suggest that miR-34a may regulate RMC proliferation by directly inhibiting expressions of PDGFR-β, MEK1, and cell cycle proteins, cyclin E and CDK2. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Dapeng</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Kidney Diseases (2011DAV00088), Department of Nephrology, Chinese PLA Institute of Nephrology, National Clinical Research Center for Kidney Disease (2013BAI09B05), Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mei</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Geng</LastName>
<ForeName>Wenjia</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Jurong</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hong</LastName>
<ForeName>Quan</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Zhe</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cai</LastName>
<ForeName>Guangyan</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Hanyu</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Suozhu</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>Xue-Yuan</ForeName>
<Initials>XY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Xiangmei</ForeName>
<Initials>X</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007518">Isoantibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C560944">MIRN34 microRNA, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C035678">anti-Thy antibody</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D020797">Receptor, Platelet-Derived Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2001 Oct 26;294(5543):858-62</RefSource>
<PMID Version="1">11679671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Cycle. 2010 Mar 15;9(6):1031-6</RefSource>
<PMID Version="1">20190569</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Soc Nephrol. 2003 Jul;14(7):1904-26</RefSource>
<PMID Version="1">12819253</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephrol Dial Transplant. 2004 Apr;19(4):852-7</RefSource>
<PMID Version="1">15031340</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 2004 Sep;66(3):920-3</RefSource>
<PMID Version="1">15327382</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 2004 Sep;66(3):1036-48</RefSource>
<PMID Version="1">15327397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 1985 Dec;28(6):944-50</RefSource>
<PMID Version="1">4087701</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Med. 1988 Jan;84(1):129-32</RefSource>
<PMID Version="1">3337116</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Nephrol. 1987 Dec;7(4):370-3</RefSource>
<PMID Version="1">3328248</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Q J Med. 1987 Sep;64(245):709-27</RefSource>
<PMID Version="1">3329736</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Kidney Dis. 1988 Nov;12(5):340-7</RefSource>
<PMID Version="1">3055955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephron. 1988;50(2):137-41</RefSource>
<PMID Version="1">3221950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Nephrol. 1990;10(3):191-7</RefSource>
<PMID Version="1">2382680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1992 May 1;175(5):1413-6</RefSource>
<PMID Version="1">1569407</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1993 Jun 18;73(6):1059-65</RefSource>
<PMID Version="1">8513492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1993 Dec 3;75(5):839-41</RefSource>
<PMID Version="1">8252620</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 1994 Oct;46(4):1192-8</RefSource>
<PMID Version="1">7861716</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Kidney Dis. 1996 May;27(5):631-9</RefSource>
<PMID Version="1">8629621</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 1996 Oct;50(4):1230-9</RefSource>
<PMID Version="1">8887282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Kidney Dis. 1997 Apr;29(4):526-32</RefSource>
<PMID Version="1">9100040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Biochem Sci. 1998 Sep;23(9):337-41</RefSource>
<PMID Version="1">9787639</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Nephrol. 1999 Aug;52(2):96-102</RefSource>
<PMID Version="1">10480220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephron Exp Nephrol. 2005;99(4):e121-9</RefSource>
<PMID Version="1">15722645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephron Exp Nephrol. 2005;100(3):e132-42</RefSource>
<PMID Version="1">15824516</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65</RefSource>
<PMID Version="1">16198274</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Life Sci. 2006 Jun 6;79(2):182-92</RefSource>
<PMID Version="1">16458938</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 2006 Oct;70(7):1296-304</RefSource>
<PMID Version="1">16929252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 2007 Jul;72(1):45-52</RefSource>
<PMID Version="1">17396111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Jun 28;447(7148):1130-4</RefSource>
<PMID Version="1">17554337</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2007 Jul 26;26(34):5017-22</RefSource>
<PMID Version="1">17297439</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7</RefSource>
<PMID Version="1">17875987</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephrol Dial Transplant. 2007 Dec;22(12):3431-41</RefSource>
<PMID Version="1">17893107</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Soc Nephrol. 2008 Jan;19(1):12-23</RefSource>
<PMID Version="1">18077793</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2008 Apr 30;582(10):1564-8</RefSource>
<PMID Version="1">18406353</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephron Exp Nephrol. 2008;108(4):e74-9</RefSource>
<PMID Version="1">18431073</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Res. 2008 May;6(5):735-42</RefSource>
<PMID Version="1">18505919</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2008 Sep 4;455(7209):58-63</RefSource>
<PMID Version="1">18668040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2008 Sep 4;27(39):5204-13</RefSource>
<PMID Version="1">18504438</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Res. 2009 Jan;19(1):92-105</RefSource>
<PMID Version="1">18955434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2009 Mar 8;275(1):44-53</RefSource>
<PMID Version="1">19006648</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1559-65</RefSource>
<PMID Version="1">19029026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Soc Nephrol. 2009 Jun;20(6):1179-87</RefSource>
<PMID Version="1">19470685</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin J Am Soc Nephrol. 2009 Jul;4(7):1255-66</RefSource>
<PMID Version="1">19581401</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2009 Oct 1;69(19):7569-76</RefSource>
<PMID Version="1">19773441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Pharmacol. 2010 Jun;77(6):1016-24</RefSource>
<PMID Version="1">20299489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2010 Jun;31(6):1037-44</RefSource>
<PMID Version="1">20351093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Genet. 2010 Sep;11(9):597-610</RefSource>
<PMID Version="1">20661255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephrology (Carlton). 2010 Sep;15(6):599-608</RefSource>
<PMID Version="1">20883280</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Nephrol. 2010;32(5):447-55</RefSource>
<PMID Version="1">20924167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Soc Nephrol. 2000 Aug;11(8):1398-408</RefSource>
<PMID Version="1">10906153</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Kidney Int. 1999 Oct;56(4):1199-207</RefSource>
<PMID Version="1">10610410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nephrol Dial Transplant. 2002 Jan;17(1):64-9</RefSource>
<PMID Version="1">11773464</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016193">G1 Phase</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005921">Glomerulonephritis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007518">Isoantibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050527">Mesangial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020797">Receptor, Platelet-Derived Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4175047</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24879293</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interferon regulatory factor 3 in adaptive immune responses.</ArticleTitle>
<Pagination>
<MedlinePgn>3873-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1653-9</ELocationID>
<Abstract>
<AbstractText>Interferon regulatory factor (IRF) 3 plays a key role in innate responses against viruses. Indeed, activation of this transcription factor triggers the expression of type I interferons and downstream interferon-stimulated genes in infected cells. Recent evidences indicate that this pathway also modulates adaptive immune responses. This review focuses on the different mechanisms that are implicated in this process. We discuss the role of IRF3 within antigen-presenting cells and T lymphocytes in the polarization of the cellular immune response and its implication in the pathogenesis of immune disorders. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ysebrant de Lendonck</LastName>
<ForeName>Laure</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>WELBIO and Institute for Medical Immunology (IMI), Université Libre de Bruxelles, 8 rue Adrienne Bolland, 6041, Charleroi-Gosselies, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martinet</LastName>
<ForeName>Valerie</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goriely</LastName>
<ForeName>Stanislas</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056704">Adaptive Immunity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000938">Antigen-Presenting Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050838">Interferon Regulatory Factor-3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007370">Interferon Type I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24898083</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Histone deacetylase inhibitors and cell death.</ArticleTitle>
<Pagination>
<MedlinePgn>3885-901</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1656-6</ELocationID>
<Abstract>
<AbstractText>Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Center for Autophagy Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Room Y9206C, Dallas, TX, 75390-9113, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA133228</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA133228</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005232">Fatty Acids, Volatile</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006877">Hydroxamic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010456">Peptides, Cyclic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24947321</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tyrosine nitration as mediator of cell death.</ArticleTitle>
<Pagination>
<MedlinePgn>3939-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1662-8</ELocationID>
<Abstract>
<AbstractText>Nitrotyrosine is used as a marker for the production of peroxynitrite and other reactive nitrogen species. For over 20 years the presence of nitrotyrosine was associated with cell death in multiple pathologies. Filling the gap between correlation and causality has proven to be a difficult task. Here, we discuss the evidence supporting tyrosine nitration as a specific posttranslational modification participating in the induction of cell death signaling pathways.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Franco</LastName>
<ForeName>María C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, 32827, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Estévez</LastName>
<ForeName>Alvaro G</ForeName>
<Initials>AG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>NS36761</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026361">Reactive Nitrogen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>14691-52-2</RegistryNumber>
<NameOfSubstance UI="D030421">Peroxynitrous Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3604-79-3</RegistryNumber>
<NameOfSubstance UI="C002744">3-nitrotyrosine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>42HK56048U</RegistryNumber>
<NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.15.1.1</RegistryNumber>
<NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016923">Cell Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018841">HSP90 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030421">Peroxynitrous Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026361">Reactive Nitrogen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014443">Tyrosine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24947324</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress.</ArticleTitle>
<Pagination>
<MedlinePgn>3951-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1666-4</ELocationID>
<Abstract>
<AbstractText>To maintain genome stability, cells have evolved various DNA repair pathways to deal with oxidative DNA damage. DNA damage response (DDR) pathways, including ATM-Chk2 and ATR-Chk1 checkpoints, are also activated in oxidative stress to coordinate DNA repair, cell cycle progression, transcription, apoptosis, and senescence. Several studies demonstrate that DDR pathways can regulate DNA repair pathways. On the other hand, accumulating evidence suggests that DNA repair pathways may modulate DDR pathway activation as well. In this review, we summarize our current understanding of how various DNA repair and DDR pathways are activated in response to oxidative DNA damage primarily from studies in eukaryotes. In particular, we analyze the functional interplay between DNA repair and DDR pathways in oxidative stress. A better understanding of cellular response to oxidative stress may provide novel avenues of treating human diseases, such as cancer and neurodegenerative disorders. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Shan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC, 28223, USA, SHAN.YAN@UNCC.EDU.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sorrell</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berman</LastName>
<ForeName>Zachary</ForeName>
<Initials>Z</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R15 GM101571</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R15 GM101571</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.11</RegistryNumber>
<NameOfSubstance UI="D064447">Checkpoint Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C576597">ATR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C081350">Checkpoint kinase 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064007">Ataxia Telangiectasia Mutated Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064447">Checkpoint Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011494">Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS606870 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4176976 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25008043</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Microglia and inflammation: conspiracy, controversy or control?</ArticleTitle>
<Pagination>
<MedlinePgn>3969-85</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1670-8</ELocationID>
<Abstract>
<AbstractText>Microglial cells contribute to normal function of the central nervous system (CNS). Besides playing a role in the innate immunity, they are also involved in neuronal plasticity and homeostasis of the CNS. While microglial cells get activated and undergo phenotypic changes in different disease contexts, they are far from being the "villains" in the CNS. Mounting evidence indicates that microglial dysfunction can exacerbate the pathogenesis of several diseases in the CNS. Several molecular mechanisms tightly regulate the production of inflammatory and toxic factors released by microglia. These mechanisms involve the interaction with other glial cells and neurons and the fine regulation of signaling and transcription activation pathways. The purpose of this review is to discuss microglia activation and to highlight the molecular pathways that can counteract the detrimental role of microglia in several neurologic diseases. Recent work presented in this review support that the understanding of microglial responses can pave the way to design new therapies for inflammatory diseases of the CNS. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fernandes</LastName>
<ForeName>Adelaide</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003, Lisbon, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller-Fleming</LastName>
<ForeName>Leonor</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pais</LastName>
<ForeName>Teresa F</ForeName>
<Initials>TF</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002493">Central Nervous System Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009473">Neuronal Plasticity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25044211</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1554-527X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Journal of orthopaedic research : official publication of the Orthopaedic Research Society</Title>
<ISOAbbreviation>J. Orthop. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of beta-catenin signaling by Pb leads to incomplete fracture healing.</ArticleTitle>
<Pagination>
<MedlinePgn>1397-405</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/jor.22677</ELocationID>
<Abstract>
<AbstractText>There is strong evidence in the clinical literature to suggest that elevated lead (Pb) exposure impairs fracture healing. Since Pb has been demonstrated to inhibit bone formation, and Wnt signaling is an important anabolic pathway in chondrocyte maturation and endochondral ossification, we investigated the impact of Wnt therapy on Pb-exposed mice undergoing bone repair in a mouse tibial fracture model. We established that tibial fracture calluses from Pb-treated mice were smaller and contained less mineralized tissue than vehicle controls. This resulted in the persistence of immature cartilage in the callus and decreased β-catenin levels. Reduction of β-catenin protein was concurrent with systemic elevation of LRP5/6 antagonists DKK1 and sclerostin in Pb-exposed mice throughout fracture healing. β-catenin stimulation by the GSK3 inhibitor BIO reversed these molecular changes and restored the amount of mineralized callus. Overall, Pb is identified as a potent inhibitor of endochondral ossification in vivo with correlated effects on bone healing with noted deficits in β-catenin signaling, suggesting the Wnt/β-catenin as a pivotal pathway in the influence of Pb on fracture repair.</AbstractText>
<CopyrightInformation>© 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Beier</LastName>
<ForeName>Eric E</ForeName>
<Initials>EE</Initials>
<AffiliationInfo>
<Affiliation>Center for Musculoskeletal Research, University of Rochester, School of Medicine and Dentistry, Rochester, New York, 14642; Department of Environmental Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, New York, 14642.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sheu</LastName>
<ForeName>Tzong-Jen</ForeName>
<Initials>TJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buckley</LastName>
<ForeName>Taylor</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yukata</LastName>
<ForeName>Kiminori</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Keefe</LastName>
<ForeName>Regis</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zuscik</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Puzas</LastName>
<ForeName>J Edward</ForeName>
<Initials>JE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 ES011854</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 ES301247</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 ES012712</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 AR053459</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 ES07026</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Orthop Res</MedlineTA>
<NlmUniqueID>8404726</NlmUniqueID>
<ISSNLinking>0736-0266</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C483321">6-bromoindirubin-3'-oxime</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495267">CTNNB1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010091">Oximes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486030">Sost protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2P299V784P</RegistryNumber>
<NameOfSubstance UI="D007854">Lead</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017102">Fracture Healing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006023">Glycoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007854">Lead</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059630">Mesenchymal Stromal Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010006">Osteoblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010012">Osteogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010091">Oximes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013978">Tibial Fractures</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051153">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014945">Wound Healing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055114">X-Ray Microtomography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Pb</Keyword>
<Keyword MajorTopicYN="N">Wnt signaling</Keyword>
<Keyword MajorTopicYN="N">fracture repair</Keyword>
<Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword>
<Keyword MajorTopicYN="N">sclerostin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25073432</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1554-527X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Journal of orthopaedic research : official publication of the Orthopaedic Research Society</Title>
<ISOAbbreviation>J. Orthop. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>TGF-β signaling regulates fibrotic expression and activity in carpal tunnel syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>1444-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/jor.22694</ELocationID>
<Abstract>
<AbstractText>Fibrosis of the subsynovial connective tissue (SSCT) is a predominant feature of carpal tunnel syndrome (CTS). While the nature of CTS has been extensively studied, little is known about the etiology of this disease. We investigated SSCT tissue from patients with CTS and control subjects using fibrosis arrays and cell culture analysis. Twofold changes in fibrotic gene expression were found in multiple genes from patient SSCT using fibrosis arrays. This data was confirmed via qRT-PCR on a subset of genes; collagen I (Col1), collagen III (Col3), connective tissue growth factor (CTGF), transforming growth factor β (TGF-β), and SMAD3 (P &lt; 0.05) which significantly corroborate the fold changes found in the fibrosis arrays. To further explore the nature of SSCT fibrosis, cells were isolated from patient and control tissue. Col1, Col3, TGF-β, and SMAD3 were highly expressed in patient SSCT fibroblasts as compared to control (P &lt; 0.05). Further, fibrotic genes expression was decreased by inhibiting TGF-β receptor I (TβRI) activity (P &lt; 0.05). TGF-β second messenger SMAD activity was significantly activated in SSCT fibroblasts from patients and this activation was abrogated by inhibiting TβRI signaling (P &lt; 0.05). These findings suggest that blocking TGF-β signaling may be an important therapeutic approach to treating the underlying fibrosis of SSCT in CTS patients.</AbstractText>
<CopyrightInformation>© 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gingery</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, Biomechanics and Tendon &amp; Soft Tissue Biology Laboratory, Mayo Clinic, Rochester, Minnesota.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Tai-Hua</ForeName>
<Initials>TH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Passe</LastName>
<ForeName>Sandra M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>An</LastName>
<ForeName>Kai-Nan</ForeName>
<Initials>KN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Chunfeng</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Amadio</LastName>
<ForeName>Peter C</ForeName>
<Initials>PC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AR49823</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F32 AR063596</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F32 AR063596</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AR049823</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 AR056950</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 AR056950</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Orthop Res</MedlineTA>
<NlmUniqueID>8404726</NlmUniqueID>
<ISSNLinking>0736-0266</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C526317">CTGF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024042">Collagen Type I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024061">Collagen Type III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011621">Pteridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C511004">SD-208</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497790">SMAD3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051900">Smad3 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>139568-91-5</RegistryNumber>
<NameOfSubstance UI="D055513">Connective Tissue Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002102">Cadaver</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002349">Carpal Tunnel Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024042">Collagen Type I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024061">Collagen Type III</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055513">Connective Tissue Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005355">Fibrosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011621">Pteridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051900">Smad3 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS639172 [Available on 11/01/15]</OtherID>
<OtherID Source="NLM">PMC4222071 [Available on 11/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">TGF-β</Keyword>
<Keyword MajorTopicYN="N">carpal tunnel syndrome</Keyword>
<Keyword MajorTopicYN="N">fibrosis</Keyword>
<Keyword MajorTopicYN="N">subsynovial connective tissue</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25255628</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0037-1017</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>86</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Seikagaku. The Journal of Japanese Biochemical Society</Title>
<ISOAbbreviation>Seikagaku</ISOAbbreviation>
</Journal>
<ArticleTitle>[Regulations of YAP transcriptional co-activator].</ArticleTitle>
<Pagination>
<MedlinePgn>464-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hata</LastName>
<ForeName>Shoji</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Katada</LastName>
<ForeName>Toshiaki</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishina</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Seikagaku</MedlineTA>
<NlmUniqueID>0413564</NlmUniqueID>
<ISSNLinking>0037-1017</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25255635</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0037-1017</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>86</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Seikagaku. The Journal of Japanese Biochemical Society</Title>
<ISOAbbreviation>Seikagaku</ISOAbbreviation>
</Journal>
<ArticleTitle>[Function of tumor suppressor protein Mig-6 in growth signaling].</ArticleTitle>
<Pagination>
<MedlinePgn>498-502</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kitagawa</LastName>
<ForeName>Masatoshi</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Seikagaku</MedlineTA>
<NlmUniqueID>0413564</NlmUniqueID>
<ISSNLinking>0037-1017</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C081350">Checkpoint kinase 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011494">Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25255640</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0037-1017</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>86</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Seikagaku. The Journal of Japanese Biochemical Society</Title>
<ISOAbbreviation>Seikagaku</ISOAbbreviation>
</Journal>
<ArticleTitle>[RNA structure recognized by Toll-like receptor 3 in innate immunity].</ArticleTitle>
<Pagination>
<MedlinePgn>523-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tatematsu</LastName>
<ForeName>Megumi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seya</LastName>
<ForeName>Tsukasa</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matsumoto</LastName>
<ForeName>Misako</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Seikagaku</MedlineTA>
<NlmUniqueID>0413564</NlmUniqueID>
<ISSNLinking>0037-1017</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009690">Nucleic Acid Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012313">RNA</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051196">Toll-Like Receptor 3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014777">Virus Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24997224</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0945</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental and molecular pathology</Title>
<ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>TLR3/4 signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.</ArticleTitle>
<Pagination>
<MedlinePgn>234-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2014.07.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4800(14)00098-7</ELocationID>
<Abstract>
<AbstractText>Activation of Toll-like receptor (TLR) signaling which stimulates inflammatory and proliferative pathways is the key element in the pathogenesis of Mallory-Denk bodies (MDBs) in mice fed DDC. However, little is known as to how TLR signaling is regulated in MDB formation during chronic liver disease development. The first systematic study of TLR signaling pathway transcript regulation in human archived formalin-fixed, paraffin-embedded (FFPE) liver biopsies with MDB formation is presented here. When compared to the activation of Toll-like signaling in alcoholic hepatitis (AH) and non-alcoholic steatohepatitis (NASH) patients, striking similarities and obvious differences were observed. Similar TLRs (TLR3 and TLR4, etc.), TLR downstream adaptors (MyD88 and TRIF, etc.) and transcript factors (NFκB and IRF7, etc.) were all upregulated in the patients' livers. MyD88, TLR3 and TLR4 were significantly induced in the livers of AH and NASH compared to normal subjects, while TRIF and IRF7 mRNA were only slightly upregulated in AH patients. This is a different pathway from the induction of the TLR4-MyD88-independent pathway in the AH and NASH patients with MDBs present. Importantly, chemokine receptor 4 and 7 (CXCR4/7) mRNAs were found to be induced in the patients livers in FAT10 positive hepatocytes. The CXCR7 pathway was significantly upregulated in patients with AH and the CXCR4 was markedly upregulated in patients with NASH, indicating that CXCR4/7 is crucial in liver MDB formation. This data constitutes the first demonstration of the upregulation of the MyD88-dependent TLR4/NFκB pathway in AH and NASH where MDBs formed, via the NFκB-CXCR4/7 pathway, and provides further insight into the mechanism of MDB formation in human liver diseases. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>LA BioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>LA BioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tillman</LastName>
<ForeName>Brittany</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>LA BioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morgan</LastName>
<ForeName>Timothy R</ForeName>
<Initials>TR</Initials>
<AffiliationInfo>
<Affiliation>VA Medical Center, Department of Medicine, Long Beach, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>French</LastName>
<ForeName>Barbara A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo>
<Affiliation>LA BioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>French</LastName>
<ForeName>Samuel W</ForeName>
<Initials>SW</Initials>
<AffiliationInfo>
<Affiliation>LA BioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA. Electronic address: sfrench@labiomed.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AAU01021898-02</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 AA011999</GrantID>
<Acronym>AA</Acronym>
<Agency>NIAAA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50-11999</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 AA021898</GrantID>
<Acronym>AA</Acronym>
<Agency>NIAAA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Mol Pathol</MedlineTA>
<NlmUniqueID>0370711</NlmUniqueID>
<ISSNLinking>0014-4800</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501896">CXCR7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494234">IRF7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050839">Interferon Regulatory Factor-7</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507779">MYD88 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054387">Receptors, CXCR</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495344">TLR3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005234">Fatty Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006519">Hepatitis, Alcoholic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050839">Interferon Regulatory Factor-7</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059609">Mallory Bodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053594">Myeloid Differentiation Factor 88</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054387">Receptors, CXCR</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019718">Receptors, CXCR4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051196">Toll-Like Receptor 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS622228 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4177360 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chemokine receptor 4 and 7 (CXCR4/7)</Keyword>
<Keyword MajorTopicYN="N">Liver disease development</Keyword>
<Keyword MajorTopicYN="N">Mallory–Denk bodies (MDBs)</Keyword>
<Keyword MajorTopicYN="N">MyD88-dependent pathway</Keyword>
<Keyword MajorTopicYN="N">Toll-like receptor (TLR) signaling</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25036402</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0945</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental and molecular pathology</Title>
<ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>191-201</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2014.07.012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4800(14)00109-9</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Jun activation domain-binding protein 1 (Jab1) was overexpressed in breast cancer, which was involved in degradation of the cyclin-dependent kinase inhibitor p27(Kip1). The objective of this study was to examine the effect of brain specific kinase 1 (BRSK1) expression on Jab1 over-expression and related signaling pathway in breast cancer.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Immunohistochemical analysis was performed in 95 human breast carcinoma samples and the data were correlated with clinicopathologic features. Furthermore, Western blot analysis was performed for BRSK1 and Jab1 in breast carcinoma samples and cell lines to evaluate their protein levels and molecular interaction.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that the cytoplasmic BRSK1 expression was inversely associated with Jab1 expression (P&lt;0.01) and correlated significantly with histologic grade (P=0.006), however nuclear BRSK1 expression couldn't obtain similar results. Kaplan-Meier analysis revealed that survival curves of low versus high expressers of cytoplasmic BRSK1 and Jab1 showed a highly significant separation in breast cancer (P&lt;0.01). While in vitro, following release of breast cancer cell lines from serum starvation, the expression of Jab1, phosphor-Akt (p-Akt) was up-regulated, whereas BRSK1 and p27(Kip1) were decreased. Treatment of phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 could diminish Jab1 expression but increase BRSK1 expression. In addition, we employed siRNA technique to knock down Jab1 and/or BRSK1 expression and observed their effects on MDA-MB-231 cell growth.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BRSK1 is a novel tumor suppressor in breast cancer which inversely correlated with Jab1 expression, may involve in the restoring Jab1-induced suppression of p27(Kip1) and may regulate cell cycle through the PI3K/Akt pathway.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hua</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Xiao-Bing</ForeName>
<Initials>XB</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jia-Hui</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qing-Qing</ForeName>
<Initials>QQ</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jin-Peng</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Jun-Fei</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sheng</LastName>
<ForeName>Chen-Yi</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ni</LastName>
<ForeName>Qi-Chao</ForeName>
<Initials>QC</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, the Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong 226001, Jiangsu, PR China. Electronic address: niqichao2013@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Mol Pathol</MedlineTA>
<NlmUniqueID>0370711</NlmUniqueID>
<ISSNLinking>0014-4800</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>154447-36-6</RegistryNumber>
<NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C523084">BRSK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-.-</RegistryNumber>
<NameOfSubstance UI="C501488">COPS5 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002867">Chromones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003593">Cytoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004795">Enzyme Stability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009025">Morpholines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010447">Peptide Hydrolases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BRSK1</Keyword>
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">Jab1</Keyword>
<Keyword MajorTopicYN="N">PI3K/Akt</Keyword>
<Keyword MajorTopicYN="N">Prognosis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043004</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7519</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.</ArticleTitle>
<Pagination>
<MedlinePgn>512-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13495</ELocationID>
<Abstract>
<AbstractText>Mutations that deregulate Notch1 and Ras/phosphoinositide 3 kinase (PI3K)/Akt signalling are prevalent in T-cell acute lymphoblastic leukaemia (T-ALL), and often coexist. Here we show that the PI3K inhibitor GDC-0941 is active against primary T-ALLs from wild-type and Kras(G12D) mice, and addition of the MEK inhibitor PD0325901 increases its efficacy. Mice invariably relapsed after treatment with drug-resistant clones, most of which unexpectedly had reduced levels of activated Notch1 protein, downregulated many Notch1 target genes, and exhibited cross-resistance to γ-secretase inhibitors. Multiple resistant primary T-ALLs that emerged in vivo did not contain somatic Notch1 mutations present in the parental leukaemia. Importantly, resistant clones upregulated PI3K signalling. Consistent with these data, inhibiting Notch1 activated the PI3K pathway, providing a likely mechanism for selection against oncogenic Notch1 signalling. These studies validate PI3K as a therapeutic target in T-ALL and raise the unexpected possibility that dual inhibition of PI3K and Notch1 signalling could promote drug resistance in T-ALL. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dail</LastName>
<ForeName>Monique</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Benniof Children's Hospital, University of California, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Benniof Children's Hospital, University of California, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lawrence</LastName>
<ForeName>Jessica</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Benniof Children's Hospital, University of California, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Connor</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Benniof Children's Hospital, University of California, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakitandwe</LastName>
<ForeName>Joy</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Shann-Ching</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Benniof Children's Hospital, University of California, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Leslie B</ForeName>
<Initials>LB</Initials>
<AffiliationInfo>
<Affiliation>Department of Translational Oncology, Genentech Inc., South San Francisco, California 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akagi</LastName>
<ForeName>Keiko</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Ohio 43210, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Division of Haematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aster</LastName>
<ForeName>Jon C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Brigham &amp;Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pear</LastName>
<ForeName>Warren S</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>Abramson Family Cancer Research Institute and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Downing</LastName>
<ForeName>James R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sampath</LastName>
<ForeName>Deepak</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Translational Oncology, Genentech Inc., South San Francisco, California 94080, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shannon</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics and Benniof Children's Hospital, University of California, San Francisco, California 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE48260</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K08 CA134649</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K99 CA157950</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA119070</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA180037</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 CA072614</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 CA72614</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA084221</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C532162">2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007191">Indazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506614">PD 0325901</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9N3CBB0BIQ</RegistryNumber>
<NameOfSubstance UI="D004159">Diphenylamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2011 Aug 1;25(15):1628-40</RefSource>
<PMID Version="1">21828272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2011 Sep 26;208(10):1931-5</RefSource>
<PMID Version="1">21948802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jan 12;481(7380):157-63</RefSource>
<PMID Version="1">22237106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2012 Jul 1;30(19):2418-20</RefSource>
<PMID Version="1">22585704</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2013 Mar;19(3):368-71</RefSource>
<PMID Version="1">23377281</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2013 Jun 13;121(24):4884-93</RefSource>
<PMID Version="1">23637129</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2007 Nov;12(5):411-3</RefSource>
<PMID Version="1">17996644</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2007 Oct;13(10):1203-10</RefSource>
<PMID Version="1">17873882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Chemother Pharmacol. 2007 Apr;59(5):671-9</RefSource>
<PMID Version="1">16944149</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1997 Apr 25;272(17):11336-43</RefSource>
<PMID Version="1">9111040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene Ther. 1994 Mar;1(2):136-8</RefSource>
<PMID Version="1">7584069</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Biol. 2004;5(10):R80</RefSource>
<PMID Version="1">15461798</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2004 Sep 15;104(6):1696-702</RefSource>
<PMID Version="1">15187027</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2003 Jan;23(2):655-64</RefSource>
<PMID Version="1">12509463</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genome Res. 2002 Apr;12(4):656-64</RefSource>
<PMID Version="1">11932250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2014 Mar 17;25(3):366-78</RefSource>
<PMID Version="1">24613413</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2013 Dec 9;24(6):766-76</RefSource>
<PMID Version="1">24291004</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2013 Aug 2;288(31):22836-48</RefSource>
<PMID Version="1">23788636</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2013 Dec 1;31(34):4333-42</RefSource>
<PMID Version="1">24166518</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2011 Aug 1;208(8):1595-603</RefSource>
<PMID Version="1">21727187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncotarget. 2011 Apr;2(4):336-46</RefSource>
<PMID Version="1">21505228</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 2011 Apr 11;208(4):653-61</RefSource>
<PMID Version="1">21464223</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Pathol. 2011 Jan;223(2):262-73</RefSource>
<PMID Version="1">20967796</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2010 Nov 24;33(5):671-84</RefSource>
<PMID Version="1">21093323</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5106-11</RefSource>
<PMID Version="1">20194733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Leukemia. 2010 Jan;24(1):239-42</RefSource>
<PMID Version="1">19829307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18351-6</RefSource>
<PMID Version="1">19805051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Sep 17;461(7262):411-4</RefSource>
<PMID Version="1">19727076</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Jul 16;114(3):647-50</RefSource>
<PMID Version="1">19458356</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2008 Nov 28;322(5906):1377-80</RefSource>
<PMID Version="1">19039135</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2007 Dec 1;13(23):6964-9</RefSource>
<PMID Version="1">18056171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Med Chem. 2008 Sep 25;51(18):5522-32</RefSource>
<PMID Version="1">18754654</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002999">Clone Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004159">Diphenylamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011905">Genes, ras</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007191">Indazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054218">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051881">Receptor, Notch1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS636078</OtherID>
<OtherID Source="NLM">PMC4213126</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043027</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7519</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>The alarmin IL-33 promotes regulatory T-cell function in the intestine.</ArticleTitle>
<Pagination>
<MedlinePgn>564-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13577</ELocationID>
<Abstract>
<AbstractText>FOXP3(+) regulatory T cells (Treg cells) are abundant in the intestine, where they prevent dysregulated inflammatory responses to self and environmental stimuli. It is now appreciated that Treg cells acquire tissue-specific adaptations that facilitate their survival and function; however, key host factors controlling the Treg response in the intestine are poorly understood. The interleukin (IL)-1 family member IL-33 is constitutively expressed in epithelial cells at barrier sites, where it functions as an endogenous danger signal, or alarmin, in response to tissue damage. Recent studies in humans have described high levels of IL-33 in inflamed lesions of inflammatory bowel disease patients, suggesting a role for this cytokine in disease pathogenesis. In the intestine, both protective and pathological roles for IL-33 have been described in murine models of acute colitis, but its contribution to chronic inflammation remains ill defined. Here we show in mice that the IL-33 receptor ST2 is preferentially expressed on colonic Treg cells, where it promotes Treg function and adaptation to the inflammatory environment. IL-33 signalling in T cells stimulates Treg responses in several ways. First, it enhances transforming growth factor (TGF)-β1-mediated differentiation of Treg cells and, second, it provides a necessary signal for Treg-cell accumulation and maintenance in inflamed tissues. Strikingly, IL-23, a key pro-inflammatory cytokine in the pathogenesis of inflammatory bowel disease, restrained Treg responses through inhibition of IL-33 responsiveness. These results demonstrate a hitherto unrecognized link between an endogenous mediator of tissue damage and a major anti-inflammatory pathway, and suggest that the balance between IL-33 and IL-23 may be a key controller of intestinal immune responses. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schiering</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>1] Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK [2] Division of Molecular Immunology, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK (C.S.); Department of Microbiology and Immunology, School of Medicine and Biomedical Sciences, University at Buffalo (SUNY), Buffalo, New York 14214-3000, USA (E.A.W.). [3].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Krausgruber</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>1] Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chomka</LastName>
<ForeName>Agnieszka</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fröhlich</LastName>
<ForeName>Anja</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, and German Rheumatism Research Center (DRFZ), D-10117 Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Adelmann</LastName>
<ForeName>Krista</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wohlfert</LastName>
<ForeName>Elizabeth A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>1] Program in Barrier Immunity and Repair, Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA [2] Division of Molecular Immunology, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK (C.S.); Department of Microbiology and Immunology, School of Medicine and Biomedical Sciences, University at Buffalo (SUNY), Buffalo, New York 14214-3000, USA (E.A.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pott</LastName>
<ForeName>Johanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Griseri</LastName>
<ForeName>Thibault</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bollrath</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hegazy</LastName>
<ForeName>Ahmed N</ForeName>
<Initials>AN</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Harrison</LastName>
<ForeName>Oliver J</ForeName>
<Initials>OJ</Initials>
<AffiliationInfo>
<Affiliation>Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Owens</LastName>
<ForeName>Benjamin M J</ForeName>
<Initials>BM</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Löhning</LastName>
<ForeName>Max</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, and German Rheumatism Research Center (DRFZ), D-10117 Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Belkaid</LastName>
<ForeName>Yasmine</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Program in Barrier Immunity and Repair, Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fallon</LastName>
<ForeName>Padraic G</ForeName>
<Initials>PG</Initials>
<AffiliationInfo>
<Affiliation>Trinity Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin 2, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Powrie</LastName>
<ForeName>Fiona</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE58164</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018123">Receptors, Interleukin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506535">interleukin-33, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Immunol. 2014 Sep;14(9):579</RefSource>
<PMID Version="1">25145753</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003106">Colon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018928">Immunity, Mucosal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053759">Interleukin-23</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007378">Interleukins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018123">Receptors, Interleukin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013950">Thymus Gland</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272642</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6837</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>71</Volume>
<Issue>2</Issue>
<PubDate>
<MedlineDate>2014 Mar-Apr</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Acta poloniae pharmaceutica</Title>
<ISOAbbreviation>Acta Pol Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>G protein-coupled receptors: abnormalities in signal transmission, disease states and pharmacotherapy.</ArticleTitle>
<Pagination>
<MedlinePgn>229-43</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The aim of this review is to present the research results and draw new conclusions about the impact of alterations in the signal transmission through the G protein-coupled receptors (GPCRs) on the formation of diseases and drug therapy. GPCR family is the largest and the most diverse group of membrane receptors. They transmit signals into the cell by interaction with different ligands, which include, inter alia, hormones, neurotransmitters, and photons. GPCRs are responsible for the proper conduction of many physiological processes such as vision, intercellular communication, the neuronal transmission, hormonal signaling and are involved in many pathological processes. They are also point on the binding pathway of multiple drugs. They are targets of nearly one third of the drugs at the current pharmaceutical market. The genes encoding GPCRs represent about 4% of the human genome. Mutations that occur in them are associated with a broad spectrum of diseases of diverse etiology. As a mutations result, there is a change in receptor activity (GPCR become inactive, overactive, or constitutively active), in the process of ligand binding and signal transduction. Changes in the GPCRs functioning can cause diseases such as retinitis pigmentosa (rhodopsin mutations), nephrogenic diabetes insipidus (vasopressin receptor mutations), obesity (melanocortin receptor mutations). Many mutational changes in genes encoding GPCR can change drug therapy of already existed diseases: heart failure (adrenergic receptors), asthma (cysteinyl leukotriene receptors). Studies concerning the structure and function of genetically modified GPCRs allow to get know a variety of mechanisms of its action, which in turn can contribute to broaden the knowledge on the etiology and pharmacotherapy of many currently incurable diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zalewska</LastName>
<ForeName>Marta</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Siara</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sajewicz</LastName>
<ForeName>Waldemar</ForeName>
<Initials>W</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Acta Pol Pharm</MedlineTA>
<NlmUniqueID>2985167R</NlmUniqueID>
<ISSNLinking>0001-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004358">Drug Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25256260</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Protective effect of Danggui (Radix Angelicae Sinensis) on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells.</ArticleTitle>
<Pagination>
<MedlinePgn>358</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-358</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Danggui (Radix Angelicae Sinensis) is an herb often used in Traditional Chinese medicine. It is used to promote blood flow and has been used in the treatment of myocardial ischemia-reperfusion injury in animal models. Angiotensin II (Ang II) has been shown to play important roles in mediating cardiovascular diseases, and may cause cardiac hypertrophy and apoptosis. This study aimed to investigate whether Danggui has protective effects on Ang II-induced apoptosis in H9c2 cardiomyoblast cells and study the mechanisms involved.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the effect of Danggui on Ang II-induced apoptosis in an in vitro model. H9c2 cardiomyoblast cells were cultured in serum-free medium for 4 hr, then treated with Danggui (50, 100 μg/ml) 1 hr pre- or post-Ang II treatment. After a further 23 hr of culture, cells were harvested for analyses with assays for apoptosis markers and cell signaling pathways.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Our results showed that Ang II induced upregulation of pro-apoptotic Bad, instability of the mitochondria membrane potential, cytochrome c release, caspase-9 and caspase-3 activation and cardiomyocyte apoptosis. Pre- or post-treatment with Danggui reversed all of the above Ang II-induced apoptotic effects in H9c2 cells. Furthermore, the JNK (SP600125) inhibitor completely blocked Danggui inhibition of caspase-3 activation in Ang II-treated H9c2 cells.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results showed that Danggui either pre-treatment or post-treatment highly attenuated the Ang II-induced apoptosis in cardiomyoblast cells. The findings demonstrated that the anti-apoptosis effect of Danggui is mediated by JNK and PI3k inhibitors.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Chih-Yang</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuo</LastName>
<ForeName>Wei-Wen</ForeName>
<Initials>WW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuo</LastName>
<ForeName>Chia-Hua</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tsai</LastName>
<ForeName>Fuu-Jen</ForeName>
<Initials>FJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Peng-Yu</ForeName>
<Initials>PY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hsieh</LastName>
<ForeName>Dennis Jine-Yuan</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>School of Medical Laboratory and Biotechnology, Chung Shan Medical University, No,110, Sec,1, Jianguo N, Rd,, Taichung 40201, Taiwan. djh@csmu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11128-99-7</RegistryNumber>
<NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-43-6</RegistryNumber>
<NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2004 Feb 13;13(3):329-40</RefSource>
<PMID Version="1">14967141</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1063-9</RefSource>
<PMID Version="1">14615277</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Endocrinology. 1981 Jan;108(1):76-82</RefSource>
<PMID Version="1">6109623</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Diabetes. 1988 Dec;37(12):1708-14</RefSource>
<PMID Version="1">2973422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Hypertens. 1992 May;5(5 Pt 1):276-80</RefSource>
<PMID Version="1">1533768</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pharmacol Rev. 1993 Jun;45(2):205-51</RefSource>
<PMID Version="1">8372104</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 1996 Jun 1;97(11):2509-16</RefSource>
<PMID Version="1">8647943</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1996 Nov 15;87(4):619-28</RefSource>
<PMID Version="1">8929531</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1998 Apr 17;93(2):215-28</RefSource>
<PMID Version="1">9568714</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1999 Apr 9;284(5412):339-43</RefSource>
<PMID Version="1">10195903</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Cell Cardiol. 1999 May;31(5):949-70</RefSource>
<PMID Version="1">10336836</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 1999 Oct 21;341(17):1276-83</RefSource>
<PMID Version="1">10528039</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2005 Jan;15(1):36-42</RefSource>
<PMID Version="1">15686625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cardiovasc Pharmacol. 2005 Jul;46(1):99-104</RefSource>
<PMID Version="1">15965361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytother Res. 2006 Jul;20(7):561-7</RefSource>
<PMID Version="1">16619337</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E306-14</RefSource>
<PMID Version="1">16825605</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Apoptosis. 2006 Jul;11(7):1075-89</RefSource>
<PMID Version="1">16699953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Zhong Yao Cai. 2006 Jun;29(6):574-6</RefSource>
<PMID Version="1">17039881</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Planta Med. 2007 Feb;73(2):134-41</RefSource>
<PMID Version="1">17325989</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Basic Clin Pharmacol Toxicol. 2007 Dec;101(6):421-6</RefSource>
<PMID Version="1">17971065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Physiol. 2008 Apr;215(1):172-81</RefSource>
<PMID Version="1">17941088</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Endocrinol. 2008 May;197(2):381-90</RefSource>
<PMID Version="1">18434368</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Endocrinol. 2008 Aug;41(2):65-74</RefSource>
<PMID Version="1">18495691</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Chromatogr A. 2009 Mar 13;1216(11):1991-2001</RefSource>
<PMID Version="1">18667208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuroscience. 2009 Mar 31;159(3):1135-47</RefSource>
<PMID Version="1">19356694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Endocrinology. 2009 Jun;150(6):2723-31</RefSource>
<PMID Version="1">19095737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Biol Macromol. 2010 Nov 1;47(4):546-50</RefSource>
<PMID Version="1">20691723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Physiol. 2012 Jan;227(1):259-68</RefSource>
<PMID Version="1">21412773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chin J Integr Med. 2011 Nov;17(11):854-9</RefSource>
<PMID Version="1">22057415</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chin J Nat Med. 2013 Nov;11(6):577-87</RefSource>
<PMID Version="1">24345498</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Diabetes Technol Ther. 2000 Spring;2(1):69-80</RefSource>
<PMID Version="1">11467325</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JOP. 2001 Jan;2(1):50-5</RefSource>
<PMID Version="1">11862023</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2002 Mar 16;359(9310):926-30</RefSource>
<PMID Version="1">11918911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Altern Complement Med. 2002 Aug;8(4):467-75</RefSource>
<PMID Version="1">12230907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Heart Fail. 2003 Mar;5(2):121-9</RefSource>
<PMID Version="1">12644001</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Cardiovasc Drugs. 2002;2(1):43-57</RefSource>
<PMID Version="1">14727998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Mol Med. 2004 Jun;13(6):915-22</RefSource>
<PMID Version="1">15138635</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029971">Angelica sinensis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000804">Angiotensin II</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053453">Caspase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032383">Myocytes, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020011">Protective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4182826</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25107644</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>N6-substituted adenosine analogues, a novel class of JAK2 inhibitors, potently block STAT3 signaling in human cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>43-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.043</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00422-4</ELocationID>
<Abstract>
<AbstractText>The JAK2/STAT3 signaling pathway plays a critical role in oncogenesis and malignancy, which makes it a promising anticancer target. We report four N(6)-substituted adenosine analogues (AAs) as potential JAK2/STAT3 inhibitors identified through a STAT3-based high-throughput drug screening system. These AAs exhibited selective anti-cancer activity on human cancer cells and xenograft tumors with constitutively activated STAT3. They rapidly and potently suppressed constitutive and IL-6/IFN-γ-induced JAK2/STAT3 signal activation. In addition, we finally proved that the STAT3 signal blockage by three of these AAs was dependent on specific JAK2 inhibition. These AAs may represent new targeted therapeutic agents for JAK2/STAT3 hyper-activated human cancers. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Peng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Liwei</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Ximing</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, Université Paris Diderot, CNRS EAC4413, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Wenchao</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Yanlong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Du</LastName>
<ForeName>Yuping</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Jinbo</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China; Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qin</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China. Electronic address: qwang@lzu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K72T3FS567</RegistryNumber>
<NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000241">Adenosine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">JAK2 inhibitors</Keyword>
<Keyword MajorTopicYN="N">N(6)-Substituted adenosine analogues</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">Targeted therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25111897</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>97-106</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.041</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00420-0</ELocationID>
<Abstract>
<AbstractText>The aberrant regulation of histone deacetylase 6 (HDAC6) contributes to malignant progression in various types of cancer, but the mechanism underlying gastric carcinogenesis remains unknown. Aberrant HDAC6 overexpression was observed in a subset of human gastric cancer cells. HDAC6 knockdown caused the significant inhibition of gastric cancer cell growth without affecting the transition of cell cycles or the processing of cell death. We demonstrate that an increase in epidermal growth factor receptor (EGFR) signaling through decreased EGFR degradation was mediated by HDAC6 in gastric carcinogenesis. These results establish a molecular mechanism responsible for oncogenic HDAC6, explaining how EGFR signaling induced by the growth factor is sustained during the malignant progression of gastric cancer. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Se Jin</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jeong Kyu</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bae</LastName>
<ForeName>Hyun Jin</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eun</LastName>
<ForeName>Jung Woo</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Qingyu</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Hyung Seok</ForeName>
<Initials>HS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Woo Chan</ForeName>
<Initials>WC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Hee Doo</ForeName>
<Initials>HD</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Eun Kyung</ForeName>
<Initials>EK</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Cancer Evolution Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>You</LastName>
<ForeName>Jueng Soo</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, School of Medicine, Konkuk University, Seoul 143-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Won Sang</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jung Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Suk Woo</ForeName>
<Initials>SW</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Cancer Evolution Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea. Electronic address: swnam@catholic.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C097227">RABEP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004705">Endocytosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011992">Endosomes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033921">Vesicular Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGF receptor</Keyword>
<Keyword MajorTopicYN="N">Endocytosis</Keyword>
<Keyword MajorTopicYN="N">Histone deacetylase 6</Keyword>
<Keyword MajorTopicYN="N">Rabaptin-5</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128647</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies.</ArticleTitle>
<Pagination>
<MedlinePgn>5-11</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.003</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00431-5</ELocationID>
<Abstract>
<AbstractText>Despite tremendous advances in the targeted therapy for various types of hematological malignancies with successful improvements in the survival rates, emerging resistance issues are startlingly high and novel therapeutic strategies are urgently needed. In addition, chemoprevention is currently becoming an elusive goal. Plant-derived natural products have garnered considerable attention in recent years due to the potential dual functions as chemotherapeutics and dietary chemoprevention. One of the particularly ubiquitous families is the polyphenolic flavonoids. Among them, baicalin and its aglycone baicalein have been widely investigated in hematological malignancies because both of them exhibit remarkable pharmacological properties. This review focuses on the recent achievements in drug discovery research associated with baicalin and baicalein for hematological malignancy therapies. The promising anticancer activities of these two flavonoids targeting diverse signaling pathways and their potential biological mechanisms in different types of hematological malignancies, as well as the combination strategy with baicalin or baicalein as chemotherapeutic adjuvants for recent therapies in these intractable diseases are discussed. Meanwhile, the biotransformation of baicalin and baicalein and the relevant approaches to improve their bioavailability are also summarized. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Haijun</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>College of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, China; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>College of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Jianlei</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>College of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yingyu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Buyuan</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Jianda</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China. Electronic address: jdhu@medmail.com.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Jia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, USA. Electronic address: jizhou@utmb.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 DA028821</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA097007</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 MH093844</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 MH093844</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044950">Flavanones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D059808">Polyphenols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>347Q89U4M5</RegistryNumber>
<NameOfSubstance UI="C038044">baicalin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>49QAH60606</RegistryNumber>
<NameOfSubstance UI="C006680">baicalein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001682">Biological Availability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001711">Biotransformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055808">Drug Discovery</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044950">Flavanones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005419">Flavonoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019337">Hematologic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059808">Polyphenols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS623770 [Available on 11/01/15]</OtherID>
<OtherID Source="NLM">PMC4179973 [Available on 11/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Baicalein</Keyword>
<Keyword MajorTopicYN="N">Baicalin</Keyword>
<Keyword MajorTopicYN="N">Cancer targets</Keyword>
<Keyword MajorTopicYN="N">Flavonoids</Keyword>
<Keyword MajorTopicYN="N">Hematological malignancies</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128651</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>An in vitro retinoblastoma human triple culture model of angiogenesis: a modulatory effect of TGF-β.</ArticleTitle>
<Pagination>
<MedlinePgn>181-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.004</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00432-7</ELocationID>
<Abstract>
<AbstractText>Retinoblastoma is the most common intraocular tumour in children. In view of understanding the molecular mechanisms through which angiogenic switch on happens in the early phases of reciprocal interaction between tumour and cells constituting retinal microvessel, Transwell co-cultures constituted by human retinal endothelial cells (HREC), pericytes (HRPC), and human retinoblastoma cell line Y-79 were performed. Y-79 enhanced HREC proliferation, reduced by the introduction of HRPC in triple culture. In HREC/HRPC cultures, TGF-β in media increased, decreasing in triple cultures. High VEGF levels in triple cultures witnessed the establishment of a strongly in vitro angiogenic environment. Y-79 induced in HREC an increase in c- and iPLA2, phospho-cPLA2, inducible COX-2 protein expressions, PLA2 activities and prostaglandin E2 (PGE2) release. These effects were attenuated when HRPC were introduced in triple culture. Moreover, antibody silencing of TGF-β demonstrated a strong correlation between the signalling pathway triggered by TGF-β of pericytal origin and the phospholipase activation and the modulation of PGE2 release. Inhibiting VEGFA effect, the HRPC loss in triple culture decreased, showing its modulatory effect on their survival. Relying on the data here presented, sustaining the pericytal survival in a tumour retinal environment could ensure the integrity of microvessels and the TGF-β supply, essential for controlling aberrant endothelial pruning and angiogenesis. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lupo</LastName>
<ForeName>Gabriella</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Biomedicina Clinica e Molecolare, Università di Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Motta</LastName>
<ForeName>Carla</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Biomedicina Clinica e Molecolare, Università di Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Salmeri</LastName>
<ForeName>Mario</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Bio-Mediche, Università di Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spina-Purrello</LastName>
<ForeName>Vittoria</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Bio-Mediche, Università di Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alberghina</LastName>
<ForeName>Mario</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Biomedicina Clinica e Molecolare, Università di Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Anfuso</LastName>
<ForeName>Carmelina Daniela</ForeName>
<Initials>CD</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Biomedicina Clinica e Molecolare, Università di Catania, Italy. Electronic address: anfudan@unict.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.-</RegistryNumber>
<NameOfSubstance UI="D010740">Phospholipases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.1.4</RegistryNumber>
<NameOfSubstance UI="D054467">Phospholipases A2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003600">Cytosol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008833">Microcirculation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009389">Neovascularization, Pathologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010539">Permeability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010740">Phospholipases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054467">Phospholipases A2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012160">Retina</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cytosolic and calcium-independent PLA(2)</Keyword>
<Keyword MajorTopicYN="N">Human retinal microvascular endothelial cells</Keyword>
<Keyword MajorTopicYN="N">Human retinal microvascular pericytes</Keyword>
<Keyword MajorTopicYN="N">Retinoblastoma</Keyword>
<Keyword MajorTopicYN="N">TGF-β</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130169</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells.</ArticleTitle>
<Pagination>
<MedlinePgn>153-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00430-3</ELocationID>
<Abstract>
<AbstractText>Persistent activation of signal transducers and activator of transcription 3 (STAT3) has been closely related to growth, survival, proliferation, metastasis, and angiogenesis of various cancer cells, and thus its inhibition can be considered a potential therapeutic strategy. In this study, we investigated the role of bergamottin (BGM) obtained from grapefruit juice in abrogating the constitutive STAT3 activation in multiple myeloma (MM) cells. This suppression was mediated through the inhibition of phosphorylation of Janus-activated kinase (JAK) 1/2 and c-Src. Pervanadate reversed the BGM induced down-regulation of STAT3 activation, suggesting the involvement of a protein tyrosine phosphatase (PTP). Furthermore, BGM induced the expression of the tyrosine phosphatase SHP-1, and gene silencing of the SHP-1 by small interfering RNA abolished the ability of BGM to inhibit STAT3 activation, suggesting a critical role for SHP-1 in the action of BGM. BGM also downregulated the expression of STAT3-regulated gene products such as COX-2, VEGF, cyclin D1, survivin, IAP-1, Bcl-2, and Bcl-xl in MM cells. This correlated with induction of substantial apoptosis as indicated by an increase in the sub-G1 cell population and caspase-3 induced PARP cleavage. Also, this agent significantly potentiated the apoptotic effects of bortezomib and thalidomide in MM cells. Overall, these results suggest that BGM is a novel blocker of STAT3 activation pathway thus may have a potential in therapy of MM and other cancers. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Moo</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jong Hyun</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sethi</LastName>
<ForeName>Gautam</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, and Cancer Science Institute of Singapore, National University of Singapore, Singapore 117597.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chulwon</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baek</LastName>
<ForeName>Seung Ho</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Dongwoo</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>Won-Seok</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hoon</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shim</LastName>
<ForeName>Bum Sang</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kwang Seok</ForeName>
<Initials>KS</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea. Electronic address: ksahn@khu.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011564">Furocoumarins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7380-40-7</RegistryNumber>
<NameOfSubstance UI="C068337">bergamottin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C509249">PTPN6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032083">Citrus paradisi</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011564">Furocoumarins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Bergamottin</Keyword>
<Keyword MajorTopicYN="N">Multiple myeloma</Keyword>
<Keyword MajorTopicYN="N">SHP-1</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135221</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>A novel β-catenin signaling pathway activated by IL-1β leads to the onset of epithelial-mesenchymal transition in breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>164-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00444-3</ELocationID>
<Abstract>
<AbstractText>Interleukin 1β has been associated with tumor development, invasiveness and metastasis in various types of cancer. However, the molecular mechanisms underlying this association have not been clearly elucidated. The present study is the first to show, in breast cancer cells, that an IL-1β/IL-1RI/β-catenin signaling pathway induces β-catenin accumulation due to GSK3β inactivation by Akt phosphorylation. Translocation to the nucleus of accumulated β-catenin and formation of the TCF/Lef/β-catenin complex induce sequential expression of c-MYC, CCDN1, SNAIL1 and MMP2, leading to up-regulation of proliferation, migration and invasion; all of the processes shown to be required, in cancerous cells, to initiate transition from a non-invading to an invasive phenotype. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Perez-Yepez</LastName>
<ForeName>Eloy Andres</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Avenida Instituto Politécnico Nacional 2508, San Pedro Zacatenco, Mexico DF 07360, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ayala-Sumuano</LastName>
<ForeName>Jorge-Tonatiuh</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Institute of Neurobiology, Universidad Nacional Autónoma de México Campus Juriquilla, Blvd. Juriquilla 3001, Querétaro 76230, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lezama</LastName>
<ForeName>Ruth</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Av. Wilfrido Massieu y Calzada Miguel Stampa s/n, México DF 07738, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meza</LastName>
<ForeName>Isaura</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Avenida Instituto Politécnico Nacional 2508, San Pedro Zacatenco, Mexico DF 07360, Mexico. Electronic address: imeza@cinvestav.mx.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551918">2-methyl-2'-F-anandamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495270">CTNNB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508585">IL1B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053284">Polyunsaturated Alkamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C448280">glycogen synthase kinase 3 beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053284">Polyunsaturated Alkamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer cell</Keyword>
<Keyword MajorTopicYN="N">IL-1RI/β-catenin signaling</Keyword>
<Keyword MajorTopicYN="N">IL-1β stimulation</Keyword>
<Keyword MajorTopicYN="N">Invasiveness</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135222</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>200-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.008</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00436-4</ELocationID>
<Abstract>
<AbstractText>Aberrant epidermal growth factor (EGF)-dependent signaling plays a key role in the progression of human carcinomas. We found that TIP30, a tumor suppressor protein, translocated into the nucleus of human lung adenocarcinoma cells following EGF treatment, and the selective inhibitors of EGFR signaling pathways blocked this effect. Chromatin immunoprecipitation assays revealed that TIP30 negatively regulated EGF-dependent transcriptional activation of CCND1 through a HDAC1-dependent mechanism. In lung adenocarcinoma patients, the level of nuclear TIP30 was inversely correlated with that of EGFR and cyclin D1. These findings suggest that nuclear TIP30-induced downregulation of cyclin D1 transcription antagonizes EGFR signaling and suppresses tumorigenesis. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shuai</LastName>
<ForeName>Shuai</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Xiao</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Oncology Department, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Junyi</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Shijun</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Fengsheng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Rongcheng</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China. Electronic address: luorc0101@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Aimin</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China. Electronic address: liaimin2005@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.-</RegistryNumber>
<NameOfSubstance UI="D000123">Acetyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="C111246">HTATIP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000123">Acetyltransferases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cyclin D1</Keyword>
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">HDAC1</Keyword>
<Keyword MajorTopicYN="N">Lung adenocarcinoma</Keyword>
<Keyword MajorTopicYN="N">TIP30</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135223</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Strategy to enhance the anticancer efficacy of X-ray radiotherapy in melanoma cells by platinum complexes, the role of ROS-mediated signaling pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>58-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.046</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00425-X</ELocationID>
<Abstract>
<AbstractText>Radiotherapy plays an important role in treatment of cancers with low toxicity to the surrounding normal tissues. However, it still fails to eradicate hypoxic tumors due to the occurrence of radioresistance. Therefore, the search for new radiation sensitizers is of great significance. Platinum (Pt) complexes have been identified as potential radiation sensitizers to increase the sensitivity of cancer cells to radiotherapy. In the present study, we have synthesized four Pt complexes containing (2 - benzimidazole [4, 5-f] - [1, 10] phenanthroline) ligand and found that they could effectively enhance the X-ray-induced growth inhibition against A375 human melanoma cells through induction of G2/M cell cycle arrest. In contrast, they showed much lower cytotoxicity toward human normal cells. The complexes also dramatically inhibited the TrxR activity and caused intracellular ROS overproduction, due to the Auger electron effect of heavy metal element under X-ray radiation. Excessive ROS triggered DNA damage and activated downstream signaling pathways, including the phosphorylation of p53 and p38MAPK, and down-regulation of phosphorylated AKT and ERK, finally resulted in increase of radiosensitivity and inhibition of tumor reproduction. Taken together, our results suggest that the synthetic Pt complexes could be further developed as sensitizers of X-ray radiotherapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Qiang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China; Wu Jing Zong Dui Hospital of Guangdong Province, Guangzhou 510507, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lan</LastName>
<ForeName>Guoqiang</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Yangliang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Jiamin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Yuanwei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Xiaoyan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Cundong</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Tianfeng</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China. Electronic address: tchentf@jnu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>49DFR088MY</RegistryNumber>
<NameOfSubstance UI="D010984">Platinum</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010984">Platinum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011836">Radiation Tolerance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011878">Radiotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017382">Reactive Oxygen Species</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Auger electron effect</Keyword>
<Keyword MajorTopicYN="N">G2/M arrest</Keyword>
<Keyword MajorTopicYN="N">Platinum complexes</Keyword>
<Keyword MajorTopicYN="N">Radiotherapy</Keyword>
<Keyword MajorTopicYN="N">Sensitizers</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25153349</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>33-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.06.023</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00445-5</ELocationID>
<Abstract>
<AbstractText>Although NDRG2 has recently been found to be a candidate tumor suppressor, its precise role in the epithelial-mesenchymal transition (EMT) is not well understood. In the present study, we demonstrated that NDRG2 overexpression in MDA-MB-231 cells down-regulated the expression of Snail, a transcriptional repressor of E-cadherin and a key regulator of EMT, as well as the phosphorylation of signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor that is activated in many human malignancies including breast cancer. In addition, we confirmed that the expression of Snail and phospho-STAT3 was recovered when NDRG2 was knocked down by siRNA in MCF7 cells in which NDRG2 is endogenously expressed. Interestingly, MDA-MB-231-NDRG2 cells showed remarkably decreased Snail expression after treatment with JSI-124 (also known as cucurbitacin I) or Stattic, STAT3 inhibitors, compared to MDA-MB-231-mock cells. Moreover, STAT3 activation by EGF treatment induced higher Snail expression, and NDRG2 overexpression resulted in the inhibition of Snail expression in MDA-MB-231 cells stimulated by EGF in the absence or presence of STAT3 inhibitor. Treatment of MDA-MB-231 cells with STAT3 inhibitor led to a moderate decrease in wound healing and migration capacity, whereas STAT3 inhibitor treatment of MDA-MB-231-NDRG2 cells resulted in a significant attenuation of migration in both resting and EGF-stimulated cells. Collectively, our data demonstrate that the inhibition of STAT3 signaling by NDRG2 suppresses EMT progression of EMT via the down-regulation of Snail expression. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Myung-Jin</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Jihyun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Young</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Myeong-Sok</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Jong-Seok</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea. Electronic address: jslim@sookmyung.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C466228">NDRG2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C086988">snail family transcription factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014945">Wound Healing</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">EMT</Keyword>
<Keyword MajorTopicYN="N">NDRG2</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">Snail</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265813</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6837</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>71</Volume>
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Acta poloniae pharmaceutica</Title>
<ISOAbbreviation>Acta Pol Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>Mycophenolate mofetil--a new atheropreventive drug?</ArticleTitle>
<Pagination>
<MedlinePgn>353-61</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Atherosclerosis is a form of chronic inflammation in which endothelial cell dysfunction, fibroproliferative process, oxidative stress and inflammatory cell activation are linked to plaque development and destabilization. T-lymphocytes also play a key role in pathogenesis of atherosclerosis. As a consequence, the suggested concept that modulation of an immunological response could be an appropriate target in the prevention of cardiovascular disease, is an important focus of research. Mycophenolate mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase (IMPDH), that exerts anti-proliferative and pro-apototic effects, particularly on activated T-lymphocytes. MMF has other anti-atherogenic effects at the level of endothelial cells, monocytes/macrophages, smooth muscle cells and dendritic cells. In addition, MMF exhibits anti-oxidative properties. The present review paper provides an overview about the mechanisms of anti-atherosclerotic properties of MMF.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Olejarz</LastName>
<ForeName>Wioletta</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bryk</LastName>
<ForeName>Dorota</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zapolska-Downar</LastName>
<ForeName>Danuta</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Acta Pol Pharm</MedlineTA>
<NlmUniqueID>2985167R</NlmUniqueID>
<ISSNLinking>0001-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9242ECW6R0</RegistryNumber>
<NameOfSubstance UI="C063008">mycophenolate mofetil</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>HU9DX48N0T</RegistryNumber>
<NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050197">Atherosclerosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002317">Cardiovascular Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018836">Inflammation Mediators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009173">Mycophenolic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032389">Myocytes, Smooth Muscle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25092123</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-5835</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>38</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia research</Title>
<ISOAbbreviation>Leuk. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>LIFRα-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>1237-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2014.07.004</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0145-2126(14)00221-5</ELocationID>
<Abstract>
<AbstractText>The distal cytoplasmic motifs of the leukemia inhibitory factor receptor α-chain (LIFRα-CT3) and its TAT fusion protein (TAT-CT3) can independently suppress cell viability and induce myeloid differentiation in human leukemia HL-60 cells in our previous studies. But its underlying mechanism remains undefined. Herein, we show that a prokaryotic expressed TAT-CT3 induced a rapid elevation of STAT3 phosphorylation (pSTAT3), and then suppress the transcription of miR-155 and induce the elevation of SOCS-1, which further inhibited STAT3 phosphorylation for a long-term period. Our result indicated a novel mechanism of TAT-CT3 to promote HL60 cells differentiation, which provides some potential therapeutic targets for future acute myelogenous leukemia therapy.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Sha</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Embryology and Histology, Second Military Medical University, Shanghai 200433, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Zhenyu</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Embryology and Histology, Second Military Medical University, Shanghai 200433, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Baohai</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Graduate School, Second Military Medical University, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Embryology and Histology, Second Military Medical University, Shanghai 200433, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Ling</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Embryology and Histology, Second Military Medical University, Shanghai 200433, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jianmin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Changhai Hospital of Shanghai, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Embryology and Histology, Second Military Medical University, Shanghai 200433, PR China. Electronic address: wangyuesmmu@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Houqi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Embryology and Histology, Second Military Medical University, Shanghai 200433, PR China. Electronic address: houqiliu@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leuk Res</MedlineTA>
<NlmUniqueID>7706787</NlmUniqueID>
<ISSNLinking>0145-2126</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507840">LIFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053680">Leukemia Inhibitory Factor Receptor alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C524942">MIRN155 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Leuk Res. 2014 Oct;38(10):1158-9</RefSource>
<PMID Version="1">25139848</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047369">Chromatin Immunoprecipitation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018922">HL-60 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053612">Janus Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053680">Leukemia Inhibitory Factor Receptor alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015514">Oncogene Proteins, Fusion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050791">STAT Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Acute myeloid leukemia</Keyword>
<Keyword MajorTopicYN="N">LIF receptor</Keyword>
<Keyword MajorTopicYN="N">Leukemia inhibitory factor</Keyword>
<Keyword MajorTopicYN="N">MicroRNA-155</Keyword>
<Keyword MajorTopicYN="N">Protein transduction</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25139848</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-5835</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>38</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia research</Title>
<ISOAbbreviation>Leuk. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>A paradigm for cybernetics, regulatory circuits and ultra-stability in cancer biology and treatment.</ArticleTitle>
<Pagination>
<MedlinePgn>1158-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2014.07.011</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0145-2126(14)00233-1</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Staege</LastName>
<ForeName>Martin S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Martin-Luther-University Halle-Wittenberg, Halle, Germany. Electronic address: martin.staege@medizin.uni-halle.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leuk Res</MedlineTA>
<NlmUniqueID>7706787</NlmUniqueID>
<ISSNLinking>0145-2126</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507840">LIFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053680">Leukemia Inhibitory Factor Receptor alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C524942">MIRN155 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Leuk Res. 2014 Oct;38(10):1237-44</RefSource>
<PMID Version="1">25092123</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053680">Leukemia Inhibitory Factor Receptor alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer cybernetics</Keyword>
<Keyword MajorTopicYN="N">Differentiation therapy</Keyword>
<Keyword MajorTopicYN="N">JAK/STAT pathway</Keyword>
<Keyword MajorTopicYN="N">SOCS1</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">Ultra-stability</Keyword>
<Keyword MajorTopicYN="N">miR-155</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25271346</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1552-4469</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>10</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature chemical biology</Title>
<ISOAbbreviation>Nat. Chem. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Endosomal generation of cAMP in GPCR signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>700-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nchembio.1611</ELocationID>
<Abstract>
<AbstractText>It has been widely assumed that the production of the ubiquitous second messenger cyclic AMP, which is mediated by cell surface G protein–coupled receptors (GPCRs), and its termination take place exclusively at the plasma membrane. Recent studies reveal that diverse GPCRs do not always follow this conventional paradigm. In the new model, GPCRs mediate G-protein signaling not only from the plasma membrane but also from endosomal membranes. This model proposes that following ligand binding and activation, cell surface GPCRs internalize and redistribute into early endosomes, where trimeric G protein signaling can be maintained for an extended period of time. This Perspective discusses the molecular and cellular mechanistic subtleties as well as the physiological consequences of this unexpected process, which is considerably changing how we think about GPCR signaling and regulation and how we study drugs that target this receptor family.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vilardaga</LastName>
<ForeName>Jean-Pierre</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jean-Alphonse</LastName>
<ForeName>Frederic G</ForeName>
<Initials>FG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gardella</LastName>
<ForeName>Thomas J</ForeName>
<Initials>TJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK102495</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 DK11794</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK087688</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Chem Biol</MedlineTA>
<NlmUniqueID>101231976</NlmUniqueID>
<ISSNLinking>1552-4450</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011992">Endosomes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272739</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0555-1099</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>50</Volume>
<Issue>2</Issue>
<PubDate>
<MedlineDate>2014 Mar-Apr</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Prikladnaia biokhimiia i mikrobiologiia</Title>
<ISOAbbreviation>Prikl. Biokhim. Mikrobiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Regulation of peroxidase activity under the influence of signaling molecules and Bacillus subtilis 26D in potato plants infected with Phytophthora infestans].</ArticleTitle>
<Pagination>
<MedlinePgn>197-202</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The influence of sequential exposure of 5 x 10(-5) M salicylic acid (SA) or 1 x 10(-7) M jasmonic acid (JA) and endophytic bacterium Bacillus subtilis strain 26D on peroxidase activity, transcription of the M21334 isoperoxidase gene from potato (Solarium tuberosum L.), and the formation of resistance to the infective agent of potato blight Phytophthora infestans (Mont.) de Bary was studied. It was found that individual application of JA or Bacillus subtilis 26D and sequential application of SA and B. subtilis 26D were the most effective in protecting plants against pathogens, while sequential application of JA and B. subtilis 26D drastically suppressed plant resistance. The results suggest the need for strict compliance with regulations when using SA and JA, as well as biological products based on living bacteria as modern plant protection products with immunomodulatory properties that trigger specific signaling pathways, which often interfere with each other.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Maksimov</LastName>
<ForeName>I V</ForeName>
<Initials>IV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abizgil'dina</LastName>
<ForeName>R R</ForeName>
<Initials>RR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sorokan'</LastName>
<ForeName>A V</ForeName>
<Initials>AV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Burkhanova</LastName>
<ForeName>G F</ForeName>
<Initials>GF</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Prikl Biokhim Mikrobiol</MedlineTA>
<NlmUniqueID>0023416</NlmUniqueID>
<ISSNLinking>0555-1099</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061046">Biological Control Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003517">Cyclopentanes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054883">Oxylipins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010937">Plant Growth Regulators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010940">Plant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6RI5N05OWW</RegistryNumber>
<NameOfSubstance UI="C011006">jasmonic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.11.1.7</RegistryNumber>
<NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>O414PZ4LPZ</RegistryNumber>
<NameOfSubstance UI="D020156">Salicylic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001412">Bacillus subtilis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061046">Biological Control Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003517">Cyclopentanes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018506">Gene Expression Regulation, Plant</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054883">Oxylipins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009195">Peroxidase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055750">Phytophthora infestans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010935">Plant Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010937">Plant Growth Regulators</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010940">Plant Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020156">Salicylic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011198">Solanum tuberosum</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272844</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[In vitro studies of Raf-CREB, Akt-CREB, and CaMK II -CREB signal transduction pathway regulated by ginsenosides Rb1, Rg1 and Re].</ArticleTitle>
<Pagination>
<MedlinePgn>2065-70</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Effects of ginsenoside Rb1, Rg1 and Re on neurotrophic factor signal transduction pathway using liposome-mediated transfection of eukaryotic cells approach.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">The injury model was established by treating SH-SY5Y cells with 0.6 mmol x L(-1) of corticosterone (CORT) by 24 h. SH-SY5Y cell were pretreated with CORT for 30 min followed by co-treated with 120,60 and 20 micromol x L(-1) of Rb1, 120, 80 and 40 micromol x L(-1) of Rg1 and 120, 80 and 40 micromol x L(-1) of Re for 24 h. Cells viability was determined by Cell Counting Kit (CCK) assay. CREB expressing Luciferase reporter gene was constructed and transfected with plasmid containing hRaf, hcAMP, hAkt, hCaMK gene into human embryonic kidney (HEK293) cells using liposornal transfection reagent lipofection 2000. The expression of CREB before and after it addion of Rb1, Rg1 and Re was examined by Luc assay system and Western blotting.</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">Compared with normal control group, CORT significantly decreased the viability of SH-SY5Y cells to 67.21% (P &lt; 0.01). CCK results show that Rb1 (60 micromol x L(-1)), Rg1 (80 micromol x L(-1)) and Re (80 micromol x L(-1)) on SH-SY5Y cells have significant protective effect (P &lt; 0.01). Lucassay and Western blotting results show that the gene and protein levels of CREB increased significantly through the pathway of Raf and Akt with Rb1 and Rg1 (P &lt; 0.01), Re can increase significantly the gene and protein levels of CREB through the pathway of Raf and CaMK II.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Rb1, Rg1 and Re protects SH-SY5Y cells from CORT-induced damage and the neuroprotective mechanism may be associated with the Raf-CREB, Akt-CREB and CaMK II -CREB pathways.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Ting-Ting</ForeName>
<Initials>TT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Xian-Zhe</ForeName>
<Initials>XZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Wan-Wan</ForeName>
<Initials>WW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yi-Hong</ForeName>
<Initials>YH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ping</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036145">Ginsenosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048490">raf Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017362">Cyclic AMP Response Element-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017930">Genes, Reporter</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036145">Ginsenosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005894">Panax</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048490">raf Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25187433</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-0103</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>351</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pharmacology and experimental therapeutics</Title>
<ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system.</ArticleTitle>
<Pagination>
<MedlinePgn>390-402</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.114.218735</ELocationID>
<Abstract>
<AbstractText>A subset of angiotensin IV (AngIV)-related molecules are known to possess procognitive/antidementia properties and have been considered as templates for potential therapeutics. However, this potential has not been realized because of two factors: 1) a lack of blood-brain barrier-penetrant analogs, and 2) the absence of a validated mechanism of action. The pharmacokinetic barrier has recently been overcome with the synthesis of the orally active, blood-brain barrier-permeable analog N-hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide (dihexa). Therefore, the goal of this study was to elucidate the mechanism that underlies dihexa's procognitive activity. Here, we demonstrate that dihexa binds with high affinity to hepatocyte growth factor (HGF) and both dihexa and its parent compound Norleucine 1-AngIV (Nle(1)-AngIV) induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering. Further, dihexa and Nle(1)-AngIV induce hippocampal spinogenesis and synaptogenesis similar to HGF itself. These actions were inhibited by an HGF antagonist and a short hairpin RNA directed at c-Met. Most importantly, the procognitive/antidementia capacity of orally delivered dihexa was blocked by an HGF antagonist delivered intracerebroventricularly as measured using the Morris water maze task of spatial learning. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Benoist</LastName>
<ForeName>Caroline C</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kawas</LastName>
<ForeName>Leen H</ForeName>
<Initials>LH</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Mingyan</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tyson</LastName>
<ForeName>Katherine A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stillmaker</LastName>
<ForeName>Lori</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Appleyard</LastName>
<ForeName>Suzanne M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wright</LastName>
<ForeName>John W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wayman</LastName>
<ForeName>Gary A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.) hardingj@vetmed.wsu.edu waymang@vetmed.wsu.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Harding</LastName>
<ForeName>Joseph W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Integrative Physiology and Neuroscience (C.C.B., L.H.K., M.Z., K.A.T., L.S., S.M.A., J.W.W., G.A.W., J.W.H.) and Department of Psychology (J.W.W., J.W.H.), Washington State University, Pullman, Washington; and M Biotechnology, Inc., Seattle, Washington (L.H.K., J.W.W., J.W.H.) hardingj@vetmed.wsu.edu waymang@vetmed.wsu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01-MH086032</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pharmacol Exp Ther</MedlineTA>
<NlmUniqueID>0376362</NlmUniqueID>
<ISSNLinking>0022-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578458">N-hexanoic-Tyr-Ile-(6) aminohexanoic amide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11128-99-7</RegistryNumber>
<NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>23025-68-5</RegistryNumber>
<NameOfSubstance UI="C012877">angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="C081092">HGF activator</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000804">Angiotensin II</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009842">Oligopeptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019859">Proto-Oncogene Proteins c-met</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012697">Serine Endopeptidases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013569">Synapses</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4201273 [Available on 11/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25276959</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Advances in studies on growth metabolism and response mechanisms of medicinal plants under drought stress].</ArticleTitle>
<Pagination>
<MedlinePgn>2432-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Drought stress exerts a considerable effect on growth, physiology and secondary metabolisms of the medicinal plants. It could inhabit the growth of the medicinal plants but promote secretion of secondary metabolites. Other researches indicated that the medicinal plants could depend on the ABA signaling pathway and secreting osmotic substances to resist the drought stress and reduce the damage by it. The article concludes the changes in growth, physiology, secondary metabolisms and response mechanisms of medicinal plants to drought stress that provides a theoretical basis for exploring the relationship between medicinal plants and drought stress.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Si</LastName>
<ForeName>Can</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jun-Yi</ForeName>
<Initials>JY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Hu-Chao</ForeName>
<Initials>HC</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010940">Plant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>059QF0KO0R</RegistryNumber>
<NameOfSubstance UI="D014867">Water</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>72S9A8J5GW</RegistryNumber>
<NameOfSubstance UI="D000040">Abscisic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000040">Abscisic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055864">Droughts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010940">Plant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010946">Plants, Medicinal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014867">Water</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25278615</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6205</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control.</ArticleTitle>
<Pagination>
<MedlinePgn>1248012</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1248012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">1248012</ELocationID>
<Abstract>
<AbstractText>Stem cells fuel tissue development, renewal, and regeneration, and these activities are controlled by the local stem cell microenvironment, the "niche." Wnt signals emanating from the niche can act as self-renewal factors for stem cells in multiple mammalian tissues. Wnt proteins are lipid-modified, which constrains them to act as short-range cellular signals. The locality of Wnt signaling dictates that stem cells exiting the Wnt signaling domain differentiate, spatially delimiting the niche in certain tissues. In some instances, stem cells may act as or generate their own niche, enabling the self-organization of patterned tissues. In this Review, we discuss the various ways by which Wnt operates in stem cell control and, in doing so, identify an integral program for tissue renewal and regeneration. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Clevers</LastName>
<ForeName>Hans</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Centre Utrecht and CancerGenomics.nl, 3584CT Utrecht, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Loh</LastName>
<ForeName>Kyle M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Department of Developmental Biology, Howard Hughes Medical Institute, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nusse</LastName>
<ForeName>Roel</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Developmental Biology, Howard Hughes Medical Institute, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA. rnusse@stanford.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002455">Cell Division</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018859">Hair Follicle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042361">Mammary Glands, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012038">Regeneration</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055153">Stem Cell Niche</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051153">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079320</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7520</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function.</ArticleTitle>
<Pagination>
<MedlinePgn>98-101</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13498</ELocationID>
<Abstract>
<AbstractText>Haematopoiesis is a developmental cascade that generates all blood cell lineages in health and disease. This process relies on quiescent haematopoietic stem cells capable of differentiating, self renewing and expanding upon physiological demand. However, the mechanisms that regulate haematopoietic stem cell homeostasis and function remain largely unknown. Here we show that the neurotrophic factor receptor RET (rearranged during transfection) drives haematopoietic stem cell survival, expansion and function. We find that haematopoietic stem cells express RET and that its neurotrophic factor partners are produced in the haematopoietic stem cell environment. Ablation of Ret leads to impaired survival and reduced numbers of haematopoietic stem cells with normal differentiation potential, but loss of cell-autonomous stress response and reconstitution potential. Strikingly, RET signals provide haematopoietic stem cells with critical Bcl2 and Bcl2l1 surviving cues, downstream of p38 mitogen-activated protein (MAP) kinase and cyclic-AMP-response element binding protein (CREB) activation. Accordingly, enforced expression of RET downstream targets, Bcl2 or Bcl2l1, is sufficient to restore the activity of Ret null progenitors in vivo. Activation of RET results in improved haematopoietic stem cell survival, expansion and in vivo transplantation efficiency. Remarkably, human cord-blood progenitor expansion and transplantation is also improved by neurotrophic factors, opening the way for exploration of RET agonists in human haematopoietic stem cell transplantation. Our work shows that neurotrophic factors are novel components of the haematopoietic stem cell microenvironment, revealing that haematopoietic stem cells and neurons are regulated by similar signals. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fonseca-Pereira</LastName>
<ForeName>Diogo</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>1] Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arroz-Madeira</LastName>
<ForeName>Sílvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rodrigues-Campos</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barbosa</LastName>
<ForeName>Inês A M</ForeName>
<Initials>IA</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Domingues</LastName>
<ForeName>Rita G</ForeName>
<Initials>RG</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bento</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Almeida</LastName>
<ForeName>Afonso R M</ForeName>
<Initials>AR</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ribeiro</LastName>
<ForeName>Hélder</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Potocnik</LastName>
<ForeName>Alexandre J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Molecular Immunology, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK [2] Institute of Immunology and Infection Research, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Enomoto</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>1] Laboratory for Neuronal Differentiation and Regeneration, RIKEN Center for Developmental Biology, Kobe 650-0047, Japan [2] Graduate School of Medicine, Kobe University7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo 650-0017, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Veiga-Fernandes</LastName>
<ForeName>Henrique</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494811">BCL2L1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494812">Bcl2l1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051020">bcl-X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D051096">Proto-Oncogene Proteins c-ret</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C099282">RET protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C494999">Ret protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017362">Cyclic AMP Response Element-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006410">Hematopoiesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006412">Hematopoietic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009414">Nerve Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051096">Proto-Oncogene Proteins c-ret</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055153">Stem Cell Niche</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051020">bcl-X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282897</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor].</ArticleTitle>
<Pagination>
<MedlinePgn>1869-73</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the effect of Buzhong Yiqi decoction on PI3K/AKT signaling pathway in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">Totally 60 nude mice were randomly divided into the blank control group, the tumor-bearing control group, the cisplatin group, the low-dose Buzhong Yiqi decoction group, the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group. After the corresponding interventions, efforts were made to measure the transplanted tumor volume and calculate the tumor inhibiting rate. The immunohistochemical method and real time PCR were used to detect the expression of PI3K and AKT level in nude mice spleen, stomach and lung.</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">Buzhong Yiqi decoction of different concentrations combined with cisplatin could inhibit the growth of the transplanted tumor, with the strongest inhibitory effect in the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group. All of the expressions of PI3K and AKT protein and gene in the spleen, stomach and lung increased, with the most significant increase in the tumor-bearing group. Along with the increase of the concentration of cisplatin and Buzhong Yiqi decoction, the expressions of PI3K and AKT gradually reduced. Compared with the tumor-bearing control group, there were statistical differences in spleen and stomach tissues (P &lt; 0.05). Compared with the cisplatin group, the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group showed statistical differences (P &lt; 0.05), but without statistical difference compared with the blank control group.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among nude mice with lung adenocarcinoma transplantation tumor, the PI3K and AKT protein and gene expressions in spleen, stomach and lung tissues increased, which might indicated the effect of cisplatin and Buzhong Yiqi decoction in reducing PI3K and AKT expressions and the relations between the reduction degree and the concentrations of Buzhong Yiqi decoction. Cisplatin combined with Buzhong Yiqi decoction could decrease the PI3K and AKT protein and gene expression in spleen, stomach and lung, and make the pathway closer to normal, so as to protect the functions of spleen, stomach and lung, there may be target spots of Buzhong Yiqi decoction in PI3K/AKT signal pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ya-Li</ForeName>
<Initials>YL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yi</LastName>
<ForeName>Jia-Li</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jing</LastName>
<ForeName>Huan</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Chun-Ying</ForeName>
<Initials>CY</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538231">Adenocarcinoma of lung</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051058">Oncogene Protein v-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013154">Spleen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282911</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Effects of Betel shisanwei ingredients pill on AC-cAMP-PKA signal transduction pathways in hippocampus and prefrontal cortex of depressive rats].</ArticleTitle>
<Pagination>
<MedlinePgn>1946-50</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effects of Mongolian pharmaceutical Betel shisanwei ingredients pill on AC-cAMP-PKA signal transduction pathways in hippocampus and prefrontal cortex of depressive rats.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">Sixty male Wistar rats were randomly divided into six groups according to the sugar consumption test (10 rats in each group), normal control group,model group,fluoxetine group (3.3 mg x kg(-1)) and low dose, medium dose and high dose group (0.25, 0.5, 1 g x kg(-1)) of Betel shisanwei ingredients pill. Except the normal control,the other groups were treated with the chronic unpredictable mild stress stimulation combined with lonely raising for 28 days. 10 mL x kg(-1) of drugs were given to each rat once daily,continuously for 28 days. The AC activity of the hippocampus and prefrontal cortex were determined by radiation immunity analysis (RIA), while cAMP and PKA quantity were determinated by Enzyme-linked immunosorbent (ELISA).</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">The AC activity, cAMP and PKA quantity of hippocampus and prefrontal of mouse model of Chronic stress depression decreased significantly than those of control group (P &lt; 0.05 or P &lt; 0.01). However, the AC activity, cAMP and PKA quantity of rat hippocampus and prefrontal cortex in the fluoxetine group and the Mongolian pharmaceutical Betel shisanwei ingredients pill group indecreased significantly than those of model group (P &lt; 0.01 or P &lt; 0.05). Especially for the high dose group of Mongolian pharmaceutical Betel shisanwei ingredients pill.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The AC-cAMP-PKA signal transduction pathways in hippocampus and prefrontal cortex of depression model of rats is down-regulated, whereas Mongolian pharmaceutical Betel shisanwei ingredients pill could up-regulated it to resist depression.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tong</LastName>
<ForeName>Hai-Ying</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Jisiguleng</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>Liang-Feng</ForeName>
<Initials>LF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bao</LastName>
<ForeName>Wu-Ye</ForeName>
<Initials>WY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Rilebagen</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.11</RegistryNumber>
<NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.6.1.1</RegistryNumber>
<NameOfSubstance UI="D000262">Adenylate Cyclase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000262">Adenylate Cyclase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017868">Cyclic AMP-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017397">Prefrontal Cortex</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25253680</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>15</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC bioinformatics</Title>
<ISOAbbreviation>BMC Bioinformatics</ISOAbbreviation>
</Journal>
<ArticleTitle>MOSBIE: a tool for comparison and analysis of rule-based biochemical models.</ArticleTitle>
<Pagination>
<MedlinePgn>316</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2105-15-316</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mechanistic models that describe the dynamical behaviors of biochemical systems are common in computational systems biology, especially in the realm of cellular signaling. The development of families of such models, either by a single research group or by different groups working within the same area, presents significant challenges that range from identifying structural similarities and differences between models to understanding how these differences affect system dynamics.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We present the development and features of an interactive model exploration system, MOSBIE, which provides utilities for identifying similarities and differences between models within a family. Models are clustered using a custom similarity metric, and a visual interface is provided that allows a researcher to interactively compare the structures of pairs of models as well as view simulation results.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We illustrate the usefulness of MOSBIE via two case studies in the cell signaling domain. We also present feedback provided by domain experts and discuss the benefits, as well as the limitations, of the approach.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wenskovitch</LastName>
<ForeName>John E</ForeName>
<Initials>JE</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author ValidYN="Y">
<LastName>Harris</LastName>
<ForeName>Leonard A</ForeName>
<Initials>LA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tapia</LastName>
<ForeName>Jose-Juan</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Faeder</LastName>
<ForeName>James R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marai</LastName>
<ForeName>G Elisabeta</ForeName>
<Initials>GE</Initials>
<AffiliationInfo>
<Affiliation>Electronic Visualization Lab, Department of Computer Science, University of Illinois at Chicago, 60607 Chicago, USA. g.elisabeta.marai@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5UL1RR024153-05</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P41GM103712</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Bioinformatics</MedlineTA>
<NlmUniqueID>100965194</NlmUniqueID>
<ISSNLinking>1471-2105</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012984">Software</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049490">Systems Biology</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25296439</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2191-7043</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>99</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Progress in the chemistry of organic natural products</Title>
<ISOAbbreviation>Prog Chem Org Nat Prod</ISOAbbreviation>
</Journal>
<ArticleTitle>Bioactive heterocyclic natural products from actinomycetes having effects on cancer-related signaling pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>147-98</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ishibashi</LastName>
<ForeName>Masami</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Austria</Country>
<MedlineTA>Prog Chem Org Nat Prod</MedlineTA>
<NlmUniqueID>101605200</NlmUniqueID>
<ISSNLinking>0071-7886</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010619">Phenazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039903">Actinobacteria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001688">Biological Products</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006571">Heterocyclic Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009285">Naphthoquinones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010619">Phenazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053221">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25300130</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2190-5215</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurobiology</Title>
<ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Thy-1 modulates neurological cell-cell and cell-matrix interactions through multiple molecular interactions.</ArticleTitle>
<Pagination>
<MedlinePgn>3-20</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Thy-1, or CD90, is a glycosylphosphatidylinositol-linked cell surface glycoprotein expressed on multiple cell types, including neurons, thymocytes, fibroblasts, endothelial cells, mesangial cells, and some hematopoietic and stromal stem cells. Thy-1 is developmentally regulated and evolutionarily conserved. Its cellular effects vary between and in some cases within cell types, tissues, and species, indicating that its biological role is context dependent. However, it most often seems to affect cell-cell or cell-matrix interactions and cellular adhesion and migration. In the nervous system, Thy-1 mediates bidirectional cell-cell communication, which modulates cell-matrix adhesion. Neurons express high levels of Thy-1, which interacts with alpha(v)beta3 integrin present in astrocytes and stimulates increased astrocyte adhesion to the underlying surface (trans signaling) and in neurites, the same ligand-receptor association triggers neurite retraction and inhibition of axonal growth (cis signaling). Although Thy-1 lacks a cytoplasmic domain, it affects multiple intracellular signaling cascades through interaction with a number of molecules within lipid raft microdomains. Improved understanding of how this enigmatic adhesion molecule modulates signaling and cell phenotype may yield novel insights into neurodevelopment and nerve recovery after injury.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leyton</LastName>
<ForeName>Lisette</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hagood</LastName>
<ForeName>James S</ForeName>
<Initials>JS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5R03TW007810</GrantID>
<Acronym>TW</Acronym>
<Agency>FIC NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Neurobiol</MedlineTA>
<NlmUniqueID>101571545</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018800">Antigens, Thy-1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018800">Antigens, Thy-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021982">Cell-Matrix Junctions</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25300133</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2190-5215</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurobiology</Title>
<ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
</Journal>
<ArticleTitle>The neuroplastins: multifunctional neuronal adhesion molecules--involvement in behaviour and disease.</ArticleTitle>
<Pagination>
<MedlinePgn>61-89</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The neuroplastins np65 and np55 are neuronal and synapse-enriched immunoglobulin (Ig) superfamily cell adhesion molecules that contain 3 and 2 Ig domains, respectively. Np65 is neuron specific whereas np55 is expressed in many tissues. They are multifunctional proteins whose physiological roles are defined by the partner proteins they bind to and the signalling pathways they activate. The neuroplastins are implicated in activity-dependent long-term synaptic plasticity. Thus neuroplastin-specific antibodies and a recombinant peptide inhibit long-term potentiation in hippocampal neurones. This is mediated by activation of the p38MAP kinase signalling pathway, resulting in the downregulation of the surface expression of GluR1 receptors. Np65, but not np55, exhibits trans-homophilic binding. Both np65 and np55 induce neurite outgrowth and both activate the FGF receptor and associated downstream signalling pathways. Np65 binds to and colocalises with GABA(A) receptor subtypes and may play a role in anchoring them to specific synaptic and extrasynaptic sites. Most recently the neuroplastins have been shown to chaperone and support the monocarboxylate transporter MCT2 in transporting lactate across the neuronal plasma membrane. Thus the neuroplastins are multifunctional adhesion molecules which support neurite outgrowth, modulate long-term activity-dependent synaptic plasticity, regulate surface expression of GluR1 receptors, modulate GABA(A) receptor localisation, and play a key role in delivery of monocarboxylate energy substrates both to the synapse and to extrasynaptic sites. The diverse functions and range of signalling pathways activated by the neuroplastins suggest that they are important in modulating behaviour and in relation to human disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Beesley</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kraus</LastName>
<ForeName>Michaela</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Parolaro</LastName>
<ForeName>Nathalie</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Neurobiol</MedlineTA>
<NlmUniqueID>101571545</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C518360">NPTN protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001519">Behavior</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002490">Central Nervous System</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008562">Membrane Glycoproteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009422">Nervous System Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009473">Neuronal Plasticity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25300136</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2190-5215</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurobiology</Title>
<ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Roundabout receptors.</ArticleTitle>
<Pagination>
<MedlinePgn>133-64</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Roundabout receptors (Robo) and their Slit ligands were discovered in the 1990s and found to be key players in axon guidance. Slit was initially described s an extracellular matrix protein that was expressed by midline glia in Drosophila. A few years later, it was shown that, in vertebrates and invertebrates, Slits acted as chemorepellents for axons crossing the midline. Robo proteins were originally discovered in Drosophila in a mutant screen for genes involved in the regulation of midline crossing. This ligand-receptor pair has since been implicated in a variety of other neuronal and non-neuronal processes ranging from cell migration to angiogenesis, tumourigenesis and even organogenesis of tissues such as kidneys, lungs and breasts.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ypsilanti</LastName>
<ForeName>Athéna R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chedotal</LastName>
<ForeName>Alain</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Neurobiol</MedlineTA>
<NlmUniqueID>101571545</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490016">roundabout protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C066819">sli protein, Drosophila</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001369">Axons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004330">Drosophila</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029721">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011971">Receptors, Immunologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25300139</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2190-5215</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurobiology</Title>
<ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Organisation and control of neuronal connectivity and myelination by cell adhesion molecule neurofascin.</ArticleTitle>
<Pagination>
<MedlinePgn>231-47</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The neuronal cell adhesion molecule neurofascin is expressed in highly complex temporally and spatially regulated patterns. Accordingly, many different functions have been described including control of neurite outgrowth, clustering of protein complexes at the axon initial segments as well as at the nodes of Ranvier and axoglial contact formation at paranodal segments. At the molecular level, neurofascin provides a link between extracellular interactions of many different interaction partners and cytoskeletal components or signal transduction. Such interactions are subject to intimate regulation by alternative splicing and posttranslational modification. The versatile functional aspects of neurofascin interactions pose it at a central position for the shaping and maintenance of neural circuitry and synaptic contacts which are implicated in nervous system disorders.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ebel</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beuter</LastName>
<ForeName>Simone</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wuchter</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kriebel</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Volkmer</LastName>
<ForeName>Hansjürgen</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Neurobiol</MedlineTA>
<NlmUniqueID>101571545</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C054305">NFASC protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009186">Myelin Sheath</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009414">Nerve Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009415">Nerve Net</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016501">Neurites</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25300140</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2190-5215</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurobiology</Title>
<ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Roles for DSCAM and DSCAML1 in central nervous system development and disease.</ArticleTitle>
<Pagination>
<MedlinePgn>249-70</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>DSCAMs (Down syndrome cell adhesion molecules) are a group of immunoglobulin-like transmembrane proteins that contain fibronectin III domains. The founding member of the family was isolated in a positional cloning study that sought to identify genes located on chromosome 21 at the locus 21q22.2-q22.3 that is implicated in the neurological and cardiac phenotypes associated with Down's syndrome. In Drosophila, Dscam proteins are involved in neuronal wiring, while in vertebrates, the role of these cell adhesion molecules in neurogenesis, dendritogenesis, axonal outgrowth, synaptogenesis, and synaptic plasticity is only just beginning to be understood. In this chapter, we will review the functions ascribed to the two paralogous proteins found in humans, DSCAM and DSCAML1 (DSCAM-like 1), based on findings in knockout mice. The signaling pathways downstream of DSCAM activation and the role of DSCAM miss-expression in disease will be also discussed, particularly with regard to the intellectual disability in Down's syndrome.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Montesinos</LastName>
<ForeName>María Luz</ForeName>
<Initials>ML</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Neurobiol</MedlineTA>
<NlmUniqueID>101571545</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C110833">DSCAM protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C432365">DSCAML1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002490">Central Nervous System</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004330">Drosophila</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029721">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25301628</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6206</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse.</ArticleTitle>
<Pagination>
<MedlinePgn>237-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.346.6206.237</ELocationID>
<Abstract>
<AbstractText>Neurogenesis is restricted in the adult mammalian brain; most neurons are neither exchanged during normal life nor replaced in pathological situations. We report that stroke elicits a latent neurogenic program in striatal astrocytes in mice. Notch1 signaling is reduced in astrocytes after stroke, and attenuated Notch1 signaling is necessary for neurogenesis by striatal astrocytes. Blocking Notch signaling triggers astrocytes in the striatum and the medial cortex to enter a neurogenic program, even in the absence of stroke, resulting in 850 ± 210 (mean ± SEM) new neurons in a mouse striatum. Thus, under Notch signaling regulation, astrocytes in the adult mouse brain parenchyma carry a latent neurogenic program that may potentially be useful for neuronal replacement strategies. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Magnusson</LastName>
<ForeName>Jens P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Göritz</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tatarishvili</LastName>
<ForeName>Jemal</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lund Stem Cell Center, University Hospital, SE-221 84 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dias</LastName>
<ForeName>David O</ForeName>
<Initials>DO</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Emma M K</ForeName>
<Initials>EM</Initials>
<AffiliationInfo>
<Affiliation>Division of Translational Cancer Research, Lund University, SE-223 63 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lindvall</LastName>
<ForeName>Olle</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Lund Stem Cell Center, University Hospital, SE-221 84 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kokaia</LastName>
<ForeName>Zaal</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Lund Stem Cell Center, University Hospital, SE-221 84 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Frisén</LastName>
<ForeName>Jonas</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden. jonas.frisen@ki.se.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051819">Immunoglobulin J Recombination Signal Sequence-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497762">Notch1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497571">Rbpj protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017353">Gene Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051819">Immunoglobulin J Recombination Signal Sequence-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058953">Neural Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055495">Neurogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051881">Receptor, Notch1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25301629</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6206</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Spatial organization of cytokinesis signaling reconstituted in a cell-free system.</ArticleTitle>
<Pagination>
<MedlinePgn>244-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1256773</ELocationID>
<Abstract>
<AbstractText>During animal cell division, the cleavage furrow is positioned by microtubules that signal to the actin cortex at the cell midplane. We developed a cell-free system to recapitulate cytokinesis signaling using cytoplasmic extract from Xenopus eggs. Microtubules grew out as asters from artificial centrosomes and met to organize antiparallel overlap zones. These zones blocked the interpenetration of neighboring asters and recruited cytokinesis midzone proteins, including the chromosomal passenger complex (CPC) and centralspindlin. The CPC was transported to overlap zones, which required two motor proteins, Kif4A and a Kif20A paralog. Using supported lipid bilayers to mimic the plasma membrane, we observed the recruitment of cleavage furrow markers, including an active RhoA reporter, at microtubule overlaps. This system opens further approaches to understanding the biophysics of cytokinesis signaling. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Phuong A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Marine Biological Laboratory, Woods Hole, MA 02543, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Groen</LastName>
<ForeName>Aaron C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Marine Biological Laboratory, Woods Hole, MA 02543, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Loose</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ishihara</LastName>
<ForeName>Keisuke</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Marine Biological Laboratory, Woods Hole, MA 02543, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wühr</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Field</LastName>
<ForeName>Christine M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Marine Biological Laboratory, Woods Hole, MA 02543, USA. Christine_Field@hms.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mitchison</LastName>
<ForeName>Timothy J</ForeName>
<Initials>TJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Marine Biological Laboratory, Woods Hole, MA 02543, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM103785</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM39565</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM039565</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C092349">chromokinesin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>86-01-1</RegistryNumber>
<NameOfSubstance UI="D006160">Guanosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="D016547">Kinesin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020742">rhoA GTP-Binding Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002474">Cell-Free System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018385">Centrosome</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D048749">Cytokinesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006160">Guanosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016547">Kinesin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008051">Lipid Bilayers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008870">Microtubules</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014982">Xenopus laevis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020742">rhoA GTP-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25324386</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6207</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Perception of root-derived peptides by shoot LRR-RKs mediates systemic N-demand signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>343-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1257800</ELocationID>
<Abstract>
<AbstractText>Nitrogen (N) is a critical nutrient for plants but is often distributed unevenly in the soil. Plants therefore have evolved a systemic mechanism by which N starvation on one side of the root system leads to a compensatory and increased nitrate uptake on the other side. Here, we study the molecular systems that support perception of N and the long-distance signaling needed to alter root development. Rootlets starved of N secrete small peptides that are translocated to the shoot and received by two leucine-rich repeat receptor kinases (LRR-RKs). Arabidopsis plants deficient in this pathway show growth retardation accompanied with N-deficiency symptoms. Thus, signaling from the root to the shoot helps the plant adapt to fluctuations in local N availability. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tabata</LastName>
<ForeName>Ryo</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Science, Graduate School of Science, Nagoya University, Chikusa, Nagoya 464-8602, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sumida</LastName>
<ForeName>Kumiko</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Science, Graduate School of Science, Nagoya University, Chikusa, Nagoya 464-8602, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshii</LastName>
<ForeName>Tomoaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Applied Molecular Biosciences, Graduate School of Bio-Agricultural Sciences, Nagoya University, Chikusa, Nagoya 464-8601, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohyama</LastName>
<ForeName>Kentaro</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Applied Molecular Biosciences, Graduate School of Bio-Agricultural Sciences, Nagoya University, Chikusa, Nagoya 464-8601, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shinohara</LastName>
<ForeName>Hidefumi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Science, Graduate School of Science, Nagoya University, Chikusa, Nagoya 464-8602, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsubayashi</LastName>
<ForeName>Yoshikatsu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Science, Graduate School of Science, Nagoya University, Chikusa, Nagoya 464-8602, Japan. matsu@bio.nagoya-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029681">Arabidopsis Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592797">CEP1 peptide, Arabidopsis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592798">CEPR1 protein, Arabidopsis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592799">CEPR2 protein, Arabidopsis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018000">Receptors, Peptide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>N762921K75</RegistryNumber>
<NameOfSubstance UI="D009584">Nitrogen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Science. 2014 Oct 17;346(6207):300-1</RefSource>
<PMID Version="1">25324371</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017360">Arabidopsis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029681">Arabidopsis Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009584">Nitrogen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018517">Plant Roots</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018520">Plant Shoots</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018000">Receptors, Peptide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25335388</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0869-2092</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>77</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Eksperimental'naia i klinicheskaia farmakologiia</Title>
<ISOAbbreviation>Eksp Klin Farmakol</ISOAbbreviation>
</Journal>
<ArticleTitle>[Influence of new N,N'-substituted piperazines on thrombin-induced platelet activation].</ArticleTitle>
<Pagination>
<MedlinePgn>28-33</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>We have studied the influence of new N,N'-substituted piperazines with variable nature of the linker between piperazine and aromatic cycles (carbonyl group in VR-0411 versus sulfonyl group in VR-0511) on thrombin-induced platelet aggregation, cytoplasmic Ca2+ mobilization in platelets, and P-selectin exposure on the platelet plasma membrane. The inhibitory effect of VR-0511 on platelet aggregation exceeds the effects of the reference compound aspirin and VR-0411 by 35 and 42%, respectively (p &lt; or = 0.01). The effects of test compounds on the mobilization of cytoplasmic Ca2+ in platelets and P-selectin exposure indicate that VR-0411 and VR-0511 inhibit platelet activation in these tests by 28 and 61%, (p &lt; or = 0.01) and 34 and 58% (p &lt; or = 0.01), respectively. The possible targets for VR-0411 and VR-0511 are thromboxane and inositol triphosphate-dependent (IP3 formation) pathways of activation signal transfer.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Veselkina</LastName>
<ForeName>O C</ForeName>
<Initials>OC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Petrishchev</LastName>
<ForeName>N N</ForeName>
<Initials>NN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vasina</LastName>
<ForeName>L V</ForeName>
<Initials>LV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Borovitov</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seliutin</LastName>
<ForeName>A V</ForeName>
<Initials>AV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chepanov</LastName>
<ForeName>S V</ForeName>
<Initials>SV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sel'kov</LastName>
<ForeName>S A</ForeName>
<Initials>SA</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Eksp Klin Farmakol</MedlineTA>
<NlmUniqueID>9215981</NlmUniqueID>
<ISSNLinking>0869-2092</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007295">Inositol Phosphates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013931">Thromboxanes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.5</RegistryNumber>
<NameOfSubstance UI="D013917">Thrombin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>R16CO5Y76E</RegistryNumber>
<NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001792">Blood Platelets</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007295">Inositol Phosphates</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019007">P-Selectin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015539">Platelet Activation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010974">Platelet Aggregation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010975">Platelet Aggregation Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013917">Thrombin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013931">Thromboxanes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25340187</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>1308-14</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Acute myeloid leukemia (AML) is a group of hematological malignancies defined by expanded clonal populations of immature progenitors (blasts) of myeloid phenotype in blood and bone marrow. Given a typical poor prognostic outlook, there is great need for novel agents with anti-AML activity. Devil’s club (Oplopanax horridus) is one of the most significant medicinal plants used among the indigenous people of Southeast Alaska and the coastal Pacific Northwest, with different linguistic groups utilizing various parts of the plant to treat many different conditions including cancer. Studies identifying medically relevant components in Devil’s club are limited. For this research study, samples were extracted in 70% ethanol before in vitro analysis, to assess effects on AML cell line viability as well as to study regulation of tyrosine phosphorylation and cysteine oxidation. The root extract displayed better in vitro anti-AML efficacy in addition to a noted anti-tyrosine kinase activity independent of an antioxidant effect. In vivo therapeutic studies using an immunocompetent murine model of AML further demonstrated that Devil’s club root extract improved the murine survival while decreasing immunosuppressive regulatory T cells and improving CD8+ T-cell functionality. This study defines for the first time an anti-AML efficacy for extracts of Devil’s club.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>McGill</LastName>
<ForeName>Colin M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alba-Rodriguez</LastName>
<ForeName>Estefania J</ForeName>
<Initials>EJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Shuo</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benson</LastName>
<ForeName>Charles J</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ondrasik</LastName>
<ForeName>Regina M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fisher</LastName>
<ForeName>Lindsey N</ForeName>
<Initials>LN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Claxton</LastName>
<ForeName>David F</ForeName>
<Initials>DF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barth</LastName>
<ForeName>Brian M</ForeName>
<Initials>BM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D028002">Oplopanax</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008517">Phytotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010946">Plants, Medicinal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25359972</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6209</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Neurodevelopment. Dendrite morphogenesis depends on relative levels of NT-3/TrkC signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>626-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1258996</ELocationID>
<Abstract>
<AbstractText>Neurotrophins regulate diverse aspects of neuronal development and plasticity, but their precise in vivo functions during neural circuit assembly in the central brain remain unclear. We show that the neurotrophin receptor tropomyosin-related kinase C (TrkC) is required for dendritic growth and branching of mouse cerebellar Purkinje cells. Sparse TrkC knockout reduced dendrite complexity, but global Purkinje cell knockout had no effect. Removal of the TrkC ligand neurotrophin-3 (NT-3) from cerebellar granule cells, which provide major afferent input to developing Purkinje cell dendrites, rescued the dendrite defects caused by sparse TrkC disruption in Purkinje cells. Our data demonstrate that NT-3 from presynaptic neurons (granule cells) is required for TrkC-dependent competitive dendrite morphogenesis in postsynaptic neurons (Purkinje cells)--a previously unknown mechanism of neural circuit development.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Joo</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute and Department of Biology, Stanford University, Stanford, CA 94305, USA. Neurosciences Program, Stanford University, Stanford, CA 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hippenmeyer</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute and Department of Biology, Stanford University, Stanford, CA 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Liqun</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute and Department of Biology, Stanford University, Stanford, CA 94305, USA. Neurosciences Program, Stanford University, Stanford, CA 94305, USA. lluo@stanford.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5 F31 NS071697</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-NS050835</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020933">Neurotrophin 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D020812">Receptor, trkC</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003712">Dendrites</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009415">Nerve Net</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055495">Neurogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020933">Neurotrophin 3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011689">Purkinje Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020812">Receptor, trkC</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013569">Synapses</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
